meta_review,paper,first_author_meta,year_meta,doi,available_age,available_IQ,available_control,available_rob,amstar_rank,intervention_general,intervention_precise,intervention_augmentation,mono_aug,outcome_general,outcome_raters,outcome_followup,outcome_type,outcome_measure,duration_month,dose,dose_unit,author,year,trial_id_supp,design,measure,n_cases,n_controls,n_tot,multiple_es,reverse_es,value,ci_lo,ci_up,sd_cases,sd_controls,mean_pre_cases,sd_pre_cases,mean_pre_controls,sd_pre_controls,sd_change_cases,sd_change_controls,rob_num,low_RoB_num,RoB_Rand_num,RoB_Deviation_num,RoB_Missing_num,RoB_Report_num,RoB_Outcome_num,RoB_Rand,RoB_Deviation,RoB_Missing,RoB_Outcome,RoB_Report,control_group,active_controls,perc_female,mean_age,mean_iq,diagnostic_criteria,amstar_rank_crit,ams_2,ams_4,ams_7,ams_9,ams_11,ams_13,ams_15,amstar_rank_non_crit,ams_1,ams_3,ams_5,ams_6,ams_8,ams_10,ams_12,ams_14,ams_16,id_row,trial_id,Duration_cct,IQ_cct,Age_cct,min_age_meta,max_age_meta,min_IQ_meta,max_IQ_meta,n_cct_intervention,n_outcome_intervention,outcome_intervention,n_meta_intervention,meta_intervention,min_age_intervention,max_age_intervention,min_IQ_intervention,max_IQ_intervention,factor,n_papers_pico,Age_precise,PICO_amstar_ID,available_control_agg,indirectness,rob1_report,rob
  93 Ang (2023) Ang,2023,10.3390/medicina59020392 100   0,100,100,Critically low,Acupuncture Acupuncture 100 Acupuncture plus conventional medicine vs. conventional medicine,Generalized anxiety,Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,Conners parents symptom questionnaire (PSQ), 2.76179517 NA NA,Meng,2012,NA RCT (parallel, crossover, open-label) MD, 36, 32   68,NA reverse,-0.0700000000 -0.880000000  7.400000e-01,  1.4500000,  1.8800000,NA NA,NA NA,NA NA 100 100 100,100,100 100 100 some some,low,some some TAU,  0, 23.529412, 9.000000,NA DSM-IV/5,2 1 1.0 1.0,1.0 0.0 1 0,3 1 1 1 1,0.5,0 0,0,1    1 Meng_2012,2-6 months NA,6-12 yo,9 9.5,NA NA,  2  4,Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  1 Ang (2023),9 9.5 NA NA Ang (2023)_Acupuncture_Generalized anxiety_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ang (2023) - Acupuncture_Generalized anxiety_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
  93 Ang (2023) Ang,2023,10.3390/medicina59020392,100   0,100 100 Critically low,Acupuncture,Acupuncture 100,Acupuncture plus conventional medicine vs. conventional medicine,Generalized anxiety Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire Conners parents symptom questionnaire (PSQ), 0.92059839 NA,NA Yu,2021,NA,RCT (parallel, crossover, open-label) MD, 52, 51, 103 NA reverse,-0.0600000000,-0.680000000  5.600000e-01   1.4100000,  1.7900000,NA,NA NA,NA NA,NA,100 100,100 100 100,100 100 some low low,some,some,TAU   0  10.679612, 9.500000 NA DSM-IV/5 2,1,1.0 1.0 1.0,0.0 1,0,3,1 1,1,1 0.5,0,0 0,1    2 Yu_2021,< 2 months NA 6-12 yo,9,9.5,NA NA,  2  4,Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 1 Ang (2023) 9 9.5,NA,NA Ang (2023)_Acupuncture_Generalized anxiety_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ang (2023) - Acupuncture_Generalized anxiety_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
  93 Ang (2023),Ang,2023,10.3390/medicina59020392 100   0 100 100,Critically low Acupuncture,Acupuncture,100 Acupuncture plus conventional medicine vs. conventional medicine,Conduct Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,Conners parents symptom questionnaire (PSQ)  2.76179517 NA,NA,Meng 2012,NA,RCT (parallel, crossover, open-label),MD, 36  32   68 NA reverse -1.1600000000,-2.130000000,-1.900000e-01,  2.0100000,  2.0500000 NA NA,NA,NA NA,NA,100 100 100,100,100 100,100 some some low,some some,TAU,  0, 23.529412, 9.000000 NA,DSM-IV/5 2,1 1.0,1.0 1.0 0.0,1 0,3 1,1,1 1,0.5,0 0,0,1,   3 Meng_2012,2-6 months,NA,6-12 yo,9 9.5 NA,NA,  2, 4 Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  1,Ang (2023) 9 9.5,NA NA,Ang (2023)_Acupuncture_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ang (2023) - Acupuncture_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
  93,Ang (2023),Ang 2023 10.3390/medicina59020392 100   0,100 100 Critically low,Acupuncture Acupuncture,100 Acupuncture plus conventional medicine vs. conventional medicine,Conduct Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,Conners parents symptom questionnaire (PSQ)  0.92059839,NA,NA Yu,2021 NA,RCT (parallel, crossover, open-label) MD  52, 51, 103,NA,reverse,-1.4700000000,-2.260000000 -6.800000e-01   2.0300000   2.0400000,NA NA NA NA,NA,NA 100 100 100,100 100,100,100,some low low some some TAU,  0, 10.679612  9.500000 NA,DSM-IV/5 2,1,1.0 1.0,1.0,0.0 1,0 3,1,1 1,1,0.5 0 0 0 1,   4 Yu_2021 < 2 months,NA 6-12 yo,9 9.5 NA,NA,  2, 4 Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  1,Ang (2023),9 9.5,NA,NA Ang (2023)_Acupuncture_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ang (2023) - Acupuncture_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
  93 Ang (2023) Ang,2023 10.3390/medicina59020392,100   0,100,100,Critically low Acupuncture,Acupuncture,100 Acupuncture plus conventional medicine vs. conventional medicine Learning disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks),Questionnaire Conners parents symptom questionnaire (PSQ)  2.76179517 NA,NA Meng 2012,NA,RCT (parallel, crossover, open-label),MD  36  32   68 NA,reverse,-1.0300000000,-1.830000000 -2.300000e-01   1.5300000,  1.8200000,NA,NA NA NA,NA NA 100,100 100 100 100 100,100 some,some low,some some TAU   0, 23.529412, 9.000000 NA,DSM-IV/5 2 1,1.0 1.0 1.0,0.0 1,0,3,1 1,1,1,0.5 0,0,0,1    5,Meng_2012 2-6 months,NA 6-12 yo,9 9.5,NA,NA,  2  4,Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 1 Ang (2023),9 9.5 NA,NA,Ang (2023)_Acupuncture_Learning disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ang (2023) - Acupuncture_Learning disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
  93,Ang (2023),Ang,2023,10.3390/medicina59020392,100,  0 100,100 Critically low,Acupuncture,Acupuncture,100,Acupuncture plus conventional medicine vs. conventional medicine Learning disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,Conners parents symptom questionnaire (PSQ), 0.92059839 NA,NA Yu 2021 NA,RCT (parallel, crossover, open-label),MD  52, 51, 103,NA,reverse,-1.0400000000,-1.680000000,-4.000000e-01   1.5100000   1.7900000,NA NA,NA,NA,NA,NA 100 100,100 100,100,100,100,some low low,some,some,TAU,  0, 10.679612  9.500000 NA DSM-IV/5 2 1,1.0 1.0 1.0,0.0 1,0 3 1 1,1 1,0.5,0,0,0,1    6 Yu_2021,< 2 months NA 6-12 yo 9,9.5,NA,NA   2  4 Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  1,Ang (2023) 9 9.5 NA NA Ang (2023)_Acupuncture_Learning disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ang (2023) - Acupuncture_Learning disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
  93,Ang (2023),Ang 2023 10.3390/medicina59020392 100   0,100,100 Critically low,Acupuncture,Acupuncture 100 Acupuncture plus conventional medicine vs. conventional medicine,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,Conners parents symptom questionnaire (PSQ), 2.76179517 NA,NA,Meng 2012 NA,RCT (parallel, crossover, open-label) MD  36  32,  68 NA reverse -1.0900000000 -1.800000000 -3.800000e-01,  1.1600000   1.7300000,NA,NA NA NA NA,NA 100,100 100 100,100 100 100 some,some,low some,some,TAU,  0, 23.529412, 9.000000 NA,DSM-IV/5 2,1 1.0,1.0 1.0 0.0 1,0 3 1,1 1 1 0.5 0 0,0 1    7 Meng_2012 2-6 months,NA,6-12 yo 9 9.5,NA,NA,  2  4,Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 1,Ang (2023) 9,9.5,NA NA Ang (2023)_Acupuncture_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ang (2023) - Acupuncture_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
  93 Ang (2023) Ang 2023 10.3390/medicina59020392,100,  0 100,100 Critically low Acupuncture,Acupuncture 100,Acupuncture plus conventional medicine vs. conventional medicine,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,Conners parents symptom questionnaire (PSQ), 0.92059839,NA NA,Yu 2021 NA RCT (parallel, crossover, open-label) MD  52, 51, 103 NA reverse,-1.2200000000 -1.790000000 -6.500000e-01,  1.1700000,  1.7400000 NA NA NA,NA NA NA 100 100,100 100,100 100,100 some low,low,some some TAU,  0, 10.679612, 9.500000 NA,DSM-IV/5 2 1 1.0 1.0 1.0,0.0,1,0 3 1,1 1 1,0.5,0,0 0 1    8,Yu_2021,< 2 months,NA 6-12 yo,9 9.5,NA,NA   2, 4 Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 1,Ang (2023),9 9.5,NA NA Ang (2023)_Acupuncture_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ang (2023) - Acupuncture_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
2157 Lopez-Pinar (2019),Lopez-Pinar 2019,10.1177/1087054719855685,100,  0,100,100 Critically low,Mindfulness,NA,  0,NA Generalized anxiety Self-rated,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA, 1.38089758,   1.0000000 h/wk,Gu,2017,NA,RCT SMD  28, 26,  54,NA NA  1.2800000000  0.790000000  1.770000e+00,NA NA NA NA NA NA NA NA,  0,  0 100   0,100,100,  0 some high low,high,low,WLC (wait-list control),  0  44.432143 21.500000,NA,DSM-IV 2,0 0.0,1.0 1.0 1.0,1,1 2,1,1,0,1 1.0 0 1,1 1,   9 Gu_2017,< 2 months NA >= 20 yo,21.5,35.8421686746988 NA,NA  13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35,NA NA Lopez-Pinar (2019)_Mindfulness_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Lopez-Pinar (2019) - Mindfulness_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low high
2157 Lopez-Pinar (2019) Lopez-Pinar,2019 10.1177/1087054719855685 100,  0 100,100 Critically low,Mindfulness NA,  0 NA Generalized anxiety,Self-rated,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 2.76179517,NA NA,Hepark,2015 NA,RCT,SMD, 41  42,  83 NA NA, 0.2200000000,-0.110000000  5.500000e-01,NA NA,NA NA,NA NA NA NA,  0   0 100   0,100 100   0,some,high low,high,low,WLC (wait-list control)   0  45.456311 35.842169 NA,DSM-IV 2 0,0.0,1.0 1.0,1.0 1 1,2,1 1 0,1,1.0,0,1 1 1,  10,Hepark_2015,2-6 months NA,>= 20 yo,21.5 35.8421686746988 NA,NA, 13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08 39.35,NA,NA Lopez-Pinar (2019)_Mindfulness_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Lopez-Pinar (2019) - Mindfulness_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,high
 343 Bikic (2017),Bikic,2017,10.1016/j.cpr.2016.12.004 100,  0,100 100 Critically low,Organizational skills interventions Organizational skills training,100,0.36 on medication,Academic/job performance Teacher-rated,At study endpoint (closest to 12 weeks) Questionnaire,Academic Performance Rating Scale, Classroom Performance Survey, or Academic Competence Evaluation Scale  2.53164557 NA,NA Abikoff 2013,NA,RCT (parallel, crossover, open-label) G  64  33   97,NA,NA, 0.7370000000  0.308000000  1.167000e+00,NA NA,NA NA,NA,NA,NA NA   0   0 100   0 100,100   0,some,high some high low,WLC (wait-list control)   0  36.000000  9.500000 NA,DSM 2 1,0.0 0.0 1.0,1.0 1,1 2,1 1 1,1 0.5,0,0,1 1   11 Abikoff_2013,2-6 months NA 6-12 yo,4,15,NA,NA, 11, 1,Academic/job performance  1 Bikic (2017) 4 15 NA NA,Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks),1,Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 serious,low high
 343 Bikic (2017),Bikic,2017,10.1016/j.cpr.2016.12.004 100,  0 100,100 Critically low Organizational skills interventions,Organizational skills training 100 0.67 on medication Academic/job performance Teacher-rated,At study endpoint (closest to 12 weeks) Questionnaire,Academic Performance Rating Scale, Classroom Performance Survey, or Academic Competence Evaluation Scale, 4.60299194,NA NA,Evans 2011,NA RCT (parallel, crossover, open-label) G, 31, 18,  49 outcomes NA  0.0890000000 -0.483000000, 6.600000e-01,NA,NA,NA,NA NA NA NA NA   0   0,100   0 100,100,  0 some,high,low high,low Unclear,  0, 29.000000 11.000000,NA,DSM,2,1,0.0 0.0,1.0 1.0 1 1 2,1,1 1,1,0.5,0 0 1,1,  12,Evans_2011 2-6 months NA,6-12 yo,4,15,NA NA  11  1 Academic/job performance  1 Bikic (2017) 4,15 NA NA,Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 serious low high
 343 Bikic (2017) Bikic 2017 10.1016/j.cpr.2016.12.004 100,  0 100 100,Critically low Organizational skills interventions,Organizational skills training 100 0.5 on medication Academic/job performance,Teacher-rated At study endpoint (closest to 12 weeks) Questionnaire Academic Performance Rating Scale, Classroom Performance Survey, or Academic Competence Evaluation Scale, 5.98388953,NA,NA,Evans,2014 NA RCT (parallel, crossover, open-label) G, 24  12   36 outcomes,NA, 0.6980000000  0.002000000  1.395000e+00,NA,NA NA NA,NA,NA,NA NA   0   0 100   0,100 100   0 some,high some high low Unclear   0  17.000000,15.000000 NA,DSM,2 1 0.0 0.0 1.0,1.0 1 1,2,1,1,1,1,0.5,0,0,1,1   13,Evans_2014 2-6 months NA 13-19 yo 4,15,NA,NA, 11  1 Academic/job performance  1,Bikic (2017),4,15,NA,NA,Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks),1 Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious,low,high
 343,Bikic (2017) Bikic,2017,10.1016/j.cpr.2016.12.004,100,  0 100,100 Critically low Organizational skills interventions,Organizational skills training 100 0.446 on medication,Academic/job performance,Teacher-rated,At study endpoint (closest to 12 weeks),Questionnaire Academic Performance Rating Scale, Classroom Performance Survey, or Academic Competence Evaluation Scale  7.36478711,NA NA,Evans,2016 NA,RCT (parallel, crossover, open-label) G 112,104  216 NA,NA  0.1990000000 -0.067000000, 4.660000e-01,NA,NA NA,NA NA NA,NA,NA,  0   0,100,  0 100,100   0 some high,low high,low Unclear,  0  26.000000 12.100000 NA,DSM 2,1,0.0 0.0 1.0 1.0 1 1,2 1 1,1 1,0.5 0,0,1 1   14,Evans_2016 7-12 months,NA 6-12 yo,4 15,NA,NA, 11, 1,Academic/job performance  1 Bikic (2017) 4,15 NA,NA Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious,low,high
 343 Bikic (2017),Bikic,2017 10.1016/j.cpr.2016.12.004 100,  0 100 100 Critically low Organizational skills interventions Organizational skills training 100,0.43 on medication Academic/job performance Teacher-rated,At study endpoint (closest to 12 weeks) Questionnaire Academic Performance Rating Scale, Classroom Performance Survey, or Academic Competence Evaluation Scale, 1.84119678,NA NA Langberg 2008,NA,RCT (parallel, crossover, open-label) G  24, 13   37,outcomes,NA, 0.2700000000,-0.393000000, 9.330000e-01,NA NA,NA NA,NA NA,NA,NA,  0   0 100   0 100,100   0 some,high low high,low,WLC (wait-list control)   0, 17.000000,11.500000,NA,DSM 2,1 0.0 0.0 1.0 1.0 1,1,2,1 1,1 1,0.5 0,0 1,1,  15 Langberg_2008 < 2 months NA,6-12 yo 4,15 NA NA, 11  1,Academic/job performance  1,Bikic (2017),4,15 NA,NA Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious low,high
 343,Bikic (2017) Bikic 2017 10.1016/j.cpr.2016.12.004   0,  0,100,100,Critically low,Organizational skills interventions Organizational skills training 100,mono,Academic/job performance Teacher-rated,At study endpoint (closest to 12 weeks) Questionnaire,Academic Performance Rating Scale, Classroom Performance Survey, or Academic Competence Evaluation Scale, 2.76179517 NA NA,Mautone 2012 NA,RCT (parallel, crossover, open-label),G, 29  32   61 NA,NA  0.5000000000 -0.070000000  1.069000e+00,NA NA NA,NA NA,NA,NA NA   0,  0,100   0,100 100   0,some high,low high,low Active (any credible active intervention),100, 43.000000,NA,NA,DSM,2,1,0.0 0.0 1.0 1.0,1 1,2 1,1 1 1 0.5 0 0,1 1   16 Mautone_2012 2-6 months,NA,NA 4 15 NA NA, 11, 1 Academic/job performance, 1,Bikic (2017) 4,15 NA,NA,Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks),1 Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious,low,high
 343,Bikic (2017),Bikic 2017 10.1016/j.cpr.2016.12.004,100   0 100,100,Critically low Organizational skills interventions,Organizational skills training,100,0.42 on medication,Academic/job performance Teacher-rated At study endpoint (closest to 12 weeks) Questionnaire,Academic Performance Rating Scale, Classroom Performance Survey, or Academic Competence Evaluation Scale, 2.76179517 NA,NA Power,2012 NA,RCT (parallel, crossover, open-label) G 100, 99, 199,NA,NA  0.1800000000 -0.112000000, 4.710000e-01,NA,NA,NA NA,NA NA NA,NA   0   0 100   0,100 100   0 some high,some high,low Active (any credible active intervention),100, 32.000000, 4.000000,NA,DSM,2,1 0.0 0.0,1.0 1.0,1,1 2 1,1,1,1,0.5 0 0,1,1,  17,Power_2012,2-6 months,NA,< 6 yo,4 15,NA,NA  11  1 Academic/job performance  1,Bikic (2017) 4 15 NA NA,Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Mixed,Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious,low high
 343,Bikic (2017) Bikic 2017 10.1016/j.cpr.2016.12.004 100   0 100,100,Critically low Organizational skills interventions Organizational skills training,100 0.67 on medication,Academic/job performance Teacher-rated,At study endpoint (closest to 12 weeks) Observational tool Grade Point Avarage  4.60299194 NA NA,Evans,2011,NA,RCT (parallel, crossover, open-label),G  31  18,  49,outcomes,NA, 0.2750000000 -0.299000000  8.490000e-01 NA NA,NA,NA,NA NA,NA,NA   0,  0 100,  0 100 100   0 some,high low high low,Unclear,  0  29.000000 11.000000 NA DSM 2,1 0.0,0.0,1.0,1.0,1,1 2,1,1,1 1 0.5 0 0,1 1,  18 Evans_2011 2-6 months,NA 6-12 yo,4 15 NA NA, 11, 1 Academic/job performance, 1 Bikic (2017) 4 15,NA NA Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks),1,Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious low,high
 343,Bikic (2017) Bikic,2017 10.1016/j.cpr.2016.12.004 100   0,100 100 Critically low,Organizational skills interventions Organizational skills training 100 0.5 on medication,Academic/job performance,Teacher-rated At study endpoint (closest to 12 weeks) Observational tool,Grade Point Avarage, 5.98388953,NA,NA Evans,2014 NA,RCT (parallel, crossover, open-label),G, 24, 12   36,outcomes NA, 0.2170000000 -0.462000000  8.970000e-01 NA,NA NA NA,NA NA,NA,NA,  0   0 100   0,100 100,  0 some high some high,low Unclear,  0  17.000000 15.000000 NA,DSM,2,1,0.0 0.0 1.0,1.0 1,1,2,1 1,1,1 0.5,0 0 1 1,  19 Evans_2014,2-6 months,NA,13-19 yo,4,15 NA,NA  11  1,Academic/job performance  1,Bikic (2017) 4 15,NA,NA Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks),1 Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious,low,high
 343,Bikic (2017) Bikic 2017,10.1016/j.cpr.2016.12.004,100,  0 100 100 Critically low,Organizational skills interventions Organizational skills training,100,0.69 on medication,Academic/job performance Teacher-rated At study endpoint (closest to 12 weeks) Observational tool Grade Point Avarage  2.53164557,NA NA Langberg,2012 NA,RCT (parallel, crossover, open-label) G, 23  24   47,outcomes NA  0.6430000000  0.066000000  1.220000e+00 NA NA NA NA NA NA NA,NA   0,  0 100,  0 100 100,  0 some,high,low,high low,WLC (wait-list control),  0, 24.000000 12.500000,NA DSM 2,1,0.0,0.0 1.0,1.0 1 1 2,1 1,1 1,0.5,0,0,1,1,  20,Langberg_2012,2-6 months NA 6-12 yo,4 15 NA,NA, 11  1,Academic/job performance  1 Bikic (2017),4 15 NA,NA,Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious low,high
 343 Bikic (2017) Bikic 2017,10.1016/j.cpr.2016.12.004 100   0,100 100 Critically low,Organizational skills interventions,Organizational skills training,100,0.389 on medication,Academic/job performance,Teacher-rated,At study endpoint (closest to 12 weeks) Observational tool Grade Point Avarage  1.38089758,NA NA Sibley 2013,NA,RCT (parallel, crossover, open-label) G  18, 18,  36 NA,NA,-0.2610000000,-1.030000000, 5.070000e-01 NA,NA NA NA NA,NA NA NA,  0,  0,100   0 100 100   0,some high,low high,low,TAU   0  28.000000,13.000000,NA,DSM,2 1 0.0,0.0,1.0,1.0,1 1,2 1,1,1 1 0.5,0,0 1,1   21,Sibley_2013 < 2 months NA,13-19 yo 4,15,NA,NA  11  1,Academic/job performance  1 Bikic (2017) 4,15 NA NA Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks),1,Mixed,Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,serious,low high
 343 Bikic (2017) Bikic 2017,10.1016/j.cpr.2016.12.004,100   0 100 100,Critically low Organizational skills interventions,Organizational skills training,100 0.609 on medication Academic/job performance Teacher-rated At study endpoint (closest to 12 weeks),Observational tool,Grade Point Avarage  1.84119678 NA NA Sibley 2014,NA RCT (parallel, crossover, open-label) G, 10, 13,  23 NA,NA  0.6000000000 -0.054000000  1.253000e+00 NA,NA NA,NA,NA,NA NA NA,100 100,100 100,100,100 100,some,some,some some,some TAU,  0  30.000000,10.500000,NA,DSM,2 1 0.0,0.0 1.0,1.0,1,1,2 1,1 1 1 0.5,0,0 1 1,  22,Sibley_2014 < 2 months,NA 6-12 yo 4 15,NA NA, 11, 1 Academic/job performance, 1 Bikic (2017),4,15,NA,NA,Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks),1,Mixed Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious low low
 343 Bikic (2017) Bikic 2017,10.1016/j.cpr.2016.12.004 100,  0,100 100 Critically low,Organizational skills interventions Organizational skills training,100,0.344 on medication,Academic/job performance Teacher-rated At study endpoint (closest to 12 weeks),Observational tool,Grade Point Avarage, 2.30149597,NA,NA,Sibley,2016 NA,RCT (parallel, crossover, open-label) G, 67  61  128 NA NA  0.2200000000 -0.126000000  5.650000e-01 NA NA NA,NA,NA NA,NA NA,  0   0,100   0,100,100,  0,some,high low,high low TAU   0  35.000000,12.700000,NA DSM,2,1 0.0,0.0,1.0 1.0 1 1,2,1 1 1 1 0.5,0,0 1,1   23 Sibley_2016 2-6 months,NA 6-12 yo,4,15 NA,NA  11  1,Academic/job performance  1 Bikic (2017),4,15 NA NA Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Mixed,Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious,low,high
 962,Ding (2018),Ding 2018 10.1142/S2575900018400013,100   0,100,100,Critically low Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT) 100,medication,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks),Questionnaire,ADHD Severity Ratings + Symptom Inventory Scale of ADHD + Conners parents symptom questionnaire  3.98388953 NA,NA,Sprich,2016 NA RCT (parallel, crossover, open-label),SMD, 24  22   46 NA,reverse -0.7700000000 -1.380000000 -1.700000e-01  10.4000000,  8.2300000 NA NA,NA NA NA NA 100,100 100,  0,100,100 100 low,high low,low some Active (any credible active intervention),100,NA,16.000000,NA,DSM-5/ICD-10,3,0,1.0,0.5 1.0 0.0 1,0 5,1 1 0 1,0.5,0,0,0,0   24 Sprich_2016,2-6 months NA,13-19 yo 10.3,16,NA NA, 19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15 NA,NA Ding (2018)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Ding (2018) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 962 Ding (2018) Ding,2018,10.1142/S2575900018400013   0   0 100,100 Critically low Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),100,methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),Questionnaire,ADHD Severity Ratings + Symptom Inventory Scale of ADHD + Conners parents symptom questionnaire  2.76179517,   1.0000000 h/wk,Yang 2012,NA RCT (parallel, crossover, open-label),SMD  29, 31   60,NA reverse -0.7600000000 -1.290000000 -2.400000e-01,  0.1000000,  0.3100000,NA,NA,NA NA NA,NA,100 100,100   0 100 100,100,some high,low some,some Active (any credible active intervention),100,NA,NA NA DSM-5/ICD-10,3 0,1.0 0.5,1.0 0.0,1 0 5,1 1 0 1,0.5,0 0,0,0,  25 Yang_2012,2-6 months NA NA 10.3 16,NA,NA  19, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA NA,Ding (2018)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ding (2018) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 962 Ding (2018),Ding,2018,10.1142/S2575900018400013 100,  0 100 100 Critically low,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),100,atomoxetine Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),Questionnaire,ADHD Severity Ratings + Symptom Inventory Scale of ADHD + Conners parents symptom questionnaire, 1.84119678    0.8333333 h/wk Xu,2015,NA RCT (parallel, crossover, open-label),SMD, 31, 30,  61 NA,reverse,-0.6100000000 -1.130000000 -1.000000e-01,  4.5800000,  5.7800000,NA,NA NA NA NA NA 100,100 100,  0,100,100 100,some,high,some,some,some Active (any credible active intervention),100 NA,10.300000,NA,DSM-5/ICD-10,3 0,1.0 0.5,1.0,0.0,1 0 5 1 1,0 1,0.5,0 0 0,0,  26 Xu_2015,< 2 months,NA 6-12 yo 10.3 16 NA,NA  19, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15 NA,NA,Ding (2018)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Ding (2018) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3419,Storebo (2019),Storebo 2019,10.1002/14651858.CD008223.pub3,100   0 100,100,High,Social skill training Social skill training,  0 NA,Social-communication skills Mixed At study endpoint (closest to 12 weeks) Mixed (different types of tool are used) Conners Behavior Rating Scale: Social Problems Index + Strength and Difficulties Questionnaire: Prosocial Behaviour Subscale (teacher-rated) + Social Skills Improvement System + Social Skills Rating Scale: Coorperation Subscale,NA,NA NA Pfiffner 1997 NA,RCT SMD   9,  9   18 outcomes NA  0.4000000000,-0.540000000  1.330000e+00  13.5000000  13.3000000 NA,NA,NA,NA,NA NA,  0   0,100   0 100   0,  0,some high,low high high WLC (wait-list control),  0  30.000000, 9.000000 NA,DSM-III-R 0,1,1.0,1.0 1.0,1.0 1 1,0 1 1 1 1,1.0 1 1 1,1   27 Pfiffner_1997 NA,NA,6-12 yo 9,11.2,94.35,100,  5  3,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance  1,Storebo (2019),9,11.2,94.3418181818182 100 Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2019) - Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
3419 Storebo (2019) Storebo,2019 10.1002/14651858.CD008223.pub3 100 100 100 100,High,Social skill training Social skill training   0,NA,Social-communication skills Mixed,At study endpoint (closest to 12 weeks) Mixed (different types of tool are used),Conners Behavior Rating Scale: Social Problems Index + Strength and Difficulties Questionnaire: Prosocial Behaviour Subscale (teacher-rated) + Social Skills Improvement System + Social Skills Rating Scale: Coorperation Subscale, 1.84119678,NA NA Storebo 2012,NA RCT SMD, 27, 27,  54 NA,NA, 0.1600000000 -0.370000000, 7.000000e-01,  5.7000000,  5.9000000 NA,NA,NA,NA NA NA 100,100 100   0 100 100,100,low,high,low,low low,TAU   0, 29.000000 10.400000, 94.35000 DSM-IV 0,1,1.0,1.0,1.0,1.0,1,1,0 1,1,1,1 1.0,1,1,1 1   28 Storebo_2012 < 2 months,Average (80-119) 6-12 yo 9,11.2 94.35,100   5, 3,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance  1,Storebo (2019) 9,11.2 94.3418181818182,100,Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2019) - Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3419 Storebo (2019) Storebo,2019,10.1002/14651858.CD008223.pub3,100   0 100 100 High,Social skill training Social skill training,  0,NA,Social-communication skills Mixed,At follow-up (closest to 26 weeks) Mixed (different types of tool are used),Conners Behavior Rating Scale: Social Problems Index + Strength and Difficulties Questionnaire: Prosocial Behaviour Subscale (teacher-rated) + Social Skills Improvement System + Social Skills Rating Scale: Coorperation Subscale NA NA,NA,Pfiffner,1997 NA,RCT,SMD   9,  9   18,outcomes,NA  0.0600000000 -0.860000000  9.800000e-01, 14.2000000,  1.1000000,NA,NA NA,NA,NA,NA,  0,  0 100,  0 100,  0   0,some,high,low high,high WLC (wait-list control)   0  30.000000, 9.000000,NA,DSM-III-R,0 1,1.0,1.0 1.0 1.0,1 1 0,1 1 1,1,1.0,1,1 1 1,  29,Pfiffner_1997,NA,NA 6-12 yo 9 10.4036363636364 94.3418181818182 94.3418181818182   5, 3 Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance  1,Storebo (2019) 9 11.2 94.3418181818182 100,Storebo (2019)_Social skill training_Social-communication skills_Mixed_At follow-up (closest to 26 weeks),1 Homogeneous,Storebo (2019) - Social skill training_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no high high
3419 Storebo (2019) Storebo,2019,10.1002/14651858.CD008223.pub3 100,100 100 100,High Social skill training Social skill training,  0 NA,Social-communication skills,Mixed At follow-up (closest to 26 weeks) Mixed (different types of tool are used),Conners Behavior Rating Scale: Social Problems Index + Strength and Difficulties Questionnaire: Prosocial Behaviour Subscale (teacher-rated) + Social Skills Improvement System + Social Skills Rating Scale: Coorperation Subscale, 1.84119678 NA NA,Storebo,2012,NA,RCT,SMD  28, 27   55 NA,NA, 0.1500000000,-0.380000000  6.800000e-01   6.0000000,  6.8000000,NA,NA NA,NA,NA,NA 100,100,100   0,100,100 100,low,high low low low,TAU   0  29.000000 10.403636  94.34182,DSM-IV 0 1 1.0,1.0,1.0,1.0,1 1,0 1 1,1 1 1.0 1 1 1 1   30 Storebo_2012 < 2 months,Average (80-119),6-12 yo,9 10.4036363636364,94.3418181818182 94.3418181818182,  5  3 Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance  1,Storebo (2019) 9,11.2 94.3418181818182 100,Storebo (2019)_Social skill training_Social-communication skills_Mixed_At follow-up (closest to 26 weeks) 1 Homogeneous Storebo (2019) - Social skill training_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low,low
3419,Storebo (2019),Storebo 2019,10.1002/14651858.CD008223.pub3 100 100,100,100 High Social skill training Social skill training   0 NA,Social-communication skills,Mixed At study endpoint (closest to 12 weeks),Mixed (different types of tool are used),Social Skills Rating Scale + Weiss Functional Impairment Scale: Social Acitivities Domain (parent-rated) + Strength and Difficulties Questionnaire: Prosocial Behavior Subscale + Social Skills Improvement System, 1.84119678,NA,NA,Antshel 2003,NA,RCT,SMD, 80, 40, 120,outcomes,NA  0.2300000000,-0.150000000, 6.100000e-01, 11.8000000, 10.6000000 NA NA,NA,NA NA,NA   0   0,100,  0 100,100   0,low,high,low,high low WLC (wait-list control)   0  25.000000 10.000000,100.00000,DSM-IV (DICA-R-P),0,1 1.0 1.0 1.0 1.0,1 1 0 1 1,1,1 1.0,1 1,1,1   31 Antshel_2003,< 2 months,Average (80-119),6-12 yo,9,11.2,94.35,100   5  3 Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance  1,Storebo (2019),9 11.2 94.3418181818182 100,Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2019) - Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
3419 Storebo (2019) Storebo,2019,10.1002/14651858.CD008223.pub3 100 100 100,100 High,Social skill training Social skill training   0 NA,Social-communication skills Mixed At study endpoint (closest to 12 weeks) Mixed (different types of tool are used) Social Skills Rating Scale + Weiss Functional Impairment Scale: Social Acitivities Domain (parent-rated) + Strength and Difficulties Questionnaire: Prosocial Behavior Subscale + Social Skills Improvement System, 1.15074799,NA,NA Hannesdottir,2017 NA,RCT,SMD  15  14,  29,NA NA, 0.1400000000 -0.590000000  8.700000e-01  12.1000000   8.1000000 NA,NA NA,NA,NA,NA   0   0,100   0,100,100   0,some,high,low,high low,WLC (wait-list control),  0, 29.000000, 9.200000 100.00000,diagnosed by a licensed clinical psychologist or medical doctor,0,1,1.0,1.0 1.0,1.0,1,1,0 1 1 1 1 1.0,1 1 1,1,  32 Hannesdottir_2017 < 2 months Average (80-119) 6-12 yo,9,11.2 94.35 100   5, 3,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance  1 Storebo (2019),9,11.2,94.3418181818182 100 Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2019) - Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
3419,Storebo (2019),Storebo,2019 10.1002/14651858.CD008223.pub3,100   0,100,100 High Social skill training Social skill training   0 NA Social-communication skills Mixed At study endpoint (closest to 12 weeks) Mixed (different types of tool are used) Social Skills Rating Scale + Weiss Functional Impairment Scale: Social Acitivities Domain (parent-rated) + Strength and Difficulties Questionnaire: Prosocial Behavior Subscale + Social Skills Improvement System,NA NA,NA,Pfiffner 1997,NA,RCT SMD   9,  9   18 outcomes NA  1.3200000000, 0.270000000  2.360000e+00, 12.8000000,  6.4000000,NA NA,NA,NA,NA,NA   0,  0,100,  0,100   0   0,some high,low,high,high,WLC (wait-list control)   0  30.000000  9.000000,NA,DSM-III-R,0 1,1.0 1.0 1.0,1.0,1 1,0,1 1,1 1,1.0 1,1 1 1   33 Pfiffner_1997,NA,NA 6-12 yo,9 11.2 94.35,100   5, 3,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance, 1,Storebo (2019),9 11.2 94.3418181818182,100 Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2019) - Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high high
3419,Storebo (2019) Storebo 2019 10.1002/14651858.CD008223.pub3,100,100 100 100 High Social skill training Social skill training,  0 NA Social-communication skills,Mixed,At study endpoint (closest to 12 weeks) Questionnaire Social Skills Rating Scale (SSRS) + Strengths and Difficulties Questionnaire (SDQ): Prosocial Behavior Subscale  1.84119678 NA,NA,Antshel,2003 NA RCT SMD  80, 40, 120 outcomes NA, 0.1600000000 -0.220000000  5.400000e-01   9.1000000  10.2000000,NA NA NA NA NA,NA   0   0 100   0,100,100   0 low,high,low high low WLC (wait-list control),  0  25.000000 10.000000,100.00000 DSM-IV (DICA-R-P) 0,1 1.0,1.0,1.0,1.0 1,1,0,1,1,1,1,1.0,1 1 1 1,  34 Antshel_2003 < 2 months Average (80-119),6-12 yo,9,11.2 94.35,100   5  3,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance, 1 Storebo (2019) 9,11.2,94.3418181818182 100,Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2019) - Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
3419,Storebo (2019) Storebo,2019 10.1002/14651858.CD008223.pub3 100 100 100,100 High Social skill training Social skill training   0,NA,Social-communication skills,Mixed,At study endpoint (closest to 12 weeks) Questionnaire Social Skills Rating Scale (SSRS) + Strengths and Difficulties Questionnaire (SDQ): Prosocial Behavior Subscale, 3.68239356,NA,NA,Choib,2015,NA,RCT,SMD, 25  24   49 NA NA, 0.3300000000 -0.230000000  8.900000e-01,  5.0000000   8.2000000,NA,NA NA,NA,NA NA,  0,  0,100   0 100,100,  0 some high,some,high some,WLC (wait-list control)   0  56.000000,11.200000,100.00000 DSM-IV,0,1,1.0 1.0,1.0,1.0,1 1,0,1 1,1 1 1.0 1 1,1 1   35 Choib_2015 2-6 months Average (80-119),6-12 yo,9,11.2,94.35 100   5, 3,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance, 1,Storebo (2019) 9 11.2 94.3418181818182 100 Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2019) - Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
3419,Storebo (2019),Storebo 2019,10.1002/14651858.CD008223.pub3,100,100,100,100,High,Social skill training,Social skill training,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),Mixed (different types of tool are used),Disruptive Behavior Disorders Rating Scale + ADHD Rating Scales: Hyperactivity and Impulsivity Subscales (total scores) + Conner Teacher Rating Scale: Hyperactivity Index + Strengths and Weaknesses of ADHD Symptoms and Normal Behaviors + ADHD Symptom Checklist + Child Symptom Inventory (ADHD (inattention) scale score) + SNAP-IV (teacher rating scale), 1.15074799 NA,NA Hannesdottir,2017,NA RCT SMD, 15  14   29,NA,reverse,-1.3500000000 -2.170000000,-5.400000e-01   7.4000000   6.6000000,NA NA,NA NA NA NA   0   0,100   0 100,100   0,some high low high low WLC (wait-list control),  0, 29.000000  9.200000,100.00000 diagnosed by a licensed clinical psychologist or medical doctor 0,1,1.0,1.0,1.0 1.0,1,1 0,1,1 1,1 1.0 1 1 1,1,  36 Hannesdottir_2017,< 2 months Average (80-119),6-12 yo,9.2,10.4,94.35 100,  5  3,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance  1 Storebo (2019) 9 11.2,94.3418181818182 100,Storebo (2019)_Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2019) - Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
3419,Storebo (2019),Storebo 2019,10.1002/14651858.CD008223.pub3,100 100 100,100,High,Social skill training Social skill training,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks) Mixed (different types of tool are used) Disruptive Behavior Disorders Rating Scale + ADHD Rating Scales: Hyperactivity and Impulsivity Subscales (total scores) + Conner Teacher Rating Scale: Hyperactivity Index + Strengths and Weaknesses of ADHD Symptoms and Normal Behaviors + ADHD Symptom Checklist + Child Symptom Inventory (ADHD (inattention) scale score) + SNAP-IV (teacher rating scale)  1.84119678 NA NA,Storebo,2012 NA,RCT SMD  27  27   54 NA,reverse  0.1800000000,-0.360000000, 7.100000e-01, 11.5000000, 13.2000000 NA,NA,NA NA NA,NA 100,100,100   0 100,100 100 low,high,low,low low TAU,  0, 29.000000,10.400000, 94.35000,DSM-IV 0 1,1.0 1.0 1.0,1.0 1 1,0 1,1 1 1 1.0 1 1,1,1   37 Storebo_2012,< 2 months,Average (80-119),6-12 yo 9.2,10.4,94.35,100,  5  3 Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance, 1,Storebo (2019) 9 11.2,94.3418181818182 100 Storebo (2019)_Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2019) - Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3419 Storebo (2019),Storebo 2019 10.1002/14651858.CD008223.pub3,100 100,100,100 High Social skill training Social skill training   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At follow-up (closest to 26 weeks),Mixed (different types of tool are used),Disruptive Behavior Disorders Rating Scale + ADHD Rating Scales: Hyperactivity and Impulsivity Subscales (total scores) + Conner Teacher Rating Scale: Hyperactivity Index + Strengths and Weaknesses of ADHD Symptoms and Normal Behaviors + ADHD Symptom Checklist + Child Symptom Inventory (ADHD (inattention) scale score) + SNAP-IV (teacher rating scale)  1.84119678,NA NA,Storebo,2012 NA RCT,SMD, 28, 27   55,NA,reverse, 0.1700000000 -0.360000000, 7.000000e-01,  9.6000000  11.9000000,NA NA NA NA NA NA,100 100,100,  0,100 100,100,low,high,low,low,low TAU   0  29.000000,10.403636, 94.34182,DSM-IV 0 1 1.0 1.0,1.0 1.0,1 1,0,1,1 1 1,1.0,1,1 1 1   38,Storebo_2012,< 2 months,Average (80-119),6-12 yo,10.4036363636364 10.4036363636364,94.3418181818182,94.3418181818182   5, 3,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance  1,Storebo (2019) 9 11.2 94.3418181818182 100,Storebo (2019)_Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Storebo (2019) - Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no low,low
3419,Storebo (2019),Storebo,2019,10.1002/14651858.CD008223.pub3,100 100,100 100 High,Social skill training,Social skill training   0,NA,Academic/job performance Teacher-rated At study endpoint (closest to 12 weeks) Mixed (different types of tool are used) Classroom Performance Survey (CPS) + Conners Behavior Rating Scale (CBRS): Academic Performance Index + Social Skills Improvement System (SSIS): Academic Competence Scale + Academic Performance Rating Scale (APRS) + Wechsler Individual Achievement Test (WIAT) + German teacher-rated questionnaire for learning and working behavior (Arbeitsverhalten Lehrer), 1.84119678,NA NA,Storebo,2012,NA,RCT SMD, 24  26,  50 NA,NA  0.1700000000 -0.380000000, 7.300000e-01  15.2000000, 10.1000000 NA,NA NA,NA,NA,NA,100 100 100   0,100 100,100,low high,low,low,low,TAU,  0  29.000000 10.392000, 94.36800 DSM-IV 0,1 1.0,1.0,1.0,1.0 1,1 0 1 1,1 1,1.0,1 1,1 1   39 Storebo_2012,< 2 months,Average (80-119) 6-12 yo 10.392,10.392,94.368,94.368   5, 3 Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance, 1 Storebo (2019) 9,11.2 94.3418181818182,100,Storebo (2019)_Social skill training_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2019) - Social skill training_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3419,Storebo (2019) Storebo,2019,10.1002/14651858.CD008223.pub3,100,100,100,100 High Social skill training Social skill training   0 NA,Academic/job performance,Teacher-rated,At follow-up (closest to 26 weeks) Mixed (different types of tool are used),Classroom Performance Survey (CPS) + Conners Behavior Rating Scale (CBRS): Academic Performance Index + Social Skills Improvement System (SSIS): Academic Competence Scale + Academic Performance Rating Scale (APRS) + Wechsler Individual Achievement Test (WIAT) + German teacher-rated questionnaire for learning and working behavior (Arbeitsverhalten Lehrer)  1.84119678 NA,NA Storebo,2012 NA,RCT SMD  26  27,  53 NA NA,-0.0400000000,-0.580000000, 5.000000e-01  12.0000000  12.6000000,NA,NA NA,NA NA,NA 100 100,100   0,100,100,100,low,high low low,low,TAU,  0  29.000000 10.396226  94.35849 DSM-IV,0,1 1.0,1.0 1.0 1.0,1,1 0 1,1 1 1,1.0,1,1,1,1,  40,Storebo_2012 < 2 months,Average (80-119) 6-12 yo 10.3962264150943,10.3962264150943 94.3584905660377 94.3584905660377   5  3 Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance  1 Storebo (2019) 9 11.2 94.3418181818182 100 Storebo (2019)_Social skill training_Academic/job performance_Teacher-rated_At follow-up (closest to 26 weeks),1 Homogeneous Storebo (2019) - Social skill training_Academic/job performance_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low low
2646,Otasowie (2014),Otasowie,2014 10.1002/14651858.CD006997.pub2,100   0 100 100,High,Desipramine NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,Conners ADHD Rating Scale, 1.38089758,   9.2000000,mg/kg/d,Biederman,1989,NA RCT (parallel, crossover, open-label) G  31  27,  58 NA reverse -1.1800000000 -1.740000000 -6.100000e-01, 25.1000000  26.5000000 NA NA,NA,NA,NA NA,100,100 100 100 100,100 100,some low low,low low Placebo,  0   6.450000 11.500000 NA,DSM-III,0 1 1.0 1.0,1.0,1.0,1 1 0 1,1 1,1,1.0,1 1,1 1   41 Biederman_1989 < 2 months,NA,6-12 yo,11 11.5 NA NA,  4, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2 Otasowie (2014) | Catala-Lopez (2017),11 11.5 NA NA,Otasowie (2014)_Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Otasowie (2014) - Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
2646 Otasowie (2014) Otasowie,2014,10.1002/14651858.CD006997.pub2,100   0,100 100 High,Desipramine NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) Questionnaire Conners ADHD Rating Scale  1.38089758    3.5000000 mg/kg/d Spencer 2002,NA,RCT (parallel, crossover, open-label) G, 21  20,  41 NA,reverse -1.7700000000,-2.500000000,-1.030000e+00, 12.0000000   7.3000000,NA,NA NA NA NA,NA,100 100,100,100 100,100 100,low,low,low,low,low,Placebo,  0  17.070000,11.000000 NA DSM-IV 0 1 1.0 1.0,1.0 1.0,1 1 0,1 1 1 1 1.0 1 1 1 1,  42,Spencer_2002 < 2 months,NA 6-12 yo,11,11.5 NA,NA   4, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Otasowie (2014) | Catala-Lopez (2017),11 11.5 NA,NA Otasowie (2014)_Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Otasowie (2014) - Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
2646 Otasowie (2014) Otasowie,2014 10.1002/14651858.CD006997.pub2,100   0 100,100,High,Desipramine,NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),Questionnaire Conners ADHD Rating Scale  1.38089758,   9.2000000,mg/kg/d Biederman,1989,NA RCT (parallel, crossover, open-label),G  31  27   58 NA,reverse,-0.6800000000 -1.210000000,-1.500000e-01, 27.3000000, 41.6000000 NA NA NA NA NA,NA 100 100 100,100,100,100,100,some,low,low low,low Placebo   0   6.450000 11.500000 NA,DSM-III,0,1,1.0 1.0,1.0,1.0,1 1,0 1,1,1,1 1.0 1 1,1 1,  43,Biederman_1989 < 2 months,NA 6-12 yo,11.5 11.5 NA NA,  4, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2,Otasowie (2014) | Catala-Lopez (2017),11,11.5 NA,NA Otasowie (2014)_Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Otasowie (2014) - Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
2646 Otasowie (2014) Otasowie 2014 10.1002/14651858.CD006997.pub2   0   0 100,100 High,Desipramine NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),Questionnaire Conners ADHD Rating Scale  0.46029919    3.4000000 mg/kg/d,Donnelly,1986 NA RCT (parallel, crossover, open-label) G, 19, 12   31,NA,reverse,-1.4000000000,-2.210000000 -5.800000e-01,  2.6000000   3.8000000 NA NA,NA,NA,NA,NA 100,100,100 100 100,100 100 some low,low low low,Placebo,  0   0.000000,NA,NA,DSM-III 0,1 1.0,1.0 1.0 1.0 1 1 0,1,1,1,1,1.0 1 1 1 1,  44 Donnelly_1986 < 2 months,NA NA 11.5,11.5,NA,NA,  4  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Otasowie (2014) | Catala-Lopez (2017),11,11.5 NA NA Otasowie (2014)_Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Otasowie (2014) - Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3090 Ruggiero (2014) Ruggiero,2014 10.1016/j.euroneuro.2014.08.001 100,  0 100 100 Critically low,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Mixed (different types of tool are used) NA, 1.84119678    3.0000000 mg/d Biederman 2008,NA RCT (parallel, crossover, open-label) RR,259, 86, 345 NA,NA, 9.1866151866  2.980279744, 2.831744e+01 NA NA NA NA NA,NA,NA NA,100 100,100 100 100 100 100 some,low low,low low,Placebo,  0 NA 10.500000,NA DSM-IV-TR 4 0,0.5 0.5 1.0,0.0,0,0 3 1 1 1 0,0.5 1,0,0,1   45 Biederman_2008,< 2 months,NA 6-12 yo,9.1 14.5 NA NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA,NA Ruggiero (2014)_Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ruggiero (2014) - Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
3090 Ruggiero (2014) Ruggiero,2014 10.1016/j.euroneuro.2014.08.001 100,  0,100,100 Critically low Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Mixed (different types of tool are used) NA  2.07134638,   2.5000000 mg/d,Sallee,2009,NA,RCT (parallel, crossover, open-label) RR,256, 66, 322 NA,NA, 2.2236328125, 1.126326403, 4.389973e+00 NA NA NA,NA,NA,NA NA,NA,100 100 100,100 100,100,100 some low low,low,low,Placebo   0 NA,11.000000,NA,DSM-IV-TR,4,0 0.5 0.5,1.0,0.0,0 0,3,1,1,1,0,0.5 1 0 0,1,  46,Sallee_2009 2-6 months NA 6-12 yo,9.1 14.5 NA,NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA NA Ruggiero (2014)_Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ruggiero (2014) - Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3090 Ruggiero (2014),Ruggiero 2014 10.1016/j.euroneuro.2014.08.001 100,  0 100 100 Critically low,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Mixed (different types of tool are used) NA  2.07134638    3.0000000 mg/d Connor,2010,NA RCT (parallel, crossover, open-label),RR,136, 78  214,NA,NA, 9.8933823529, 3.754976542  2.606648e+01 NA NA,NA,NA,NA NA NA,NA,100,100 100 100,100 100,100,some,low some,low,some Placebo   0,NA, 9.400000 NA DSM-IV-TR,4 0 0.5 0.5,1.0 0.0,0 0 3 1 1,1,0 0.5 1 0 0,1   47,Connor_2010 2-6 months NA,6-12 yo 9.1,14.5 NA,NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA NA Ruggiero (2014)_Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ruggiero (2014) - Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
3090,Ruggiero (2014) Ruggiero 2014,10.1016/j.euroneuro.2014.08.001,100   0,100 100,Critically low,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0,NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Mixed (different types of tool are used) NA  1.38089758    2.5000000 mg/d Kollins,2011,NA RCT (parallel, crossover, open-label) RR 121  57, 178 NA NA, 1.8118245391  1.074294233, 3.055688e+00,NA NA NA,NA NA NA NA,NA 100,100 100,100 100 100,100 some,low,low low some,Placebo   0,NA 12.600000,NA DSM-IV-TR,4,0 0.5,0.5 1.0,0.0 0 0 3 1 1 1 0 0.5 1 0 0 1,  48,Kollins_2011 < 2 months,NA,6-12 yo,9.1 14.5 NA,NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA,NA Ruggiero (2014)_Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ruggiero (2014) - Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3090 Ruggiero (2014) Ruggiero 2014,10.1016/j.euroneuro.2014.08.001,100,  0,100 100,Critically low,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0 NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Mixed (different types of tool are used) NA, 1.84119678,   2.5000000,mg/d Newcorn,2013,NA,RCT (parallel, crossover, open-label) RR,221 112  333 NA NA  3.5475113122  2.126499627, 5.918100e+00,NA,NA,NA,NA NA,NA,NA NA 100,100 100 100 100 100 100,some low low,low,low Placebo,  0 NA  9.100000,NA,DSM-IV-TR 4 0 0.5 0.5 1.0,0.0 0 0 3 1,1 1 0,0.5,1,0 0,1,  49,Newcorn_2013,< 2 months,NA,6-12 yo,9.1 14.5,NA NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA NA,Ruggiero (2014)_Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ruggiero (2014) - Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3090,Ruggiero (2014) Ruggiero 2014 10.1016/j.euroneuro.2014.08.001 100   0,100,100 Critically low Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Mixed (different types of tool are used),NA, 2.99194476    4.0000000,mg/d NCT01081132,2014 NA RCT (parallel, crossover, open-label) RR 157 155  312 NA NA  2.0642733063, 1.453984361, 2.930722e+00,NA NA,NA NA NA,NA NA,NA,  0   0,  0,  0   0,  0   0,high,high,high,high,high,Placebo   0,NA,14.500000,NA,DSM-IV-TR,4 0,0.5 0.5,1.0,0.0,0,0 3 1,1,1 0 0.5 1 0 0,1,  50,NCT01081132_2014,2-6 months,NA 13-19 yo 9.1,14.5,NA NA, 20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA,NA Ruggiero (2014)_Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ruggiero (2014) - Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
8992,Fahrat (2024) Fahrat,2024,10.1089/cap.2024.0049 100   0,100 100 High,Alpha-2 agonists (guanfacine / clonidine),NA,  0,NA Tics/Tourette disorder symptoms,Mixed At study endpoint (closest to 12 weeks),Questionnaire The Yale Global Tic Severity Scale  1.84119678    1.5000000,mg/d Scahill 2001 NA RCT (parallel, crossover, open-label) SMD  17  17,  34,NA,reverse -0.7500000000 -1.470000000 -3.000000e-02 NA NA NA,NA,NA NA NA,NA 100 100 100,100,100,100,100 low low some low low,Placebo   0,  8.800000,10.400000 NA,DSM-IV 0 1,1.0 1.0 1.0,1.0 1,1,1 1,1 1,1 1.0 1 1 0 1   51 Scahill_2001,< 2 months,NA 6-12 yo 9.07 10.6 NA,NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA,NA Fahrat (2024)_Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Fahrat (2024) - Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
8992,Fahrat (2024),Fahrat 2024 10.1089/cap.2024.0049 100   0,100 100 High Alpha-2 agonists (guanfacine / clonidine),NA   0 NA Tics/Tourette disorder symptoms Mixed At study endpoint (closest to 12 weeks) Questionnaire,The Yale Global Tic Severity Scale, 1.38089758    0.1900000 mg/d Singer,1995,NA RCT (parallel, crossover, open-label) SMD  34, 34   68 NA,reverse,-0.6900000000 -1.180000000 -2.000000e-01,NA,NA NA,NA,NA,NA NA NA 100 100,100 100,100 100 100,some low low low some Placebo,  0   8.800000 10.600000 NA DSM-III-R,0,1,1.0 1.0 1.0 1.0,1,1 1,1,1 1 1 1.0,1,1 0,1   52,Singer_1995,< 2 months NA,6-12 yo,9.07,10.6,NA NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA,NA Fahrat (2024)_Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Fahrat (2024) - Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
8992,Fahrat (2024),Fahrat 2024 10.1089/cap.2024.0049 100   0 100 100 High Alpha-2 agonists (guanfacine / clonidine),NA   0 NA,Tics/Tourette disorder symptoms Mixed,At study endpoint (closest to 12 weeks),Questionnaire,The Yale Global Tic Severity Scale, 3.68239356    0.2500000 mg/d,TSSG,2002 NA,RCT (parallel, crossover, open-label),SMD,NA, 32,NA,NA reverse,-0.6900000000 -1.180000000 -2.000000e-01 NA NA,NA NA,NA NA NA,NA,100,100 100,100 100 100 100 low low some low,low,Placebo   0, 14.600000,10.200000,NA DSM-IV 0,1 1.0,1.0,1.0,1.0,1 1 1 1 1 1 1 1.0,1,1,0 1   53,TSSG_2002 2-6 months,NA 6-12 yo 9.07 10.6 NA,NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA,NA Fahrat (2024)_Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Fahrat (2024) - Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
8992 Fahrat (2024),Fahrat,2024,10.1089/cap.2024.0049 100   0 100,100 High Alpha-2 agonists (guanfacine / clonidine) NA,  0,NA,Tics/Tourette disorder symptoms Mixed,At study endpoint (closest to 12 weeks),Questionnaire,VAS (ADHD symptoms and TICS), 1.84119678    1.5000000 mg/d,Chen 2024,NA,RCT (parallel, crossover, open-label),SMD, 98  29  127,NA reverse,-0.9300000000 -1.360000000,-5.000000e-01 NA,NA NA NA NA,NA,NA NA 100 100,100,100 100,100,100 low low some low low Placebo   0,  9.400000  9.070000,NA,DSM-IV,0,1 1.0 1.0,1.0 1.0,1 1,1,1 1 1,1,1.0,1 1,0,1   54 Chen_2024,< 2 months NA,6-12 yo 9.07,10.6 NA,NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA NA,Fahrat (2024)_Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Fahrat (2024) - Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
1110,Faraone (2002),Faraone,2002,10.1177/108705470200600203 100   0,100 100 Critically low,Amphetamine Adderall,  0 NA,Disruptive behaviors,Mixed,At study endpoint (closest to 12 weeks),Questionnaire,Iowa Conners Rating Scale,NA,NA,mg Pelham, Aronoff,1999 NA RCT (crossover),G, 25  25   50,outcomes NA, 1.1300000000  0.530000000  1.730000e+00 NA,NA,NA,NA NA NA NA,NA   0,  0   0,  0,  0,  0   0 high,high,high,high high Placebo   0 NA  9.500000 NA,NA,6,0 0.0 0.0,0.0,0.0,0 1,6 1,1 0 0,0.5 0 0 0 0,  55,Pelham, Aronoff_1999 NA NA,6-12 yo 8 9.5 NA,NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA NA Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Faraone (2002) - Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high,high
1110,Faraone (2002),Faraone 2002,10.1177/108705470200600203 100,  0,100,100,Critically low,Amphetamine,Adderall   0,NA Disruptive behaviors,Mixed At study endpoint (closest to 12 weeks),Questionnaire,Iowa Conners Rating Scale NA,NA mg,Pelham, Aronoff,1999 NA,RCT (crossover),G, 25  25,  50,outcomes,NA  1.5100000000  0.880000000  2.140000e+00,NA NA,NA,NA NA NA NA,NA,  0   0   0,  0   0   0,  0,high,high high,high,high,Placebo   0,NA  9.500000 NA,NA 6 0,0.0 0.0,0.0 0.0,0 1 6,1 1 0 0 0.5,0,0 0 0   56,Pelham, Aronoff_1999,NA,NA 6-12 yo 8,9.5 NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA NA Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Faraone (2002) - Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high,high
1110,Faraone (2002),Faraone 2002 10.1177/108705470200600203 100,  0,100 100,Critically low Amphetamine,Adderall,  0 NA,Disruptive behaviors,Mixed,At study endpoint (closest to 12 weeks),Questionnaire,Iowa Conners Rating Scale,NA NA,mg Pelham, Aronoff,1999,NA,RCT (crossover) G, 25  25   50,outcomes NA, 1.1800000000  0.570000000  1.780000e+00 NA,NA,NA,NA,NA NA NA NA   0   0   0,  0,  0   0,  0,high high high,high,high,Placebo   0 NA  9.500000,NA,NA,6,0,0.0 0.0 0.0 0.0,0,1 6,1 1 0 0 0.5,0,0 0,0,  57,Pelham, Aronoff_1999,NA NA 6-12 yo,8,9.5 NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Faraone (2002) - Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high,high
1110 Faraone (2002),Faraone 2002 10.1177/108705470200600203,100,  0 100 100,Critically low,Amphetamine Adderall   0,NA Disruptive behaviors,Mixed At study endpoint (closest to 12 weeks) Questionnaire,Iowa Conners Rating Scale NA,   0.6000000,mg/kg/d Pelham, Gnagy 1999,NA RCT (crossover),G, 21  21   42,outcomes,NA, 1.0200000000, 0.380000000  1.670000e+00,NA,NA,NA NA,NA,NA,NA,NA,  0   0,  0   0,  0   0   0,high,high,high high,high,Placebo,  0,NA  9.500000,NA NA 6 0 0.0 0.0 0.0,0.0 0 1,6,1,1,0 0,0.5 0,0,0 0   58 Pelham, Gnagy_1999,NA NA,6-12 yo 8,9.5 NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Faraone (2002) - Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high,high
1110,Faraone (2002),Faraone 2002 10.1177/108705470200600203 100,  0,100,100,Critically low Amphetamine,Adderall,  0,NA,Disruptive behaviors,Mixed At study endpoint (closest to 12 weeks) Questionnaire Iowa Conners Rating Scale,NA    0.6000000 mg/kg/d,Pelham, Gnagy,1999,NA,RCT (crossover),G  21, 21,  42 outcomes NA  1.5200000000  0.830000000, 2.210000e+00,NA,NA,NA,NA,NA NA,NA NA   0,  0,  0   0,  0,  0   0,high high high,high high Placebo,  0,NA, 9.500000,NA,NA 6,0,0.0 0.0,0.0,0.0 0,1 6,1 1,0,0 0.5,0 0,0,0   59 Pelham, Gnagy_1999 NA,NA 6-12 yo 8,9.5,NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA,Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Faraone (2002) - Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high high
1110,Faraone (2002),Faraone,2002,10.1177/108705470200600203 100   0 100,100 Critically low Amphetamine,Adderall   0 NA,Disruptive behaviors Mixed,At study endpoint (closest to 12 weeks) Questionnaire Iowa Conners Rating Scale,NA    0.6000000,mg/kg/d,Pelham, Gnagy,1999 NA,RCT (crossover),G, 21, 21   42,outcomes,NA, 1.1000000000  0.450000000, 1.760000e+00,NA,NA NA NA NA,NA,NA NA,  0   0   0   0,  0,  0   0 high high,high,high high Placebo,  0 NA, 9.500000,NA NA,6,0,0.0,0.0,0.0 0.0,0,1 6 1,1 0 0 0.5 0 0,0,0,  60,Pelham, Gnagy_1999 NA NA 6-12 yo 8 9.5 NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA,Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Faraone (2002) - Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high,high
1110 Faraone (2002),Faraone 2002,10.1177/108705470200600203 100,  0,100 100 Critically low Amphetamine,Adderall   0 NA,Disruptive behaviors,Mixed At study endpoint (closest to 12 weeks),Questionnaire Iowa Conners Rating Scale  0.69044879,NA,NA,Pliszka,2000 NA RCT (parallel) G  20  18   38 NA,NA  0.6000000000,-0.050000000  1.260000e+00 NA NA,NA NA,NA NA,NA,NA,  0,  0   0   0,  0   0   0 high high high high high,Placebo   0 NA  8.000000,NA NA,6,0,0.0 0.0,0.0,0.0 0 1,6 1 1,0,0 0.5,0 0,0,0,  61,Pliszka_2000,< 2 months,NA 6-12 yo 8,9.5 NA NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA,Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Faraone (2002) - Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high high
2877,Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2,100   0,100,100,High,Amphetamine Mixed amphetamine salts (short acting),  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,ADHD Rating Scale, Fourth Version, 1.00000000   15.0000000,mg/d,Barkley 2000 NA,RCT (parallel, crossover, open-label),G, 31  31,  62,NA reverse,-0.1600000000,-0.660000000, 3.400000e-01   9.0000000  12.5000000 NA NA NA NA NA NA 100,100 100 100,  0,100,100 some some high,some some Placebo,  0  14.000000,14.000000,NA DSM-IV 0 1 1.0 1.0,1.0,1.0,1 1 0,1 1,1 1,1.0,1,1,1 1,  62 Barkley_2000,< 2 months,NA,13-19 yo 8.2,14,NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA,Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
2877 Punja (2016),Punja,2016,10.1002/14651858.CD009996.pub2,100   0 100,100,High,Amphetamine,Mixed amphetamine salts (long acting)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire Conners Global Index  0.69044879   20.0000000,mg/d Biederman 2002,NA,RCT (parallel, crossover, open-label),G,360 203, 563 NA reverse -0.3971889218,-0.570922486,-2.234554e-01, 10.7000000,  8.8000000,NA NA NA NA,NA,NA,100,100,100,100 100 100,100,some,some low,some,some,Placebo   0  23.000000, 8.600000 NA DSM-IV,0,1,1.0 1.0,1.0 1.0,1 1,0 1 1 1,1 1.0,1 1,1,1,  63 Biederman_2002,< 2 months,NA 6-12 yo 8.2,14,NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA,NA,Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
2877,Punja (2016) Punja 2016,10.1002/14651858.CD009996.pub2,100   0 100 100,High Amphetamine Lisdexamphetamine (long acting)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,ADHD Rating Scale, Fourth Version, and the Conners' Parent Rating Scale-Revised: Short Form  1.00000000,  50.0000000,mg/d,Biederman 2007b NA RCT (parallel, crossover, open-label) G 213  72  285,NA reverse -0.2900000000,-0.550000000,-2.000000e-02  59.8000000  34.8000000 NA,NA NA,NA,NA NA 100,100 100,100 100 100 100,some,low,low,some some Placebo   0  31.000000  9.000000 NA,DSM-IV-TR 0 1,1.0 1.0 1.0 1.0 1 1,0,1,1 1 1 1.0 1,1,1,1   64 Biederman_2007b < 2 months NA,6-12 yo,8.2 14 NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA,Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
2877 Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2 100   0 100 100 High Amphetamine,Lisdexampehtamine (long acting)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,Conners' Parent Rating Scale - Revised, 1.61104718,  50.0000000 mg/d Coghill 2013 NA,RCT (parallel, crossover, open-label) G, 98 103  201,NA,reverse,-1.1700000000,-1.470000000 -8.700000e-01, 17.6000000, 18.0000000 NA NA NA,NA NA NA   0,  0 100,100   0,  0,100,some,low high some,high,Placebo,  0  19.000000,10.900000,NA,DSM-IV-TR,0,1,1.0 1.0,1.0,1.0 1 1 0 1,1 1 1,1.0 1,1 1 1   65 Coghill_2013,< 2 months,NA,6-12 yo 8.2,14,NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high,high
2877 Punja (2016),Punja 2016 10.1002/14651858.CD009996.pub2,100,  0 100,100 High Amphetamine,Mixed amphetamine salts (short acting),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) Questionnaire Conners' Abbreviated Symptoms Questionnaire, 0.92059839,  10.0000000 mg/d,Manos,1999,NA,RCT (parallel, crossover, open-label),G  42  42,  84 NA,reverse,-0.7500000000 -1.200000000,-3.100000e-01   9.9000000  11.7000000,NA NA,NA NA,NA NA,100 100 100 100,100 100,100 some low some low,some Placebo,  0  21.000000,10.100000 NA DSM-IV,0,1,1.0 1.0 1.0 1.0 1,1 0,1,1 1 1,1.0 1,1,1 1,  66,Manos_1999,< 2 months NA,6-12 yo 8.2,14,NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA,Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
2877,Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2 100   0 100,100 High,Amphetamine,Dextroamphetamine (short acting)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire Conners' Parent Rating Scale  0.46029919   15.0000000,mg/d,Nemzer 1986,NA RCT (parallel, crossover, open-label) G, 14, 14,  28,NA reverse -0.6000000000 -1.360000000, 1.600000e-01,  6.4000000   6.2000000,NA NA,NA,NA,NA,NA,100,100,100 100,100,100 100 some low,some some some Placebo,  0, 21.000000, 9.360000 NA,DSM-III 0,1 1.0,1.0,1.0,1.0 1,1,0,1,1,1 1,1.0,1 1,1 1   67 Nemzer_1986,< 2 months NA 6-12 yo 8.2 14 NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA,Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
2877 Punja (2016),Punja 2016 10.1002/14651858.CD009996.pub2 100,  0,100 100,High Amphetamine,Mixed amphetamine salts (short acting),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,Conners' Parent Global Index  0.69044879   22.5000000,mg Pliszka 2000,NA,RCT (parallel, crossover, open-label),G  12, 12   24,NA,reverse,-0.6200000000,-1.450000000  2.000000e-01,  0.7000000,  0.9000000,NA,NA,NA NA NA NA,100 100,100 100,100,100 100 some,low,low,some some Placebo   0 NA  8.200000,NA,Diagnostic Interview Schedule for Children,0 1,1.0 1.0 1.0,1.0 1,1,0 1,1,1 1,1.0 1 1,1,1   68,Pliszka_2000,< 2 months,NA 6-12 yo,8.2,14,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
2877,Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2,100   0,100 100,High Amphetamine,Mixed amphetamine salts (short acting),  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks),Questionnaire,ADHD Rating Scale, Fourth Version  1.00000000   15.0000000 mg/d,Barkley 2000 NA RCT (parallel, crossover, open-label) G  15, 15,  30,NA reverse -0.0500000000,-0.770000000, 6.600000e-01, 14.7000000  13.8000000 NA,NA NA,NA,NA,NA,100,100 100 100   0 100,100 some,some,high,some some Placebo   0  14.000000,14.000000,NA DSM-IV,0 1 1.0 1.0 1.0 1.0,1 1 0,1 1 1,1,1.0 1 1,1 1,  69,Barkley_2000 < 2 months,NA 13-19 yo,8,14,NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
2877,Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2,100,  0 100 100,High,Amphetamine Mixed amphetamine salts (long acting)   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks),Questionnaire,Conners Global Index  0.69044879   20.0000000,mg/d Biederman,2002 NA,RCT (parallel, crossover, open-label),G 360,203, 563,NA,reverse,-0.3917394022,-0.565430566 -2.180482e-01  11.0000000   9.4000000 NA NA NA NA,NA,NA 100,100 100 100 100,100,100,some,some low,some,some,Placebo   0  23.000000, 8.600000,NA,DSM-IV,0 1,1.0,1.0,1.0 1.0 1,1,0 1 1 1,1 1.0,1 1 1,1,  70,Biederman_2002 < 2 months,NA,6-12 yo,8 14,NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
2877 Punja (2016),Punja,2016,10.1002/14651858.CD009996.pub2 100,  0 100 100 High,Amphetamine,Dextroamphetamine (short acting),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks),Questionnaire,Conners' Teacher Rating Scale, 2.00000000,NA,NA Donnelly,1989 NA RCT (parallel, crossover, open-label) G  20  20,  40,NA,reverse,-0.8800000000,-1.530000000 -2.200000e-01   3.1000000   3.8000000,NA NA,NA NA,NA,NA,100,100,100,100 100,100,100 some some low some some,Placebo   0,  0.000000, 8.000000,NA DSM-III 0,1,1.0,1.0 1.0 1.0,1 1 0 1,1,1 1 1.0,1,1 1,1,  71,Donnelly_1989,2-6 months NA 6-12 yo,8,14,NA,NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
2877 Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2 100   0 100 100,High,Amphetamine,Mixed amphetamine salts (short acting)   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks) Questionnaire,Conners' Abbreviated Symptoms Questionnaire - Teacher Version  0.92059839   10.0000000,mg/d,Manos,1999,NA,RCT (parallel, crossover, open-label) G  42, 42,  84 NA reverse,-0.8600000000 -1.310000000,-4.200000e-01  10.4000000, 13.6000000 NA,NA,NA,NA,NA,NA,100 100 100 100 100 100,100,some,low,some low some,Placebo,  0  21.000000 10.100000,NA DSM-IV,0,1,1.0,1.0,1.0 1.0 1 1 0 1,1,1,1 1.0,1,1,1,1,  72 Manos_1999 < 2 months NA,6-12 yo,8 14,NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
2877 Punja (2016),Punja,2016 10.1002/14651858.CD009996.pub2,100,  0,100 100,High,Amphetamine,Dextroamphetamine (short acting)   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks) Questionnaire,Conners' Teacher Rating Scale, 0.46029919,  15.0000000 mg/d Nemzer,1986 NA RCT (parallel, crossover, open-label),G  14, 14,  28 NA reverse -0.6900000000 -1.460000000  8.000000e-02  18.9000000, 18.6000000 NA NA NA NA NA,NA,100,100 100 100 100 100 100 some low some,some some,Placebo,  0, 21.000000, 9.360000 NA,DSM-III,0 1 1.0 1.0,1.0,1.0 1 1 0,1,1 1 1 1.0 1,1,1,1,  73 Nemzer_1986 < 2 months NA 6-12 yo,8 14 NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
2877,Punja (2016),Punja 2016 10.1002/14651858.CD009996.pub2 100   0,100,100 High Amphetamine Dextroamphetamine (short acting),  0 NA CGI Mixed,At study endpoint (closest to 12 weeks) Observational tool CGI  2.00000000,  55.0000000 mg/d,Borcherding,1990 NA,RCT (parallel, crossover, open-label),G  31, 31,  62,NA reverse,-0.5000000000 -1.010000000, 0.000000e+00   3.9000000,  3.9000000 NA NA,NA,NA,NA NA,100 100 100,100,  0 100,100 some some high,some some,Placebo   0,  0.000000  8.600000 NA DSM-III 0 1 1.0,1.0 1.0 1.0 1,1,0 1 1,1,1 1.0,1,1 1 1,  74,Borcherding_1990 2-6 months NA 6-12 yo,8.2 8.6,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA Punja (2016)_Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Punja (2016) - Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
2877 Punja (2016),Punja,2016,10.1002/14651858.CD009996.pub2,100   0 100 100 High,Amphetamine Mixed amphetamine salts (short acting),  0,NA,CGI,Mixed At study endpoint (closest to 12 weeks),Observational tool,CGI, 0.69044879,  22.5000000 mg,Pliszka,2000,NA RCT (parallel, crossover, open-label),G  12, 12,  24 NA reverse,-1.3900000000 -2.300000000 -4.800000e-01,  0.7000000,  1.4000000,NA NA,NA,NA NA NA 100,100 100 100,100 100 100 some,low,low,some,some,Placebo,  0 NA  8.200000,NA,Diagnostic Interview Schedule for Children 0,1 1.0,1.0,1.0,1.0,1,1,0,1,1 1,1,1.0,1,1 1,1   75 Pliszka_2000,< 2 months NA,6-12 yo 8.2 8.6,NA,NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA Punja (2016)_Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Punja (2016) - Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
2877 Punja (2016) Punja 2016,10.1002/14651858.CD009996.pub2 100   0 100 100 High,Amphetamine,Mixed amphetamine salts (long acting) or Lisdexamphetamine (long acting),  0,NA,Academic/job performance NA At study endpoint (closest to 12 weeks),Test,Permanent Product Measure of Performance scale  0.69044879   30.0000000,mg/d,Biederman 2007a,NA,RCT (parallel, crossover, open-label),G, 50  50, 100,NA,NA  0.5900000000  0.190000000, 9.900000e-01  76.0000000, 76.0000000,NA,NA NA NA,NA NA,100 100,100 100,100,100 100 some,some low some low Placebo,  0  36.000000  9.100000,NA DSM-IV-TR 0,1 1.0,1.0,1.0,1.0,1,1,0,1 1,1,1,1.0 1,1 1,1,  76,Biederman_2007a < 2 months,NA 6-12 yo 8.6,10.58,NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA,Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
2877,Punja (2016) Punja,2016 10.1002/14651858.CD009996.pub2,100,  0,100 100,High Amphetamine,Dextroamphetamine (short acting),  0,NA,Academic/job performance NA,At study endpoint (closest to 12 weeks),Test,Barnell LoT, Ltd, Developing Key Concepts in Math test, 2.00000000,  55.0000000 mg/d,Borcherding,1990,NA,RCT (parallel, crossover, open-label) G, 33, 33,  66,NA,NA  0.4700000000 -0.020000000  9.600000e-01,  4.6000000,  7.9000000 NA,NA NA,NA NA NA,100,100 100 100   0 100,100,some,some high,some,some Placebo   0   0.000000  8.600000,NA DSM-III 0 1 1.0 1.0,1.0 1.0 1 1 0 1 1,1,1,1.0,1,1 1 1,  77 Borcherding_1990 2-6 months,NA,6-12 yo,8.6,10.58,NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
2877 Punja (2016),Punja,2016 10.1002/14651858.CD009996.pub2 100,  0,100 100,High,Amphetamine,Mixed amphetamine salts (short acting),  0 NA,Academic/job performance NA At study endpoint (closest to 12 weeks) Test Permanent Product Measure of Performance  0.46029919   46.8000000,mg/d,Childress 2015 NA RCT (parallel, crossover, open-label) G  97  97  194,NA NA, 0.7500000000  0.460000000  1.040000e+00, 37.4000000, 35.8000000 NA NA,NA,NA NA,NA 100 100,100,100 100,100 100,some some low some,low Placebo   0, 39.200000, 9.600000,NA,DSM-IV-TR,0,1,1.0 1.0 1.0,1.0 1 1 0 1,1 1,1,1.0,1 1 1,1   78 Childress_2015 < 2 months NA 6-12 yo 8.6,10.58 NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA,Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
2877,Punja (2016) Punja,2016 10.1002/14651858.CD009996.pub2,100   0 100 100 High,Amphetamine Dextroamphetamine (short acting) or Dextroamphetamine spansules (long acting) or Mixed amphetamine salts (long acting)*,  0 NA Academic/job performance,NA,At study endpoint (closest to 12 weeks),Test,5-minute timed math task, 1.84119678,NA,NA James,2001 NA RCT (parallel, crossover, open-label),G, 35  35   70 NA NA  0.5600000000, 0.090000000  1.040000e+00, 52.7000000, 51.3000000 NA NA,NA,NA,NA,NA,100,100,100 100 100,100 100,some low,low some some Placebo,  0, 40.000000, 9.100000,NA,DSM-IV 0,1 1.0 1.0 1.0,1.0,1 1,0,1 1,1,1,1.0,1,1,1 1   79,James_2001 < 2 months,NA 6-12 yo 8.6,10.58,NA,NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA NA Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
2877,Punja (2016) Punja 2016,10.1002/14651858.CD009996.pub2,100,  0,100,100 High,Amphetamine Mixed amphetamine salts (short acting and long acting)   0,NA,Academic/job performance,NA At study endpoint (closest to 12 weeks),Test,Permanent Product Measure of Performance, 1.15074799,  20.0000000 mg/d McCracken 2003,NA,RCT (parallel, crossover, open-label),G, 49, 49,  98 NA,NA  0.2800000000 -0.120000000, 6.700000e-01, 52.0000000, 50.3000000,NA,NA NA NA,NA NA 100,100 100,100 100 100,100 some some,low,some some,Placebo,  0  14.000000  9.500000,NA,DSM-IV,0,1,1.0,1.0 1.0,1.0 1,1,0 1,1,1,1,1.0 1,1,1 1,  80 McCracken_2003 < 2 months,NA,6-12 yo,8.6,10.58,NA NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA NA Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
2877,Punja (2016),Punja,2016,10.1002/14651858.CD009996.pub2 100   0,100 100 High,Amphetamine Dextroamphetamine (short acting),  0 NA,Academic/job performance,NA,At study endpoint (closest to 12 weeks),Test,Wechsler Intelligence Scale for Children - Revised, 0.46029919,  15.0000000,mg/d Nemzer,1986,NA RCT (parallel, crossover, open-label),G  14, 14,  28,NA NA, 0.4600000000,-0.300000000  1.210000e+00  16.7000000  17.4000000,NA,NA NA NA NA NA 100 100 100 100,100 100,100,some low,some,some some,Placebo   0  21.000000, 9.360000 NA,DSM-III 0,1 1.0,1.0 1.0,1.0,1 1 0 1 1,1,1 1.0 1,1 1 1,  81,Nemzer_1986 < 2 months,NA 6-12 yo 8.6,10.58,NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA,Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
2877,Punja (2016) Punja 2016 10.1002/14651858.CD009996.pub2 100   0,100 100 High Amphetamine,Dextroamphetamine (short acting),  0 NA,Academic/job performance NA,At study endpoint (closest to 12 weeks),Test Wide Range Achievement Test - math subset  0.92059839 NA,NA,Shekim 1986,NA RCT (parallel, crossover, open-label),G, 22  22,  44 NA NA,-0.0100000000,-0.600000000  5.900000e-01,  9.5000000  11.7000000 NA NA,NA,NA NA,NA 100,100 100 100,  0 100 100 some some high some some Placebo   0   0.000000  9.750000 NA DSM-III 0,1 1.0,1.0,1.0 1.0 1 1 0 1,1,1 1 1.0,1 1 1 1   82 Shekim_1986,< 2 months,NA 6-12 yo,8.6 10.58 NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA NA Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
2877 Punja (2016) Punja 2016 10.1002/14651858.CD009996.pub2,100   0 100 100,High,Amphetamine Lisdexamphetamine (long acting)   0,NA,Academic/job performance,NA At study endpoint (closest to 12 weeks),Test,Permanent Product Measure of Performance, 0.46029919   50.0000000,mg/d Wigal 2009 NA,RCT (parallel, crossover, open-label) G 113 113, 226,NA NA, 0.7800000000, 0.510000000, 1.050000e+00  36.3000000  36.3000000,NA,NA,NA NA NA,NA 100,100 100,100,100 100,100 some,low,low some,some Placebo,  0  24.000000,10.580000,NA,DSM-IV-TR 0,1 1.0 1.0,1.0,1.0 1 1 0 1 1,1 1,1.0 1 1,1 1   83 Wigal_2009 < 2 months,NA 6-12 yo 8.6,10.58 NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA,Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
2877,Punja (2016),Punja 2016 10.1002/14651858.CD009996.pub2,100,  0 100 100,High Amphetamine,Mixed amphetamine salts (long acting)   0,NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Interview Adverse events, 0.69044879,  20.0000000 mg/d Biederman 2002,NA,RCT (parallel, crossover, open-label) RR,374 210, 584,NA reverse,11.5106951872  4.280245271  3.095526e+01 NA,NA NA NA,NA NA,NA NA,100,100 100 100 100,100,100,some some low some some,Placebo   0, 23.000000, 8.600000 NA DSM-IV 0,1,1.0,1.0,1.0,1.0 1 1 0 1,1,1 1,1.0,1 1,1 1   84,Biederman_2002,< 2 months,NA,6-12 yo 8.2 14.6,NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
2877,Punja (2016),Punja 2016 10.1002/14651858.CD009996.pub2,100,  0 100 100,High Amphetamine,Mixed amphetamine salts (long acting) or Lisdexamphetamine (long acting)   0 NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Interview,Adverse events  0.69044879   30.0000000,mg/d,Biederman,2007a,NA,RCT (parallel, crossover, open-label) RR, 52, 52  104 NA,reverse, 5.0000000000  0.245868146  1.016805e+02 NA NA,NA,NA NA NA NA NA,100,100,100 100 100,100,100,some,some low some low Placebo   0, 36.000000, 9.100000,NA DSM-IV-TR,0,1,1.0,1.0,1.0 1.0,1 1,0 1 1 1,1,1.0,1,1,1 1,  85 Biederman_2007a,< 2 months,NA,6-12 yo 8.2,14.6,NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
2877,Punja (2016) Punja 2016 10.1002/14651858.CD009996.pub2 100   0 100,100,High Amphetamine,Lisdexamphetamine (long acting)   0 NA Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Interview Adverse events  1.00000000,  50.0000000 mg/d Biederman 2007b NA RCT (parallel, crossover, open-label) RR 218  72, 290,NA,reverse  9.3577981651  3.052844863, 2.868419e+01 NA,NA,NA NA NA NA NA NA,100,100,100 100 100,100,100,some,low low some some,Placebo   0, 31.000000, 9.000000,NA,DSM-IV-TR 0,1 1.0,1.0 1.0,1.0 1,1,0 1 1,1,1 1.0 1 1,1,1   86,Biederman_2007b,< 2 months,NA,6-12 yo,8.2,14.6 NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA NA,Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
2877,Punja (2016),Punja 2016,10.1002/14651858.CD009996.pub2 100,  0 100 100,High Amphetamine Mixed amphetamine salts (short acting),  0,NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Interview Adverse events  0.46029919   46.8000000 mg/d Childress 2015,NA RCT (parallel, crossover, open-label),RR, 97, 97, 194,NA,reverse  9.0000000000, 0.491118361, 1.649297e+02 NA NA,NA,NA NA,NA NA NA 100,100,100,100,100,100 100 some,some low some,low,Placebo,  0, 39.200000, 9.600000 NA DSM-IV-TR 0 1 1.0 1.0,1.0 1.0 1 1,0 1 1,1 1,1.0 1 1 1 1   87 Childress_2015 < 2 months,NA 6-12 yo 8.2,14.6 NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
2877,Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2 100   0 100 100,High,Amphetamine,Lisdexampehtamine (long acting)   0 NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Interview,Adverse events, 1.61104718,  50.0000000 mg/d Coghill 2013 NA RCT (parallel, crossover, open-label) RR 111 110  221 NA,reverse  9.2492492492  2.896326694, 2.953693e+01,NA NA,NA,NA,NA,NA NA,NA,  0,  0 100 100   0,  0,100,some low,high,some,high Placebo   0, 19.000000,10.900000,NA,DSM-IV-TR,0,1,1.0 1.0,1.0 1.0 1 1 0,1,1,1 1,1.0,1 1 1 1   88 Coghill_2013 < 2 months,NA 6-12 yo,8.2 14.6,NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA NA Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high,high
2877,Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2,100   0 100 100 High Amphetamine,Lisdexamphetamine (long acting)   0 NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Interview,Adverse events  0.92059839,  50.0000000,mg/d,Findling,2011 NA,RCT (parallel, crossover, open-label) RR 233, 79  312,NA reverse 13.3927038627, 3.369509385, 5.323164e+01 NA,NA NA,NA,NA NA,NA,NA,100 100 100 100,100,100 100 low,some low,some,low,Placebo   0  21.000000,14.600000,NA,DSM-IV-TR 0,1,1.0,1.0,1.0,1.0,1,1 0 1 1,1,1 1.0,1,1 1 1,  89 Findling_2011,< 2 months NA 13-19 yo,8.2 14.6 NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
2877,Punja (2016),Punja 2016,10.1002/14651858.CD009996.pub2 100,  0,100 100 High Amphetamine Mixed amphetamine salts (short acting and long acting),  0 NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Interview Adverse events  1.15074799   20.0000000 mg/d McCracken,2003 NA RCT (parallel, crossover, open-label),RR  51  51  102,NA,reverse  1.8181818182  0.973182335  3.396882e+00 NA,NA,NA NA,NA NA,NA,NA,100 100 100,100 100,100 100,some,some low some,some,Placebo   0, 14.000000  9.500000,NA,DSM-IV,0,1 1.0 1.0,1.0,1.0,1,1 0 1 1,1 1,1.0 1 1,1,1   90 McCracken_2003,< 2 months,NA 6-12 yo 8.2 14.6 NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
2877 Punja (2016),Punja,2016,10.1002/14651858.CD009996.pub2,100,  0 100 100,High Amphetamine,Mixed amphetamine salts (short acting)   0,NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Interview Adverse events  0.69044879,  22.5000000 mg Pliszka 2000 NA,RCT (parallel, crossover, open-label) RR, 20, 18   38 NA,reverse, 6.3333333333, 0.349360980, 1.148128e+02,NA,NA NA,NA,NA NA,NA,NA,100,100 100 100,100 100 100,some low,low some,some Placebo   0 NA, 8.200000,NA Diagnostic Interview Schedule for Children,0,1 1.0,1.0 1.0,1.0 1 1,0,1 1,1 1 1.0 1 1 1 1   91 Pliszka_2000 < 2 months,NA,6-12 yo,8.2,14.6,NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA,Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
2877,Punja (2016),Punja,2016 10.1002/14651858.CD009996.pub2,100,  0,100,100,High Amphetamine,Dextroamphetamine (short acting),  0 NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Interview Adverse events, 1.61104718   15.0000000 mg/d Ramtvedt 2013,NA RCT (parallel, crossover, open-label) RR, 34  34,  68 NA,reverse  1.4117647059  0.946262289  2.106265e+00 NA NA,NA,NA,NA NA,NA NA   0,  0 100,  0,  0,  0,100 some,high high some high Placebo,  0  19.000000,11.400000 NA DSM-IV-TR 0,1 1.0,1.0 1.0,1.0,1,1,0 1 1 1,1 1.0 1 1 1 1   92 Ramtvedt_2013 < 2 months NA 6-12 yo 8.2,14.6,NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA,Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
2877 Punja (2016),Punja 2016 10.1002/14651858.CD009996.pub2,100,  0 100,100 High Amphetamine,Mixed amphetamine salts (long acting)   0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Interview,Adverse events  0.92059839,  25.0000000 mg/d,Spencer 2006 NA RCT (parallel, crossover, open-label),RR 233, 63  296,NA,reverse,22.4420600858, 3.186564226  1.580530e+02,NA NA NA,NA,NA,NA,NA NA 100 100 100,100,100,100,100,some,some low some,low Placebo   0  34.000000 14.200000,NA DSM-IV-TR,0 1 1.0,1.0 1.0,1.0 1,1,0,1 1,1,1 1.0,1,1,1,1   93,Spencer_2006,< 2 months,NA 13-19 yo,8.2,14.6,NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA,Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
2877 Punja (2016),Punja 2016 10.1002/14651858.CD009996.pub2 100,  0,100,100 High,Amphetamine,Lisdexamphetamine (long acting)   0,NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Interview Adverse events  0.46029919   50.0000000 mg/d Wigal,2009,NA RCT (parallel, crossover, open-label),RR 129 129  258 NA reverse  7.0000000000  0.873612191, 5.608896e+01 NA NA,NA NA NA,NA,NA,NA,100,100,100 100,100,100,100,some,low low some,some,Placebo   0  24.000000 10.580000,NA DSM-IV-TR 0 1,1.0 1.0 1.0,1.0,1,1 0 1,1 1,1 1.0,1 1 1,1,  94,Wigal_2009,< 2 months,NA,6-12 yo,8.2 14.6,NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
2877,Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2 100   0,100 100 High,Amphetamine Mixed amphetamine salts (long acting)   0 NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Interview Adverse events, 0.69044879,  20.0000000,mg/d Biederman,2002 NA,RCT (parallel, crossover, open-label) RR,374,210, 584,NA reverse  8.7032085561  3.211752542  2.358396e+01 NA,NA,NA,NA,NA,NA NA,NA 100,100,100 100 100 100,100 some some,low,some some,Placebo,  0, 23.000000  8.600000,NA,DSM-IV,0,1,1.0 1.0 1.0,1.0 1,1,0,1,1,1 1 1.0 1 1 1,1,  95,Biederman_2002,< 2 months,NA 6-12 yo 8.6,14.6,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
2877 Punja (2016),Punja 2016,10.1002/14651858.CD009996.pub2,100   0 100,100 High,Amphetamine Mixed amphetamine salts (long acting) or Lisdexamphetamine (long acting)   0 NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Interview Adverse events, 0.69044879,  30.0000000 mg/d,Biederman 2007a,NA RCT (parallel, crossover, open-label) RR  52  52  104 NA,reverse, 1.0000000000, 0.064246613  1.556502e+01 NA,NA,NA NA NA,NA NA NA,100 100 100,100 100,100 100 some some,low,some low,Placebo,  0  36.000000, 9.100000 NA,DSM-IV-TR 0 1 1.0,1.0 1.0 1.0,1,1,0 1,1 1,1 1.0 1,1 1,1   96,Biederman_2007a < 2 months NA 6-12 yo,8.6,14.6,NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
2877 Punja (2016),Punja 2016,10.1002/14651858.CD009996.pub2,100,  0 100 100,High,Amphetamine Lisdexamphetamine (long acting),  0 NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Interview Adverse events, 1.00000000,  50.0000000 mg/d Biederman,2007b NA,RCT (parallel, crossover, open-label) RR 218  72, 290 NA,reverse, 6.7706422018  1.679539590, 2.729414e+01,NA NA NA NA NA,NA,NA,NA,100,100 100 100,100,100,100,some,low low some some Placebo   0  31.000000, 9.000000,NA DSM-IV-TR,0,1 1.0 1.0,1.0 1.0,1,1 0,1 1,1,1,1.0,1 1,1,1   97 Biederman_2007b,< 2 months NA 6-12 yo,8.6,14.6,NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA,Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
2877,Punja (2016) Punja,2016 10.1002/14651858.CD009996.pub2 100,  0 100,100 High,Amphetamine Mixed amphetamine salts (short acting),  0 NA,Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Interview Adverse events  0.46029919,  46.8000000 mg/d,Childress 2015 NA RCT (parallel, crossover, open-label) RR  97, 97, 194 NA,reverse  7.0000000000  0.366404012, 1.337322e+02,NA,NA NA,NA,NA NA NA NA,100,100,100,100,100 100 100 some,some low some low,Placebo   0  39.200000  9.600000 NA DSM-IV-TR 0 1,1.0,1.0,1.0 1.0,1 1,0,1 1 1 1 1.0,1 1 1,1,  98,Childress_2015 < 2 months,NA 6-12 yo,8.6 14.6 NA NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
2877 Punja (2016),Punja 2016,10.1002/14651858.CD009996.pub2,100,  0 100,100 High,Amphetamine Lisdexampehtamine (long acting),  0 NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Interview Adverse events  1.61104718,  50.0000000 mg/d Coghill 2013,NA RCT (parallel, crossover, open-label),RR 111 110, 221 NA reverse 12.3873873874  3.006416510  5.103996e+01 NA NA NA,NA,NA NA,NA NA   0   0,100,100,  0,  0,100 some,low high some,high,Placebo,  0  19.000000,10.900000 NA DSM-IV-TR 0 1 1.0 1.0,1.0 1.0 1,1 0 1 1,1,1 1.0 1,1,1,1   99 Coghill_2013,< 2 months NA,6-12 yo 8.6,14.6 NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA NA,Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
2877,Punja (2016) Punja 2016 10.1002/14651858.CD009996.pub2,100   0,100,100 High,Amphetamine,Lisdexamphetamine (long acting),  0,NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Interview Adverse events, 0.92059839   50.0000000 mg/d Findling,2011 NA RCT (parallel, crossover, open-label),RR,233  79  312 NA,reverse  2.9384835479, 0.914265404  9.444397e+00 NA NA,NA NA,NA NA NA NA 100 100 100 100 100 100,100 low some low,some,low,Placebo   0  21.000000 14.600000 NA,DSM-IV-TR 0 1 1.0 1.0,1.0 1.0 1 1 0 1,1 1 1 1.0 1,1 1 1  100,Findling_2011 < 2 months NA,13-19 yo,8.6,14.6,NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
2877,Punja (2016),Punja 2016 10.1002/14651858.CD009996.pub2 100   0,100,100 High,Amphetamine Mixed amphetamine salts (short acting and long acting)   0,NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Interview Adverse events  1.15074799,  20.0000000 mg/d,McCracken 2003 NA RCT (parallel, crossover, open-label) RR  51, 51  102 NA reverse  1.6000000000, 0.803983687  3.184144e+00,NA,NA NA NA NA NA,NA NA,100,100 100,100,100,100 100,some,some low some,some,Placebo   0  14.000000  9.500000 NA,DSM-IV,0 1,1.0 1.0 1.0,1.0,1 1,0 1,1 1,1 1.0,1,1 1 1, 101,McCracken_2003,< 2 months,NA 6-12 yo,8.6,14.6,NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA,Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
2877 Punja (2016) Punja,2016,10.1002/14651858.CD009996.pub2 100   0,100 100,High,Amphetamine Dextroamphetamine (short acting),  0 NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Interview,Adverse events  1.61104718,  15.0000000 mg/d Ramtvedt 2013,NA RCT (parallel, crossover, open-label) RR  34  34,  68 NA reverse, 2.1428571429  1.407839526, 3.261619e+00 NA NA,NA NA,NA,NA NA,NA   0   0 100,  0   0,  0 100,some,high,high some,high,Placebo   0  19.000000 11.400000 NA DSM-IV-TR 0,1 1.0 1.0,1.0,1.0,1 1,0 1 1 1,1 1.0 1,1 1,1  102 Ramtvedt_2013,< 2 months NA 6-12 yo 8.6 14.6 NA,NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high,high
2877,Punja (2016),Punja,2016,10.1002/14651858.CD009996.pub2,100   0 100,100 High Amphetamine,Mixed amphetamine salts (long acting),  0,NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Interview Adverse events, 0.92059839   25.0000000 mg/d,Spencer,2006,NA,RCT (parallel, crossover, open-label) RR 233, 63  296 NA,reverse  3.7854077253, 0.926690873  1.546288e+01 NA NA,NA,NA,NA,NA,NA,NA 100,100 100,100,100,100 100 some some,low,some,low,Placebo   0, 34.000000,14.200000,NA DSM-IV-TR,0,1 1.0 1.0 1.0 1.0 1,1,0,1 1,1 1,1.0,1 1,1 1, 103,Spencer_2006 < 2 months NA 13-19 yo,8.6 14.6,NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA,Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
2877,Punja (2016) Punja 2016 10.1002/14651858.CD009996.pub2,100,  0 100 100 High,Amphetamine,Lisdexamphetamine (long acting)   0 NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Interview,Adverse events, 0.46029919,  50.0000000,mg/d Wigal,2009,NA RCT (parallel, crossover, open-label),RR,129 129  258,NA,reverse,11.0000000000, 0.614504884  1.969065e+02,NA,NA,NA NA NA NA,NA,NA,100,100 100,100 100,100,100 some,low,low some some Placebo   0, 24.000000,10.580000 NA DSM-IV-TR 0 1,1.0,1.0,1.0 1.0,1,1 0,1 1 1 1 1.0,1,1,1 1, 104,Wigal_2009,< 2 months NA 6-12 yo,8.6 14.6 NA,NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA,Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
1598 Huang (2022) Huang 2022,10.1542/peds.2022-057745 100   0,100 100,Low Physical training Physical training 100,augumentation,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test Digit Symbol Scores  1.38089758 NA NA,Kang,2011 NA,RCT SMD,  7,  6   13 outcomes reverse,-0.6300000000 -1.750000000  4.900000e-01,NA NA,NA NA NA,NA NA NA,  0,  0,  0   0,100 100 100 high high,some some some Not a therapeutic intervention   0,  0.000000  8.400000,NA,DSM-IV, DSM-V 1,1 1.0,0.0,0.5,1.0 1,1,2,1 1,0 1,1.0,0 1,1,1  105 Kang_2011,< 2 months NA,6-12 yo 7.7 15.8 NA,NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
1598,Huang (2022) Huang 2022,10.1542/peds.2022-057745,100,  0 100 100 Low Physical training,Physical training 100 augumentation Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test,TMT-B, 1.38089758,NA,NA,Kang,2011,NA,RCT,SMD,  8,  7,  15,outcomes,reverse -0.5700000000 -1.610000000  4.700000e-01,NA NA NA NA NA NA,NA,NA   0,  0   0   0 100 100 100 high high,some some,some,Not a therapeutic intervention,  0,  0.000000  8.400000,NA,DSM-IV, DSM-V 1 1,1.0 0.0,0.5 1.0,1,1,2 1,1,0,1 1.0 0 1 1,1  106 Kang_2011,< 2 months,NA 6-12 yo,7.7 15.8 NA,NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
1598,Huang (2022) Huang,2022 10.1542/peds.2022-057745,100,  0 100 100,Low,Physical training Physical training   0,NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test Digit span task, 2.76179517 NA,NA Ziereis,2014,NA,RCT,SMD, 13   8   21,outcomes reverse,-1.2100000000 -2.170000000 -2.500000e-01 NA,NA,NA,NA NA NA,NA,NA   0,  0,  0,  0 100 100 100 high,high some some,some,No intervention,  0, 25.600000  9.200000 NA,DSM-IV, DSM-V,1,1,1.0,0.0 0.5,1.0 1,1,2,1,1 0 1 1.0 0,1 1,1, 107 Ziereis_2014 2-6 months,NA,6-12 yo 7.7,15.8 NA NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
1598,Huang (2022),Huang 2022,10.1542/peds.2022-057745 100   0,100 100,Low,Physical training,Physical training   0,NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test Digit span task, 2.76179517,NA NA Ziereis 2014,NA,RCT,SMD, 14,  8,  22,outcomes reverse -0.9900000000,-1.910000000,-6.000000e-02 NA NA NA NA NA NA NA NA   0   0   0   0,100 100,100 high,high,some some,some,No intervention,  0, 25.600000  9.200000 NA,DSM-IV, DSM-V 1,1,1.0 0.0,0.5 1.0 1,1 2,1,1 0 1,1.0,0 1,1,1  108 Ziereis_2014,2-6 months,NA,6-12 yo 7.7,15.8,NA NA  22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769 NA NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
1598 Huang (2022) Huang,2022 10.1542/peds.2022-057745,100,  0 100,100,Low,Physical training Physical training,  0 NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,WCST, 1.38089758 NA,NA Choi,2015,NA,RCT SMD, 13, 17,  30 NA,reverse,-0.8000000000,-1.550000000 -5.000000e-02,NA,NA NA NA NA NA NA,NA   0   0,  0   0   0   0,  0,high high,high,high high,Not a therapeutic intervention   0,  0.000000,15.800000,NA,DSM-IV, DSM-V 1 1,1.0 0.0 0.5 1.0,1 1 2,1 1 0 1 1.0,0 1 1 1  109,Choi_2015,< 2 months,NA,13-19 yo,7.7,15.8,NA,NA, 22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
1598 Huang (2022) Huang,2022,10.1542/peds.2022-057745,100,  0 100 100 Low,Physical training,Physical training   0 NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test,Stroop test  1.84119678,NA,NA,Memarmoghaddam,2016,NA RCT,SMD, 19  17,  36,NA,reverse,-1.5400000000 -2.280000000,-7.900000e-01,NA NA,NA,NA NA,NA,NA,NA   0   0,  0   0 100,  0 100 high high,some some high Not a therapeutic intervention   0,  0.000000  8.300000 NA,DSM-IV, DSM-V,1 1,1.0,0.0,0.5,1.0,1,1,2 1,1,0,1,1.0 0 1 1,1, 110,Memarmoghaddam_2016 < 2 months NA,6-12 yo 7.7 15.8 NA NA  22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769,NA NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high,high
1598,Huang (2022) Huang 2022 10.1542/peds.2022-057745 100   0,100,100,Low Physical training Physical training,100,augumentation Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test Stroop color-word test  2.76179517,NA,NA,Pan 2016,NA RCT SMD, 16  16,  32,NA,reverse,-2.2000000000 -3.090000000,-1.310000e+00 NA NA NA,NA NA,NA,NA,NA,  0   0,  0,  0 100,100,100 high high,low some some,Not a therapeutic intervention   0   0.000000  8.900000,NA DSM-IV, DSM-V,1 1 1.0,0.0,0.5,1.0 1,1,2 1,1,0 1 1.0 0,1,1 1  111 Pan_2016,2-6 months,NA,6-12 yo 7.7,15.8 NA NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769,NA NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
1598 Huang (2022),Huang 2022 10.1542/peds.2022-057745 100   0,100 100,Low Physical training,Physical training   0 NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks) Test STOPIT, 2.30149597 NA NA,Bustamante,2017 NA RCT SMD   6   5,  11 outcomes reverse -0.0900000000,-1.280000000  1.100000e+00 NA,NA NA,NA NA,NA NA,NA   0,  0,  0,  0,  0,  0,  0,high high high high high,Not a therapeutic intervention,  0, 31.000000  9.400000 NA DSM-IV, DSM-V,1 1 1.0 0.0 0.5 1.0,1 1,2,1,1 0,1 1.0,0,1 1 1  112,Bustamante_2017 2-6 months NA,6-12 yo,7.7 15.8 NA NA  22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high,high
1598,Huang (2022) Huang 2022,10.1542/peds.2022-057745,100   0,100 100,Low,Physical training,Physical training   0 NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test,AWMA Verbal  2.30149597,NA,NA Bustamante,2017,NA,RCT SMD, 13, 11   24 outcomes,reverse,-0.2200000000,-1.350000000, 9.200000e-01 NA NA,NA,NA NA NA,NA,NA,  0,  0,  0,  0,  0   0   0 high high high high high Not a therapeutic intervention,  0  31.000000, 9.400000 NA,DSM-IV, DSM-V 1,1,1.0,0.0 0.5 1.0 1,1,2,1 1,0 1,1.0 0 1,1 1  113,Bustamante_2017 2-6 months,NA,6-12 yo 7.7,15.8,NA NA  22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769 NA,NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high,high
1598,Huang (2022) Huang,2022,10.1542/peds.2022-057745 100   0 100 100,Low,Physical training Physical training,  0,NA,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test AWMA Visuospatial  2.30149597 NA NA Bustamante 2017,NA RCT,SMD, 13  11   24 outcomes reverse, 0.1900000000 -0.960000000, 1.340000e+00 NA,NA NA NA,NA NA,NA NA,  0   0   0,  0   0,  0   0,high high,high,high,high Not a therapeutic intervention,  0  31.000000  9.400000,NA,DSM-IV, DSM-V,1,1,1.0 0.0 0.5,1.0 1,1,2,1 1,0 1,1.0,0,1 1,1  114,Bustamante_2017,2-6 months,NA 6-12 yo,7.7 15.8 NA NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769,NA,NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high,high
1598,Huang (2022) Huang,2022 10.1542/peds.2022-057745 100   0 100,100,Low,Physical training,Physical training,  0 NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test Stroop color-word test, 2.76179517,NA NA,Lee,2017 NA,RCT,SMD   6,  6,  12 NA,reverse,-1.2000000000,-2.450000000, 5.000000e-02 NA NA,NA NA NA,NA NA,NA   0   0,  0   0,100,  0,100 high,high low some high Not a therapeutic intervention   0   0.000000  8.800000,NA,DSM-IV, DSM-V,1 1,1.0,0.0 0.5 1.0,1,1,2,1,1,0 1 1.0,0,1,1 1, 115,Lee_2017 2-6 months NA,6-12 yo,7.7 15.8,NA NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
1598,Huang (2022) Huang 2022,10.1542/peds.2022-057745   0,  0,100 100,Low Physical training,Physical training   0,NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test Coris Test, 3.22209436 NA NA,Liu 2018,NA,RCT SMD, 32, 32,  64,NA,reverse,-0.7200000000,-1.230000000,-2.100000e-01,NA,NA NA NA,NA NA NA NA   0   0,  0   0,  0,100,100,high,high high,some,some,Not a therapeutic intervention,  0  50.000000 NA NA,DSM-IV, DSM-V,1 1,1.0,0.0,0.5 1.0,1 1 2 1 1,0 1,1.0 0 1 1,1  116 Liu_2018 2-6 months,NA NA,7.7,15.8 NA NA  22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769 NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
1598,Huang (2022) Huang 2022 10.1542/peds.2022-057745 100   0,100 100,Low,Physical training Physical training   0 NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test,Simon Task, 1.84119678,NA NA Benzing 2019,NA,RCT,SMD,  9   7   16 outcomes,reverse,-0.3300000000,-1.330000000, 6.600000e-01 NA,NA NA NA,NA NA NA,NA   0,  0,  0   0 100,100,100 high,high low,low,low,Not a therapeutic intervention,  0  17.600000,10.500000 NA,DSM-IV, DSM-V,1,1 1.0 0.0,0.5 1.0 1,1 2 1 1 0,1,1.0,0,1,1,1, 117 Benzing_2019,< 2 months,NA 6-12 yo,7.7 15.8,NA,NA, 22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769 NA,NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
1598,Huang (2022) Huang,2022 10.1542/peds.2022-057745 100,  0 100,100,Low,Physical training Physical training   0 NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test Flanker Task  1.84119678,NA,NA Benzing 2019 NA RCT,SMD,  9,  8   17,outcomes,reverse -0.3900000000,-1.350000000, 5.700000e-01 NA,NA NA,NA NA,NA NA NA,  0   0,  0   0 100 100 100,high,high,low low low,Not a therapeutic intervention   0, 17.600000 10.500000 NA,DSM-IV, DSM-V,1,1,1.0 0.0 0.5 1.0,1 1 2 1,1 0,1,1.0,0,1,1 1, 118,Benzing_2019 < 2 months,NA 6-12 yo,7.7 15.8,NA,NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
1598,Huang (2022) Huang 2022 10.1542/peds.2022-057745 100,  0,100,100,Low Physical training Physical training,  0,NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test,Color span backward, 1.84119678,NA NA,Benzing,2019 NA,RCT,SMD, 10,  8,  18 outcomes reverse,-0.1900000000 -1.120000000  7.400000e-01,NA NA,NA NA,NA,NA,NA,NA,  0,  0,  0   0 100 100,100 high,high low low low Not a therapeutic intervention   0  17.600000,10.500000,NA DSM-IV, DSM-V,1 1 1.0,0.0,0.5 1.0,1,1,2 1,1 0,1 1.0 0 1 1 1, 119 Benzing_2019 < 2 months NA,6-12 yo,7.7,15.8 NA,NA, 22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
1598 Huang (2022),Huang,2022,10.1542/peds.2022-057745,100,  0 100,100,Low Physical training,Physical training,100,augumentation,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test Cognitive Flexibility Test  1.84119678 NA NA,Da Silva,2019,NA RCT,SMD  36  30,  66 NA,reverse -1.0000000000 -1.510000000 -4.800000e-01 NA NA NA,NA,NA NA,NA NA   0,  0,  0,  0,100   0,100,high,high,some,some,high,Not a therapeutic intervention   0, 30.000000 12.000000,NA DSM-IV, DSM-V,1,1,1.0 0.0,0.5 1.0,1 1,2 1 1,0 1,1.0 0,1 1,1, 120 Da Silva_2019,< 2 months,NA 6-12 yo 7.7,15.8 NA NA  22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769 NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high high
1598 Huang (2022),Huang 2022,10.1542/peds.2022-057745 100   0,100 100,Low,Physical training,Physical training   0 NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test,Stroop test, 2.76179517,NA NA,Hattabi 2019,NA RCT,SMD  10, 10,  20,outcomes,reverse,-0.8200000000,-1.740000000, 9.000000e-02,NA,NA,NA NA NA NA NA,NA,  0   0   0   0,100 100,100,high high,some,some,some,Not a therapeutic intervention   0 NA,10.000000 NA,DSM-IV, DSM-V,1,1,1.0,0.0,0.5 1.0,1 1 2 1,1,0,1 1.0,0,1 1 1, 121,Hattabi_2019,2-6 months NA 6-12 yo,7.7 15.8 NA,NA, 22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769 NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
1598 Huang (2022),Huang,2022,10.1542/peds.2022-057745,100   0 100 100,Low Physical training Physical training,  0 NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test,ROCF Test  2.76179517 NA NA Hattabi,2019 NA,RCT SMD, 10, 10   20 outcomes,reverse -0.5700000000,-1.470000000, 3.200000e-01,NA NA NA,NA,NA,NA NA,NA,  0,  0   0,  0,100 100,100 high high,some some some Not a therapeutic intervention,  0 NA 10.000000,NA,DSM-IV, DSM-V,1,1,1.0 0.0,0.5 1.0,1,1,2,1 1 0 1 1.0 0 1 1,1  122,Hattabi_2019,2-6 months,NA,6-12 yo,7.7 15.8,NA,NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769 NA NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
1598,Huang (2022),Huang 2022,10.1542/peds.2022-057745,100,  0,100,100 Low Physical training Physical training   0 NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test Stroop color-word test 16.57077100 NA,NA,Kadri,2019 NA,RCT SMD  20  20,  40 NA reverse,-2.7800000000,-3.660000000 -1.900000e+00,NA NA,NA NA NA NA,NA,NA   0,  0,  0,  0 100 100 100,high,high,some,some some Not a therapeutic intervention   0  10.000000,14.500000 NA DSM-IV, DSM-V 1,1 1.0,0.0,0.5,1.0 1 1,2,1,1 0 1,1.0,0 1,1 1  123,Kadri_2019,> 12 months,NA 13-19 yo 7.7 15.8 NA NA  22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769,NA NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
1598 Huang (2022) Huang 2022 10.1542/peds.2022-057745,100   0,100,100,Low,Physical training,Physical training   0,NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,Stroop color-word test, 2.76179517 NA NA,Chen,2022,NA RCT,SMD, 11  11   22,outcomes,reverse -1.4800000000 -2.440000000,-5.300000e-01,NA NA NA NA NA NA NA NA   0,  0,  0,  0,  0   0,  0 high,high,high,high high Not a therapeutic intervention,  0  17.200000, 8.400000 NA DSM-IV, DSM-V,1 1 1.0,0.0,0.5,1.0 1,1,2 1,1,0 1,1.0,0,1,1,1  124,Chen_2022 2-6 months,NA 6-12 yo,7.7,15.8 NA NA, 22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769 NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
1598 Huang (2022),Huang,2022,10.1542/peds.2022-057745,100,  0 100 100,Low Physical training,Physical training   0,NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test Cognitive Flexibility Test, 2.76179517,NA NA Chen,2022,NA RCT SMD  11  11,  22 outcomes reverse -0.6900000000,-1.550000000  1.700000e-01 NA,NA,NA NA,NA NA,NA NA,  0   0   0   0,  0,  0,  0,high high high high high Not a therapeutic intervention   0, 17.200000  8.400000 NA DSM-IV, DSM-V 1,1,1.0 0.0,0.5 1.0,1 1,2,1 1 0 1,1.0 0,1 1 1, 125,Chen_2022 2-6 months NA,6-12 yo 7.7 15.8,NA,NA, 22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769 NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high,high
1598,Huang (2022) Huang 2022,10.1542/peds.2022-057745 100   0 100 100 Low Physical training,Physical training   0,NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test N-Back  2.76179517 NA NA,Chen 2022 NA RCT SMD  10, 10   20,outcomes,reverse -0.8500000000 -1.770000000, 7.000000e-02,NA,NA NA NA NA,NA,NA,NA   0   0,  0   0,  0   0   0,high,high high high high,Not a therapeutic intervention   0  17.200000, 8.400000 NA DSM-IV, DSM-V,1,1,1.0 0.0,0.5 1.0 1,1,2 1,1,0,1 1.0 0 1 1,1  126,Chen_2022 2-6 months NA,6-12 yo,7.7 15.8,NA,NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769 NA,NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high,high
1598,Huang (2022) Huang 2022 10.1542/peds.2022-057745,100,  0 100 100 Low Physical training Physical training,  0 NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test,Stroop color-word test, 1.38089758 NA NA Song,2022,NA RCT SMD   2   2    4 outcomes reverse -0.7600000000 -2.860000000, 1.330000e+00 NA,NA NA NA NA NA,NA,NA   0   0   0,  0,  0   0,  0,high high,high high high Not a therapeutic intervention   0   0.000000, 7.700000,NA DSM-IV, DSM-V 1 1,1.0,0.0 0.5,1.0,1,1 2,1,1 0,1,1.0,0,1,1 1, 127,Song_2022,< 2 months NA,6-12 yo,7.7 15.8 NA NA  22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769,NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high high
1598 Huang (2022),Huang 2022,10.1542/peds.2022-057745,100,  0 100 100,Low Physical training,Physical training,  0 NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,TMT-B  1.38089758,NA NA Song 2022,NA RCT SMD   3   3    6,outcomes reverse -2.0700000000,-4.220000000, 8.000000e-02,NA,NA,NA NA,NA NA,NA NA,  0   0,  0   0,  0,  0   0 high,high,high high high,Not a therapeutic intervention,  0,  0.000000, 7.700000 NA DSM-IV, DSM-V 1,1 1.0 0.0 0.5,1.0 1 1 2 1 1,0 1 1.0,0 1 1,1, 128,Song_2022,< 2 months NA,6-12 yo,7.7,15.8 NA,NA, 22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769 NA,NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high,high
1598,Huang (2022),Huang,2022,10.1542/peds.2022-057745 100,  0,100,100 Low Physical training,Physical training   0,NA,Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test ROCF test, 1.38089758,NA NA,Song,2022,NA,RCT SMD,  3,  3    6,outcomes,reverse -0.7800000000 -2.470000000  9.100000e-01,NA,NA NA NA NA,NA NA NA,  0   0,  0,  0,  0   0,  0,high,high high high,high,Not a therapeutic intervention,  0,  0.000000, 7.700000 NA,DSM-IV, DSM-V 1 1 1.0 0.0,0.5,1.0,1,1 2 1,1,0 1,1.0,0 1 1,1  129,Song_2022 < 2 months NA 6-12 yo,7.7 15.8 NA,NA  22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769,NA NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high high
1598 Huang (2022),Huang 2022,10.1542/peds.2022-057745 100,  0,100,100,Low,Physical training Physical training,  0,NA,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks) Test Flanker Task  2.76179517,NA,NA Liang,2022 NA RCT SMD, 13, 13   26,outcomes,reverse -0.6000000000 -1.390000000  1.900000e-01,NA NA,NA,NA,NA NA,NA,NA,  0   0,  0   0,100,  0,  0,high,high low,high,high,Not a therapeutic intervention,  0, 22.500000, 8.400000 NA,DSM-IV, DSM-V,1,1 1.0,0.0 0.5 1.0,1,1 2,1 1 0 1,1.0,0 1,1 1  130 Liang_2022,2-6 months,NA,6-12 yo 7.7 15.8,NA NA, 22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high,high
1598,Huang (2022) Huang,2022,10.1542/peds.2022-057745 100   0,100 100,Low,Physical training,Physical training,  0,NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks) Test,Tower of London  2.76179517,NA NA Liang 2022 NA,RCT,SMD  13, 13   26,outcomes,reverse -0.5000000000 -1.290000000, 2.800000e-01,NA,NA,NA NA,NA,NA,NA NA,  0,  0   0   0 100   0   0,high,high,low,high high,Not a therapeutic intervention   0, 22.500000, 8.400000 NA,DSM-IV, DSM-V 1 1 1.0 0.0,0.5,1.0,1,1,2,1 1,0 1 1.0 0,1 1,1, 131,Liang_2022,2-6 months,NA 6-12 yo,7.7,15.8 NA,NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA,NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high,high
1598 Huang (2022) Huang 2022,10.1542/peds.2022-057745,100,  0,100 100,Low,Physical training,Physical training,  0,NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test TMT-B, 2.76179517 NA NA,Liang 2022,NA RCT SMD  13, 13,  26,outcomes,reverse -0.5100000000 -1.300000000, 2.700000e-01 NA NA NA,NA NA,NA,NA NA   0,  0,  0   0,100,  0   0 high,high low high,high Not a therapeutic intervention   0  22.500000, 8.400000 NA DSM-IV, DSM-V,1,1 1.0 0.0,0.5,1.0 1,1,2,1 1 0 1 1.0,0,1 1,1, 132,Liang_2022 2-6 months,NA,6-12 yo 7.7,15.8,NA,NA  22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769 NA NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
1598 Huang (2022),Huang,2022 10.1542/peds.2022-057745 100,  0 100,100 Low Physical training,Physical training 100,augumentation,Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test Stroop color-word test  2.76179517,NA,NA Chang 2022,NA,RCT SMD   8,  4   12,outcomes reverse,-0.7400000000 -1.980000000  5.000000e-01,NA NA,NA NA NA NA,NA NA,  0   0,  0   0 100   0   0,high,high low high,high,Not a therapeutic intervention,  0  18.700000, 8.300000,NA DSM-IV, DSM-V,1,1 1.0 0.0,0.5,1.0,1,1 2,1 1 0,1 1.0,0,1 1 1  133,Chang_2022 2-6 months,NA,6-12 yo,7.7 15.8 NA,NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769,NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
1598 Huang (2022),Huang,2022 10.1542/peds.2022-057745,100   0 100,100,Low,Physical training Physical training 100,augumentation,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks) Test,Stroop color-word test, 2.76179517 NA,NA,Chang 2022 NA,RCT SMD   8,  4,  12 outcomes reverse,-0.5100000000 -1.300000000, 2.700000e-01,NA,NA,NA NA,NA,NA,NA,NA   0   0,  0,  0 100   0,  0 high,high low,high,high Not a therapeutic intervention   0  18.700000, 8.300000 NA,DSM-IV, DSM-V 1,1,1.0,0.0 0.5,1.0 1,1,2 1 1,0,1 1.0 0 1 1 1  134,Chang_2022 2-6 months NA 6-12 yo 7.7 15.8,NA,NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA,Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high,high
1598 Huang (2022) Huang,2022,10.1542/peds.2022-057745,100   0,100 100 Low Physical training Physical training 100 augumentation,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test,WCST, 2.76179517,NA,NA,Chang,2022,NA,RCT,SMD,  8   4,  12 outcomes reverse,-0.1600000000,-1.360000000  1.040000e+00,NA NA,NA NA NA,NA,NA NA   0   0   0,  0 100,  0,  0 high,high low high,high,Not a therapeutic intervention   0, 18.700000, 8.300000,NA,DSM-IV, DSM-V,1,1,1.0,0.0 0.5 1.0,1,1,2,1 1,0,1,1.0 0,1,1 1, 135 Chang_2022,2-6 months,NA,6-12 yo 7.7,15.8 NA,NA  22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769 NA,NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high high
1598,Huang (2022) Huang,2022 10.1542/peds.2022-057745,100   0 100 100,Low Physical training Physical training,100,augumentation Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test,WCST, 2.76179517 NA NA,Chang 2022 NA,RCT,SMD   8   4,  12 outcomes reverse -0.1700000000,-1.370000000, 1.030000e+00 NA NA NA NA NA,NA NA NA   0   0   0,  0,100   0   0,high,high,low high,high,Not a therapeutic intervention,  0  18.700000, 8.300000 NA DSM-IV, DSM-V,1 1 1.0,0.0 0.5,1.0 1,1 2 1 1,0 1,1.0 0,1,1,1, 136 Chang_2022 2-6 months,NA 6-12 yo,7.7 15.8 NA NA  22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769 NA NA Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high high
3228 Seiffer (2022) Seiffer 2022,10.1177/10870547211017982,100,  0,100 100,High,Physical training,Physical training,  0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA NA  1.84119678,  24.0000000,sessions,Benzing,2019,NA RCT RR  26, 25   51 NA reverse, 1.8857142857, 1.210856203  2.936697e+00 NA,NA,NA,NA,NA NA NA,NA,  0,  0 100,100,100 100,  0,low some low,high low WLC (wait-list control)   0  18.000000 10.430000 NA,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-10 0 1,1.0,1.0,1.0 1.0 1 1,1,1 1,1,1,1.0 0 1,1 1, 137 Benzing_2019 < 2 months,NA,6-12 yo 8.49 15.9 NA,NA  22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA NA Seiffer (2022)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Seiffer (2022) - Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
3228,Seiffer (2022) Seiffer,2022,10.1177/10870547211017982 100   0 100,100,High,Physical training,Physical training   0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA, 1.38089758   18.0000000 sessions,Choi,2015,NA RCT,RR  18  17   35 NA reverse, 2.8333333333, 0.477447713, 1.681394e+01 NA NA NA NA NA,NA,NA,NA 100,100,100,100,  0,100,100 low,some high,low,some,Not a therapeutic intervention,  0,  0.000000 15.900000,NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-11 0 1 1.0,1.0 1.0,1.0,1 1,1,1,1 1,1,1.0 0,1 1 1  138 Choi_2015 < 2 months NA,13-19 yo,8.49 15.9 NA,NA  22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA NA,Seiffer (2022)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Seiffer (2022) - Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3228,Seiffer (2022) Seiffer,2022,10.1177/10870547211017982 100   0,100,100,High Physical training Physical training   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA, 1.84119678    8.0000000,sessions Felmet 1998 NA,RCT RR  20, 20,  40,NA,reverse  4.3157894737, 0.317557276, 5.865411e+01,NA,NA,NA,NA NA NA,NA,NA 100 100 100 100   0 100,100 low some high,low some,WLC (wait-list control),  0   0.000000, 9.700000,NA,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-12 0 1,1.0,1.0 1.0,1.0 1,1,1,1,1 1,1 1.0,0 1,1,1, 139 Felmet_1998,< 2 months NA 6-12 yo,8.49 15.9 NA,NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769,NA,NA Seiffer (2022)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Seiffer (2022) - Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3228,Seiffer (2022),Seiffer 2022 10.1177/10870547211017982 100   0,100,100,High,Physical training,Physical training   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA  1.84119678   20.0000000,sessions Garcia 2016 NA,RCT,RR   9,  9   18 NA reverse, 0.5294117647, 0.253494031, 1.105655e+00,NA NA,NA,NA,NA,NA NA,NA   0,  0 100 100,  0 100   0,low,some,high high some,WLC (wait-list control),  0, 33.000000,10.490000,NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-13,0 1 1.0,1.0 1.0 1.0,1 1,1,1 1,1,1 1.0 0 1,1 1, 140,Garcia_2016,< 2 months NA 6-12 yo 8.49,15.9,NA,NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769 NA,NA Seiffer (2022)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Seiffer (2022) - Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
3228,Seiffer (2022),Seiffer 2022,10.1177/10870547211017982 100,  0 100,100 High,Physical training,Physical training,  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA CBCL, 1.38089758,  12.0000000,sessions,Kang 2011 NA,RCT RR  16  16,  32 NA,reverse, 0.5555555556  0.302402695, 1.020632e+00,NA NA NA,NA NA,NA,NA NA,  0,  0,100 100,100 100,  0 low,some,low,high,some Not a therapeutic intervention,  0,  0.000000, 8.490000,NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-15,0 1 1.0,1.0 1.0 1.0,1,1 1 1,1 1,1,1.0,0,1 1,1  141,Kang_2011,< 2 months,NA,6-12 yo,8.49 15.9 NA,NA, 22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA NA Seiffer (2022)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Seiffer (2022) - Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
3228 Seiffer (2022) Seiffer 2022 10.1177/10870547211017982,100,  0 100,100 High Physical training,Physical training,  0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,NA, 1.38089758   18.0000000 sessions Soori,2020 NA RCT RR, 28, 28,  56 NA reverse, 0.5160493827  0.332044802  8.020212e-01,NA,NA NA NA,NA NA NA NA,  0   0,100,100,  0,100,  0 low,some high,high,some,No intervention,  0  53.000000 12.530000 NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-17,0 1 1.0 1.0,1.0 1.0,1,1 1 1,1 1 1,1.0,0 1,1 1  142,Soori_2020 < 2 months NA,6-12 yo,8.49,15.9,NA NA  22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3,Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769 NA NA Seiffer (2022)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Seiffer (2022) - Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
3228 Seiffer (2022) Seiffer,2022 10.1177/10870547211017982 100   0,100 100,High Physical training,Physical training   0 NA Social-communication skills,Mixed,At study endpoint (closest to 12 weeks),Questionnaire SDQ, 0.92059839    8.0000000 sessions,Davis,2017 NA,RCT,G   4,  4    8 NA,reverse,-2.2000000000,-4.250000000 -1.500000e-01,NA,NA NA,NA NA NA,NA,NA,100 100,100 100 100,100 100,low some,low,low,some,WLC (wait-list control),  0, 12.000000 10.270000 NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-12,0 1 1.0,1.0,1.0,1.0,1 1 1 1 1 1 1,1.0,0 1,1 1  143 Davis_2017,< 2 months,NA,6-12 yo,8.49 10.49,NA,NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA NA,Seiffer (2022)_Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Seiffer (2022) - Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3228 Seiffer (2022) Seiffer 2022,10.1177/10870547211017982 100,  0,100,100,High,Physical training Physical training,  0 NA Social-communication skills,Mixed,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  1.84119678   20.0000000 sessions Garcia 2016 NA RCT,G   9   9,  18,NA reverse  0.6000000000,-0.520000000, 1.720000e+00 NA,NA NA,NA NA NA,NA NA   0,  0 100,100,  0,100,  0 low,some high high some WLC (wait-list control),  0, 33.000000 10.490000,NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-13 0,1,1.0 1.0 1.0,1.0,1 1,1 1,1 1,1 1.0 0,1 1 1  144,Garcia_2016 < 2 months NA,6-12 yo,8.49 10.49,NA NA, 22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769 NA NA Seiffer (2022)_Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Seiffer (2022) - Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
3228,Seiffer (2022),Seiffer 2022,10.1177/10870547211017982 100,  0,100 100 High Physical training,Physical training   0 NA Social-communication skills Mixed,At study endpoint (closest to 12 weeks),Questionnaire,CBCL, 1.38089758   12.0000000,sessions Kang,2011,NA RCT G  16, 16   32 NA,reverse -0.6700000000 -1.440000000, 1.000000e-01 NA,NA,NA NA,NA NA,NA NA   0   0 100 100 100 100   0,low,some low high some,Not a therapeutic intervention   0,  0.000000  8.490000 NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-15,0,1 1.0 1.0 1.0,1.0 1,1,1 1 1,1,1 1.0,0 1,1 1, 145 Kang_2011,< 2 months NA,6-12 yo,8.49,10.49 NA,NA  22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769,NA NA Seiffer (2022)_Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Seiffer (2022) - Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
3228,Seiffer (2022) Seiffer 2022 10.1177/10870547211017982,100   0,100,100,High Physical training Physical training,  0,NA,Social-communication skills,Mixed,At study endpoint (closest to 12 weeks) Questionnaire,CBCL, 2.76179517,  24.0000000,sessions,Pan,2016,NA,RCT G, 16, 16,  32,NA reverse,-0.2800000000,-0.970000000, 4.200000e-01,NA NA,NA NA,NA NA,NA NA   0,  0 100,100 100,100,  0,low some,low,high some WLC (wait-list control),  0,  0.000000, 8.900000,NA,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-17,0,1,1.0,1.0 1.0 1.0 1 1 1,1 1 1 1 1.0 0,1 1 1  146 Pan_2016 2-6 months,NA 6-12 yo 8.49,10.49,NA NA  22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA,Seiffer (2022)_Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Seiffer (2022) - Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
3228,Seiffer (2022),Seiffer,2022 10.1177/10870547211017982 100,  0 100 100,High,Physical training,Physical training,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) NA Passive, 2.76179517,  36.0000000 sessions Bahram,2014,NA,RCT,G, 15  15,  30 NA reverse -0.8000000000,-1.550000000,-6.000000e-02 NA NA,NA,NA NA NA NA NA   0,  0,100 100,100,100   0 low,some low,high,some,No intervention   0,100.000000  9.470000 NA NA 0 1 1.0,1.0,1.0,1.0,1 1,1,1,1,1,1,1.0,0,1,1,1  147 Bahram_2014 2-6 months,NA 6-12 yo,8.49,15.9,NA NA, 22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA NA,Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
3228 Seiffer (2022),Seiffer 2022,10.1177/10870547211017982,100,  0 100 100 High,Physical training,Physical training,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),NA Passive, 1.84119678   24.0000000,sessions,Benzing 2019,NA,RCT G  26, 25   51 NA,reverse -0.1200000000,-0.670000000, 4.400000e-01 NA NA NA,NA,NA,NA,NA NA   0,  0 100 100 100 100,  0 low some low,high,low,WLC (wait-list control)   0  18.000000,10.430000,NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-10 0 1,1.0,1.0,1.0 1.0 1 1 1,1,1,1,1,1.0 0,1 1 1, 148 Benzing_2019 < 2 months,NA,6-12 yo 8.49 15.9 NA,NA  22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769 NA NA,Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
3228,Seiffer (2022) Seiffer 2022,10.1177/10870547211017982 100,  0 100 100,High Physical training,Physical training,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) NA Passive  1.38089758   18.0000000 sessions,Choi 2015,NA RCT,G, 18, 17,  35 NA reverse,-1.2900000000 -2.090000000,-4.900000e-01,NA NA,NA,NA,NA,NA,NA,NA,100 100,100 100,  0 100,100,low,some high low some Not a therapeutic intervention   0   0.000000 15.900000,NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-11,0,1 1.0 1.0 1.0 1.0,1,1,1 1,1,1,1,1.0,0 1 1 1, 149,Choi_2015 < 2 months,NA,13-19 yo,8.49 15.9 NA,NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769 NA NA Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3228 Seiffer (2022),Seiffer 2022 10.1177/10870547211017982 100,  0,100,100 High Physical training Physical training,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),NA Passive, 0.92059839,   8.0000000 sessions,Davis 2017 NA,RCT,G   4,  4,   8,NA,reverse -0.1700000000 -1.560000000  1.210000e+00,NA,NA,NA NA,NA,NA,NA,NA 100 100 100,100 100 100,100,low,some,low,low some,WLC (wait-list control),  0  12.000000 10.270000 NA,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-12,0 1 1.0 1.0,1.0,1.0,1 1,1 1,1,1,1,1.0 0 1 1,1  150,Davis_2017 < 2 months NA,6-12 yo 8.49,15.9 NA NA  22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769 NA NA,Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3228,Seiffer (2022) Seiffer 2022 10.1177/10870547211017982,100   0 100,100,High Physical training Physical training   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),NA Passive  1.84119678,   8.0000000 sessions,Felmet 1998,NA,RCT G  20, 20,  40,NA reverse -0.3400000000,-1.020000000  3.400000e-01,NA,NA NA NA,NA NA,NA NA,100 100 100,100   0 100 100,low some,high low,some WLC (wait-list control),  0,  0.000000, 9.700000,NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-12,0,1 1.0,1.0 1.0,1.0 1 1,1,1,1,1,1 1.0,0,1 1,1  151,Felmet_1998,< 2 months,NA 6-12 yo 8.49,15.9,NA,NA  22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769 NA NA Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3228,Seiffer (2022),Seiffer 2022 10.1177/10870547211017982 100,  0,100 100,High,Physical training Physical training,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks),NA,Passive, 1.84119678,  20.0000000 sessions Garcia 2016,NA,RCT G   9   9   18,NA,reverse  0.2500000000,-0.850000000  1.350000e+00 NA NA NA,NA,NA,NA NA NA   0   0,100 100,  0,100   0,low some,high high,some WLC (wait-list control),  0  33.000000,10.490000,NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-13 0 1 1.0,1.0 1.0 1.0 1 1 1,1 1,1 1 1.0,0,1 1,1, 152 Garcia_2016 < 2 months,NA,6-12 yo 8.49,15.9 NA NA, 22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769 NA,NA,Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
3228,Seiffer (2022),Seiffer,2022 10.1177/10870547211017982 100   0 100,100,High Physical training,Physical training   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),NA Passive, 1.38089758,  12.0000000,sessions,Kang 2011,NA,RCT G  16, 16   32 NA,reverse,-0.8300000000,-1.610000000 -5.000000e-02 NA,NA,NA NA NA NA NA,NA   0,  0,100,100,100 100   0,low,some low high some,Not a therapeutic intervention,  0,  0.000000, 8.490000,NA,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-15,0,1,1.0 1.0,1.0,1.0,1 1 1 1,1 1,1 1.0 0 1 1 1  153 Kang_2011,< 2 months,NA 6-12 yo,8.49,15.9 NA NA  22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769 NA,NA Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
3228,Seiffer (2022),Seiffer 2022 10.1177/10870547211017982 100,  0,100 100 High,Physical training,Physical training   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),NA Passive  2.76179517,  24.0000000,sessions Pan 2016,NA,RCT,G  16, 16   32,NA reverse,-0.5000000000,-1.200000000  2.100000e-01 NA,NA NA,NA,NA NA NA,NA   0   0 100,100 100,100,  0 low some,low,high some WLC (wait-list control),  0,  0.000000  8.900000,NA,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-17,0 1 1.0,1.0 1.0,1.0,1 1,1,1 1,1 1,1.0,0 1 1 1  154 Pan_2016,2-6 months NA 6-12 yo,8.49 15.9 NA NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive), 3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769 NA NA,Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
3228,Seiffer (2022) Seiffer,2022 10.1177/10870547211017982,100,  0,100,100,High,Physical training,Physical training,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) NA,Passive, 1.38089758   18.0000000,sessions,Soori,2020 NA RCT G, 28  28,  56 NA reverse -0.4300000000,-1.050000000, 1.900000e-01,NA NA NA,NA NA,NA,NA NA,  0   0 100,100,  0 100,  0,low some high high,some,No intervention   0  53.000000,12.530000,NA DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-17,0,1,1.0 1.0 1.0,1.0,1,1 1,1 1,1 1,1.0 0 1,1 1, 155,Soori_2020,< 2 months,NA,6-12 yo 8.49 15.9,NA,NA  22  4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3,Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769 NA NA Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 798 Heirs (2007) Heirs 2007,10.1002/14651858.CD005648.pub2,100   0 100,100 High,Homeopathy Homeopathy   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),Questionnaire Conners' Parent Rating Scale–Revised, ADHD Index subscale  4.14269275,NA,NA Jacobs,2005,NA RCT SMD, 21  22   43 NA reverse  0.1700000000 -0.430000000, 7.700000e-01  13.8800000   8.8200000,NA,NA,NA NA NA,NA,  0,  0,100,  0 100,  0 100 low high some low high Placebo,  0,NA, 9.000000,NA Diagnostic Interview Schedule for Children,0 1 1.0 1.0 1.0 1.0,1 1,0,1,1,1,1,1.0 1,1 1,1  156 Jacobs_2005,2-6 months NA 6-12 yo 8.5 9,NA,NA   3, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 2 Heirs (2007) | Catala-Lopez (2017) 8.5 9.3,NA NA Heirs (2007)_Homeopathy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Heirs (2007) - Homeopathy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high,high
 798 Heirs (2007) Heirs,2007 10.1002/14651858.CD005648.pub2,100,  0 100 100,High,Homeopathy Homeopathy,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,Conners' Parent Rating Scale–Revised, ADHD Index subscale  2.00000000 NA,NA Strauss,2000,NA RCT SMD  10, 10   20,NA reverse -0.1700000000,-1.050000000, 7.100000e-01   6.1500000,  5.1900000 NA NA,NA,NA,NA NA,  0   0 100,  0   0   0 100,some,high,high low,high Placebo   0, 10.000000, 8.500000 NA NA 0,1,1.0 1.0,1.0 1.0 1 1,0,1,1 1,1,1.0,1,1,1,1, 157 Strauss_2000,2-6 months,NA 6-12 yo 8.5,9,NA,NA,  3, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  2,Heirs (2007) | Catala-Lopez (2017),8.5,9.3 NA NA Heirs (2007)_Homeopathy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Heirs (2007) - Homeopathy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high high
 798 Heirs (2007) Heirs 2007,10.1002/14651858.CD005648.pub2,100   0,100,100 High,Homeopathy,Homeopathy,  0 NA,Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire Conners' Parent Rating Scale–Revised, Oppositional subscale, 4.14269275,NA,NA Jacobs 2005 NA RCT,SMD, 22  21   43 NA,reverse  0.1000000000,-0.500000000, 7.000000e-01, 13.1700000, 14.3900000,NA,NA NA NA,NA,NA,  0   0 100,  0,100,  0,100 low,high some,low high,Placebo   0,NA, 9.000000,NA,Diagnostic Interview Schedule for Children 0 1 1.0,1.0,1.0,1.0 1 1,0 1 1,1,1 1.0 1,1,1,1  158,Jacobs_2005,2-6 months,NA 6-12 yo,8.5,9,NA NA   3  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 2 Heirs (2007) | Catala-Lopez (2017) 8.5 9.3 NA NA,Heirs (2007)_Homeopathy_Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Heirs (2007) - Homeopathy_Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high,high
 798 Heirs (2007) Heirs,2007,10.1002/14651858.CD005648.pub2,100,  0,100 100 High,Homeopathy Homeopathy   0 NA Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire Conners' Parent Rating Scale–Revised, Oppositional subscale  2.00000000,NA,NA Strauss 2000,NA RCT,SMD, 10, 10,  20 NA,reverse -0.2600000000 -1.140000000, 6.300000e-01,  5.4600000,  8.4800000 NA,NA NA NA,NA NA,  0,  0 100   0   0   0 100,some high high,low high Placebo,  0  10.000000, 8.500000 NA,NA,0 1,1.0,1.0,1.0,1.0,1 1,0 1 1 1 1,1.0 1,1 1,1, 159,Strauss_2000,2-6 months NA 6-12 yo 8.5,9,NA,NA,  3  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 2,Heirs (2007) | Catala-Lopez (2017),8.5,9.3,NA,NA,Heirs (2007)_Homeopathy_Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Heirs (2007) - Homeopathy_Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high,high
 563,Castells (2018),Castells,2018,10.1002/14651858.CD007813.pub3 100   0,100,100,High,Amphetamine,mixed amphetamine salts 100,monotherapy CGI,Mixed,At study endpoint (closest to 12 weeks),Questionnaire,CGI, 0.69044879,  60.0000000 mg/d,Spencer,2001 NA,RCT (parallel, crossover, open-label),G  27, 27   54,NA,reverse,-1.0400000000,-1.610000000,-4.700000e-01   1.0000000,  0.9000000,NA,NA NA,NA NA NA,100 100,100,100,100 100 100 some some,some,some,some,Placebo   0, 44.400000 38.000000,NA DSM-IV,0,1,1.0,1.0 1.0 1.0 1 1 0,1,1,1,1 1.0,1 1 1,1, 160 Spencer_2001,< 2 months NA,>= 20 yo,33.6 41.04,NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA,Castells (2018)_Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Castells (2018) - Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 563,Castells (2018) Castells 2018,10.1002/14651858.CD007813.pub3 100,  0 100 100 High Amphetamine lisdexamphetamine 100,monotherapy CGI Mixed At study endpoint (closest to 12 weeks) Questionnaire,CGI  0.92059839   54.5000000 mg/d,Waxmonsky 2014,NA,RCT (parallel, crossover, open-label) G  11, 13,  24,NA,reverse,-1.2200000000 -2.100000000 -3.300000e-01,  0.8000000   0.8000000 NA,NA,NA NA,NA NA,100 100,100 100,100,100,100 some,some,some some,low,Placebo   0, 74.100000,41.040000,NA DSM-IV 0,1,1.0 1.0 1.0 1.0,1 1,0,1 1 1 1 1.0,1 1,1,1  161 Waxmonsky_2014 < 2 months,NA,>= 20 yo,33.6 41.04 NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Castells (2018)_Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Castells (2018) - Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 563 Castells (2018),Castells 2018,10.1002/14651858.CD007813.pub3 100   0 100,100 High,Amphetamine triple bead mixed amphetamine salts   0 NA,CGI Mixed At study endpoint (closest to 12 weeks),Questionnaire,CGI  0.92059839 NA,mg/d,Weisler,2017 NA RCT (parallel, crossover, open-label) G 177  86, 263,NA,reverse -0.7500000000 -1.010000000 -4.800000e-01   1.3000000,  1.1000000 NA,NA,NA,NA,NA,NA 100,100 100 100,100,100,100,low some,some some some,Placebo   0  42.400000 33.600000,NA DSM-IV 0 1,1.0,1.0,1.0 1.0 1,1,0,1 1 1,1 1.0,1 1 1 1  162 Weisler_2017,< 2 months NA,>= 20 yo 33.6,41.04,NA,NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA NA Castells (2018)_Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Castells (2018) - Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 563,Castells (2018) Castells 2018,10.1002/14651858.CD007813.pub3,100,  0,100 100,High,Amphetamine lisdexamphetamine 100 monotherapy Depressive disorder symptoms Clinician-rated At study endpoint (closest to 12 weeks) Questionnaire,HAM-D, 1.38089758,  70.0000000 mg/d,Biederman 2012,NA,RCT (parallel, crossover, open-label),G  31  30,  61,outcomes,reverse  0.0600000000 -0.440000000  5.600000e-01,  1.7000000,  1.6000000,NA,NA,NA,NA NA,NA 100,100 100,100 100,100 100,some some some some low,Placebo   0, 38.000000 21.600000 NA,DSM-IV,0 1 1.0,1.0,1.0 1.0 1,1 0 1 1,1,1 1.0 1,1 1,1, 163,Biederman_2012,< 2 months,NA,>= 20 yo,21.6 37.5,NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA,Castells (2018)_Amphetamine_Depressive disorder symptoms_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Castells (2018) - Amphetamine_Depressive disorder symptoms_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 563,Castells (2018),Castells,2018,10.1002/14651858.CD007813.pub3 100   0 100 100 High,Amphetamine,dexamphetamine,100 augmentation to psychotherapy Depressive disorder symptoms,Clinician-rated,At study endpoint (closest to 12 weeks),Questionnaire,HAM-D, 4.60299194,  20.0000000 mg/d Weiss,2006,NA RCT (parallel, crossover, open-label) G, 23  26   49,outcomes,reverse, 0.2800000000,-0.290000000, 8.400000e-01,  7.3000000,  3.3000000,NA,NA,NA,NA,NA,NA,100,100,100,100,100,100,100,some,some some some,some,Placebo   0, 36.000000 37.500000 NA DSM-IV 0 1 1.0 1.0,1.0,1.0,1 1,0 1 1 1 1,1.0,1,1 1,1  164,Weiss_2006 2-6 months NA,>= 20 yo 21.6,37.5,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,Castells (2018)_Amphetamine_Depressive disorder symptoms_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Castells (2018) - Amphetamine_Depressive disorder symptoms_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 563 Castells (2018),Castells 2018,10.1002/14651858.CD007813.pub3,100   0,100 100,High,Amphetamine lisdexamphetamine 100 monotherapy,Generalized anxiety Clinician-rated,At study endpoint (closest to 12 weeks) Questionnaire,HAM-A  1.38089758,  70.0000000,mg/d Biederman 2012,NA RCT (parallel, crossover, open-label),G  31, 30,  61 outcomes,reverse  0.0500000000,-0.450000000  5.500000e-01,  1.9000000   2.1000000 NA NA,NA NA NA NA 100,100,100 100 100 100,100,some some,some some,low Placebo   0, 38.000000,21.600000,NA,DSM-IV 0 1,1.0 1.0 1.0,1.0 1,1,0,1,1 1 1 1.0,1,1 1 1  165,Biederman_2012,< 2 months,NA >= 20 yo,21.6 37.5,NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Castells (2018)_Amphetamine_Generalized anxiety_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Castells (2018) - Amphetamine_Generalized anxiety_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 563,Castells (2018),Castells 2018 10.1002/14651858.CD007813.pub3 100,  0 100,100,High,Amphetamine dexamphetamine,100,augmentation to psychotherapy Generalized anxiety,Clinician-rated At study endpoint (closest to 12 weeks),Questionnaire HAM-A  4.60299194   20.0000000 mg/d,Weiss,2006,NA,RCT (parallel, crossover, open-label),G, 23  26,  49,outcomes reverse  0.2300000000,-0.330000000  8.000000e-01   7.8000000,  4.5000000 NA NA,NA NA,NA,NA 100,100,100 100 100 100,100,some some,some some some,Placebo,  0  36.000000 37.500000,NA,DSM-IV 0 1 1.0 1.0 1.0,1.0 1,1 0,1 1 1,1 1.0 1 1 1 1  166 Weiss_2006,2-6 months NA,>= 20 yo,21.6,37.5 NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA,Castells (2018)_Amphetamine_Generalized anxiety_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Castells (2018) - Amphetamine_Generalized anxiety_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
1056,Elliott (2020),Elliott,2020,10.1371/journal.pone.0240584,100   0 100 100,Critically low Amphetamine,mixed amphetamine salts xr 100,monotherapy,Executive functioning (report) Mixed,At study endpoint (closest to 12 weeks),Questionnaire,BRIEF-A, 1.61104718   43.7500000,mg/d Spencer,2008 NA RCT (parallel, crossover, open-label),G,137,137, 274,NA,reverse -0.6500000000,-0.890000000,-4.100000e-01 NA NA,NA,NA NA NA NA,NA   0,  0,100   0   0,  0 100,some,high,high,some,high Placebo,  0, 50.000000 36.550000 NA DSM-IV-TR 2,1,0.0 0.0,1.0 1.0 1 1 1,1,1 1,0,1.0 1 1,1 1, 167,Spencer_2008 < 2 months NA >= 20 yo 29.1 36.55 NA NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA,Elliott (2020)_Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Elliott (2020) - Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high high
1056,Elliott (2020),Elliott 2020 10.1371/journal.pone.0240584 100   0,100,100 Critically low,Amphetamine mixed amphetamine salts 100,monotherapy Executive functioning (report) Mixed At study endpoint (closest to 12 weeks),Questionnaire,BRIEF-A, 0.69044879   50.0000000 mg/d,Wigal,2018a,p481 RCT (parallel, crossover, open-label),G, 86  43, 129 outcomes,reverse,-0.4300000000 -0.800000000 -6.000000e-02 NA,NA,NA NA,NA NA,NA,NA   0   0 100,  0 100,  0 100,some high some low high,Placebo,  0  38.400000 33.100000 NA,DSM-IV-TR,2 1 0.0 0.0 1.0 1.0,1,1,1,1 1,1,0 1.0 1 1,1 1  168 Wigal_2018a,< 2 months NA,>= 20 yo 29.1,36.55,NA NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA,Elliott (2020)_Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Elliott (2020) - Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,high high
1056 Elliott (2020),Elliott 2020,10.1371/journal.pone.0240584,100,  0,100,100,Critically low,Amphetamine lisdexamphetamine 100 monotherapy Executive functioning (report),Mixed,At study endpoint (closest to 12 weeks) Questionnaire BRIEF-A, 2.30149597,  50.0000000 mg/d Adler 2013,NA,RCT (parallel, crossover, open-label),G, 80, 81  161,NA reverse -0.7300000000 -1.050000000,-4.100000e-01 NA,NA,NA,NA NA NA,NA NA,  0   0 100,  0,  0   0 100 low,high high,low,high Placebo   0  47.790062,34.552174 NA,DSM-IV-TR 2,1 0.0,0.0,1.0 1.0 1 1,1 1,1 1 0 1.0 1,1,1 1, 169,Adler_2013 2-6 months,NA >= 20 yo,29.1 36.55,NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA,Elliott (2020)_Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Elliott (2020) - Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high high
1056,Elliott (2020) Elliott 2020,10.1371/journal.pone.0240584 100,  0 100 100,Critically low Amphetamine,triple bead mixed amphetamine salts 100 monotherapy,Executive functioning (report),Mixed,At study endpoint (closest to 12 weeks) Questionnaire BRIEF-A, 0.46029919   25.0000000,mg/d Wigal 2018b p111 RCT (parallel, crossover, open-label),G, 79  79, 158 NA reverse -0.7200000000 -1.040000000,-3.900000e-01 NA NA,NA,NA NA NA NA,NA   0   0 100,  0 100,  0,100 some high,low,some,high Placebo   0, 44.900000,29.100000 NA,DSM-IV-TR,2,1,0.0 0.0,1.0 1.0 1 1,1 1,1 1,0,1.0,1 1,1,1  170 Wigal_2018b < 2 months,NA,>= 20 yo,29.1 36.55 NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA Elliott (2020)_Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Elliott (2020) - Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high,high
1056 Elliott (2020) Elliott,2020 10.1371/journal.pone.0240584,100   0,100,100 Critically low,Amphetamine,mixed amphetamine salts,100 monotherapy,Executive functioning (report) Mixed At study endpoint (closest to 12 weeks) Questionnaire,BRIEF-A  0.69044879   50.0000000,mg/d,Wigal,2018a p481,RCT (parallel, crossover, open-label),G, 86  43  129 outcomes reverse -0.5700000000,-0.940000000,-1.900000e-01,NA NA NA,NA NA NA NA,NA   0   0,100,  0,100,  0 100 some high some low,high,Placebo,  0  38.400000,33.100000,NA,DSM-IV-TR 2,1,0.0,0.0 1.0,1.0 1 1,1 1 1,1 0,1.0,1,1,1,1  171,Wigal_2018a < 2 months,NA >= 20 yo 29.1,36.55,NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA,Elliott (2020)_Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Elliott (2020) - Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high,high
3490 Talebi (2021) Talebi 2021,10.1080/10408398.2021.1940833 100,  0,100 100,Low,Zinc NA,100,Methylphenidate,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),Mixed (different types of tool are used) PTR-ADHDS  1.38089758   15.0000000,mg/d Akhondzadeh,2004,NA RCT (parallel, crossover, open-label) G  22, 22,  44,NA,reverse,-1.2300000000,-1.870000000,-5.800000e-01,NA,NA,NA,NA NA NA NA NA,  0   0 100 100 100   0 100,low,low low,low,high,Active (any credible active intervention) 100,NA  7.880000 NA,DSM-IV 1,0,0.5 1.0 1.0 1.0,1 1 2,1,1,0 1,1.0 0,1,1,1  172 Akhondzadeh_2004 < 2 months NA 6-12 yo 7.14 9.92,NA,NA   6, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Talebi (2021) | Catala-Lopez (2017) 7.14,9.92 NA,NA,Talebi (2021)_Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Talebi (2021) - Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high high
3490 Talebi (2021),Talebi 2021 10.1080/10408398.2021.1940833 100   0 100 100,Low Zinc,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),Mixed (different types of tool are used) ADHDS, 2.76179517   40.0000000 mg/d Bilici 2004 NA RCT (parallel, crossover, open-label),G  95  98, 193,NA,reverse,-1.6200000000,-1.940000000 -1.290000e+00,NA NA,NA NA,NA NA NA,NA,100,100,100 100,  0,100 100 some,low,high some low,Placebo   0,NA, 9.550000 NA,DSM-IV,1 0,0.5 1.0,1.0,1.0,1 1,2,1,1,0 1,1.0,0 1 1 1, 173,Bilici_2004,2-6 months NA 6-12 yo 7.14 9.92,NA NA,  6  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Talebi (2021) | Catala-Lopez (2017) 7.14,9.92 NA,NA,Talebi (2021)_Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Talebi (2021) - Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
3490 Talebi (2021) Talebi,2021 10.1080/10408398.2021.1940833,100,  0 100 100 Low Zinc,NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) Mixed (different types of tool are used),CPTRS & SNAP, 1.84119678   15.0000000,mg/d Arnold 2011,NA,RCT (parallel, crossover, open-label),G  28  24,  52,NA,reverse  0.0400000000,-0.500000000  5.900000e-01 NA,NA,NA NA,NA NA NA NA,  0   0,  0,100 100 100   0 high,low,low high,low Placebo,  0 NA, 9.920000,NA,DSM-IV 1 0,0.5,1.0,1.0 1.0,1 1 2 1 1,0 1,1.0 0,1,1 1, 174,Arnold_2011 < 2 months,NA 6-12 yo 7.14,9.92,NA,NA,  6  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2,Talebi (2021) | Catala-Lopez (2017) 7.14,9.92,NA NA,Talebi (2021)_Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Talebi (2021) - Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
3490 Talebi (2021) Talebi 2021 10.1080/10408398.2021.1940833 100,  0,100,100,Low Zinc NA,100 Methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Mixed (different types of tool are used),CGI, 1.38089758,  10.0000000 mg/d Zamora,2011,NA RCT (parallel, crossover, open-label) G  20, 20   40 NA,reverse,-0.4300000000,-1.060000000  1.900000e-01,NA,NA,NA NA,NA NA NA NA   0,  0,100 100,100,  0 100 some,low,low,some high Active (any credible active intervention) 100,NA  7.140000,NA DSM-IV 1 0 0.5 1.0,1.0 1.0,1,1 2,1,1 0,1 1.0 0,1,1 1, 175 Zamora_2011 < 2 months NA,6-12 yo 7.14,9.92 NA,NA,  6, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Talebi (2021) | Catala-Lopez (2017),7.14 9.92,NA,NA,Talebi (2021)_Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Talebi (2021) - Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high high
3490 Talebi (2021) Talebi 2021 10.1080/10408398.2021.1940833 100   0,100,100 Low Zinc NA 100 Methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) Mixed (different types of tool are used) CPTRS  1.84119678   22.0000000 mg/d,Salehi 2016,NA RCT (parallel, crossover, open-label) G  50, 50  100,NA,reverse,-0.4800000000 -0.880000000,-8.000000e-02 NA NA NA NA,NA,NA NA NA   0,  0,100 100 100   0 100 low,low,low,some,high,Active (any credible active intervention) 100,NA, 9.310000,NA DSM-IV 1 0,0.5 1.0 1.0 1.0 1,1,2,1 1,0 1,1.0 0 1,1 1  176 Salehi_2016,< 2 months NA,6-12 yo 7.14,9.92,NA,NA   6  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Talebi (2021) | Catala-Lopez (2017),7.14 9.92 NA NA,Talebi (2021)_Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Talebi (2021) - Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
3490,Talebi (2021) Talebi 2021,10.1080/10408398.2021.1940833 100,  0 100 100 Low Zinc NA 100,Methylphenidate,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) Mixed (different types of tool are used) CPQ, 1.38089758   10.0000000 mg/d,Noorazar 2019,NA,RCT (parallel, crossover, open-label),G, 30, 30   60,NA reverse  0.0400000000,-0.460000000  5.500000e-01 NA,NA NA NA,NA,NA,NA,NA,100,100 100,100,100,100 100,low low,low,some,low Active (any credible active intervention) 100 NA, 9.500000,NA Psychiatrist & K-SADS,1,0,0.5 1.0,1.0,1.0,1 1 2,1 1,0 1,1.0,0 1,1,1, 177 Noorazar_2019,< 2 months,NA,6-12 yo,7.14 9.92,NA NA   6  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Talebi (2021) | Catala-Lopez (2017) 7.14 9.92,NA NA Talebi (2021)_Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Talebi (2021) - Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
8997,Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885 100,  0 100,100 Low,Viloxazine,Viloxazine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire,ADHD-RS, 1.38089758  100.0000000,mg,Nasser 2020 NCT3247530 100 mg,RCT (parallel, crossover, open-label) MD 147 155  302,outcomes NA  5.7000000000  2.520000000, 8.880000e+00,NA NA,NA NA NA NA NA,NA 100 100 100,100 100,100,100 some low,low low low Placebo   0  36.767219  8.500000 NA,DSM-5 1,1 0.5,1.0 1.0,1.0,0,1 3,1,1 1,1 0.5 0 0,0,1, 178 Nasser_2020,< 2 months,NA 6-12 yo,8.45 13.9015384615385,NA NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684,NA,NA,Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
8997 Yu (2024),Yu,2024,10.1001/jamanetworkopen.2024.45885 100,  0,100,100 Low,Viloxazine Viloxazine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) Questionnaire ADHD-RS, 1.38089758, 200.0000000,mg,Nasser 2020,NCT3247530 200 mg RCT (parallel, crossover, open-label) MD,158 155, 313,outcomes,NA, 6.8000000000  3.670000000, 9.930000e+00,NA NA,NA,NA,NA,NA NA,NA,100 100,100,100,100 100,100,some low low low,low Placebo   0  37.498083  8.500000,NA DSM-5 1,1 0.5,1.0 1.0 1.0 0,1 3,1,1,1,1,0.5 0 0,0,1, 179 Nasser_2020,< 2 months,NA 6-12 yo 8.45,13.9015384615385 NA NA   6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684 NA NA,Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
8997,Yu (2024),Yu,2024,10.1001/jamanetworkopen.2024.45885,100   0 100,100 Low,Viloxazine Viloxazine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) Questionnaire ADHD-RS, 1.61104718, 400.0000000 mg,Nasser 2021a NCT3247556 400 mg RCT (parallel, crossover, open-label) MD  99, 96, 195 outcomes NA  5.1000000000  1.290000000  8.910000e+00 NA,NA NA,NA,NA,NA NA NA 100 100,100,100,100 100 100 some low,low,low,low Placebo   0, 34.875385,13.901538 NA DSM-5,1,1 0.5,1.0 1.0 1.0 0 1,3 1,1,1,1,0.5,0,0 0,1  180 Nasser_2021a,< 2 months NA,13-19 yo,8.45,13.9015384615385,NA,NA,  6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA NA Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
8997,Yu (2024) Yu,2024 10.1001/jamanetworkopen.2024.45885,100,  0,100 100,Low,Viloxazine,Viloxazine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) Questionnaire ADHD-RS  1.61104718  600.0000000 mg Nasser 2021a,NCT3247556 600 mg,RCT (parallel, crossover, open-label) MD  97  96, 193 outcomes,NA  3.5000000000,-0.330000000  7.330000e+00 NA NA,NA NA NA,NA,NA,NA,100,100,100 100 100 100 100,some low low low low Placebo,  0  31.624870,13.749741,NA,DSM-5,1,1,0.5,1.0 1.0 1.0 0,1,3,1,1 1 1,0.5 0,0 0,1, 181,Nasser_2021a,< 2 months,NA 13-19 yo,8.45 13.9015384615385 NA NA   6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684,NA,NA Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
8997,Yu (2024),Yu,2024 10.1001/jamanetworkopen.2024.45885 100,  0,100 100 Low Viloxazine,Viloxazine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),Questionnaire,ADHD-RS, 1.38089758  200.0000000,mg,Nasser 2021b NCT3247517 200 mg RCT (parallel, crossover, open-label),MD, 94 104, 198,outcomes,NA, 4.6000000000, 0.690000000, 8.510000e+00 NA NA,NA NA,NA,NA NA,NA,100 100 100 100,100 100 100,some some low,low,low,Placebo   0, 37.363636 13.847475 NA,DSM-5 1 1 0.5 1.0,1.0,1.0,0 1,3 1,1,1 1,0.5,0,0 0 1, 182 Nasser_2021b < 2 months,NA 13-19 yo,8.45 13.9015384615385 NA NA   6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684,NA,NA,Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
8997 Yu (2024) Yu 2024 10.1001/jamanetworkopen.2024.45885 100,  0 100,100 Low,Viloxazine,Viloxazine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) Questionnaire,ADHD-RS  1.38089758  400.0000000,mg,Nasser,2021b,NCT3247517 400 mg RCT (parallel, crossover, open-label) MD 103,104  207 outcomes,NA  5.1000000000, 1.280000000  8.920000e+00 NA NA NA,NA NA,NA,NA,NA,100 100,100 100,100 100,100,some some low low low,Placebo   0, 39.622222 13.899517,NA DSM-5,1,1 0.5 1.0 1.0,1.0 0 1 3 1 1,1 1,0.5,0 0 0,1  183 Nasser_2021b,< 2 months,NA 13-19 yo,8.45 13.9015384615385,NA NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025),8.45,34.7573446327684 NA,NA,Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
8997 Yu (2024),Yu 2024 10.1001/jamanetworkopen.2024.45885 100,  0,100,100,Low,Viloxazine,Viloxazine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire ADHD-RS  1.84119678  200.0000000 mg,Nasser 2021c,NCT3247543 200 mg,RCT (parallel, crossover, open-label),MD 107  97  204,outcomes,NA, 5.9000000000, 1.870000000, 9.930000e+00 NA,NA,NA NA NA NA,NA,NA,100 100 100 100 100,100 100 some low low,low low Placebo   0, 33.795588, 8.500000 NA,DSM-5 1,1,0.5 1.0,1.0 1.0,0,1,3,1,1,1 1,0.5 0,0,0 1, 184,Nasser_2021c < 2 months NA 6-12 yo,8.45,13.9015384615385,NA NA   6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA NA Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
8997 Yu (2024) Yu,2024 10.1001/jamanetworkopen.2024.45885 100,  0 100,100 Low Viloxazine Viloxazine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) Questionnaire,ADHD-RS  1.84119678  400.0000000 mg,Nasser,2021c NCT3247543 400 mg RCT (parallel, crossover, open-label) MD, 97  97, 194,outcomes NA, 5.8000000000, 1.670000000  9.930000e+00 NA,NA,NA NA,NA NA,NA,NA,100,100 100,100,100,100,100 some,low,low,low,low,Placebo   0  38.150000  8.450000 NA,DSM-5 1 1 0.5,1.0 1.0,1.0,0 1,3,1,1 1 1 0.5,0 0 0 1, 185 Nasser_2021c < 2 months,NA,6-12 yo 8.45,13.9015384615385,NA,NA   6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684,NA NA,Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
8997 Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885,100   0,100,100 Low,Viloxazine,Viloxazine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) Questionnaire ADHD-RS  1.84119678, 100.0000000,mg,Johnson 2020,100 mg RCT (parallel, crossover, open-label),MD, 45, 24   69,outcomes NA  6.2000000000 -9.420000000, 2.182000e+01 NA NA,NA NA NA,NA NA NA,100,100 100,100 100 100,100,low low,low,low low Placebo,  0  44.939130  8.569565,NA,DSM-5 1,1 0.5 1.0,1.0 1.0,0,1,3 1 1,1 1 0.5 0,0,0 1, 186 Johnson_2020 < 2 months NA,6-12 yo,8.45 13.9015384615385 NA NA   6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684 NA NA,Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
8997 Yu (2024) Yu,2024,10.1001/jamanetworkopen.2024.45885 100,  0,100 100 Low Viloxazine,Viloxazine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),Questionnaire,ADHD-RS, 1.84119678, 200.0000000,mg,Johnson 2020,200 mg RCT (parallel, crossover, open-label) MD, 46  24,  70 outcomes NA  7.9000000000,-7.660000000  2.346000e+01 NA,NA NA,NA NA,NA NA,NA,100,100,100 100 100,100 100,low low low low low Placebo   0, 37.180000  8.897143,NA DSM-5,1 1,0.5 1.0,1.0,1.0,0,1,3,1,1,1,1,0.5,0 0,0 1  187,Johnson_2020,< 2 months NA 6-12 yo 8.45 13.9015384615385,NA NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684,NA,NA Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
8997,Yu (2024) Yu,2024,10.1001/jamanetworkopen.2024.45885,100,  0,100,100 Low,Viloxazine Viloxazine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) Questionnaire ADHD-RS, 1.84119678  300.0000000 mg,Johnson,2020 300 mg,RCT (parallel, crossover, open-label),MD, 47, 24,  71,outcomes,NA  8.1000000000 -7.410000000, 2.361000e+01 NA NA NA NA,NA,NA,NA NA 100,100 100 100 100 100 100 low,low low low low,Placebo   0, 33.811268, 8.898592,NA DSM-5,1 1,0.5 1.0 1.0 1.0,0 1 3,1,1,1,1 0.5 0,0 0 1, 188 Johnson_2020,< 2 months NA 6-12 yo,8.45,13.9015384615385 NA NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684 NA,NA Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8997 Yu (2024),Yu,2024,10.1001/jamanetworkopen.2024.45885,100   0 100 100,Low,Viloxazine Viloxazine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) Questionnaire ADHD-RS  1.84119678  400.0000000 mg Johnson 2020 400 mg,RCT (parallel, crossover, open-label),MD, 44, 24   68 outcomes,NA, 8.5000000000 -7.190000000, 2.419000e+01,NA,NA,NA NA,NA NA NA NA,100 100,100 100 100,100 100,low low low low,low Placebo   0, 38.217647, 8.894118 NA,DSM-5 1 1,0.5 1.0 1.0 1.0,0,1 3 1 1 1 1 0.5,0,0,0 1, 189 Johnson_2020,< 2 months NA,6-12 yo 8.45 13.9015384615385 NA,NA,  6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025),8.45,34.7573446327684 NA,NA Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
8997,Yu (2024) Yu,2024,10.1001/jamanetworkopen.2024.45885 100,  0,100,100,Low,Viloxazine,Viloxazine   0,NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA  1.38089758  100.0000000,mg,Nasser 2020 NCT3247530 100 mg RCT (parallel, crossover, open-label),RR,147 155  302,outcomes reverse  4.9200000000  1.440000000  1.677000e+01,NA,NA NA NA,NA NA NA,NA,100 100 100 100 100,100,100 some,low low low,low,Placebo,  0  36.767219  8.500000 NA DSM-5,1,1 0.5 1.0 1.0,1.0,0,1 3 1 1 1,1,0.5 0,0,0 1  190 Nasser_2020,< 2 months NA 6-12 yo,8.45 13.9015384615385,NA NA,  6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684 NA NA Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
8997 Yu (2024),Yu 2024 10.1001/jamanetworkopen.2024.45885,100   0,100,100,Low,Viloxazine Viloxazine   0 NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA  1.38089758, 200.0000000 mg,Nasser,2020 NCT3247530 200 mg,RCT (parallel, crossover, open-label) RR,158 155, 313,outcomes,reverse, 4.5800000000  1.340000000  1.562000e+01 NA,NA,NA,NA,NA,NA,NA,NA 100,100 100 100 100,100,100 some low low,low low Placebo   0  37.498083, 8.500000 NA,DSM-5,1,1 0.5 1.0,1.0 1.0 0,1 3 1,1 1 1,0.5 0,0,0,1, 191 Nasser_2020 < 2 months,NA,6-12 yo 8.45 13.9015384615385 NA,NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684,NA,NA Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
8997 Yu (2024) Yu,2024 10.1001/jamanetworkopen.2024.45885 100   0,100,100 Low,Viloxazine Viloxazine,  0 NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA, 1.61104718  400.0000000,mg,Nasser 2021a,NCT3247556 400 mg,RCT (parallel, crossover, open-label) RR, 99  96, 195,outcomes reverse, 4.2000000000  1.240000000, 1.428000e+01 NA NA,NA NA,NA,NA NA NA,100,100 100 100 100 100,100,some low,low,low,low,Placebo   0  34.875385,13.901538,NA,DSM-5 1 1,0.5,1.0,1.0,1.0,0,1 3 1 1,1,1,0.5,0,0,0,1, 192,Nasser_2021a < 2 months,NA 13-19 yo,8.45,13.9015384615385,NA NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684 NA NA Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
8997,Yu (2024) Yu 2024,10.1001/jamanetworkopen.2024.45885 100   0 100 100,Low Viloxazine,Viloxazine,  0 NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA, 1.61104718  600.0000000 mg,Nasser 2021a,NCT3247556 600 mg,RCT (parallel, crossover, open-label) RR, 97, 96, 193,outcomes reverse, 5.6100000000, 1.700000000, 1.852000e+01,NA,NA NA,NA NA,NA NA NA,100,100,100,100 100 100 100 some low low,low,low Placebo,  0, 31.624870 13.749741 NA DSM-5 1,1,0.5,1.0,1.0,1.0,0 1 3 1 1 1 1,0.5 0,0 0 1, 193,Nasser_2021a,< 2 months,NA,13-19 yo 8.45,13.9015384615385,NA NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025),8.45 34.7573446327684,NA,NA Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
8997 Yu (2024) Yu 2024,10.1001/jamanetworkopen.2024.45885,100,  0,100 100 Low,Viloxazine,Viloxazine,  0,NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA, 1.38089758  200.0000000,mg Nasser 2021b,NCT3247517 200 mg,RCT (parallel, crossover, open-label),RR  94,104, 198,outcomes reverse  2.0500000000  0.860000000  4.930000e+00,NA,NA NA,NA,NA,NA,NA,NA 100 100 100,100 100,100 100 some,some low low,low,Placebo   0, 37.363636 13.847475 NA,DSM-5,1,1 0.5 1.0 1.0 1.0 0,1,3 1 1,1 1,0.5,0,0,0,1, 194 Nasser_2021b < 2 months NA 13-19 yo,8.45,13.9015384615385,NA NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45,34.7573446327684 NA,NA Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
8997 Yu (2024) Yu,2024,10.1001/jamanetworkopen.2024.45885,100   0 100 100 Low,Viloxazine,Viloxazine   0 NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  1.38089758, 400.0000000 mg Nasser 2021b,NCT3247517 400 mg,RCT (parallel, crossover, open-label),RR 103,104  207,outcomes,reverse  2.1600000000, 0.920000000, 5.090000e+00 NA,NA,NA NA,NA,NA,NA NA,100 100 100,100,100 100,100 some some,low,low,low,Placebo,  0, 39.622222,13.899517,NA,DSM-5 1,1 0.5 1.0,1.0 1.0,0 1 3,1 1,1 1,0.5 0 0 0 1  195 Nasser_2021b < 2 months NA 13-19 yo 8.45 13.9015384615385,NA NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025),8.45,34.7573446327684,NA NA,Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
8997 Yu (2024) Yu,2024,10.1001/jamanetworkopen.2024.45885 100   0 100,100,Low,Viloxazine Viloxazine,  0,NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  1.84119678, 200.0000000 mg Nasser 2021c,NCT3247543 200 mg RCT (parallel, crossover, open-label) RR,107, 97, 204,outcomes,reverse 13.6000000000, 1.830000000  1.010300e+02 NA,NA,NA NA NA,NA,NA,NA,100,100 100 100 100,100 100,some low low low,low Placebo   0  33.795588, 8.500000 NA DSM-5,1,1 0.5,1.0 1.0,1.0 0,1,3,1,1,1 1,0.5 0 0 0,1, 196 Nasser_2021c,< 2 months NA 6-12 yo 8.45,13.9015384615385,NA,NA   6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684,NA NA,Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
8997 Yu (2024) Yu,2024,10.1001/jamanetworkopen.2024.45885,100,  0,100 100 Low,Viloxazine,Viloxazine   0,NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 1.84119678  400.0000000 mg,Nasser 2021c,NCT3247543 400 mg,RCT (parallel, crossover, open-label),RR  97  97, 194,outcomes,reverse,14.0000000000  1.880000000, 1.044000e+02 NA,NA NA NA,NA NA NA NA,100 100 100,100,100,100,100,some,low low low,low,Placebo,  0, 38.150000, 8.450000 NA,DSM-5 1 1 0.5 1.0 1.0,1.0 0 1 3,1 1 1,1 0.5 0 0 0,1  197,Nasser_2021c,< 2 months NA,6-12 yo,8.45 13.9015384615385,NA,NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684 NA,NA Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
8997 Yu (2024),Yu 2024 10.1001/jamanetworkopen.2024.45885,100   0 100 100 Low Viloxazine Viloxazine,  0 NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 1.84119678  100.0000000,mg Johnson 2020 100 mg RCT (parallel, crossover, open-label) RR  45, 24,  69,outcomes,reverse  3.7300000000, 0.490000000, 2.859000e+01 NA,NA,NA NA NA,NA NA NA 100 100,100,100,100 100 100 low low,low,low low,Placebo   0, 44.939130, 8.569565,NA,DSM-5 1 1,0.5 1.0,1.0 1.0 0 1 3 1 1,1 1,0.5,0 0,0,1  198,Johnson_2020,< 2 months NA 6-12 yo 8.45,13.9015384615385 NA NA   6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684 NA NA,Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
8997,Yu (2024) Yu 2024,10.1001/jamanetworkopen.2024.45885 100   0,100,100,Low,Viloxazine Viloxazine   0 NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  1.84119678, 200.0000000 mg,Johnson 2020 200 mg RCT (parallel, crossover, open-label),RR, 46, 24,  70,outcomes reverse, 5.2200000000  0.710000000  3.838000e+01 NA,NA NA,NA NA NA,NA,NA,100 100,100 100 100 100 100 low low,low low low,Placebo,  0  37.180000, 8.897143 NA,DSM-5 1 1,0.5,1.0,1.0,1.0 0 1,3 1,1 1 1 0.5 0 0,0,1  199,Johnson_2020,< 2 months,NA 6-12 yo 8.45,13.9015384615385,NA NA   6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA,NA Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
8997,Yu (2024) Yu,2024,10.1001/jamanetworkopen.2024.45885,100,  0,100 100,Low Viloxazine Viloxazine   0,NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA  1.84119678  300.0000000,mg Johnson 2020 300 mg RCT (parallel, crossover, open-label) RR  47, 24   71,outcomes reverse, 5.6200000000, 0.770000000, 4.098000e+01 NA,NA,NA NA NA,NA NA,NA,100,100 100,100 100,100,100 low low low low,low,Placebo,  0  33.811268, 8.898592 NA,DSM-5,1 1,0.5 1.0 1.0 1.0,0 1 3,1,1,1,1 0.5,0,0,0,1  200,Johnson_2020 < 2 months,NA,6-12 yo,8.45 13.9015384615385,NA,NA   6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684 NA,NA,Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
8997,Yu (2024),Yu,2024,10.1001/jamanetworkopen.2024.45885 100,  0,100 100,Low,Viloxazine Viloxazine   0,NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA  1.84119678  400.0000000 mg,Johnson 2020,400 mg,RCT (parallel, crossover, open-label),RR, 44, 24   68 outcomes reverse  6.5500000000, 0.910000000  4.733000e+01,NA NA NA NA,NA NA NA,NA 100 100 100,100,100,100,100 low low low,low low,Placebo,  0  38.217647, 8.894118 NA,DSM-5 1,1,0.5,1.0,1.0 1.0,0 1,3 1 1,1,1 0.5 0 0,0,1, 201 Johnson_2020,< 2 months NA 6-12 yo,8.45 13.9015384615385 NA,NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA,NA Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
8997 Yu (2024),Yu,2024 10.1001/jamanetworkopen.2024.45885 100   0 100,100 Low,Viloxazine,Viloxazine   0,NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA  1.61104718, 400.0000000,mg,Nasser,2021a NCT3247556 400 mg,RCT (parallel, crossover, open-label),RR, 99, 96  195 outcomes reverse  2.9100000000  0.600000000, 1.406000e+01 NA,NA,NA,NA,NA NA,NA,NA,100,100,100 100,100,100 100,some low,low,low low Placebo   0  34.875385 13.901538,NA DSM-5,1 1,0.5 1.0 1.0 1.0 0 1,3,1,1 1,1 0.5 0 0,0 1  202,Nasser_2021a,< 2 months NA,13-19 yo,8.45,13.9015384615385,NA,NA   6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684 NA NA Yu (2024)_Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
8997 Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885,100   0 100 100,Low,Viloxazine Viloxazine,  0 NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA, 1.61104718, 600.0000000,mg,Nasser 2021a NCT3247556 600 mg,RCT (parallel, crossover, open-label),RR  97, 96  193 outcomes reverse, 2.9700000000, 0.610000000, 1.435000e+01 NA NA,NA NA NA,NA NA,NA,100 100,100,100 100,100,100,some low,low low,low Placebo   0, 31.624870 13.749741,NA DSM-5,1,1,0.5 1.0,1.0 1.0 0 1 3 1 1 1 1 0.5 0,0,0,1  203 Nasser_2021a < 2 months,NA 13-19 yo,8.45 13.9015384615385,NA,NA   6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025),8.45,34.7573446327684,NA NA,Yu (2024)_Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
8997 Yu (2024) Yu 2024 10.1001/jamanetworkopen.2024.45885,100   0,100 100 Low,Viloxazine,Viloxazine,  0 NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  1.38089758  200.0000000,mg,Nasser,2021b,NCT3247517 200 mg,RCT (parallel, crossover, open-label) RR, 94 104  198 outcomes,reverse,12.1600000000, 0.680000000, 2.169600e+02,NA NA NA NA,NA,NA NA NA 100,100,100 100,100,100,100 some some,low low,low Placebo   0, 37.363636,13.847475 NA,DSM-5,1 1,0.5,1.0,1.0 1.0,0,1,3 1 1 1,1,0.5 0,0,0,1  204 Nasser_2021b,< 2 months,NA,13-19 yo,8.45 13.9015384615385 NA NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA NA,Yu (2024)_Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
8997,Yu (2024),Yu,2024,10.1001/jamanetworkopen.2024.45885,100,  0 100,100 Low,Viloxazine,Viloxazine   0,NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA, 1.38089758  400.0000000 mg,Nasser,2021b,NCT3247517 400 mg,RCT (parallel, crossover, open-label) RR,103,104  207,outcomes,reverse 19.1800000000  1.130000000, 3.253400e+02,NA NA NA,NA NA NA,NA NA 100,100,100 100,100,100 100,some,some,low,low,low,Placebo   0, 39.622222,13.899517,NA DSM-5 1,1 0.5 1.0,1.0,1.0,0,1 3,1,1 1,1 0.5 0 0 0,1, 205,Nasser_2021b,< 2 months,NA,13-19 yo 8.45 13.9015384615385 NA NA   6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA NA Yu (2024)_Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
8997 Yu (2024) Yu 2024,10.1001/jamanetworkopen.2024.45885 100,  0 100,100,Low,Viloxazine,Viloxazine   0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA  1.84119678  200.0000000,mg,Nasser 2021c NCT3247543 200 mg RCT (parallel, crossover, open-label) RR 107, 97, 204 outcomes,reverse 15.4300000000, 0.900000000, 2.637700e+02 NA,NA,NA NA,NA,NA,NA,NA 100,100 100,100 100 100,100,some low,low low low,Placebo,  0, 33.795588, 8.500000,NA DSM-5 1,1 0.5 1.0,1.0,1.0 0 1,3,1,1,1,1,0.5,0 0 0,1, 206,Nasser_2021c,< 2 months NA 6-12 yo,8.45,13.9015384615385,NA,NA,  6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684 NA,NA Yu (2024)_Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Yu (2024) - Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8997,Yu (2024),Yu 2024 10.1001/jamanetworkopen.2024.45885 100,  0,100 100,Low,Viloxazine,Viloxazine   0,NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA, 1.84119678, 400.0000000,mg Nasser,2021c NCT3247543 400 mg,RCT (parallel, crossover, open-label) RR  97, 97, 194,outcomes,reverse 17.0000000000, 0.990000000  2.905000e+02,NA,NA,NA,NA NA NA,NA,NA 100,100 100,100,100 100 100 some,low,low,low,low,Placebo,  0, 38.150000  8.450000 NA,DSM-5 1,1,0.5,1.0 1.0 1.0 0 1,3,1,1 1 1,0.5 0 0 0 1  207 Nasser_2021c,< 2 months NA,6-12 yo,8.45 13.9015384615385 NA,NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45,34.7573446327684,NA NA Yu (2024)_Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
8997 Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885 100   0,100 100 Low,Viloxazine,Viloxazine   0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA NA  1.38089758, 100.0000000 mg Nasser 2020,NCT3247530 100 mg,RCT (parallel, crossover, open-label),RR 147,155, 302 outcomes reverse, 2.6400000000, 0.520000000, 1.338000e+01,NA,NA,NA,NA,NA NA,NA,NA 100,100 100,100 100,100,100 some,low,low,low low,Placebo,  0  36.767219, 8.500000,NA,DSM-5,1 1,0.5,1.0 1.0,1.0,0,1 3 1,1,1 1,0.5 0 0,0 1  208 Nasser_2020,< 2 months NA,6-12 yo,8.45,13.9015384615385,NA,NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684,NA NA,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
8997 Yu (2024),Yu,2024 10.1001/jamanetworkopen.2024.45885,100   0,100 100 Low Viloxazine Viloxazine   0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,NA  1.38089758, 200.0000000 mg,Nasser,2020,NCT3247530 200 mg RCT (parallel, crossover, open-label),RR,158,155  313 outcomes,reverse  0.9800000000  0.140000000, 6.880000e+00,NA NA NA,NA,NA NA NA NA 100,100 100,100 100 100,100 some low,low,low low Placebo   0  37.498083, 8.500000 NA DSM-5 1,1 0.5 1.0,1.0,1.0 0 1,3,1,1 1,1 0.5,0,0,0 1, 209,Nasser_2020,< 2 months NA,6-12 yo 8.45 13.9015384615385 NA NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA NA,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
8997,Yu (2024) Yu 2024,10.1001/jamanetworkopen.2024.45885 100   0,100,100 Low Viloxazine,Viloxazine   0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,NA  1.61104718, 400.0000000 mg,Nasser,2021a NCT3247556 400 mg RCT (parallel, crossover, open-label) RR, 99, 96, 195,outcomes reverse, 3.8800000000, 0.440000000  3.408000e+01 NA NA NA NA,NA NA,NA,NA 100 100 100,100 100 100 100 some,low low,low low,Placebo   0, 34.875385,13.901538,NA,DSM-5 1 1 0.5,1.0,1.0,1.0,0 1 3 1 1 1 1,0.5 0,0,0 1, 210 Nasser_2021a,< 2 months,NA,13-19 yo 8.45 13.9015384615385,NA NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684 NA NA Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
8997 Yu (2024),Yu,2024 10.1001/jamanetworkopen.2024.45885,100,  0,100 100,Low,Viloxazine,Viloxazine   0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA NA  1.61104718  600.0000000 mg Nasser 2021a NCT3247556 600 mg RCT (parallel, crossover, open-label) RR  97  96  193,outcomes,reverse, 4.9500000000  0.590000000  4.157000e+01,NA,NA,NA NA,NA NA,NA,NA,100,100 100 100,100 100,100 some low low,low,low,Placebo   0  31.624870,13.749741,NA DSM-5,1,1,0.5,1.0 1.0 1.0 0,1 3,1,1 1 1 0.5,0 0 0 1  211,Nasser_2021a < 2 months,NA 13-19 yo,8.45 13.9015384615385,NA NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA NA,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
8997 Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885 100,  0 100,100,Low,Viloxazine,Viloxazine   0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA NA  1.38089758  200.0000000 mg,Nasser,2021b NCT3247517 200 mg,RCT (parallel, crossover, open-label) RR  94,104, 198 outcomes,reverse, 9.9500000000  0.540000000, 1.823300e+02,NA NA NA NA,NA NA,NA NA,100 100 100,100,100 100,100,some,some low low low Placebo,  0  37.363636 13.847475,NA DSM-5,1 1 0.5,1.0,1.0,1.0 0,1,3,1 1 1 1,0.5 0,0,0 1  212,Nasser_2021b,< 2 months,NA 13-19 yo 8.45 13.9015384615385 NA,NA   6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684 NA,NA Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
8997 Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885,100,  0,100 100 Low Viloxazine Viloxazine,  0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,NA  1.38089758  400.0000000 mg Nasser 2021b NCT3247517 400 mg RCT (parallel, crossover, open-label),RR 103,104, 207,outcomes reverse, 5.0500000000  0.250000000  1.038800e+02 NA NA NA,NA NA,NA NA NA,100,100,100 100,100,100,100,some some low,low,low,Placebo,  0  39.622222,13.899517,NA,DSM-5,1 1,0.5 1.0 1.0,1.0,0 1 3,1 1 1 1 0.5 0 0,0,1, 213,Nasser_2021b < 2 months,NA,13-19 yo 8.45 13.9015384615385 NA,NA   6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684,NA NA Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
8997 Yu (2024) Yu,2024 10.1001/jamanetworkopen.2024.45885,100,  0,100 100 Low,Viloxazine Viloxazine   0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,NA, 1.84119678  200.0000000,mg Nasser,2021c,NCT3247543 200 mg,RCT (parallel, crossover, open-label) RR,107, 97, 204,outcomes,reverse  1.8100000000  0.470000000  7.050000e+00 NA NA NA NA NA NA NA NA 100 100 100,100,100 100,100,some low,low,low low,Placebo,  0, 33.795588, 8.500000 NA DSM-5,1 1 0.5 1.0 1.0 1.0,0,1,3 1 1,1 1,0.5,0,0 0,1, 214,Nasser_2021c < 2 months,NA,6-12 yo 8.45,13.9015384615385 NA,NA   6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684 NA,NA,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
8997,Yu (2024),Yu,2024 10.1001/jamanetworkopen.2024.45885 100,  0 100 100,Low,Viloxazine Viloxazine,  0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA NA  1.84119678, 400.0000000,mg Nasser 2021c,NCT3247543 400 mg,RCT (parallel, crossover, open-label),RR  97  97  194 outcomes reverse, 1.3300000000  0.310000000  5.800000e+00,NA,NA NA NA NA,NA,NA NA,100,100 100 100 100 100,100,some low low low low Placebo   0  38.150000  8.450000,NA,DSM-5 1,1 0.5,1.0 1.0,1.0 0,1 3 1,1 1,1,0.5 0 0,0 1  215,Nasser_2021c,< 2 months NA,6-12 yo,8.45,13.9015384615385 NA NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA,NA,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
8997,Yu (2024) Yu 2024 10.1001/jamanetworkopen.2024.45885 100,  0 100 100,Low,Viloxazine,Viloxazine   0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA NA  1.84119678  100.0000000,mg Johnson 2020 100 mg,RCT (parallel, crossover, open-label) RR, 45, 24,  69,outcomes reverse  4.8900000000, 0.270000000, 8.721000e+01 NA,NA NA,NA NA NA NA,NA,100 100 100,100 100,100,100,low,low,low,low low Placebo,  0, 44.939130  8.569565 NA,DSM-5,1 1 0.5,1.0 1.0,1.0 0,1,3 1,1,1,1,0.5,0 0 0,1  216,Johnson_2020,< 2 months NA 6-12 yo,8.45,13.9015384615385 NA,NA,  6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025),8.45 34.7573446327684,NA NA Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
8997,Yu (2024),Yu 2024 10.1001/jamanetworkopen.2024.45885 100   0,100 100 Low Viloxazine,Viloxazine   0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,NA  1.84119678, 200.0000000 mg,Johnson,2020,200 mg RCT (parallel, crossover, open-label),RR, 46  24   70 outcomes reverse, 3.7200000000, 0.200000000, 6.926000e+01,NA,NA,NA,NA NA,NA,NA,NA 100 100 100 100 100 100 100,low,low,low,low low,Placebo,  0  37.180000  8.897143,NA DSM-5 1,1 0.5,1.0 1.0 1.0,0 1 3 1 1 1,1,0.5 0,0 0 1  217,Johnson_2020,< 2 months NA 6-12 yo,8.45,13.9015384615385,NA,NA   6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684,NA NA Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
8997,Yu (2024) Yu,2024,10.1001/jamanetworkopen.2024.45885,100   0 100,100 Low Viloxazine Viloxazine   0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA NA, 1.84119678  300.0000000,mg Johnson,2020,300 mg,RCT (parallel, crossover, open-label) RR, 47, 24,  71 outcomes,reverse  1.5600000000  0.070000000, 3.697000e+01,NA NA,NA,NA NA NA NA NA,100 100 100 100 100 100 100 low,low,low,low,low Placebo   0, 33.811268  8.898592,NA DSM-5 1 1,0.5 1.0 1.0 1.0,0,1,3,1,1,1,1,0.5 0,0,0,1  218 Johnson_2020,< 2 months,NA,6-12 yo,8.45,13.9015384615385,NA,NA,  6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684,NA,NA,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
8997 Yu (2024) Yu,2024 10.1001/jamanetworkopen.2024.45885,100,  0,100 100,Low,Viloxazine,Viloxazine   0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,NA  1.84119678  400.0000000 mg Johnson,2020,400 mg,RCT (parallel, crossover, open-label) RR  44, 24   68,outcomes reverse  6.1100000000, 0.350000000, 1.060200e+02 NA,NA NA,NA NA,NA,NA NA 100 100,100,100,100,100,100,low,low,low,low,low,Placebo   0  38.217647  8.894118,NA,DSM-5 1,1 0.5,1.0,1.0 1.0 0 1,3 1,1,1,1,0.5,0 0 0 1, 219,Johnson_2020,< 2 months NA,6-12 yo 8.45 13.9015384615385 NA,NA   6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684,NA NA,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8997 Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885,100,  0 100 100,Low Viloxazine,Viloxazine,  0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA NA  1.38089758  100.0000000,mg,Nasser 2020,NCT3247530 100 mg,RCT (parallel, crossover, open-label) RR 147 155, 302,outcomes,reverse  1.2100000000, 0.760000000  1.930000e+00,NA,NA NA,NA NA NA,NA NA,100,100,100,100,100 100,100 some,low,low low low Placebo   0  36.767219  8.500000,NA DSM-5,1 1,0.5 1.0 1.0 1.0,0,1,3,1 1,1 1 0.5,0,0,0 1  220,Nasser_2020,< 2 months,NA 6-12 yo 8.45 13.9015384615385,NA,NA   6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45,34.7573446327684,NA,NA Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
8997 Yu (2024),Yu 2024 10.1001/jamanetworkopen.2024.45885,100   0 100,100 Low,Viloxazine,Viloxazine   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA NA, 1.38089758, 200.0000000 mg,Nasser 2020,NCT3247530 200 mg RCT (parallel, crossover, open-label),RR,158 155  313,outcomes reverse, 0.7300000000  0.430000000  1.240000e+00,NA NA,NA,NA NA NA,NA NA,100 100 100 100 100,100,100 some,low low low,low,Placebo,  0, 37.498083, 8.500000 NA DSM-5 1 1 0.5 1.0,1.0 1.0,0 1,3,1,1,1 1 0.5,0,0,0,1, 221 Nasser_2020 < 2 months NA 6-12 yo,8.45,13.9015384615385 NA,NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025),8.45 34.7573446327684,NA,NA Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
8997,Yu (2024) Yu,2024 10.1001/jamanetworkopen.2024.45885,100   0 100,100 Low,Viloxazine Viloxazine,  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA NA, 1.61104718  400.0000000 mg,Nasser 2021a,NCT3247556 400 mg,RCT (parallel, crossover, open-label),RR  99  96  195,outcomes reverse  0.9700000000  0.460000000, 2.050000e+00 NA,NA NA,NA,NA NA,NA,NA,100 100 100,100,100,100 100 some low low,low,low Placebo   0  34.875385 13.901538,NA,DSM-5 1,1,0.5,1.0 1.0 1.0,0 1,3 1 1 1 1 0.5 0,0 0 1, 222,Nasser_2021a < 2 months,NA 13-19 yo,8.45 13.9015384615385,NA,NA   6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA NA,Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
8997,Yu (2024) Yu,2024 10.1001/jamanetworkopen.2024.45885,100,  0 100,100 Low,Viloxazine,Viloxazine,  0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA NA, 1.61104718  600.0000000,mg,Nasser,2021a NCT3247556 600 mg,RCT (parallel, crossover, open-label) RR, 97, 96, 193,outcomes reverse  1.4800000000  0.760000000, 2.910000e+00 NA,NA NA NA,NA NA NA,NA 100,100 100 100,100,100 100,some,low low low,low,Placebo   0, 31.624870 13.749741,NA DSM-5 1 1 0.5,1.0 1.0 1.0,0,1,3 1 1,1,1 0.5 0,0,0 1  223 Nasser_2021a,< 2 months NA 13-19 yo,8.45,13.9015384615385,NA,NA,  6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025),8.45,34.7573446327684 NA,NA,Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
8997,Yu (2024) Yu 2024,10.1001/jamanetworkopen.2024.45885,100,  0,100 100 Low Viloxazine,Viloxazine,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA NA  1.38089758  200.0000000,mg Nasser,2021b,NCT3247517 200 mg RCT (parallel, crossover, open-label) RR  94,104  198 outcomes reverse, 2.7700000000  1.280000000, 5.980000e+00,NA NA,NA,NA,NA NA,NA,NA 100 100,100,100 100 100,100,some,some,low low low,Placebo,  0, 37.363636 13.847475 NA DSM-5 1,1 0.5,1.0,1.0,1.0 0 1 3,1 1 1,1 0.5,0 0 0 1, 224 Nasser_2021b,< 2 months,NA 13-19 yo 8.45 13.9015384615385,NA,NA,  6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684 NA,NA Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
8997 Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885,100   0,100 100,Low Viloxazine Viloxazine   0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA NA  1.38089758, 400.0000000,mg,Nasser 2021b NCT3247517 400 mg,RCT (parallel, crossover, open-label),RR 103,104  207,outcomes,reverse  1.7700000000  0.770000000  4.030000e+00,NA,NA,NA NA,NA NA,NA,NA,100,100 100,100 100,100,100 some some low low low,Placebo,  0  39.622222,13.899517,NA,DSM-5,1,1 0.5 1.0 1.0 1.0 0,1 3,1 1,1,1 0.5 0,0,0 1  225 Nasser_2021b,< 2 months NA,13-19 yo,8.45,13.9015384615385,NA NA,  6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025),8.45,34.7573446327684 NA,NA,Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
8997,Yu (2024),Yu,2024 10.1001/jamanetworkopen.2024.45885,100,  0,100 100 Low,Viloxazine,Viloxazine   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA, 1.84119678  200.0000000 mg,Nasser,2021c,NCT3247543 200 mg RCT (parallel, crossover, open-label) RR,107  97, 204 outcomes reverse, 1.0100000000, 0.560000000, 1.830000e+00,NA NA,NA NA,NA NA,NA,NA,100,100,100,100 100,100 100,some,low,low,low,low,Placebo   0, 33.795588  8.500000,NA DSM-5 1 1,0.5,1.0,1.0,1.0,0 1 3 1,1 1 1 0.5,0,0,0,1  226,Nasser_2021c < 2 months,NA 6-12 yo 8.45 13.9015384615385,NA,NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684 NA,NA Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
8997 Yu (2024),Yu 2024,10.1001/jamanetworkopen.2024.45885 100,  0 100,100,Low,Viloxazine,Viloxazine   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,NA  1.84119678  400.0000000 mg,Nasser 2021c NCT3247543 400 mg RCT (parallel, crossover, open-label),RR, 97, 97  194 outcomes,reverse  1.3500000000  0.770000000  2.370000e+00 NA NA NA NA,NA,NA,NA NA 100 100,100,100,100 100,100,some,low low low low Placebo,  0, 38.150000, 8.450000,NA DSM-5 1,1 0.5 1.0,1.0 1.0 0,1,3,1 1 1,1 0.5 0 0 0 1, 227 Nasser_2021c,< 2 months NA 6-12 yo,8.45,13.9015384615385,NA,NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA NA,Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8997,Yu (2024) Yu,2024,10.1001/jamanetworkopen.2024.45885,100,  0 100 100,Low Viloxazine Viloxazine   0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA NA, 1.84119678, 100.0000000 mg,Johnson 2020,100 mg,RCT (parallel, crossover, open-label),RR, 45, 24   69,outcomes reverse  1.9600000000, 0.600000000  6.340000e+00,NA NA,NA,NA NA NA NA NA 100 100,100 100 100 100,100,low,low low,low low,Placebo,  0  44.939130  8.569565 NA DSM-5 1,1 0.5 1.0,1.0,1.0,0 1,3,1 1,1 1 0.5,0,0 0,1  228 Johnson_2020,< 2 months NA,6-12 yo,8.45 13.9015384615385 NA,NA,  6, 6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2,Yu (2024) | Ostinelli (2025),8.45,34.7573446327684 NA,NA,Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
8997 Yu (2024) Yu 2024 10.1001/jamanetworkopen.2024.45885,100,  0,100 100,Low,Viloxazine,Viloxazine,  0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA NA, 1.84119678  200.0000000 mg,Johnson,2020 200 mg,RCT (parallel, crossover, open-label),RR, 46, 24,  70,outcomes reverse  2.9600000000, 0.960000000, 9.100000e+00,NA NA NA,NA,NA,NA,NA,NA 100 100 100,100,100,100 100 low low,low,low low Placebo   0  37.180000  8.897143 NA,DSM-5,1 1,0.5 1.0,1.0 1.0,0 1,3 1 1 1,1,0.5,0,0,0,1  229 Johnson_2020,< 2 months NA,6-12 yo,8.45,13.9015384615385 NA NA,  6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA,NA Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
8997 Yu (2024),Yu 2024 10.1001/jamanetworkopen.2024.45885,100   0,100,100 Low,Viloxazine Viloxazine   0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA  1.84119678, 300.0000000 mg Johnson,2020,300 mg,RCT (parallel, crossover, open-label),RR  47, 24   71 outcomes reverse  2.3800000000  0.760000000, 7.500000e+00,NA NA NA NA,NA,NA NA,NA 100 100,100,100 100 100,100 low,low,low low,low,Placebo   0  33.811268  8.898592 NA,DSM-5 1,1 0.5,1.0 1.0,1.0 0 1,3 1,1 1 1 0.5 0,0,0,1, 230,Johnson_2020 < 2 months NA,6-12 yo,8.45,13.9015384615385,NA,NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA,NA Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
8997,Yu (2024) Yu,2024,10.1001/jamanetworkopen.2024.45885 100,  0 100 100 Low,Viloxazine Viloxazine,  0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,NA, 1.84119678, 400.0000000,mg,Johnson 2020,400 mg RCT (parallel, crossover, open-label),RR  44  24   68 outcomes,reverse, 3.0900000000  1.010000000, 9.490000e+00,NA,NA NA,NA,NA,NA,NA NA,100,100 100,100,100 100,100,low,low low low,low Placebo,  0, 38.217647  8.894118,NA DSM-5 1 1 0.5 1.0 1.0 1.0,0,1,3 1 1 1,1 0.5 0,0,0 1, 231,Johnson_2020,< 2 months NA 6-12 yo 8.45 13.9015384615385 NA NA   6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA NA Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
1255 Gan (2019) Gan,2019 10.1089/cap.2019.0059 100,  0,100 100,Low,Vitamin D,Vitamin D 100 methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) Questionnaire Conners Parent Questionnaire + Attention-deficit/hyperactivity disorder  1.84119678,2000.0000000 IU/d,Mohammadpour,2018 NA,RCT SMD, 29, 25   54,NA NA  0.0900000000 -0.440000000  6.300000e-01,  9.6000000  10.2000000,NA,NA,NA,NA NA,NA,100 100,100,100,100 100 100,some low low,low low Active (any credible active intervention) 100, 25.806452, 8.500000 NA DSM-IV,1 1,1.0,1.0,1.0 1.0,1 0 1 1 1,1,1 1.0 1 0,1,1, 232 Mohammadpour_2018,< 2 months NA 6-12 yo 8.5,9.5 NA,NA,  3, 2,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Oppositional Defiant Disorder symptoms  1 Gan (2019),8.5 10.5 NA,NA,Gan (2019)_Vitamin D_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Gan (2019) - Vitamin D_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
1255,Gan (2019),Gan 2019 10.1089/cap.2019.0059 100,  0 100 100 Low,Vitamin D,Vitamin D 100 methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire Conners Parent Questionnaire  3.00000000,1000.0000000,IU/d,Naeini,2019,NA RCT,SMD, 35, 36   71,NA,NA  0.7400000000  0.260000000  1.220000e+00  16.6600000  14.5000000,NA,NA NA NA,NA,NA,100,100 100 100 100,100,100 some,low,low low low,Active (any credible active intervention) 100  19.354839, 9.500000,NA,DSM-IV,1 1,1.0 1.0,1.0,1.0,1 0,1,1,1,1,1,1.0 1 0,1 1  233 Naeini_2019,2-6 months,NA 6-12 yo,8.5,9.5,NA,NA   3, 2,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Oppositional Defiant Disorder symptoms, 1 Gan (2019) 8.5,10.5 NA,NA,Gan (2019)_Vitamin D_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Gan (2019) - Vitamin D_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
1255,Gan (2019) Gan 2019,10.1089/cap.2019.0059 100,  0 100 100 Low Vitamin D Vitamin D,100,methylphenidate Oppositional Defiant Disorder symptoms Mixed At study endpoint (closest to 12 weeks) Questionnaire,Conners Parent Questionnaire, ODD subscale, 2.76179517,3000.0000000,IU/d,Elshorbagy,2018,NA RCT MD  19  16   35 NA,NA,15.0700000000  8.650000000  2.149000e+01   9.1620000, 10.0450000 NA,NA NA NA NA NA,100,100 100 100,100 100,100,some,low,low low low Active (any credible active intervention) 100  16.666667,10.500000 NA,DSM-IV,1 1 1.0,1.0 1.0,1.0,1,0,1 1,1,1 1 1.0 1 0,1,1, 234 Elshorbagy_2018 2-6 months,NA,6-12 yo,8.5 10.5 NA,NA   3  2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Oppositional Defiant Disorder symptoms, 1 Gan (2019) 8.5 10.5 NA NA Gan (2019)_Vitamin D_Oppositional Defiant Disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Gan (2019) - Vitamin D_Oppositional Defiant Disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
1255,Gan (2019),Gan,2019,10.1089/cap.2019.0059 100   0 100,100,Low,Vitamin D Vitamin D,100,methylphenidate Oppositional Defiant Disorder symptoms Mixed,At study endpoint (closest to 12 weeks) Questionnaire Conners Parent Questionnaire, ODD subscale, 1.84119678,2000.0000000 IU/d,Mohammadpour 2018,NA RCT,MD, 29  25,  54 NA NA  4.4800000000 -1.850000000  1.081000e+01  12.1000000, 11.6000000,NA NA,NA,NA NA,NA,100,100,100,100 100,100 100,some low low low low,Active (any credible active intervention),100, 25.806452  8.500000 NA,DSM-IV,1 1,1.0,1.0,1.0 1.0 1 0,1,1 1,1,1 1.0 1 0 1,1  235 Mohammadpour_2018,< 2 months,NA,6-12 yo,8.5,10.5 NA NA   3, 2,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Oppositional Defiant Disorder symptoms  1 Gan (2019),8.5,10.5 NA NA,Gan (2019)_Vitamin D_Oppositional Defiant Disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Gan (2019) - Vitamin D_Oppositional Defiant Disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
1056,Elliott (2020),Elliott,2020,10.1371/journal.pone.0240584,100   0,100 100 Critically low Atomoxetine Atomoxetine   0 NA Executive functioning (report) Mixed At study endpoint (closest to 12 weeks) Questionnaire,BRIEF-A  2.30149597,NA,mg/d,Goto 2017,NA,RCT (parallel, crossover, open-label) SMD,195 196  391,NA,reverse,-0.3800000000,-0.580000000 -1.800000e-01 NA NA NA NA NA NA 13.6000000 10.4000000   0   0,100,  0 100   0,100,some,high low,low high Placebo   0  52.347315,32.248593 NA DSM-IV-TR 2 1 0.0 0.0,1.0,1.0 1 1,1 1 1,1 0,1.0 1 1,1,1, 236,Goto_2017,2-6 months,NA >= 20 yo 32.2485933503836 37,NA NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA,Elliott (2020)_Atomoxetine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Elliott (2020) - Atomoxetine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high high
1056,Elliott (2020) Elliott 2020,10.1371/journal.pone.0240584,100   0 100 100 Critically low,Atomoxetine Atomoxetine,  0,NA,Executive functioning (report) Mixed At study endpoint (closest to 12 weeks) Questionnaire,BRIEF-A  1.84119678 NA mg/d,Sutherland 2012,NA RCT (parallel, crossover, open-label),SMD, 97, 47, 144 NA,reverse,-0.3900000000 -0.740000000,-4.000000e-02,NA,NA NA NA,NA NA 25.6000000,26.3000000,  0   0 100   0,  0   0 100,some high high,some,high Placebo   0, 41.000000 37.000000,NA DSM-IV-TR 2,1 0.0 0.0,1.0,1.0 1,1,1 1 1,1,0,1.0,1 1 1,1  237,Sutherland_2012 < 2 months,NA >= 20 yo,32.2485933503836,37,NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA,Elliott (2020)_Atomoxetine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Elliott (2020) - Atomoxetine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,high high
3442 Stuhec (2015),Stuhec,2015,10.1016/j.jad.2015.03.006,  0,  0 100 100 Critically low,Bupropion Bupropion,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),Questionnaire Conners' Parent Rating Scale  0.92059839,   5.3000000 mg/d Clay,1998,NA RCT (parallel, crossover, open-label) G, 18, 10   28,NA,reverse,-0.3900000000 -1.170000000, 3.900000e-01   7.2000000   7.3000000 NA,NA,NA,NA NA NA,  0,  0 100 100   0,  0 100,some,low high,low,high Placebo   0,  3.600000 NA,NA DSM-III 3 0,1.0 0.0 1.0 1.0,0 1,2,1 1,1,0,0.5,1 0,1 1  238,Clay_1998 < 2 months NA,NA,8.5,8.5,NA,NA  10, 7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5,40.25 NA NA Stuhec (2015)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Stuhec (2015) - Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high,high
3442,Stuhec (2015) Stuhec 2015 10.1016/j.jad.2015.03.006,100,  0,100 100 Critically low,Bupropion Bupropion   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),Questionnaire,Conners' Parent Rating Scale, 0.92059839 NA NA Conners,1996,NA,RCT (parallel, crossover, open-label) G, 62  34   96,NA reverse -0.2900000000,-0.710000000, 1.300000e-01 NA,NA NA NA,NA NA, 6.2000000, 6.8000000,100,100 100,100,100,100 100,low low some some,low Placebo   0  10.000000  8.500000,NA,DSM-III,3,0,1.0,0.0,1.0 1.0 0 1,2,1,1,1 0 0.5 1,0 1 1, 239,Conners_1996,< 2 months,NA 6-12 yo,8.5,8.5 NA,NA  10, 7 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5 40.25,NA,NA,Stuhec (2015)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Stuhec (2015) - Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3681,Verbeeck (2017) Verbeeck 2017 10.1002/14651858.CD009504.pub2 100,  0 100,100 High,Bupropion,Bupropion   0 NA,Depressive disorder symptoms,Mixed At study endpoint (closest to 12 weeks) Questionnaire,HAM-D  1.61104718, 300.0000000,mg/d Kuperman 2001 NA RCT (parallel, crossover, open-label) MD, 11, 11,  22,NA,NA  1.4000000000 -1.750000000, 4.550000e+00,NA,NA,NA NA NA NA, 4.4000000  3.0000000 100,100 100,100   0,100 100 some,some high some some Placebo   0  30.000000 32.700000,NA,DSM-IV,0,1,1.0,1.0,1.0 1.0,1 1,0 1,1,1 1 1.0 1,1 1 1  240,Kuperman_2001 < 2 months NA,>= 20 yo,32.7,40.25 NA NA, 10  7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5 40.25 NA,NA,Verbeeck (2017)_Bupropion_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Verbeeck (2017) - Bupropion_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
3681 Verbeeck (2017),Verbeeck,2017 10.1002/14651858.CD009504.pub2,100   0,100,100,High,Bupropion Bupropion   0,NA,Depressive disorder symptoms Mixed,At study endpoint (closest to 12 weeks) Questionnaire,HAM-D, 1.84119678  450.0000000 mg/d Wilens,2005 NA,RCT (parallel, crossover, open-label),MD  81  81, 162,NA NA, 0.4300000000 -0.600000000  1.460000e+00 NA NA NA,NA NA,NA, 3.1000000, 3.6000000 100,100 100,100   0,100 100 some some high some some Placebo,  0  40.000000 40.250000,NA DSM-IV 0,1 1.0,1.0,1.0 1.0 1 1,0 1,1,1,1,1.0 1 1,1 1  241,Wilens_2005 < 2 months,NA >= 20 yo 32.7 40.25 NA NA  10, 7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5,40.25 NA,NA,Verbeeck (2017)_Bupropion_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Verbeeck (2017) - Bupropion_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
3681,Verbeeck (2017),Verbeeck,2017 10.1002/14651858.CD009504.pub2 100   0,100 100,High Bupropion,Bupropion   0,NA,Generalized anxiety,Mixed At study endpoint (closest to 12 weeks) Questionnaire,HAM-A  1.61104718, 300.0000000 mg/d,Kuperman,2001,NA RCT (parallel, crossover, open-label),MD  11, 11   22,NA,NA,-0.5000000000 -2.910000000, 1.910000e+00 NA NA,NA NA,NA NA  3.6000000, 1.9000000 100,100 100,100   0 100,100 some some,high,some,some Placebo,  0  30.000000 32.700000 NA DSM-IV,0,1,1.0,1.0 1.0 1.0,1,1,0,1 1,1,1,1.0,1,1 1,1  242,Kuperman_2001,< 2 months,NA >= 20 yo 32.7 40.25 NA NA, 10  7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5 40.25 NA NA Verbeeck (2017)_Bupropion_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Verbeeck (2017) - Bupropion_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
3681 Verbeeck (2017),Verbeeck,2017,10.1002/14651858.CD009504.pub2 100   0 100,100 High Bupropion Bupropion   0,NA,Generalized anxiety Mixed At study endpoint (closest to 12 weeks),Questionnaire,HAM-A  1.84119678  450.0000000 mg/d,Wilens,2005 NA RCT (parallel, crossover, open-label),MD, 81, 81, 162,NA,NA  0.5700000000 -0.630000000, 1.770000e+00 NA,NA NA NA,NA,NA  4.0000000, 3.8000000,100,100 100 100,  0 100 100 some some,high,some some Placebo,  0, 40.000000 40.250000 NA,DSM-IV,0,1,1.0 1.0,1.0 1.0 1,1,0,1,1,1,1 1.0 1 1 1 1, 243,Wilens_2005,< 2 months,NA,>= 20 yo 32.7,40.25,NA NA, 10, 7 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5 40.25,NA,NA,Verbeeck (2017)_Bupropion_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Verbeeck (2017) - Bupropion_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
8991,Maiti - Children (2024),Maiti - Children 2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0,100,100 Critically low,Dasotraline,Dasotraline,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Questionnaire,ADHD Rating Scale IV  1.38089758,   2.0000000 mg/d Findling,2019,Subgroup 1: Dasotreline 2mg vs Placebo RCT (parallel, crossover, open-label),SMD,107, 58, 165 outcomes reverse -0.0300000000,-0.350000000  2.900000e-01,NA,NA NA NA,NA,NA 13.4500000,14.0000000 100 100 100 100,100,100,100 low,low low,low,low,Placebo   0,NA, 9.000000,NA DSM 5,2 1 0.5 0.0 1.0,1.0,0,1,2 1,1,1 1,1.0,0,0 1,1  244,Findling_2019 < 2 months,NA,6-12 yo,9 9 NA,NA   5  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2 Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5,NA NA Maiti - Children (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Maiti - Children (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8991,Maiti - Children (2024) Maiti - Children,2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0,100,100,Critically low,Dasotraline,Dasotraline   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks),Questionnaire,ADHD Rating Scale IV  1.38089758,   4.0000000,mg/d Findling,2019 Subgroup 2: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label),SMD,113, 58  171 outcomes,reverse,-0.4400000000 -0.760000000 -1.200000e-01,NA NA NA NA,NA NA,13.8200000,14.0000000,100 100 100,100,100,100 100,low,low,low,low low,Placebo   0,NA, 9.000000,NA,DSM 5 2 1 0.5,0.0,1.0 1.0 0,1 2,1 1 1 1,1.0,0 0,1 1  245,Findling_2019 < 2 months NA 6-12 yo 9,9 NA NA,  5  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5,NA NA,Maiti - Children (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Maiti - Children (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
8991,Maiti - Children (2024) Maiti - Children 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100,  0,100,100,Critically low,Dasotraline,Dasotraline   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Observational tool,Swanson, Kotkin, Agler, M-Flynn, and Pelham rating scale (SCAMP-CS), 0.46029919    4.0000000,mg/d Wigal,2020 NA,RCT (parallel, crossover, open-label),SMD, 56, 56  112 NA reverse -0.7700000000 -1.150000000 -3.800000e-01,NA NA NA NA,NA,NA, 6.7300000  6.7300000,100 100 100 100 100 100 100 low low,low low low,Placebo,  0,NA  9.000000 NA DSM 5 2 1 0.5 0.0 1.0 1.0,0,1,2,1,1 1,1 1.0,0,0 1,1, 246 Wigal_2020,< 2 months,NA 6-12 yo 9,9 NA NA   5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2 Maiti - Children (2024) | Maiti - Adults (2024),9 36.5 NA,NA,Maiti - Children (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Maiti - Children (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
8991,Maiti - Children (2024) Maiti - Children 2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0,100,100,Critically low,Dasotraline Dasotraline,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Observational tool,Swanson, Kotkin, Agler, M-Flynn, and Pelham rating scale (SCAMP-CS)  0.46029919    2.0000000,mg/d,Wigal 2022,NA,RCT (parallel, crossover, open-label) SMD, 47  48   95,NA,reverse,-0.9500000000,-1.380000000 -5.300000e-01,NA,NA,NA NA,NA,NA, 5.4800000  5.5400000 100,100,100,100 100,100,100,low,low low,low,low,Placebo   0 NA, 9.000000 NA,DSM 5,2,1,0.5,0.0,1.0 1.0 0,1,2,1 1 1 1 1.0,0,0 1,1, 247 Wigal_2022,< 2 months NA 6-12 yo,9 9,NA,NA   5, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2 Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5,NA,NA Maiti - Children (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Maiti - Children (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
8991,Maiti - Adults (2024),Maiti - Adults 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0 100 100,Critically low Dasotraline,Dasotraline,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),Questionnaire,ADHD Rating Scale IV  0.92059839,   4.0000000 mg/d Koblan 2015,Subgroup 3: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label) SMD,114  55  169,outcomes,reverse,-0.2300000000 -0.550000000  9.000000e-02,NA NA,NA NA NA,NA,11.7400000,11.5400000 100,100,100,100,100 100 100 low low,some low,low Placebo,  0 NA,36.500000 NA,DSM 5,2 1,0.5,0.0,1.0 1.0 0 1 2,1 1,1,1,1.0 0,0 1,1, 248,Koblan_2015 < 2 months,NA >= 20 yo,36.5 36.5 NA NA   5, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2 Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5 NA NA Maiti - Adults (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Maiti - Adults (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
8991 Maiti - Adults (2024) Maiti - Adults 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0 100,100 Critically low Dasotraline,Dasotraline   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),Questionnaire ADHD Rating Scale IV  0.92059839,   8.0000000 mg/d Koblan 2015,Subgroup 4: Dasotreline 8mg vs Placebo,RCT (parallel, crossover, open-label) SMD,107  55  162 outcomes reverse -0.3400000000,-0.670000000 -2.000000e-02 NA NA,NA NA NA NA 12.4100000,11.5400000 100 100 100,100,100 100,100 low,low,some,low low,Placebo   0,NA 36.500000 NA,DSM 5 2,1,0.5,0.0 1.0 1.0,0,1 2,1 1,1,1,1.0 0 0 1 1  249 Koblan_2015,< 2 months NA >= 20 yo,36.5,36.5 NA NA   5, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2 Maiti - Children (2024) | Maiti - Adults (2024),9 36.5 NA NA,Maiti - Adults (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Maiti - Adults (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
8991 Maiti - Adults (2024) Maiti - Adults 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100,  0,100 100,Critically low,Dasotraline,Dasotraline   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) Questionnaire,ADHD Rating Scale IV, 1.84119678    4.0000000 mg/d Adler 2021 Subgroup 5: Dasotreline 4mg vs Placebo,RCT (parallel, crossover, open-label) SMD,207 106, 313 outcomes,reverse -0.0800000000,-0.320000000  1.500000e-01 NA NA,NA,NA NA,NA 12.9500000,13.0700000,100,100,100 100 100,100,100 low low some,low low Placebo   0,NA 36.500000 NA,DSM 5,2 1 0.5,0.0 1.0 1.0,0 1,2 1 1,1 1,1.0 0 0,1,1, 250,Adler_2021 < 2 months,NA,>= 20 yo 36.5 36.5 NA NA,  5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2 Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5,NA,NA,Maiti - Adults (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Maiti - Adults (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
8991 Maiti - Adults (2024) Maiti - Adults,2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0,100,100,Critically low,Dasotraline Dasotraline   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Questionnaire ADHD Rating Scale IV  1.84119678    6.0000000 mg/d Adler,2021 Subgroup 6: Dasotreline 6mg vs Placebo,RCT (parallel, crossover, open-label),SMD,206 105  311,outcomes reverse,-0.2000000000 -0.440000000  4.000000e-02 NA,NA,NA,NA NA NA,12.9200000,13.0700000,100 100,100 100,100,100,100,low low some,low,low,Placebo   0 NA 36.500000 NA,DSM 5 2 1 0.5,0.0 1.0,1.0,0 1 2 1,1,1 1 1.0 0 0 1,1  251,Adler_2021,< 2 months NA >= 20 yo,36.5 36.5 NA NA   5, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024),9,36.5 NA,NA Maiti - Adults (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Maiti - Adults (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
8991 Maiti - Adults (2024) Maiti - Adults,2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100   0,100 100,Critically low Dasotraline,Dasotraline   0 NA CGI Mixed,At study endpoint (closest to 12 weeks) Observational tool,Clinical Global Impression-Severity scale, 0.92059839,   4.0000000,mg/d Koblan 2015,Subgroup 3: Dasotreline 4mg vs Placebo,RCT (parallel, crossover, open-label) G 114  55, 169 outcomes reverse -0.3750856347,-0.700259573,-4.991170e-02   1.0677000   1.0488000,NA NA NA,NA, 1.0700000  1.0500000,100 100 100,100 100 100 100 low,low some low,low,Placebo,  0 NA 36.500000,NA DSM 5,2 1 0.5,0.0 1.0 1.0,0 1 2,1,1,1,1,1.0 0 0,1 1, 252,Koblan_2015,< 2 months,NA >= 20 yo 36.5,36.5,NA,NA   5, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2 Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5 NA NA,Maiti - Adults (2024)_Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Maiti - Adults (2024) - Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
8991 Maiti - Adults (2024) Maiti - Adults 2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0 100 100 Critically low,Dasotraline,Dasotraline,  0,NA,CGI,Mixed,At study endpoint (closest to 12 weeks) Observational tool Clinical Global Impression-Severity scale  0.92059839,   8.0000000,mg/d Koblan 2015,Subgroup 4: Dasotreline 8mg vs Placebo,RCT (parallel, crossover, open-label),G,107  55, 162 outcomes,reverse -0.3830735622,-0.711896716 -5.425041e-02,  1.0344000,  1.0488000,NA NA NA NA, 1.0300000, 1.0500000,100,100,100,100,100 100 100 low low some low low Placebo,  0,NA,36.500000 NA DSM 5,2 1,0.5 0.0,1.0 1.0,0 1,2 1 1,1,1 1.0,0,0 1,1  253 Koblan_2015 < 2 months NA >= 20 yo,36.5 36.5 NA NA   5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2 Maiti - Children (2024) | Maiti - Adults (2024),9 36.5,NA,NA Maiti - Adults (2024)_Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Maiti - Adults (2024) - Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
8991,Maiti - Adults (2024),Maiti - Adults 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0 100 100 Critically low,Dasotraline,Dasotraline   0,NA CGI Mixed,At study endpoint (closest to 12 weeks) Observational tool,Clinical Global Impression-Severity scale, 1.84119678    4.0000000 mg/d Adler 2021,Subgroup 5: Dasotreline 4mg vs Placebo,RCT (parallel, crossover, open-label),G,207,106  313 outcomes,reverse,-0.0691132538 -0.303613144  1.653866e-01,  1.4387000   1.4526000 NA NA,NA,NA, 1.4400000, 1.4500000,100,100,100,100 100 100,100 low low,some,low,low Placebo,  0 NA,36.500000 NA,DSM 5 2,1 0.5,0.0 1.0,1.0,0 1 2 1,1,1,1 1.0 0,0,1 1, 254,Adler_2021 < 2 months NA,>= 20 yo,36.5 36.5,NA NA,  5  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2 Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5 NA NA Maiti - Adults (2024)_Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Maiti - Adults (2024) - Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
8991,Maiti - Adults (2024) Maiti - Adults,2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100   0,100,100 Critically low,Dasotraline,Dasotraline,  0,NA,CGI Mixed At study endpoint (closest to 12 weeks),Observational tool Clinical Global Impression-Severity scale  1.84119678,   6.0000000 mg/d Adler,2021 Subgroup 6: Dasotreline 6mg vs Placebo,RCT (parallel, crossover, open-label) G,206,105  311,outcomes reverse,-0.2076619509,-0.443599809, 2.827591e-02,  1.4353000   1.4526000 NA,NA NA,NA  1.4400000, 1.4500000 100,100 100 100,100,100,100,low low,some low,low,Placebo,  0,NA 36.500000,NA DSM 5 2 1,0.5,0.0 1.0,1.0,0 1 2 1,1 1,1 1.0 0,0,1 1, 255 Adler_2021 < 2 months,NA,>= 20 yo,36.5 36.5 NA,NA,  5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2,Maiti - Children (2024) | Maiti - Adults (2024),9,36.5 NA NA,Maiti - Adults (2024)_Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Maiti - Adults (2024) - Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
8991 Maiti - Children (2024),Maiti - Children,2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100   0 100 100 Critically low,Dasotraline,Dasotraline   0 NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA, 1.38089758,   2.0000000 mg/d,Findling 2019 Subgroup 1: Dasotreline 2mg vs Placebo RCT (parallel, crossover, open-label) RR 111  58, 169,outcomes,reverse  2.9609609610  0.904771963, 9.690055e+00,NA,NA NA,NA NA NA,NA,NA 100,100 100,100,100,100,100,low,low,low,low low,Placebo,  0,NA, 9.000000 NA,DSM 5 2,1 0.5,0.0,1.0,1.0 0 1,2,1 1 1,1 1.0 0,0 1,1, 256 Findling_2019,< 2 months NA 6-12 yo,9 9 NA NA   5, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2 Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5 NA,NA,Maiti - Children (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Maiti - Children (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
8991 Maiti - Children (2024) Maiti - Children 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100,  0,100 100 Critically low,Dasotraline,Dasotraline   0 NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA, 0.46029919    2.0000000,mg/d,Wigal,2022,NA RCT (parallel, crossover, open-label),RR  47, 48,  95 NA reverse, 4.0851063830  0.473912738  3.521343e+01 NA NA,NA NA NA NA,NA NA,100 100,100 100 100 100,100 low,low,low low,low Placebo,  0 NA, 9.000000,NA DSM 5,2,1 0.5 0.0 1.0 1.0,0,1,2 1,1,1,1,1.0 0 0,1,1  257,Wigal_2022,< 2 months,NA,6-12 yo 9 9 NA,NA,  5  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2 Maiti - Children (2024) | Maiti - Adults (2024),9 36.5,NA,NA,Maiti - Children (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Maiti - Children (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
8991 Maiti - Children (2024) Maiti - Children,2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0,100,100,Critically low,Dasotraline Dasotraline,  0 NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA, 1.38089758,   4.0000000,mg/d Findling 2019,Subgroup 2: Dasotreline 4mg vs Placebo,RCT (parallel, crossover, open-label) RR 115, 58, 173 outcomes,reverse, 6.3043478261  1.546479302  2.570018e+01,NA,NA,NA NA NA NA NA,NA 100 100 100,100,100,100,100 low,low,low,low low,Placebo   0 NA  9.000000,NA,DSM 5,2 1 0.5 0.0 1.0 1.0 0,1,2,1,1 1 1,1.0,0 0 1,1, 258,Findling_2019 < 2 months NA,6-12 yo,9 9,NA,NA,  5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2,Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5,NA,NA Maiti - Children (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Maiti - Children (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
8991 Maiti - Children (2024) Maiti - Children 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0 100,100 Critically low Dasotraline Dasotraline,  0 NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA  0.46029919    4.0000000,mg/d,Wigal 2020,NA RCT (parallel, crossover, open-label) RR, 56, 56, 112 NA reverse  5.5000000000  1.276793143, 2.369217e+01 NA,NA,NA NA NA,NA,NA NA,100,100 100 100 100 100,100,low,low,low low,low,Placebo,  0 NA, 9.000000 NA DSM 5,2 1 0.5 0.0,1.0,1.0,0,1,2,1,1,1 1,1.0,0 0,1 1  259,Wigal_2020 < 2 months,NA,6-12 yo 9 9,NA,NA,  5, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2,Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5,NA,NA,Maiti - Children (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Maiti - Children (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
8991 Maiti - Adults (2024),Maiti - Adults 2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100   0 100 100 Critically low Dasotraline Dasotraline   0,NA,Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA  0.92059839,   4.0000000 mg/d Koblan 2015,Subgroup 3: Dasotreline 4mg vs Placebo,RCT (parallel, crossover, open-label),RR,116  56, 172 outcomes,reverse, 2.4137931034, 1.212101884, 4.806854e+00,NA,NA NA NA,NA NA,NA,NA,100 100 100,100 100,100 100 low low some low low Placebo,  0 NA,36.500000 NA,DSM 5,2 1,0.5,0.0 1.0 1.0 0,1 2,1 1 1,1 1.0 0 0 1,1  260 Koblan_2015 < 2 months NA,>= 20 yo,36.5,36.5,NA,NA,  5, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2,Maiti - Children (2024) | Maiti - Adults (2024),9 36.5 NA,NA Maiti - Adults (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Maiti - Adults (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
8991,Maiti - Adults (2024),Maiti - Adults 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0 100 100 Critically low,Dasotraline Dasotraline,  0,NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA, 1.84119678    4.0000000,mg/d Adler 2021 Subgroup 5: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label),RR 210 110  320 outcomes reverse, 4.3869047619  2.187382061, 8.798158e+00 NA NA,NA,NA,NA NA NA NA 100 100,100,100 100,100,100,low low some,low low,Placebo,  0,NA 36.500000 NA DSM 5 2 1 0.5,0.0,1.0 1.0 0,1,2,1 1,1 1,1.0,0,0,1 1  261 Adler_2021,< 2 months NA >= 20 yo 36.5 36.5 NA NA   5, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5 NA,NA,Maiti - Adults (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Maiti - Adults (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
8991 Maiti - Adults (2024),Maiti - Adults,2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100,  0,100,100,Critically low Dasotraline,Dasotraline   0,NA,Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA, 1.84119678    6.0000000,mg/d Adler,2021,Subgroup 6: Dasotreline 6mg vs Placebo,RCT (parallel, crossover, open-label) RR 207,109  316 outcomes reverse, 2.8303140097, 1.750332805, 4.576660e+00,NA,NA,NA,NA,NA,NA,NA,NA 100,100 100,100,100 100,100 low,low some,low,low Placebo   0 NA,36.500000,NA DSM 5 2 1,0.5 0.0 1.0,1.0,0 1 2,1 1 1,1,1.0,0,0 1,1  262 Adler_2021,< 2 months,NA,>= 20 yo,36.5,36.5,NA NA   5, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2 Maiti - Children (2024) | Maiti - Adults (2024),9,36.5 NA,NA Maiti - Adults (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Maiti - Adults (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
8991,Maiti - Adults (2024) Maiti - Adults 2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100,  0 100,100 Critically low Dasotraline,Dasotraline,  0 NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA, 0.92059839,   8.0000000 mg/d,Koblan,2015,Subgroup 4: Dasotreline 8mg vs Placebo RCT (parallel, crossover, open-label),RR 111  55  166,outcomes reverse  2.7527527528  1.463417284, 5.178050e+00 NA NA NA NA NA NA NA NA 100 100,100 100,100 100,100,low,low some,low low Placebo   0 NA 36.500000 NA DSM 5 2 1,0.5 0.0,1.0 1.0,0,1,2 1,1,1,1,1.0,0 0,1 1, 263,Koblan_2015 < 2 months NA >= 20 yo,36.5 36.5,NA NA,  5, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5 NA,NA,Maiti - Adults (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Maiti - Adults (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
8991,Maiti - Children (2024) Maiti - Children 2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,100,  0 100 100,Critically low Dasotraline,Dasotraline   0 NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA, 1.38089758,   2.0000000 mg/d Findling,2019,Subgroup 1: Dasotreline 2mg vs Placebo RCT (parallel, crossover, open-label) RR,111  58  169,outcomes reverse, 2.4384384384, 0.730171042, 8.143273e+00 NA NA NA,NA NA,NA NA NA,100,100 100 100 100 100,100,low low,low low low Placebo   0,NA  9.000000,NA,DSM 5 2 1 0.5 0.0,1.0,1.0 0 1 2 1 1,1 1,1.0,0,0,1 1, 264 Findling_2019,< 2 months NA 6-12 yo 9,9,NA,NA   5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2,Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5,NA,NA,Maiti - Children (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Maiti - Children (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
8991,Maiti - Children (2024) Maiti - Children 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100,  0,100 100 Critically low,Dasotraline Dasotraline   0 NA Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA, 0.46029919,   2.0000000,mg/d Wigal 2022,NA,RCT (parallel, crossover, open-label) RR, 47  48,  95,outcomes,reverse, 5.1041666667  0.251552256  1.035670e+02,NA,NA,NA NA NA,NA,NA NA 100 100,100,100,100 100 100,low,low,low low,low Placebo,  0 NA  9.000000 NA,DSM 5 2,1,0.5 0.0,1.0,1.0 0 1,2,1,1,1,1 1.0 0,0 1 1, 265,Wigal_2022 < 2 months,NA 6-12 yo 9 9 NA,NA,  5, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2 Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5 NA,NA,Maiti - Children (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Maiti - Children (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
8991 Maiti - Children (2024),Maiti - Children 2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100,  0,100 100 Critically low Dasotraline,Dasotraline,  0 NA Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA  1.38089758,   4.0000000,mg/d,Findling 2019,Subgroup 2: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label),RR 115, 58  173 outcomes,reverse, 4.2028985507  1.323877714  1.334289e+01 NA NA NA NA NA NA,NA,NA 100,100 100 100 100,100 100,low,low low,low,low,Placebo,  0,NA  9.000000 NA,DSM 5 2,1 0.5,0.0,1.0,1.0,0,1 2,1 1 1,1,1.0 0 0,1,1, 266,Findling_2019,< 2 months NA 6-12 yo,9,9 NA NA   5  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5 NA NA,Maiti - Children (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Maiti - Children (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8991 Maiti - Children (2024),Maiti - Children,2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0 100 100 Critically low,Dasotraline,Dasotraline,  0 NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA  0.46029919    4.0000000 mg/d,Wigal,2020 NA,RCT (parallel, crossover, open-label) RR, 56, 56  112,outcomes,reverse, 3.0000000000, 0.632398010  1.423154e+01,NA,NA NA,NA NA NA NA NA 100,100,100,100 100 100 100,low low low low low Placebo,  0,NA  9.000000 NA DSM 5,2 1,0.5,0.0 1.0,1.0 0 1 2,1,1,1 1 1.0 0,0,1 1  267 Wigal_2020,< 2 months,NA,6-12 yo 9,9,NA,NA,  5, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2 Maiti - Children (2024) | Maiti - Adults (2024),9 36.5,NA,NA Maiti - Children (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Maiti - Children (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
8991 Maiti - Adults (2024) Maiti - Adults 2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0 100,100 Critically low Dasotraline Dasotraline   0,NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 0.92059839,   4.0000000,mg/d,Koblan 2015 Subgroup 3: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label),RR,116  56  172,outcomes,reverse  5.7931034483  0.772407525, 4.344863e+01,NA NA NA NA,NA NA,NA NA 100 100,100,100 100,100 100,low low some low low Placebo,  0,NA 36.500000,NA DSM 5,2,1 0.5 0.0,1.0,1.0 0,1,2 1 1 1,1,1.0 0,0,1 1, 268,Koblan_2015,< 2 months NA >= 20 yo,36.5 36.5,NA,NA   5, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024),9 36.5,NA NA,Maiti - Adults (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Maiti - Adults (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
8991,Maiti - Adults (2024) Maiti - Adults,2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0 100,100 Critically low Dasotraline Dasotraline,  0,NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  1.84119678    4.0000000,mg/d,Adler 2021 Subgroup 5: Dasotreline 4mg vs Placebo,RCT (parallel, crossover, open-label) RR,210 109  319 outcomes,reverse, 2.9066666667  1.154878171, 7.315673e+00,NA NA,NA,NA,NA,NA NA,NA 100,100,100 100,100,100,100 low low some low low Placebo,  0,NA 36.500000 NA DSM 5 2,1 0.5,0.0 1.0 1.0,0 1 2,1 1,1 1,1.0 0,0 1,1, 269,Adler_2021,< 2 months,NA,>= 20 yo,36.5,36.5,NA,NA   5, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2,Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5 NA,NA,Maiti - Adults (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Maiti - Adults (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
8991,Maiti - Adults (2024),Maiti - Adults 2024,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100,  0,100 100,Critically low Dasotraline Dasotraline   0 NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  1.84119678    6.0000000,mg/d,Adler,2021,Subgroup 6: Dasotreline 6mg vs Placebo RCT (parallel, crossover, open-label),RR,207 110  317,outcomes reverse, 4.2512077295  1.878791830  9.619356e+00 NA NA,NA NA,NA NA,NA,NA 100 100,100,100,100,100,100,low low some,low low Placebo,  0 NA 36.500000,NA,DSM 5 2,1 0.5 0.0 1.0,1.0,0 1 2,1 1 1,1,1.0 0,0 1,1  270 Adler_2021,< 2 months NA,>= 20 yo,36.5,36.5,NA,NA,  5, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite, 2,Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5 NA,NA Maiti - Adults (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Maiti - Adults (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
8991,Maiti - Adults (2024),Maiti - Adults,2024 10.4103/indianjpsychiatry.indianjpsychiatry_3_24 100   0 100 100,Critically low Dasotraline Dasotraline   0 NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA  0.92059839    8.0000000 mg/d Koblan,2015,Subgroup 4: Dasotreline 8mg vs Placebo RCT (parallel, crossover, open-label) RR 111  55  166,outcomes reverse  6.1936936937  1.521942965, 2.520583e+01 NA NA NA NA,NA NA NA NA,100,100 100,100 100 100,100 low low,some low low Placebo   0,NA,36.500000 NA DSM 5,2 1 0.5,0.0 1.0,1.0 0 1,2 1,1,1 1 1.0 0,0 1 1, 271 Koblan_2015,< 2 months NA,>= 20 yo,36.5,36.5,NA NA   5, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite  2,Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5 NA NA,Maiti - Adults (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Maiti - Adults (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 381 Boesen (2022) Boesen 2022,10.1002/14651858.CD012857.pub2 100   0 100 100,High Methylphenidate,OROS methylphenidate   0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Interview Interview  1.61104718   72.0000000,mg/daily Adler,2006,NA,RCT (parallel, crossover, open-label) RR,110,116  226,NA reverse, 4.2181818182  1.921901135, 9.258051e+00,NA NA,NA,NA,NA NA NA,NA   0,  0 100 100   0,  0,100 low,some high,some,high,Placebo   0, 44.000000,39.000000 NA,DSM-IV,0,1 1.0 1.0 1.0,1.0,1 1 0,1 1,1 1,1.0,1,1,1 1  272,Adler_2006,< 2 months,NA,>= 20 yo,33,42 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,high,high
 381 Boesen (2022),Boesen,2022,10.1002/14651858.CD012857.pub2 100   0 100 100 High,Methylphenidate,OROS methylphenidate   0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Interview,Interview  1.38089758   40.0000000,mg/daily,Biederman 2003,NA RCT (parallel, crossover, open-label) RR 109,114, 223 NA reverse  4.5321100917, 1.941029323  1.058203e+01 NA NA,NA,NA,NA,NA,NA NA,  0   0,100 100,  0   0 100 low,some high,some high Placebo   0, 45.000000 36.000000 NA,DSM-IV,0 1 1.0 1.0,1.0 1.0 1 1,0 1 1,1,1,1.0 1 1,1,1, 273 Biederman_2003 < 2 months,NA,>= 20 yo,33,42,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no high,high
 381 Boesen (2022),Boesen 2022 10.1002/14651858.CD012857.pub2 100,  0,100,100,High Methylphenidate,OROS methylphenidate,  0,NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Interview,Interview, 2.99194476   63.0000000,mg/daily,Casas,2008 NA RCT (parallel, crossover, open-label),RR 181, 97  278 NA reverse, 4.6088397790, 1.887661173, 1.125276e+01 NA NA,NA,NA,NA NA,NA,NA 100 100,100 100   0 100,100 low,some,high,some,some,Placebo   0, 48.000000 36.000000,NA,DSM-IV TR,0 1,1.0 1.0,1.0,1.0,1 1 0 1,1 1 1 1.0,1 1 1 1, 274,Casas_2008 2-6 months NA,>= 20 yo,33 42 NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 381,Boesen (2022) Boesen 2022 10.1002/14651858.CD012857.pub2 100,  0,100 100,High,Methylphenidate extended-release methylphenidate,  0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Interview Interview,11.96777906,  70.0000000,mg/daily,Compas 2007 NA,RCT (parallel, crossover, open-label) RR,205,209, 414,NA reverse  5.8621951220, 2.837349694  1.211177e+01 NA,NA NA NA,NA,NA,NA NA,100,100,100 100   0 100,100 low some,high some low Placebo   0, 50.100000 35.000000 NA,DSM-IV,0 1,1.0,1.0 1.0,1.0,1,1,0 1 1 1,1,1.0 1 1,1,1, 275 Compas_2007,7-12 months,NA >= 20 yo 33,42,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 381 Boesen (2022) Boesen 2022,10.1002/14651858.CD012857.pub2,100,  0,100,100,High Methylphenidate,OROS methylphenidate,  0,NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Interview,Interview  1.15074799   72.0000000,mg/daily,Ginsberg,2007 NA RCT (parallel, crossover, open-label) RR  15  15,  30 NA,reverse, 9.0000000000, 0.526684293  1.537923e+02 NA,NA NA,NA,NA NA,NA NA,100,100 100,100 100,100,100 low,some,some some,low,Placebo   0,  0.000000 34.000000 NA DSM-IV,0 1 1.0,1.0,1.0 1.0 1 1 0 1 1 1 1,1.0 1,1 1,1, 276 Ginsberg_2007 < 2 months NA,>= 20 yo 33 42,NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 381 Boesen (2022) Boesen,2022,10.1002/14651858.CD012857.pub2 100,  0 100,100,High Methylphenidate,OROS methylphenidate   0 NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Interview Interview, 1.38089758   45.0000000,mg/daily Goodman 2009 NA RCT (parallel, crossover, open-label) RR 174 175  349 NA reverse, 3.5919540230  1.595635195  8.085892e+00,NA,NA NA,NA NA NA NA NA   0   0 100,100,  0   0,100,low some high,some,high Placebo,  0, 46.000000,36.000000,NA,DSM-IV 0,1 1.0 1.0,1.0,1.0,1,1,0 1,1,1,1 1.0 1,1,1,1  277,Goodman_2009 < 2 months NA >= 20 yo 33 42,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high,high
 381,Boesen (2022) Boesen,2022 10.1002/14651858.CD012857.pub2,100,  0 100 100,High,Methylphenidate Long-acting (LA) methylphenidate   0 NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Interview Interview  2.07134638,  60.0000000,mg/daily Huss 2010,NA RCT (parallel, crossover, open-label),RR 542,180, 722,NA reverse, 5.6457564576, 2.823802336, 1.128782e+01 NA NA,NA,NA NA,NA NA NA,  0   0,100 100,  0   0,100 low some,high some,high,Placebo   0, 45.000000,35.000000 NA DSM-IV,0 1,1.0 1.0,1.0 1.0,1 1 0,1,1 1 1 1.0,1 1 1,1  278 Huss_2010,2-6 months,NA,>= 20 yo,33,42,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high,high
 381 Boesen (2022),Boesen,2022,10.1002/14651858.CD012857.pub2 100,  0 100,100 High,Methylphenidate,OROS methylphenidate   0,NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Interview,Interview, 5.52359033,  99.0000000,mg/daily Konstenius 2007 NA RCT (parallel, crossover, open-label),RR  27  27   54 NA reverse 15.0000000000, 0.899130072, 2.502419e+02,NA NA NA NA,NA,NA NA,NA   0,  0,100 100,  0,  0 100,low,some high,some high Placebo,  0,  0.000000,42.000000,NA,DSM-IV 0 1 1.0 1.0,1.0 1.0,1 1 0 1 1 1,1 1.0 1 1 1,1  279,Konstenius_2007 2-6 months,NA,>= 20 yo 33,42,NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high,high
 381,Boesen (2022),Boesen 2022 10.1002/14651858.CD012857.pub2,100,  0,100,100,High,Methylphenidate OROS methylphenidate,  0,NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Interview,Interview, 1.15074799   45.0000000 mg/daily,Medori 2005,NA RCT (parallel, crossover, open-label) RR,305, 96  401 NA,reverse, 3.4622950820, 1.653631531, 7.249189e+00 NA,NA NA,NA,NA,NA NA,NA 100,100,100,100   0,100 100,low some high,some some Placebo,  0  46.000000,34.000000,NA,DSM-IV 0,1,1.0 1.0 1.0 1.0 1,1,0 1,1 1 1 1.0,1 1,1,1, 280 Medori_2005,< 2 months NA,>= 20 yo,33,42,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 381,Boesen (2022),Boesen,2022 10.1002/14651858.CD012857.pub2 100,  0 100,100 High Methylphenidate,extended-release methylphenidate,  0,NA Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Interview Interview, 1.84119678, 160.0000000,mg/daily Retz 2008,NA,RCT (parallel, crossover, open-label),RR  84  78  162,NA,reverse  4.6428571429  2.320115480, 9.290970e+00 NA,NA NA NA,NA NA NA NA,  0,  0,100 100,100,  0,100,low,some,low,some,high Placebo,  0  53.000000 37.000000,NA DSM-IV 0 1,1.0,1.0,1.0,1.0 1 1,0 1,1 1,1,1.0 1,1 1,1, 281,Retz_2008 < 2 months NA >= 20 yo 33,42,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no high high
 381 Boesen (2022) Boesen,2022,10.1002/14651858.CD012857.pub2 100   0 100,100,High Methylphenidate,Extended-release (ER) methylphenidate   0,NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Interview,Interview  5.52359033,  70.0000000,mg/daily,Rösler 2004,NA,RCT (parallel, crossover, open-label) RR,241,118, 359 NA,reverse  3.0030428769, 1.822608354, 4.948000e+00,NA,NA NA,NA NA NA NA NA   0   0,100,100   0   0,100 some,some high some high,Placebo   0  50.000000 35.000000,NA DSM-IV,0,1 1.0,1.0,1.0 1.0 1 1,0 1 1 1 1 1.0 1,1,1 1  282,Rösler_2004,2-6 months,NA,>= 20 yo,33,42,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high,high
 381,Boesen (2022),Boesen,2022,10.1002/14651858.CD012857.pub2,100   0 100,100 High Methylphenidate dex-methylphenidate extended-release
Spencer 2003a 
Extended-release   0,NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Interview,Interview, 1.15074799   30.0000000,mg/daily Spencer,2003 NA RCT (parallel, crossover, open-label),RR 165  53  218,NA,reverse, 1.6060606061, 0.707303932  3.646849e+00,NA NA NA NA NA NA NA,NA,  0   0,100,100,  0   0 100,some some high,some high Placebo,  0  42.000000 39.000000,NA DSM-IV,0 1,1.0,1.0,1.0 1.0 1 1,0,1 1,1 1 1.0,1,1 1,1  283,Spencer_2003 < 2 months,NA >= 20 yo,33 42,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high high
 381 Boesen (2022) Boesen 2022 10.1002/14651858.CD012857.pub2,100   0 100 100,High,Methylphenidate OROS methylphenidate,  0 NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Interview Interview  1.84119678,  45.0000000,mg/daily,Takahashi,2011 NA RCT (parallel, crossover, open-label),RR 143 141, 284 NA reverse  5.6202797203  2.992051366  1.055715e+01,NA NA NA,NA NA NA,NA,NA,  0   0,100 100,100   0,100,low,some,low,some,high Placebo,  0, 51.000000,34.000000,NA,DSM-IV TR 0 1 1.0,1.0,1.0 1.0,1 1 0 1 1,1 1,1.0 1,1 1 1, 284,Takahashi_2011,< 2 months,NA >= 20 yo 33,42,NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high,high
 381 Boesen (2022),Boesen,2022,10.1002/14651858.CD012857.pub2 100   0 100 100 High,Methylphenidate OROS methylphenidate   0 NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Interview,Interview, 1.38089758   54.0000000,mg/daily Weisler 2009 NA,RCT (parallel, crossover, open-label),RR, 68  73  141,NA reverse  5.6360294118, 2.038542515, 1.558213e+01 NA NA,NA NA,NA NA,NA,NA,  0,  0 100 100   0,  0,100,low some,high some,high,Placebo   0, 38.000000,33.000000 NA,DSM-IV TR 0,1 1.0,1.0,1.0,1.0,1,1,0 1 1 1,1 1.0,1 1 1 1  285 Weisler_2009,< 2 months,NA,>= 20 yo,33,42,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high,high
 381,Boesen (2022) Boesen 2022 10.1002/14651858.CD012857.pub2,100,  0 100,100 High Methylphenidate,Controlled-release (CR) methylphenidate   0,NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Interview Interview  0.92059839   62.5000000,mg/daily,Weiss 2014,NA RCT (parallel, crossover, open-label),RR,297  78, 375,NA,reverse, 4.3333333333  1.062905986, 1.766645e+01 NA NA NA NA,NA NA NA,NA   0,  0 100,100   0   0,100 low,some high,some high Placebo,  0  53.000000,36.000000,NA,DSM-5 0 1 1.0 1.0,1.0 1.0,1,1,0 1 1,1,1 1.0 1 1,1 1, 286 Weiss_2014,< 2 months,NA >= 20 yo,33 42,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high,high
 381,Boesen (2022) Boesen 2022 10.1002/14651858.CD012857.pub2 100,  0,100,100 High,Methylphenidate,OROS methylphenidate   0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Interview,Interview, 2.53164557   45.0000000,mg/daily Winhusen 2005 NA RCT (parallel, crossover, open-label),RR 127 128, 255,NA,reverse, 3.3115860517, 1.473694598  7.441570e+00,NA NA,NA NA NA NA,NA,NA,  0   0,100 100,  0,  0,100 low some high,some,high Placebo   0, 43.000000,38.000000,NA,DSM-IV 0,1,1.0 1.0 1.0 1.0,1,1 0,1 1 1,1,1.0,1,1,1,1, 287 Winhusen_2005,2-6 months,NA >= 20 yo,33,42,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high,high
 381 Boesen (2022) Boesen 2022 10.1002/14651858.CD012857.pub2,100,  0,100 100 High,Methylphenidate OROS methylphenidate   0,NA,Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Interview Interview, 1.61104718,  72.0000000,mg/daily Adler,2006,NA RCT (parallel, crossover, open-label),RR 110,116  226,NA,reverse, 2.1090909091, 0.653584043  6.805956e+00,NA NA NA,NA,NA,NA NA,NA   0,  0,100,100   0,  0,100 low,some,high,some high Placebo,  0, 44.000000 39.000000 NA,DSM-IV 0,1,1.0,1.0,1.0,1.0 1,1,0,1,1 1 1 1.0,1,1 1 1  288 Adler_2006 < 2 months,NA,>= 20 yo,33 42,NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high high
 381 Boesen (2022),Boesen,2022 10.1002/14651858.CD012857.pub2,100,  0 100,100 High Methylphenidate OROS methylphenidate,  0,NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Interview,Interview, 1.38089758,  40.0000000,mg/daily Biederman 2003,NA RCT (parallel, crossover, open-label),RR,109,114, 223 NA,reverse  3.1376146789, 1.043687498, 9.432542e+00,NA NA NA,NA,NA,NA,NA,NA   0,  0 100 100,  0,  0,100 low,some high some high,Placebo,  0  45.000000,36.000000 NA DSM-IV 0 1 1.0,1.0 1.0,1.0,1 1 0 1,1,1 1,1.0 1 1,1 1, 289 Biederman_2003,< 2 months NA >= 20 yo 33 42,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,high,high
 381 Boesen (2022),Boesen,2022 10.1002/14651858.CD012857.pub2 100   0 100 100 High Methylphenidate,OROS methylphenidate,  0 NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Interview Interview, 2.99194476,  63.0000000,mg/daily,Casas,2008,NA,RCT (parallel, crossover, open-label) RR 181  97, 278,NA,reverse, 4.2872928177, 1.006541050, 1.826143e+01,NA NA NA,NA NA NA,NA NA,100,100 100,100,  0,100 100,low,some high,some some,Placebo   0  48.000000,36.000000 NA DSM-IV TR 0 1,1.0,1.0 1.0 1.0 1 1 0,1 1 1,1 1.0,1 1 1 1  290 Casas_2008,2-6 months NA >= 20 yo,33 42,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 381 Boesen (2022),Boesen 2022,10.1002/14651858.CD012857.pub2,100   0 100 100,High Methylphenidate extended-release methylphenidate,  0 NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Interview Interview,11.96777906,  70.0000000 mg/daily Compas 2007,NA RCT (parallel, crossover, open-label),RR 205,209, 414,NA,reverse  1.8351219512, 0.868041890  3.879620e+00,NA NA NA,NA,NA NA NA NA,100 100 100,100,  0,100 100 low,some high,some,low,Placebo   0  50.100000,35.000000,NA,DSM-IV 0,1 1.0 1.0,1.0 1.0,1,1 0 1 1 1 1,1.0,1,1,1 1  291 Compas_2007 7-12 months NA,>= 20 yo 33 42 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 381,Boesen (2022) Boesen 2022,10.1002/14651858.CD012857.pub2,100,  0,100 100 High,Methylphenidate,OROS methylphenidate   0,NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Interview Interview  1.15074799   72.0000000 mg/daily,Ginsberg 2007 NA RCT (parallel, crossover, open-label) RR, 15  15   30 NA,reverse  0.3333333333, 0.014650138  7.584305e+00 NA,NA,NA,NA NA NA NA NA 100 100,100,100,100,100 100 low some some some low,Placebo   0   0.000000 34.000000,NA,DSM-IV 0,1,1.0,1.0,1.0,1.0 1,1 0 1 1 1,1 1.0,1 1 1,1  292,Ginsberg_2007,< 2 months,NA >= 20 yo,33,42 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 381 Boesen (2022) Boesen 2022,10.1002/14651858.CD012857.pub2,100   0 100,100 High,Methylphenidate OROS methylphenidate   0 NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Interview Interview, 1.38089758,  45.0000000,mg/daily Goodman 2009,NA RCT (parallel, crossover, open-label),RR 174 175  349,NA reverse, 5.6992337165, 1.700672407, 1.909907e+01,NA NA NA,NA,NA,NA NA,NA   0   0 100,100,  0   0,100,low,some high,some high,Placebo   0  46.000000,36.000000 NA,DSM-IV 0,1 1.0 1.0 1.0,1.0 1,1 0 1,1 1,1,1.0,1 1,1 1  293 Goodman_2009 < 2 months,NA >= 20 yo 33 42 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high,high
 381,Boesen (2022),Boesen,2022,10.1002/14651858.CD012857.pub2,100   0,100 100,High Methylphenidate Long-acting (LA) methylphenidate,  0,NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Interview Interview, 2.07134638   60.0000000 mg/daily,Huss 2010,NA RCT (parallel, crossover, open-label),RR 542 180  722 NA,reverse, 4.6494464945  1.118674605, 1.932408e+01,NA NA,NA NA,NA,NA,NA,NA   0,  0,100 100,  0,  0 100,low some high,some,high Placebo,  0  45.000000,35.000000,NA DSM-IV 0 1,1.0,1.0,1.0,1.0,1 1 0 1,1 1 1,1.0,1,1,1,1, 294,Huss_2010,2-6 months NA,>= 20 yo 33,42 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high,high
 381,Boesen (2022) Boesen 2022,10.1002/14651858.CD012857.pub2,100,  0,100 100 High,Methylphenidate OROS methylphenidate   0,NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Interview,Interview, 5.52359033,  99.0000000,mg/daily,Konstenius 2007,NA,RCT (parallel, crossover, open-label),RR, 27  27   54 NA,reverse, 3.0000000000  0.663538308, 1.356365e+01 NA,NA NA,NA NA NA,NA NA   0,  0,100 100   0   0 100,low,some high some high Placebo,  0   0.000000,42.000000,NA,DSM-IV,0,1 1.0 1.0,1.0 1.0 1 1,0 1,1 1 1 1.0 1,1,1 1, 295 Konstenius_2007,2-6 months,NA >= 20 yo 33,42 NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high high
 381 Boesen (2022),Boesen 2022,10.1002/14651858.CD012857.pub2 100,  0 100,100,High,Methylphenidate,methylphenidate sustained-release (SR)   0,NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Interview Interview  2.99194476, 100.0000000 mg/daily,Levin,1998 NA,RCT (parallel, crossover, open-label),RR, 53, 53  106 NA,reverse  5.0000000000, 0.604371002, 4.136532e+01 NA NA,NA NA NA NA,NA,NA,  0   0,100 100   0,  0 100 some some,high some,high,Placebo,  0  17.000000 37.000000 NA DSM-IV,0,1,1.0,1.0 1.0,1.0 1 1,0 1,1 1 1 1.0,1 1,1,1  296 Levin_1998 2-6 months NA >= 20 yo 33,42,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high,high
 381 Boesen (2022) Boesen 2022 10.1002/14651858.CD012857.pub2,100,  0,100,100 High,Methylphenidate,OROS methylphenidate,  0 NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Interview,Interview  1.15074799,  45.0000000 mg/daily Medori,2005 NA,RCT (parallel, crossover, open-label),RR 305, 96  401,NA reverse, 1.5737704918  0.350890689  7.058476e+00 NA NA NA NA,NA NA NA NA 100,100 100 100,  0,100 100,low some,high,some,some,Placebo   0, 46.000000,34.000000,NA DSM-IV,0 1 1.0,1.0,1.0 1.0,1 1,0,1 1 1,1 1.0,1 1 1 1  297 Medori_2005 < 2 months,NA,>= 20 yo,33,42 NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 381,Boesen (2022),Boesen,2022,10.1002/14651858.CD012857.pub2 100,  0,100 100,High,Methylphenidate Extended-release (ER) methylphenidate,  0 NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Interview,Interview, 5.52359033   70.0000000,mg/daily,Rösler,2004,NA,RCT (parallel, crossover, open-label) RR 241,118  359,NA,reverse, 1.3989330172, 0.896035917  2.184079e+00 NA,NA,NA NA NA NA NA,NA,  0,  0,100,100   0,  0 100,some some high,some high,Placebo   0, 50.000000 35.000000,NA,DSM-IV 0,1 1.0,1.0 1.0 1.0 1 1 0 1,1,1 1,1.0 1 1 1 1, 298 Rösler_2004,2-6 months,NA >= 20 yo 33 42 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high high
 381,Boesen (2022) Boesen,2022,10.1002/14651858.CD012857.pub2,100,  0 100 100 High,Methylphenidate,dex-methylphenidate extended-release
Spencer 2003a 
Extended-release,  0,NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Interview Interview  1.15074799,  30.0000000,mg/daily,Spencer,2003,NA,RCT (parallel, crossover, open-label),RR 165  53  218,NA,reverse, 1.9272727273  0.237364655  1.564841e+01,NA NA NA NA NA,NA,NA,NA,  0,  0,100 100,  0,  0,100,some some,high some high,Placebo   0  42.000000,39.000000,NA DSM-IV,0,1,1.0 1.0 1.0 1.0,1,1 0,1,1 1,1,1.0 1,1 1 1, 299 Spencer_2003,< 2 months NA >= 20 yo 33,42,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no high high
 381 Boesen (2022) Boesen 2022,10.1002/14651858.CD012857.pub2,100,  0,100 100,High Methylphenidate OROS methylphenidate,  0,NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Interview Interview, 1.84119678,  45.0000000,mg/daily,Takahashi,2011 NA,RCT (parallel, crossover, open-label),RR 143,141  284,NA,reverse, 1.0564435564, 0.529779537, 2.106674e+00,NA NA,NA NA NA NA NA NA   0,  0,100 100,100,  0,100 low,some low,some high,Placebo   0  51.000000 34.000000 NA DSM-IV TR 0 1,1.0 1.0,1.0 1.0,1,1,0,1,1 1 1,1.0 1 1,1 1  300,Takahashi_2011 < 2 months,NA >= 20 yo 33,42,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,high high
 381 Boesen (2022) Boesen 2022 10.1002/14651858.CD012857.pub2,100,  0 100,100 High,Methylphenidate,OROS methylphenidate,  0,NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Interview,Interview  1.38089758   54.0000000 mg/daily,Weisler 2009 NA RCT (parallel, crossover, open-label),RR, 68  73, 141 NA reverse  3.2205882353, 1.237216820, 8.383485e+00 NA,NA,NA NA NA,NA NA,NA,  0,  0 100 100,  0   0 100,low,some,high some high Placebo   0, 38.000000 33.000000 NA DSM-IV TR 0 1 1.0,1.0 1.0,1.0 1 1 0,1 1 1 1 1.0 1,1 1,1, 301 Weisler_2009,< 2 months,NA,>= 20 yo 33 42,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high high
 381,Boesen (2022) Boesen,2022 10.1002/14651858.CD012857.pub2,100   0 100,100 High,Methylphenidate Controlled-release (CR) methylphenidate   0,NA,Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Interview Interview  0.92059839,  62.5000000 mg/daily Weiss 2014,NA RCT (parallel, crossover, open-label),RR 297  78, 375 NA reverse, 4.7272727273, 0.640937648  3.486627e+01,NA,NA NA NA NA,NA NA,NA   0   0 100,100,  0,  0 100 low,some high,some,high,Placebo,  0, 53.000000,36.000000,NA DSM-5 0,1 1.0,1.0,1.0,1.0 1,1 0,1,1 1 1 1.0 1 1,1 1, 302,Weiss_2014 < 2 months,NA,>= 20 yo,33,42 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high high
 381 Boesen (2022) Boesen,2022 10.1002/14651858.CD012857.pub2,100,  0,100 100 High,Methylphenidate OROS methylphenidate   0 NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Interview,Interview  2.53164557,  45.0000000,mg/daily,Winhusen,2005 NA RCT (parallel, crossover, open-label),RR,127 128, 255,NA,reverse, 1.8141732283, 0.625209239, 5.264197e+00 NA,NA,NA,NA,NA NA NA,NA   0   0 100,100,  0   0,100 low,some,high some,high,Placebo,  0, 43.000000,38.000000 NA DSM-IV,0,1 1.0,1.0,1.0,1.0,1 1 0 1 1 1 1 1.0 1,1,1,1  303,Winhusen_2005 2-6 months NA,>= 20 yo 33 42 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high,high
1056 Elliott (2020),Elliott 2020 10.1371/journal.pone.0240584,100,  0 100,100,Critically low Methylphenidate Methylphenidate Hydrochloride – Long-Acting Capsule,  0 NA,Executive functioning (report),Self-rated,At study endpoint (closest to 12 weeks) Questionnaire,Brief Rating Inventory of Executive Function for Adults [BRIEF-A], 2.07134638   60.0000000 mg/d Huss,2014,NA RCT (parallel, crossover, open-label) SMD,544,181  725 NA,reverse -0.3800000000,-0.550000000,-2.100000e-01 NA NA,NA NA NA NA,NA,NA   0,  0 100,  0,100   0,100,low high,some,low,high Placebo   0, 42.774345 35.299310,NA DSM-IV, ADHD-RS 2,1,0.0 0.0,1.0 1.0 1 1 1,1,1 1,0 1.0 1,1,1,1  304 Huss_2014 2-6 months NA,>= 20 yo 33.9675810473815,42,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Elliott (2020)_Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Elliott (2020) - Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,high,high
1056,Elliott (2020),Elliott,2020,10.1371/journal.pone.0240584,100   0 100 100,Critically low Methylphenidate Methylphenidate Osmotic-Controlled Release Oral System   0 NA,Executive functioning (report),Self-rated At study endpoint (closest to 12 weeks),Questionnaire Brief Rating Inventory of Executive Function for Adults [BRIEF-A]  1.15074799,  54.0000000 mg/d Ginsberg,2012,NA RCT (parallel, crossover, open-label) SMD, 15  15,  30,NA,reverse -2.4000000000,-3.360000000,-1.430000e+00,NA NA,NA NA,NA NA NA,NA,  0   0,100   0,100   0,100 low high,low low,high,Placebo,  0,  0.000000 34.400000 NA,DSM-IV 2 1 0.0,0.0 1.0,1.0,1,1 1 1 1 1 0 1.0,1 1,1 1, 305 Ginsberg_2012 < 2 months,NA,>= 20 yo 33.9675810473815,42 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Elliott (2020)_Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Elliott (2020) - Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high,high
1056 Elliott (2020),Elliott 2020,10.1371/journal.pone.0240584,100   0 100,100,Critically low Methylphenidate,Methylphenidate Osmotic-Controlled Release Oral System   0 NA Executive functioning (report) Self-rated At study endpoint (closest to 12 weeks),Questionnaire,Brief Rating Inventory of Executive Function for Adults [BRIEF-A]  1.38089758   72.0000000 mg/d,Goodman 2017 NA RCT (parallel, crossover, open-label),SMD,178,179, 357 NA,reverse -0.5300000000 -0.740000000 -3.200000e-01,NA NA,NA NA NA NA NA,NA   0   0 100   0,100   0 100 low,high,low,low,high Placebo   0  47.100000 35.747059 NA DSM-IV 2,1,0.0,0.0,1.0,1.0 1 1 1,1 1 1,0,1.0 1 1 1 1, 306,Goodman_2017,< 2 months,NA >= 20 yo,33.9675810473815,42,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Elliott (2020)_Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Elliott (2020) - Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high high
1056,Elliott (2020) Elliott 2020,10.1371/journal.pone.0240584 100,  0,100,100 Critically low Methylphenidate Methylphenidate Osmotic-Controlled Release Oral System,  0,NA,Executive functioning (report),Self-rated At study endpoint (closest to 12 weeks),Questionnaire Brief Rating Inventory of Executive Function for Adults [BRIEF-A], 1.15074799,  36.0000000,mg/d,Medori 2008,NA RCT (parallel, crossover, open-label),SMD 305, 96, 401 NA reverse -0.3700000000,-0.600000000,-1.400000e-01 NA NA,NA,NA,NA,NA,NA,NA   0,  0,100,  0,100,  0,100,low high,low some,high Placebo   0  50.973815 33.967581,NA DSM-IV by CAADID 2 1,0.0,0.0 1.0 1.0,1,1,1 1,1 1 0 1.0 1,1,1,1, 307 Medori_2008 < 2 months,NA >= 20 yo,33.9675810473815,42 NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Elliott (2020)_Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Elliott (2020) - Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high high
1056,Elliott (2020),Elliott 2020,10.1371/journal.pone.0240584 100   0 100,100 Critically low Methylphenidate Methylphenidate Immediate-Release   0,NA,Executive functioning (report),Self-rated At study endpoint (closest to 12 weeks) Questionnaire Brief Rating Inventory of Executive Function for Adults [BRIEF-A]  2.07134638,  27.5000000 mg/d Tenenbaum 2002 NA RCT (parallel, crossover, open-label),SMD, 33  33,  66 NA reverse -0.0300000000,-0.510000000  4.500000e-01 NA NA NA,NA NA NA NA,NA   0   0,100   0,  0   0 100 some high,high low high,Placebo   0, 54.200000 42.000000 NA DSM-IV, ADSA,2 1,0.0 0.0 1.0 1.0,1,1,1,1 1,1 0,1.0,1 1 1,1, 308 Tenenbaum_2002 2-6 months NA >= 20 yo 33.9675810473815 42 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Elliott (2020)_Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Elliott (2020) - Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,high high
2785 Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100   0,100,100 Critically low,Methylphenidate,methylphenidate,  0,NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 0.03278689,  15.0000000 mg Agay,2010,NA RCT (parallel, crossover, open-label),G, 13  13   26 outcomes,NA, 0.8600000000 NA NA  11.5600000, 13.6600000,NA,NA NA,NA,NA NA 100,100 100 100,  0,100,100,some low,high low,low Placebo,  0  58.000000 32.450000,NA NA 2,0 0.0,1.0,1.0,1.0 1 1 2 1,1,1 0,0.5,0,1,1,1  309 Agay_2010,< 2 months,NA >= 20 yo,28.44 50.1 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
2785 Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100,  0 100 100,Critically low Methylphenidate methylphenidate   0,NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  0.03278689,  15.0000000,mg Agay,2010,NA RCT (parallel, crossover, open-label) G, 13  13   26 outcomes NA, 1.2200000000 NA,NA,  6.8700000,  7.3300000 NA,NA NA NA,NA,NA,100 100,100,100,  0 100 100 some,low high,low low,Placebo   0  58.000000 32.450000,NA,NA,2 0 0.0,1.0,1.0 1.0 1 1,2,1 1 1 0 0.5,0,1,1 1  310 Agay_2010 < 2 months NA,>= 20 yo 28.44,50.1 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
2785 Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012   0,  0,100 100,Critically low Methylphenidate methylphenidate Immediate release,  0,NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  0.03278689,   0.2800000,mg/kg Agay 2014,NA,RCT (parallel, crossover, open-label) G  20, 20   40 outcomes,NA, 0.0100000000 NA,NA  62.8800000, 67.6800000,NA NA NA NA NA NA   0   0,100,100,  0,  0 100 low,low,high,low,high Placebo   0,NA NA NA,NA 2 0,0.0 1.0 1.0 1.0 1 1 2,1 1,1 0 0.5,0,1,1,1, 311,Agay_2014 < 2 months,NA NA 28.44,50.1 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high high
2785,Pievsky (2018) Pievsky,2018,10.1016/j.neubiorev.2018.05.012,  0   0,100,100 Critically low Methylphenidate,methylphenidate Immediate release,  0,NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 0.03278689    0.2800000 mg/kg Agay 2014,NA RCT (parallel, crossover, open-label),G, 20, 20   40,outcomes NA -0.0100000000,NA NA  39.8100000, 38.3500000,NA,NA,NA NA,NA NA   0   0,100 100   0   0 100 low low,high,low high,Placebo   0 NA,NA,NA NA,2 0 0.0 1.0 1.0,1.0,1 1 2 1 1,1,0,0.5 0,1,1 1, 312,Agay_2014 < 2 months NA,NA,28.44 50.1 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high,high
2785 Pievsky (2018) Pievsky,2018,10.1016/j.neubiorev.2018.05.012   0   0 100,100,Critically low,Methylphenidate,methylphenidate Immediate release,  0,NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 0.03278689,   0.2800000,mg/kg Agay,2014 NA RCT (parallel, crossover, open-label),G  20  20   40,outcomes,NA, 0.0400000000 NA NA, 66.2700000  61.6200000 NA,NA NA,NA,NA,NA,  0   0,100,100   0   0 100,low low,high low high,Placebo   0,NA,NA,NA,NA,2 0 0.0 1.0 1.0,1.0,1 1,2,1,1,1,0,0.5 0 1 1 1  313,Agay_2014,< 2 months,NA NA,28.44 50.1 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high,high
2785 Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012,  0,  0 100,100,Critically low,Methylphenidate methylphenidate Immediate release   0,NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 0.03278689    0.2800000 mg/kg Agay 2014 NA,RCT (parallel, crossover, open-label) G  20  20,  40 outcomes NA,-0.0300000000 NA NA, 19.0800000  26.0700000,NA NA,NA,NA NA,NA,  0   0 100,100   0,  0,100,low low,high,low high Placebo,  0 NA,NA,NA NA,2 0 0.0,1.0 1.0,1.0,1 1 2 1,1 1,0 0.5,0 1 1 1, 314,Agay_2014,< 2 months NA,NA 28.44,50.1,NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high,high
2785 Pievsky (2018) Pievsky,2018 10.1016/j.neubiorev.2018.05.012 100,  0 100 100,Critically low,Methylphenidate methylphenidate Immediate release   0 NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918   49.0000000,mg,Biehl,2016,NA,RCT (parallel, crossover, open-label) G  15, 14,  29 outcomes NA  0.4000000000,NA,NA,  3.2000000,  6.0000000 NA NA NA,NA,NA,NA,100,100,100 100 100,100 100 some low,low low,low Placebo,  0, 38.000000,36.100000,NA,NA,2,0,0.0 1.0,1.0,1.0 1,1,2 1,1 1 0,0.5 0 1,1,1, 315 Biehl_2016,< 2 months,NA,>= 20 yo 28.44 50.1 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
2785 Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100,  0,100,100,Critically low Methylphenidate,methylphenidate Immediate release,  0 NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks) Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  1.37704918,  49.0000000 mg,Biehl,2016,NA,RCT (parallel, crossover, open-label) G, 15, 14   29 outcomes,NA  0.0900000000,NA NA,  3.0000000   3.7000000,NA,NA NA,NA NA NA,100 100,100,100,100 100,100,some,low low,low low Placebo   0, 38.000000 36.100000,NA NA 2 0,0.0,1.0,1.0 1.0,1,1 2,1,1 1 0,0.5,0,1,1,1  316,Biehl_2016,< 2 months,NA,>= 20 yo 28.44,50.1,NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
2785 Pievsky (2018),Pievsky,2018,10.1016/j.neubiorev.2018.05.012 100   0,100 100,Critically low,Methylphenidate,methylphenidate Immediate release   0,NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  1.37704918   49.0000000 mg,Biehl 2016 NA RCT (parallel, crossover, open-label) G  15, 14   29 outcomes NA, 0.7200000000,NA NA,  0.6000000,  3.1000000,NA,NA NA NA,NA,NA,100 100,100,100 100 100,100 some low low,low,low Placebo,  0  38.000000 36.100000,NA,NA 2 0 0.0,1.0 1.0,1.0,1,1 2 1,1 1 0,0.5,0 1 1,1, 317 Biehl_2016,< 2 months NA >= 20 yo,28.44 50.1 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
2785 Pievsky (2018) Pievsky,2018,10.1016/j.neubiorev.2018.05.012 100,  0 100,100,Critically low,Methylphenidate methylphenidate Immediate release,  0 NA,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  1.37704918,  49.0000000 mg,Biehl 2016 NA RCT (parallel, crossover, open-label),G, 15, 14,  29 outcomes,NA  0.1700000000 NA NA, 15.9000000, 19.7000000,NA NA NA NA NA,NA 100,100 100 100 100,100,100,some low,low,low low Placebo   0  38.000000,36.100000,NA NA,2 0 0.0,1.0 1.0,1.0,1,1,2 1 1,1,0 0.5,0 1 1,1  318 Biehl_2016 < 2 months,NA >= 20 yo 28.44 50.1,NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
2785,Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100,  0,100,100,Critically low,Methylphenidate methylphenidate Immediate release   0 NA,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918,  49.0000000 mg,Biehl,2016,NA,RCT (parallel, crossover, open-label),G  15, 14   29 outcomes NA  0.0600000000,NA,NA   6.1000000,  6.8000000,NA NA,NA,NA,NA,NA 100 100 100,100,100 100,100 some,low low,low low Placebo,  0  38.000000 36.100000 NA NA 2,0 0.0,1.0,1.0,1.0 1,1,2 1,1 1 0 0.5 0 1 1 1, 319 Biehl_2016,< 2 months NA >= 20 yo,28.44,50.1,NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
2785,Pievsky (2018) Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100   0 100 100 Critically low Methylphenidate methylphenidate Immediate release,  0 NA,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  1.37704918,  49.0000000 mg Biehl 2016 NA RCT (parallel, crossover, open-label) G, 15  14,  29,outcomes,NA  0.1700000000,NA NA  14.9000000  16.2000000 NA,NA NA,NA,NA NA,100,100 100 100 100 100,100,some,low,low low low,Placebo,  0  38.000000,36.100000,NA,NA 2 0 0.0,1.0,1.0 1.0 1 1,2 1,1 1,0,0.5 0 1 1,1  320 Biehl_2016,< 2 months,NA >= 20 yo 28.44 50.1,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
2785,Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100,  0 100 100 Critically low Methylphenidate methylphenidate Immediate release   0 NA,Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  1.37704918   49.0000000,mg Biehl 2016,NA,RCT (parallel, crossover, open-label),G, 15, 14   29 outcomes NA,-0.1900000000 NA,NA  21.7000000, 21.6000000,NA,NA NA NA NA NA 100,100 100 100,100,100 100 some low,low low,low,Placebo,  0  38.000000,36.100000 NA NA 2,0 0.0 1.0 1.0,1.0 1,1 2 1 1 1,0,0.5 0,1 1 1, 321,Biehl_2016 < 2 months NA >= 20 yo,28.44 50.1 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
2785,Pievsky (2018),Pievsky,2018 10.1016/j.neubiorev.2018.05.012,100,  0 100,100 Critically low Methylphenidate methylphenidate Immediate release   0 NA,Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918,  49.0000000,mg Biehl 2016,NA RCT (parallel, crossover, open-label) G, 15, 14,  29,outcomes,NA, 0.0300000000 NA,NA, 13.8000000,  9.8000000,NA,NA NA,NA NA,NA,100,100,100 100,100 100 100 some low low,low low,Placebo   0, 38.000000 36.100000 NA NA 2 0,0.0 1.0,1.0 1.0 1 1,2,1,1 1 0 0.5,0,1,1,1  322 Biehl_2016,< 2 months,NA >= 20 yo 28.44,50.1 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
2785,Pievsky (2018),Pievsky,2018 10.1016/j.neubiorev.2018.05.012 100   0,100 100,Critically low,Methylphenidate methylphenidate Immediate release   0,NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918   49.0000000,mg Biehl,2016 NA,RCT (parallel, crossover, open-label),G, 15, 14,  29,outcomes NA,-0.2300000000,NA,NA, 19.6000000  20.7000000 NA,NA NA NA NA NA,100,100,100 100 100,100 100 some low low low,low,Placebo   0, 38.000000 36.100000,NA,NA,2,0 0.0,1.0,1.0,1.0 1,1,2 1 1,1 0 0.5,0 1 1 1, 323 Biehl_2016 < 2 months NA,>= 20 yo 28.44 50.1 NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
2785 Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100,  0,100,100 Critically low,Methylphenidate methylphenidate Immediate release,  0 NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918,  49.0000000 mg,Biehl,2016,NA RCT (parallel, crossover, open-label) G, 15, 14   29 outcomes,NA,-0.0700000000 NA NA,  2.1000000,  3.2000000,NA,NA,NA,NA NA NA,100,100 100,100 100,100 100,some,low,low,low,low Placebo   0  38.000000 36.100000 NA NA,2,0 0.0 1.0 1.0 1.0 1,1 2 1 1,1 0 0.5 0 1,1,1  324 Biehl_2016 < 2 months NA >= 20 yo,28.44 50.1,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
2785 Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100   0,100,100 Critically low,Methylphenidate,methylphenidate Immediate release,  0 NA,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918,  49.0000000,mg,Biehl,2016,NA,RCT (parallel, crossover, open-label) G, 15, 14,  29 outcomes NA,-0.0800000000 NA,NA   2.1000000   2.6000000,NA NA NA NA,NA NA 100,100,100,100,100 100,100,some low low,low low,Placebo   0  38.000000,36.100000 NA,NA 2 0,0.0 1.0 1.0,1.0 1,1,2,1,1,1 0 0.5,0 1,1,1, 325 Biehl_2016,< 2 months,NA >= 20 yo,28.44,50.1 NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
2785 Pievsky (2018) Pievsky,2018 10.1016/j.neubiorev.2018.05.012 100   0,100 100,Critically low Methylphenidate,methylphenidate Immediate release   0 NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks) Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918,  49.0000000,mg Biehl,2016,NA RCT (parallel, crossover, open-label),G  15  14,  29 outcomes NA  0.1300000000 NA NA   0.6000000   0.9000000,NA NA NA,NA,NA,NA,100,100,100 100,100 100,100,some low low low,low Placebo   0  38.000000 36.100000,NA NA 2,0,0.0 1.0 1.0 1.0 1,1,2,1 1 1,0,0.5 0 1,1,1, 326,Biehl_2016,< 2 months NA >= 20 yo 28.44 50.1 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
2785,Pievsky (2018) Pievsky,2018,10.1016/j.neubiorev.2018.05.012 100,  0,100 100,Critically low,Methylphenidate methylphenidate Immediate release   0 NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918,  49.0000000 mg,Biehl,2016,NA RCT (parallel, crossover, open-label),G, 15  14   29 outcomes,NA -0.1200000000 NA,NA  17.0000000, 13.2000000,NA NA NA NA,NA,NA 100 100 100,100 100 100,100,some,low,low,low,low,Placebo   0  38.000000,36.100000,NA NA,2 0,0.0 1.0,1.0,1.0 1 1,2,1,1 1 0 0.5 0,1 1 1  327 Biehl_2016 < 2 months NA,>= 20 yo 28.44 50.1,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
2785,Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100   0 100 100,Critically low Methylphenidate methylphenidate Immediate release,  0 NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  1.37704918   49.0000000 mg Biehl,2016,NA RCT (parallel, crossover, open-label),G, 15, 14   29,outcomes,NA,-0.2500000000 NA NA  12.0000000,  5.3000000 NA,NA,NA,NA,NA,NA 100 100 100 100,100 100 100 some low low low low Placebo,  0  38.000000,36.100000 NA NA 2,0,0.0,1.0,1.0 1.0,1,1,2 1,1 1,0,0.5,0,1 1 1  328 Biehl_2016,< 2 months,NA >= 20 yo 28.44,50.1 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
2785,Pievsky (2018),Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100,  0,100,100,Critically low,Methylphenidate,methylphenidate Immediate release,  0,NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918,  49.0000000 mg,Biehl,2016 NA,RCT (parallel, crossover, open-label),G, 15, 14,  29 outcomes NA  0.0400000000 NA,NA  12.0000000  12.6000000,NA NA NA,NA NA NA,100 100 100,100,100,100 100 some,low,low,low low,Placebo   0, 38.000000,36.100000 NA NA 2 0 0.0 1.0 1.0,1.0,1 1,2,1,1 1,0,0.5,0,1 1 1, 329 Biehl_2016 < 2 months NA >= 20 yo 28.44 50.1 NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
2785 Pievsky (2018),Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100,  0,100 100,Critically low,Methylphenidate methylphenidate Immediate release,  0,NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918   49.0000000 mg,Biehl,2016,NA RCT (parallel, crossover, open-label),G, 15, 14,  29,outcomes,NA,-0.0600000000 NA,NA  18.0000000  17.0000000,NA,NA,NA NA,NA NA 100 100 100,100,100 100,100,some low,low low,low,Placebo,  0, 38.000000 36.100000 NA NA 2,0,0.0,1.0,1.0,1.0 1,1 2 1,1 1,0,0.5 0,1,1 1  330,Biehl_2016 < 2 months,NA,>= 20 yo 28.44,50.1 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
2785,Pievsky (2018) Pievsky,2018 10.1016/j.neubiorev.2018.05.012 100,  0,100 100 Critically low,Methylphenidate,methylphenidate Immediate release   0 NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks),Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918,  49.0000000,mg,Biehl,2016,NA,RCT (parallel, crossover, open-label) G  15, 14,  29,outcomes NA, 0.2600000000 NA,NA  11.2000000  24.7000000,NA,NA NA,NA NA,NA 100,100,100,100,100 100,100,some,low,low low low,Placebo,  0, 38.000000 36.100000 NA NA,2 0 0.0 1.0 1.0,1.0,1,1 2 1,1 1,0 0.5,0 1,1 1  331,Biehl_2016,< 2 months,NA,>= 20 yo 28.44 50.1 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
2785,Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100   0,100,100,Critically low Methylphenidate methylphenidate Immediate release,  0 NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.37704918,  49.0000000 mg Biehl 2016 NA,RCT (parallel, crossover, open-label),G, 15  14,  29,outcomes NA,-0.0900000000 NA NA  16.6000000, 17.9000000,NA,NA NA,NA,NA,NA,100,100,100 100 100,100 100,some,low,low,low,low Placebo,  0  38.000000 36.100000 NA,NA,2,0 0.0,1.0,1.0 1.0 1,1,2,1 1,1,0 0.5,0,1 1,1  332,Biehl_2016,< 2 months,NA >= 20 yo 28.44,50.1,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
2785,Pievsky (2018) Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100,  0 100 100 Critically low Methylphenidate,Methylphenidate,  0 NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 1.60655738    0.9000000 mg/kg Kuperman 2001,NA RCT (parallel, crossover, open-label) G   8  10,  18 outcomes NA  0.1500000000 NA NA NA NA NA,NA,NA,NA NA,NA,  0,  0 100,100,100,  0,  0,some,low,low high,high Placebo,  0, 26.000000,31.840000,NA NA,2,0,0.0 1.0,1.0,1.0 1 1 2,1,1,1,0,0.5 0 1,1 1  333,Kuperman_2001,< 2 months,NA >= 20 yo,28.44,50.1 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high high
2785,Pievsky (2018) Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100   0 100 100 Critically low Methylphenidate,Methylphenidate   0,NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  0.03278689   30.0000000,mg Turner,2005,NA RCT (parallel, crossover, open-label),G  18  18,  36 outcomes NA,-0.0800000000 NA NA,  7.4900000   7.8000000 NA,NA,NA NA,NA,NA 100,100 100,100 100 100 100,low low,low low,low,Placebo,  0, 30.000000 28.440000,NA,NA 2 0 0.0 1.0 1.0,1.0 1 1,2 1 1 1,0 0.5,0,1,1 1  334 Turner_2005 < 2 months NA,>= 20 yo 28.44,50.1,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
2785 Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100,  0 100,100,Critically low,Methylphenidate Methylphenidate,  0 NA,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks) Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 0.03278689,  30.0000000 mg,Turner,2005,NA,RCT (parallel, crossover, open-label),G  18, 18,  36,outcomes,NA, 0.8600000000 NA,NA   3.1000000   6.7000000 NA,NA NA NA,NA,NA,100,100,100,100,100,100 100,low low,low low,low Placebo,  0  30.000000 28.440000,NA NA 2,0,0.0 1.0,1.0 1.0,1,1 2 1,1,1,0 0.5,0 1,1 1, 335,Turner_2005,< 2 months NA >= 20 yo 28.44 50.1,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
2785 Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100   0,100 100,Critically low,Methylphenidate Methylphenidate,  0 NA,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  0.03278689,  30.0000000,mg,Turner 2005,NA,RCT (parallel, crossover, open-label) G  18  18,  36,outcomes NA, 0.1400000000 NA NA  10.6000000, 10.9000000,NA,NA NA NA,NA NA 100,100 100,100 100,100,100,low low,low low low Placebo,  0, 30.000000,28.440000 NA,NA 2 0,0.0,1.0,1.0 1.0 1,1 2 1,1,1,0 0.5 0 1,1 1  336,Turner_2005 < 2 months NA,>= 20 yo,28.44 50.1 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
2785 Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100,  0,100,100 Critically low Methylphenidate Methylphenidate,  0,NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  0.03278689   30.0000000,mg Turner,2005 NA RCT (parallel, crossover, open-label),G, 18  18,  36 outcomes NA  0.3300000000 NA NA,  4.1000000   5.4000000 NA NA NA NA,NA NA 100 100 100,100,100 100,100 low,low low low,low,Placebo   0  30.000000 28.440000 NA,NA,2 0 0.0,1.0 1.0,1.0,1 1 2,1,1 1 0,0.5 0 1 1,1  337,Turner_2005 < 2 months,NA,>= 20 yo,28.44,50.1,NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
2785,Pievsky (2018),Pievsky,2018 10.1016/j.neubiorev.2018.05.012 100,  0,100,100,Critically low Methylphenidate Methylphenidate   0 NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test,Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors  0.03278689,  30.0000000 mg,Turner 2005 NA,RCT (parallel, crossover, open-label) G  18, 18,  36,outcomes,NA, 0.0000000000,NA,NA,  1.3400000,  1.1500000 NA NA,NA NA NA,NA,100 100 100 100 100,100 100,low low,low,low low Placebo   0  30.000000,28.440000,NA NA 2,0,0.0,1.0,1.0 1.0,1,1 2,1,1 1,0 0.5,0 1 1,1  338 Turner_2005 < 2 months NA >= 20 yo 28.44,50.1,NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
2785 Pievsky (2018),Pievsky,2018,10.1016/j.neubiorev.2018.05.012 100,  0 100 100,Critically low,Methylphenidate,Methylphenidate,  0,NA,Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors, 0.03278689   30.0000000,mg Turner 2005,NA RCT (parallel, crossover, open-label) G, 18  18,  36,outcomes,NA, 0.0200000000 NA NA, 27.1000000, 22.3000000 NA,NA NA,NA NA,NA,100 100 100,100,100,100,100,low low low,low low Placebo   0, 30.000000 28.440000,NA,NA 2 0 0.0 1.0 1.0,1.0,1 1 2 1,1,1 0 0.5,0,1 1,1, 339 Turner_2005,< 2 months,NA,>= 20 yo,28.44,50.1 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
2785,Pievsky (2018),Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100   0 100 100,Critically low,Methylphenidate,methylphenidate   0,NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689,  15.0000000 mg Agay,2010 NA,RCT (parallel, crossover, open-label),G  13, 13,  26,outcomes NA  0.1800000000 NA,NA,  8.7100000,  8.5400000 NA NA NA,NA,NA NA 100,100,100,100   0,100 100 some low,high low,low Placebo,  0, 58.000000 32.450000 NA NA 2,0,0.0 1.0,1.0 1.0,1 1,2 1 1 1 0 0.5,0,1 1,1, 340,Agay_2010,< 2 months,NA,>= 20 yo 28.44 50.1,NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
2785,Pievsky (2018) Pievsky,2018 10.1016/j.neubiorev.2018.05.012,100   0 100 100,Critically low Methylphenidate methylphenidate Immediate release,  0,NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689   15.0000000 mg,Barkley 2005,NA,RCT (parallel, crossover, open-label),G  52  52  104 outcomes NA  0.1400000000,NA NA,  7.1000000,  6.8000000 NA NA,NA NA NA,NA 100 100 100 100,100,100,100,low low low,low low,Placebo   0, 26.000000 31.300000,NA,NA 2 0,0.0,1.0,1.0,1.0 1,1 2,1 1,1 0 0.5 0 1,1,1  341 Barkley_2005 < 2 months NA,>= 20 yo 28.44 50.1 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
2785 Pievsky (2018) Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100,  0 100 100 Critically low,Methylphenidate,methylphenidate Immediate release,  0,NA,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689   15.0000000,mg,Barkley,2005,NA,RCT (parallel, crossover, open-label),G, 52, 52  104,outcomes NA, 0.2000000000 NA,NA,  6.5000000   6.8000000,NA NA,NA,NA,NA,NA,100 100 100 100,100 100 100,low low,low low,low,Placebo,  0, 26.000000,31.300000,NA NA,2,0,0.0,1.0 1.0,1.0 1,1 2,1 1,1 0,0.5 0 1 1 1  342 Barkley_2005,< 2 months,NA >= 20 yo,28.44 50.1 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
2785,Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100,  0,100 100 Critically low,Methylphenidate methylphenidate mixed release,  0 NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks) Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH, 1.37704918,  84.6000000,mg Biederman 2011 NA RCT (parallel, crossover, open-label),G, 40, 47,  87 NA NA -0.0800000000 NA NA,126.2200000,159.8400000 NA,NA,NA NA NA,NA,100 100,100 100,100 100 100 low,low,some low,low Placebo,  0  39.000000 33.870000,NA,NA 2,0 0.0 1.0,1.0 1.0 1 1 2 1 1,1 0,0.5 0 1 1,1  343 Biederman_2011 < 2 months NA >= 20 yo 28.44,50.1,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
2785 Pievsky (2018) Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100,  0,100 100,Critically low,Methylphenidate,Methylphenidate,  0,NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.68852459   70.6000000,mg Boonstra 2005 NA RCT (parallel, crossover, open-label),G, 43, 43,  86 NA NA  0.3900000000,NA NA   7.2000000,  7.6000000 NA NA,NA,NA,NA,NA 100,100 100 100 100,100,100,low low low low low Placebo   0, 51.000000,38.900000 NA,NA 2,0 0.0,1.0 1.0 1.0,1 1,2,1 1 1,0,0.5,0 1,1 1, 344,Boonstra_2005,< 2 months NA >= 20 yo,28.44,50.1 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
2785 Pievsky (2018) Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100   0,100,100,Critically low,Methylphenidate Methylphenidate   0,NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks) Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH, 0.03278689,  37.5000000,mg Bouffard,2003 NA RCT (parallel, crossover, open-label) G, 30, 30,  60,outcomes,NA, 0.5900000000,NA,NA, 14.1000000  13.2000000,NA NA NA NA NA NA   0   0   0 100,100,100 100 high,low,low low low Placebo   0  20.000000 34.000000,NA NA 2 0 0.0,1.0,1.0,1.0,1,1,2,1 1,1,0,0.5 0,1 1 1  345 Bouffard_2003 < 2 months,NA >= 20 yo,28.44 50.1,NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low high
2785,Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100,  0 100 100,Critically low,Methylphenidate,Methylphenidate   0 NA,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks) Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689   37.5000000 mg Bouffard 2003,NA,RCT (parallel, crossover, open-label) G, 30  30   60 outcomes NA, 0.6300000000,NA NA  14.3000000  14.1000000,NA,NA,NA NA NA NA   0,  0,  0,100 100,100,100 high low low,low,low,Placebo   0, 20.000000 34.000000,NA NA 2,0,0.0 1.0,1.0,1.0 1 1,2,1 1 1,0,0.5 0,1,1,1  346 Bouffard_2003 < 2 months NA >= 20 yo 28.44 50.1,NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low high
2785,Pievsky (2018) Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100   0 100 100,Critically low Methylphenidate,methylphenidate mixed release   0,NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.45901639,  72.0000000 mg,Bron,2014 NA RCT (parallel, crossover, open-label) G  22, 22   44,outcomes NA, 0.3300000000 NA NA NA,NA NA,NA NA,NA NA,NA,100,100 100,100 100,100,100,low low low,low low,Placebo,  0, 23.000000,30.500000 NA NA 2,0 0.0,1.0 1.0,1.0 1 1 2 1 1 1 0 0.5 0,1 1,1, 347 Bron_2014,< 2 months,NA >= 20 yo 28.44,50.1 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
2785,Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100,  0 100,100 Critically low Methylphenidate methylphenidate mixed release   0,NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH, 0.45901639   72.0000000,mg Bron,2014,NA,RCT (parallel, crossover, open-label) G  22, 22   44,outcomes,NA, 0.3100000000,NA,NA,NA NA NA NA,NA NA NA,NA 100 100,100,100 100 100 100 low low,low low low Placebo   0  23.000000,30.500000,NA NA 2,0 0.0 1.0 1.0 1.0 1 1 2,1,1 1,0,0.5,0,1 1 1, 348 Bron_2014,< 2 months NA >= 20 yo 28.44,50.1 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
2785,Pievsky (2018) Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100,  0 100 100 Critically low Methylphenidate Methylphenidate,  0 NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689   20.0000000,mg Epstein 2007,NA,RCT (parallel, crossover, open-label),G, 15, 15,  30 NA,NA, 0.1900000000,NA,NA   6.6400000   9.2700000,NA NA,NA,NA,NA NA 100 100 100,100 100,100,100 some low low low low,Placebo,  0, 67.000000 50.100000 NA,NA 2 0 0.0 1.0 1.0,1.0,1,1,2,1,1,1 0,0.5 0 1 1 1  349,Epstein_2007,< 2 months,NA >= 20 yo,28.44,50.1,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
2785 Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100   0 100,100 Critically low,Methylphenidate,Methylphenidate   0,NA,Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks) Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689    2.0000000 mg,Kollins 2013,NA RCT (parallel, crossover, open-label),G, 16  16   32,outcomes,NA -0.1200000000 NA NA  10.6800000   8.7500000,NA NA,NA,NA,NA NA,  0   0 100 100,100,  0 100 low low,low low high,Placebo,  0  50.000000 29.800000,NA NA 2 0,0.0 1.0,1.0 1.0,1,1 2 1,1 1 0 0.5 0,1,1 1  350 Kollins_2013,< 2 months,NA,>= 20 yo,28.44,50.1,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,high,high
2785 Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100   0,100,100 Critically low Methylphenidate Methylphenidate,  0,NA,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks) Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH, 0.03278689    2.0000000 mg Kollins,2013 NA,RCT (parallel, crossover, open-label) G, 16, 16,  32,outcomes,NA,-0.2600000000 NA,NA   9.3900000   8.7500000 NA NA,NA NA,NA,NA,  0   0,100 100,100   0 100,low low,low,low high,Placebo   0  50.000000,29.800000,NA,NA 2,0,0.0 1.0 1.0,1.0,1 1,2 1,1 1,0,0.5,0,1,1,1, 351 Kollins_2013,< 2 months NA,>= 20 yo,28.44,50.1,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high high
2785,Pievsky (2018),Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100,  0,100 100 Critically low Methylphenidate,methylphenidate Sustained release,  0,NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.91803279,  20.0000000 mg,Levin 2001 NA RCT (parallel, crossover, open-label),G,  9,  7,  16 outcomes NA,-0.4700000000,NA NA,  8.1000000   7.1400000 NA,NA,NA,NA,NA NA,  0   0 100,100   0,  0 100 some,low,high low high Placebo,  0, 35.000000 37.750000,NA,NA,2 0 0.0 1.0 1.0 1.0 1,1 2,1 1,1,0 0.5 0 1,1 1, 352,Levin_2001 < 2 months NA,>= 20 yo,28.44 50.1 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high high
2785 Pievsky (2018) Pievsky,2018,10.1016/j.neubiorev.2018.05.012 100,  0,100 100 Critically low,Methylphenidate methylphenidate Sustained release,  0 NA Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.91803279   20.0000000,mg,Levin 2001,NA,RCT (parallel, crossover, open-label) G   9,  7,  16 outcomes NA  0.1100000000 NA NA   7.2000000   8.4700000,NA,NA NA,NA,NA,NA   0   0 100 100,  0   0,100,some low,high,low,high,Placebo,  0, 35.000000,37.750000 NA,NA,2 0 0.0 1.0,1.0 1.0 1 1 2 1,1 1,0 0.5,0 1 1 1, 353 Levin_2001 < 2 months NA >= 20 yo,28.44 50.1,NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high high
2785,Pievsky (2018),Pievsky,2018 10.1016/j.neubiorev.2018.05.012 100   0 100,100,Critically low Methylphenidate,Methylphenidate   0 NA,Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH, 0.03278689,   0.5000000,mg/kg,Overtoom,2009,NA RCT (parallel, crossover, open-label) G, 12, 12,  24,outcomes NA, 0.0500000000,NA NA,  2.1000000   1.6000000,NA,NA NA,NA,NA,NA 100 100,100,100 100,100,100 some low,low low,low Placebo   0  50.000000 35.900000,NA,NA 2,0,0.0 1.0 1.0 1.0 1 1,2,1,1,1,0 0.5 0 1 1,1  354 Overtoom_2009,< 2 months,NA >= 20 yo,28.44 50.1,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
2785 Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100   0,100 100 Critically low,Methylphenidate,Methylphenidate,  0,NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689,   0.5000000 mg/kg,Overtoom,2009,NA RCT (parallel, crossover, open-label) G  12  12   24,outcomes,NA,-0.4100000000 NA,NA,  9.6000000   3.8000000 NA NA,NA NA,NA NA,100 100,100 100,100,100,100 some low,low,low,low Placebo   0  50.000000 35.900000 NA,NA 2 0,0.0 1.0 1.0 1.0,1 1,2,1 1 1,0,0.5,0,1,1,1  355,Overtoom_2009,< 2 months,NA,>= 20 yo,28.44,50.1 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
2785,Pievsky (2018) Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100,  0 100 100 Critically low Methylphenidate,Methylphenidate,  0 NA,Executive functioning (tests) Clinician-rated At study endpoint (closest to 12 weeks) Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689    0.5000000,mg/kg Overtoom 2009,NA,RCT (parallel, crossover, open-label),G, 12, 12   24,outcomes NA  0.4300000000 NA NA, 60.0000000  47.0000000,NA NA NA,NA NA,NA 100 100 100,100,100 100 100,some,low low low,low,Placebo   0  50.000000,35.900000 NA NA 2,0,0.0,1.0 1.0,1.0,1 1,2 1 1,1 0,0.5 0 1,1 1  356,Overtoom_2009,< 2 months NA >= 20 yo,28.44,50.1,NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
2785,Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100   0,100 100,Critically low Methylphenidate Methylphenidate,  0 NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks) Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH, 0.03278689    0.5000000 mg/kg Overtoom,2009,NA,RCT (parallel, crossover, open-label) G  12  12,  24,outcomes,NA  0.9000000000 NA,NA   1.5000000   1.6000000 NA NA,NA NA NA,NA 100 100 100 100 100 100,100 some,low low low low Placebo,  0  50.000000,35.900000 NA NA 2,0 0.0 1.0,1.0,1.0 1,1,2,1 1 1 0 0.5,0 1 1 1, 357 Overtoom_2009 < 2 months NA >= 20 yo 28.44,50.1,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
2785 Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100   0,100,100 Critically low,Methylphenidate,Methylphenidate   0,NA,Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test,TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689    0.5000000 mg/kg Overtoom 2009,NA,RCT (parallel, crossover, open-label),G, 12  12,  24 outcomes NA  0.5100000000,NA,NA,  4.7000000,  3.8000000,NA,NA NA,NA,NA,NA 100 100 100,100 100 100 100 some low low,low,low Placebo,  0, 50.000000,35.900000,NA NA 2 0 0.0 1.0 1.0 1.0 1 1,2,1,1,1,0,0.5,0,1,1,1, 358 Overtoom_2009 < 2 months NA >= 20 yo 28.44 50.1 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
2785,Pievsky (2018) Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100,  0,100 100 Critically low,Methylphenidate Methylphenidate   0 NA Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks),Test TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH  0.03278689,   0.5000000 mg/kg Overtoom,2009,NA RCT (parallel, crossover, open-label) G  12  12   24 outcomes NA, 0.6100000000 NA,NA, 55.0000000  47.0000000,NA NA,NA NA,NA,NA 100,100 100,100 100,100 100 some low low,low,low Placebo   0  50.000000,35.900000,NA NA,2,0,0.0,1.0 1.0,1.0,1 1 2,1 1,1,0 0.5,0 1,1,1, 359 Overtoom_2009,< 2 months,NA >= 20 yo 28.44 50.1,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
2785 Pievsky (2018),Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100   0 100 100 Critically low Methylphenidate methylphenidate mixed release,  0 NA Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks),Test,CNSVS Shifting Attention Test accuracy + Trails B, 1.37704918   52.0000000,mg,Goodman 2016 NA RCT (parallel, crossover, open-label) G,169 172, 341,NA NA  0.0400000000 NA,NA, 17.6700000  17.4000000 NA NA NA,NA NA,NA,100 100 100,100,100 100,100,some low,low,low low Placebo,  0, 47.000000,35.740000,NA NA,2,0,0.0 1.0,1.0 1.0 1 1 2 1 1,1,0 0.5,0 1,1,1, 360 Goodman_2016,< 2 months,NA,>= 20 yo,28.44 50.1 NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
2785,Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100   0,100,100 Critically low,Methylphenidate Methylphenidate   0,NA Executive functioning (tests),Clinician-rated,At study endpoint (closest to 12 weeks),Test,CNSVS Shifting Attention Test accuracy + Trails B  1.60655738,   0.9000000,mg/kg Kuperman 2001 NA,RCT (parallel, crossover, open-label) G,  8, 10,  18 outcomes,NA,-0.0100000000,NA NA NA NA,NA NA,NA,NA NA,NA   0   0,100,100,100   0   0,some low low,high high,Placebo   0, 26.000000,31.840000 NA NA,2 0,0.0 1.0,1.0 1.0,1 1,2,1 1 1 0,0.5 0 1 1,1, 361 Kuperman_2001 < 2 months,NA >= 20 yo,28.44,50.1,NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high,high
2785 Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100   0 100,100,Critically low,Methylphenidate,methylphenidate Immediate release   0,NA Driving Clinician-rated,At study endpoint (closest to 12 weeks),Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm)  0.03278689,  15.0000000,mg,Barkley 2005 NA RCT (parallel, crossover, open-label),G  52, 52  104,outcomes NA, 0.0000000000,NA NA   2.2000000,  1.7000000,NA NA NA NA,NA,NA,100 100,100,100,100 100,100 low,low low,low low,Placebo   0, 26.000000 31.300000 NA NA 2,0,0.0,1.0 1.0 1.0,1 1 2 1,1 1 0,0.5,0,1,1 1  362 Barkley_2005 < 2 months,NA >= 20 yo,22.14 38.3,NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
2785 Pievsky (2018),Pievsky,2018,10.1016/j.neubiorev.2018.05.012,100   0 100,100 Critically low Methylphenidate methylphenidate Immediate release,  0,NA,Driving Clinician-rated At study endpoint (closest to 12 weeks) Test Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm), 0.03278689,  15.0000000 mg,Barkley 2005,NA RCT (parallel, crossover, open-label),G  52, 52  104 outcomes NA, 0.0000000000 NA NA   1.2000000   1.1000000,NA,NA,NA NA,NA NA 100,100,100,100 100 100,100,low,low low low,low Placebo   0  26.000000 31.300000,NA NA 2,0 0.0,1.0 1.0 1.0 1,1 2,1,1 1,0,0.5 0,1,1 1, 363 Barkley_2005,< 2 months,NA,>= 20 yo 22.14 38.3 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
2785,Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012 100,  0 100 100,Critically low Methylphenidate,methylphenidate Immediate release   0,NA,Driving,Clinician-rated At study endpoint (closest to 12 weeks),Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm)  0.03278689,  15.0000000 mg,Barkley 2005,NA RCT (parallel, crossover, open-label),G, 52, 52  104,outcomes NA  0.1700000000,NA,NA, 19.4000000  24.3000000,NA,NA NA NA,NA,NA 100,100 100,100 100,100 100 low low,low low,low Placebo,  0, 26.000000 31.300000 NA NA,2,0,0.0 1.0,1.0,1.0 1,1,2 1,1,1 0 0.5,0,1,1,1  364 Barkley_2005 < 2 months,NA,>= 20 yo,22.14,38.3 NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
2785,Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100   0,100,100,Critically low Methylphenidate methylphenidate Immediate release   0,NA,Driving,Clinician-rated,At study endpoint (closest to 12 weeks) Test Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm)  0.03278689,  15.0000000,mg,Barkley,2005,NA,RCT (parallel, crossover, open-label),G  52  52  104,outcomes,NA, 0.2100000000 NA NA   3.8000000   4.0000000 NA NA,NA,NA NA,NA 100 100 100,100 100 100 100 low,low low low low,Placebo   0, 26.000000 31.300000 NA NA 2,0 0.0 1.0 1.0 1.0 1,1,2,1,1,1 0 0.5 0,1,1,1  365,Barkley_2005 < 2 months,NA,>= 20 yo,22.14 38.3,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
2785,Pievsky (2018) Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100   0,100 100,Critically low Methylphenidate methylphenidate Immediate release   0,NA Driving Clinician-rated At study endpoint (closest to 12 weeks) Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm), 0.03278689   15.0000000,mg,Barkley,2005 NA,RCT (parallel, crossover, open-label),G  52  52  104,outcomes,NA, 0.0000000000,NA,NA   1.8000000,  1.7000000,NA NA NA NA,NA NA,100 100,100 100 100 100 100 low,low,low,low,low Placebo   0  26.000000 31.300000,NA,NA,2 0 0.0,1.0 1.0,1.0,1,1,2 1,1,1 0,0.5,0 1 1,1  366,Barkley_2005,< 2 months NA >= 20 yo,22.14 38.3,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
2785 Pievsky (2018),Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100,  0 100 100 Critically low Methylphenidate,methylphenidate Immediate release   0 NA Driving Clinician-rated,At study endpoint (closest to 12 weeks) Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm), 0.03278689   15.0000000 mg,Barkley,2005,NA RCT (parallel, crossover, open-label),G  52, 52, 104,outcomes,NA, 0.2000000000,NA NA   0.9000000,  1.1000000 NA NA NA,NA,NA,NA 100 100 100,100,100 100,100 low low,low,low low,Placebo,  0, 26.000000,31.300000,NA,NA,2 0,0.0 1.0 1.0,1.0 1 1,2,1 1 1,0,0.5,0,1,1,1  367 Barkley_2005 < 2 months,NA,>= 20 yo 22.14,38.3 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
2785,Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100,  0 100 100 Critically low Methylphenidate,methylphenidate Immediate release,  0,NA Driving,Clinician-rated At study endpoint (closest to 12 weeks) Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm)  0.03278689,  15.0000000,mg,Barkley 2005 NA,RCT (parallel, crossover, open-label) G, 52, 52  104,outcomes,NA  0.4200000000,NA NA, 11.6000000, 24.3000000 NA,NA,NA NA NA,NA,100,100,100 100,100,100 100,low,low low,low,low Placebo   0  26.000000,31.300000,NA,NA,2,0 0.0 1.0 1.0,1.0,1 1,2,1 1,1 0 0.5,0 1,1 1  368,Barkley_2005,< 2 months NA >= 20 yo 22.14 38.3,NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
2785 Pievsky (2018),Pievsky 2018,10.1016/j.neubiorev.2018.05.012,100   0 100 100 Critically low,Methylphenidate,methylphenidate Immediate release,  0,NA Driving,Clinician-rated,At study endpoint (closest to 12 weeks) Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm)  0.03278689   15.0000000,mg Barkley,2005,NA,RCT (parallel, crossover, open-label),G, 52, 52  104 outcomes NA  0.0500000000,NA NA   3.9000000,  4.0000000 NA,NA,NA NA NA NA 100 100,100,100,100 100,100 low,low,low low low,Placebo,  0, 26.000000,31.300000 NA NA 2,0,0.0 1.0 1.0 1.0,1,1,2,1 1,1,0,0.5 0,1 1,1, 369 Barkley_2005 < 2 months,NA,>= 20 yo,22.14 38.3 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
2785 Pievsky (2018) Pievsky 2018,10.1016/j.neubiorev.2018.05.012 100   0,100,100,Critically low,Methylphenidate methylphenidate Immediate release,  0 NA Driving,Clinician-rated At study endpoint (closest to 12 weeks) Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm), 0.03278689   10.0000000,mg,Cox,2000 NA RCT (parallel, crossover, open-label) G,  7,  7,  14,NA NA, 1.3700000000 NA NA,NA NA NA,NA,NA,NA,NA,NA,  0   0   0 100,  0,100 100 high,low,high low,low Placebo,  0   0.000000,22.140000,NA,NA 2,0 0.0 1.0 1.0 1.0 1,1 2,1 1,1,0,0.5 0,1 1,1  370,Cox_2000,< 2 months,NA,>= 20 yo,22.14 38.3 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,high
2785,Pievsky (2018),Pievsky,2018 10.1016/j.neubiorev.2018.05.012 100,  0 100 100 Critically low Methylphenidate,methylphenidate Immediate release,  0 NA,Driving Clinician-rated At study endpoint (closest to 12 weeks),Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm)  0.03278689,NA NA Verster,2008 NA,RCT (parallel, crossover, open-label) G, 18, 18   36,outcomes NA, 0.8700000000 NA,NA   1.0000000,  3.1000000 NA NA NA NA,NA NA,  0   0,100,100,100,  0 100,low low,low low,high Placebo,  0, 39.000000,38.300000 NA NA 2 0 0.0 1.0 1.0,1.0 1 1 2,1,1,1,0 0.5 0,1 1 1, 371,Verster_2008 < 2 months,NA,>= 20 yo,22.14,38.3 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high high
2785 Pievsky (2018),Pievsky,2018 10.1016/j.neubiorev.2018.05.012 100,  0 100 100,Critically low,Methylphenidate,methylphenidate Immediate release,  0,NA,Driving,Clinician-rated,At study endpoint (closest to 12 weeks) Test,Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm)  0.03278689,NA,NA,Verster 2008,NA RCT (parallel, crossover, open-label) G  18, 18   36 outcomes,NA  0.7700000000,NA,NA, 18.0000000  47.6000000,NA,NA,NA NA NA NA,  0,  0,100,100 100   0 100,low,low low low,high,Placebo,  0, 39.000000 38.300000 NA,NA,2 0 0.0,1.0,1.0 1.0,1,1 2 1,1,1 0,0.5 0 1,1 1, 372,Verster_2008 < 2 months,NA,>= 20 yo 22.14 38.3,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high high
2785 Pievsky (2018),Pievsky,2018,10.1016/j.neubiorev.2018.05.012 100   0 100,100 Critically low,Methylphenidate methylphenidate Immediate release,  0 NA Driving,Clinician-rated At study endpoint (closest to 12 weeks),Test Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm), 0.03278689 NA,NA,Verster 2008 NA,RCT (parallel, crossover, open-label) G, 18  18,  36 outcomes,NA  0.6400000000 NA,NA   3.5000000   4.0000000 NA,NA,NA NA NA,NA   0,  0,100 100,100   0,100,low,low low low,high,Placebo   0, 39.000000 38.300000 NA,NA 2 0,0.0,1.0 1.0 1.0,1,1 2,1,1 1 0 0.5 0,1 1 1, 373 Verster_2008 < 2 months,NA >= 20 yo 22.14 38.3 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,high high
2785 Pievsky (2018) Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100,  0,100 100 Critically low,Methylphenidate methylphenidate Immediate release,  0,NA Driving Clinician-rated,At study endpoint (closest to 12 weeks) Test Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm), 0.03278689 NA,NA Verster 2008,NA RCT (parallel, crossover, open-label) G, 18, 18   36 outcomes NA  0.6100000000,NA,NA,  3.5000000,  4.0000000,NA NA,NA,NA,NA,NA   0   0 100 100 100,  0,100,low,low,low,low high,Placebo,  0  39.000000 38.300000 NA NA,2,0 0.0,1.0,1.0 1.0 1 1,2,1,1,1 0 0.5 0,1 1 1, 374,Verster_2008 < 2 months NA,>= 20 yo 22.14,38.3,NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,high,high
2785 Pievsky (2018) Pievsky 2018 10.1016/j.neubiorev.2018.05.012,100,  0 100,100,Critically low Methylphenidate,methylphenidate Immediate release,  0,NA,Driving Clinician-rated At study endpoint (closest to 12 weeks),Test Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm)  0.03278689,NA,NA,Verster,2008 NA,RCT (parallel, crossover, open-label) G, 18  18,  36,outcomes NA, 0.0600000000,NA NA  20.1000000, 16.8000000 NA,NA,NA NA,NA,NA   0,  0,100 100 100,  0,100 low,low,low,low high Placebo,  0  39.000000,38.300000,NA NA 2,0 0.0 1.0,1.0,1.0,1,1,2 1 1 1,0,0.5 0 1 1,1, 375 Verster_2008,< 2 months NA,>= 20 yo 22.14 38.3 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,high high
 529,Candido (2021),Candido,2021,10.1002/14651858.CD013011.pub2,100   0 100 100,High,Methylphenidate methylphenidate immediate release 100 mono,CGI Clinician-rated At study endpoint (closest to 12 weeks) Observational tool Clinical impression: severity (change scores), 3.91254315   40.0000000,mg/daily Schrantee,2016,NA RCT (parallel, crossover, open-label),MD, 25  24,  49,outcomes reverse -0.6000000000,-0.920000000 -2.800000e-01,NA NA,NA NA NA,NA  0.6300000  0.5000000,  0   0,100 100,100,  0,100 low,low,low some high Placebo,  0   0.000000 28.600000,NA,DSM-IV, Diagnostic Interview
for ADHA in Adults (DIVA) 0,1,1.0,1.0,1.0 1.0 1 1 0 1 1,1,1,1.0 1 1,1,1  376 Schrantee_2016 2-6 months NA,>= 20 yo 28.6,39 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Candido (2021)_Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Candido (2021) - Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,high,high
 529,Candido (2021) Candido 2021 10.1002/14651858.CD013011.pub2 100   0,100,100,High Methylphenidate methylphenidate immediate release 100,mono CGI,Clinician-rated At study endpoint (closest to 12 weeks),Observational tool Clinical impression: severity (change scores)  1.61104718,  10.0000000 mg/4-5timesad,Kooij 2004,NA,RCT (parallel, crossover, open-label),MD, 45, 45   90 NA,reverse,-0.4400000000 -1.050000000, 1.700000e-01,NA NA NA NA NA,NA  1.4700000  1.4700000   0,  0 100 100 100,  0,100,some,low low some high,Placebo,  0  46.670000 39.000000,NA,DSM-IV 0 1 1.0,1.0,1.0,1.0 1,1 0,1 1 1,1 1.0,1 1 1,1, 377,Kooij_2004 < 2 months,NA >= 20 yo,28.6 39,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Candido (2021)_Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Candido (2021) - Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high,high
 529 Candido (2021),Candido 2021 10.1002/14651858.CD013011.pub2 100,  0,100 100 High,Methylphenidate,methylphenidate immediate release 100 mono CGI Clinician-rated,At study endpoint (closest to 12 weeks) Observational tool Clinical Global Impression Scale (CGI) – Improvement (-I) ; End scores, 3.91254315   40.0000000 mg/daily Schrantee,2016,NA RCT (parallel, crossover, open-label),MD  25  24,  49,outcomes,reverse,-0.9400000000 -1.370000000,-5.100000e-01,NA NA NA NA,NA,NA, 0.8700000, 0.6600000   0   0,100,100,100   0,100 low,low,low,some high Placebo   0,  0.000000,28.600000 NA,DSM-IV, Diagnostic Interview
for ADHA in Adults (DIVA),0,1,1.0,1.0,1.0 1.0,1 1 0 1 1 1,1,1.0 1 1,1 1, 378 Schrantee_2016 2-6 months,NA >= 20 yo,28.6 39,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Candido (2021)_Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Candido (2021) - Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,high,high
3425,Storebo (2023),Storebo,2023,10.1002/14651858.CD009885.pub3 100   0,100,100 High,Methylphenidate,LA-MPH 100 Omega3/6,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks),Questionnaire,ADHD-RS,11.96777906    0.6500000 mg/kg/d,Barragan 2017 NA RCT (parallel, crossover, open-label) G  30, 30,  60,NA,reverse,-0.5100000000 -1.030000000  0.000000e+00   5.0900000,  7.8400000 NA NA,NA,NA,NA NA   0,  0,  0   0   0,100,  0 high,high high high some,Active (any credible active intervention) 100, 33.300000  8.270000,NA,DSM-IV-TR 0 1,1.0 1.0 1.0 1.0 1 1 0 1 1 1,1 1.0,1 1 1,1  379 Barragan_2017,7-12 months,NA 6-12 yo 8.27,8.4,100.4,100.4 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Storebo (2023)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low high
3425 Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3 100 100 100,100 High Methylphenidate,MPH   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks),Questionnaire,SNAP Inattention and Hyperactivity-Impulsivity subscale 13.80897583,  37.8000000,mg/d,Jensen 1999,NA RCT (parallel, crossover, open-label) G,133 129  262 NA,reverse -0.5800000000,-0.820000000,-3.300000e-01,  0.6300000   0.7200000,NA NA,NA,NA,NA NA   0   0,100   0,  0,100,  0,low,high,high high,low TAU,  0, 20.000000, 8.400000,100.40000 DSM-IV 0,1,1.0,1.0,1.0,1.0,1 1 0 1 1,1,1,1.0 1 1,1 1  380 Jensen_1999 > 12 months Average (80-119) 6-12 yo 8.27 8.4,100.4 100.4 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Storebo (2023)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low,high
3425,Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3,100,  0 100,100,High Methylphenidate ER-MPH   0,NA,Quality of life (patients),Mixed At study endpoint (closest to 12 weeks),Questionnaire,Child Health Questionnaire (CHQ), 1.38089758   39.9000000 mg/d Newcorn,2008,NA RCT (parallel, crossover, open-label) G 193  64, 257 NA,NA, 0.5400000000  0.250000000, 8.300000e-01, 12.7000000, 12.0000000,NA,NA NA NA NA,NA,100 100 100,100,100 100,100,some low,low,low,low Placebo,  0  28.200000 10.175097 NA,DSM-IV,0 1,1.0,1.0,1.0,1.0,1,1,0 1,1 1,1,1.0 1 1,1 1  381 Newcorn_2008 < 2 months,NA 6-12 yo,10.1750972762646 11.6 94.7 94.7 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Storebo (2023)_Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
3425,Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3,100,100,100,100 High,Methylphenidate SODAS-MPH,  0,NA Quality of life (patients),Mixed,At study endpoint (closest to 12 weeks) Questionnaire Children´s Global Assessment Scale (CGAS) NA,   0.7200000,mg/kg/d Szobot,2004,NA RCT (parallel, crossover, open-label) G, 19  17,  36,NA,NA  0.7900000000  0.100000000  1.470000e+00, 11.3000000, 12.1000000,NA NA,NA,NA NA,NA,100 100,100 100,100,100 100 low low,low,low some,Placebo,  0   0.000000,11.600000, 94.70000,DSM-IV,0 1 1.0 1.0,1.0 1.0,1 1 0,1,1 1,1,1.0,1,1,1 1, 382 Szobot_2004,NA,Average (80-119),6-12 yo,10.1750972762646 11.6,94.7 94.7 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Storebo (2023)_Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
3425,Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3,100   0 100,100 High Methylphenidate ER-MPH   0,NA,Quality of life (patients) Mixed At study endpoint (closest to 12 weeks),Questionnaire Child Health and Illness Profile, 2.76179517,  45.4000000 mg/d Coghill,2013 NA RCT (parallel, crossover, open-label) G,111,110, 221 NA NA, 0.6400000000  0.370000000, 9.100000e-01  11.5892000  11.2230000,NA NA,NA NA,NA NA 100,100,100 100,100 100,100,low,low some low,low Placebo   0  18.000000 10.900000,NA,DSM-IV-TR,0 1 1.0,1.0 1.0 1.0,1 1,0,1,1,1,1 1.0,1 1,1,1, 383 Coghill_2013 2-6 months NA 6-12 yo 10.1750972762646 11.6,94.7,94.7,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Storebo (2023)_Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
3425,Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3,100 100,100 100,High Methylphenidate,MPH   0,NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Questionnaire Barkley Side Effects Rating Scale:  0.23014960    0.8000000 mg/kg/d,Barkley 1989 NA RCT (parallel, crossover, open-label),RR  82  82  164,NA,NA, 7.4500000000  3.510000000, 1.581000e+01 NA,NA,NA,NA NA,NA,NA NA 100 100,100 100,100 100 100,some,low some,low,low,Placebo,  0, 14.450000, 8.200000,105.10000,DSM-III-R 0 1,1.0 1.0 1.0 1.0,1 1,0 1,1,1 1,1.0,1,1 1,1, 384,Barkley_1989,< 2 months,Average (80-119) 6-12 yo,4.76 15 85 109.9,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3425,Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3 100   0 100,100,High Methylphenidate MPH,  0 NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Questionnaire,Barkley Side Effects Rating Scale  0.46029919,   0.5000000,mg/kg/d Bhat 2020,NA,RCT (parallel, crossover, open-label),RR,526 526,1052,NA,NA,18.2200000000,10.380000000  3.197000e+01 NA,NA,NA,NA NA NA NA,NA 100 100,100,100,100 100 100 low,low,some low low Placebo,  0  22.400000, 9.030000 NA,DSM-IV 0,1,1.0 1.0,1.0 1.0 1,1 0 1 1,1 1,1.0 1 1 1,1  385,Bhat_2020 < 2 months,NA,6-12 yo,4.76,15 85 109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3425 Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3 100,  0 100 100 High Methylphenidate ER-d-MPH   0,NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Interview,Spontaneously reported Aes, 0.46029919,  20.0000000,mg/d Brams 2012,NA,RCT (parallel, crossover, open-label) RR 163,159, 322 NA NA 21.8200000000  1.270000000  3.756200e+02,NA,NA,NA NA,NA,NA NA NA 100,100 100 100 100,100 100 low low low,low,some,Placebo,  0, 38.400000  9.500000,NA,DSM-IV,0,1,1.0 1.0 1.0,1.0,1 1,0,1 1,1,1 1.0,1,1 1,1, 386,Brams_2012 < 2 months,NA 6-12 yo 4.76,15 85 109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
3425 Storebo (2023),Storebo,2023,10.1002/14651858.CD009885.pub3,100,100 100,100,High,Methylphenidate MPH,  0 NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Questionnaire,Adverse effects checklist, 2.30149597    0.6000000,mg/kg/d Buitelaar,1995,NA RCT (parallel, crossover, open-label) RR  26, 11,  37,NA,NA  0.8200000000, 0.130000000, 5.290000e+00,NA,NA NA,NA NA NA NA NA 100 100 100,100,100 100,100 some,low,low,some,some Placebo,  0  11.500000  9.300000, 94.20000,DSM-III-R 0 1 1.0 1.0 1.0 1.0 1 1,0 1 1,1,1,1.0,1 1,1 1  387 Buitelaar_1995 2-6 months Average (80-119) 6-12 yo,4.76 15 85,109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3425,Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3,100,  0,100 100,High,Methylphenidate MPH,  0,NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Questionnaire,Side Effects Rating Scale, 0.23014960,   0.4500000 mg/kg/d,Bukstein,1998,NA RCT (parallel, crossover, open-label) RR  18  18,  36 NA NA, 2.8100000000  2.150000000, 3.680000e+00 NA,NA NA NA NA NA,NA,NA 100,100,100 100 100 100 100,some,low low low some Placebo,  0, 22.200000, 9.400000 NA,DSM-III-R 0 1 1.0,1.0,1.0,1.0,1,1 0,1 1,1,1 1.0,1 1,1 1, 388,Bukstein_1998,< 2 months,NA,6-12 yo,4.76 15,85 109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
3425 Storebo (2023),Storebo,2023,10.1002/14651858.CD009885.pub3 100,100 100,100,High Methylphenidate MPH   0,NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),AEs  2.07134638    0.9500000,mg/kg/d,Castellanos,1997 NA,RCT (parallel, crossover, open-label) RR, 22, 22,  44 NA,NA, 3.3200000000, 0.320000000, 3.465000e+01 NA NA,NA,NA,NA,NA,NA NA,  0   0 100,100,  0,  0,100,some low high,some,high Placebo   0   0.000000, 9.400000  98.80000,DSM-III 0,1,1.0 1.0 1.0 1.0,1,1 0 1,1 1 1 1.0,1 1,1 1, 389 Castellanos_1997,2-6 months Average (80-119) 6-12 yo 4.76,15 85,109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high high
3425 Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3,100,  0,100,100 High Methylphenidate,MPH   0 NA Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Questionnaire,daily ratings of the presence and severity
of common stimulant side effects, 1.38089758,   0.4500000,mg/kg/d Chacko 2005 NA RCT (parallel, crossover, open-label) RR  36, 36   72,NA,NA, 6.5400000000, 1.320000000  3.244000e+01 NA,NA NA NA NA,NA NA NA,  0   0 100 100,100   0,100 some low,low,some high,Placebo,  0  11.000000, 6.130000,NA DSM-III-R 0,1 1.0 1.0 1.0,1.0,1,1 0,1 1 1,1,1.0 1 1 1 1, 390,Chacko_2005,< 2 months,NA,6-12 yo,4.76 15 85,109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
3425 Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3 100 100,100 100 High,Methylphenidate IR-MPH,  0,NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Questionnaire,Pittsburgh Side Effects Rating Scale  1.84119678    0.6000000,mg/kg/d,Chronis 2003 NA,RCT (parallel, crossover, open-label),RR, 21, 21   42,NA NA  1.6000000000, 0.410000000, 6.190000e+00,NA NA,NA,NA NA NA,NA,NA 100,100 100 100,100,100 100 some,low,some,low,low Placebo   0   9.500000 10.300000,109.90000,DSM-IV 0 1,1.0 1.0 1.0,1.0 1,1 0 1 1,1 1,1.0,1,1 1,1, 391 Chronis_2003,< 2 months Average (80-119),6-12 yo,4.76,15,85 109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3425,Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3 100,  0,100,100 High,Methylphenidate LA-MPH,  0 NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) Monitoring and reporting of Aes  1.84119678,  40.0000000 mg/d CRIT124US02 NA NA RCT (parallel, crossover, open-label) RR 102,101  203,NA NA 30.7000000000, 1.860000000  5.062100e+02 NA,NA,NA NA,NA,NA NA,NA   0,  0,100,100,  0,  0,100 some low,high some high Placebo,  0 100.000000,13.800000,NA,not stated,0,1,1.0 1.0,1.0 1.0,1,1,0 1 1,1 1,1.0 1 1 1,1  392 CRIT124US02_NA,< 2 months NA,13-19 yo 4.76,15 85,109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
3425 Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100   0,100,100 High,Methylphenidate,MPH   0,NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Questionnaire Barkley Side Effects Rating Scale, 0.92059839,   0.5800000 mg/kg/d,DuPaul,1996 NA,RCT (parallel, crossover, open-label) RR, 24, 24   48,NA NA  2.1000000000  0.240000000, 1.821000e+01 NA NA NA NA,NA,NA,NA,NA,100 100 100 100 100,100 100,low,low,low low low,Placebo,  0, 20.800000 11.090000 NA,DSM-III-R 0,1 1.0 1.0,1.0,1.0,1,1 0,1 1,1 1 1.0 1,1,1 1  393,DuPaul_1996 < 2 months,NA,6-12 yo 4.76,15,85 109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3,100,  0,100,100,High Methylphenidate MPH,  0,NA Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Questionnaire,Side Effects/Behavior Monitoring Scale  0.92059839,  30.0000000 mg/d,Findling,2007,NA,RCT (parallel, crossover, open-label),RR, 16, 16,  32,NA,NA, 6.8200000000  0.690000000, 6.691000e+01,NA NA,NA,NA,NA NA NA NA 100,100 100,100 100 100 100,low,low,low low,some,Placebo   0  20.000000 10.430000,NA,DSM-IV,0 1,1.0 1.0,1.0 1.0,1,1,0 1,1 1,1,1.0 1,1,1,1, 394 Findling_2007,< 2 months NA,6-12 yo,4.76 15 85,109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
3425 Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3,100   0 100,100 High Methylphenidate MPH,  0,NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Questionnaire Side effects questionnaire:, 0.23014960,   0.9000000,mg/kg/d,Fine 1993,NA RCT (parallel, crossover, open-label),RR  12, 12   24 NA,NA, 2.0300000000  0.890000000  4.660000e+00,NA NA NA NA,NA,NA NA NA,100,100,100,100,100,100 100 low low some low some Placebo,  0 NA, 8.500000,NA DSM-III-R,0,1 1.0 1.0 1.0 1.0 1,1 0,1,1 1,1,1.0,1 1,1 1, 395 Fine_1993 < 2 months NA 6-12 yo 4.76 15 85,109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3425,Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3,100   0 100 100,High Methylphenidate MPH 100 ER-MPH, Standard-MPH or combination,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Interview Interviewed: 12 side effect symptoms: drawn from Subject’s Treatment Emergent Symptom Scale  0.46029919   18.5000000 mg/d,Fitzpatrick,1992 NA,RCT (parallel, crossover, open-label) RR, 19, 19   38,NA NA  3.3800000000  0.320000000, 3.579000e+01 NA,NA,NA,NA NA,NA,NA NA,  0   0   0,100,100,100 100 high,low some,some,some Placebo,  0  10.500000, 8.710000,NA DSM-III 0 1,1.0 1.0 1.0,1.0 1,1,0 1 1 1 1,1.0 1 1,1 1, 396,Fitzpatrick_1992 < 2 months NA 6-12 yo,4.76,15,85,109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
3425,Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3,100 100,100 100,High,Methylphenidate ER-MPH,  0,NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Questionnaire,Pittsburgh Side Effect Rating Scale  0.92059839,  36.0000000 mg/d Froehlich 2018 NA RCT (parallel, crossover, open-label),RR,171,171, 342 NA NA, 3.5000000000, 1.180000000  1.042000e+01,NA,NA,NA NA NA NA NA,NA,  0,  0 100 100,100   0,100 low low low,low high Placebo   0, 28.600000, 8.400000 105.60000 DSM-IV,0,1,1.0,1.0,1.0,1.0,1 1,0 1 1,1 1 1.0,1,1 1 1  397 Froehlich_2018,< 2 months Average (80-119) 6-12 yo 4.76 15,85 109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high high
3425 Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3 100   0 100 100,High,Methylphenidate LA-MPH,  0,NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Interview,A structured interview  0.46029919   30.0000000 mg/d Huang 2021,NA RCT (parallel, crossover, open-label) RR 110 101  211,NA NA,48.6600000000, 6.860000000, 3.453900e+02 NA NA,NA NA,NA,NA,NA NA   0,  0,100,100 100   0 100 some,some low some high Placebo,  0  29.200000  9.160000,NA DSM-5 0,1,1.0 1.0 1.0,1.0,1 1 0,1 1 1 1,1.0,1 1,1,1  398,Huang_2021 < 2 months,NA,6-12 yo,4.76,15 85,109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high high
3425 Storebo (2023),Storebo,2023,10.1002/14651858.CD009885.pub3,100,100,100 100,High Methylphenidate MPH   0 NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 1.38089758   35.2100000 mg/d,Klorman 1990 NA,RCT (parallel, crossover, open-label) RR  48, 48,  96 NA NA  3.1900000000  1.040000000  9.830000e+00,NA NA,NA,NA,NA NA,NA NA 100 100 100 100 100 100,100,low low some low,some,Placebo   0, 12.500000,15.000000,108.62000 DSM-III,0,1 1.0 1.0 1.0,1.0 1,1 0 1 1,1 1 1.0,1 1 1,1, 399 Klorman_1990,< 2 months,Average (80-119),13-19 yo,4.76 15 85 109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
3425,Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100,100 100,100,High Methylphenidate MPH   0 NA Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Questionnaire Pittsburgh Side Effects Rating Scale, 0.92059839,  14.2200000 mg/d,Kollins,2006 NA RCT (parallel, crossover, open-label),RR 136,160  296,NA,NA, 1.0100000000  0.450000000, 2.260000e+00 NA,NA,NA NA NA NA NA,NA,100 100 100 100 100,100,100 low,low,low,low low,Placebo,  0, 25.400000  4.760000, 97.45000,DSM-IV,0 1,1.0,1.0,1.0,1.0,1,1 0,1 1 1 1 1.0 1 1 1 1  400 Kollins_2006,< 2 months Average (80-119) < 6 yo 4.76 15,85 109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3425 Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3 100   0 100 100 High Methylphenidate,MPH,  0,NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Questionnaire Side Effects Behavior Monitoring Scale, 0.92059839    9.7000000,mg/d Manos,1999 NA,RCT (parallel, crossover, open-label),RR,177 177  354,NA NA  2.7200000000  1.300000000  5.660000e+00 NA,NA,NA NA NA,NA NA NA,  0,  0,  0   0,100 100,  0,high,high some,high some,Placebo,  0 NA,10.100000 NA DSM-IV,0,1 1.0,1.0 1.0 1.0,1 1 0,1 1 1 1 1.0,1,1 1 1  401,Manos_1999 < 2 months NA 6-12 yo,4.76 15 85 109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
3425,Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3 100,  0,100 100,High,Methylphenidate MPH   0 NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 0.92059839    0.7200000 mg/kg/d McBride 1988,NA,RCT (parallel, crossover, open-label),RR  48, 48   96,NA NA  8.0200000000, 0.950000000  6.798000e+01,NA NA,NA NA,NA NA NA NA,  0,  0,  0 100 100 100,100,high low low,some,low Placebo   0, 24.300000 11.500000,NA,DSM-III,0,1 1.0,1.0 1.0,1.0,1,1 0,1 1 1 1 1.0,1,1 1 1  402,McBride_1988,< 2 months,NA 6-12 yo,4.76,15 85 109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
3425,Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100,  0 100,100,High Methylphenidate,MPH transdermal   0,NA,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA, 0.46029919   18.0000000,mg/d,McGough 2006 NA RCT (parallel, crossover, open-label) RR  80, 80  160 NA NA  5.1300000000  0.240000000, 1.085100e+02 NA NA,NA NA,NA,NA NA NA,100 100 100 100 100 100,100,low,low low,low,low Placebo,  0, 28.000000  9.100000,NA DSM-IV-TR 0 1,1.0,1.0,1.0 1.0,1,1,0,1,1,1 1,1.0 1 1,1,1  403 McGough_2006 < 2 months NA 6-12 yo 4.76,15,85,109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3425 Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100,  0,100,100,High,Methylphenidate ER-d-MPH,  0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) monitoring and recording all Aes  1.15074799,  37.0000000,mg/d,Muniz 2008,NA RCT (parallel, crossover, open-label),RR, 84  83  167,NA NA  3.0000000000  0.120000000  7.470000e+01,NA NA NA NA,NA NA,NA,NA,100 100 100,100,100,100,100,some,low low,low,low Placebo   0, 34.500000  9.500000 NA,DSM-IV,0,1,1.0,1.0,1.0,1.0 1 1 0,1 1,1 1 1.0 1 1,1,1, 404 Muniz_2008,< 2 months NA,6-12 yo,4.76,15,85 109.9,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3425,Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3,100 100 100 100 High Methylphenidate,MPH   0 NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Questionnaire,Side Effects Rating Scale (Barkley 1990), 0.69044879    0.8000000 mg/kg/d,Musten,1997,NA RCT (parallel, crossover, open-label) RR  41, 41,  82 NA,NA  3.2700000000, 2.040000000  5.240000e+00,NA NA,NA NA,NA,NA NA NA 100,100,100,100,  0 100,100,low,low high low some Placebo,  0, 12.200000, 4.800000, 99.26000 DSM-III-R,0 1,1.0 1.0 1.0 1.0,1,1 0,1 1 1 1,1.0 1,1 1 1, 405,Musten_1997,< 2 months Average (80-119) < 6 yo,4.76,15,85,109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
3425 Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3 100   0 100 100 High Methylphenidate,MPH   0 NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Questionnaire,Pittsburgh Side Effect Rating Scale  0.92059839,  36.0000000 mg/d NCT02039908,NA NA,RCT (parallel, crossover, open-label) RR 138,129, 267 NA,NA, 1.0200000000, 0.810000000, 1.290000e+00 NA NA,NA NA NA,NA,NA NA 100,100 100,100 100 100,100,some some some some low,Placebo,  0  20.200000, 9.000000,NA,DSM-IV,0 1 1.0 1.0 1.0,1.0 1,1,0 1,1,1 1,1.0 1 1,1,1  406 NCT02039908_NA,< 2 months,NA 6-12 yo 4.76 15 85 109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3425 Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3,100   0 100,100 High,Methylphenidate,ER-MPH,  0 NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA, 0.92059839   45.0000000,mg/d NCT02536105 NA,NA RCT (parallel, crossover, open-label),RR  80, 74, 154,NA NA,37.9200000000, 5.350000000  2.688100e+02 NA NA,NA NA,NA NA,NA,NA   0   0 100,100,100,  0 100 low,low low,low high Placebo,  0, 27.600000, 9.450000 NA DSM-5 0 1 1.0,1.0,1.0 1.0,1 1 0 1 1,1 1,1.0 1 1,1 1  407 NCT02536105_NA < 2 months NA,6-12 yo,4.76,15 85,109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high,high
3425 Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100,100,100,100 High,Methylphenidate MPH,  0 NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA  0.92059839    0.6900000,mg/kg/d Pearson,2013,NA RCT (parallel, crossover, open-label) RR, 24, 24   48 NA,NA 13.8000000000  1.580000000  1.203800e+02 NA NA NA,NA NA NA NA NA 100,100,100,  0,  0 100,100 low,high,high low low Placebo,  0  20.800000  8.800000  85.00000 DSM-IV 0 1 1.0,1.0 1.0 1.0 1 1 0 1,1,1 1,1.0,1,1,1,1, 408 Pearson_2013,< 2 months,Average (80-119) 6-12 yo 4.76,15 85,109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100,100 100 100 High,Methylphenidate IR-MPH or ER-MPH,  0,NA Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Questionnaire,side effect checklist,NA NA NA Pelham,1990,NA,RCT (parallel, crossover, open-label),RR  22  22   44 NA NA  4.0800000000  1.110000000, 1.502000e+01 NA NA,NA NA NA,NA,NA NA,100,100 100,100 100 100,100,some low low some some,Placebo,  0,  0.000000 10.390000,105.68000 DSM-III-R 0,1,1.0,1.0,1.0 1.0 1,1 0 1 1 1,1,1.0 1 1,1,1, 409 Pelham_1990,NA Average (80-119),6-12 yo,4.76,15,85 109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
3425,Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100,  0,100 100,High,Methylphenidate IR-MPH,  0,NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA  1.38089758   27.0000000 mg/d Pelham 1999 NA,RCT (parallel, crossover, open-label),RR, 25, 25   50,NA,NA, 2.8800000000, 0.500000000, 1.648000e+01 NA NA,NA NA,NA NA,NA NA,100 100,100,100,100,100 100,some,some,some,some,some,Placebo   0, 16.000000, 9.600000 NA DSM-IV,0 1,1.0,1.0,1.0 1.0,1,1,0,1 1,1,1,1.0,1 1 1,1  410 Pelham_1999,< 2 months,NA,6-12 yo 4.76,15,85,109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
3425 Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100 100,100,100,High Methylphenidate IR-MPH or ER-MPH   0,NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Interview parents provided responses to questions on Aes  0.69044879,   0.7500000,mg/kg/d,Pelham,2001,NA,RCT (parallel, crossover, open-label) RR, 68, 68, 136 NA,NA, 4.6400000000, 1.250000000, 1.729000e+01,NA,NA NA,NA NA NA NA,NA,100,100 100 100,100 100 100,some low some low,some,Placebo,  0, 11.000000  9.100000,104.80000,DSM-IV 0,1 1.0,1.0 1.0,1.0 1,1 0 1 1,1 1 1.0,1,1,1,1  411 Pelham_2001,< 2 months,Average (80-119),6-12 yo,4.76,15,85 109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
3425 Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3 100 100 100 100 High Methylphenidate MPH transdermal   0,NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Questionnaire,Pittsburgh Side Effects Rating Scale, 0.23014960,   1.1250000,mg/h/d Pelham,2005,NA,RCT (parallel, crossover, open-label) RR, 36  36,  72 NA,NA 10.8200000000  2.240000000, 5.229000e+01,NA NA,NA NA NA NA,NA NA,100 100,100,100,  0,100,100 some,low,high,low,some Placebo,  0   8.300000, 9.600000 105.30000 DSM-IV 0,1 1.0,1.0,1.0,1.0,1,1 0 1,1,1,1 1.0,1,1,1 1  412,Pelham_2005 < 2 months,Average (80-119),6-12 yo 4.76 15,85,109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3425 Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3,100,100 100 100 High Methylphenidate IR-MPH or transdermal-MPH   0,NA Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),AEs, 0.69044879,  30.0000000,mg/d,Pelham 2011 NA RCT (parallel, crossover, open-label) RR  10, 10   20,NA,NA  1.7100000000, 0.220000000, 1.341000e+01 NA NA,NA,NA,NA NA NA NA,100,100,100,100 100 100 100 some,low low low,some,Placebo,  0   0.000000, 8.600000  95.30000,DSM-IV 0,1 1.0,1.0,1.0,1.0,1 1,0,1,1,1,1 1.0 1 1 1,1  413 Pelham_2011 < 2 months,Average (80-119),6-12 yo 4.76 15 85,109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
3425,Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3,100,100 100 100 High,Methylphenidate,MPH   0 NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Questionnaire Barkley Side Effect Rating Scale  1.38089758,  35.0000000 mg/d Ramtvedt 2013 NA RCT (parallel, crossover, open-label),RR  34  34,  68,NA,NA  1.7300000000, 1.070000000, 2.810000e+00 NA NA,NA,NA NA NA NA NA 100,100,100,  0,100,100 100,some,high some,some,some Placebo   0  19.400000 11.400000, 90.90000,DSM-IV-TR,0 1,1.0 1.0 1.0 1.0,1,1 0,1 1,1 1 1.0,1,1 1,1  414 Ramtvedt_2013,< 2 months,Average (80-119) 6-12 yo,4.76,15 85 109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
3425,Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3 100,100 100,100 High,Methylphenidate,IR-MPH,  0 NA Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 1.15074799   12.5000000 mg/d,Rapport,2008,NA RCT (parallel, crossover, open-label),RR, 65  65, 130,NA NA  2.1100000000  0.890000000, 5.010000e+00 NA,NA NA,NA,NA,NA NA NA 100 100 100,100 100,100 100 low low,low,low,low,Placebo   0, 10.700000  8.560000 102.80000,DSM-IV 0 1,1.0 1.0,1.0,1.0,1,1 0 1 1 1,1 1.0 1 1,1,1, 415 Rapport_2008 < 2 months,Average (80-119),6-12 yo,4.76,15,85 109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
3425 Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3,100   0,100 100,High,Methylphenidate,ER-MPH   0 NA Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Mixed (different types of tool are used),NA  0.69044879   20.0000000,mg/d Schulz 2010,NA,RCT (parallel, crossover, open-label),RR 147,146  293 NA,NA, 1.5000000000  0.250000000, 9.110000e+00,NA,NA,NA NA NA NA NA,NA 100 100,100,100 100 100 100,some,low,low,low some,Placebo,  0  19.000000 10.200000,NA,DSM-IV,0,1 1.0 1.0 1.0 1.0 1,1 0 1,1 1 1,1.0 1 1 1 1, 416 Schulz_2010 < 2 months,NA,6-12 yo 4.76,15,85,109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
3425 Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100   0 100,100,High Methylphenidate MPH,  0,NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA, 0.69044879,   0.8650000 mg/kg/d,Sharp 1999 NA RCT (parallel, crossover, open-label),RR, 48, 48   96,NA,NA 64.1200000000, 3.730000000  1.101910e+03,NA NA,NA NA,NA,NA NA,NA,100 100 100 100,100,100 100 some,low some low,some,Placebo,  0  43.000000  9.100000 NA,DSM-IV 0,1 1.0 1.0 1.0,1.0,1 1,0,1,1,1 1 1.0,1,1,1 1  417 Sharp_1999 < 2 months NA,6-12 yo,4.76 15,85 109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
3425,Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3 100,  0,100 100 High Methylphenidate,ER-MPH,  0 NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks),Interview,Recorded AEs described  0.46029919,  20.0000000,mg/d Silva,2006 NA,RCT (parallel, crossover, open-label) RR, 54  54, 108,NA NA 12.1100000000  0.650000000, 2.246700e+02,NA NA,NA NA NA NA NA NA,100,100 100,100 100 100 100,low,low,low low some,Placebo   0, 30.000000, 9.400000,NA,DSM-IV 0 1,1.0,1.0 1.0,1.0,1,1 0,1,1,1 1 1.0,1 1 1,1, 418,Silva_2006 < 2 months NA,6-12 yo,4.76 15,85 109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
3425 Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100   0 100,100,High,Methylphenidate MPH,  0,NA,Specific adverse events: decreased appetite,NA At study endpoint (closest to 12 weeks) Questionnaire Stimulant Side Effects Rating Scale (SSERS)  1.15074799,   0.7500000 mg/kg/d Stein,1996 NA,RCT (parallel, crossover, open-label) RR, 25, 25   50 NA NA, 5.4600000000  1.630000000, 1.836000e+01 NA,NA NA,NA NA NA,NA,NA 100 100 100 100 100 100,100,low,low,low low low Placebo   0,  0.000000, 8.000000 NA,DSM-III-R,0,1,1.0 1.0,1.0 1.0,1 1,0 1 1,1,1,1.0,1 1 1 1  419 Stein_1996 < 2 months,NA,6-12 yo,4.76 15 85 109.9,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3425,Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3,100 100 100 100,High Methylphenidate,MPH,  0 NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Questionnaire,Side Effect Rating Scale (SERS; Barkley 1990)  0.92059839   36.0000000 mg/d,Stein,2003,NA RCT (parallel, crossover, open-label) RR, 47  47   94,NA,NA  5.6500000000  2.320000000, 1.377000e+01,NA NA NA NA,NA NA NA,NA   0   0,100,  0,100   0,100,some,high some low high Placebo   0, 30.000000, 9.020000 106.80000,DSM-IV,0,1 1.0,1.0,1.0,1.0,1,1 0 1 1 1,1,1.0 1 1,1,1, 420 Stein_2003,< 2 months Average (80-119),6-12 yo 4.76 15 85 109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high,high
3425 Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3,100,  0 100,100,High,Methylphenidate ER-MPH,  0,NA Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks),Questionnaire,Stimulant Side Effects Rating Scale (Barkley 1990)  1.84119678   20.0000000 mg/d Stein,2011,NA RCT (parallel, crossover, open-label) RR  42, 45   87 NA NA, 3.3800000000  0.340000000, 3.389000e+01,NA,NA,NA,NA,NA NA,NA,NA,100,100 100,100 100 100 100 low,low,low low low Placebo   0  27.000000,11.780000 NA,DSM-IV 0 1 1.0,1.0 1.0,1.0 1 1,0,1 1,1 1,1.0,1,1 1,1, 421 Stein_2011 < 2 months NA,6-12 yo 4.76,15 85,109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
3425,Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3 100,  0,100,100 High,Methylphenidate ER-MPH,  0,NA,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Questionnaire Barkley Side Effects Rating Scale  0.69044879   39.0000000,mg/d Swanson 2004,NA,RCT (parallel, crossover, open-label),RR 181,183, 364,NA,NA  6.2400000000  0.740000000, 5.236000e+01 NA NA NA NA,NA NA,NA NA,100,100,100 100 100,100,100 some,low low some,some,Placebo,  0, 26.000000  9.600000 NA,DSM-IV,0,1,1.0,1.0,1.0 1.0,1,1 0 1 1 1,1 1.0,1,1 1 1  422,Swanson_2004 < 2 months,NA 6-12 yo,4.76,15,85 109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
3425,Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3 100,  0,100 100,High,Methylphenidate MPH transdermal,  0,NA,Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) AEs, 0.92059839   20.0000000 mg/d,Wilens,2010,NA,RCT (parallel, crossover, open-label) RR, 30  30,  60 NA,NA,47.0600000000, 2.630000000, 8.410900e+02 NA NA,NA NA,NA NA NA,NA,100,100,100 100,  0 100,100 some some high some,low Placebo   0  16.600000  9.170000 NA,DSM-IV,0 1,1.0,1.0,1.0,1.0 1,1,0,1,1 1,1 1.0,1,1,1 1  423,Wilens_2010,< 2 months NA 6-12 yo,4.76,15 85 109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3425 Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100,  0 100,100 High,Methylphenidate,MPH,100 MPH and aripiprazol,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks),Questionnaire Serious Adverse Event Rating Scale (SAERS)  0.92059839,  25.0000000 mg/d,Zeni 2009,NA RCT (parallel, crossover, open-label),RR  16  16,  32 NA,NA  0.8300000000, 0.410000000  1.660000e+00,NA NA NA,NA,NA,NA NA,NA,100,100 100,100 100 100,100 low,low,low,low low,Placebo + aripiprazol,  0  43.700000,10.710000,NA DSM-IV,0,1,1.0 1.0,1.0 1.0,1 1,0 1,1 1,1 1.0 1,1 1,1  424,Zeni_2009,< 2 months,NA,6-12 yo,4.76 15,85 109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3425 Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3 100,100 100,100,High,Methylphenidate MPH   0,NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Questionnaire Barkley Side Effects Rating Scale:, 0.23014960,   0.8000000 mg/kg/d Barkley,1989,NA RCT (parallel, crossover, open-label),RR  82, 82, 164 NA NA, 3.2000000000  1.680000000  6.070000e+00 NA,NA,NA NA NA,NA NA,NA,100,100 100 100 100,100 100 some,low,some low,low,Placebo,  0, 14.450000, 8.200000,105.10000,DSM-III-R,0,1 1.0 1.0,1.0 1.0,1,1 0,1,1,1,1 1.0,1 1,1,1, 425,Barkley_1989 < 2 months Average (80-119) 6-12 yo,4.76,15 85,109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3 100,  0,100 100 High,Methylphenidate MPH,  0,NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Questionnaire,Barkley Side Effects Rating Scale  0.46029919,   0.5000000,mg/kg/d Bhat,2020 NA RCT (parallel, crossover, open-label) RR,526 526 1052,NA NA, 8.8200000000  4.850000000, 1.604000e+01 NA NA NA,NA,NA,NA NA NA,100 100,100,100 100 100,100,low low some,low,low,Placebo,  0  22.400000  9.030000 NA DSM-IV 0,1 1.0 1.0,1.0 1.0,1,1,0,1 1 1,1 1.0 1,1 1,1  426 Bhat_2020,< 2 months,NA 6-12 yo 4.76,15 85 109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3425 Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3,100,  0,100,100 High Methylphenidate ER-d-MPH,  0,NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Interview Spontaneously reported Aes, 0.46029919,  20.0000000,mg/d Brams 2012 NA RCT (parallel, crossover, open-label) RR,163,159  322 NA,NA, 6.9600000000, 0.360000000  1.357800e+02 NA NA NA NA,NA,NA NA NA,100 100,100,100,100 100 100,low low,low,low,some,Placebo   0  38.400000  9.500000 NA,DSM-IV,0,1 1.0 1.0,1.0,1.0,1 1,0,1 1 1 1 1.0,1,1,1 1  427,Brams_2012,< 2 months,NA 6-12 yo 4.76 15,85,109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
3425,Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3,100,100,100,100 High Methylphenidate,MPH   0 NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Questionnaire,Adverse effects checklist  2.30149597,   0.6000000 mg/kg/d,Buitelaar 1995 NA RCT (parallel, crossover, open-label) RR, 26  11   37 NA,NA  1.6700000000  0.360000000, 7.810000e+00 NA,NA NA NA NA,NA,NA,NA 100,100 100,100 100,100 100,some,low,low,some,some Placebo   0, 11.500000, 9.300000  94.20000 DSM-III-R 0 1 1.0,1.0,1.0,1.0 1,1 0 1,1,1 1 1.0,1,1,1 1, 428 Buitelaar_1995,2-6 months,Average (80-119),6-12 yo,4.76 15 85,109.9,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
3425 Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3,100,100 100 100 High Methylphenidate,MPH   0 NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),AEs  2.07134638,   0.9500000,mg/kg/d Castellanos 1997,NA,RCT (parallel, crossover, open-label),RR, 22, 22,  44 NA,NA, 2.1000000000, 0.180000000  2.501000e+01 NA NA,NA NA,NA NA NA NA   0   0 100 100   0,  0,100 some,low,high,some,high Placebo   0,  0.000000, 9.400000  98.80000 DSM-III 0 1 1.0 1.0 1.0 1.0 1,1 0,1 1,1 1 1.0 1,1,1,1  429 Castellanos_1997,2-6 months Average (80-119),6-12 yo,4.76 15 85 109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high high
3425 Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3,100,100 100,100 High,Methylphenidate IR-MPH   0,NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Questionnaire,Pittsburgh Side Effects Rating Scale  1.84119678,   0.6000000 mg/kg/d Chronis,2003,NA,RCT (parallel, crossover, open-label) RR, 21, 21,  42 NA NA  0.7500000000, 0.170000000, 3.310000e+00 NA NA NA NA NA,NA,NA,NA,100 100 100 100,100,100 100,some,low some low,low,Placebo   0   9.500000 10.300000 109.90000,DSM-IV,0 1,1.0,1.0,1.0,1.0,1 1 0 1 1 1,1 1.0 1 1 1 1  430 Chronis_2003 < 2 months Average (80-119),6-12 yo 4.76 15,85,109.9,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3425,Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3 100   0 100 100 High,Methylphenidate IR-MPH   0 NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Mixed (different types of tool are used),Sleep Disturbances Scale for Children; Actigraphy; Sleep diary, 0.69044879,  30.0000000 mg/d Corkum,2008 NA RCT (parallel, crossover, open-label),RR, 21, 21,  42,NA,NA, 2.9500000000, 1.540000000  5.660000e+00,NA NA NA NA,NA,NA NA NA,100,100,100 100,100 100,100,low low some,low low Placebo,  0, 28.500000  9.000000 NA DSM-IV 0 1,1.0 1.0 1.0,1.0 1 1,0 1,1,1,1 1.0,1 1 1,1  431 Corkum_2008 < 2 months,NA 6-12 yo,4.76 15 85,109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3425 Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3 100   0 100,100,High Methylphenidate,LA-MPH   0,NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) Monitoring and reporting of Aes  1.84119678   40.0000000,mg/d,CRIT124US02 NA NA,RCT (parallel, crossover, open-label),RR 102 101  203,NA,NA, 0.9900000000  0.300000000  3.320000e+00 NA NA NA,NA,NA NA,NA NA,  0   0 100,100   0,  0 100 some,low,high,some high,Placebo   0 100.000000,13.800000 NA not stated 0 1 1.0,1.0,1.0 1.0 1 1 0,1 1,1 1,1.0,1 1,1 1, 432 CRIT124US02_NA,< 2 months,NA,13-19 yo 4.76,15 85 109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
3425,Storebo (2023),Storebo,2023,10.1002/14651858.CD009885.pub3 100,  0,100 100 High,Methylphenidate,MPH,  0,NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Questionnaire Barkley Side Effects Rating Scale  0.92059839    0.5800000,mg/kg/d DuPaul 1996,NA RCT (parallel, crossover, open-label),RR, 24, 24   48,NA NA, 1.3600000000, 0.770000000, 2.410000e+00,NA NA NA,NA NA,NA NA NA,100 100 100,100 100 100,100,low,low,low low,low,Placebo   0  20.800000,11.090000 NA DSM-III-R,0 1 1.0 1.0,1.0 1.0 1,1,0 1 1 1,1 1.0,1,1 1,1, 433 DuPaul_1996 < 2 months NA,6-12 yo,4.76 15 85 109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3425,Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3,100,  0,100 100,High Methylphenidate MPH,  0 NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Questionnaire Side Effects/Behavior Monitoring Scale  0.92059839   30.0000000,mg/d Findling,2007 NA RCT (parallel, crossover, open-label),RR  16  16   32 NA,NA, 3.1800000000, 0.520000000, 1.964000e+01,NA,NA NA NA NA NA,NA,NA,100 100 100 100 100 100 100 low,low low low,some,Placebo,  0, 20.000000,10.430000,NA DSM-IV 0,1 1.0 1.0 1.0,1.0,1,1 0,1,1 1 1 1.0,1 1,1,1, 434,Findling_2007 < 2 months NA,6-12 yo,4.76 15 85,109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
3425,Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3 100   0 100,100,High,Methylphenidate,MPH   0,NA,Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Questionnaire Side effects questionnaire:, 0.23014960    0.9000000 mg/kg/d,Fine 1993 NA,RCT (parallel, crossover, open-label) RR, 12, 12   24,NA,NA  1.4100000000  0.630000000  3.170000e+00,NA,NA,NA NA,NA NA NA NA 100 100,100,100,100 100 100 low low,some,low,some Placebo,  0 NA, 8.500000,NA DSM-III-R,0 1,1.0,1.0 1.0,1.0,1 1 0 1,1,1 1,1.0 1 1 1,1  435 Fine_1993 < 2 months NA 6-12 yo,4.76 15,85 109.9,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
3425 Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100,  0 100,100,High,Methylphenidate,MPH 100 ER-MPH, Standard-MPH or combination Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Interview Interviewed: 12 side effect symptoms: drawn from Subject’s Treatment Emergent Symptom Scale, 0.46029919,  18.5000000,mg/d,Fitzpatrick,1992 NA,RCT (parallel, crossover, open-label) RR, 19  19   38 NA,NA, 3.8800000000, 0.840000000  1.796000e+01 NA,NA NA,NA,NA,NA,NA,NA   0   0   0 100,100,100 100,high low,some,some some,Placebo   0  10.500000  8.710000 NA DSM-III 0,1,1.0 1.0 1.0 1.0 1,1 0 1,1 1 1 1.0,1 1,1,1  436 Fitzpatrick_1992 < 2 months NA,6-12 yo,4.76 15,85,109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
3425 Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3 100,100 100,100 High,Methylphenidate ER-MPH   0 NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Questionnaire Pittsburgh Side Effect Rating Scale  0.92059839   36.0000000,mg/d,Froehlich 2018 NA RCT (parallel, crossover, open-label),RR 171,171  342,NA NA 14.0000000000  1.860000000, 1.052900e+02,NA NA,NA,NA,NA,NA NA,NA   0,  0 100 100 100   0,100 low,low low low,high Placebo,  0  28.600000  8.400000,105.60000,DSM-IV 0 1 1.0 1.0 1.0,1.0,1,1,0,1 1 1 1,1.0,1,1,1 1  437 Froehlich_2018 < 2 months Average (80-119),6-12 yo 4.76,15 85,109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high,high
3425,Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3,100   0 100 100,High,Methylphenidate,LA-MPH,  0,NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Interview,A structured interview  0.46029919   30.0000000 mg/d Huang 2021,NA RCT (parallel, crossover, open-label) RR,110 101, 211,NA NA,41.3500000000  2.540000000  6.728500e+02 NA,NA,NA,NA NA,NA NA NA   0   0,100 100 100,  0,100,some,some low some,high,Placebo,  0, 29.200000, 9.160000 NA,DSM-5 0 1 1.0,1.0 1.0 1.0,1,1 0,1 1 1 1,1.0 1 1 1 1  438,Huang_2021 < 2 months NA,6-12 yo,4.76 15 85,109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high,high
3425,Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3,100 100,100,100 High Methylphenidate MPH,  0,NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  1.38089758   35.2100000,mg/d Klorman,1990,NA,RCT (parallel, crossover, open-label),RR, 48  48   96,NA,NA  1.1700000000, 0.390000000, 3.530000e+00,NA NA,NA NA NA,NA NA NA,100,100 100,100 100 100 100 low low,some,low,some Placebo   0, 12.500000 15.000000,108.62000 DSM-III 0,1 1.0 1.0 1.0 1.0 1 1,0,1,1 1 1,1.0 1 1,1 1  439 Klorman_1990 < 2 months Average (80-119),13-19 yo,4.76,15 85,109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3425 Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3,100 100 100 100,High Methylphenidate MPH,  0,NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Questionnaire Parent Adverse Events Checklist  0.92059839,  14.2200000,mg/d Kollins 2006,NA RCT (parallel, crossover, open-label),RR,136 160  296 NA,NA  1.2000000000, 0.530000000  2.670000e+00,NA NA,NA NA NA,NA,NA NA,100,100,100 100 100 100,100 low low low,low,low,Placebo,  0  25.400000, 4.760000, 97.45000 DSM-IV,0 1 1.0 1.0 1.0 1.0,1,1,0,1,1 1,1,1.0,1,1 1,1, 440,Kollins_2006 < 2 months,Average (80-119),< 6 yo 4.76 15 85,109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3425,Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3 100,  0,100,100 High Methylphenidate MPH,  0,NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Questionnaire,Side Effects Behavior Monitoring Scale, 0.92059839,   9.7000000 mg/d Manos 1999 NA,RCT (parallel, crossover, open-label) RR,177 177, 354,NA NA  2.4500000000, 0.920000000, 6.520000e+00 NA,NA NA NA NA,NA,NA,NA,  0   0   0,  0,100,100   0 high high,some,high,some Placebo   0 NA 10.100000,NA,DSM-IV 0 1 1.0 1.0 1.0,1.0,1,1 0 1 1,1 1 1.0,1 1 1,1  441 Manos_1999,< 2 months NA 6-12 yo 4.76,15,85,109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
3425,Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3,100   0,100 100,High Methylphenidate ER-d-MPH   0 NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) monitoring and recording all Aes  1.15074799   37.0000000,mg/d Muniz 2008 NA RCT (parallel, crossover, open-label),RR  84  83, 167 NA NA, 3.0000000000, 0.120000000  7.470000e+01,NA,NA NA NA NA NA NA NA 100 100,100,100 100,100 100 some low,low low,low Placebo,  0, 34.500000, 9.500000 NA DSM-IV 0 1 1.0,1.0,1.0,1.0,1,1 0 1,1 1 1,1.0,1 1 1 1, 442,Muniz_2008 < 2 months,NA,6-12 yo 4.76,15,85 109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3425,Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3,100,100 100 100,High Methylphenidate MPH   0 NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Questionnaire,Side Effects Rating Scale (Barkley 1990)  0.69044879,   0.8000000,mg/kg/d,Musten 1997 NA RCT (parallel, crossover, open-label) RR, 41  41,  82 NA NA, 0.4900000000, 0.310000000, 7.600000e-01,NA,NA,NA NA NA,NA NA,NA,100,100,100,100,  0,100 100,low low,high low,some,Placebo,  0, 12.200000  4.800000  99.26000,DSM-III-R 0,1 1.0,1.0 1.0,1.0,1 1 0,1,1 1,1 1.0,1 1 1,1, 443 Musten_1997 < 2 months Average (80-119) < 6 yo,4.76 15 85 109.9,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3425 Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3,100,  0 100,100 High Methylphenidate,MPH   0,NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Questionnaire,Pittsburgh Side Effect Rating Scale, 0.92059839,  36.0000000 mg/d NCT02039908,NA NA,RCT (parallel, crossover, open-label) RR 138,129  267 NA,NA  1.0100000000, 0.750000000, 1.350000e+00,NA,NA NA NA NA NA NA NA,100 100 100 100 100,100 100 some some some,some,low Placebo   0  20.200000  9.000000 NA DSM-IV 0 1 1.0,1.0,1.0 1.0 1,1,0 1,1 1 1 1.0,1 1 1 1  444 NCT02039908_NA,< 2 months NA 6-12 yo 4.76,15,85 109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3425 Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3,100,  0,100 100 High Methylphenidate,ER-MPH   0,NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  0.92059839,  45.0000000,mg/d NCT02536105,NA NA,RCT (parallel, crossover, open-label),RR  80, 74, 154,NA,NA 28.6700000000, 4.010000000  2.048000e+02 NA,NA,NA,NA,NA,NA,NA NA,  0,  0 100,100 100,  0 100 low,low low,low,high Placebo   0  27.600000, 9.450000 NA,DSM-5,0,1 1.0,1.0,1.0 1.0,1 1 0,1 1 1,1,1.0 1,1,1,1  445,NCT02536105_NA,< 2 months NA 6-12 yo 4.76,15 85 109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high,high
3425 Storebo (2023) Storebo 2023 10.1002/14651858.CD009885.pub3,100 100,100 100,High Methylphenidate MPH   0 NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  0.92059839,   0.6900000 mg/kg/d,Pearson 2013,NA RCT (parallel, crossover, open-label) RR, 24, 24,  48,NA,NA  3.8000000000  1.070000000  1.352000e+01,NA NA,NA,NA NA,NA,NA NA 100,100 100   0   0,100,100,low,high,high low,low,Placebo,  0  20.800000  8.800000  85.00000,DSM-IV,0,1,1.0 1.0,1.0 1.0 1,1 0,1 1,1 1 1.0 1,1,1,1, 446,Pearson_2013 < 2 months Average (80-119) 6-12 yo 4.76 15 85,109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
3425,Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3 100,100 100 100,High Methylphenidate IR-MPH or ER-MPH,  0,NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Questionnaire side effect checklist NA NA,NA Pelham 1990,NA RCT (parallel, crossover, open-label) RR  22, 22,  44,NA,NA  4.6700000000  0.270000000  7.963000e+01,NA,NA,NA,NA NA NA NA NA 100 100,100,100,100,100,100 some,low,low some,some Placebo,  0   0.000000,10.390000 105.68000 DSM-III-R 0 1,1.0 1.0 1.0 1.0,1 1,0,1 1,1,1,1.0,1,1,1 1  447 Pelham_1990 NA,Average (80-119) 6-12 yo 4.76,15 85 109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3425,Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3,100   0 100,100 High,Methylphenidate IR-MPH,  0,NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA  1.38089758,  27.0000000 mg/d,Pelham,1999,NA,RCT (parallel, crossover, open-label) RR  25, 25   50 NA NA, 2.3200000000  0.510000000  1.054000e+01,NA,NA NA NA NA NA,NA NA 100,100,100 100,100,100 100 some,some some,some,some,Placebo   0  16.000000, 9.600000 NA DSM-IV 0,1,1.0,1.0,1.0,1.0 1 1,0,1,1,1 1 1.0,1,1 1,1  448,Pelham_1999,< 2 months NA 6-12 yo,4.76,15,85,109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
3425 Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3 100 100,100 100 High Methylphenidate,IR-MPH or ER-MPH,  0 NA Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks),Interview parents provided responses to questions on Aes, 0.69044879    0.7500000 mg/kg/d,Pelham 2001,NA,RCT (parallel, crossover, open-label) RR  68, 68, 136,NA,NA, 0.6900000000, 0.210000000  2.300000e+00 NA NA NA,NA,NA NA,NA NA,100,100 100 100 100,100 100 some low some low some Placebo,  0  11.000000  9.100000 104.80000 DSM-IV,0 1,1.0,1.0,1.0,1.0 1,1 0 1,1,1 1,1.0 1 1 1 1, 449 Pelham_2001,< 2 months,Average (80-119) 6-12 yo 4.76,15 85 109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
3425,Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3,100 100 100,100 High,Methylphenidate MPH transdermal,  0 NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Questionnaire,Pittsburgh Side Effects Rating Scale, 0.23014960,   1.1250000 mg/h/d Pelham 2005 NA,RCT (parallel, crossover, open-label) RR, 36, 36,  72,NA,NA  2.6600000000  0.630000000  1.122000e+01,NA,NA,NA NA,NA NA,NA NA,100 100,100,100   0 100,100 some,low,high,low some Placebo   0,  8.300000  9.600000 105.30000,DSM-IV,0 1 1.0 1.0,1.0 1.0,1 1,0 1,1 1,1 1.0 1,1,1 1, 450 Pelham_2005 < 2 months,Average (80-119) 6-12 yo,4.76,15 85,109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
3425 Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3,100 100,100,100 High,Methylphenidate,MPH   0 NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Questionnaire,Barkley Side Effect Rating Scale, 1.38089758,  35.0000000 mg/d Ramtvedt,2013 NA RCT (parallel, crossover, open-label),RR  34, 34   68,NA,NA, 1.3200000000, 0.820000000, 2.130000e+00,NA NA,NA,NA,NA NA NA,NA,100 100 100   0,100,100,100,some,high,some some some Placebo,  0  19.400000 11.400000  90.90000 DSM-IV-TR 0 1,1.0,1.0,1.0 1.0 1 1 0,1,1 1,1,1.0 1 1,1,1  451 Ramtvedt_2013 < 2 months,Average (80-119) 6-12 yo 4.76 15,85,109.9,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3425,Storebo (2023),Storebo,2023,10.1002/14651858.CD009885.pub3,100,100 100 100,High Methylphenidate,IR-MPH,  0,NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  1.15074799,  12.5000000 mg/d Rapport,2008 NA RCT (parallel, crossover, open-label),RR  65, 65, 130,NA,NA, 0.6900000000, 0.210000000  2.300000e+00 NA NA,NA,NA,NA NA NA,NA,100 100,100 100,100 100 100 low low low,low low,Placebo,  0, 10.700000  8.560000 102.80000,DSM-IV,0,1 1.0,1.0 1.0 1.0 1 1 0 1 1 1,1 1.0 1,1 1 1, 452 Rapport_2008 < 2 months,Average (80-119) 6-12 yo,4.76 15 85,109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3425,Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3,100   0,100,100,High Methylphenidate MPH   0 NA,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  0.69044879    0.8650000,mg/kg/d Sharp,1999,NA,RCT (parallel, crossover, open-label) RR, 48, 48,  96,NA NA  2.2000000000, 0.910000000, 5.350000e+00,NA NA NA,NA,NA NA,NA,NA,100 100 100,100,100,100,100,some low some low some,Placebo   0, 43.000000, 9.100000,NA,DSM-IV,0 1 1.0 1.0 1.0,1.0,1 1 0 1 1 1 1,1.0,1 1,1 1  453 Sharp_1999,< 2 months,NA 6-12 yo,4.76,15 85 109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3425 Storebo (2023),Storebo 2023 10.1002/14651858.CD009885.pub3 100   0,100,100,High Methylphenidate ER-MPH,  0,NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Interview Recorded AEs described, 0.46029919   20.0000000 mg/d Silva 2006,NA RCT (parallel, crossover, open-label) RR  54, 54  108 NA NA  5.1900000000  0.240000000, 1.106900e+02,NA,NA NA NA NA,NA NA NA,100 100 100,100,100 100,100 low low,low low some,Placebo,  0, 30.000000  9.400000 NA DSM-IV 0,1 1.0,1.0,1.0 1.0,1,1,0,1 1,1,1 1.0,1 1 1,1  454,Silva_2006,< 2 months NA 6-12 yo 4.76 15 85 109.9,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3425 Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3 100,  0 100 100,High,Methylphenidate MPH   0 NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks) Observational tool,Sleep log, 1.15074799,   0.7500000,mg/kg/d,Stein,1996,NA,RCT (parallel, crossover, open-label) RR  25, 25,  50,NA NA, 1.6200000000, 0.530000000, 4.980000e+00 NA NA NA,NA,NA NA,NA NA,100 100 100 100 100,100 100 low low,low low low,Placebo   0,  0.000000  8.000000 NA DSM-III-R,0 1 1.0 1.0,1.0,1.0 1 1,0 1,1,1,1 1.0,1,1 1,1, 455,Stein_1996,< 2 months,NA,6-12 yo,4.76 15 85,109.9 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3425,Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3,100 100 100 100,High Methylphenidate,MPH,  0 NA Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks) Questionnaire Side Effect Rating Scale (SERS; Barkley 1990)  0.92059839,  36.0000000,mg/d Stein 2003 NA RCT (parallel, crossover, open-label) RR, 47  47   94 NA,NA  2.1800000000, 0.960000000, 5.000000e+00,NA NA NA,NA NA NA,NA,NA   0,  0 100   0 100,  0 100,some,high,some low,high Placebo,  0  30.000000  9.020000 106.80000,DSM-IV,0,1 1.0,1.0 1.0 1.0,1 1,0 1,1 1 1,1.0 1 1,1,1, 456 Stein_2003,< 2 months,Average (80-119),6-12 yo 4.76,15 85,109.9 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
3425 Storebo (2023),Storebo,2023,10.1002/14651858.CD009885.pub3 100   0,100 100 High Methylphenidate ER-MPH,  0,NA,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Observational tool,Sleep measured by actigraphy and questionnaires  1.84119678,  20.0000000,mg/d Stein,2011 NA RCT (parallel, crossover, open-label) RR  42, 45   87 NA NA  1.6500000000  0.260000000, 1.042000e+01 NA NA NA NA,NA NA,NA,NA 100,100 100,100 100 100,100 low,low low,low low,Placebo   0, 27.000000,11.780000 NA DSM-IV 0,1 1.0,1.0 1.0,1.0,1,1 0,1 1 1 1,1.0 1,1,1,1, 457,Stein_2011 < 2 months,NA 6-12 yo 4.76,15,85,109.9 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3425,Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3 100   0 100,100,High,Methylphenidate ER-MPH   0 NA Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Questionnaire Barkley Side Effects Rating Scale  0.69044879   39.0000000,mg/d Swanson 2004,NA,RCT (parallel, crossover, open-label),RR 181 183  364 NA,NA  0.5000000000, 0.120000000, 2.020000e+00 NA,NA,NA NA NA,NA,NA,NA 100 100,100,100,100 100 100,some,low low,some,some Placebo,  0, 26.000000  9.600000 NA,DSM-IV 0 1,1.0 1.0,1.0,1.0,1,1 0 1,1 1 1,1.0 1 1,1,1, 458 Swanson_2004,< 2 months,NA,6-12 yo 4.76 15,85 109.9,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3425 Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3 100,  0 100,100,High,Methylphenidate,MPH-MLR,  0,NA Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA, 0.46029919,  32.0000000 mg/d,Wigal 2014,NA,RCT (parallel, crossover, open-label) RR  21  22,  43 NA,NA, 0.3500000000, 0.010000000, 8.110000e+00 NA,NA NA,NA NA,NA NA,NA,  0   0,  0,100,100,100 100,high low,low,low low,Placebo   0, 38.000000  8.700000 NA DSM-IV-TR 0 1,1.0,1.0 1.0 1.0,1 1 0,1,1,1,1 1.0,1 1 1,1  459 Wigal_2014,< 2 months NA,6-12 yo,4.76,15 85 109.9 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
3425,Storebo (2023) Storebo,2023 10.1002/14651858.CD009885.pub3,100,  0,100,100 High,Methylphenidate MPH transdermal,  0 NA,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),AEs  0.92059839   20.0000000 mg/d,Wilens 2010 NA,RCT (parallel, crossover, open-label) RR  30, 30,  60,NA,NA 23.0400000000  1.260000000, 4.203500e+02 NA,NA NA NA NA,NA,NA NA 100,100,100,100   0 100 100 some,some high some,low,Placebo,  0  16.600000, 9.170000,NA,DSM-IV 0 1 1.0 1.0,1.0 1.0,1 1 0,1,1,1,1,1.0,1,1 1 1  460,Wilens_2010,< 2 months NA 6-12 yo,4.76 15 85 109.9,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
3425 Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3 100,  0,100,100,High Methylphenidate,MPH 100,MPH and aripiprazol,Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),Questionnaire,Serious Adverse Event Rating Scale (SAERS), 0.92059839,  25.0000000,mg/d,Zeni 2009 NA RCT (parallel, crossover, open-label) RR, 16, 16   32,NA NA  0.9600000000  0.480000000, 1.920000e+00,NA NA NA NA NA,NA,NA,NA 100,100 100 100,100,100 100 low low,low,low low,Placebo + aripiprazol   0, 43.700000,10.710000,NA,DSM-IV,0 1 1.0,1.0 1.0 1.0 1 1,0,1,1 1,1 1.0 1 1 1 1, 461 Zeni_2009 < 2 months NA 6-12 yo,4.76 15,85,109.9,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3425 Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3 100,  0 100 100,High Methylphenidate,ER-MPH   0 NA,Suicidal ideation/behavior Mixed,At study endpoint (closest to 12 weeks) Questionnaire,C-SSRS  0.23014960    0.4000000 mg/d,Childress 2017 NA,RCT (parallel, crossover, open-label) RR, 44, 41   85,outcomes,NA  0.9333333333  0.018943386  4.598497e+01 NA NA NA NA NA,NA,NA NA 100 100 100 100,100 100,100,some,some low some low,Placebo,  0  34.100000, 9.200000,NA,DSM-IV-TR,0,1,1.0,1.0 1.0,1.0,1 1 0,1 1,1,1,1.0,1,1,1,1  462 Childress_2017 < 2 months,NA 6-12 yo 9 14.7,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3425,Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3 100   0 100,100,High,Methylphenidate,ER-MPH   0 NA Suicidal ideation/behavior Mixed,At study endpoint (closest to 12 weeks),Questionnaire,C-SSRS  0.23014960,  55.0000000 mg/d Childress 2020 NA RCT (parallel, crossover, open-label),RR  74  73, 147 outcomes,NA  0.9866666667  0.019837640  4.907394e+01 NA NA NA NA,NA NA NA,NA 100 100,100 100 100,100 100 low low,low,low,low,Placebo   0  34.600000, 9.400000 NA DSM-5,0,1 1.0,1.0 1.0,1.0,1,1 0,1 1 1 1 1.0 1,1 1 1, 463 Childress_2020 < 2 months NA,6-12 yo,9 14.7 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3425,Storebo (2023),Storebo,2023,10.1002/14651858.CD009885.pub3,100   0,100 100,High Methylphenidate,MPH,  0 NA,Suicidal ideation/behavior Mixed At study endpoint (closest to 12 weeks),Questionnaire C-SSRS  0.92059839 NA,NA,NCT02293655 NA NA RCT (parallel, crossover, open-label) RR, 18, 92  110 NA NA, 1.6315789474, 0.069059072, 3.854743e+01,NA NA,NA,NA,NA,NA NA NA   0,  0 100,100 100   0 100 some,low,some low,high,Placebo   0  34.000000  9.000000 NA,DSM-5 0,1 1.0,1.0 1.0,1.0 1,1,0,1 1 1 1,1.0 1 1 1,1, 464,NCT02293655_NA < 2 months NA 6-12 yo 9,14.7 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high,high
3425 Storebo (2023),Storebo,2023 10.1002/14651858.CD009885.pub3,100,  0 100,100,High,Methylphenidate,ER-MPH   0 NA Suicidal ideation/behavior,Mixed At study endpoint (closest to 12 weeks) Questionnaire C-SSRS, 1.84119678,  44.4700000,mg/d Newcorn,2017a NA,RCT (parallel, crossover, open-label) RR 184  91, 275,NA NA  0.4972972973, 0.009946719  2.486293e+01,NA,NA NA,NA NA NA NA,NA,100 100 100 100   0,100,100 some low high some low Placebo   0, 33.600000 14.700000,NA,DSM-IV-TR 0,1 1.0 1.0,1.0 1.0,1 1 0 1 1 1 1,1.0 1 1,1,1, 465,Newcorn_2017a,< 2 months,NA,13-19 yo 9 14.7,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
3425,Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3,100,  0,100,100,High,Methylphenidate,ER-MPH   0,NA,Suicidal ideation/behavior Mixed At study endpoint (closest to 12 weeks) Questionnaire C-SSRS  1.38089758   45.0000000,mg/d Newcorn,2017b NA,RCT (parallel, crossover, open-label),RR 219,110, 329 NA NA  0.5045454545  0.010078225  2.525902e+01,NA,NA NA NA NA NA NA,NA,100 100,100,100   0,100 100,some,low high,some low Placebo   0  34.000000,14.700000 NA DSM-IV-TR 0,1 1.0,1.0,1.0 1.0,1 1,0 1,1,1,1 1.0 1,1 1,1, 466,Newcorn_2017b,< 2 months,NA 13-19 yo 9 14.7,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
3425,Storebo (2023),Storebo 2023,10.1002/14651858.CD009885.pub3,100   0,100 100,High,Methylphenidate ER-MPH,  0 NA,Suicidal ideation/behavior Mixed At study endpoint (closest to 12 weeks),Questionnaire,C-SSRS, 0.23014960   40.0000000,mg/d Wigal 2017,NA RCT (parallel, crossover, open-label),RR  42, 44,  86 outcomes NA, 1.0465116279  0.021234712, 5.157530e+01,NA,NA NA NA,NA,NA NA,NA 100 100,100 100 100 100,100,low,some,low low,low,Placebo,  0  37.600000  9.600000,NA,DSM 0 1 1.0 1.0 1.0 1.0 1 1,0 1 1,1 1 1.0 1 1 1 1, 467 Wigal_2017 < 2 months NA,6-12 yo,9 14.7 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3425,Storebo (2023) Storebo,2023,10.1002/14651858.CD009885.pub3,100   0 100,100 High Methylphenidate,ER-MPH   0 NA Suicidal ideation/behavior Mixed,At study endpoint (closest to 12 weeks),Questionnaire,C-SSRS, 0.23014960   55.0000000 mg/d Childress 2020,NA,RCT (parallel, crossover, open-label),RR, 74, 73, 147 outcomes,NA, 0.9866666667  0.019837640  4.907394e+01 NA NA NA NA NA NA,NA NA,100 100 100 100 100 100,100 low,low low,low low Placebo   0, 34.600000, 9.400000,NA DSM-5,0,1 1.0,1.0 1.0,1.0 1,1 0,1,1,1 1,1.0 1,1 1 1, 468,Childress_2020 < 2 months NA,6-12 yo 9,14.7 NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3425,Storebo (2023) Storebo 2023,10.1002/14651858.CD009885.pub3 100,  0,100,100 High Methylphenidate ER-MPH   0 NA,Suicidal ideation/behavior,Mixed At study endpoint (closest to 12 weeks),Questionnaire C-SSRS, 0.23014960,  40.0000000,mg/d Wigal 2017 NA RCT (parallel, crossover, open-label),RR  42  44,  86 outcomes NA  1.0465116279, 0.021234712  5.157530e+01 NA,NA NA,NA,NA NA NA NA,100,100 100 100 100 100 100,low some,low low,low,Placebo,  0  37.600000, 9.600000 NA,DSM,0,1,1.0,1.0,1.0,1.0 1 1 0,1 1,1,1,1.0,1 1 1 1, 469 Wigal_2017,< 2 months NA,6-12 yo 9 14.7 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
8992 Farhat (2024) Farhat 2024,10.1089/cap.2024.0049 100   0,100 100,High Methylphenidate,NA,  0,NA Tics/Tourette disorder symptoms,Mixed,At study endpoint (closest to 12 weeks),Observational tool,YGTSS, Yale Global Tic Severity Scale, 0.69044879,  57.5000000 mg/d,Castellanos,1997 NA,RCT (crossover),SMD   5   5,  10,NA,reverse  0.4400000000 -0.450000000, 1.330000e+00,NA NA NA NA NA,NA NA NA 100 100 100 100 100,100,100,some some some,some some,Placebo,  0   0.000000, 9.500000 NA DSM-III-R 0,1 1.0,1.0,1.0 1.0,1,1,1,1 1 1,1,1.0,1 1 0 1  470,Castellanos_1997 < 2 months NA,6-12 yo 8.9 10.2,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Farhat (2024)_Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Farhat (2024) - Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
8992,Farhat (2024),Farhat 2024 10.1089/cap.2024.0049,100,  0 100,100,High Methylphenidate NA   0 NA Tics/Tourette disorder symptoms Mixed,At study endpoint (closest to 12 weeks) Observational tool YGTSS, Yale Global Tic Severity Scale, 0.46029919,   0.6000000,mg/kg/d Gadow 2007,NA RCT (crossover),SMD  36  35,  71 NA reverse -0.0500000000 -0.380000000, 2.800000e-01,NA,NA,NA NA,NA NA NA,NA,100 100 100 100 100 100 100,some,low some low,low Placebo,  0  19.700000  8.900000 NA DSM-III-R,0,1 1.0,1.0,1.0,1.0,1,1,1 1 1 1,1 1.0 1 1,0,1, 471 Gadow_2007,< 2 months,NA,6-12 yo 8.9 10.2 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Farhat (2024)_Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Farhat (2024) - Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
8992,Farhat (2024),Farhat 2024 10.1089/cap.2024.0049,100   0,100,100 High,Methylphenidate,NA   0,NA,Tics/Tourette disorder symptoms,Mixed,At study endpoint (closest to 12 weeks) Observational tool YGTSS, Yale Global Tic Severity Scale  3.68239356   25.7000000 mg/d,TSSG,2002,NA,RCT (parallel),SMD  68  68  136 NA,reverse -0.5900000000,-1.070000000,-1.100000e-01,NA,NA,NA,NA NA NA,NA NA 100 100 100,100,100 100,100,low low,some low,low,Placebo,  0, 14.600000 10.200000 NA,DSM-IV 0 1,1.0,1.0 1.0,1.0,1 1,1 1,1 1,1,1.0,1,1 0 1  472,TSSG_2002,2-6 months NA,6-12 yo 8.9,10.2,NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Farhat (2024)_Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Farhat (2024) - Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3836,Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7,100   0 100 100,High Cognitive training NA   0 NA Academic/job performance,NA,At follow-up (closest to 26 weeks),NA,Reading Comprehension Test  1.15074799    2.6000000 h/week Bigorra,2016,NA RCT G, 22, 20,  42 NA,NA -0.1000000000,-0.730000000  5.300000e-01 NA,NA NA,NA NA NA,NA,NA,  0,  0 100 100,100,  0 100 low,low some low,high Non-adaptive,  0,NA, 8.980000 NA DSM-IV 0,1 1.0,1.0,1.0,1.0 1 1 1 1,1 1,1,0.5 0 1,1,1, 473,Bigorra_2016 < 2 months NA,6-12 yo,8.98 11.59 NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,high high
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0,100,100,High Cognitive training,NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA CRS-R, 1.15074799,   2.6000000,h/week,Bigorra,2016,NA RCT,G, 30, 27   57 outcomes NA, 0.0300000000 -0.500000000, 5.600000e-01,NA,NA,NA NA NA NA NA,NA   0   0,100,100,100,  0,100,low low some low high,Non-adaptive   0 NA, 8.980000,NA,DSM-IV,0 1 1.0,1.0,1.0 1.0 1 1,1,1,1 1,1,0.5,0,1 1,1  474,Bigorra_2016,< 2 months NA 6-12 yo,8.4,12.41,NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high,high
3836,Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0 100 100 High,Cognitive training NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks),NA CRS-R  1.15074799    2.6000000,h/week,Bigorra 2016 NA RCT,G, 30  27   57 outcomes,NA  0.2700000000,-0.260000000  8.000000e-01,NA NA,NA,NA,NA NA NA NA,  0,  0 100 100,100,  0,100,low low,some,low,high,Non-adaptive   0 NA  8.980000 NA DSM-IV 0,1 1.0,1.0 1.0 1.0,1,1,1 1 1 1,1 0.5,0 1 1 1, 475 Bigorra_2016 < 2 months NA,6-12 yo,6.55 10.6,NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high high
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100,  0 100 100,High Cognitive training NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks),NA,CRS-R, 1.15074799,   2.6000000 h/week,Bigorra,2016 NA RCT,G  22  20   42 NA,NA, 0.3700000000,-0.240000000, 9.800000e-01,NA,NA,NA,NA NA NA,NA,NA   0,  0,100,100 100,  0,100 low low some,low,high,Non-adaptive,  0,NA, 8.980000 NA DSM-IV 0,1,1.0 1.0,1.0,1.0,1,1,1 1 1,1,1 0.5 0 1,1 1, 476 Bigorra_2016 < 2 months NA,6-12 yo 8.98 12.41 NA NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,high,high
3836,Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7,100   0 100,100 High Cognitive training NA   0 NA Executive functioning (report),Parent-rated,At study endpoint (closest to 12 weeks) NA BRIEF, 1.15074799    2.6000000 h/week,Bigorra,2016 NA,RCT,G, 30, 27,  57 NA,NA,-0.2400000000 -0.770000000, 2.900000e-01,NA,NA NA NA NA NA,NA,NA,  0,  0,100,100 100   0 100,low,low,some,low,high,Non-adaptive,  0 NA  8.980000,NA,DSM-IV,0 1,1.0 1.0,1.0,1.0 1,1 1 1,1,1,1 0.5 0,1,1,1  477 Bigorra_2016,< 2 months NA,6-12 yo 6.55,11.59 NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
3836,Westwood - Children (2024),Westwood - Children 2024,10.1038/s41380-023-02000-7,100,  0,100,100,High Cognitive training,NA,  0 NA,Executive functioning (report),Parent-rated,At follow-up (closest to 26 weeks),NA BRIEF, 1.15074799    2.6000000,h/week,Bigorra 2016,NA RCT,G  22, 20,  42 NA,NA  0.2600000000,-0.270000000  7.900000e-01,NA,NA,NA,NA NA,NA,NA NA   0,  0,100 100,100   0,100 low,low,some,low high,Non-adaptive,  0 NA, 8.980000 NA,DSM-IV,0 1,1.0,1.0,1.0 1.0,1 1 1,1 1,1 1 0.5 0,1,1 1, 478 Bigorra_2016 < 2 months NA,6-12 yo,8.98 11.59,NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (report)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no high high
3836,Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0,100,100,High Cognitive training,NA   0 NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA Conners' CPT-II - oms  1.15074799    2.6000000 h/week Bigorra 2016,NA RCT G  30  27   57,outcomes NA, 0.2100000000,-0.320000000, 7.400000e-01,NA,NA NA NA,NA NA NA NA,  0,  0,100,100,100,  0,100,low,low some low,high Non-adaptive   0 NA, 8.980000 NA DSM-IV,0 1,1.0 1.0 1.0,1.0,1 1 1 1,1 1 1,0.5 0 1,1 1  479 Bigorra_2016,< 2 months,NA 6-12 yo,6.55,12.41,NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high,high
3836,Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7 100,  0 100 100,High Cognitive training,NA,  0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,Conners' CPT-II - coms, 1.15074799    2.6000000,h/week,Bigorra,2016,NA,RCT G  30  27,  57,outcomes,NA  0.4500000000 -0.080000000  9.800000e-01 NA,NA NA,NA,NA NA NA NA   0   0,100 100 100   0,100 low low,some,low,high,Non-adaptive,  0 NA  8.980000,NA,DSM-IV 0 1,1.0,1.0,1.0,1.0,1,1 1 1 1 1,1 0.5 0,1 1 1  480 Bigorra_2016 < 2 months,NA 6-12 yo 6.55 12.41,NA NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high high
3836 Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7 100   0,100 100,High Cognitive training NA   0,NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA,TMT B, 1.15074799    2.6000000 h/week,Bigorra 2016,NA RCT G  31, 29   60,outcomes,NA, 0.5100000000, 0.000000000  1.020000e+00,NA NA,NA NA,NA,NA NA,NA   0   0,100 100 100   0 100 low low,some low high Non-adaptive,  0 NA, 8.980000,NA DSM-IV 0,1 1.0 1.0,1.0 1.0,1 1 1,1 1 1,1,0.5,0,1,1 1  481 Bigorra_2016,< 2 months,NA,6-12 yo 6.55,12.41,NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high,high
3836,Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7,100   0,100,100,High,Cognitive training,NA,  0,NA Executive functioning (tests),NA,At follow-up (closest to 26 weeks) NA,Conners' CPT-II - oms, 1.15074799,   2.6000000,h/week,Bigorra 2016 NA RCT,G, 22  20   42,outcomes,NA -0.3700000000 -0.860000000, 1.200000e-01,NA NA NA NA NA NA,NA,NA,  0,  0 100,100 100,  0,100 low low,some low,high,Non-adaptive   0,NA  8.980000,NA,DSM-IV 0,1 1.0,1.0 1.0 1.0,1,1 1 1,1,1 1,0.5 0 1,1 1  482 Bigorra_2016,< 2 months NA,6-12 yo,8.98 12.41,NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no high,high
3836,Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7,100   0,100,100,High,Cognitive training NA,  0 NA,Executive functioning (tests) NA,At follow-up (closest to 26 weeks),NA Conners' CPT-II - coms, 1.15074799,   2.6000000 h/week,Bigorra 2016 NA,RCT G  22, 20,  42 outcomes,NA  0.2000000000,-0.410000000  8.100000e-01 NA NA,NA,NA NA,NA,NA NA,  0   0 100 100 100,  0,100,low,low some,low high Non-adaptive,  0 NA  8.980000 NA,DSM-IV,0 1 1.0,1.0,1.0,1.0 1,1 1 1 1 1,1 0.5 0,1,1 1  483,Bigorra_2016,< 2 months,NA 6-12 yo 8.98,12.41 NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,high high
3836 Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0,100 100 High Cognitive training,NA   0 NA Academic/job performance,NA,At study endpoint (closest to 12 weeks) NA,WRAT - Word Reading  1.15074799    3.1250000 h/week Chacko,2014,NA RCT,G  44  41   85 outcomes NA,-0.0500000000,-0.480000000  3.800000e-01 NA,NA NA NA NA NA NA,NA,100 100 100,100,  0,100,100 low low,high low,some Non-adaptive,  0 NA, 8.400000,NA DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)",0,1,1.0 1.0 1.0,1.0,1 1 1 1 1,1,1,0.5 0 1 1,1  484,Chacko_2014 < 2 months NA,6-12 yo 8.4,11.59,NA,NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3836 Westwood - Children (2024),Westwood - Children 2024,10.1038/s41380-023-02000-7 100   0 100 100 High Cognitive training NA   0,NA,Academic/job performance NA,At study endpoint (closest to 12 weeks) NA WRAT-Math Computation, 1.15074799    3.1250000 h/week,Chacko,2014,NA RCT,G  44  41,  85,outcomes,NA  0.1000000000 -0.330000000  5.300000e-01 NA,NA NA NA NA,NA NA NA,100,100 100,100,  0 100,100 low low high low,some Non-adaptive   0 NA  8.400000,NA,DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)" 0,1 1.0 1.0 1.0 1.0,1,1,1 1 1,1 1 0.5,0 1,1 1  485 Chacko_2014,< 2 months,NA,6-12 yo,8.4,11.59,NA,NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3836,Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0 100,100 High,Cognitive training NA   0,NA,Academic/job performance,NA At study endpoint (closest to 12 weeks) NA,WRAT Sentence Comprehension  1.15074799,   3.1250000,h/week Chacko 2014,NA,RCT G, 44  41   85,outcomes NA  0.3000000000,-0.130000000  7.300000e-01,NA,NA NA NA,NA NA,NA,NA,100,100,100 100,  0 100,100 low,low,high low,some Non-adaptive,  0,NA  8.400000 NA DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)" 0,1 1.0 1.0,1.0,1.0 1,1,1 1 1,1,1,0.5,0,1 1,1, 486,Chacko_2014,< 2 months,NA,6-12 yo 8.4 11.59 NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3836,Westwood - Children (2024),Westwood - Children 2024,10.1038/s41380-023-02000-7,100,  0,100 100 High Cognitive training,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) NA DBD (Pelham et al., 1992)  1.15074799,   3.1250000,h/week,Chacko 2014,NA,RCT G, 44, 41   85 outcomes,NA -0.2400000000,-0.550000000  7.000000e-02 NA NA NA,NA NA NA,NA,NA 100,100,100,100,  0,100 100,low low high low,some Non-adaptive   0,NA  8.400000,NA,DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)",0 1 1.0 1.0,1.0,1.0,1,1,1 1,1 1 1 0.5,0,1,1 1  487 Chacko_2014,< 2 months,NA,6-12 yo,8.4 12.41,NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
3836 Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0 100 100,High,Cognitive training,NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks) NA DBD  1.15074799    3.1250000 h/week,Chacko 2014,NA,RCT,G, 44, 41,  85,outcomes NA, 0.0200000000,-0.270000000  3.100000e-01 NA,NA,NA NA,NA,NA,NA NA,100 100 100,100,  0,100 100 low low high,low some Non-adaptive,  0,NA  8.400000,NA DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)",0,1,1.0,1.0 1.0 1.0 1 1 1 1,1,1 1 0.5,0,1,1 1  488 Chacko_2014,< 2 months NA 6-12 yo,6.55 10.6 NA,NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
3836,Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7,100   0,100,100 High,Cognitive training NA   0 NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,A-X CPT Coms, 1.15074799    3.1250000 h/week,Chacko,2014 NA,RCT,G  44, 41,  85 outcomes NA,-0.0200000000,-0.450000000, 4.100000e-01,NA NA NA,NA NA,NA,NA NA 100,100 100,100,  0,100 100 low low,high low some Non-adaptive   0,NA, 8.400000 NA,DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)" 0 1,1.0,1.0 1.0 1.0 1 1,1 1,1 1 1,0.5,0,1 1,1, 489 Chacko_2014 < 2 months NA,6-12 yo 6.55,12.41,NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
3836 Westwood - Children (2024),Westwood - Children 2024,10.1038/s41380-023-02000-7,100,  0,100,100 High Cognitive training NA,  0,NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA,A-X CPT Oms  1.15074799,   3.1250000,h/week,Chacko,2014,NA RCT,G, 44  41,  85 outcomes,NA, 0.0700000000 -0.360000000  5.000000e-01 NA,NA,NA,NA NA NA NA,NA 100,100 100 100   0 100,100,low low high,low some Non-adaptive   0 NA, 8.400000,NA,DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)",0 1 1.0,1.0,1.0 1.0 1 1,1,1 1 1,1 0.5,0,1 1,1, 490 Chacko_2014 < 2 months NA,6-12 yo,6.55,12.41 NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
3836 Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0,100,100,High,Cognitive training NA,  0 NA Academic/job performance NA At study endpoint (closest to 12 weeks),NA,WIAT-II Mathematical Reasoning  1.15074799    3.1250000,h/week,Dentz 2020a NA,RCT,G, 17, 18   35 outcomes,NA  0.0200000000 -0.650000000  6.900000e-01,NA NA,NA NA NA NA,NA NA,100,100,100,100,  0 100,100,low low high low some Non-adaptive,  0 NA,10.020000 NA DSM-IV 0 1 1.0 1.0 1.0,1.0,1 1,1 1 1,1 1 0.5 0,1,1,1  491 Dentz_2020a < 2 months NA,6-12 yo 8.4,11.59,NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
3836 Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7,100,  0 100,100 High Cognitive training NA   0,NA,Academic/job performance,NA At study endpoint (closest to 12 weeks),NA,WIAT-II Reading Comprehension, 1.15074799    3.1250000,h/week Dentz 2020a,NA RCT,G, 17, 18   35 outcomes NA  0.1700000000 -0.500000000, 8.400000e-01 NA NA,NA,NA NA NA,NA NA 100,100 100 100,  0 100,100 low low,high low some,Non-adaptive,  0,NA,10.020000,NA DSM-IV,0,1,1.0 1.0,1.0,1.0,1,1 1,1,1,1 1,0.5,0,1 1 1, 492 Dentz_2020a,< 2 months NA,6-12 yo,8.4 11.59 NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
3836,Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7,100   0,100,100 High Cognitive training NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),NA Conners-3AI, 1.15074799,   3.1250000 h/week,Dentz,2020a NA,RCT G  17  15,  32,NA,NA,-0.0400000000 -0.730000000  6.500000e-01,NA NA,NA NA,NA NA,NA NA 100 100 100,100,  0,100,100 low low high low,some Non-adaptive,  0,NA 10.020000,NA DSM-IV,0 1 1.0 1.0 1.0 1.0 1,1,1,1 1 1 1 0.5,0 1 1 1, 493,Dentz_2020a,< 2 months NA,6-12 yo 8.4 12.41,NA NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
3836,Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7 100   0,100 100,High,Cognitive training NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks) NA Conners-3AI  1.15074799    3.1250000,h/week,Dentz 2020a NA,RCT G, 17  14,  31 NA NA,-0.4100000000 -0.941759707, 1.217597e-01 NA NA,NA,NA NA NA NA,NA,100,100,100 100,  0 100 100,low,low high,low,some,Non-adaptive   0 NA 10.020000,NA,DSM-IV 0 1,1.0,1.0,1.0 1.0,1,1,1,1 1,1,1 0.5 0,1 1,1  494,Dentz_2020a < 2 months NA 6-12 yo 8.98,12.41 NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low,low
3836,Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0,100,100 High Cognitive training NA   0 NA,Executive functioning (report),NA At study endpoint (closest to 12 weeks) NA,BRIEF  1.15074799,   3.1250000,h/week Dentz,2020a NA RCT G  17  15,  32 NA,NA -0.1400000000 -0.830000000  5.500000e-01 NA,NA,NA,NA,NA NA,NA,NA 100 100,100,100   0,100,100,low low,high low some,Non-adaptive,  0 NA 10.020000 NA DSM-IV,0 1 1.0 1.0,1.0 1.0,1 1 1,1,1 1 1 0.5,0,1 1,1, 495 Dentz_2020a,< 2 months NA 6-12 yo,10.02,12.41,NA NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
3836,Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0,100,100 High,Cognitive training NA   0,NA,Executive functioning (report) NA,At follow-up (closest to 26 weeks),NA,BRIEF, 1.15074799,   3.1250000 h/week,Dentz,2020a,NA,RCT G  17, 14,  31,NA NA, 0.1500000000,-0.565830375, 8.658304e-01,NA,NA,NA NA,NA NA NA NA 100 100 100,100,  0 100 100 low,low,high low,some Non-adaptive   0 NA 10.020000,NA DSM-IV,0,1 1.0,1.0,1.0,1.0 1 1,1,1 1 1,1 0.5,0 1,1,1, 496,Dentz_2020a,< 2 months,NA 6-12 yo 10.02,12.41,NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low low
3836 Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0 100,100 High Cognitive training NA,  0,NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA Raven's porgressive matrices, 1.15074799,   3.1250000,h/week,Dentz,2020a NA RCT,G  17, 19   36,outcomes,NA,-0.2000000000,-0.870000000  4.700000e-01,NA NA NA NA NA,NA,NA,NA,100 100,100,100   0,100 100 low,low,high low,some Non-adaptive   0 NA 10.020000 NA DSM-IV,0 1 1.0,1.0,1.0,1.0,1,1 1 1,1 1,1 0.5 0 1,1 1  497 Dentz_2020a,< 2 months,NA,6-12 yo 6.55 12.41 NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
3836 Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0 100 100 High,Cognitive training,NA,  0 NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA,CPT  1.15074799,   3.1250000,h/week,Dentz 2020a NA RCT G  17, 19   36,outcomes NA,-0.0800000000,-0.730000000, 5.700000e-01 NA,NA NA,NA NA NA,NA,NA,100,100 100 100   0 100 100 low low,high,low,some,Non-adaptive,  0,NA,10.020000,NA DSM-IV,0 1,1.0,1.0,1.0,1.0 1,1 1 1 1 1 1,0.5,0,1 1,1  498,Dentz_2020a,< 2 months NA,6-12 yo,6.55,12.41 NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
3836,Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7,100,  0,100,100,High,Cognitive training,NA   0,NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA,Conners' CPT-II - Oms, 1.15074799,   3.1250000,h/week Dentz,2020a,NA RCT G, 17, 19   36,outcomes NA  0.2400000000,-0.410000000, 8.900000e-01 NA,NA NA,NA,NA,NA,NA,NA 100,100,100,100,  0 100,100 low,low high,low some,Non-adaptive   0 NA,10.020000 NA DSM-IV,0 1 1.0 1.0 1.0,1.0,1 1,1 1,1 1 1,0.5 0,1,1,1  499 Dentz_2020a,< 2 months,NA 6-12 yo 6.55 12.41 NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3836 Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0,100 100 High,Cognitive training NA   0 NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA,Wechsler Spatial Span (Combined Forward/Backward), 1.15074799    3.1250000,h/week Dentz 2020a NA,RCT,G, 17, 19,  36,outcomes NA  0.1300000000,-0.340000000, 6.000000e-01 NA NA,NA,NA NA,NA,NA NA 100,100,100 100,  0 100 100 low,low,high,low some Non-adaptive,  0 NA 10.020000,NA DSM-IV,0 1 1.0 1.0,1.0,1.0,1 1,1 1,1,1,1,0.5,0,1 1 1, 500,Dentz_2020a < 2 months NA,6-12 yo,6.55,12.41 NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
3836,Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0,100,100,High,Cognitive training NA,  0,NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA WISC-IV Digit Span Backward & Forward  1.15074799,   3.1250000,h/week,Dentz,2020a,NA RCT G, 17  19   36 outcomes,NA, 0.5700000000  0.100000000, 1.040000e+00,NA,NA NA,NA,NA,NA NA,NA 100,100,100 100   0 100 100 low low high low some,Non-adaptive,  0,NA,10.020000 NA DSM-IV 0 1,1.0 1.0,1.0,1.0 1,1 1,1,1,1 1 0.5,0,1,1,1, 501,Dentz_2020a,< 2 months NA,6-12 yo,6.55 12.41,NA,NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
3836 Westwood - Adults (2024),Westwood - Adults,2024,10.1038/s41380-023-02000-7,100   0 100 100,High Cognitive training,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) NA,Conners-3AI  1.15074799    3.1250000,h/week,Dentz,2020b,NA,RCT,G  23  21,  44 NA,NA  0.2500000000 -0.340000000  8.400000e-01 NA,NA NA NA NA,NA NA NA,100 100 100 100   0 100 100,low,low high,low,some,Cognitive placebo,  0 NA,38.910000,NA DSM-IV 0,1 1.0 1.0 1.0 1.0,1 1 1 1 1,1 1,0.5,0 1 1 1, 502 Dentz_2020b < 2 months,NA >= 20 yo 38.91,38.91 NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA Westwood - Adults (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Adults (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
3836 Westwood - Adults (2024) Westwood - Adults,2024 10.1038/s41380-023-02000-7,100   0 100 100 High Cognitive training,NA   0,NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA,WAIS-III Matrix Reasoning subtest, 1.15074799,   3.1250000 h/week,Dentz 2020b,NA RCT,G  23, 21   44 outcomes,NA, 0.1000000000 -0.490000000, 6.900000e-01 NA NA NA,NA,NA NA NA,NA 100,100,100,100,  0,100,100 low low,high,low some Cognitive placebo,  0,NA,38.910000 NA DSM-IV 0,1 1.0 1.0,1.0,1.0,1,1,1,1,1,1,1 0.5 0,1,1 1, 503 Dentz_2020b < 2 months,NA >= 20 yo,22.2 38.91 NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA,Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
3836 Westwood - Adults (2024) Westwood - Adults 2024 10.1038/s41380-023-02000-7 100   0,100,100 High Cognitive training,NA,  0 NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA,Corsi Block Tapping Task (Combined Forward/Backward), 1.15074799,   3.1250000,h/week Dentz,2020b,NA RCT,G  23, 21   44 outcomes NA  0.2100000000,-0.380000000  8.000000e-01 NA NA,NA NA NA,NA NA NA,100,100,100,100   0 100 100,low,low,high,low some,Cognitive placebo   0 NA 38.910000,NA DSM-IV,0,1 1.0,1.0,1.0 1.0 1,1 1,1 1,1 1,0.5 0,1 1 1  504,Dentz_2020b < 2 months,NA,>= 20 yo,22.2 38.91,NA NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
3836,Westwood - Adults (2024),Westwood - Adults,2024,10.1038/s41380-023-02000-7,100,  0 100 100,High,Cognitive training NA,  0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA WAIS-III Digit Span (Combined Forward/Backward), 1.15074799    3.1250000 h/week Dentz,2020b,NA,RCT,G, 23  21,  44 outcomes NA  0.5300000000 -0.080000000, 1.140000e+00 NA,NA,NA,NA NA,NA NA,NA,100,100,100,100,  0 100,100 low low,high,low some Cognitive placebo   0,NA 38.910000,NA DSM-IV,0,1 1.0,1.0,1.0 1.0 1 1,1 1,1,1,1,0.5,0,1,1 1  505 Dentz_2020b,< 2 months NA >= 20 yo,22.2,38.91 NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA NA Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
3836,Westwood - Adults (2024) Westwood - Adults 2024,10.1038/s41380-023-02000-7,100,  0 100,100,High Cognitive training,NA   0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA Attentional Network Task (aka Flanker Task), Flanker RT Effect (No-cue Incongruent-Congruent),NA,NA,NA Dotare,2020,NA,RCT,G  14  16,  30,NA NA  1.3900000000  0.590000000, 2.190000e+00 NA NA,NA,NA NA NA NA,NA   0,  0,  0 100 100,100 100 high,some low,some some Non-adaptive   0 NA,24.500000,NA,DSM-IV-TR,0 1 1.0,1.0 1.0 1.0,1 1,1,1,1 1 1 0.5,0 1,1 1, 506,Dotare_2020 NA NA,>= 20 yo 22.2,38.91 NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA NA,Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,high
3836,Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0,100,100,High,Cognitive training NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks),NA DBDRS  1.15074799    2.5000000 h/week Dovis,2015 NA,RCT,G, 31, 30   61 NA NA  0.1500000000 -0.200000000  5.000000e-01 NA NA,NA,NA,NA NA,NA,NA 100 100 100,100,  0,100 100,low,low high,low,some Non-adaptive,  0 NA 10.600000,NA DSM-IV-TR 0 1 1.0 1.0,1.0 1.0,1,1 1 1,1 1,1,0.5,0 1,1 1  507 Dovis_2015 < 2 months NA 6-12 yo 6.55,10.6 NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7,100,  0,100,100 High Cognitive training NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA,DBDRS  1.15074799    2.5000000,h/week Dovis 2015 NA,RCT,G  31, 30   61,NA,NA, 0.1800000000,-0.170000000, 5.300000e-01,NA NA,NA,NA NA NA NA,NA,100,100,100 100,  0,100 100 low low,high,low some,Non-adaptive   0 NA,10.600000,NA,DSM-IV-TR,0,1 1.0 1.0,1.0,1.0 1 1,1,1 1 1 1,0.5 0 1,1,1, 508 Dovis_2015 < 2 months,NA,6-12 yo,8.4,12.41 NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3836,Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7,100,  0,100 100 High,Cognitive training,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks) NA DBDRS, 1.15074799,   2.5000000,h/week,Dovis,2015 NA RCT G  31  30,  61 NA NA, 0.0500000000,-0.300000000, 4.000000e-01 NA,NA,NA,NA,NA,NA,NA,NA 100,100 100 100,  0,100,100 low low high,low,some,Non-adaptive,  0,NA 10.600000,NA,DSM-IV-TR 0,1 1.0,1.0,1.0,1.0,1,1,1,1 1 1 1 0.5,0,1,1,1, 509,Dovis_2015 < 2 months NA 6-12 yo,8.98,12.41,NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low low
3836 Westwood - Children (2024),Westwood - Children 2024,10.1038/s41380-023-02000-7 100,  0,100,100,High Cognitive training NA   0 NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA,Raven coloured progressive matrices, 1.15074799,   2.5000000,h/week Dovis,2015 NA RCT,G, 31  30,  61,outcomes NA, 0.0000000000,-0.510000000, 5.100000e-01,NA,NA NA NA,NA,NA NA,NA 100,100,100 100   0,100,100,low low high,low,some,Non-adaptive   0,NA,10.600000 NA DSM-IV-TR 0,1,1.0 1.0 1.0 1.0 1 1 1 1 1 1 1 0.5,0,1 1 1  510,Dovis_2015 < 2 months,NA,6-12 yo,6.55 12.41,NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
3836 Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100   0 100 100,High Cognitive training,NA,  0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA,WISC-III Digit Span (Combined Forward/Backward), 1.15074799,   2.5000000 h/week,Dovis,2015 NA,RCT G, 31  30   61,outcomes,NA, 0.1800000000 -0.330000000, 6.900000e-01,NA,NA NA NA NA,NA NA NA 100,100,100 100,  0,100,100,low low,high low some,Non-adaptive   0 NA 10.600000,NA DSM-IV-TR,0,1 1.0,1.0,1.0,1.0,1,1,1,1 1,1 1 0.5 0 1,1,1  511 Dovis_2015,< 2 months,NA 6-12 yo 6.55,12.41,NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
3836,Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7,100,  0 100 100 High Cognitive training,NA,  0 NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,Stop task, 1.15074799    2.5000000,h/week Dovis 2015,NA,RCT G  31  30   61 outcomes,NA  0.5900000000, 0.080000000, 1.100000e+00,NA,NA NA NA NA,NA,NA,NA 100,100 100,100   0 100 100,low,low high low some Non-adaptive   0,NA,10.600000 NA DSM-IV-TR 0 1,1.0 1.0 1.0 1.0,1 1,1,1,1,1,1,0.5,0,1,1 1, 512 Dovis_2015,< 2 months,NA,6-12 yo,6.55,12.41 NA,NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
3836,Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0,100 100 High Cognitive training,NA   0,NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA,Corsi Block Tapping Task (Combined Forward/Backward), 1.15074799,   2.5000000 h/week,Dovis,2015 NA,RCT,G, 31, 30,  61 outcomes NA, 0.6400000000  0.290000000, 9.900000e-01 NA NA NA,NA,NA NA,NA,NA 100 100 100,100,  0 100,100,low low,high,low,some Non-adaptive,  0 NA 10.600000 NA,DSM-IV-TR,0,1 1.0 1.0 1.0 1.0 1 1 1,1 1,1 1,0.5,0,1 1 1, 513,Dovis_2015,< 2 months NA 6-12 yo,6.55,12.41,NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
3836 Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0,100,100 High,Cognitive training NA,  0,NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA Stroop Colour & Word Test, Stroop RT Effect  1.15074799    2.5000000 h/week,Dovis 2015 NA,RCT G  31, 30,  61,outcomes,NA, 0.1100000000 -0.400000000  6.200000e-01 NA NA,NA NA,NA,NA NA,NA 100,100,100 100   0,100,100,low low high,low some Non-adaptive   0 NA,10.600000 NA,DSM-IV-TR,0,1,1.0,1.0,1.0,1.0,1 1,1 1 1,1 1 0.5,0 1,1,1, 514 Dovis_2015 < 2 months,NA,6-12 yo,6.55 12.41 NA,NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3836,Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7 100   0,100 100,High,Cognitive training NA   0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA,TMT  1.15074799    2.5000000,h/week Dovis,2015 NA RCT,G  31, 30   61 outcomes,NA, 0.0700000000,-0.440000000, 5.800000e-01 NA NA,NA NA,NA NA,NA NA,100,100,100,100,  0,100,100 low,low high low some Non-adaptive   0 NA 10.600000,NA,DSM-IV-TR,0,1,1.0 1.0 1.0 1.0,1 1 1,1 1 1 1 0.5,0,1 1,1, 515,Dovis_2015 < 2 months NA,6-12 yo 6.55 12.41 NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3836 Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7 100   0,100 100 High Cognitive training,NA   0 NA,Executive functioning (tests),NA,At follow-up (closest to 26 weeks),NA WISC-III Digiti Span Foward & Backward (Digit Recall)  1.15074799    2.5000000,h/week Dovis 2015,NA RCT,G  31, 30,  61,outcomes NA, 0.3200000000,-0.190000000, 8.300000e-01 NA NA,NA NA,NA,NA,NA NA,100 100,100 100   0 100,100,low low,high,low some,Non-adaptive,  0,NA,10.600000,NA,DSM-IV-TR,0,1,1.0 1.0,1.0 1.0 1,1 1,1,1 1 1,0.5,0 1,1 1, 516,Dovis_2015,< 2 months NA 6-12 yo 8.98,12.41 NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,low low
3836 Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0,100,100 High,Cognitive training NA   0 NA,Executive functioning (tests),NA At follow-up (closest to 26 weeks) NA Stop task, 1.15074799,   2.5000000,h/week Dovis 2015 NA,RCT G  31, 30,  61 outcomes,NA, 0.5100000000  0.000000000  1.020000e+00,NA,NA,NA,NA,NA NA,NA,NA 100,100,100,100   0,100,100,low low,high,low,some Non-adaptive   0,NA 10.600000,NA DSM-IV-TR 0,1 1.0,1.0 1.0,1.0 1 1,1 1,1,1,1,0.5,0,1 1 1, 517 Dovis_2015,< 2 months,NA 6-12 yo 8.98 12.41 NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low low
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0,100 100 High Cognitive training NA   0,NA Academic/job performance,NA At study endpoint (closest to 12 weeks),NA,Key Math,NA,NA,NA Egeland,2013 NA RCT,G  33, 34   67,outcomes NA  0.2800000000 -0.210000000, 7.700000e-01 NA NA NA NA,NA,NA NA,NA   0   0,100 100 100 100   0 low low,some,high some TAU,  0,NA 10.500000 NA,F-90 ICD-10 0,1 1.0 1.0 1.0,1.0,1,1 1 1 1 1 1,0.5,0 1 1 1, 518 Egeland_2013,NA,NA,6-12 yo,8.4 11.59 NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
3836,Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0 100,100 High Cognitive training NA   0,NA,Academic/job performance NA,At study endpoint (closest to 12 weeks) NA,LOGOS Reading Fluency NA,NA,NA,Egeland 2013,NA,RCT,G  33  34   67 outcomes,NA, 0.4500000000,-0.040000000  9.400000e-01 NA NA,NA NA,NA NA,NA NA,  0,  0 100 100 100,100   0,low,low some high some,TAU   0,NA,10.500000 NA F-90 ICD-10,0,1 1.0,1.0,1.0,1.0 1,1,1,1,1,1,1 0.5 0,1 1 1  519,Egeland_2013,NA NA,6-12 yo 8.4 11.59 NA,NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
3836,Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0,100,100 High,Cognitive training,NA   0,NA,Academic/job performance,NA At study endpoint (closest to 12 weeks) NA,LOGOS Word Decoding Quality NA NA,NA,Egeland,2013 NA,RCT G  33  34,  67,outcomes NA  0.5600000000, 0.070000000, 1.050000e+00 NA,NA NA,NA NA,NA NA NA   0   0 100 100 100 100,  0 low low,some,high,some,TAU,  0 NA 10.500000 NA F-90 ICD-10,0,1 1.0,1.0,1.0 1.0 1 1,1 1,1 1,1 0.5,0 1 1,1  520 Egeland_2013 NA,NA,6-12 yo 8.4 11.59,NA NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
3836,Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7 100   0,100 100,High,Cognitive training NA,  0 NA,Academic/job performance NA At follow-up (closest to 26 weeks) NA LOGOS Word Decoding Quality NA,NA NA Egeland,2013 NA RCT,G  33, 34   67,NA NA, 0.0600000000 -0.650000000, 7.700000e-01,NA,NA NA NA NA,NA,NA NA   0,  0,100,100 100,100   0 low,low some,high,some,TAU   0 NA 10.500000,NA F-90 ICD-10 0 1,1.0 1.0,1.0,1.0 1,1,1,1,1 1,1,0.5 0 1,1 1  521 Egeland_2013 NA NA,6-12 yo 8.98,11.59,NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low high
3836,Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0 100 100,High,Cognitive training NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA ADHD-RS (DuPaul et al., 1998),NA NA,NA Egeland 2013 NA RCT,G, 33  34   67,NA NA  0.2500000000 -0.240000000, 7.400000e-01 NA,NA,NA,NA NA,NA,NA,NA   0   0 100,100 100,100,  0,low,low,some,high some,TAU,  0 NA 10.500000 NA F-90 ICD-10 0 1 1.0 1.0,1.0 1.0,1,1 1,1 1 1,1,0.5,0 1,1 1  522 Egeland_2013,NA,NA 6-12 yo 6.55,10.6,NA,NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
3836 Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0,100,100,High Cognitive training,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At follow-up (closest to 26 weeks),NA ADHD-RS,NA,NA NA,Egeland 2013 NA RCT G, 33, 34   67,NA,NA, 0.2900000000 -0.180000000, 7.600000e-01 NA NA,NA NA NA NA,NA NA,  0   0,100 100 100,100   0 low,low,some,high,some,TAU   0,NA 10.500000,NA,F-90 ICD-10 0,1 1.0 1.0 1.0 1.0,1,1 1,1,1,1,1 0.5,0 1,1,1, 523 Egeland_2013 NA,NA,6-12 yo,10.5 10.5 NA,NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,low high
3836,Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7,100   0 100,100,High Cognitive training NA   0,NA,Executive functioning (report),NA,At study endpoint (closest to 12 weeks) NA,BRIEF,NA,NA NA Egeland 2013,NA,RCT G  33, 34,  67 NA,NA  0.0700000000,-0.400000000  5.400000e-01 NA NA,NA,NA,NA,NA NA,NA,  0,  0 100 100,100 100,  0 low low some,high,some,TAU   0,NA,10.500000,NA,F-90 ICD-10 0 1 1.0 1.0,1.0 1.0,1 1,1 1,1 1,1,0.5 0,1,1 1  524,Egeland_2013,NA,NA,6-12 yo,10.02 12.41,NA,NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
3836,Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0 100,100,High Cognitive training NA   0,NA,Executive functioning (report),NA At follow-up (closest to 26 weeks) NA BRIEF,NA,NA,NA,Egeland 2013 NA RCT,G  33  34   67 NA,NA  0.1700000000 -0.309313098  6.400000e-01,NA,NA,NA,NA NA NA,NA NA   0,  0,100 100,100,100,  0 low,low some high some TAU   0,NA,10.500000 NA F-90 ICD-10 0,1 1.0,1.0 1.0,1.0 1 1,1,1,1,1 1 0.5 0 1,1,1  525 Egeland_2013 NA NA 6-12 yo 10.02,12.41 NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,low,high
3836 Westwood - Children (2024),Westwood - Children 2024,10.1038/s41380-023-02000-7,100,  0 100,100 High,Cognitive training,NA   0 NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA,Conners' CPT-II,NA,NA,NA Egeland,2013,NA,RCT,G, 33  34,  67 outcomes NA -0.1400000000 -0.610000000  3.300000e-01,NA,NA NA,NA,NA,NA,NA NA   0   0 100 100 100 100   0,low,low some high,some,TAU   0,NA,10.500000 NA,F-90 ICD-10 0,1 1.0 1.0,1.0 1.0 1,1,1 1 1,1 1 0.5,0,1 1,1  526 Egeland_2013,NA NA,6-12 yo 6.55,12.41,NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
3836,Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7 100   0,100,100,High Cognitive training NA   0 NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA Conners’ CPT-II,NA NA NA,Egeland,2013 NA,RCT G  33  34,  67,outcomes NA, 0.3400000000,-0.130000000, 8.100000e-01,NA,NA,NA,NA,NA,NA NA NA   0   0 100,100 100,100,  0 low low some high some,TAU,  0,NA 10.500000 NA,F-90 ICD-10 0 1,1.0,1.0 1.0 1.0 1 1,1 1 1 1 1,0.5,0 1,1 1, 527,Egeland_2013,NA,NA,6-12 yo,6.55 12.41,NA NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
3836,Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0,100,100 High Cognitive training NA,  0 NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA LOGOS Word Decoding Quality NA,NA,NA,Egeland,2013 NA RCT G, 33, 34   67,outcomes,NA, 0.5600000000, 0.070000000  1.050000e+00 NA NA,NA,NA,NA NA,NA NA   0   0 100 100,100 100   0,low low some high,some,TAU   0 NA 10.500000,NA F-90 ICD-10 0 1 1.0,1.0,1.0,1.0 1,1 1,1 1,1 1 0.5,0 1,1 1  528,Egeland_2013 NA,NA 6-12 yo,6.55,12.41 NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
3836 Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0,100 100,High,Cognitive training,NA   0 NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA D-KEFS Color Word Interference Condition Trials, CW Interference Time,NA,NA NA Egeland,2013 NA RCT,G, 33, 34,  67 outcomes,NA -0.0200000000 -0.490000000  4.500000e-01,NA,NA,NA NA NA,NA,NA,NA   0,  0 100 100 100 100   0 low low some high,some,TAU   0 NA 10.500000 NA,F-90 ICD-10,0 1,1.0 1.0,1.0,1.0,1 1,1,1 1 1,1 0.5,0 1,1 1  529 Egeland_2013,NA,NA 6-12 yo 6.55,12.41 NA NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
3836,Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0 100 100,High,Cognitive training,NA   0,NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA TMT (Task 4),NA NA NA,Egeland 2013,NA RCT G  33  34   67 outcomes,NA, 0.0500000000 -0.420000000, 5.200000e-01 NA,NA NA NA NA NA,NA,NA,  0,  0,100 100 100 100   0 low,low,some,high some TAU,  0 NA,10.500000 NA F-90 ICD-10,0 1 1.0,1.0 1.0 1.0,1,1 1 1 1,1,1,0.5 0,1,1,1, 530 Egeland_2013 NA NA 6-12 yo 6.55 12.41,NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
3836 Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7 100,  0 100 100,High,Cognitive training,NA   0 NA,Executive functioning (tests) NA At follow-up (closest to 26 weeks),NA Conners' CPT-II NA NA,NA Egeland 2013 NA RCT,G  33  34   67 outcomes,NA  0.0400000000,-0.570000000  6.500000e-01 NA NA NA NA NA,NA NA,NA,  0   0 100 100 100 100,  0 low low,some,high some,TAU   0 NA 10.500000 NA,F-90 ICD-10 0,1 1.0,1.0 1.0,1.0,1 1 1,1,1,1,1 0.5 0,1 1 1  531 Egeland_2013 NA NA,6-12 yo,8.98 12.41 NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low,high
3836 Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7,100,  0 100 100 High Cognitive training,NA,  0,NA Executive functioning (tests) NA At follow-up (closest to 26 weeks),NA,Conners’ CPT-II,NA NA NA,Egeland,2013 NA RCT,G  33, 34   67,outcomes NA  0.2700000000,-0.200000000, 7.400000e-01,NA,NA NA,NA,NA,NA,NA NA,  0   0,100,100,100,100,  0 low low,some high,some,TAU   0,NA 10.500000 NA F-90 ICD-10,0,1,1.0 1.0,1.0 1.0,1 1 1,1 1,1 1,0.5 0 1,1,1  532 Egeland_2013,NA NA,6-12 yo,8.98 12.41,NA,NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low high
3836 Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7,100   0 100 100,High,Cognitive training NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),NA CPRS NA,NA,NA,Green,2012,NA,RCT G  12  14   26 outcomes NA -0.2100000000 -0.990000000  5.700000e-01,NA,NA,NA,NA,NA NA NA,NA 100,100 100 100 100,100,100,some,low,some low some Non-adaptive   0,NA, 9.750000 NA DSM-IV,0 1,1.0 1.0,1.0 1.0,1 1 1,1,1,1,1 0.5 0,1 1,1, 533,Green_2012 NA NA,6-12 yo 8.4 12.41 NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
3836,Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7,100   0,100,100 High Cognitive training NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA,CPRS,NA,NA NA,Green 2012,NA,RCT G, 12  14   26 outcomes NA,-0.2100000000,-0.990000000, 5.700000e-01 NA NA NA,NA,NA NA NA,NA,100,100 100 100,100 100,100 some low,some,low some Non-adaptive,  0,NA  9.750000,NA,DSM-IV 0,1 1.0 1.0,1.0,1.0 1,1 1,1,1 1 1,0.5 0 1 1 1  534,Green_2012,NA,NA,6-12 yo 8.4 12.41 NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7,100,  0 100,100,High,Cognitive training NA,  0,NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA,WISC-IV Digit Span (Combined Forward/Backward),NA NA NA Green,2012 NA,RCT,G  12, 14   26,NA,NA, 0.3900000000 -0.390000000  1.170000e+00,NA,NA NA NA NA NA NA,NA,100 100,100 100,100,100 100 some,low,some,low some Non-adaptive   0,NA, 9.750000,NA,DSM-IV 0,1 1.0,1.0 1.0,1.0,1,1 1,1,1,1,1 0.5,0 1 1,1  535 Green_2012 NA,NA 6-12 yo,6.55 12.41 NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
3836,Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7,100   0,100,100,High Cognitive training NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA,Conners Rating Scale, 1.15074799    3.7500000,h/week,Hasslinger 2021 NA RCT,G, 50  49,  99 NA NA, 0.1200000000 -0.270000000, 5.100000e-01 NA,NA,NA,NA NA NA,NA NA   0,  0 100,100 100,100,  0,some,low low high,some,TAU,  0 NA 12.410000 NA,ICD-10 0 1 1.0,1.0,1.0,1.0,1 1,1 1 1 1 1,0.5 0 1 1 1  536 Hasslinger_2021,< 2 months,NA 6-12 yo,8.4 12.41 NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
3836,Westwood - Children (2024),Westwood - Children 2024,10.1038/s41380-023-02000-7,100   0,100 100,High,Cognitive training NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks),NA,Conners Rating Scale, 1.15074799    3.7500000 h/week Hasslinger 2021,NA RCT,G, 50  49   99,NA,NA, 0.2000000000,-0.190000000  5.900000e-01 NA,NA,NA,NA,NA NA NA,NA,  0   0,100 100,100,100,  0,some,low,low high,some,TAU,  0,NA 12.410000,NA,ICD-10 0,1 1.0,1.0 1.0 1.0,1,1 1,1 1 1,1,0.5 0,1,1 1, 537,Hasslinger_2021 < 2 months,NA 6-12 yo 8.98 12.41 NA NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low,high
3836 Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7,100   0,100 100 High Cognitive training NA,  0,NA,Executive functioning (report),NA At study endpoint (closest to 12 weeks),NA,BRIEF  1.15074799,   3.7500000,h/week,Hasslinger 2022 NA RCT,G, 48, 48   96,NA,NA  0.1800000000,-0.210000000, 5.700000e-01 NA NA,NA NA,NA,NA,NA NA   0   0,100,100   0 100,  0 some low,high,high some TAU,  0,NA 12.410000,NA ICD-10 0,1 1.0,1.0 1.0,1.0 1 1,1,1 1 1,1,0.5,0 1,1,1  538 Hasslinger_2022,< 2 months,NA 6-12 yo 10.02,12.41,NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
3836,Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100   0 100 100,High Cognitive training,NA   0,NA Executive functioning (report),NA,At follow-up (closest to 26 weeks) NA,BRIEF  1.15074799,   3.7500000,h/week,Hasslinger 2022,NA RCT,G  48, 49   97 NA NA  0.1500000000,-0.240000000, 5.400000e-01 NA NA,NA NA,NA NA,NA,NA,  0,  0 100 100   0,100   0,some,low,high,high some TAU   0,NA,12.410000,NA,ICD-10,0,1 1.0 1.0,1.0 1.0 1 1,1 1 1 1 1 0.5 0,1 1,1, 539,Hasslinger_2022,< 2 months,NA 6-12 yo,10.02 12.41 NA,NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low high
3836,Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7 100,  0 100 100 High Cognitive training,NA   0 NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA,CPT-II, 1.15074799    3.7500000 h/week,Hasslinger 2022,NA,RCT,G, 50, 49,  99,outcomes,NA -0.2200000000 -0.610000000, 1.700000e-01 NA,NA,NA NA,NA,NA NA,NA   0   0,100 100,  0,100   0,some low high high some TAU   0,NA,12.410000 NA,ICD-10,0,1 1.0 1.0 1.0,1.0,1 1 1,1 1 1,1,0.5 0 1 1,1, 540,Hasslinger_2022 < 2 months,NA,6-12 yo,6.55 12.41 NA NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
3836 Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0,100,100 High,Cognitive training NA,  0 NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA Conners' CPT-II, 1.15074799,   3.7500000,h/week,Hasslinger,2022,NA,RCT,G  50  49   99 outcomes NA,-0.1900000000 -0.580000000  2.000000e-01,NA NA,NA NA NA NA,NA NA   0   0,100,100   0 100,  0,some,low high,high,some,TAU,  0 NA,12.410000,NA ICD-10,0 1,1.0,1.0 1.0 1.0 1,1,1,1,1,1,1,0.5 0 1,1,1  541,Hasslinger_2022 < 2 months,NA 6-12 yo 6.55 12.41 NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
3836,Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100   0,100 100 High Cognitive training NA,  0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA,WISC-IV/WAIS-IV Digit Span (Combined Forward/Backward)  1.15074799,   3.7500000 h/week Hasslinger 2022 NA,RCT G, 51, 50, 101 outcomes NA, 0.2800000000  0.010000000, 5.500000e-01 NA,NA,NA,NA NA,NA,NA NA   0,  0 100,100,  0,100   0,some low high,high,some TAU,  0,NA,12.410000,NA ICD-10 0,1,1.0,1.0,1.0 1.0,1 1,1,1,1 1 1 0.5 0 1 1,1  542,Hasslinger_2022,< 2 months,NA 6-12 yo 6.55 12.41 NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
3836,Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7,100,  0,100 100 High,Cognitive training NA,  0,NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA,Block Tapping (Combined Forward/Backward)  1.15074799    3.7500000,h/week Hasslinger 2022 NA,RCT,G, 51  50, 101,outcomes NA  0.5900000000  0.300000000, 8.800000e-01,NA,NA NA,NA NA NA,NA,NA,  0   0 100 100   0 100   0,some,low,high high some,TAU   0,NA 12.410000,NA,ICD-10,0 1 1.0,1.0,1.0,1.0 1,1 1 1,1,1 1 0.5 0,1 1,1  543,Hasslinger_2022 < 2 months,NA,6-12 yo,6.55 12.41 NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
3836,Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0 100,100 High,Cognitive training NA,  0 NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA CPT Hit MRTs  1.15074799,   3.7500000,h/week,Hasslinger 2022,NA,RCT,G, 50, 49,  99 outcomes NA,-0.1200000000,-0.510000000, 2.700000e-01 NA,NA NA,NA NA,NA NA NA,  0   0 100,100,  0 100,  0 some low high,high,some TAU   0,NA 12.410000 NA,ICD-10 0,1,1.0 1.0,1.0 1.0 1 1,1 1,1 1 1,0.5 0 1 1,1, 544 Hasslinger_2022 < 2 months NA,6-12 yo 6.55 12.41,NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0 100 100 High Cognitive training,NA,  0,NA,Executive functioning (tests) NA At follow-up (closest to 26 weeks),NA Conners' CPT-II, 1.15074799,   3.7500000,h/week,Hasslinger 2022 NA RCT G, 50, 49   99 outcomes,NA -0.0300000000 -0.420000000  3.600000e-01,NA NA,NA,NA,NA,NA,NA,NA,  0,  0,100 100,  0 100,  0,some,low,high,high,some TAU   0,NA,12.410000 NA ICD-10 0,1,1.0 1.0,1.0 1.0,1,1 1,1 1,1 1 0.5 0,1 1 1  545 Hasslinger_2022 < 2 months,NA,6-12 yo,8.98,12.41,NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low,high
3836 Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0 100,100,High,Cognitive training,NA   0 NA,Executive functioning (tests),NA At follow-up (closest to 26 weeks) NA,CPT-II  1.15074799,   3.7500000 h/week Hasslinger,2022,NA RCT G, 50, 49   99,outcomes,NA,-0.0300000000,-0.420000000, 3.600000e-01,NA,NA NA NA,NA NA NA NA   0,  0,100,100,  0 100   0 some,low high,high some TAU,  0,NA,12.410000 NA ICD-10,0,1,1.0 1.0 1.0,1.0,1,1 1,1,1,1,1,0.5 0 1 1 1  546 Hasslinger_2022,< 2 months NA 6-12 yo 8.98,12.41,NA,NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low,high
3836 Westwood - Children (2024),Westwood - Children 2024,10.1038/s41380-023-02000-7 100   0 100 100 High Cognitive training,NA,  0 NA,Executive functioning (tests) NA At follow-up (closest to 26 weeks) NA WISC-IV/WAIS-IV Digit Span (Forward), 1.15074799,   3.7500000,h/week Hasslinger 2022 NA,RCT G, 51  50, 101,outcomes,NA  0.2800000000, 0.010000000  5.500000e-01 NA,NA,NA,NA NA NA NA NA,  0,  0 100 100   0,100,  0 some low high,high some TAU,  0,NA 12.410000,NA ICD-10,0,1 1.0,1.0 1.0,1.0,1 1,1,1,1,1 1,0.5,0 1 1 1  547,Hasslinger_2022,< 2 months,NA 6-12 yo 8.98,12.41 NA NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low high
3836 Westwood - Children (2024),Westwood - Children 2024,10.1038/s41380-023-02000-7 100,  0,100,100 High Cognitive training NA   0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA WISC-IV Digit Span Forward & Backward NA NA NA,Hovik,2013,NA RCT,G  33, 34,  67,NA NA  0.6000000000, 0.110000000  1.090000e+00,NA NA,NA NA NA,NA NA NA   0   0,100,100,100,100   0 low low,some,high some TAU,  0 NA 10.500000 NA F-90 ICD-10,0 1 1.0 1.0,1.0 1.0 1,1 1 1,1 1,1,0.5 0,1 1,1, 548 Hovik_2013 NA NA 6-12 yo 6.55,12.41,NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
3836 Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100   0,100,100 High,Cognitive training NA,  0,NA,Executive functioning (tests),NA At follow-up (closest to 26 weeks) NA WISC-IV Digit Span Forward & Backward,NA NA NA Hovik,2013 NA RCT,G, 33  34,  67,NA,NA  0.4800000000,-0.010000000, 9.700000e-01,NA,NA NA NA NA NA NA NA,  0,  0 100,100 100 100   0,low,low,some,high,some TAU,  0,NA,10.500000,NA,F-90 ICD-10 0 1,1.0 1.0 1.0 1.0,1 1,1,1 1,1 1,0.5 0 1 1 1, 549,Hovik_2013,NA,NA,6-12 yo,8.98 12.41 NA,NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,low high
3836,Westwood - Adults (2024) Westwood - Adults 2024 10.1038/s41380-023-02000-7 100,  0 100 100 High Cognitive training,NA   0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA WAIS-IV Digit Span (Combined Forward/Backward),NA,NA NA,Jaquerod 2020 NA,RCT,G, 14, 14,  28 NA,NA, 0.1300000000,-0.610000000  8.700000e-01,NA NA NA,NA,NA,NA NA,NA,  0,  0   0,100 100,100,100,high,some low some some Non-adaptive   0 NA 22.200000 NA DSM-IV 0,1,1.0,1.0,1.0,1.0,1,1 1 1 1 1,1,0.5,0 1,1 1, 550,Jaquerod_2020 NA,NA,>= 20 yo,22.2 38.91,NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA,Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,high
3836,Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7,100,  0,100,100 High Cognitive training,NA   0,NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA,GNG, 1.15074799    2.5000000 h/week,Johnstone,2010 NA RCT,G  15  14   29 outcomes,NA,-0.0800000000 -0.810000000  6.500000e-01,NA,NA,NA NA,NA,NA,NA,NA 100,100,100,100   0 100,100,some,low high,low,some,Non-adaptive,  0,NA,10.700000 NA DSM-IV,0,1 1.0 1.0 1.0,1.0,1,1 1 1 1,1 1,0.5,0 1,1 1, 551 Johnstone_2010,< 2 months,NA 6-12 yo 6.55 12.41,NA NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0,100 100,High,Cognitive training NA   0 NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,GNG, 1.15074799,   2.5000000 h/week Johnstone 2010 NA,RCT G  15  14   29,outcomes,NA, 0.2100000000 -0.520000000  9.400000e-01 NA,NA NA,NA,NA NA NA,NA 100 100,100 100   0,100,100,some,low,high low some Non-adaptive   0 NA 10.700000,NA,DSM-IV 0 1 1.0,1.0 1.0 1.0,1 1,1,1 1,1 1 0.5,0 1 1,1  552,Johnstone_2010 < 2 months NA,6-12 yo 6.55,12.41 NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3836,Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100   0,100,100 High Cognitive training,NA,  0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA,GNG, Go MRTs, 1.15074799,   2.5000000 h/week Johnstone 2010,NA RCT G, 15, 14   29 outcomes,NA,-0.3700000000,-1.110000000  3.700000e-01,NA NA NA,NA NA NA,NA,NA 100 100 100 100,  0,100,100,some low high,low,some Non-adaptive,  0,NA 10.700000,NA DSM-IV 0 1 1.0,1.0 1.0,1.0 1 1 1,1,1 1,1,0.5,0,1,1 1  553,Johnstone_2010,< 2 months,NA,6-12 yo 6.55 12.41 NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
3836,Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0 100,100 High,Cognitive training NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks) NA Conners Rating Scale,NA NA,NA Klingberg,2005,NA RCT G  26  27   53,outcomes,NA, 0.2000000000,-0.390000000  7.900000e-01 NA NA NA,NA,NA NA,NA NA 100,100 100,100   0 100 100 low,low,high low some,Non-adaptive,  0,NA  9.900000 NA,DSM-IV,0,1,1.0,1.0,1.0 1.0 1,1 1 1,1,1,1 0.5 0 1 1 1  554 Klingberg_2005 NA,NA,6-12 yo 6.55 10.6,NA NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3836,Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0 100 100 High,Cognitive training,NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA,Conners Rating Scale,NA,NA NA,Klingberg 2005,NA RCT G  26  27,  53,outcomes NA  0.5500000000,-0.040000000, 1.140000e+00 NA NA NA NA,NA NA NA NA 100 100 100,100   0,100 100,low,low high,low some Non-adaptive,  0 NA  9.900000 NA DSM-IV,0 1 1.0 1.0,1.0 1.0,1,1 1,1 1,1,1,0.5 0,1 1,1, 555 Klingberg_2005,NA,NA,6-12 yo 8.4 12.41,NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0,100,100 High,Cognitive training NA,  0,NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,Raven's Matrix NA NA,NA,Klingberg,2005,NA,RCT,G  20  24,  44,outcomes NA, 0.2300000000,-0.360000000, 8.200000e-01 NA NA,NA NA NA NA,NA NA,100 100,100 100   0 100 100,low,low,high,low some,Non-adaptive,  0 NA  9.900000,NA,DSM-IV 0 1,1.0,1.0,1.0,1.0 1 1 1 1,1 1 1,0.5,0 1,1 1  556 Klingberg_2005 NA,NA,6-12 yo 6.55,12.41,NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
3836,Westwood - Children (2024),Westwood - Children 2024,10.1038/s41380-023-02000-7 100   0 100,100,High,Cognitive training NA,  0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,Digit Span (Combined Forward/Backward) NA NA NA,Klingberg 2005 NA RCT,G, 20  24   44 outcomes NA, 0.5700000000 -0.040000000  1.180000e+00 NA NA,NA,NA,NA NA NA,NA,100,100 100 100,  0,100,100 low low,high low,some,Non-adaptive   0 NA, 9.900000 NA DSM-IV 0 1,1.0 1.0 1.0 1.0 1 1,1 1 1 1,1 0.5,0,1 1 1  557 Klingberg_2005 NA,NA,6-12 yo 6.55 12.41 NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
3836 Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100   0,100,100,High Cognitive training NA,  0,NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,Span-Board (Combined Forward/Backward) NA,NA,NA Klingberg,2005,NA RCT,G  20, 24,  44,outcomes,NA  0.7800000000, 0.170000000  1.390000e+00,NA NA NA NA NA,NA,NA NA,100 100 100 100,  0 100,100 low,low,high low some Non-adaptive,  0,NA, 9.900000,NA,DSM-IV,0 1,1.0 1.0 1.0,1.0,1 1,1,1 1,1,1,0.5 0,1 1 1, 558 Klingberg_2005 NA NA,6-12 yo,6.55,12.41 NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3836,Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7,100,  0,100 100,High,Cognitive training,NA,  0 NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,Stroop Task Incongruent Trials, Accuracy,NA,NA,NA Klingberg,2005,NA RCT G, 20, 23,  43,outcomes NA  0.4800000000 -0.130000000, 1.090000e+00 NA,NA NA,NA,NA NA NA,NA 100,100,100 100,  0 100,100,low low high low,some,Non-adaptive,  0 NA  9.900000,NA DSM-IV,0,1,1.0 1.0,1.0,1.0,1,1 1 1 1,1 1 0.5,0 1 1,1  559,Klingberg_2005,NA NA 6-12 yo,6.55 12.41 NA NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3836 Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7 100   0 100 100 High Cognitive training NA,  0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA,Digit Span (Forward & Backward),NA,NA,NA,Klingberg,2005,NA,RCT G, 18, 23   41,outcomes NA, 0.5200000000 -0.110000000  1.150000e+00,NA NA,NA NA NA NA NA NA 100 100,100 100   0,100,100,low low high low some,Non-adaptive,  0,NA  9.900000 NA,DSM-IV 0 1,1.0,1.0 1.0,1.0,1 1 1 1,1,1 1,0.5,0 1 1,1, 560 Klingberg_2005 NA NA,6-12 yo 6.55 12.41 NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
3836 Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7,100,  0 100 100 High,Cognitive training NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks) NA,CRS-R  0.92059839,   1.2500000 h/week,Meyer,2020 NA,RCT,G  20  20   40,outcomes NA  0.0600000000,-0.370000000  4.900000e-01,NA,NA NA NA NA NA,NA NA,  0   0   0,100,100,100 100 high,low,low,low,some,Non-adaptive,  0 NA 10.330000 NA,DSM-IV --> "Confirmation of ADHD diagnosis was performed using the DISC-IV",0 1,1.0,1.0 1.0 1.0,1,1,1,1 1,1 1 0.5,0,1,1,1, 561 Meyer_2020 < 2 months,NA 6-12 yo,6.55 10.6,NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
3836,Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7,100   0 100,100,High Cognitive training,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA SNAP-IV, 0.92059839,   1.2500000,h/week,Meyer 2020 NA,RCT,G, 20  20,  40 outcomes,NA, 0.4100000000 -0.020000000  8.400000e-01,NA NA,NA,NA,NA NA NA,NA   0,  0,  0 100,100 100,100,high low low,low,some Non-adaptive   0 NA 10.330000 NA,DSM-IV --> "Confirmation of ADHD diagnosis was performed using the DISC-IV",0,1,1.0,1.0 1.0 1.0 1,1,1,1 1 1 1 0.5 0,1,1 1  562,Meyer_2020 < 2 months,NA,6-12 yo,8.4,12.41 NA NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
3836 Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100   0,100,100,High,Cognitive training,NA,  0,NA,Academic/job performance,NA At follow-up (closest to 26 weeks) NA WIAT-II Reading Comprehension, 1.15074799,   3.1250000 h/week,Rivard (Dentz 2020a),2020 NA RCT,G, 17, 14,  31,NA,NA, 0.2500000000 -0.300000000  8.000000e-01,NA,NA NA,NA NA NA,NA NA 100 100 100 100,  0,100,100 low,low,high low,some Non-adaptive   0,NA,10.000000,NA,DSM-IV,0 1,1.0,1.0 1.0,1.0,1 1,1 1,1 1,1 0.5 0 1,1,1  563,Rivard (Dentz 2020a)_2020 < 2 months NA,6-12 yo 8.98,11.59,NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low low
3836 Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7,100,  0 100,100 High,Cognitive training,NA   0,NA,Executive functioning (tests) NA,At follow-up (closest to 26 weeks),NA,CPT, 1.15074799,   3.1250000 h/week,Rivard (Dentz 2020a) 2020 NA,RCT G, 17, 14   31,outcomes NA, 0.1500000000 -0.560000000, 8.600000e-01 NA NA,NA,NA NA,NA NA,NA,100 100 100 100,  0 100,100 low low,high low some,Non-adaptive,  0 NA 10.000000,NA,DSM-IV,0,1 1.0,1.0 1.0,1.0 1,1,1 1 1,1 1,0.5,0 1,1,1  564 Rivard (Dentz 2020a)_2020 < 2 months NA,6-12 yo,8.98,12.41,NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,low,low
3836 Westwood - Children (2024),Westwood - Children 2024,10.1038/s41380-023-02000-7 100   0,100,100,High,Cognitive training,NA   0 NA,Executive functioning (tests) NA At follow-up (closest to 26 weeks) NA,WISC-IV Digit Span Forward & Backward Combined, 1.15074799    3.1250000,h/week Rivard (Dentz 2020a),2020 NA RCT G  17, 14   31 outcomes NA, 0.1400000000 -0.510000000, 7.900000e-01 NA NA,NA,NA NA NA NA,NA 100 100,100,100   0,100 100 low low high low some Non-adaptive,  0 NA,10.000000,NA DSM-IV 0,1,1.0,1.0 1.0 1.0,1 1,1 1,1 1 1,0.5,0 1 1,1  565,Rivard (Dentz 2020a)_2020,< 2 months NA 6-12 yo,8.98,12.41,NA NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,low,low
3836,Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0 100,100,High Cognitive training,NA,  0,NA Executive functioning (tests),NA At follow-up (closest to 26 weeks) NA,CPT - Oms, 1.15074799,   3.1250000,h/week Rivard (Dentz 2020a) 2020,NA,RCT G  17  19   36,outcomes,NA, 0.4600000000,-0.250000000  1.170000e+00,NA,NA NA,NA NA NA NA NA 100 100,100,100,  0 100,100,low,low,high low some,Non-adaptive,  0,NA,10.000000,NA,DSM-IV,0 1,1.0 1.0,1.0 1.0,1,1,1,1,1 1,1,0.5 0 1,1 1, 566,Rivard (Dentz 2020a)_2020,< 2 months,NA 6-12 yo 8.98 12.41 NA,NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low low
3836 Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7,100,  0 100 100 High,Cognitive training NA   0 NA,Executive functioning (tests) NA At follow-up (closest to 26 weeks),NA Conners' CPT-II - Coms, 1.15074799    3.1250000,h/week,Rivard (Dentz 2020a) 2020,NA,RCT G, 17, 14,  31,outcomes,NA  0.4600000000 -0.250000000, 1.170000e+00 NA NA,NA,NA NA NA,NA NA 100,100,100 100   0,100 100 low low,high,low,some,Non-adaptive   0,NA 10.000000,NA,DSM-IV,0 1,1.0 1.0,1.0,1.0 1 1 1,1 1 1 1 0.5,0,1,1,1  567,Rivard (Dentz 2020a)_2020,< 2 months NA 6-12 yo,8.98 12.41 NA NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no low,low
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7 100,  0,100,100 High,Cognitive training,NA   0 NA Academic/job performance NA,At study endpoint (closest to 12 weeks),NA WIAT-III Math  2.30149597,   1.7500000,h/week,Sandberg 2021 NA RCT,G  20  20   40,outcomes,NA,-0.1300000000,-0.760000000  5.000000e-01 NA NA NA,NA,NA NA NA NA,  0   0 100 100 100 100   0 some low,low,high,some,WLC   0 NA 11.590000,NA DSM-V 0,1 1.0,1.0,1.0 1.0,1,1 1 1 1,1,1,0.5 0 1 1 1, 568,Sandberg_2021,2-6 months NA,6-12 yo,8.4,11.59 NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
3836 Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7,100,  0 100 100,High Cognitive training,NA,  0 NA Academic/job performance,NA,At study endpoint (closest to 12 weeks) NA,WIAT - Reading Comprehension  2.30149597    1.7500000,h/week,Sandberg,2021 NA RCT,G, 20, 20   40,outcomes NA, 0.0300000000 -0.600000000  6.600000e-01 NA NA,NA,NA,NA NA,NA NA,  0,  0,100 100 100,100,  0 some,low,low high some WLC   0 NA,11.590000,NA,DSM-V,0,1 1.0,1.0,1.0,1.0,1 1,1 1,1 1 1,0.5 0 1,1 1, 569 Sandberg_2021 2-6 months,NA,6-12 yo,8.4 11.59,NA NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
3836,Westwood - Children (2024),Westwood - Children 2024,10.1038/s41380-023-02000-7,100,  0 100 100,High,Cognitive training NA,  0 NA,Academic/job performance NA,At study endpoint (closest to 12 weeks) NA WIAT - Reading Fluency  2.30149597,   1.7500000,h/week,Sandberg,2021 NA,RCT G, 25  25   50,outcomes,NA, 0.3100000000 -0.320000000  9.400000e-01,NA,NA,NA NA,NA,NA,NA NA,  0,  0 100,100,100 100,  0 some,low low high some,WLC   0 NA,11.590000 NA DSM-V,0 1 1.0,1.0 1.0,1.0 1 1 1 1,1 1,1,0.5 0,1 1 1  570,Sandberg_2021,2-6 months NA,6-12 yo,8.4,11.59 NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
3836,Westwood - Children (2024),Westwood - Children 2024,10.1038/s41380-023-02000-7,100,  0 100 100 High,Cognitive training,NA   0 NA,Academic/job performance,NA,At follow-up (closest to 26 weeks) NA WIAT - Reading Comprehension, 2.30149597    1.7500000,h/week,Sandberg 2021,NA RCT G  20  20   40,NA,NA, 0.6300000000  0.140000000, 1.120000e+00 NA NA NA,NA,NA NA NA NA   0   0 100,100 100 100,  0 some low low high some WLC   0,NA,11.590000,NA DSM-V,0,1 1.0,1.0 1.0 1.0,1,1 1,1 1,1 1,0.5,0 1 1 1  571 Sandberg_2021 2-6 months NA 6-12 yo,8.98,11.59 NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low,high
3836,Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100   0 100,100,High Cognitive training,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA,CBCL, 2.30149597,   1.7500000,h/week,Sandberg 2021 NA,RCT G  20, 20   40,NA,NA, 0.1800000000,-0.450000000, 8.100000e-01,NA NA,NA NA,NA NA NA,NA,  0,  0 100 100,100 100,  0,some low low,high,some,WLC,  0 NA 11.590000,NA DSM-V,0 1 1.0 1.0,1.0 1.0 1,1,1 1 1 1,1 0.5 0 1,1,1, 572,Sandberg_2021 2-6 months,NA 6-12 yo 8.4,12.41,NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0 100,100,High,Cognitive training,NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks) NA,CBCL - ADHD Total, 2.30149597,   1.7500000 h/week Sandberg,2021 NA RCT G, 20  20,  40 NA NA, 0.6000000000,-0.030000000, 1.230000e+00,NA NA NA NA NA NA NA NA,  0,  0,100,100,100,100,  0 some low,low,high,some WLC,  0,NA,11.590000,NA,DSM-V,0,1 1.0,1.0,1.0,1.0,1,1 1 1 1 1,1 0.5 0 1,1 1  573,Sandberg_2021 2-6 months NA,6-12 yo 8.98 12.41 NA,NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low,high
3836 Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0 100,100,High Cognitive training NA,  0,NA Executive functioning (report),Parent-rated,At study endpoint (closest to 12 weeks) NA,BRIEF, 2.30149597,   1.7500000,h/week,Sandberg 2021 NA RCT G  20, 20,  40 NA,NA, 0.2600000000 -0.370000000  8.900000e-01 NA NA,NA NA NA,NA,NA,NA,  0   0 100 100,100,100,  0 some low low high some WLC,  0,NA 11.590000,NA DSM-V 0 1 1.0,1.0,1.0 1.0 1 1,1,1,1 1,1,0.5,0 1 1 1, 574 Sandberg_2021,2-6 months NA 6-12 yo,6.55,11.59 NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
3836 Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0 100 100,High,Cognitive training,NA,  0,NA,Executive functioning (report),Parent-rated At follow-up (closest to 26 weeks) NA BRIEF  2.30149597    1.7500000 h/week Sandberg,2021 NA RCT,G  20  20   40 NA NA, 0.7000000000, 0.050000000, 1.350000e+00,NA NA NA NA NA NA,NA,NA,  0   0,100,100,100 100,  0 some,low,low,high,some WLC   0 NA 11.590000 NA,DSM-V 0,1 1.0 1.0,1.0,1.0,1 1,1 1,1,1 1,0.5 0,1,1 1, 575,Sandberg_2021,2-6 months,NA 6-12 yo 8.98,11.59 NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low,high
3836,Westwood - Children (2024),Westwood - Children,2024 10.1038/s41380-023-02000-7 100,  0,100,100,High,Cognitive training,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA BOSS, 4.60299194    1.5000000,h/week,Steiner 2014 NA,RCT G  34  36,  70,NA NA, 0.0700000000 -0.260000000, 4.000000e-01 NA NA,NA,NA,NA,NA NA,NA,100 100 100 100,100 100,100,low low some,some,some WLC,  0 NA, 8.650000 NA,DSM-IV 0 1,1.0 1.0 1.0,1.0,1 1 1 1,1,1 1,0.5 0,1,1,1  576 Steiner_2014 2-6 months NA,6-12 yo 6.55,8.65,NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
3836 Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100,  0,100,100 High Cognitive training NA,  0 NA Executive functioning (report),Parent-rated,At study endpoint (closest to 12 weeks) NA,BRIEF, 4.60299194    1.5000000 h/week,Steiner,2014 NA RCT G  34  36,  70,NA,NA  0.0600000000,-0.410000000, 5.300000e-01,NA,NA,NA NA NA,NA NA,NA,100,100,100 100,100,100,100,low low some,some,some WLC,  0 NA, 8.650000 NA,DSM-IV,0 1 1.0 1.0 1.0 1.0,1,1,1,1 1,1,1 0.5,0 1,1,1, 577 Steiner_2014,2-6 months NA,6-12 yo 6.55 11.59,NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
3836 Westwood - Adults (2024),Westwood - Adults 2024,10.1038/s41380-023-02000-7,100,  0,100 100 High,Cognitive training NA   0,NA,Executive functioning (report),Self-rated At study endpoint (closest to 12 weeks),NA,BRIEF,NA NA h/week Stern,2016 NA,RCT G  26, 13   39 NA NA -0.0500000000,-0.720000000  6.200000e-01,NA,NA NA,NA NA,NA,NA,NA,  0   0,100   0,  0,100,  0,low,high high,high some Non-adaptive   0,NA 37.200000 NA DSM-IV-TR 0,1,1.0,1.0,1.0,1.0 1 1,1 1,1 1 1 0.5 0,1,1 1  578 Stern_2016,NA NA >= 20 yo,37.2 37.2,NA NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA Westwood - Adults (2024)_Cognitive training_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Adults (2024) - Cognitive training_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low high
3836 Westwood - Adults (2024) Westwood - Adults 2024,10.1038/s41380-023-02000-7,100   0,100 100 High Cognitive training,NA   0 NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA GNG - Coms,NA,NA h/week,Stern 2016 NA,RCT G, 26, 13   39,outcomes NA -0.3900000000 -1.060000000  2.800000e-01,NA,NA,NA,NA,NA,NA NA NA   0   0,100,  0   0 100   0 low,high high,high,some,Non-adaptive   0,NA,37.200000 NA DSM-IV-TR 0 1 1.0,1.0,1.0 1.0 1 1 1,1 1,1 1,0.5,0,1,1,1  579,Stern_2016 NA,NA >= 20 yo 22.2 38.91 NA NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low high
3836 Westwood - Adults (2024),Westwood - Adults,2024,10.1038/s41380-023-02000-7,100,  0,100 100,High,Cognitive training,NA,  0,NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA,IntegNeuro - Digit Span (Combined
Forward/Backward) NA NA h/week Stern,2016 NA RCT,G  26  13   39 outcomes NA, 0.1100000000 -0.630000000, 8.500000e-01 NA,NA,NA,NA NA,NA NA NA,  0,  0,100   0   0,100   0 low high,high,high,some,Non-adaptive   0,NA 37.200000 NA DSM-IV-TR,0,1 1.0 1.0,1.0 1.0 1,1 1 1 1 1 1,0.5 0,1,1,1, 580,Stern_2016 NA,NA >= 20 yo,22.2 38.91 NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,high
3836 Westwood - Adults (2024),Westwood - Adults,2024 10.1038/s41380-023-02000-7,100,  0,100,100 High,Cognitive training,NA   0 NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,GNG - Oms,NA,NA,h/week,Stern 2016,NA,RCT G  26, 13   39,outcomes NA  0.3900000000 -0.280000000  1.060000e+00 NA,NA NA NA,NA,NA NA,NA,  0   0 100   0   0,100,  0,low high high,high,some,Non-adaptive   0,NA 37.200000 NA DSM-IV-TR 0,1,1.0,1.0 1.0,1.0 1 1,1 1 1 1,1,0.5 0 1,1,1  581,Stern_2016 NA,NA,>= 20 yo 22.2,38.91 NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA,Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low high
3836 Westwood - Adults (2024),Westwood - Adults,2024,10.1038/s41380-023-02000-7 100   0 100 100 High,Cognitive training,NA   0 NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,IntegNeuro - Choice RT, MRT,NA NA,h/week Stern,2016 NA,RCT G  23  10   33 outcomes NA -1.0000000000,-1.780000000 -2.200000e-01,NA,NA NA,NA,NA,NA,NA NA,  0,  0,100   0,  0,100   0 low,high,high,high,some,Non-adaptive   0 NA,37.200000 NA DSM-IV-TR,0 1 1.0 1.0 1.0,1.0,1 1,1 1,1 1,1 0.5 0,1,1 1  582,Stern_2016 NA NA,>= 20 yo,22.2,38.91 NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA,Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low high
3836 Westwood - Adults (2024),Westwood - Adults 2024,10.1038/s41380-023-02000-7,100,  0,100 100 High Cognitive training,NA   0,NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,IntegNeuro - Switching of Attention NA,NA h/week,Stern,2016,NA RCT G  26  13,  39,outcomes NA  0.6900000000  0.000000000  1.380000e+00 NA NA NA,NA,NA NA,NA NA   0   0 100   0,  0 100,  0,low,high,high,high,some Non-adaptive,  0 NA 37.200000,NA DSM-IV-TR,0,1 1.0,1.0,1.0 1.0 1 1 1 1,1 1,1 0.5,0,1,1,1, 583,Stern_2016,NA,NA,>= 20 yo,22.2 38.91 NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,high
3836 Westwood - Children (2024) Westwood - Children,2024 10.1038/s41380-023-02000-7,100   0,100,100,High,Cognitive training,NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),NA,DBDRS NA,   1.2500000 h/week van da oord 2014,NA RCT G  18, 22,  40,NA,NA  0.9500000000, 0.480000000  1.420000e+00,NA,NA NA,NA,NA NA NA NA,  0,  0 100 100,100,100,  0 low,low some high,some WLC,  0,NA  9.790000 NA DSM-IV,0 1,1.0,1.0,1.0,1.0 1 1,1 1 1 1 1,0.5,0,1 1 1  584,van da oord_2014 NA,NA,6-12 yo 8.4 12.41,NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
3836 Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7,100   0 100,100 High Cognitive training NA   0 NA,Executive functioning (report) Parent-rated,At study endpoint (closest to 12 weeks),NA BRIEF,NA    1.2500000 h/week,van da oord 2014,NA RCT G  18  22   40 NA NA  0.5600000000,-0.070000000  1.190000e+00 NA,NA NA NA NA,NA,NA NA   0,  0,100 100 100 100   0 low,low,some high some,WLC,  0 NA, 9.790000,NA,DSM-IV,0 1 1.0 1.0,1.0 1.0 1,1 1 1 1 1 1 0.5,0,1,1,1  585,van da oord_2014,NA,NA,6-12 yo,6.55 11.59 NA,NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
3836 Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7,100   0 100,100,High,Cognitive training NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks) NA ADHD-RS  1.15074799,   1.2500000 h/week van Dongen-Boomsma 2014 NA,RCT,G  18, 14,  32,NA NA,-0.0100000000,-0.724795360  7.047954e-01,NA NA NA,NA NA NA NA,NA 100 100 100,100,100,100 100,low low some,low,some,Non-adaptive   0,NA, 6.550000,NA,DSM-IV-TR,0,1,1.0 1.0,1.0,1.0,1,1 1,1 1 1 1 0.5,0 1 1 1  586,van Dongen-Boomsma_2014 < 2 months,NA 6-12 yo 6.55 10.6 NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3836,Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7 100   0,100 100 High Cognitive training NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA,ADHD-RS, 1.15074799    1.2500000 h/week,van Dongen-Boomsma,2014 NA,RCT,G, 22, 19,  41,NA,NA, 0.2800000000 -0.350000000, 9.100000e-01,NA NA NA NA,NA,NA,NA,NA 100,100 100,100 100,100,100 low low,some low,some Non-adaptive   0 NA  6.550000,NA,DSM-IV-TR,0 1,1.0 1.0,1.0,1.0 1,1,1 1 1,1 1 0.5,0 1 1,1  587 van Dongen-Boomsma_2014,< 2 months NA 6-12 yo,6.55 8.65 NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3836 Westwood - Children (2024) Westwood - Children 2024 10.1038/s41380-023-02000-7,100   0 100,100,High Cognitive training NA,  0,NA,Executive functioning (report) Parent-rated At study endpoint (closest to 12 weeks),NA BRIEF  1.15074799,   1.2500000 h/week van Dongen-Boomsma,2014 NA,RCT,G, 15  16   31,NA,NA,-0.0300000000,-0.740000000, 6.800000e-01,NA,NA,NA NA NA NA NA,NA,100 100 100,100 100,100,100 low,low,some low,some Non-adaptive,  0,NA, 6.550000,NA DSM-IV-TR,0 1,1.0,1.0,1.0 1.0,1,1 1,1 1,1,1,0.5,0 1 1 1  588,van Dongen-Boomsma_2014,< 2 months NA,6-12 yo 6.55 11.59,NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
3836 Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100,  0 100,100,High Cognitive training NA,  0 NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA,Shortened Raven Coloured Progressive Matrices, 1.15074799,   1.2500000,h/week,van Dongen-Boomsma,2014 NA RCT G, 26, 21,  47 outcomes,NA,-0.0800000000,-0.650000000  4.900000e-01,NA NA NA,NA NA NA NA NA,100 100 100 100,100,100 100 low,low,some low some,Non-adaptive,  0 NA, 6.550000,NA DSM-IV-TR,0,1 1.0 1.0,1.0 1.0,1,1,1 1 1,1,1 0.5 0,1 1 1, 589,van Dongen-Boomsma_2014 < 2 months NA,6-12 yo 6.55,12.41,NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
3836,Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7 100   0,100 100 High,Cognitive training NA   0,NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA Knox Cubes LDT (Combined Forward/Backward)  1.15074799,   1.2500000,h/week van Dongen-Boomsma,2014 NA RCT G  26  19   45,outcomes NA, 0.0800000000,-0.330000000  4.900000e-01,NA NA NA NA,NA NA,NA,NA 100,100 100 100 100 100,100,low low some low,some Non-adaptive   0 NA, 6.550000 NA,DSM-IV-TR,0 1,1.0,1.0 1.0,1.0,1 1 1,1 1,1,1 0.5 0 1 1,1, 590,van Dongen-Boomsma_2014 < 2 months NA,6-12 yo 6.55,12.41,NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
3836 Westwood - Children (2024) Westwood - Children 2024,10.1038/s41380-023-02000-7 100,  0,100 100 High,Cognitive training NA   0 NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA,SA-DOTS-02K, 1.15074799,   1.2500000,h/week,van Dongen-Boomsma 2014,NA,RCT G  23  20   43,outcomes,NA  0.2900000000,-0.230000000, 7.900000e-01 NA,NA,NA,NA,NA NA NA,NA,100 100 100,100 100 100 100,low low,some,low,some,Non-adaptive,  0 NA, 6.550000,NA DSM-IV-TR,0 1,1.0,1.0 1.0 1.0,1 1 1,1,1,1 1 0.5,0,1 1,1, 591 van Dongen-Boomsma_2014 < 2 months,NA 6-12 yo 6.55,12.41,NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
3836,Westwood - Children (2024) Westwood - Children,2024,10.1038/s41380-023-02000-7 100   0,100 100,High,Cognitive training NA   0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA Adapted WISC-III Digit Span (Combined Forward/Backward)  1.15074799,   1.2500000,h/week,van Dongen-Boomsma,2014,NA,RCT G, 22, 21,  43,outcomes NA  0.5500000000,-0.140000000, 1.240000e+00,NA,NA NA,NA,NA,NA NA NA 100,100,100,100 100 100,100,low low,some,low some Non-adaptive,  0,NA  6.550000,NA DSM-IV-TR 0,1 1.0 1.0 1.0 1.0,1,1,1 1 1 1,1,0.5,0,1 1,1, 592,van Dongen-Boomsma_2014,< 2 months NA 6-12 yo 6.55 12.41,NA,NA  28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA NA,Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
3836 Westwood - Children (2024),Westwood - Children 2024 10.1038/s41380-023-02000-7 100   0,100,100 High,Cognitive training NA,  0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA Day-Night Stroop Task, Completion Time (Congruent-Incongruent controlling for correct responses)  1.15074799    1.2500000 h/week,van Dongen-Boomsma,2014 NA RCT G, 20  20   40 outcomes NA -0.6100000000,-1.240000000  2.000000e-02 NA NA NA NA NA NA,NA,NA,100 100 100 100,100 100,100,low,low,some low,some Non-adaptive   0,NA  6.550000,NA DSM-IV-TR 0,1 1.0,1.0,1.0 1.0,1,1 1 1 1,1 1 0.5,0,1 1,1  593,van Dongen-Boomsma_2014 < 2 months,NA,6-12 yo,6.55,12.41 NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA,NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
3836 Westwood - Children (2024),Westwood - Children,2024,10.1038/s41380-023-02000-7,100,  0,100 100,High Cognitive training NA   0,NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA SA-DOTS-02K, Hit MRT controlling for N, 1.15074799    1.2500000 h/week,van Dongen-Boomsma,2014 NA,RCT,G  23  20   43,outcomes,NA -0.2800000000 -0.890000000, 3.300000e-01,NA NA,NA NA NA,NA,NA,NA,100 100,100 100 100 100 100 low,low some low,some Non-adaptive,  0,NA, 6.550000,NA,DSM-IV-TR,0,1 1.0 1.0 1.0 1.0 1,1 1,1,1,1 1,0.5,0 1 1 1  594 van Dongen-Boomsma_2014 < 2 months NA,6-12 yo,6.55 12.41 NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 998,Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100   0 100,100 Moderate Neurofeedback,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At follow-up (closest to 26 weeks),NA,ADHD FBB-HKS  2.30149597,   1.6700000,h/week,Aggensteiner,2019,NA RCT,G  65  60, 125 NA,NA  0.2000000000 -0.150000000  5.500000e-01 NA,NA NA NA,NA NA NA,NA   0   0 100,100,100,100,  0 low,low,low,high,some Sham_semi_active,  0 NA, 8.590000 NA,DSM-IV 0,1 0.5,1.0,1.0,1.0 1,1 2 0,1 1,1,0.5,0,1 1,1, 595 Aggensteiner_2019,2-6 months,NA 6-12 yo 8.59,8.59,NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low high
 998,Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0,100 100 Moderate Neurofeedback,NA   0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA CPT, 2.30149597    1.6700000,h/week Aggensteiner 2021,NA RCT G, 40  37   77,outcomes NA -0.2700000000 -0.720000000  1.800000e-01 NA NA NA NA,NA NA,NA NA   0   0,100,100,100,100,  0 low,low,low,high some Sham_semi_active,  0 NA, 8.590000,NA DSM-IV 0 1,0.5,1.0,1.0 1.0 1,1 2 0,1 1,1 0.5 0 1,1 1, 596 Aggensteiner_2021 2-6 months NA,6-12 yo,8.59 16.1 NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100,  0 100 100,Moderate Neurofeedback,NA,  0 NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA,CPT  2.30149597,   1.6700000,h/week Aggensteiner,2021,NA,RCT G, 40  37,  77,outcomes,NA  0.0000000000 -0.450000000  4.500000e-01 NA,NA NA NA,NA,NA NA,NA,  0,  0 100 100 100,100,  0 low low low high some Sham_semi_active,  0,NA, 8.590000,NA,DSM-IV 0 1,0.5 1.0,1.0,1.0,1 1,2 0 1,1 1,0.5,0,1 1,1, 597 Aggensteiner_2021,2-6 months,NA 6-12 yo,8.59,16.1,NA,NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
 998 Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100,  0,100,100,Moderate,Neurofeedback,NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) NA,ADHS -RS  0.46029919,NA h/week Alegria,2017 NA RCT G  18  13,  31 outcomes,NA, 0.2000000000,-0.510000000  9.100000e-01,NA NA NA NA,NA,NA NA,NA,100,100,100 100 100 100 100 low low,low,low,some,Sham_semi_active   0 NA 13.900000,NA,DSM-IV 0,1 0.5,1.0 1.0,1.0 1 1 2 0 1 1,1 0.5,0 1,1 1  598,Alegria_2017,< 2 months NA,13-19 yo,8.57 13.9 NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 998 Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100,  0 100,100,Moderate Neurofeedback NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated Closest to 52 weeks NA,ADHS -RS  0.46029919 NA,h/week Alegria 2017,NA,RCT G, 13, 10,  23 outcomes NA, 0.3900000000 -0.450000000, 1.220000e+00 NA,NA NA,NA,NA NA NA,NA 100 100 100,100,100 100 100,low,low,low low some,Sham_semi_active   0,NA 13.900000,NA,DSM-IV 0 1,0.5 1.0 1.0,1.0,1,1,2 0 1 1,1,0.5 0,1 1 1, 599,Alegria_2017 < 2 months NA 13-19 yo,8.58 13.9,NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,100.00000,no,low low
 998 Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0,100 100,Moderate,Neurofeedback,NA   0 NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA,Continuous Performance Task  0.46029919 NA h/week Alegria 2017 NA RCT,G  18  13   31 outcomes NA,-0.5800000000 -1.310000000, 1.500000e-01,NA,NA,NA,NA NA NA,NA,NA,100,100 100,100,100,100 100,low,low,low low,some,Sham_semi_active   0 NA 13.900000 NA,DSM-IV 0 1 0.5,1.0 1.0,1.0 1 1,2,0 1,1,1 0.5 0,1,1 1  600,Alegria_2017 < 2 months NA 13-19 yo,8.59,16.1,NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 998 Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100,  0,100 100,Moderate,Neurofeedback NA   0 NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA CPT  0.46029919,NA h/week,Alegria 2017 NA RCT,G  18, 13,  31,outcomes,NA, 2.0700000000  1.170000000  2.970000e+00,NA,NA NA NA,NA NA,NA NA 100,100 100,100,100 100,100,low low,low,low some Sham_semi_active,  0 NA 13.900000,NA DSM-IV,0,1 0.5 1.0 1.0,1.0 1,1 2 0,1 1,1 0.5 0 1,1,1, 601 Alegria_2017,< 2 months NA 13-19 yo,8.59,16.1,NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 998 Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100   0 100,100,Moderate Neurofeedback NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),NA Conners 3P  2.99194476    1.7500000 h/week,Arnold 2021 NA RCT G  84, 58  142,NA NA -0.0600000000 -0.297246446, 1.772464e-01,NA,NA,NA,NA,NA NA NA NA,100,100 100 100 100,100 100,low,low,some,low low Sham_semi_active,  0,NA, 8.580000 NA DSM-5,0,1 0.5,1.0 1.0 1.0,1,1,2,0 1 1,1 0.5,0 1 1,1  602,Arnold_2021 2-6 months,NA 6-12 yo,8.57 13.9 NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 998 Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100,  0,100 100,Moderate,Neurofeedback,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) NA SNAP-IV, 3.91254315    1.8800000,h/week,Arnold,2013 NA RCT G  25  11   36,NA NA  0.2600000000,-0.450000000, 9.700000e-01,NA NA NA NA NA,NA,NA,NA,  0   0 100,100,100,100   0,some,low low high,some,Sham_semi_active   0,NA, 8.850000,NA,DSM-IV,0 1 0.5,1.0 1.0,1.0,1,1 2,0,1 1 1,0.5,0,1,1,1  603,Arnold_2013 2-6 months NA,6-12 yo 8.57,13.9 NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
 998 Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0,100,100 Moderate Neurofeedback NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,Closest to 52 weeks NA Conners 3P, 2.99194476,   1.7500000 h/week Arnold 2023,NA RCT,G, 48  50   98 outcomes NA,-0.1000000000 -0.460000000, 2.700000e-01,NA,NA,NA NA NA,NA,NA NA,100 100,100,100 100,100 100 low low some low,low,Sham_semi_active   0 NA  8.580000 NA,DSM-5 0,1 0.5 1.0,1.0,1.0,1,1,2,0,1,1 1 0.5,0 1,1 1, 604,Arnold_2023 2-6 months NA 6-12 yo,8.58 8.58 NA,NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_Closest to 52 weeks 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_Closest to 52 weeks_6-17 yo,100.00000 no,low,low
 998 Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100,  0,100 100 Moderate Neurofeedback,NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated Closest to 52 weeks NA,Conners 3P  2.99194476,   1.7500000,h/week Arnold 2023,NA,RCT G  48, 50   98,outcomes,NA  0.1200000000 -0.237297176  4.772972e-01 NA NA NA NA NA,NA NA NA 100 100,100 100,100 100,100,low low some,low low Sham_semi_active   0 NA  8.580000 NA DSM-5 0,1 0.5 1.0,1.0,1.0 1 1 2,0,1,1 1 0.5 0 1,1 1, 605 Arnold_2023 2-6 months,NA,6-12 yo 8.58 13.9 NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000 no,low low
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100   0,100 100,Moderate,Neurofeedback,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA SNAP-IV, 3.91254315,   1.8800000,h/week Arnold,2013,NA,RCT,G  25, 11   36 NA,NA -0.1900000000 -0.900000000  5.200000e-01,NA,NA NA NA,NA,NA NA,NA   0,  0 100,100 100 100,  0 some,low,low high,some,Sham_semi_active   0,NA, 8.850000 NA,DSM-IV,0 1,0.5,1.0,1.0 1.0,1 1 2 0,1,1,1,0.5,0 1,1 1  606 Arnold_2013 2-6 months NA,6-12 yo 8.58 12.4,NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100,  0 100,100,Moderate Neurofeedback NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA Conners 3P, 2.99194476    1.7500000 h/week,Arnold,2021,NA,RCT,G  84  58, 142,NA,NA  0.1400000000,-0.090000000, 3.772464e-01,NA NA NA NA,NA NA NA,NA 100,100 100,100,100,100,100,low low some,low,low,Sham_semi_active,  0,NA, 8.580000 NA,DSM-5 0,1,0.5,1.0,1.0 1.0,1 1,2,0,1 1,1,0.5 0 1,1 1, 607 Arnold_2021,2-6 months NA 6-12 yo,8.58,12.4,NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 998,Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100,  0 100 100,Moderate Neurofeedback,NA   0,NA,Executive functioning (report) Parent-rated At study endpoint (closest to 12 weeks) NA BRIEF  3.91254315    1.8800000 h/week Arnold 2013 NA,RCT G, 25  11   36,outcomes,NA  0.1700000000 -0.540000000, 8.800000e-01,NA NA,NA NA NA NA NA NA,  0,  0 100 100,100,100   0 some,low,low,high,some,Sham_semi_active,  0,NA  8.850000,NA DSM-IV 0,1 0.5 1.0 1.0,1.0,1 1,2,0 1 1,1,0.5,0 1 1,1, 608 Arnold_2013,2-6 months NA 6-12 yo 8.57 12.4,NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0,100,100 Moderate Neurofeedback NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA FBB-HKS  2.99194476,   1.2500000 h/week Bakhshayesh,2011,NA,RCT,G, 18, 17   35 NA,NA, 0.7600000000  0.070000000  1.450000e+00 NA,NA,NA NA NA NA,NA NA,  0,  0 100,100,100 100,  0 low low low high,some,Sham_semi_active   0,NA, 9.340000,NA,ICD-10,0,1,0.5 1.0,1.0,1.0 1 1 2,0,1 1 1,0.5,0,1,1 1  609,Bakhshayesh_2011,2-6 months,NA,6-12 yo,8.57,13.9 NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
 998,Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100,  0 100 100,Moderate,Neurofeedback NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks) NA,FBB-HKS  2.99194476,   1.2500000,h/week Bakhshayesh 2011,NA RCT,G  18, 17   35 NA NA  0.4000000000,-0.270000000, 1.070000e+00 NA NA,NA NA NA,NA,NA,NA   0   0,100,100 100 100   0,low,low low high some,Sham_semi_active,  0,NA, 9.340000 NA,ICD-10,0 1 0.5 1.0,1.0,1.0 1 1,2 0,1,1 1,0.5 0 1,1,1, 610,Bakhshayesh_2011,2-6 months NA,6-12 yo,8.58 12.4 NA,NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
 998,Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100   0 100 100 Moderate Neurofeedback NA   0 NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA CPT  2.99194476    1.2500000,h/week Bakhshayesh,2011 NA,RCT G, 18  17   35 outcomes,NA  0.5900000000,-0.090000000, 1.270000e+00 NA,NA NA NA,NA,NA,NA,NA   0,  0 100 100,100 100,  0,low,low low high some Sham_semi_active,  0,NA  9.340000 NA,ICD-10 0,1,0.5 1.0,1.0 1.0 1 1,2 0 1,1 1 0.5,0,1 1 1  611 Bakhshayesh_2011 2-6 months,NA,6-12 yo 8.59,16.1,NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
 998 Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0,100 100 Moderate,Neurofeedback,NA   0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA CPT, 2.99194476    1.2500000 h/week,Bakhshayesh,2011,NA,RCT,G, 18  17,  35 outcomes,NA, 0.6400000000,-0.040000000  1.330000e+00,NA NA NA,NA,NA,NA,NA NA,  0,  0 100,100,100,100   0 low low low high,some Sham_semi_active   0 NA, 9.340000,NA,ICD-10,0,1 0.5,1.0 1.0 1.0,1,1,2 0,1,1 1,0.5,0,1,1,1, 612 Bakhshayesh_2011,2-6 months,NA 6-12 yo,8.59,16.1,NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
 998 Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100,  0,100,100,Moderate Neurofeedback NA,  0 NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,CPT, 2.99194476,   1.2500000,h/week,Bakhshayesh 2011 NA,RCT G  18, 17   35,outcomes NA  0.9900000000  0.290000000, 1.700000e+00,NA,NA,NA,NA NA,NA NA,NA,  0,  0 100,100 100,100   0,low low,low,high some,Sham_semi_active   0 NA, 9.340000,NA,ICD-10 0 1 0.5,1.0 1.0,1.0,1,1 2 0 1 1,1,0.5 0 1 1,1, 613 Bakhshayesh_2011 2-6 months,NA,6-12 yo,8.59,16.1,NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
 998 Westwood - Adults (2025),Westwood - Adults 2025,10.1001/jamapsychiatry.2024.3702,100,  0,100,100,Moderate Neurofeedback NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At follow-up (closest to 26 weeks) 4_mprox,ADHD-SB Global  4.14269275,   1.6000000 h/week,Barth 2021 NA NA,G, 21, 20   41,outcomes,NA  0.4900000000  0.050000000  9.300000e-01 NA,NA,NA,NA,NA,NA NA NA   0   0,100,100 100,100,  0 some low low high low,Sham_semi_active   0,NA 33.640000,NA DSM-IV,0 1 0.5 1.0,1.0 1.0 1,1,2,0 1,1 1,0.5 0 1 1 1, 614,Barth_2021,2-6 months NA,>= 20 yo,33.64 33.64 NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA NA,Westwood - Adults (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),1 Homogeneous Westwood - Adults (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no low high
 998 Westwood - Adults (2025) Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702,100   0 100 100 Moderate,Neurofeedback,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) 1_mprox,ADHD-SB Global  4.14269275    1.6000000,h/week,Barth,2021 NA,NA G  21  20,  41 outcomes,NA  0.6800000000  0.040000000  1.310000e+00 NA,NA,NA NA,NA NA NA NA,  0   0,100,100 100 100   0 some low,low,high low Sham_semi_active   0,NA,33.640000 NA DSM-IV,0,1 0.5 1.0 1.0 1.0 1,1 2 0,1,1 1 0.5,0 1 1 1  615,Barth_2021,2-6 months,NA,>= 20 yo,33.64 36.9 NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA Westwood - Adults (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Adults (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low high
 998 Westwood - Adults (2025),Westwood - Adults 2025,10.1001/jamapsychiatry.2024.3702,100   0,100 100 Moderate,Neurofeedback,NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At follow-up (closest to 26 weeks),4_mprox,ADHD-SB Global  4.14269275    1.6000000,h/week Barth,2021 NA NA G, 24  20   44,outcomes,NA,-0.5600000000,-1.160000000  5.000000e-02,NA,NA,NA,NA,NA,NA,NA,NA   0   0,100 100 100,100   0,some low,low,high,low Sham_semi_active   0,NA,33.640000,NA,DSM-IV,0,1,0.5 1.0,1.0,1.0 1 1 2,0 1,1,1 0.5,0,1,1,1  616 Barth_2021 2-6 months NA,>= 20 yo,33.64 33.64,NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA Westwood - Adults (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Westwood - Adults (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no,low high
 998 Westwood - Adults (2025),Westwood - Adults 2025 10.1001/jamapsychiatry.2024.3702 100   0 100 100 Moderate Neurofeedback,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At follow-up (closest to 26 weeks) 1_mprox,ADHD-SB Global, 4.14269275,   1.6000000,h/week Barth 2021,NA,NA,G  26  20   46,outcomes NA -0.1000000000 -0.690000000, 4.900000e-01 NA,NA NA NA NA NA,NA,NA   0,  0 100,100,100 100   0 some low,low,high low Sham_semi_active,  0,NA,33.640000,NA DSM-IV 0,1,0.5 1.0 1.0,1.0,1 1,2 0 1,1,1,0.5,0 1,1 1  617 Barth_2021 2-6 months NA >= 20 yo,33.64 33.64,NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA NA Westwood - Adults (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),1 Homogeneous Westwood - Adults (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no low high
 998,Westwood - Adults (2025) Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702,100   0 100 100 Moderate,Neurofeedback,NA,  0,NA,Executive functioning (tests),Self-rated At study endpoint (closest to 12 weeks),NA,d2-R Accuracy, 4.14269275    1.6000000 h/week Barth,2021 NA,NA,G, 21  20,  41,outcomes NA, 0.1300000000,-0.450000000, 7.200000e-01 NA,NA NA,NA NA,NA NA NA   0,  0 100 100 100 100,  0,some,low,low,high low Sham_semi_active   0,NA 33.640000 NA DSM-IV 0 1 0.5 1.0 1.0,1.0 1,1 2 0,1,1 1 0.5 0 1 1 1, 618 Barth_2021 2-6 months,NA,>= 20 yo,33.64 36.9 NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA,NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,high
 998 Westwood - Adults (2025) Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702,100,  0 100,100,Moderate,Neurofeedback,NA,  0 NA,Executive functioning (tests),Self-rated,At study endpoint (closest to 12 weeks),NA,d2-R Accuracy, 4.14269275    1.6000000,h/week,Barth 2021,NA NA,G  26  20   46 outcomes,NA -0.2300000000 -0.820000000  3.500000e-01 NA NA,NA NA,NA NA NA,NA   0,  0 100 100,100 100,  0,some low low high low Sham_semi_active   0 NA 33.640000 NA DSM-IV,0,1 0.5 1.0,1.0 1.0 1,1,2,0 1,1,1,0.5,0,1,1 1  619,Barth_2021,2-6 months NA,>= 20 yo 33.64 36.9,NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low high
 998,Westwood - Adults (2025) Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702,100,  0 100,100,Moderate Neurofeedback NA,  0,NA Executive functioning (tests),Self-rated,At study endpoint (closest to 12 weeks) NA GNG - False alarms, 4.14269275    1.6000000 h/week,Barth 2021 NA,NA G  21  20   41 outcomes,NA -0.0400000000 -0.650000000, 5.700000e-01,NA,NA NA NA NA NA,NA NA   0,  0 100 100 100 100   0 some,low low high low,Sham_semi_active,  0,NA,33.640000,NA,DSM-IV,0 1,0.5,1.0 1.0 1.0 1,1 2,0 1,1,1,0.5 0,1,1,1, 620 Barth_2021 2-6 months NA,>= 20 yo 33.64,36.9,NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low high
 998 Westwood - Adults (2025),Westwood - Adults 2025,10.1001/jamapsychiatry.2024.3702,100   0,100 100 Moderate,Neurofeedback,NA,  0 NA,Executive functioning (tests),Self-rated,At study endpoint (closest to 12 weeks),NA GNG - False alarms, 4.14269275    1.6000000 h/week Barth 2021 NA,NA G  26, 20   46 outcomes NA,-0.4900000000 -1.080000000, 1.000000e-01 NA NA,NA NA,NA,NA NA,NA,  0,  0,100 100,100,100,  0,some low,low,high low,Sham_semi_active   0,NA 33.640000 NA,DSM-IV 0 1 0.5,1.0,1.0,1.0,1 1 2,0 1 1 1,0.5 0 1 1 1, 621,Barth_2021,2-6 months NA >= 20 yo,33.64,36.9,NA NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low high
 998 Westwood - Adults (2025),Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702 100   0 100 100,Moderate,Neurofeedback NA,  0,NA Executive functioning (tests),Self-rated At study endpoint (closest to 12 weeks),NA n-back Composite Combined 1-back & 2-back  4.14269275,   1.6000000,h/week Barth,2021 NA,NA,G  21, 20   41 outcomes,NA, 0.0400000000 -0.390000000  4.800000e-01,NA,NA NA NA NA NA NA NA   0   0 100 100 100,100   0,some low,low,high low Sham_semi_active,  0,NA,33.640000 NA,DSM-IV 0 1 0.5 1.0 1.0,1.0,1,1,2 0,1 1 1 0.5 0 1 1,1  622,Barth_2021 2-6 months NA,>= 20 yo,33.64,36.9,NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low high
 998,Westwood - Adults (2025),Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702 100   0,100 100 Moderate Neurofeedback,NA   0 NA Executive functioning (tests),Self-rated At study endpoint (closest to 12 weeks),NA n-back Composite Combined 1-back & 2-back  4.14269275,   1.6000000 h/week Barth,2021 NA,NA,G, 26, 20   46,outcomes NA  0.0900000000,-0.520000000, 3.300000e-01 NA NA,NA NA,NA,NA NA NA   0   0,100,100,100,100   0,some,low low,high,low,Sham_semi_active   0,NA,33.640000,NA,DSM-IV,0,1,0.5 1.0 1.0,1.0 1 1 2 0 1 1 1 0.5,0 1 1,1, 623,Barth_2021 2-6 months,NA,>= 20 yo,33.64,36.9 NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,high
 998 Westwood - Adults (2025),Westwood - Adults 2025 10.1001/jamapsychiatry.2024.3702,100   0,100,100,Moderate Neurofeedback NA   0,NA,Executive functioning (tests),Self-rated At study endpoint (closest to 12 weeks) NA nback Reaction time 0b, 4.14269275    1.6000000 h/week Barth 2021,NA,NA,G  21, 20,  41 outcomes,NA  0.7000000000, 0.070000000, 1.330000e+00,NA NA,NA NA NA,NA,NA,NA   0,  0,100 100,100 100,  0,some,low,low high,low Sham_semi_active   0,NA 33.640000 NA,DSM-IV 0,1 0.5 1.0,1.0 1.0 1,1,2 0 1 1 1,0.5 0 1 1,1  624,Barth_2021,2-6 months,NA,>= 20 yo,33.64 36.9,NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,high
 998 Westwood - Adults (2025) Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702 100,  0 100 100 Moderate Neurofeedback NA,  0,NA,Executive functioning (tests),Self-rated,At study endpoint (closest to 12 weeks) NA nback Reaction time 0b  4.14269275,   1.6000000,h/week,Barth 2021 NA NA,G, 26, 20,  46 outcomes NA, 0.6400000000  0.040000000  1.240000e+00,NA,NA,NA,NA NA,NA,NA NA   0,  0,100 100,100 100,  0 some,low,low,high low,Sham_semi_active,  0,NA 33.640000,NA DSM-IV 0 1 0.5,1.0 1.0,1.0 1 1 2 0,1,1 1,0.5,0,1 1 1  625,Barth_2021,2-6 months NA >= 20 yo,33.64 36.9,NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low high
 998 Westwood - Adults (2025),Westwood - Adults,2025 10.1001/jamapsychiatry.2024.3702 100   0 100,100 Moderate,Neurofeedback NA,  0,NA,Executive functioning (tests) Self-rated,At follow-up (closest to 26 weeks) NA,d2-R Accuracy  4.14269275    1.6000000 h/week,Barth 2021 NA NA G  21  20   41 outcomes,NA  0.4800000000,-0.140000000, 1.100000e+00,NA NA NA NA,NA NA,NA,NA   0   0,100,100,100 100,  0 some low low high low Sham_semi_active,  0,NA,33.640000 NA,DSM-IV 0 1 0.5 1.0 1.0,1.0,1,1 2,0,1,1 1,0.5,0 1 1 1  626,Barth_2021 2-6 months NA,>= 20 yo 33.64,33.64,NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA,NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no,low high
 998 Westwood - Adults (2025) Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702,100   0,100,100 Moderate,Neurofeedback NA,  0 NA Executive functioning (tests),Self-rated,At follow-up (closest to 26 weeks) NA d2-R Accuracy  4.14269275    1.6000000 h/week Barth 2021 NA,NA G, 26  20,  46,outcomes NA,-0.0700000000 -0.650000000  5.100000e-01,NA NA,NA NA,NA,NA NA NA,  0,  0 100,100,100,100,  0,some low,low,high,low Sham_semi_active   0,NA 33.640000 NA,DSM-IV,0 1,0.5,1.0 1.0 1.0 1 1,2,0,1 1 1 0.5,0 1 1 1  627 Barth_2021 2-6 months,NA,>= 20 yo 33.64 33.64 NA NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no low high
 998,Westwood - Adults (2025) Westwood - Adults 2025 10.1001/jamapsychiatry.2024.3702,100   0 100,100 Moderate,Neurofeedback,NA   0,NA,Executive functioning (tests) Self-rated,At follow-up (closest to 26 weeks),NA GNG - False alarms  4.14269275,   1.6000000 h/week Barth,2021,NA NA G, 26, 26   52 outcomes,NA,-0.0100000000 -0.590000000, 5.800000e-01,NA,NA,NA NA NA,NA,NA,NA,  0,  0,100,100,100 100   0 some low,low,high,low Sham_semi_active   0,NA 33.640000 NA,DSM-IV 0,1,0.5,1.0 1.0,1.0,1 1 2,0,1,1 1,0.5,0 1 1 1  628,Barth_2021,2-6 months NA >= 20 yo,33.64 33.64 NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks),1 Homogeneous Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no,low high
 998 Westwood - Adults (2025),Westwood - Adults 2025 10.1001/jamapsychiatry.2024.3702,100   0,100 100 Moderate,Neurofeedback,NA   0 NA,Executive functioning (tests) Self-rated,At follow-up (closest to 26 weeks) NA GNG - False alarms, 4.14269275,   1.6000000,h/week,Barth 2021 NA NA,G, 21, 21,  42,outcomes NA,-0.3600000000 -0.970000000  2.500000e-01,NA,NA,NA NA,NA,NA,NA,NA   0   0,100 100 100,100   0,some low,low,high,low,Sham_semi_active   0 NA 33.640000 NA,DSM-IV,0 1,0.5,1.0,1.0 1.0,1 1 2,0 1 1 1 0.5 0 1,1,1, 629,Barth_2021 2-6 months NA,>= 20 yo,33.64 33.64,NA NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no,low high
 998 Westwood - Adults (2025) Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702 100   0,100 100 Moderate,Neurofeedback,NA   0 NA,Executive functioning (tests) Self-rated,At follow-up (closest to 26 weeks),NA nback Reaction time 0b, 4.14269275,   1.6000000 h/week Barth,2021 NA NA G, 21, 20,  41,outcomes NA  0.5300000000 -0.100000000  1.150000e+00,NA NA,NA,NA,NA,NA NA NA   0   0 100,100,100 100   0 some,low low,high low,Sham_semi_active   0 NA,33.640000 NA,DSM-IV,0 1 0.5 1.0 1.0,1.0,1 1,2,0 1,1,1,0.5,0 1,1 1, 630,Barth_2021 2-6 months,NA,>= 20 yo,33.64,33.64,NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no low high
 998 Westwood - Adults (2025),Westwood - Adults 2025,10.1001/jamapsychiatry.2024.3702,100   0,100 100,Moderate,Neurofeedback NA,  0,NA,Executive functioning (tests) Self-rated,At follow-up (closest to 26 weeks),NA,nback Reaction time 0b, 4.14269275,   1.6000000 h/week Barth 2021,NA,NA G, 26, 20,  46 outcomes NA, 0.2000000000,-0.380000000, 7.900000e-01 NA NA NA,NA,NA,NA NA,NA   0,  0,100,100,100 100,  0,some low,low,high,low,Sham_semi_active,  0 NA,33.640000,NA DSM-IV,0,1 0.5,1.0 1.0 1.0,1,1 2,0,1,1 1,0.5 0,1 1 1  631 Barth_2021,2-6 months NA >= 20 yo,33.64 33.64 NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no,low high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100   0,100,100,Moderate,Neurofeedback,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) NA,DISYPS-II NA,NA h/week Baumeister 2018 NA RCT G   8   7   15 outcomes NA  0.9000000000 -0.288202761, 2.088203e+00 NA NA,NA NA NA,NA NA,NA,100 100 100,100 100,100 100,some,low low low,some,Sham_semi_active   0 NA 11.750000 NA DSM-IV,0 1,0.5,1.0,1.0 1.0 1 1,2 0 1 1,1,0.5,0 1,1 1  632,Baumeister_2018 NA,NA 6-12 yo 8.57 13.9 NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 998,Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100,  0 100,100 Moderate,Neurofeedback,NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA,DISYPS-II NA NA,h/week Baumeister 2018,NA RCT G   8,  7   15,outcomes,NA, 0.9000000000,-0.288202761, 2.088203e+00 NA,NA,NA,NA NA,NA NA NA,100,100 100,100,100 100 100,some low,low,low some Sham_semi_active   0,NA,11.750000 NA,DSM-IV 0,1 0.5 1.0 1.0,1.0 1,1 2,0 1 1,1,0.5 0 1 1 1  633 Baumeister_2018,NA NA 6-12 yo 8.57,13.9 NA,NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 998 Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100   0,100 100 Moderate Neurofeedback NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA,CPRS-R, 2.99194476    3.0000000,h/week Beauregard 2006,NA RCT,G  15   5,  20,NA,NA  1.1700000000, 0.410000000, 1.930000e+00,NA NA NA,NA NA,NA,NA NA   0   0 100 100 100 100   0,some,low,low,high,some WLC   0 NA 10.200000,NA DSM-IV 0 1 0.5,1.0,1.0 1.0,1,1 2,0 1 1 1 0.5,0 1 1 1  634 Beauregard_2006,2-6 months,NA,6-12 yo,8.57,13.9 NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
 998 Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100   0 100 100 Moderate,Neurofeedback NA   0,NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA Digit Span  2.99194476    3.0000000 h/week,Beauregard,2006 NA RCT,G, 15   5,  20 outcomes NA, 0.2100000000 -0.800000000  1.230000e+00,NA NA NA NA NA,NA,NA,NA   0,  0,100 100,100,100,  0 some,low low high some WLC,  0,NA,10.200000,NA,DSM-IV 0 1,0.5 1.0,1.0,1.0,1 1,2,0,1 1 1,0.5,0 1,1,1, 635 Beauregard_2006 2-6 months NA 6-12 yo,8.59,16.1 NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
 998 Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100   0,100 100,Moderate Neurofeedback NA,  0,NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA Go/No-go Task  2.99194476    3.0000000 h/week,Beauregard 2006,NA,RCT G, 15,  5,  20,outcomes NA, 0.4300000000,-0.590000000, 1.460000e+00 NA,NA,NA,NA,NA NA,NA NA   0,  0 100 100,100,100,  0,some low low,high,some,WLC   0 NA 10.200000 NA DSM-IV 0,1 0.5,1.0,1.0,1.0 1 1,2,0 1,1,1,0.5,0 1,1,1, 636,Beauregard_2006,2-6 months,NA,6-12 yo,8.59 16.1 NA,NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100   0 100 100 Moderate Neurofeedback NA,  0,NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA,Integrated Visual and Auditory (IVA) CPT, 2.99194476    3.0000000 h/week,Beauregard,2006,NA RCT G  15,  5   20 outcomes,NA, 0.3100000000 -0.710000000  1.330000e+00,NA,NA,NA,NA,NA,NA NA NA,  0   0 100 100,100,100   0 some low low high,some WLC   0 NA,10.200000 NA,DSM-IV,0 1,0.5 1.0 1.0,1.0 1,1,2 0,1 1 1 0.5 0,1,1,1, 637 Beauregard_2006,2-6 months NA,6-12 yo,8.59 16.1 NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
 998 Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100   0,100 100 Moderate,Neurofeedback,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),NA At study endpoint (closest to 12 weeks),NA,ADHS -RS, 3.79746835 NA,h/week Bink 2016,NA,RCT,G, 45  26,  71 outcomes NA  0.0300000000 -0.260000000, 3.200000e-01,NA NA,NA NA NA,NA,NA,NA   0   0 100 100 100,100   0 low,low,low high,some,TAU   0,NA,16.100000,NA DSM-IV 0,1,0.5 1.0 1.0,1.0,1,1,2,0 1 1,1,0.5,0,1,1,1  638 Bink_2016,2-6 months,NA 13-19 yo 16.1 16.1 NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100,  0 100 100,Moderate Neurofeedback NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) NA At study endpoint (closest to 12 weeks) NA ADHS -RS, 3.79746835,NA h/week Bink,2016,NA RCT G  41  19,  60 outcomes,NA, 0.3700000000,-0.020000000, 7.600000e-01 NA,NA NA NA NA,NA,NA NA   0,  0 100,100 100,100,  0 low low,low high some,TAU,  0,NA 16.100000 NA,DSM-IV 0,1,0.5 1.0 1.0 1.0,1 1 2 0 1,1 1 0.5,0 1 1 1  639,Bink_2016,2-6 months NA 13-19 yo,16.1 16.1 NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
 998 Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100,  0 100,100 Moderate,Neurofeedback NA,  0 NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA,D2 Test of attention  3.79746835 NA,h/week Bink,2016,NA RCT G  44, 26,  70,outcomes NA, 0.0200000000,-0.470000000, 5.000000e-01 NA NA NA,NA NA NA NA NA   0   0 100 100 100 100,  0,low,low,low high,some,TAU,  0,NA 16.100000,NA DSM-IV 0,1,0.5,1.0,1.0 1.0,1,1,2,0,1 1,1 0.5 0 1 1,1, 640,Bink_2016 2-6 months NA 13-19 yo,8.59,16.1,NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100   0 100 100,Moderate Neurofeedback,NA,  0 NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA,stroop color word test  3.79746835 NA h/week,Bink 2016 NA,RCT G, 43  26,  69,outcomes,NA,-0.0100000000 -0.500000000  4.700000e-01,NA,NA,NA,NA,NA,NA,NA,NA   0   0 100 100 100 100,  0,low,low low high some,TAU   0 NA 16.100000 NA,DSM-IV 0 1,0.5,1.0 1.0 1.0 1,1 2,0 1,1 1 0.5 0,1,1,1, 641,Bink_2016,2-6 months NA,13-19 yo 8.59 16.1 NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100,  0 100,100 Moderate,Neurofeedback NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA Conners3 - DSM-IV,NA,NA,h/week,Blume 2020,NA,RCT,G  12  11,  23,outcomes,NA -0.4600000000,-1.050000000  1.300000e-01,NA,NA,NA NA NA NA NA NA,100 100,100,100,100 100,100 low low low some,low Sham_semi_active,  0,NA  9.030000 NA,DSM-5,0,1 0.5 1.0 1.0 1.0 1,1 2 0,1 1,1,0.5,0,1 1 1, 642 Blume_2020 NA NA,6-12 yo,8.58,12.4,NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 998,Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100,  0,100,100 Moderate,Neurofeedback,NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks) NA Conners3 - DSM-IV NA,NA,h/week,Blume,2020 NA RCT,G  12  11   23,outcomes,NA -0.1000000000 -0.680000000  4.800000e-01 NA NA NA NA,NA,NA,NA NA 100,100 100,100,100,100,100 low,low low,some,low Sham_semi_active,  0,NA, 9.030000,NA DSM-5,0,1,0.5 1.0 1.0 1.0 1,1 2 0 1 1 1,0.5 0 1,1 1, 643 Blume_2020 NA,NA 6-12 yo 8.58 12.4,NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100,  0,100 100,Moderate,Neurofeedback NA   0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,Conner's CPT - Coms,NA NA h/week,Blume 2020 NA RCT G,  9, 10   19,outcomes,NA -0.3200000000,-1.220000000  5.900000e-01,NA NA,NA,NA NA,NA,NA,NA,100,100 100 100 100,100,100,low,low,low some,low,Sham_semi_active,  0,NA  9.030000,NA,DSM-5,0 1 0.5,1.0,1.0 1.0,1 1,2 0,1,1 1,0.5 0,1 1,1  644 Blume_2020 NA,NA,6-12 yo,8.59 16.1,NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 998 Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100   0 100 100 Moderate Neurofeedback,NA   0,NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA Conner's CPT - Coms NA,NA,h/week,Blume,2020,NA,RCT,G  11  10,  21 outcomes NA,-0.1400000000,-1.000000000  7.100000e-01,NA,NA NA NA NA,NA,NA,NA,100 100 100,100 100,100,100 low,low low,some,low Sham_semi_active,  0,NA, 9.030000 NA DSM-5,0 1,0.5,1.0,1.0 1.0,1 1,2 0,1 1 1,0.5,0 1 1,1  645 Blume_2020,NA,NA,6-12 yo 8.59 16.1 NA,NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100   0,100 100 Moderate Neurofeedback,NA   0,NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA Conner's CPT - Oms,NA NA h/week Blume,2020,NA,RCT G  12, 11   23 outcomes NA, 0.0700000000 -0.790000000  9.200000e-01,NA,NA NA,NA,NA NA,NA NA 100,100,100,100,100 100,100,low low,low some,low,Sham_semi_active,  0 NA  9.030000 NA,DSM-5,0,1 0.5,1.0,1.0,1.0 1,1,2,0,1,1,1,0.5,0 1,1,1, 646 Blume_2020 NA NA 6-12 yo,8.59,16.1,NA,NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 998,Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100   0,100,100,Moderate Neurofeedback,NA   0,NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA,Conner's CPT - Oms NA,NA h/week,Blume,2020 NA RCT,G, 12, 11   23 outcomes NA,-0.6000000000,-1.520000000, 3.200000e-01,NA NA,NA,NA,NA NA,NA NA,100,100,100 100 100 100,100,low,low,low some,low Sham_semi_active,  0,NA, 9.030000,NA DSM-5 0 1,0.5,1.0,1.0,1.0 1 1 2,0,1 1 1 0.5,0,1 1,1, 647,Blume_2020 NA NA 6-12 yo 8.59 16.1 NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 998 Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0 100,100,Moderate,Neurofeedback,NA,  0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA n-back,NA NA,h/week Dobrakowski,2020,NA RCT G  24  24   48,NA NA  0.3400000000,-0.230000000, 9.100000e-01 NA,NA,NA,NA NA NA,NA NA,100 100 100,100   0 100,100,low low high,low,some WLC   0,NA  8.730000,NA,ICD-10,0 1 0.5 1.0 1.0,1.0 1,1 2 0 1 1,1,0.5,0 1 1,1  648,Dobrakowski_2020,NA,NA,6-12 yo 8.59,16.1,NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0,100,100 Moderate Neurofeedback,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),NA SWAN  2.53164557 NA,h/week,Gelade 2016,NA RCT,G, 39  37   76 NA NA, 0.1600000000 -0.150000000, 4.700000e-01,NA,NA,NA NA,NA NA,NA NA,  0   0 100,100 100 100   0 low,low some,high some,Sham_semi_active,  0,NA  9.600000,NA DSM-IV,0 1 0.5 1.0,1.0,1.0 1,1,2,0 1,1,1,0.5,0,1 1,1, 649 Gelade_2016,2-6 months,NA 6-12 yo,8.57,13.9 NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998,Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100   0,100,100,Moderate,Neurofeedback,NA   0,NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA Oddball task, 2.53164557 NA h/week Gelade,2017,NA,RCT G  30  30   60,outcomes NA  0.0000000000,-0.510000000, 5.100000e-01,NA NA,NA NA,NA,NA NA,NA   0   0 100 100,100 100   0,low low some,high some Sham_semi_active   0,NA  9.600000 NA,DSM-IV,0 1,0.5,1.0,1.0,1.0 1 1,2 0 1,1 1 0.5 0,1,1,1, 650 Gelade_2017 2-6 months NA,6-12 yo 8.59 16.1,NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
 998 Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100   0,100,100 Moderate Neurofeedback,NA   0,NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA Oddball task, 2.53164557,NA,h/week,Gelade,2017,NA,RCT G, 30  30,  60,outcomes,NA  0.1700000000,-0.340000000  6.800000e-01,NA,NA NA,NA NA,NA NA NA,  0,  0 100 100 100 100,  0 low,low some,high some,Sham_semi_active,  0 NA  9.600000 NA DSM-IV 0 1 0.5,1.0 1.0,1.0 1 1,2 0,1,1 1 0.5,0 1,1,1, 651,Gelade_2017,2-6 months,NA 6-12 yo 8.59,16.1 NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100   0,100 100 Moderate,Neurofeedback,NA   0 NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA Stop-signal task, 2.53164557,NA h/week,Gelade 2017,NA RCT,G  36, 33,  69,outcomes,NA, 0.1200000000,-0.360000000, 5.900000e-01 NA,NA NA,NA NA NA NA,NA,  0   0 100,100 100,100   0 low,low,some,high,some Sham_semi_active,  0 NA  9.600000 NA DSM-IV 0,1 0.5 1.0,1.0 1.0,1 1 2,0 1 1 1 0.5 0,1 1,1, 652,Gelade_2017 2-6 months NA 6-12 yo,8.59,16.1 NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100,  0 100 100 Moderate Neurofeedback NA   0 NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA VSWM  2.53164557,NA,h/week Gelade 2017 NA,RCT,G, 39  37,  76,outcomes,NA -0.0700000000 -0.380000000, 2.500000e-01 NA,NA NA,NA,NA NA NA,NA,  0,  0 100,100,100 100,  0 low,low,some,high,some Sham_semi_active,  0 NA, 9.600000,NA DSM-IV 0,1 0.5 1.0 1.0,1.0,1 1,2 0 1,1 1,0.5,0,1 1,1, 653 Gelade_2017,2-6 months,NA 6-12 yo,8.59 16.1,NA,NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998 Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100,  0 100 100 Moderate,Neurofeedback,NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA,FBB-HKS, 1.38089758,NA h/week,Gevensleben 2009 NA,RCT,G  59, 35   94,NA,NA  0.5300000000, 0.100000000  9.600000e-01 NA,NA,NA,NA NA,NA,NA NA   0,  0,100,100,100,100,  0 low low low high some Sham_semi_active   0,NA, 9.700000,NA DSM-IV,0,1,0.5,1.0 1.0 1.0 1 1 2 0,1,1 1,0.5 0 1 1 1  654,Gevensleben_2009,< 2 months,NA 6-12 yo 8.57,13.9 NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
 998,Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100   0 100,100 Moderate Neurofeedback,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks),NA FBB-HKS, 1.38089758 NA,h/week,Gevensleben 2010 NA,RCT G  38, 23,  61 NA NA  0.6400000000, 0.110000000, 1.170000e+00 NA NA NA,NA NA,NA NA,NA   0,  0 100,100 100,100   0 low,low,low high some Sham_semi_active   0,NA  9.700000,NA,DSM-IV 0,1,0.5 1.0 1.0 1.0 1 1 2,0 1,1 1,0.5,0 1 1 1, 655,Gevensleben_2010 < 2 months,NA,6-12 yo 8.57,13.2,NA,NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,low high
 998,Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0,100 100,Moderate,Neurofeedback,NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks),NA FBB-HKS  1.38089758,NA h/week,Gevensleben 2009 NA RCT,G  59  35   94,NA,NA  0.4200000000, 0.000000000  8.400000e-01,NA NA,NA,NA NA NA,NA,NA   0,  0 100 100 100 100   0,low,low low high,some Sham_semi_active   0 NA  9.700000,NA,DSM-IV,0 1,0.5 1.0 1.0,1.0 1 1,2 0 1 1 1 0.5,0 1,1,1  656 Gevensleben_2009 < 2 months,NA 6-12 yo 8.58 12.4 NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
 998,Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100,  0,100,100 Moderate,Neurofeedback,NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA,ADHD-C3 parent, 1.15074799,NA h/week,Hasslinger 2021 NA RCT G, 49  49,  98 outcomes NA, 0.1300000000,-0.260000000  5.300000e-01,NA,NA NA NA,NA NA,NA,NA   0   0 100,100 100 100,  0 some low,low high,some,TAU   0 NA,12.400000 NA,DSM-5,0,1,0.5,1.0 1.0 1.0,1,1,2 0,1 1 1,0.5 0,1,1 1  657,Hasslinger_2021,< 2 months NA,6-12 yo 8.57 13.9,NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
 998,Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100,  0 100 100,Moderate,Neurofeedback NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA ADHD-C3 parent, 1.15074799,NA h/week,Hasslinger 2021,NA,RCT G  51  49  100,outcomes NA, 0.1700000000 -0.220000000, 5.700000e-01 NA,NA,NA,NA NA NA NA NA,  0   0,100,100 100,100   0,some low,low,high,some,TAU   0,NA 12.400000 NA DSM-5,0,1 0.5 1.0 1.0 1.0 1 1,2,0,1 1 1,0.5,0 1 1,1, 658 Hasslinger_2021,< 2 months,NA 6-12 yo 8.57,13.9 NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
 998,Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0 100,100 Moderate Neurofeedback NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks),NA,ADHD-C3 parent, 1.15074799 NA h/week,Hasslinger 2021,NA,RCT G, 51  49, 100 outcomes NA  0.1000000000,-0.257204142, 4.572041e-01,NA,NA,NA NA NA NA NA NA,  0   0 100 100 100,100,  0,some,low low high,some,TAU,  0,NA,12.400000 NA DSM-5,0,1,0.5,1.0 1.0 1.0,1,1,2,0,1,1,1,0.5,0,1 1,1, 659 Hasslinger_2021 < 2 months NA 6-12 yo,8.57 13.2 NA NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no low high
 998 Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100   0,100 100 Moderate,Neurofeedback,NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks),NA,ADHD-C3 parent, 1.15074799 NA,h/week Hasslinger 2021 NA RCT G  49  49   98 outcomes,NA  0.1800000000 -0.177297176  5.372972e-01 NA NA NA NA,NA NA,NA,NA,  0   0,100,100 100 100   0 some low low high some TAU,  0,NA 12.400000,NA DSM-5,0,1 0.5,1.0 1.0,1.0,1,1,2,0,1 1,1 0.5 0,1 1 1  660,Hasslinger_2021 < 2 months,NA 6-12 yo 8.57 13.2,NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,low,high
 998,Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100,  0,100 100,Moderate Neurofeedback,NA,  0,NA Executive functioning (report) NA,At study endpoint (closest to 12 weeks) NA,BRIEF  1.15074799 NA h/week,Hasslinger,2021 NA,RCT,G  50  49   99,outcomes,NA, 0.2100000000,-0.180000000, 6.069446e-01,NA NA,NA,NA NA NA NA,NA   0   0 100,100 100 100,  0 some,low,low,high,some TAU,  0 NA 12.400000,NA DSM-5 0,1 0.5,1.0,1.0 1.0,1,1,2 0,1 1 1,0.5 0,1 1,1, 661,Hasslinger_2021,< 2 months NA,6-12 yo 10.3 12.4 NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100   0 100,100 Moderate,Neurofeedback NA   0,NA,Executive functioning (report),NA At study endpoint (closest to 12 weeks),NA BRIEF  1.15074799 NA,h/week,Hasslinger,2021 NA,RCT G  51, 49, 100 outcomes NA, 0.4700000000, 0.073106509, 8.668935e-01,NA NA NA NA,NA NA NA NA   0   0 100 100 100 100   0,some low low high some,TAU,  0 NA 12.400000,NA DSM-5 0,1 0.5,1.0,1.0 1.0 1 1,2 0,1 1 1 0.5,0,1,1 1  662 Hasslinger_2021,< 2 months NA,6-12 yo 10.3 12.4 NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100   0,100 100,Moderate Neurofeedback NA,  0,NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA,Block-tapping task - Combined Forward & Backward, 1.15074799,NA,h/week Hasslinger,2021,NA,RCT,G, 51, 50  101 outcomes NA -0.0900000000,-0.370000000, 1.900000e-01 NA NA NA NA,NA NA,NA NA,  0,  0 100 100 100 100   0,some,low low high,some,TAU   0 NA 12.400000 NA DSM-5 0,1,0.5 1.0 1.0 1.0 1,1 2,0 1 1 1,0.5 0,1 1,1, 663,Hasslinger_2021,< 2 months NA,6-12 yo,8.59 16.1,NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0 100,100 Moderate,Neurofeedback,NA,  0 NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA Block-tapping task - Combined Forward & Backward, 1.15074799 NA,h/week Hasslinger,2021,NA RCT,G, 51, 50, 101 outcomes,NA,-0.0300000000 -0.300000000  2.500000e-01 NA NA,NA NA NA,NA,NA,NA,  0,  0 100 100 100,100   0,some low low high some TAU,  0 NA,12.400000,NA,DSM-5 0 1 0.5 1.0 1.0,1.0,1 1 2 0,1,1,1 0.5 0 1 1 1, 664 Hasslinger_2021 < 2 months,NA 6-12 yo 8.59 16.1,NA,NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
 998,Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100,  0 100 100 Moderate,Neurofeedback NA   0,NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA,CPT-II - Hit RT  1.15074799 NA h/week Hasslinger 2021,NA RCT,G, 50  49,  99,outcomes NA,-0.0700000000,-0.460000000, 3.300000e-01 NA,NA NA,NA,NA NA,NA NA   0   0 100 100 100,100,  0,some,low,low high some,TAU   0,NA,12.400000 NA DSM-5,0,1 0.5,1.0 1.0 1.0,1,1 2 0,1,1 1,0.5,0,1,1 1, 665 Hasslinger_2021,< 2 months NA,6-12 yo,8.59,16.1 NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998,Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0 100,100,Moderate,Neurofeedback NA,  0,NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA CPT-II - Hit RT  1.15074799 NA,h/week,Hasslinger 2021,NA,RCT G  51  49, 100 outcomes,NA -0.0600000000 -0.450000000, 3.300000e-01 NA,NA,NA NA,NA,NA NA NA,  0,  0 100,100 100,100,  0 some,low low high some TAU,  0,NA,12.400000,NA DSM-5,0 1,0.5 1.0 1.0,1.0,1 1,2 0 1,1 1,0.5 0 1,1,1  666 Hasslinger_2021 < 2 months NA 6-12 yo 8.59 16.1 NA NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
 998,Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100   0,100,100 Moderate,Neurofeedback,NA   0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,CPT-II Commission  1.15074799 NA h/week,Hasslinger 2021 NA,RCT G  50  49,  99 outcomes NA -0.1100000000,-0.506944637, 2.800000e-01 NA NA NA,NA,NA NA,NA,NA   0,  0 100 100 100 100,  0,some,low low high,some TAU,  0 NA,12.400000,NA,DSM-5 0,1 0.5,1.0,1.0,1.0,1 1,2,0,1,1,1 0.5 0 1,1 1  667 Hasslinger_2021,< 2 months,NA,6-12 yo 8.59 16.1 NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
 998 Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100   0,100,100,Moderate,Neurofeedback,NA   0,NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA,CPT-II Commission, 1.15074799 NA,h/week,Hasslinger,2022 NA RCT G  51  49  100,outcomes NA  0.0200000000,-0.380000000  4.200000e-01,NA,NA NA NA NA,NA,NA NA   0   0 100 100,100 100,  0 some,low low,high some,TAU   0 NA 12.400000,NA DSM-5,0,1,0.5 1.0,1.0 1.0,1,1 2,0,1 1 1 0.5 0,1 1,1, 668 Hasslinger_2022,< 2 months,NA 6-12 yo 8.59,16.1 NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
 998,Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0,100 100,Moderate,Neurofeedback NA   0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA CPT-II Commission  1.15074799,NA h/week,Hasslinger,2022 NA,RCT,G  51  49  100 outcomes,NA  0.0700000000,-0.326893491  4.668935e-01 NA,NA NA,NA,NA NA NA NA   0   0 100,100 100,100   0,some,low low,high,some TAU,  0,NA 12.400000 NA DSM-5 0,1,0.5,1.0,1.0,1.0,1,1 2 0 1,1,1,0.5,0 1,1,1  669,Hasslinger_2022,< 2 months,NA,6-12 yo 8.59 16.1 NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
 998 Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100   0,100 100 Moderate Neurofeedback NA,  0 NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA,CPT-II Commission  1.15074799,NA h/week Hasslinger,2022 NA,RCT,G, 50  49,  99,outcomes NA, 0.1700000000,-0.226944637, 5.669446e-01,NA NA,NA NA,NA NA NA,NA   0   0,100 100 100 100,  0 some low low,high,some,TAU   0,NA 12.400000,NA DSM-5 0,1 0.5 1.0 1.0,1.0 1 1 2 0 1,1,1,0.5,0 1,1,1  670,Hasslinger_2022,< 2 months,NA,6-12 yo,8.59 16.1,NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
 998,Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0,100,100 Moderate,Neurofeedback NA   0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA CPT-II Omission  1.15074799 NA h/week,Hasslinger,2022 NA RCT,G  50, 49   99 outcomes,NA -0.1700000000,-0.566944637, 2.269446e-01,NA,NA NA,NA,NA,NA NA NA   0,  0 100 100 100 100,  0,some,low,low high,some TAU,  0 NA,12.400000 NA,DSM-5,0 1 0.5,1.0 1.0 1.0 1,1,2 0,1,1,1 0.5 0,1,1 1, 671,Hasslinger_2022,< 2 months NA,6-12 yo 8.59 16.1,NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
 998 Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0 100,100 Moderate,Neurofeedback,NA,  0,NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA,CPT-II Omission, 1.15074799,NA h/week Hasslinger,2022,NA RCT,G  51, 49, 100 outcomes NA, 0.0400000000,-0.356893491  4.300000e-01,NA,NA NA,NA,NA,NA,NA NA   0   0 100 100,100,100   0 some,low,low high,some TAU   0 NA,12.400000 NA,DSM-5 0,1,0.5,1.0 1.0,1.0,1,1 2 0 1 1,1 0.5 0 1,1,1, 672 Hasslinger_2022,< 2 months,NA 6-12 yo,8.59,16.1 NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998 Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0,100 100,Moderate,Neurofeedback NA   0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA Digit Span Composite, 1.15074799 NA,h/week,Hasslinger,2021 NA RCT G, 49, 50,  99,outcomes,NA,-0.1300000000,-0.407861246  1.478612e-01 NA,NA,NA,NA NA NA,NA NA,  0,  0,100,100,100 100,  0,some low low,high some TAU   0,NA 12.400000 NA,DSM-5 0 1,0.5,1.0,1.0 1.0 1,1,2,0 1 1,1 0.5,0,1 1 1, 673,Hasslinger_2021,< 2 months NA,6-12 yo,8.59,16.1 NA NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
 998,Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100   0,100,100,Moderate Neurofeedback,NA   0,NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA,Digit Span Composite, 1.15074799 NA,h/week,Hasslinger,2021 NA RCT G  51, 50, 101,outcomes,NA -0.0800000000,-0.357790373, 1.900000e-01,NA NA,NA,NA NA,NA,NA,NA   0   0,100 100 100,100   0 some low low,high some,TAU,  0,NA 12.400000 NA DSM-5 0 1 0.5,1.0,1.0,1.0 1,1 2,0 1 1 1 0.5 0,1,1 1  674 Hasslinger_2021,< 2 months NA 6-12 yo,8.59 16.1,NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0 100,100,Moderate Neurofeedback NA   0 NA Executive functioning (tests),NA,At follow-up (closest to 26 weeks),NA,CPT-II - Hit RT, 1.15074799,NA h/week Hasslinger,2021,NA RCT,G  50, 50  100 outcomes,NA,-0.0800000000 -0.470000000  3.100000e-01,NA NA NA NA,NA NA NA NA,  0   0 100,100 100 100   0,some,low low high some TAU   0,NA,12.400000,NA DSM-5 0 1,0.5,1.0 1.0,1.0 1 1,2,0 1,1,1,0.5 0 1 1 1, 675,Hasslinger_2021,< 2 months,NA,6-12 yo 12.4 13.2 NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,low high
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0 100 100 Moderate,Neurofeedback NA,  0 NA,Executive functioning (tests) NA At follow-up (closest to 26 weeks) NA,CPT-II - Hit RT  1.15074799,NA h/week Hasslinger 2021 NA RCT G  51, 50, 101 outcomes,NA,-0.0700000000 -0.470000000, 3.200000e-01,NA,NA NA,NA,NA NA NA NA   0,  0,100,100,100 100   0,some,low,low high,some,TAU   0,NA 12.400000,NA,DSM-5,0,1,0.5,1.0,1.0 1.0,1,1,2 0 1 1,1 0.5 0,1,1 1  676 Hasslinger_2021,< 2 months,NA 6-12 yo 12.4 13.2,NA,NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low high
 998 Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100   0,100,100 Moderate Neurofeedback NA   0 NA Executive functioning (tests),NA At follow-up (closest to 26 weeks) NA,CPT-II Omission  1.15074799 NA h/week,Hasslinger,2022 NA RCT,G  51  49, 100,outcomes,NA  0.0900000000 -0.300000000  4.800000e-01,NA NA NA NA NA NA,NA,NA   0,  0 100,100,100 100,  0 some low low high some TAU,  0 NA,12.400000,NA DSM-5,0 1 0.5,1.0,1.0,1.0 1 1 2 0 1 1 1 0.5 0 1,1 1  677 Hasslinger_2022 < 2 months NA,6-12 yo,12.4 13.2 NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no low high
 998,Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0 100,100,Moderate Neurofeedback NA,  0,NA,Executive functioning (tests) NA,At follow-up (closest to 26 weeks) NA CPT-II Omission  1.15074799,NA,h/week Hasslinger,2022 NA,RCT,G  50  49   99 outcomes NA  0.1700000000,-0.220000000, 5.700000e-01 NA NA NA NA NA NA,NA NA,  0,  0,100 100 100 100   0,some,low low high some TAU,  0 NA 12.400000,NA,DSM-5 0 1,0.5 1.0 1.0 1.0 1 1 2,0,1 1 1,0.5 0,1,1,1, 678 Hasslinger_2022,< 2 months NA,6-12 yo,12.4,13.2 NA,NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low high
 998 Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100   0 100,100,Moderate,Neurofeedback NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA,FBB-HKS,NA,NA,h/week,Heinrich 2004,NA,RCT,G  13,  9,  22 NA,NA, 0.8400000000,-0.060000000, 1.740000e+00,NA NA NA NA,NA,NA,NA,NA   0   0 100 100,100,100,  0,low,low,low high some WLC   0 NA,10.800000 NA,DSM-IV 0 1,0.5 1.0,1.0,1.0 1,1 2 0,1 1,1,0.5 0 1,1 1  679 Heinrich_2004,NA NA 6-12 yo,8.57 13.9,NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
 998,Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100   0,100,100 Moderate,Neurofeedback NA   0 NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA,CPT,NA,NA,h/week Heinrich 2004,NA,RCT G  13   9   22 outcomes,NA -0.3400000000 -1.200000000  5.100000e-01 NA NA NA,NA,NA NA,NA NA,  0,  0 100 100,100,100,  0 low,low,low,high some WLC,  0 NA,10.800000 NA DSM-IV 0,1,0.5 1.0,1.0,1.0 1 1,2,0 1,1,1,0.5 0 1,1 1, 680 Heinrich_2004 NA NA 6-12 yo 8.59 16.1,NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
 998 Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100,  0 100,100 Moderate Neurofeedback,NA,  0,NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA,CPT,NA,NA,h/week Heinrich 2004,NA,RCT,G  13,  9   22 outcomes,NA, 0.3800000000 -0.480000000, 1.240000e+00,NA,NA NA,NA NA NA NA NA   0   0 100 100 100 100,  0,low,low,low high some,WLC,  0 NA,10.800000 NA DSM-IV 0,1 0.5,1.0,1.0,1.0,1 1 2,0,1 1,1 0.5,0 1 1 1  681 Heinrich_2004 NA NA 6-12 yo,8.59 16.1 NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
 998 Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100,  0,100,100,Moderate Neurofeedback NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) NA,FBB-HKS - Total Score,NA,NA,NA,Holtmann,2009 NA,NA G, 20  14,  34,NA NA  0.0000000000,-0.690000000  6.900000e-01,NA,NA NA NA NA,NA,NA,NA   0   0 100,100 100,100,  0 low low low,high some,Active (any credible active intervention),100,NA,10.250000,NA NA 0 1,0.5,1.0,1.0,1.0,1 1,2,0 1,1,1,0.5 0,1 1 1  682 Holtmann_2009,NA NA,6-12 yo 8.57 13.9 NA NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 998 Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100,  0,100,100 Moderate Neurofeedback,NA,  0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,Stop signal - Commissions NA,NA,NA,Holtmann 2009,NA NA,G  20, 14   34 outcomes,NA  0.8500000000, 0.130000000  1.560000e+00 NA NA,NA,NA,NA NA,NA NA,  0   0 100,100,100 100   0 low,low low,high,some,Active (any credible active intervention) 100,NA,10.250000,NA NA 0,1 0.5 1.0,1.0 1.0,1 1,2 0,1 1,1 0.5,0 1 1,1, 683,Holtmann_2009 NA NA,6-12 yo,8.59 16.1,NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
 998 Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100,  0 100 100 Moderate Neurofeedback,NA   0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks) NA,Stop signal - Omission,NA NA NA,Holtmann,2009 NA,NA G, 20, 14   34,outcomes,NA, 0.2700000000 -0.410000000, 9.600000e-01 NA NA,NA,NA NA NA NA,NA   0   0,100 100 100,100   0 low,low,low,high some Active (any credible active intervention) 100 NA 10.250000 NA NA,0 1 0.5,1.0,1.0 1.0 1 1 2 0 1,1,1,0.5 0,1,1 1, 684 Holtmann_2009,NA NA,6-12 yo 8.59 16.1 NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998,Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100   0 100,100,Moderate Neurofeedback NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) NA,ADHD-RS NA NA,h/week,Lam 2022,NA,RCT G, 43, 43,  86,outcomes NA,-0.2300000000,-0.660000000  1.900000e-01 NA,NA NA NA NA,NA,NA NA,100 100 100 100 100 100,100 low,low,low,some low,Sham_semi_active   0,NA 13.200000 NA,DSM-5,0,1 0.5 1.0,1.0 1.0,1 1,2,0 1 1 1,0.5 0,1,1 1, 685 Lam_2022,NA,NA,13-19 yo,8.57,13.9,NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 998,Westwood - Children (2025) Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100,  0 100,100,Moderate Neurofeedback,NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks) NA,ADHD-RS NA,NA h/week Lam,2022,NA RCT,G  43  40,  83 outcomes,NA -0.0600000000,-0.490000000  3.700000e-01,NA,NA,NA NA NA,NA NA,NA 100 100 100,100 100 100 100,low low,low,some,low Sham_semi_active   0,NA,13.200000,NA DSM-5,0,1 0.5,1.0,1.0 1.0 1 1,2,0,1 1 1 0.5 0,1 1,1, 686,Lam_2022 NA NA 13-19 yo 8.57 13.2,NA NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low low
 998 Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100   0 100 100 Moderate,Neurofeedback NA   0,NA Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA,CPT NA,NA h/week Lam,2022,NA RCT,G, 38  40   78,outcomes,NA,-0.1700000000 -0.620000000, 2.700000e-01 NA,NA,NA NA NA,NA NA,NA,100 100,100 100,100,100 100,low low,low,some,low,Sham_semi_active   0,NA,13.200000 NA,DSM-5,0,1,0.5 1.0 1.0 1.0,1 1 2 0,1,1,1,0.5 0,1 1 1, 687 Lam_2022 NA,NA,13-19 yo,8.59 16.1 NA NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 998 Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100,  0 100 100,Moderate,Neurofeedback NA   0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,CPT,NA NA,h/week,Lam,2022,NA RCT G, 44  43   87,outcomes,NA -0.1200000000 -0.537536261  2.975363e-01 NA NA NA NA,NA,NA NA NA,100 100 100 100,100,100,100,low,low low,some,low Sham_semi_active,  0 NA,13.200000,NA DSM-5,0 1,0.5,1.0 1.0,1.0 1,1,2,0,1,1 1,0.5,0,1,1,1  688 Lam_2022 NA,NA,13-19 yo 8.59,16.1,NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 998,Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0 100 100 Moderate,Neurofeedback NA,  0 NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA CPT - Oms,NA,NA h/week Lam 2022 NA RCT G, 44, 43,  87,outcomes NA  0.0300000000,-0.387536261, 4.475363e-01 NA NA NA,NA NA,NA NA NA 100 100,100,100 100,100 100 low,low,low,some low,Sham_semi_active   0,NA 13.200000 NA,DSM-5,0 1 0.5,1.0,1.0,1.0 1,1 2 0 1,1 1,0.5,0 1,1,1, 689,Lam_2022,NA,NA 13-19 yo,8.59,16.1 NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100   0 100,100,Moderate Neurofeedback NA,  0 NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA WIH WM Sorting NA,NA h/week,Lam,2022 NA,RCT,G  44, 43   87 outcomes,NA,-0.1900000000,-0.627418940  2.474189e-01,NA NA,NA,NA,NA NA,NA NA,100 100 100 100,100,100 100,low low,low some,low,Sham_semi_active   0 NA,13.200000 NA DSM-5,0 1,0.5,1.0,1.0 1.0 1,1,2,0 1 1 1,0.5,0,1,1 1, 690,Lam_2022,NA,NA,13-19 yo 8.59,16.1 NA,NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 998 Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100   0,100 100,Moderate,Neurofeedback NA,  0 NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,CPT -MRT,NA,NA,h/week,Lam,2022,NA RCT G  44  43   87 outcomes,NA, 0.1100000000,-0.310000000  5.300000e-01 NA NA NA NA,NA NA,NA NA 100 100,100,100,100,100 100 low low low,some low Sham_semi_active   0 NA 13.200000,NA,DSM-5,0,1,0.5,1.0 1.0 1.0 1,1 2 0,1,1 1 0.5 0,1,1 1, 691,Lam_2022 NA NA 13-19 yo,8.59,16.1,NA NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 998 Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702,100,  0,100 100,Moderate,Neurofeedback NA,  0,NA,Executive functioning (tests),NA,At follow-up (closest to 26 weeks),NA,CPT - Oms NA NA,h/week,Lam,2022,NA RCT,G, 38  40,  78,outcomes,NA, 0.0600000000 -0.387536261, 5.180847e-01,NA NA NA,NA,NA NA NA,NA 100,100,100 100,100,100,100 low,low low,some low Sham_semi_active   0,NA 13.200000 NA DSM-5 0,1 0.5,1.0,1.0 1.0 1 1,2,0,1 1,1 0.5 0,1 1,1  692,Lam_2022,NA NA 13-19 yo,12.4,13.2 NA NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low low
 998,Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100,  0,100,100 Moderate,Neurofeedback,NA,  0 NA Executive functioning (tests) NA At follow-up (closest to 26 weeks) NA CPT -MRT,NA,NA h/week Lam 2022,NA RCT,G  38  40,  78,outcomes NA,-0.0200000000 -0.470000000  4.200000e-01 NA,NA,NA NA NA,NA NA,NA,100 100,100 100,100,100 100,low low low some low,Sham_semi_active,  0,NA 13.200000 NA,DSM-5,0,1 0.5 1.0 1.0 1.0,1 1,2,0,1 1,1,0.5 0,1,1 1, 693,Lam_2022 NA,NA,13-19 yo 12.4,13.2 NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low,low
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100,  0,100 100 Moderate,Neurofeedback,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA ADHD-RS, 1.84119678 NA,h/week,Lim 2019 NA,RCT G  81  82  163,NA NA -0.2800000000 -0.590000000  3.000000e-02 NA NA,NA NA,NA,NA NA,NA,  0   0 100,100,100 100   0,some low,low high,some WLC   0,NA, 8.600000,NA DSM-IV,0 1 0.5 1.0 1.0 1.0,1,1,2,0 1,1,1 0.5,0,1 1 1, 694,Lim_2019 < 2 months,NA,6-12 yo 8.57 10.6 NA,NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998,Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100   0 100,100,Moderate Neurofeedback NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA,ADHD-RS, 1.84119678,NA h/week Lim 2019 NA RCT,G  81, 82, 163,NA NA  0.5100000000  0.200000000  8.200000e-01 NA,NA,NA NA NA,NA,NA NA   0,  0,100,100,100 100   0,some,low low,high,some WLC   0,NA  8.600000 NA,DSM-IV 0,1,0.5 1.0 1.0 1.0 1 1,2 0 1,1 1 0.5,0,1,1,1, 695 Lim_2019 < 2 months NA 6-12 yo 8.57,13.9 NA NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0,100 100 Moderate Neurofeedback NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) NA CPRS  3.45224396 NA h/week Maurizio,2014 NA RCT,G, 13, 12,  25 NA,NA  0.3300000000 -0.450000000, 1.110000e+00 NA NA,NA NA,NA NA,NA,NA   0   0,100 100,100,100,  0,some low low high some Sham_semi_active   0,NA 10.300000 NA,DSM-IV 0 1 0.5,1.0,1.0 1.0,1 1,2,0 1 1 1 0.5,0,1 1 1  696,Maurizio_2014,2-6 months,NA,6-12 yo 8.57,13.9 NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
 998,Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100   0 100 100,Moderate Neurofeedback,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks),NA,CTRS  3.45224396,NA h/week Maurizio 2014,NA RCT G, 13, 12   25,NA,NA -0.1000000000,-0.890000000  6.800000e-01,NA,NA,NA,NA NA,NA,NA NA   0   0 100 100,100,100   0,some low,low,high some Sham_semi_active,  0 NA,10.300000,NA DSM-IV 0,1,0.5,1.0 1.0 1.0 1 1,2,0 1 1 1,0.5,0,1,1 1  697,Maurizio_2014,2-6 months,NA 6-12 yo,8.58 12.4,NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100   0,100,100 Moderate Neurofeedback NA,  0,NA Executive functioning (report) NA,At study endpoint (closest to 12 weeks),NA,BRIEF, 3.45224396 NA h/week Maurizio 2014,NA,RCT G  13, 12,  25 NA,NA, 0.0100000000,-0.550000000  5.600000e-01,NA,NA NA NA NA,NA NA,NA,  0   0 100,100 100 100   0 some low low,high some Sham_semi_active,  0 NA,10.300000,NA DSM-IV 0,1,0.5,1.0,1.0,1.0 1 1,2,0 1,1,1 0.5 0,1 1,1, 698 Maurizio_2014,2-6 months NA,6-12 yo,10.3,12.4,NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
 998,Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0,100 100 Moderate,Neurofeedback NA,  0,NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA D2 - Total Score, 3.45224396 NA h/week,Maurizio,2014,NA,RCT,G  13  12,  25 NA,NA,-0.2400000000 -1.030000000  5.500000e-01 NA NA,NA NA,NA,NA,NA,NA,  0,  0,100 100,100,100,  0,some,low,low,high,some,Sham_semi_active   0 NA,10.300000 NA,DSM-IV,0,1,0.5,1.0,1.0 1.0 1,1 2,0 1,1,1 0.5,0,1,1,1, 699 Maurizio_2014,2-6 months NA 6-12 yo,8.59,16.1,NA NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
 998,Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100,  0 100,100,Moderate Neurofeedback NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA,ADHD-RS, 2.76179517 NA,h/week,Rahami,2022,NA RCT,G  26, 26,  52,NA NA  0.8500000000, 0.280000000  1.420000e+00 NA,NA NA,NA,NA,NA,NA NA,  0,  0,100,100 100,100,  0,low,low,low,high some,WLC   0 NA 11.560000,NA DSM-5 0 1 0.5,1.0,1.0,1.0,1,1 2 0,1 1 1,0.5,0,1 1,1  700,Rahami_2022 2-6 months,NA 6-12 yo,8.57,13.9,NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
 998 Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100,  0 100,100,Moderate,Neurofeedback NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) NA,ADHD RS, 3.91254315,   1.3300000,h/week,Shereena,2019,NA RCT,G, 15  15,  30,outcomes NA, 1.3200000000, 0.520000000, 2.120000e+00 NA,NA NA,NA,NA,NA,NA,NA,  0,  0,100,100   0 100,  0,some,low high high some,TAU   0,NA, 9.200000,NA,ICD-10 0,1 0.5 1.0 1.0,1.0 1,1,2,0,1,1 1,0.5 0,1 1 1  701 Shereena_2019,2-6 months,NA 6-12 yo 8.57 13.9 NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
 998,Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0,100 100,Moderate,Neurofeedback,NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks),NA,ADHD RS, 3.91254315    1.3300000,h/week,Shereena,2019,NA,RCT,G, 14, 11   25,outcomes NA  1.3200000000, 0.430000000, 2.200000e+00,NA,NA NA,NA,NA NA NA NA,  0   0,100,100,  0,100,  0 some,low,high,high some,TAU   0,NA  9.200000 NA,ICD-10 0,1,0.5 1.0 1.0,1.0 1 1 2 0,1,1 1,0.5 0 1,1,1, 702 Shereena_2019 2-6 months NA 6-12 yo,8.58,12.4,NA,NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
 998 Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100,  0 100,100 Moderate,Neurofeedback NA,  0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks),NA,Go/No-go test  3.91254315,   1.3300000 h/week Shereena 2019 NA RCT,G  15, 15   30 outcomes NA -0.4100000000,-1.130000000, 3.100000e-01,NA,NA NA NA NA NA NA NA   0   0,100 100   0 100   0 some low high,high some,TAU   0,NA, 9.200000 NA,ICD-10,0 1,0.5,1.0,1.0,1.0,1 1,2 0 1,1,1,0.5 0,1 1 1  703,Shereena_2019,2-6 months NA 6-12 yo,8.59,16.1 NA NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
 998,Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100   0 100 100 Moderate Neurofeedback,NA   0,NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA Go/No-go test  3.91254315,   1.3300000,h/week Shereena,2019,NA RCT,G, 15  15,  30 outcomes,NA  0.6200000000 -0.110000000, 1.360000e+00,NA,NA NA,NA,NA NA,NA,NA   0,  0,100 100   0,100   0 some low,high high some TAU,  0 NA  9.200000,NA ICD-10,0 1 0.5,1.0,1.0,1.0 1 1 2,0 1,1 1,0.5,0 1,1 1  704,Shereena_2019,2-6 months,NA,6-12 yo,8.59,16.1 NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
 998 Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100   0,100,100 Moderate,Neurofeedback NA,  0,NA Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA,n-back, 3.91254315,   1.3300000,h/week,Shereena,2019 NA RCT G, 26  20,  46,outcomes,NA  0.4600000000,-0.460000000, 1.380000e+00 NA NA NA NA,NA NA NA NA   0,  0 100 100   0,100   0,some,low high high,some,TAU   0,NA  9.200000,NA ICD-10 0 1,0.5,1.0,1.0,1.0 1,1,2,0 1 1 1 0.5,0,1 1 1, 705 Shereena_2019,2-6 months,NA,6-12 yo 8.59,16.1 NA,NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100,  0 100,100 Moderate Neurofeedback NA,  0 NA,Executive functioning (tests) NA,At study endpoint (closest to 12 weeks),NA,Spatial Span Test  3.91254315,   1.3300000,h/week,Shereena 2019 NA,RCT,G, 15, 15,  30,outcomes NA -0.1000000000,-0.600000000, 4.100000e-01,NA,NA,NA NA NA,NA,NA,NA   0   0 100 100   0,100   0 some low,high,high some TAU   0,NA, 9.200000,NA,ICD-10 0 1 0.5 1.0,1.0,1.0,1,1 2,0,1,1,1 0.5,0 1 1,1, 706 Shereena_2019 2-6 months,NA 6-12 yo 8.59,16.1 NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998 Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100   0 100,100 Moderate,Neurofeedback NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA,BOSS Classroom Observation, 2.99194476    2.2500000 h/week,Steiner 2014 NA,RCT G  34, 36   70 NA,NA  0.0100000000 -0.810000000, 8.200000e-01 NA,NA,NA,NA NA,NA NA NA,  0   0 100,100 100 100,  0 low,low low high some,TAU,  0,NA, 8.570000,NA DSM-IV,0 1,0.5 1.0,1.0,1.0,1,1 2,0,1 1 1,0.5,0 1 1,1, 707,Steiner_2014,2-6 months NA 6-12 yo,8.57,10.6,NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
 998,Westwood - Children (2025) Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702,100,  0 100,100 Moderate Neurofeedback NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA Conners 3 P  2.99194476    2.2500000,h/week Steiner 2014 NA RCT G  34, 36   70,NA,NA, 0.4300000000,-0.060000000  9.200000e-01,NA NA NA,NA,NA,NA NA,NA   0   0 100 100,100,100,  0,low,low,low high some TAU,  0 NA, 8.570000,NA,DSM-IV 0 1,0.5,1.0 1.0 1.0 1,1,2,0,1,1 1 0.5 0 1,1,1, 708 Steiner_2014,2-6 months NA,6-12 yo 8.57,13.9,NA,NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
 998 Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100,  0 100 100,Moderate Neurofeedback,NA   0 NA,Executive functioning (report),Parent-rated,At study endpoint (closest to 12 weeks),NA,BRIEF  2.99194476,   2.2500000,h/week,Steiner,2014,NA,RCT,G  34, 36,  70,NA NA  0.6300000000, 0.150000000  1.110000e+00 NA,NA NA NA NA NA NA,NA,  0   0,100,100 100 100   0 low low low,high some,TAU   0,NA  8.570000 NA DSM-IV,0,1,0.5,1.0 1.0,1.0 1,1 2 0,1,1 1,0.5 0 1,1 1, 709,Steiner_2014 2-6 months NA 6-12 yo 8.57,12.4,NA NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
 998 Westwood - Children (2025),Westwood - Children,2025,10.1001/jamapsychiatry.2024.3702 100   0,100 100 Moderate Neurofeedback NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks) NA Conners 3 P  2.99194476,   2.2500000,h/week Steiner,2014,NA,RCT G, 34  36,  70,NA NA  0.5400000000, 0.150000000, 9.300000e-01 NA NA,NA NA NA,NA,NA,NA,  0   0 100,100 100 100,  0 low,low low high,some,TAU,  0,NA  8.570000 NA,DSM-IV,0 1,0.5 1.0,1.0 1.0 1 1,2,0,1 1 1 0.5,0,1 1 1, 710,Steiner_2014,2-6 months NA,6-12 yo 8.57,13.2,NA NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low,high
 998 Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702,100,  0 100,100,Moderate,Neurofeedback NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA CRS-R  3.68239356    1.0000000 h/week Steiner,2011,NA,NA,G,  9, 11   20 NA,NA, 1.1900000000  0.230000000, 2.150000e+00,NA,NA NA,NA,NA NA NA NA   0   0 100 100 100,100,  0 low,low,low high,some,WLC   0,NA 12.400000,NA,NA,0,1,0.5 1.0 1.0,1.0,1,1,2 0,1,1,1,0.5,0 1 1 1  711,Steiner_2011,2-6 months,NA 6-12 yo,8.57 13.9 NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
 998 Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0,100,100 Moderate,Neurofeedback NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA,CRS-R, 3.68239356    1.0000000,h/week,Steiner,2011,NA,NA,G   9  13,  22,NA,NA,-0.2500000000 -1.110000000  6.000000e-01,NA,NA NA,NA,NA NA NA NA   0,  0 100,100,100,100,  0,low low low high,some,WLC   0,NA,12.400000 NA,NA,0,1 0.5 1.0,1.0 1.0 1,1 2,0 1,1,1,0.5 0 1 1,1, 712,Steiner_2011 2-6 months NA,6-12 yo 8.58 12.4 NA NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
 998 Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100   0 100,100 Moderate Neurofeedback,NA,  0 NA,Executive functioning (report),Parent-rated,At study endpoint (closest to 12 weeks),NA,BRIEF, 3.68239356    1.0000000,h/week,Steiner,2011,NA NA G,  9  11,  20,NA,NA, 0.1900000000 -0.700000000  1.070000e+00 NA NA,NA,NA NA NA NA,NA,  0   0,100,100 100 100,  0 low,low low high,some WLC,  0 NA 12.400000,NA,NA,0 1,0.5,1.0,1.0,1.0,1,1,2,0,1,1 1,0.5,0,1,1,1  713,Steiner_2011,2-6 months NA,6-12 yo 8.57,12.4,NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
 998,Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0 100,100,Moderate Neurofeedback NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) NA ADHD FBB-HKS  2.30149597    1.6700000 h/week Strehl 2017,NA,RCT,G  75, 69, 144 NA NA, 0.3900000000, 0.060000000  7.200000e-01,NA,NA,NA,NA,NA,NA NA,NA,  0,  0 100 100,100 100   0,low low,low high,some Sham_semi_active   0 NA, 8.590000,NA,DSM-IV 0 1 0.5 1.0 1.0,1.0,1,1 2,0 1,1 1,0.5 0,1,1,1  714,Strehl_2017,2-6 months,NA,6-12 yo 8.57,13.9 NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
 998 Westwood - Children (2025),Westwood - Children,2025 10.1001/jamapsychiatry.2024.3702 100   0 100 100,Moderate,Neurofeedback,NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA,ADHD FBB-HKS, 2.30149597    1.6700000 h/week Strehl,2017,NA RCT G  75  69, 144,NA,NA, 0.1200000000,-0.210000000, 4.500000e-01,NA NA NA,NA NA NA NA NA,  0,  0 100,100,100 100   0 low,low low high some Sham_semi_active   0 NA, 8.590000,NA,DSM-IV 0,1,0.5 1.0,1.0,1.0,1 1 2 0,1 1,1 0.5 0,1,1,1  715 Strehl_2017 2-6 months NA 6-12 yo,8.58 12.4,NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
 998 Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0,100 100 Moderate,Neurofeedback NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA ADHD-RS  3.45224396 NA,h/week van Dongen-Boomsma,2013,NA RCT G  22  19   41 NA,NA  0.1700000000,-0.440000000  7.800000e-01,NA,NA,NA NA,NA,NA NA NA,100,100 100,100 100,100 100,low,low,low low some Sham_semi_active   0 NA 10.600000,NA DSM-IV 0,1 0.5 1.0 1.0,1.0 1,1,2 0 1 1 1 0.5 0 1 1 1, 716 van Dongen-Boomsma_2013 2-6 months NA,6-12 yo 8.57 10.6 NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 998,Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0,100 100 Moderate,Neurofeedback,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks) NA,ADHD-RS, 3.45224396 NA,h/week van Dongen-Boomsma,2013,NA,RCT,G  22  19   41 NA NA,-0.1400000000 -0.760000000, 4.700000e-01,NA,NA,NA NA,NA,NA,NA NA,100 100,100 100,100 100,100,low low,low,low,some,Sham_semi_active,  0,NA 10.600000 NA DSM-IV 0,1,0.5 1.0,1.0,1.0,1,1 2,0 1,1 1 0.5,0 1 1 1, 717,van Dongen-Boomsma_2013 2-6 months NA,6-12 yo,8.58,12.4 NA,NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 998 Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0,100,100,Moderate Neurofeedback NA,  0,NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA Digit span WISC III  3.45224396,NA h/week,Vollebregt 2014 NA,RCT G, 22  19,  41 outcomes NA,-0.2000000000,-0.827034185, 4.270342e-01,NA NA NA NA,NA,NA NA,NA,100 100 100 100 100,100 100 low,low low,low some,Sham_semi_active   0 NA 10.600000 NA,DSM-IV,0,1,0.5,1.0,1.0 1.0,1 1,2,0 1,1,1 0.5 0,1,1,1, 718,Vollebregt_2014 2-6 months,NA,6-12 yo 8.59 16.1,NA NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 998,Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100,  0,100 100,Moderate Neurofeedback NA,  0 NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks) NA Sustained Attention dots task (SA-DOTS)  3.45224396 NA,h/week,Vollebregt 2014 NA RCT G  22  19,  41 outcomes,NA -0.2100000000 -0.830000000, 4.100000e-01,NA,NA NA,NA,NA,NA,NA NA 100,100,100 100,100,100,100,low low,low,low some,Sham_semi_active,  0 NA,10.600000 NA,DSM-IV 0,1,0.5 1.0 1.0 1.0 1,1 2,0 1,1,1,0.5,0 1,1,1, 719 Vollebregt_2014 2-6 months,NA 6-12 yo 8.59 16.1 NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 998,Westwood - Children (2025),Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100,  0,100 100,Moderate,Neurofeedback NA,  0,NA,Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA Sustained Attention dots task (SA-DOTS)  3.45224396,NA,h/week Vollebregt 2014,NA,RCT,G, 22  19   41 outcomes,NA,-0.1100000000 -0.737034185, 5.170342e-01,NA,NA,NA NA,NA,NA NA NA,100 100 100 100,100 100,100 low low low,low,some,Sham_semi_active,  0 NA,10.600000 NA DSM-IV 0 1 0.5 1.0,1.0,1.0,1 1 2 0 1,1,1,0.5,0,1 1,1, 720,Vollebregt_2014 2-6 months,NA,6-12 yo,8.59,16.1,NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 998 Westwood - Children (2025),Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0,100 100 Moderate,Neurofeedback,NA   0 NA,Executive functioning (tests),NA At study endpoint (closest to 12 weeks),NA,Visuospatial Sequencing (VSS)  3.45224396 NA,h/week Vollebregt,2014 NA,RCT G, 22, 19,  41 outcomes NA,-0.5800000000 -1.227261094  6.726109e-02,NA,NA NA,NA NA,NA,NA NA 100,100 100,100 100,100 100,low,low,low low,some,Sham_semi_active   0 NA,10.600000,NA DSM-IV,0 1 0.5,1.0 1.0 1.0 1,1 2 0 1,1 1,0.5,0,1,1,1  721 Vollebregt_2014,2-6 months,NA,6-12 yo 8.59,16.1,NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 998 Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702,100   0 100,100 Moderate,Neurofeedback NA   0,NA,Executive functioning (tests),NA,At study endpoint (closest to 12 weeks) NA Attention Network Test - Conflict, 1.38089758,NA h/week,Wangler,2011 NA,RCT G, 56, 28   84,outcomes,NA,-0.2900000000 -0.747543268, 1.675433e-01,NA NA,NA NA,NA,NA,NA,NA   0,  0,100 100,100 100   0 low low,some,high,some,Sham_semi_active,  0,NA, 9.700000,NA,DSM-IV 0,1 0.5,1.0 1.0 1.0 1,1,2 0 1,1,1 0.5,0,1 1,1, 722 Wangler_2011 < 2 months,NA,6-12 yo,8.59,16.1,NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 998 Westwood - Children (2025) Westwood - Children 2025,10.1001/jamapsychiatry.2024.3702 100,  0,100 100 Moderate,Neurofeedback,NA,  0 NA Executive functioning (tests) NA,At study endpoint (closest to 12 weeks) NA,Attention Network Test - MRT, 1.38089758,NA,h/week,Wangler,2011,NA,RCT G  56, 28   84 outcomes NA, 0.3200000000,-0.100000000  7.400000e-01 NA,NA NA,NA NA,NA NA NA,  0,  0 100 100,100 100,  0,low low,some high some,Sham_semi_active   0,NA  9.700000,NA DSM-IV,0 1,0.5,1.0 1.0 1.0 1,1 2,0,1,1,1,0.5 0 1 1,1, 723 Wangler_2011 < 2 months,NA,6-12 yo 8.59 16.1 NA NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 998,Westwood - Children (2025) Westwood - Children 2025 10.1001/jamapsychiatry.2024.3702 100,  0 100,100,Moderate,Neurofeedback NA,  0,NA Executive functioning (tests) NA At study endpoint (closest to 12 weeks),NA Attention Network Test - Orienting  1.38089758,NA h/week,Wangler 2011,NA,RCT G  56  28,  84,outcomes,NA,-0.1000000000,-0.560000000, 3.500000e-01 NA NA NA,NA NA,NA NA,NA   0   0 100 100,100 100   0 low low some,high,some,Sham_semi_active   0 NA  9.700000,NA,DSM-IV 0 1 0.5 1.0,1.0,1.0,1,1 2 0,1,1 1 0.5,0 1 1,1, 724 Wangler_2011 < 2 months NA,6-12 yo 8.59 16.1,NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA,NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
 998 Westwood - Adults (2025) Westwood - Adults,2025 10.1001/jamapsychiatry.2024.3702,100   0 100,100,Moderate Neurofeedback NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) NA ADHD DSM-IV rating scale - Combined, 0.92059839,NA,h/week,Zilverstand 2017,NA,RCT G   7,  6   13,NA,NA  0.3400000000 -0.826522135, 1.506522e+00,NA,NA,NA NA NA,NA,NA NA,100,100,100,100 100,100,100 low low,low,low,some Sham_semi_active   0 NA,36.900000,NA DSM-IV 0,1 0.5,1.0,1.0 1.0,1,1,2,0 1 1 1 0.5,0 1 1 1, 725,Zilverstand_2017 < 2 months,NA,>= 20 yo 33.64,36.9,NA,NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA Westwood - Adults (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Westwood - Adults (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 998 Westwood - Adults (2025) Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702 100,  0 100 100 Moderate Neurofeedback,NA   0,NA Executive functioning (tests) Self-rated,At study endpoint (closest to 12 weeks),NA,2-back visuospatial task % correct  0.92059839 NA h/week Zilverstand,2017,NA RCT G,  7,  6,  13,outcomes,NA  0.2600000000 -0.840000000  1.350000e+00 NA,NA,NA NA,NA,NA,NA NA 100,100 100 100,100 100,100,low,low low low some,Sham_semi_active,  0 NA 36.900000 NA DSM-IV 0 1,0.5 1.0 1.0,1.0 1,1 2 0 1,1 1 0.5,0 1 1 1  726 Zilverstand_2017,< 2 months,NA,>= 20 yo 33.64 36.9,NA NA  36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 998 Westwood - Adults (2025),Westwood - Adults 2025 10.1001/jamapsychiatry.2024.3702 100,  0,100 100 Moderate,Neurofeedback NA,  0,NA,Executive functioning (tests),Self-rated At study endpoint (closest to 12 weeks) NA Digit Span IQ, 0.92059839 NA,h/week,Zilverstand,2017,NA RCT,G   7   6   13,outcomes NA,-0.1400000000,-1.230000000  9.500000e-01 NA,NA NA NA NA,NA,NA NA,100 100,100,100,100 100 100 low low,low,low some,Sham_semi_active   0,NA 36.900000 NA DSM-IV,0,1,0.5,1.0 1.0 1.0,1,1,2,0,1 1 1,0.5,0,1,1,1, 727 Zilverstand_2017,< 2 months NA >= 20 yo 33.64 36.9 NA NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 998,Westwood - Adults (2025) Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702,100,  0,100 100,Moderate,Neurofeedback,NA,  0,NA Executive functioning (tests),Self-rated At study endpoint (closest to 12 weeks) NA SA-DOTS - False Alarms, 0.92059839 NA,h/week,Zilverstand 2017 NA RCT,G,  7   6,  13,outcomes,NA  0.5100000000,-0.610000000  1.620000e+00 NA,NA NA NA NA NA NA NA 100,100 100,100 100 100,100,low,low low,low some Sham_semi_active,  0 NA,36.900000 NA,DSM-IV 0,1,0.5,1.0,1.0 1.0,1 1 2,0 1,1 1,0.5 0,1,1,1, 728,Zilverstand_2017,< 2 months NA >= 20 yo,33.64 36.9 NA,NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 998,Westwood - Adults (2025) Westwood - Adults,2025,10.1001/jamapsychiatry.2024.3702,100   0,100 100,Moderate Neurofeedback,NA,  0,NA,Executive functioning (tests) Self-rated At study endpoint (closest to 12 weeks),NA,SART (equivalent to GNG) - Coms, 0.92059839 NA,h/week,Zilverstand,2017 NA RCT,G   7,  6   13,outcomes NA  0.1600000000 -0.940000000, 1.250000e+00 NA NA NA,NA NA,NA,NA NA 100,100 100 100,100 100,100 low,low,low low some Sham_semi_active   0 NA,36.900000 NA,DSM-IV 0 1 0.5,1.0,1.0 1.0 1 1,2 0,1 1 1,0.5,0 1 1,1  729,Zilverstand_2017,< 2 months,NA,>= 20 yo,33.64 36.9,NA,NA  36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
2118 Liu (2023) Liu,2023,10.1111/papt.12455,100,  0 100,100,Low Mindfulness,Mindfulness-based CBT,100,TaU Depressive disorder symptoms,Mixed,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA  1.38089758    1.0000000 session/week Gu,2018 NA,RCT (parallel, crossover, open-label) SMD, 28  26,  54 NA,reverse,-0.7700000000 -1.330000000 -2.200000e-01,  2.9000000,  3.1400000 NA NA NA NA NA NA   0   0 100,  0,100 100,  0 some high low,high low WLC (wait-list control)   0, 44.444444,20.291852,NA DSM-V,1,1,0.0,1.0 1.0 1.0,1,1 1,1 1 1 1 1.0,0 1,1 1  730 Gu_2018 < 2 months,NA >= 20 yo,20.2918518518519,35.8941747572816 NA NA, 13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35 NA,NA,Liu (2023)_Mindfulness_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Liu (2023) - Mindfulness_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low high
2118 Liu (2023),Liu 2023 10.1111/papt.12455 100   0 100 100,Low Mindfulness,Mindfulness-based CBT 100 TaU Depressive disorder symptoms Mixed,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA, 2.76179517    1.0000000 session/week Hepark,2019 NA,RCT (parallel, crossover, open-label) SMD  55, 48  103 NA,reverse,-0.2800000000,-0.670000000, 1.000000e-01,  5.2900000,  5.9000000 NA NA,NA,NA NA,NA,100 100 100   0 100 100,100,some,high low low low WLC (wait-list control)   0  54.543689 35.894175,NA,DSM-IV,1 1 0.0 1.0,1.0 1.0 1,1,1 1,1 1 1,1.0,0 1 1,1, 731,Hepark_2019 2-6 months NA >= 20 yo,20.2918518518519,35.8941747572816,NA,NA  13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35 NA,NA Liu (2023)_Mindfulness_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Liu (2023) - Mindfulness_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
2118,Liu (2023),Liu,2023,10.1111/papt.12455,100,  0 100,100,Low Mindfulness Mindfulness-based CBT,100,TaU Quality of life (patients) Mixed,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome),NA, 2.76179517,   1.0000000,session/week,Hepark,2019 NA RCT (parallel, crossover, open-label),SMD  55  48, 103 NA,reverse, 0.2700000000 -0.120000000, 6.600000e-01  12.0400000  14.5000000,NA NA,NA,NA NA NA 100,100 100   0,100,100,100 some,high low low low,WLC (wait-list control)   0, 54.543689 35.894175,NA DSM-IV 1,1,0.0,1.0,1.0,1.0,1,1,1 1 1 1 1,1.0,0,1,1 1, 732 Hepark_2019 2-6 months NA >= 20 yo,35.8941747572816,39.35 NA,NA, 13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35,NA,NA,Liu (2023)_Mindfulness_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Liu (2023) - Mindfulness_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
2118,Liu (2023),Liu 2023,10.1111/papt.12455,100   0 100 100 Low,Mindfulness,Mindfulness-based CBT 100 TaU,Quality of life (patients) Mixed,At study endpoint (closest to 12 weeks),Unclear (not able to identify the tools used to measure the outcome) NA  1.84119678,   1.0000000 session/week,Janssen,2019,NA,RCT (parallel, crossover, open-label) SMD, 60, 60, 120,NA,reverse -0.0100000000 -0.370000000  3.500000e-01, 10.9700000, 13.5200000 NA,NA,NA,NA,NA NA   0   0   0,  0 100,100,100 high,high low low,low,TAU   0  53.000000,39.350000,NA DSM-IV 1 1 0.0 1.0,1.0,1.0 1,1 1,1,1 1 1,1.0 0,1 1 1, 733 Janssen_2019 < 2 months NA >= 20 yo,35.8941747572816,39.35,NA NA, 13, 8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35 NA NA,Liu (2023)_Mindfulness_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Liu (2023) - Mindfulness_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,high
8996 Yin - adults (2024) Yin - adults 2024 10.3390/brainsci14121237   0   0 100,100,Critically low,tDCS (transcranial direct current stimulation),NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Questionnaire,NA,NA   20.0000000,min/session,Allenby 2018 NA,RCT (parallel, crossover, open-label) G  37  37,  74 outcomes,reverse,-1.6100000000 -2.140000000 -1.080000e+00   1.5000000   1.8000000,NA NA,NA NA,NA,NA   0   0,100 100 100,100   0 low,low low,high,low Sham   0  25.710000 NA,NA,NA 2 1,0.0 0.0,1.0 1.0 1 1,3 1,1,0 1 0.5 0 1 0,1, 734,Allenby_2018,NA NA,NA 22,38.3 NA,NA  19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857,NA,NA Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low high
8996,Yin - adults (2024),Yin - adults,2024,10.3390/brainsci14121237,100   0,100,100,Critically low,tDCS (transcranial direct current stimulation),NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) Questionnaire NA,NA   20.0000000 min/session Barham,2022 NA,RCT (parallel, crossover, open-label),G, 11  11,  22 NA reverse -0.4700000000,-1.320000000, 3.800000e-01,  1.0700000,  1.3400000 NA NA NA,NA NA,NA,100 100,100,100,100,100,100,low some low,some,low Sham,  0  68.200000 22.000000 NA NA 2 1 0.0,0.0 1.0,1.0,1 1,3 1 1,0,1,0.5,0,1,0 1, 735 Barham_2022 NA,NA >= 20 yo 22,38.3 NA,NA, 19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA,NA Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
8996,Yin - adults (2024) Yin - adults,2024 10.3390/brainsci14121237,100   0 100 100 Critically low,tDCS (transcranial direct current stimulation) NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire,ASRS,NA,  20.0000000,min/session Cachoeria,2017 NA RCT (parallel, crossover, open-label),G   9   8   17,outcomes,reverse -2.5100000000 -3.860000000 -1.160000e+00   2.1900000,  1.9200000 NA NA NA NA NA,NA,100 100,100,100,100 100 100,low,some low,low,low,Sham   0  52.940000 32.294118,NA NA 2,1 0.0,0.0 1.0,1.0 1 1,3,1 1 0,1,0.5 0,1,0,1  736 Cachoeria_2017 NA,NA >= 20 yo 22,38.3,NA,NA, 19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857 NA,NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
8996,Yin - adults (2024) Yin - adults 2024,10.3390/brainsci14121237 100,  0 100,100 Critically low tDCS (transcranial direct current stimulation) NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) Questionnaire NA NA   20.0000000 min/session Jacoby 2018,NA,RCT (parallel, crossover, open-label) G  20  20,  40 outcomes,reverse -0.1000000000 -0.720000000, 5.200000e-01, 50.8300000, 53.4800000,NA NA NA NA,NA NA 100 100,100,100,100,100 100 low,some low,low low,Sham   0, 55.000000,22.750000 NA,NA,2 1 0.0 0.0,1.0,1.0 1 1 3,1,1 0 1 0.5 0 1,0,1  737,Jacoby_2018 NA,NA >= 20 yo 22,38.3 NA,NA, 19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA,NA Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
8996,Yin - adults (2024) Yin - adults 2024 10.3390/brainsci14121237 100   0 100 100 Critically low,tDCS (transcranial direct current stimulation) NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),Questionnaire ASRS NA,  30.0000000 min/session,Leffa 2022,NA,RCT (parallel, crossover, open-label) G, 32, 32,  64 outcomes,reverse,-0.9500000000,-1.460000000,-4.300000e-01   5.7900000,  3.9700000,NA,NA NA,NA NA,NA 100 100,100 100,100 100,100,low low low,low low Sham   0, 46.880000,38.300000 NA NA 2,1 0.0 0.0,1.0,1.0 1,1 3,1,1,0 1 0.5,0,1 0 1  738 Leffa_2022,NA NA >= 20 yo 22,38.3,NA NA, 19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857,NA,NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
8996,Yin - children (2024),Yin - children,2024 10.3390/brainsci14121237,100,  0,100,100 Critically low,tDCS (transcranial direct current stimulation) NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks),Questionnaire NA NA   30.0000000 min/session Guimaraes 2024,NA RCT (parallel, crossover, open-label),G  15, 15,  30,NA reverse,-0.0800000000 -0.800000000, 6.400000e-01, 24.3000000  27.7500000,NA,NA,NA,NA NA NA 100,100 100,100,100 100 100,low,low low low,low Sham,  0, 33.330000,11.200000 NA NA 2 1,0.0,0.0 1.0 1.0 1 1 3 1 1,0 1 0.5,0,1,0,1, 739,Guimaraes_2024 NA,NA 6-12 yo 11.2,14.2,NA,NA  19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857 NA NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
8996,Yin - children (2024) Yin - children 2024 10.3390/brainsci14121237,100,  0 100 100 Critically low tDCS (transcranial direct current stimulation) NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) Questionnaire,FBB-ADHD,NA,  20.0000000,min/session,Soff 2017 NA,RCT (parallel, crossover, open-label),G, 15  15   30 outcomes,reverse  0.6200000000 -0.120000000, 1.360000e+00,  0.4600000   0.5700000 NA NA NA NA NA NA,100,100,100,100,100 100 100,low some,low,some,low,Sham,  0  20.000000 14.200000 NA,NA,2,1,0.0 0.0,1.0,1.0,1 1,3,1,1 0,1,0.5 0,1,0 1  740,Soff_2017,NA NA 13-19 yo,11.2 14.2 NA NA  19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857,NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
8996,Yin - adults (2024) Yin - adults 2024,10.3390/brainsci14121237,100   0 100,100,Critically low tDCS (transcranial direct current stimulation) NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire,ASRS,NA   20.0000000,min/session Cachoeria 2017,NA,RCT (parallel, crossover, open-label) G   9   8   17,outcomes reverse,-1.7800000000 -2.960000000,-6.100000e-01,  2.9000000   3.3800000 NA,NA,NA NA NA,NA 100,100,100 100 100 100 100 low,some low,low,low Sham,  0  52.940000,32.294118 NA,NA 2 1,0.0 0.0 1.0 1.0,1,1,3,1 1 0,1,0.5 0,1,0,1, 741 Cachoeria_2017,NA,NA >= 20 yo 22 38.3,NA,NA, 19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857,NA NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
8996,Yin - adults (2024),Yin - adults,2024 10.3390/brainsci14121237 100,  0,100,100,Critically low tDCS (transcranial direct current stimulation),NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) Questionnaire,NA,NA,  20.0000000 min/session,Jacoby 2018 NA,RCT (parallel, crossover, open-label),G  20, 20,  40,outcomes,reverse -0.4700000000,-1.100000000  1.600000e-01,  4.4300000,  6.3300000,NA NA,NA,NA,NA NA,100 100 100 100 100 100 100 low some,low low,low,Sham,  0, 55.000000 22.750000 NA,NA 2,1,0.0 0.0 1.0 1.0,1,1,3 1,1 0 1 0.5 0 1 0,1  742 Jacoby_2018,NA NA,>= 20 yo 22 38.3,NA NA, 19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857 NA NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
8996,Yin - adults (2024) Yin - adults,2024,10.3390/brainsci14121237,100   0 100,100,Critically low,tDCS (transcranial direct current stimulation) NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Questionnaire,ASRS,NA,  30.0000000,min/session,Leffa 2022 NA,RCT (parallel, crossover, open-label),G  32  32,  64 outcomes,reverse -0.2700000000,-0.760000000, 2.200000e-01,  7.5500000   6.7000000 NA NA NA,NA NA,NA 100,100,100 100,100 100 100,low,low low,low low,Sham,  0, 46.880000,38.300000,NA,NA 2 1,0.0,0.0,1.0,1.0,1 1,3,1 1 0 1,0.5,0 1,0 1  743,Leffa_2022 NA,NA,>= 20 yo,22 38.3,NA,NA, 19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857,NA NA Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
8996,Yin - children (2024),Yin - children,2024,10.3390/brainsci14121237,100   0 100 100,Critically low tDCS (transcranial direct current stimulation) NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire,FBB-ADHD,NA,  20.0000000,min/session,Soff,2017,NA RCT (parallel, crossover, open-label),G, 15, 15   30,outcomes,reverse, 0.3800000000 -0.340000000, 1.110000e+00,  0.4800000,  0.6300000,NA,NA,NA NA NA NA 100 100 100,100,100 100 100,low some low,some,low,Sham   0  20.000000,14.200000,NA NA 2 1,0.0 0.0 1.0,1.0,1,1,3,1 1 0,1,0.5 0 1 0 1  744 Soff_2017,NA,NA 13-19 yo,11.2 14.2,NA,NA, 19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857 NA,NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
8996 Yin - adults (2024) Yin - adults,2024,10.3390/brainsci14121237,  0,  0 100 100,Critically low,tDCS (transcranial direct current stimulation),NA,  0,NA,Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks) Test stop-signal task,NA   20.0000000 min/session Allenby 2018,NA RCT (parallel, crossover, open-label),G  37, 37   74,outcomes reverse,-0.2600000000,-0.720000000  2.000000e-01, 12.5000000  11.2000000,NA,NA,NA NA NA,NA,  0   0 100,100 100,100   0,low low,low high low Sham   0, 25.710000,NA NA NA,2,1,0.0 0.0 1.0 1.0,1 1,3 1,1,0 1,0.5 0 1,0,1  745,Allenby_2018 NA,NA,NA 22 32.25 NA,NA, 19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA,NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,high
8996 Yin - adults (2024) Yin - adults,2024 10.3390/brainsci14121237,100   0 100,100,Critically low tDCS (transcranial direct current stimulation),NA   0 NA,Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks),Test,stroop task NA,  20.0000000,min/session Barham 2022 NA,RCT (parallel, crossover, open-label),G  11, 11,  22 outcomes,reverse,-0.9800000000,-1.870000000,-8.000000e-02,  0.0001000   0.5000000 NA NA NA,NA,NA NA,100,100,100 100 100,100,100 low,some,low,some low,Sham,  0  68.200000 22.000000,NA NA 2,1,0.0 0.0 1.0 1.0 1 1 3,1,1 0 1 0.5,0,1 0,1  746 Barham_2022,NA NA,>= 20 yo 22,32.25,NA,NA  19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857,NA,NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
8996 Yin - adults (2024),Yin - adults,2024,10.3390/brainsci14121237 100,  0,100 100 Critically low tDCS (transcranial direct current stimulation) NA   0 NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks) Test,go/no-go NA   20.0000000,min/session,Cosmo 2015 NA,RCT (parallel, crossover, open-label),G  30, 30,  60 NA,reverse -0.0700000000 -0.570000000, 4.400000e-01  17.1400000, 20.4100000 NA NA,NA NA NA NA 100 100 100,100 100 100 100 low,some,some low low Sham,  0  41.665000 32.250000,NA NA 2,1 0.0 0.0,1.0 1.0 1 1 3,1,1 0 1 0.5,0,1 0 1, 747,Cosmo_2015 NA NA >= 20 yo 22,32.25,NA NA, 19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
8996,Yin - children (2024),Yin - children,2024,10.3390/brainsci14121237 100   0 100,100 Critically low,tDCS (transcranial direct current stimulation),NA,  0 NA,Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks) Test,flanker,NA,  20.0000000 min/session,Breitling,2016,NA,RCT (parallel, crossover, open-label),G   7   7   14,outcomes,reverse -0.2200000000 -1.270000000, 8.300000e-01,  7.8000000   9.2000000 NA NA NA,NA,NA,NA   0   0,100,100,100,  0 100,some some,low,low,high Sham,  0   0.000000,13.300000,NA NA 2,1,0.0,0.0,1.0,1.0,1 1,3 1 1,0 1,0.5,0 1 0 1, 748,Breitling_2016 NA NA 13-19 yo,8.86,16.06,NA NA, 19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857 NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high,high
8996 Yin - children (2024),Yin - children 2024 10.3390/brainsci14121237,100   0 100 100 Critically low tDCS (transcranial direct current stimulation) NA,  0,NA,Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks),Test flanker,NA,  20.0000000 min/session,Breitling,2016 NA RCT (parallel, crossover, open-label) G,  7   7,  14 outcomes reverse -0.0900000000 -1.130000000  9.600000e-01   8.3000000   9.2000000,NA NA NA NA,NA,NA   0   0,100,100,100,  0,100,some,some,low low,high Sham,  0   0.000000,13.300000,NA NA,2 1,0.0,0.0,1.0 1.0,1 1 3,1,1 0,1,0.5,0,1,0 1, 749 Breitling_2016,NA,NA,13-19 yo 8.86 16.06,NA,NA, 19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857,NA,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high,high
8996,Yin - children (2024) Yin - children 2024,10.3390/brainsci14121237 100   0 100 100 Critically low tDCS (transcranial direct current stimulation) NA,  0 NA Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks) Test go/no-go,NA,  20.0000000 min/session,Breitling-Ziegler,2021 NA RCT (parallel, crossover, open-label) G,  9  13,  22,outcomes reverse, 0.4600000000,-0.410000000  1.320000e+00  18.1300000, 12.7300000 NA,NA,NA,NA,NA NA,100 100 100 100 100,100,100 low,some,low,low low Sham   0, 13.630000,13.409091,NA,NA,2,1 0.0,0.0 1.0,1.0 1,1,3,1 1 0,1,0.5 0,1,0,1  750 Breitling-Ziegler_2021,NA NA 13-19 yo,8.86 16.06 NA NA, 19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857 NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
8996 Yin - children (2024) Yin - children 2024,10.3390/brainsci14121237 100,  0 100,100 Critically low tDCS (transcranial direct current stimulation) NA,  0 NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks) Test stop-signal task NA,  20.0000000 min/session D'Aiello 2023,NA RCT (parallel, crossover, open-label),G, 26  26   52,outcomes,reverse -0.1000000000,-0.640000000, 4.400000e-01, 15.1600000, 20.6800000,NA,NA NA,NA,NA NA 100 100 100 100 100 100 100 low,some low some,low,Sham,  0,  7.700000,10.630000,NA,NA 2,1 0.0 0.0 1.0 1.0,1 1 3,1,1,0,1,0.5,0,1,0,1  751 D'Aiello_2023,NA NA,6-12 yo 8.86,16.06 NA NA  19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857 NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8996,Yin - children (2024) Yin - children,2024 10.3390/brainsci14121237,100,  0,100 100,Critically low,tDCS (transcranial direct current stimulation) NA   0 NA Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks),Test go/no-go,NA   15.0000000 min/session,Nejati,2020,NA RCT (parallel, crossover, open-label),G, 15, 15   30,outcomes reverse -0.0900000000,-0.800000000, 6.300000e-01  11.4200000,  7.8000000 NA NA,NA,NA NA NA,  0   0 100,100 100   0,100 low some some,low high Sham,  0, 50.000000  9.000000,NA,NA 2 1 0.0,0.0,1.0 1.0,1 1 3,1 1,0,1 0.5,0,1,0 1, 752,Nejati_2020 NA,NA 6-12 yo,8.86 16.06,NA NA, 19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
8996,Yin - children (2024) Yin - children,2024 10.3390/brainsci14121237,100,  0,100,100,Critically low tDCS (transcranial direct current stimulation) NA,  0 NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks) Test go/no-go NA,  15.0000000,min/session Nejati 2020 NA,RCT (parallel, crossover, open-label),G  10, 10,  20,outcomes reverse,-1.0400000000,-1.990000000 -9.000000e-02,  1.2200000,  4.3900000 NA NA NA NA NA NA   0   0,100 100,100,  0,100 low,some some low,high,Sham,  0, 50.000000  9.000000,NA NA 2 1 0.0,0.0,1.0,1.0 1,1,3 1 1,0 1,0.5,0 1 0 1  753 Nejati_2020,NA NA,6-12 yo 8.86 16.06,NA NA  19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857 NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high,high
8996,Yin - children (2024),Yin - children,2024,10.3390/brainsci14121237,100,  0 100,100 Critically low,tDCS (transcranial direct current stimulation) NA,  0 NA,Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks) Test,go/no-go NA   15.0000000 min/session Nejati,2020,NA,RCT (parallel, crossover, open-label),G  10, 10,  20 outcomes reverse -0.5900000000,-1.490000000  3.100000e-01,  1.3300000,  4.3900000,NA,NA,NA,NA NA,NA,  0,  0 100 100 100   0 100,low,some some,low high Sham   0  50.000000  9.000000,NA,NA 2 1 0.0 0.0 1.0 1.0 1 1 3,1,1,0,1,0.5,0,1,0,1  754,Nejati_2020 NA,NA 6-12 yo 8.86 16.06,NA NA  19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857,NA,NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high,high
8996,Yin - children (2024),Yin - children,2024 10.3390/brainsci14121237 100,  0,100 100,Critically low tDCS (transcranial direct current stimulation),NA,  0,NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks),Test go/no-go NA,  20.0000000 min/session,Nejati 2021 NA RCT (parallel, crossover, open-label) G, 11, 11   22,outcomes,reverse -0.6400000000,-1.500000000  2.200000e-01,  8.4700000, 17.0000000 NA,NA NA,NA,NA NA,100 100,100 100 100,100,100,some,some,low,some,low,Sham   0  36.370000  9.250000,NA,NA,2,1 0.0,0.0,1.0,1.0,1,1,3,1,1 0,1 0.5 0 1,0 1, 755 Nejati_2021,NA NA 6-12 yo 8.86 16.06 NA,NA  19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857 NA NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
8996,Yin - children (2024) Yin - children,2024 10.3390/brainsci14121237 100,  0 100,100,Critically low tDCS (transcranial direct current stimulation) NA,  0,NA Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks),Test go/no-go NA,  20.0000000,min/session,Nejati 2021 NA,RCT (parallel, crossover, open-label) G  13, 13,  26,outcomes reverse  0.6500000000,-0.140000000  1.440000e+00  17.5900000, 13.2800000,NA,NA NA,NA NA NA 100,100,100 100 100,100 100,some some low some low Sham   0, 36.370000  9.250000,NA,NA 2,1 0.0,0.0,1.0,1.0,1,1 3 1 1,0 1,0.5,0 1,0,1, 756 Nejati_2021,NA,NA,6-12 yo,8.86 16.06,NA,NA  19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857,NA,NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
8996 Yin - children (2024),Yin - children,2024 10.3390/brainsci14121237 100,  0 100 100,Critically low tDCS (transcranial direct current stimulation),NA   0 NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks),Test,go/no-go,NA   20.0000000 min/session,Nejati 2022,NA RCT (parallel, crossover, open-label) G  24, 24   48,outcomes reverse -0.1100000000 -0.680000000, 4.600000e-01  14.8200000, 16.5600000 NA NA,NA,NA,NA,NA,100 100 100,100 100,100,100,some,some low low low,Sham,  0  33.330000  9.250000 NA,NA,2,1 0.0 0.0,1.0 1.0 1 1 3 1,1,0 1,0.5 0 1,0 1  757 Nejati_2022,NA,NA 6-12 yo 8.86 16.06,NA,NA  19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857,NA,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
8996 Yin - children (2024) Yin - children 2024 10.3390/brainsci14121237 100,  0 100,100 Critically low,tDCS (transcranial direct current stimulation) NA,  0,NA,Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks) Test go/no-go NA   23.0000000,min/session,Salehinejad 2020 NA RCT (parallel, crossover, open-label) G  17, 17   34 NA reverse -0.2300000000 -0.900000000  4.400000e-01, 23.1060000  26.4570000 NA NA,NA,NA NA NA,100 100 100,100 100,100,100,some,low low,some low,Sham,  0  29.410000, 9.530000,NA NA,2 1 0.0 0.0 1.0,1.0 1,1 3 1,1,0 1,0.5 0,1 0 1, 758,Salehinejad_2020 NA,NA,6-12 yo 8.86 16.06,NA NA, 19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857,NA,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
8996 Yin - children (2024),Yin - children,2024 10.3390/brainsci14121237 100,  0 100 100 Critically low,tDCS (transcranial direct current stimulation) NA   0,NA Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks) Test go/no-go NA   15.0000000 min/session,Salehinejad,2022 NA,RCT (parallel, crossover, open-label),G  22  22,  44,outcomes,reverse -0.1500000000,-0.740000000  4.400000e-01  19.5100000, 27.1320000 NA,NA,NA NA NA,NA,100,100 100,100 100,100 100 some,some,low,some low,Sham,  0  50.000000  8.860000 NA,NA 2 1 0.0 0.0,1.0,1.0,1 1,3 1,1,0,1,0.5,0,1,0,1  759,Salehinejad_2022,NA NA 6-12 yo,8.86,16.06,NA NA, 19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857,NA NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
8996,Yin - children (2024) Yin - children,2024,10.3390/brainsci14121237 100,  0 100 100,Critically low tDCS (transcranial direct current stimulation),NA,  0 NA,Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks) Test go/no-go,NA,  15.0000000,min/session Soltaninejad 2019 NA RCT (parallel, crossover, open-label),G  20, 20   40,outcomes reverse -0.7300000000,-1.370000000 -9.000000e-02,  1.8600000,  6.8900000 NA,NA,NA,NA NA NA   0,  0 100 100,100   0 100,some some,low,low,high,Sham   0 NA,16.060000,NA NA,2 1 0.0 0.0 1.0,1.0 1,1,3 1 1 0,1,0.5 0,1,0,1  760 Soltaninejad_2019,NA NA 13-19 yo 8.86,16.06,NA NA  19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857,NA NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high,high
8996,Yin - children (2024),Yin - children,2024,10.3390/brainsci14121237,100,  0,100,100,Critically low,tDCS (transcranial direct current stimulation) NA   0 NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks),Test,go/no-go NA,  15.0000000 min/session,Soltaninejad,2019,NA,RCT (parallel, crossover, open-label) G  20, 20   40 outcomes,reverse,-0.0500000000 -0.670000000, 5.700000e-01,  8.2000000,  6.8900000 NA,NA NA NA NA NA   0   0,100,100 100   0 100,some some,low,low,high Sham   0,NA 16.060000,NA NA 2,1 0.0,0.0,1.0 1.0 1 1 3 1,1 0,1 0.5 0,1 0 1  761 Soltaninejad_2019 NA,NA,13-19 yo,8.86,16.06,NA,NA  19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857,NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
8996,Yin - adults (2024),Yin - adults,2024 10.3390/brainsci14121237   0   0 100 100,Critically low tDCS (transcranial direct current stimulation) NA,  0,NA Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks) Test n-bask task NA,  20.0000000,min/session Allenby 2018 NA,RCT (parallel, crossover, open-label),G  37  37,  74,outcomes NA, 0.4600000000  0.000000000, 9.300000e-01,  1.6000000,  2.2000000 NA,NA NA,NA,NA NA   0   0 100 100,100,100,  0,low low,low,high,low,Sham,  0  25.710000,NA NA,NA,2 1 0.0 0.0,1.0 1.0 1 1,3,1 1 0,1,0.5 0 1 0,1  762 Allenby_2018 NA NA,NA 22 32.25 NA,NA  19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857,NA,NA Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low high
8996 Yin - adults (2024) Yin - adults 2024,10.3390/brainsci14121237 100   0 100 100,Critically low,tDCS (transcranial direct current stimulation),NA,  0 NA,Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks) Test digit span task NA   20.0000000,min/session Barham,2022 NA,RCT (parallel, crossover, open-label) G  11, 11   22 outcomes,NA, 0.4000000000,-0.440000000, 1.250000e+00   1.0500000,  1.0000000 NA NA,NA,NA NA,NA,100,100 100 100 100 100 100,low some,low,some low,Sham   0, 68.200000,22.000000 NA NA 2 1 0.0 0.0 1.0 1.0 1 1,3 1,1,0,1 0.5,0,1 0,1  763,Barham_2022 NA,NA >= 20 yo 22 32.25 NA,NA  19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
8996,Yin - children (2024),Yin - children 2024 10.3390/brainsci14121237,100   0,100,100,Critically low,tDCS (transcranial direct current stimulation) NA,  0,NA,Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks),Test n-bask task,NA   20.0000000,min/session,Breitling,2020,NA,RCT (parallel, crossover, open-label),G, 14, 14,  28,outcomes,NA, 0.1400000000 -0.600000000, 8.900000e-01,  4.4000000,  8.4000000,NA,NA NA,NA,NA,NA,  0,  0,  0,100 100,100,100,high some,low,some,low,Sham,  0  13.330000 13.300000,NA NA,2,1,0.0,0.0 1.0 1.0,1 1 3 1 1,0 1,0.5 0,1,0,1, 764 Breitling_2020 NA NA,13-19 yo 8.86,16.06,NA,NA  19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857,NA,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
8996 Yin - children (2024),Yin - children 2024,10.3390/brainsci14121237 100   0,100,100 Critically low,tDCS (transcranial direct current stimulation),NA,  0,NA Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks) Test,n-bask task,NA,  20.0000000 min/session Breitling 2020,NA,RCT (parallel, crossover, open-label),G  14, 14,  28 outcomes,NA  0.3600000000,-0.390000000  1.100000e+00   3.9000000   8.4000000,NA NA NA,NA NA,NA   0   0   0 100,100 100 100 high some,low,some,low Sham   0  13.330000 13.300000 NA,NA,2 1,0.0 0.0,1.0 1.0,1 1,3 1 1,0 1,0.5,0,1,0 1, 765 Breitling_2020,NA NA 13-19 yo,8.86 16.06,NA NA, 19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857 NA NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
8996,Yin - children (2024),Yin - children,2024 10.3390/brainsci14121237,100,  0,100 100,Critically low,tDCS (transcranial direct current stimulation) NA,  0,NA,Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks),Test,n-bask task NA,  20.0000000,min/session Breitling-Ziegler 2021,NA RCT (parallel, crossover, open-label) G,  9  13,  22 outcomes NA -0.3100000000,-1.170000000  5.400000e-01  24.0500000, 27.2300000,NA,NA NA,NA,NA NA,100,100,100 100,100,100 100,low,some,low,low low Sham,  0  13.630000 13.409091,NA,NA 2 1 0.0 0.0 1.0,1.0 1 1,3 1 1 0,1,0.5,0 1,0 1, 766 Breitling-Ziegler_2021 NA,NA,13-19 yo,8.86,16.06 NA NA  19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857 NA,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
8996 Yin - children (2024) Yin - children,2024 10.3390/brainsci14121237,100   0 100,100,Critically low,tDCS (transcranial direct current stimulation),NA,  0,NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks),Test n-bask task NA,  20.0000000,min/session,D'Aiello,2023 NA,RCT (parallel, crossover, open-label) G, 26, 26,  52 outcomes NA  0.4200000000 -0.130000000  9.700000e-01,  0.4000000,  0.3400000 NA NA,NA NA,NA NA 100 100,100,100 100 100 100,low,some low some low,Sham   0,  7.700000 10.630000,NA,NA 2,1 0.0,0.0,1.0,1.0,1 1 3 1 1 0 1 0.5 0,1 0 1, 767,D'Aiello_2023,NA NA 6-12 yo 8.86,16.06,NA NA  19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857,NA,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
8996 Yin - children (2024) Yin - children,2024 10.3390/brainsci14121237,100   0,100 100,Critically low tDCS (transcranial direct current stimulation) NA,  0,NA Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks) Test digit span task,NA,  30.0000000,min/session Guimaraes,2024,NA RCT (parallel, crossover, open-label),G  15  15,  30 NA NA -0.3300000000,-1.050000000  4.000000e-01   1.4700000,  1.7500000,NA NA,NA NA NA NA,100 100,100 100,100 100 100,low low low low low Sham,  0  33.330000 11.200000 NA NA 2 1 0.0 0.0 1.0,1.0 1,1,3,1 1,0 1,0.5,0 1 0,1  768 Guimaraes_2024,NA NA 6-12 yo 8.86,16.06,NA NA  19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857 NA,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
8996,Yin - children (2024) Yin - children 2024,10.3390/brainsci14121237,100   0,100 100,Critically low tDCS (transcranial direct current stimulation),NA,  0,NA,Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks) Test,n-bask task,NA   15.0000000 min/session Nejati 2020 NA,RCT (parallel, crossover, open-label),G  15  15   30 outcomes,NA, 0.1100000000 -0.610000000, 8.200000e-01,  8.3200000   7.4200000,NA,NA,NA NA,NA,NA,  0,  0,100 100,100   0 100,low,some some,low high,Sham,  0, 50.000000, 9.000000,NA NA 2 1,0.0 0.0,1.0 1.0 1,1 3,1 1,0,1,0.5 0 1,0 1  769 Nejati_2020 NA,NA,6-12 yo 8.86 16.06 NA,NA  19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857 NA NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high,high
8996 Yin - children (2024),Yin - children,2024 10.3390/brainsci14121237 100,  0,100,100,Critically low tDCS (transcranial direct current stimulation) NA   0,NA Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks),Test n-bask task NA,  15.0000000,min/session Nejati,2020,NA,RCT (parallel, crossover, open-label) G, 10  10,  20 outcomes NA, 1.9400000000, 0.830000000, 3.040000e+00,  2.2600000,  3.7000000,NA NA NA NA NA,NA,  0   0,100,100,100,  0,100 low some,some,low,high Sham   0  50.000000  9.000000 NA NA 2,1 0.0,0.0,1.0,1.0,1,1,3 1,1 0,1,0.5 0,1,0,1, 770,Nejati_2020 NA NA 6-12 yo 8.86,16.06,NA NA, 19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857,NA NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high,high
8996 Yin - children (2024) Yin - children 2024 10.3390/brainsci14121237,100   0 100,100,Critically low,tDCS (transcranial direct current stimulation) NA   0,NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks) Test,n-bask task NA   15.0000000,min/session Nejati,2020,NA,RCT (parallel, crossover, open-label),G, 10, 10   20 outcomes,NA, 1.4400000000, 0.430000000, 2.440000e+00,  2.2700000   3.7000000,NA,NA,NA NA NA,NA   0,  0,100 100,100,  0,100 low,some some low,high Sham,  0  50.000000  9.000000 NA,NA,2 1,0.0 0.0,1.0,1.0 1 1,3,1,1 0 1,0.5 0 1 0,1  771,Nejati_2020,NA,NA 6-12 yo,8.86 16.06,NA,NA, 19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857 NA,NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high high
8996 Yin - children (2024) Yin - children,2024,10.3390/brainsci14121237,100,  0 100 100 Critically low tDCS (transcranial direct current stimulation),NA,  0 NA Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks) Test n-bask task NA   20.0000000,min/session Nejati,2022 NA,RCT (parallel, crossover, open-label),G, 25  25   50,outcomes NA, 0.1100000000,-0.440000000, 6.700000e-01, 32.9500000, 22.6900000,NA NA NA NA NA,NA,100 100 100,100 100 100 100,some,some low,low low,Sham,  0  33.330000, 9.250000 NA,NA 2,1 0.0 0.0,1.0,1.0 1 1,3 1,1,0 1,0.5 0,1,0,1, 772 Nejati_2022 NA,NA 6-12 yo,8.86,16.06,NA NA  19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857 NA,NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
8996 Yin - children (2024) Yin - children,2024,10.3390/brainsci14121237 100,  0,100 100 Critically low tDCS (transcranial direct current stimulation),NA,  0,NA,Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks) Test n-bask task,NA,  15.0000000,min/session Salehinejad 2022 NA,RCT (parallel, crossover, open-label) G  22, 22,  44,outcomes NA,-0.0300000000 -0.620000000, 5.600000e-01  15.6800000  14.0200000,NA NA NA NA NA NA,100 100,100 100,100 100,100 some,some,low some low Sham,  0  50.000000, 8.860000,NA NA,2 1 0.0 0.0 1.0 1.0,1,1 3 1,1 0,1,0.5 0 1 0 1, 773 Salehinejad_2022 NA NA 6-12 yo,8.86 16.06,NA NA, 19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857,NA,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
8996 Yin - children (2024),Yin - children 2024,10.3390/brainsci14121237,100,  0 100 100,Critically low tDCS (transcranial direct current stimulation),NA   0,NA,Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks) Test,wisconsin card sorting NA   15.0000000 min/session,Nejati 2020 NA RCT (parallel, crossover, open-label) G  15, 15   30 outcomes,reverse,-0.0600000000,-0.770000000, 6.600000e-01,  3.6000000,  8.9800000,NA NA,NA,NA NA,NA,  0   0,100 100 100,  0 100 low,some some low high Sham,  0, 50.000000  9.000000 NA NA 2 1 0.0,0.0,1.0 1.0 1 1 3,1 1 0,1 0.5,0 1,0 1, 774,Nejati_2020,NA,NA,6-12 yo 8.86,16.06,NA,NA, 19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857 NA,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
8996,Yin - children (2024) Yin - children,2024 10.3390/brainsci14121237 100,  0 100 100,Critically low,tDCS (transcranial direct current stimulation),NA   0,NA Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks),Test wisconsin card sorting,NA   15.0000000 min/session Nejati,2020 NA RCT (parallel, crossover, open-label),G  10, 10,  20,outcomes,reverse,-2.1400000000,-3.290000000,-9.900000e-01,  2.4400000   3.7000000 NA NA NA NA,NA,NA,  0   0 100,100,100   0,100,low,some,some low high,Sham,  0  50.000000, 9.000000,NA,NA,2,1 0.0 0.0 1.0,1.0,1,1,3,1,1,0 1 0.5 0,1,0,1  775,Nejati_2020 NA NA 6-12 yo,8.86 16.06,NA,NA, 19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857,NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high high
8996 Yin - children (2024) Yin - children 2024 10.3390/brainsci14121237 100   0 100,100,Critically low tDCS (transcranial direct current stimulation),NA,  0 NA,Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks),Test,wisconsin card sorting NA   15.0000000,min/session,Nejati 2020 NA,RCT (parallel, crossover, open-label),G  10  10,  20,outcomes,reverse -0.8200000000,-1.740000000  1.000000e-01   3.2900000   3.7000000,NA NA NA NA,NA NA   0,  0 100 100 100,  0 100,low some some,low,high,Sham   0, 50.000000  9.000000 NA,NA,2 1,0.0,0.0 1.0 1.0 1 1 3 1,1 0,1 0.5,0 1 0,1, 776 Nejati_2020,NA,NA 6-12 yo 8.86 16.06,NA NA  19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857,NA,NA Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high high
8996,Yin - children (2024) Yin - children,2024 10.3390/brainsci14121237 100,  0 100,100,Critically low tDCS (transcranial direct current stimulation),NA,  0 NA Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks) Test wisconsin card sorting,NA,  15.0000000,min/session,Salehinejad 2022 NA RCT (parallel, crossover, open-label) G  22, 22   44,outcomes,reverse, 0.1500000000,-0.440000000  7.400000e-01,  8.3090000   9.7720000 NA NA,NA,NA NA NA,100 100,100 100 100 100 100,some some,low some low,Sham,  0  50.000000, 8.860000,NA,NA,2 1,0.0,0.0 1.0,1.0 1,1 3,1,1,0,1,0.5,0 1,0 1  777,Salehinejad_2022,NA,NA,6-12 yo 8.86,16.06,NA NA  19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857,NA NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
2118 Liu (2022),Liu 2022 10.1111/papt.12455   0,  0 100 100 Low,Cognitive Behavioral Therapy (CBT) CBT,  0 NA CGI,Clinician-rated At study endpoint (closest to 12 weeks) Questionnaire,Clinical global impression (CGI), 1.84119678,NA,NA,Emilsson,2011 NA RCT (parallel, crossover, open-label),SMD  27  27,  54 NA,reverse -0.5300000000 -1.070000000, 2.000000e-02,  0.8800000,  0.8400000,NA NA,NA,NA,NA NA,100,100,100,  0 100,100,100 some,high,low,low,low,TAU,  0, 30.000000,NA,NA,DSM-IV, DSM-V,1,1 0.0,1.0 1.0 1.0 1,1 1,1,1,1,1 1.0,0,1,1 1, 778 Emilsson_2011,< 2 months NA NA,35.1695789473684,43.15,NA,NA, 19, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15,NA NA,Liu (2022)_Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Liu (2022) - Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
2118,Liu (2022),Liu 2022 10.1111/papt.12455 100,  0,100 100,Low Cognitive Behavioral Therapy (CBT),CBT   0,NA,CGI Clinician-rated At study endpoint (closest to 12 weeks),Questionnaire,NA  1.84119678,NA,NA,Nakashima 2021 NA RCT (parallel, crossover, open-label),SMD, 24, 24   48,NA reverse -2.8500000000 -3.680000000 -2.030000e+00   0.6400000,  0.6000000 NA,NA NA,NA NA,NA,  0,  0,  0,  0,100 100,100 high,high low,low,low TAU   0, 88.000000 39.105000,NA DSM-IV, DSM-V 1,1 0.0,1.0 1.0,1.0 1,1,1 1,1 1,1 1.0,0,1,1,1  779 Nakashima_2021,< 2 months NA >= 20 yo,35.1695789473684 43.15,NA,NA, 19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA,NA,Liu (2022)_Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Liu (2022) - Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low high
2118,Liu (2022) Liu 2022 10.1111/papt.12455   0,  0,100 100,Low,Cognitive Behavioral Therapy (CBT) CBT   0 NA,CGI,Clinician-rated At study endpoint (closest to 12 weeks),Questionnaire,NA, 3.45224396,NA,NA,Safren 2005 NA RCT (parallel, crossover, open-label),SMD, 16  15,  31,NA reverse,-1.3500000000 -2.140000000 -5.600000e-01,  0.7600000   0.9100000 NA NA NA NA NA NA,100,100 100,100 100,100,100 some,low,low low,low,TAU   0  55.000000 NA,NA,DSM-IV, DSM-V 1 1,0.0 1.0,1.0,1.0 1,1,1,1,1 1 1 1.0,0 1 1,1, 780 Safren_2005 2-6 months NA,NA,35.1695789473684 43.15 NA,NA, 19, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15,NA NA Liu (2022)_Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Liu (2022) - Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
2118,Liu (2022),Liu,2022 10.1111/papt.12455 100,  0 100 100 Low Cognitive Behavioral Therapy (CBT) CBT   0,NA,CGI,Clinician-rated,At study endpoint (closest to 12 weeks),Questionnaire NA  2.76179517 NA NA Safren,2010,NA,RCT (parallel, crossover, open-label) SMD, 43, 43,  86,NA,reverse -0.6300000000 -1.060000000 -2.000000e-01   0.9600000   1.0500000,NA NA NA,NA,NA,NA 100,100 100 100 100 100 100,some,low low,low low,TAU   0, 44.000000 43.150000 NA,DSM-IV, DSM-V,1 1 0.0,1.0 1.0,1.0,1,1 1 1,1 1 1,1.0 0 1 1,1  781,Safren_2010 2-6 months,NA,>= 20 yo 35.1695789473684,43.15 NA,NA, 19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15 NA,NA,Liu (2022)_Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Liu (2022) - Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
2118,Liu (2022),Liu,2022,10.1111/papt.12455,100,  0 100 100 Low,Cognitive Behavioral Therapy (CBT),CBT   0 NA CGI,Clinician-rated,At study endpoint (closest to 12 weeks),Questionnaire NA  2.76179517 NA,NA Vidal,2013,NA RCT (parallel, crossover, open-label) SMD, 17  15   32,NA,reverse,-0.3200000000,-1.020000000  3.700000e-01,  0.4000000,  0.4900000,NA,NA NA NA NA NA,  0   0 100,100 100,100,  0,some low,low,high low TAU,  0  51.718750 39.460938 NA DSM-IV, DSM-V 1,1,0.0,1.0 1.0 1.0 1 1 1,1 1,1 1,1.0 0,1 1,1  782 Vidal_2013 2-6 months,NA,>= 20 yo,35.1695789473684,43.15 NA NA  19, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA NA Liu (2022)_Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Liu (2022) - Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low high
2118 Liu (2022),Liu,2022 10.1111/papt.12455,100   0 100 100 Low Cognitive Behavioral Therapy (CBT) CBT,  0 NA CGI,Clinician-rated At study endpoint (closest to 12 weeks) Questionnaire NA, 1.84119678 NA NA Young 2015 NA,RCT (parallel, crossover, open-label),SMD  48  47   95 NA reverse -0.9200000000,-1.340000000 -4.900000e-01   0.8600000,  0.8900000 NA,NA,NA NA,NA NA 100 100 100,  0,100,100,100 low high,low low low TAU   0, 65.473684,35.169579,NA DSM-IV, DSM-V,1 1,0.0 1.0 1.0,1.0,1 1,1 1 1,1 1,1.0,0 1 1 1, 783,Young_2015 < 2 months,NA >= 20 yo,35.1695789473684,43.15,NA NA  19, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15,NA,NA Liu (2022)_Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Liu (2022) - Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
2154 Lopez (2018) Lopez 2018,10.1002/14651858.CD010840.pub2,100,  0 100,100 High Cognitive Behavioral Therapy (CBT) CBT   0,NA,Depressive disorder symptoms Self-rated At study endpoint (closest to 12 weeks) Questionnaire,Anxiety and Depression - Hospital anxiety and depression scale, 1.38089758,NA,NA Moell 2015 NA,RCT (parallel, crossover, open-label),G  29  28,  57,NA,reverse -0.2300000000 -0.750000000, 2.900000e-01   4.5000000,  4.7000000 NA NA,NA NA,NA,NA 100,100,100   0 100 100 100 some,high low,low low WLC (wait-list control),  0  68.421053 36.791228,NA,DSM-IV 0,1,1.0,1.0,1.0 1.0,1,1,0,1,1,1 1 1.0 1 1 1 1, 784 Moell_2015 < 2 months,NA >= 20 yo 33.5 41.5 NA,NA, 19, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15,NA NA Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
2154,Lopez (2018),Lopez,2018 10.1002/14651858.CD010840.pub2 100,  0 100 100 High Cognitive Behavioral Therapy (CBT) CBT,  0,NA,Depressive disorder symptoms Self-rated,At study endpoint (closest to 12 weeks) Questionnaire Beck Depression Inventory, second edition  2.30149597,NA NA,Pettersson,2017 NA RCT (parallel, crossover, open-label) G  27, 18   45 NA reverse -0.1600000000,-0.760000000  4.400000e-01, 12.6000000  10.3000000,NA,NA NA NA NA,NA 100,100,100   0   0,100,100 low high,high low,low WLC (wait-list control)   0, 64.444444 37.400000 NA,DSM-IV-TR 0,1 1.0,1.0,1.0 1.0 1,1,0,1,1,1 1,1.0,1,1 1 1  785,Pettersson_2017 2-6 months NA >= 20 yo 33.5,41.5 NA,NA  19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA NA Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
2154 Lopez (2018),Lopez,2018 10.1002/14651858.CD010840.pub2 100   0,100,100 High Cognitive Behavioral Therapy (CBT),CBT,  0,NA,Depressive disorder symptoms Self-rated At study endpoint (closest to 12 weeks),Questionnaire Beck Depression Inventory, second edition  2.30149597,NA NA Virta,2010,NA,RCT (parallel, crossover, open-label),G, 10   9,  19 NA reverse -0.3700000000,-1.280000000  5.400000e-01   8.9000000,  6.9000000 NA NA,NA NA NA NA,100 100 100,  0,100,100,100,some,high,low,low low,WLC (wait-list control),  0  51.724138,33.500000 NA,DSM-IV,0 1 1.0,1.0,1.0,1.0,1 1,0,1,1 1,1,1.0,1 1,1 1, 786 Virta_2010,2-6 months,NA,>= 20 yo 33.5,41.5 NA,NA  19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA,NA Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
2154,Lopez (2018),Lopez,2018 10.1002/14651858.CD010840.pub2 100,  0,100 100 High,Cognitive Behavioral Therapy (CBT),CBT   0,NA Generalized anxiety Self-rated,At study endpoint (closest to 12 weeks) Questionnaire,Anxiety and Depression - Hospital anxiety and depression scale  1.38089758,NA NA Moell,2015,NA,RCT (parallel, crossover, open-label),G  29, 28,  57 NA,reverse,-0.2400000000,-0.760000000, 2.800000e-01   4.1000000   2.8000000,NA NA NA NA NA NA 100,100,100   0,100 100 100,some high,low low,low WLC (wait-list control)   0, 68.421053,36.791228,NA,DSM-IV,0,1,1.0,1.0 1.0,1.0 1,1,0 1,1 1,1,1.0,1 1 1 1  787 Moell_2015 < 2 months NA,>= 20 yo 33.8 41.5 NA NA, 19  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15,NA,NA,Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
2154 Lopez (2018),Lopez,2018,10.1002/14651858.CD010840.pub2 100   0 100,100,High Cognitive Behavioral Therapy (CBT),CBT,  0,NA,Generalized anxiety Self-rated,At study endpoint (closest to 12 weeks) Questionnaire Anxiety - Beck Anxiety Inventory  2.30149597 NA NA Pettersson 2017 NA RCT (parallel, crossover, open-label) G  27, 18   45,NA,reverse -0.1400000000,-0.730000000  4.600000e-01  11.5000000  10.5000000,NA,NA,NA,NA,NA,NA,100 100 100,  0   0 100 100 low,high high low low WLC (wait-list control),  0, 64.444444,37.400000 NA,DSM-IV-TR,0,1 1.0 1.0 1.0 1.0 1 1 0,1,1,1,1,1.0,1 1,1 1  788,Pettersson_2017 2-6 months NA >= 20 yo 33.8,41.5,NA NA, 19, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA NA,Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
2154,Lopez (2018) Lopez,2018,10.1002/14651858.CD010840.pub2 100   0 100 100,High,Cognitive Behavioral Therapy (CBT) CBT,100 Medication Depressive disorder symptoms Self-rated At study endpoint (closest to 12 weeks) Questionnaire Beck Depression Inventory (BDI), 1.84119678   90.0000000 mn/session Emilsson 2011 NA RCT (parallel, crossover, open-label) G  18, 17,  35,NA reverse -0.9680120502 -1.680325383 -2.556987e-01   6.8000000,  9.6000000 NA NA,NA NA,NA NA 100 100,100,  0   0,100,100 some,high,high low low,Active (any credible active intervention) 100  62.962963 33.800000,NA,DSM-IV,0,1,1.0,1.0 1.0 1.0,1,1 0 1,1,1,1 1.0,1,1,1 1, 789 Emilsson_2011,< 2 months,NA,>= 20 yo 33.5 41.5,NA,NA, 19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA NA,Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
2154,Lopez (2018),Lopez,2018 10.1002/14651858.CD010840.pub2,100   0 100,100,High,Cognitive Behavioral Therapy (CBT) CBT,100,Medication Depressive disorder symptoms Self-rated,At study endpoint (closest to 12 weeks),Questionnaire,Depression - Hamilton Depression Scale (HAM-D), 2.76179517 NA,NA Safren 2005 NA RCT (parallel, crossover, open-label) G, 16  15   31 NA reverse -0.7564656748 -1.498789783,-1.414157e-02,  4.3000000,  7.7000000 NA,NA NA NA,NA,NA 100,100,100   0 100,100 100 low,high,low,low low,Active (any credible active intervention) 100  44.186047,41.500000 NA,DSM-IV,0 1 1.0,1.0 1.0 1.0,1 1,0 1 1,1 1,1.0 1,1 1,1  790,Safren_2005,2-6 months,NA,>= 20 yo 33.5,41.5,NA NA, 19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA,NA,Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
2154,Lopez (2018),Lopez,2018 10.1002/14651858.CD010840.pub2,100   0,100,100,High Cognitive Behavioral Therapy (CBT) CBT 100 Medication Generalized anxiety Self-rated,At study endpoint (closest to 12 weeks) Questionnaire Beck Anxiety Inventory  1.84119678   90.0000000 mn/session,Emilsson,2011,NA RCT (parallel, crossover, open-label) G, 18, 17   35,NA,reverse -0.3945495027,-1.073656048  2.845570e-01  10.6000000, 10.7000000 NA,NA NA,NA,NA NA,100 100,100   0,  0,100 100,some high,high low low,Active (any credible active intervention),100, 62.962963,33.800000,NA,DSM-IV 0,1 1.0 1.0 1.0 1.0 1,1 0 1,1,1,1 1.0,1,1,1,1  791,Emilsson_2011 < 2 months,NA >= 20 yo 33.8 41.5 NA NA, 19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA,NA Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
2154 Lopez (2018) Lopez 2018 10.1002/14651858.CD010840.pub2,100   0 100,100 High,Cognitive Behavioral Therapy (CBT) CBT 100 Medication Generalized anxiety,Self-rated,At study endpoint (closest to 12 weeks) Questionnaire Anxiety - Hamilton Anxiety Scale (HAM-A)  2.76179517,NA NA,Safren,2005 NA RCT (parallel, crossover, open-label),G  16  15,  31,NA,reverse,-0.8050345542 -1.550797125 -5.927198e-02   3.5000000   4.9000000 NA NA NA,NA,NA NA 100,100 100,  0 100 100 100,low high,low,low,low Active (any credible active intervention),100  44.186047,41.500000,NA,DSM-IV 0 1 1.0 1.0,1.0,1.0 1,1 0,1 1 1,1,1.0,1 1 1 1  792,Safren_2005,2-6 months NA >= 20 yo,33.8,41.5,NA NA  19  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15 NA,NA,Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
8888 Bellato - adults (2024) Bellato - adults 2024,10.1016/j.jaac.2024.05.023,100   0 100,100,High,Amphetamine,LDX   0 NA,Quality of life (patients) Self-rated At study endpoint (closest to 12 weeks),Questionnaire,The ADHD Impact Module–Adult  2.30149597 NA NA,Adler 2013 NA,RCT (parallel, crossover, open-label) G  80  81, 161,outcomes NA  0.8384000000, 0.516100000, 1.160800e+00 NA,NA,NA,NA,NA NA NA NA 100 100,100 100,100 100 100 low low some low,low Placebo   0  47.790062,34.500000,NA,DSM-III, DSM-IV, DSM-V,0 1 1.0 1.0 1.0,1.0 1,1 1 1 1,1 1 1.0 0 1,1 1  793 Adler_2013,2-6 months NA,>= 20 yo,34.5 36.5 NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
8888,Bellato - adults (2024) Bellato - adults 2024,10.1016/j.jaac.2024.05.023,100,  0,100,100 High Amphetamine LDX,  0,NA,Quality of life (patients),Self-rated At study endpoint (closest to 12 weeks),Questionnaire,The ADHD Impact Module–Adult  2.30149597,NA,NA,Adler,2013,NA,RCT (parallel, crossover, open-label) G, 80  81, 161 outcomes,NA  0.6521000000  0.335000000  9.692000e-01 NA,NA NA NA,NA NA,NA NA,100 100 100,100 100 100 100 low,low,some low,low Placebo   0  47.790062,34.500000 NA,DSM-III, DSM-IV, DSM-V,0,1,1.0,1.0,1.0 1.0 1 1,1,1 1 1,1,1.0,0,1 1 1  794 Adler_2013,2-6 months NA,>= 20 yo 34.5,36.5 NA,NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
8888 Bellato - adults (2024),Bellato - adults 2024,10.1016/j.jaac.2024.05.023 100   0 100 100 High Amphetamine,LDX,  0 NA Quality of life (patients),Self-rated At study endpoint (closest to 12 weeks) Questionnaire,The ADHD Impact Module–Adult  2.30149597,NA NA Adler,2013 NA,RCT (parallel, crossover, open-label),G  80  81, 161 outcomes,NA, 0.5873000000, 0.271700000, 9.029000e-01,NA NA,NA,NA,NA,NA,NA NA 100,100,100 100,100,100,100,low low,some low,low Placebo   0  47.790062 34.500000 NA DSM-III, DSM-IV, DSM-V,0 1 1.0,1.0,1.0 1.0,1 1 1 1 1 1,1,1.0 0 1,1,1  795,Adler_2013 2-6 months,NA >= 20 yo,34.5,36.5 NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA NA,Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
8888,Bellato - adults (2024) Bellato - adults,2024,10.1016/j.jaac.2024.05.023,100   0,100 100,High,Amphetamine,LDX,  0 NA Quality of life (patients) Self-rated At study endpoint (closest to 12 weeks) Questionnaire The ADHD Impact Module–Adult, 2.30149597,NA NA,Adler,2013 NA RCT (parallel, crossover, open-label) G, 80, 81, 161 outcomes,NA, 0.3447000000  0.033500000, 6.560000e-01 NA,NA NA,NA,NA NA,NA,NA 100,100 100 100 100,100,100 low low some low low,Placebo   0  47.790062,34.500000 NA,DSM-III, DSM-IV, DSM-V,0,1 1.0,1.0 1.0 1.0 1 1,1,1 1,1 1,1.0 0 1,1 1, 796,Adler_2013,2-6 months NA,>= 20 yo 34.5,36.5 NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA,Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
8888,Bellato - adults (2024),Bellato - adults,2024,10.1016/j.jaac.2024.05.023,100,  0 100,100,High Amphetamine,LDX,  0 NA Quality of life (patients),Self-rated,At study endpoint (closest to 12 weeks) Questionnaire,The ADHD Impact Module–Adult, 2.30149597,NA NA Adler 2013 NA RCT (parallel, crossover, open-label) G  80, 81, 161,outcomes NA  0.7723000000, 0.451900000, 1.092600e+00,NA,NA,NA NA,NA,NA NA,NA,100 100 100 100 100 100,100,low,low some low,low Placebo   0  47.790062,34.500000,NA,DSM-III, DSM-IV, DSM-V,0,1,1.0,1.0 1.0,1.0,1 1 1 1 1 1,1,1.0,0,1,1,1  797,Adler_2013 2-6 months,NA >= 20 yo,34.5 36.5 NA NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
8888 Bellato - adults (2024) Bellato - adults,2024,10.1016/j.jaac.2024.05.023,100   0,100,100 High Amphetamine,LDX   0,NA Quality of life (patients),Self-rated At study endpoint (closest to 12 weeks),Questionnaire The ADHD Impact Module–Adult  2.30149597 NA,NA Adler,2013,NA,RCT (parallel, crossover, open-label) G, 80  81  161 outcomes NA, 0.6983000000, 0.380000000, 1.016600e+00 NA,NA,NA NA,NA NA NA NA,100 100 100,100 100 100,100,low,low some low,low,Placebo,  0  47.790062,34.500000,NA DSM-III, DSM-IV, DSM-V,0 1,1.0 1.0,1.0 1.0 1,1,1 1,1,1,1,1.0 0,1,1,1  798 Adler_2013,2-6 months,NA >= 20 yo 34.5,36.5,NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
8888 Bellatto - children (2024),Bellatto - children 2024,10.1016/j.jaac.2024.05.023 100,  0 100,100,High Amphetamine LDX,  0 NA Quality of life (patients),Self-rated,At study endpoint (closest to 12 weeks),Questionnaire Child Health and Illness Profile–Child Edition  1.61104718 NA NA Coghill,2013,NA RCT (parallel, crossover, open-label) G,104,106  210 outcomes NA  0.9867000000  0.700100000, 1.273300e+00 NA,NA,NA,NA,NA,NA NA,NA 100 100 100 100,  0,100,100,low low,high low low,Placebo,  0  19.429524 10.900000 NA DSM-III, DSM-IV, DSM-V 0,1 1.0 1.0,1.0 1.0,1 1,1,1,1,1 1,1.0 0 1,1,1, 799 Coghill_2013,< 2 months NA 6-12 yo 10.9,15 NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA NA,Bellatto - children (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Bellatto - children (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
8888,Bellatto - children (2024),Bellatto - children 2024 10.1016/j.jaac.2024.05.023,100,  0 100 100,High Amphetamine LDX   0 NA Quality of life (patients),Self-rated At study endpoint (closest to 12 weeks) Questionnaire,Youth Quality of Life–Research Version  0.92059839 NA NA,Findling,2011 NA,RCT (parallel, crossover, open-label),G,232  79, 311,outcomes,NA -0.0321000000 -0.287400000, 2.232000e-01,NA NA NA,NA NA NA,NA NA,100,100 100 100 100,100 100 low low low,low,low Placebo   0, 29.700000,15.000000,NA DSM-III, DSM-IV, DSM-V,0,1 1.0,1.0 1.0 1.0 1,1 1 1,1,1,1 1.0,0,1,1 1, 800,Findling_2011 < 2 months,NA 13-19 yo,10.9,15 NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA Bellatto - children (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Bellatto - children (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
8888,Bellato - adults (2024) Bellato - adults 2024,10.1016/j.jaac.2024.05.023,100,  0 100 100 High,Amphetamine,Triple Bead MAS,  0,NA Quality of life (patients),Self-rated,At study endpoint (closest to 12 weeks) Questionnaire,The ADHD Impact Module–Adult, 1.61104718,NA NA Spencer 2008 NA,RCT (parallel, crossover, open-label),G 136,132, 268 outcomes NA  0.4377000000  0.195300000, 6.800000e-01,NA,NA NA,NA,NA NA NA NA 100 100,100,100,  0 100 100,low,low,high,low low,Placebo,  0, 49.994030 36.500000,NA,DSM-III, DSM-IV, DSM-V,0,1 1.0,1.0 1.0,1.0,1,1 1,1,1,1,1 1.0 0 1,1 1, 801 Spencer_2008 < 2 months NA >= 20 yo 34.5 36.5,NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
8888 Bellato - adults (2024) Bellato - adults 2024,10.1016/j.jaac.2024.05.023 100   0 100,100 High,Amphetamine Triple Bead MAS   0,NA Quality of life (patients),Self-rated,At study endpoint (closest to 12 weeks) Questionnaire The ADHD Impact Module–Adult, 1.61104718,NA NA,Spencer,2008 NA,RCT (parallel, crossover, open-label),G 136,132  268,outcomes NA, 0.4234000000, 0.181300000  6.656000e-01 NA,NA,NA,NA,NA,NA NA,NA 100 100 100,100,  0 100,100 low,low high low low,Placebo   0, 49.994030,36.500000,NA,DSM-III, DSM-IV, DSM-V,0,1,1.0 1.0,1.0,1.0,1,1,1,1 1,1 1 1.0,0 1 1,1  802,Spencer_2008,< 2 months NA >= 20 yo 34.5,36.5,NA NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
8888,Bellato - adults (2024),Bellato - adults,2024,10.1016/j.jaac.2024.05.023,100   0 100,100 High Amphetamine,Triple Bead MAS,  0,NA Quality of life (patients) Self-rated,At study endpoint (closest to 12 weeks) Questionnaire,The ADHD Impact Module–Adult, 1.61104718 NA,NA,Spencer 2008 NA,RCT (parallel, crossover, open-label) G 136,132, 268,outcomes,NA  0.6954000000, 0.448700000  9.420000e-01,NA NA,NA NA NA NA NA NA 100 100,100 100   0 100,100 low,low,high,low low,Placebo   0  49.994030,36.500000 NA DSM-III, DSM-IV, DSM-V 0,1,1.0,1.0,1.0 1.0 1,1,1,1 1,1 1 1.0,0,1,1,1, 803,Spencer_2008 < 2 months NA,>= 20 yo,34.5 36.5,NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
8888,Bellato - adults (2024),Bellato - adults 2024,10.1016/j.jaac.2024.05.023,100   0 100,100,High Amphetamine,Triple Bead MAS   0 NA Quality of life (patients) Self-rated At study endpoint (closest to 12 weeks),Questionnaire,The ADHD Impact Module–Adult  1.61104718 NA NA,Spencer,2008,NA,RCT (parallel, crossover, open-label),G,136,132  268,outcomes NA, 0.5441000000, 0.300300000  7.880000e-01 NA NA NA NA NA NA,NA NA,100,100,100 100,  0,100,100,low low high low low,Placebo,  0, 49.994030,36.500000 NA,DSM-III, DSM-IV, DSM-V 0,1,1.0,1.0,1.0,1.0,1,1,1,1 1,1 1 1.0 0,1 1 1  804,Spencer_2008 < 2 months NA,>= 20 yo 34.5,36.5 NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA,Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
8888,Bellato - adults (2024),Bellato - adults,2024,10.1016/j.jaac.2024.05.023,100   0 100 100,High Amphetamine Triple Bead MAS   0 NA Quality of life (patients),Self-rated,At study endpoint (closest to 12 weeks) Questionnaire,The ADHD Impact Module–Adult, 1.61104718 NA NA Spencer,2008,NA RCT (parallel, crossover, open-label),G,136,132, 268 outcomes,NA, 0.2289000000,-0.011400000  4.691000e-01 NA,NA,NA,NA,NA,NA,NA,NA 100 100 100 100   0,100 100 low,low,high low low,Placebo   0, 49.994030,36.500000 NA DSM-III, DSM-IV, DSM-V 0,1 1.0,1.0,1.0 1.0,1 1,1,1,1,1,1,1.0 0 1,1,1  805 Spencer_2008 < 2 months NA >= 20 yo,34.5 36.5 NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
8888 Bellato - adults (2024),Bellato - adults,2024 10.1016/j.jaac.2024.05.023,100,  0,100,100 High Amphetamine Triple Bead MAS,  0 NA,Quality of life (patients),Self-rated,At study endpoint (closest to 12 weeks),Questionnaire The ADHD Impact Module–Adult, 1.61104718,NA,NA,Spencer,2008,NA,RCT (parallel, crossover, open-label),G 136 132  268,outcomes NA  0.3183000000  0.077300000  5.592000e-01 NA,NA,NA NA NA,NA NA NA 100,100 100 100,  0,100 100,low,low high,low,low Placebo,  0, 49.994030 36.500000,NA DSM-III, DSM-IV, DSM-V 0,1 1.0 1.0,1.0 1.0,1 1,1,1,1,1,1 1.0 0,1 1,1  806 Spencer_2008,< 2 months,NA,>= 20 yo 34.5 36.5 NA NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
8888,Bellatto - children (2024),Bellatto - children 2024 10.1016/j.jaac.2024.05.023,100   0,100 100 High Atomoxetine NA,  0,NA,Quality of life (patients),NA At study endpoint (closest to 12 weeks) Questionnaire,NA, 1.84119678 NA,NA Bangs 2008 NA RCT (parallel, crossover, open-label) G 151  67  218,outcomes,NA  0.3887000000  0.099000000  6.784000e-01 NA NA NA,NA NA NA NA NA 100 100,100,100,100,100 100,low,low low low,some Placebo   0,  8.300000  9.000000 NA DSM-III, DSM-IV, DSM-V,0 1,1.0 1.0,1.0,1.0,1,1 1,1 1 1 1,1.0,0 1,1 1, 807,Bangs_2008 < 2 months,NA 6-12 yo,9 13,NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
8888,Bellatto - children (2024) Bellatto - children 2024,10.1016/j.jaac.2024.05.023 100   0,100,100,High,Atomoxetine,NA,  0 NA,Quality of life (patients) NA At study endpoint (closest to 12 weeks),Questionnaire NA, 1.84119678 NA,NA Bangs,2008,NA RCT (parallel, crossover, open-label),G,151, 67, 218 outcomes,NA -0.0399000000,-0.329100000, 2.494000e-01,NA NA,NA,NA,NA NA,NA,NA,100 100 100 100 100 100 100,low,low,low,low,some,Placebo   0   8.300000  9.000000 NA,DSM-III, DSM-IV, DSM-V,0,1,1.0 1.0,1.0 1.0 1,1 1,1 1 1,1,1.0 0 1 1 1, 808,Bangs_2008 < 2 months NA,6-12 yo,9 13 NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA,Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
8888 Bellatto - children (2024) Bellatto - children 2024,10.1016/j.jaac.2024.05.023,100,  0 100 100 High Atomoxetine NA   0 NA Quality of life (patients) NA At study endpoint (closest to 12 weeks) Questionnaire,NA, 1.84119678 NA NA Bangs,2008 NA RCT (parallel, crossover, open-label) G,151, 67  218 outcomes NA  0.3006000000, 0.011500000, 5.897000e-01,NA,NA,NA,NA,NA NA NA NA,100,100,100 100,100 100,100,low,low,low low,some Placebo   0   8.300000  9.000000,NA DSM-III, DSM-IV, DSM-V 0 1 1.0 1.0,1.0,1.0 1 1 1 1,1,1 1 1.0 0 1,1,1, 809,Bangs_2008,< 2 months,NA 6-12 yo,9,13,NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA,Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
8888,Bellatto - children (2024) Bellatto - children,2024 10.1016/j.jaac.2024.05.023 100,  0,100,100 High,Atomoxetine,NA   0 NA Quality of life (patients) NA,At study endpoint (closest to 12 weeks) Questionnaire,NA  1.84119678 NA NA,Dittmann 2011 NA RCT (parallel, crossover, open-label),G,118  59, 177,NA NA  0.2657000000 -0.048000000, 5.795000e-01,NA NA,NA,NA NA,NA NA NA 100,100 100,100,  0,100,100,low low,high low some,Placebo,  0  16.000000,13.000000 NA,DSM-III, DSM-IV, DSM-V 0 1,1.0 1.0 1.0,1.0 1 1,1 1,1 1 1 1.0 0 1 1 1, 810,Dittmann_2011,< 2 months,NA 13-19 yo,9 13 NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
8888,Bellatto - children (2024) Bellatto - children,2024 10.1016/j.jaac.2024.05.023 100   0 100 100 High Atomoxetine,NA   0,NA,Quality of life (patients) NA,At study endpoint (closest to 12 weeks),Questionnaire NA  1.84119678 NA,NA,Michelson 2001 NA,RCT (parallel, crossover, open-label),G,213  83, 296 outcomes NA  0.4656000000, 0.092800000  8.384000e-01 NA NA,NA NA,NA,NA NA NA   0   0,  0 100,  0 100 100,high low high,low some Placebo,  0, 28.600000 11.000000 NA,DSM-III, DSM-IV, DSM-V 0,1,1.0,1.0 1.0 1.0,1 1 1 1 1,1 1 1.0 0,1,1 1  811 Michelson_2001 < 2 months,NA 6-12 yo 9 13 NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA,Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
8888 Bellatto - children (2024) Bellatto - children,2024,10.1016/j.jaac.2024.05.023,100,  0,100 100,High,Atomoxetine,NA   0 NA Quality of life (patients),NA At study endpoint (closest to 12 weeks),Questionnaire,NA, 1.84119678,NA NA Michelson,2001,NA RCT (parallel, crossover, open-label) G 213, 83  296 outcomes,NA, 0.6551000000  0.343600000, 9.665000e-01 NA,NA,NA,NA NA NA,NA,NA   0,  0   0,100   0,100 100 high low,high,low some Placebo,  0, 28.600000 11.000000,NA DSM-III, DSM-IV, DSM-V 0 1 1.0 1.0,1.0 1.0,1,1,1,1,1,1,1,1.0,0 1 1,1, 812,Michelson_2001 < 2 months,NA 6-12 yo 9,13 NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA,Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
8888,Bellatto - children (2024),Bellatto - children 2024 10.1016/j.jaac.2024.05.023 100,  0,100 100,High Atomoxetine,NA   0 NA,Quality of life (patients),NA,At study endpoint (closest to 12 weeks) Questionnaire NA  1.84119678,NA NA Michelson,2001,NA RCT (parallel, crossover, open-label),G 213, 83  296 outcomes NA, 0.8688000000, 0.549400000  1.188100e+00 NA NA,NA NA NA NA NA,NA   0,  0   0 100   0 100,100 high low high,low,some,Placebo,  0, 28.600000 11.000000,NA,DSM-III, DSM-IV, DSM-V,0 1 1.0 1.0,1.0 1.0,1,1,1 1,1,1 1,1.0 0 1 1,1, 813,Michelson_2001 < 2 months NA 6-12 yo 9 13,NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA,Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
8888,Bellatto - children (2024),Bellatto - children 2024 10.1016/j.jaac.2024.05.023 100   0,100,100 High Atomoxetine NA,  0 NA,Quality of life (patients),NA,At study endpoint (closest to 12 weeks) Questionnaire NA  2.07134638 NA NA,Newcorn 2008 NA RCT (parallel, crossover, open-label),G,193, 64, 257 NA,NA  0.3679000000, 0.083400000, 6.524000e-01,NA NA NA NA,NA NA NA,NA,100,100,100,100 100,100,100 low low,some,low low,Placebo   0, 25.700000,11.000000,NA,DSM-III, DSM-IV, DSM-V 0 1 1.0,1.0 1.0,1.0,1 1 1,1 1 1,1,1.0,0,1 1 1  814,Newcorn_2008,2-6 months NA 6-12 yo,9 13,NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA,Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
8888 Bellatto - children (2024) Bellatto - children 2024,10.1016/j.jaac.2024.05.023 100   0,100 100,High Atomoxetine,NA,  0 NA Quality of life (patients) NA At study endpoint (closest to 12 weeks),Questionnaire,NA  1.84119678 NA,NA Svanborg 2009 NA RCT (parallel, crossover, open-label),G  49, 50,  99 NA NA, 0.1662000000 -0.228500000  5.609000e-01,NA,NA NA NA NA,NA,NA NA 100 100 100,100 100 100,100,some low low,low some,Placebo   0, 19.200000 11.500000 NA,DSM-III, DSM-IV, DSM-V 0 1 1.0 1.0,1.0,1.0,1,1,1 1 1 1,1,1.0,0,1 1 1, 815,Svanborg_2009 < 2 months NA,6-12 yo,9 13,NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA,Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
8888,Bellatto - children (2024) Bellatto - children 2024 10.1016/j.jaac.2024.05.023 100   0,100 100 High,Atomoxetine,NA,  0 NA Quality of life (patients),NA At study endpoint (closest to 12 weeks),Questionnaire NA, 1.84119678,NA NA,Weiss,2005 NA,RCT (parallel, crossover, open-label) G, 84, 48  132 NA NA, 0.2916000000 -0.056700000  6.400000e-01 NA NA NA,NA,NA NA,NA,NA 100 100,100,100 100 100 100 low low low low,some Placebo   0 NA, 9.900000,NA DSM-III, DSM-IV, DSM-V 0,1,1.0 1.0 1.0,1.0 1,1 1,1 1,1 1,1.0,0,1 1,1, 816 Weiss_2005,< 2 months,NA 6-12 yo,9,13,NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
1318,Gillies (2023),Gillies,2023 10.1002/14651858.CD007986.pub2 100,  0 100,100,High Polyunsaturated fatty acids,NA,100 Metilphenidate,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  0.46029919  354.0000000,mg/d,Assareh 2017 NA RCT (parallel, crossover, open-label) G  20, 20,  40 NA reverse  0.0000000000 -0.620000000  6.200000e-01,NA,NA NA NA NA,NA,NA,NA,100 100 100 100,100,100,100 some,some,some some,low Active (any credible active intervention),100 NA  9.100000,NA DSM-IV 0 1 1.0,1.0 1.0 1.0,1,1,0 1,1,1,1,1.0,1,1,1 1  817,Assareh_2017,< 2 months,NA 6-12 yo,7.94166666666667,9.1,NA,NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
1318,Gillies (2023),Gillies,2023,10.1002/14651858.CD007986.pub2 100,  0 100,100 High,Polyunsaturated fatty acids,NA 100,Metilphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.,12.00000000, 792.0000000,mg/d,Barragan,2017 NA RCT (parallel, crossover, open-label) G  30  30   60,NA reverse, 0.7800000000  0.260000000  1.310000e+00 NA,NA,NA,NA NA NA,NA NA,  0,  0,  0   0 100 100,  0,high high some high low,Active (any credible active intervention),100 NA, 8.270000 NA DSM-IV TR 0,1,1.0,1.0,1.0,1.0,1,1 0,1,1 1,1,1.0,1 1,1 1, 818,Barragan_2017,7-12 months,NA 6-12 yo 7.94166666666667,9.1,NA,NA  28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
1318 Gillies (2023) Gillies 2023 10.1002/14651858.CD007986.pub2 100   0 100,100 High Polyunsaturated fatty acids NA 100 Metilphenidate,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  1.84119678, 600.0000000,mg/d Behdani 2013 NA RCT (parallel, crossover, open-label) G, 36, 33,  69 NA,reverse, 0.2520209000,-0.694158300  1.198200e+00 NA,NA,NA,NA NA,NA NA NA 100 100,100 100 100,100 100 some,some,some,some low Active (any credible active intervention),100  20.300000, 8.700000,NA DSM-IV TR,0 1 1.0,1.0 1.0 1.0 1 1,0,1 1,1 1,1.0,1,1,1,1  819,Behdani_2013 < 2 months NA,6-12 yo 7.94166666666667,9.1 NA NA, 28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
1318,Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2 100,  0,100 100 High,Polyunsaturated fatty acids NA 100 MPH,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 1.84119678, 600.0000000 mg/d Mohammadzadeh,2019,NA,RCT (parallel, crossover, open-label),G, 31  29,  60 NA reverse  0.2200000000,-0.290000000, 7.300000e-01 NA,NA,NA NA NA,NA,NA,NA   0,  0 100 100,100   0,100,low low some low high,Active (any credible active intervention) 100  25.760000, 7.941667,NA,DSM-IV TR 0,1,1.0,1.0,1.0 1.0 1,1,0,1,1,1,1,1.0 1 1,1,1  820 Mohammadzadeh_2019,< 2 months NA 6-12 yo,7.94166666666667,9.1,NA NA, 28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7 NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high high
1318 Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2 100,  0 100 100 High Polyunsaturated fatty acids NA 100,MPH,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 1.84119678, 250.0000000,mg/d Salehi 2016 NA RCT (parallel, crossover, open-label),G  50, 50, 100,NA,reverse  0.0600000000,-0.340000000  4.500000e-01,NA NA,NA NA NA,NA NA,NA 100,100,100,100 100 100,100 some some,some,some some,Active (any credible active intervention) 100, 29.000000, 8.850000,NA DSM-IV TR,0 1,1.0,1.0 1.0 1.0 1,1 0,1,1,1,1,1.0 1,1 1 1  821 Salehi_2016,< 2 months,NA 6-12 yo,7.94166666666667,9.1,NA,NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
1318 Gillies (2023),Gillies 2023 10.1002/14651858.CD007986.pub2 100   0 100,100 High,Polyunsaturated fatty acids NA 100,Atomoxetine Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At follow-up (closest to 26 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 4.00000000, 300.0000000,mg/d Anand,2016 NA,RCT (parallel, crossover, open-label),G  25  25,  50 NA,reverse -0.3600000000 -0.920000000  2.000000e-01   2.2100000   2.1800000 NA,NA,NA,NA,NA,NA,100,100 100,100,100 100,100,low,some low,some some,Active (any credible active intervention) 100  30.000000  6.000000,NA DSM-IV,0,1,1.0 1.0 1.0,1.0,1 1,0,1,1,1,1 1.0,1 1,1 1, 822 Anand_2016 2-6 months,NA 6-12 yo,6 13.7 NA NA  28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low low
1318,Gillies (2023) Gillies 2023 10.1002/14651858.CD007986.pub2 100   0 100,100 High Polyunsaturated fatty acids,NA,100,Metilphenidate,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At follow-up (closest to 26 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.,12.00000000, 792.0000000,mg/d Barragan 2017,NA RCT (parallel, crossover, open-label),G, 30  30,  60 NA reverse, 0.2600000000,-0.250000000  7.700000e-01,  5.5400000,  4.7000000 NA NA NA NA NA,NA   0   0,  0,  0,100,100   0 high high some high,low,Active (any credible active intervention),100,NA, 8.270000,NA DSM-IV TR,0,1,1.0,1.0,1.0 1.0 1,1 0 1 1,1 1 1.0,1,1,1,1, 823,Barragan_2017,7-12 months NA,6-12 yo,6,13.7,NA,NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low,high
1318,Gillies (2023),Gillies,2023 10.1002/14651858.CD007986.pub2 100   0,100,100 High Polyunsaturated fatty acids,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks),Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 3.68239356 1300.0000000,mg/d,Bos 2015 NA RCT (parallel, crossover, open-label),G, 19, 19,  38,NA,reverse,-0.8400000000 -1.500000000 -1.700000e-01,  3.5000000   2.2000000,NA,NA NA NA,NA,NA   0,  0,  0,100 100 100,100 high low low low some,Placebo,  0   0.000000 10.300000,NA,DSM-IV,0,1,1.0,1.0,1.0 1.0,1,1,0 1,1 1 1 1.0,1,1 1 1  824,Bos_2015 2-6 months NA,6-12 yo 6 13.7,NA NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low,high
1318 Gillies (2023),Gillies 2023 10.1002/14651858.CD007986.pub2 100,  0 100 100 High,Polyunsaturated fatty acids,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At follow-up (closest to 26 weeks),Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  2.76179517 NA mg/d,Chang 2019,NA RCT (parallel, crossover, open-label) G, 48, 48,  96 NA,reverse, 0.2800000000 -0.130000000, 6.900000e-01, 10.0200000, 10.1700000 NA NA NA NA NA NA 100 100 100,100,100,100,100 some,some some,low,some Placebo   0, 14.130000  9.490000 NA DSM-5,0,1,1.0,1.0,1.0 1.0 1,1 0 1,1 1,1,1.0 1 1 1 1, 825 Chang_2019 2-6 months,NA,6-12 yo,6 13.7,NA NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low low
1318 Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2 100,  0,100,100 High,Polyunsaturated fatty acids,NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks),Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  3.00000000, 630.0000000,mg/d Cornu 2018,NA,RCT (parallel, crossover, open-label),G  77  77  154,NA reverse  0.2000000000 -0.120000000  5.100000e-01  11.4000000, 10.9000000 NA NA NA NA,NA,NA 100,100,100,100 100 100 100 low,low,low low,some,Placebo,  0  26.200000, 9.900000,NA,DSM-IV TR,0 1 1.0,1.0 1.0,1.0 1,1,0,1,1 1 1 1.0,1,1,1 1  826,Cornu_2018 2-6 months,NA,6-12 yo,6,13.7 NA NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low low
1318,Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2,100   0 100 100 High,Polyunsaturated fatty acids NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At follow-up (closest to 26 weeks) Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  6.00000000, 500.0000000,mg/d Crippa,2019,NA,RCT (parallel, crossover, open-label),G, 25  25,  50 NA,reverse, 0.0000000000,-0.560000000, 5.500000e-01,  8.6700000, 11.8900000 NA NA,NA,NA,NA NA   0,  0 100,100 100,  0,100 low,low,low low,high Placebo   0   8.000000 10.985000,NA,DSM-IV TR 0,1,1.0 1.0,1.0 1.0 1,1 0,1,1 1 1,1.0 1 1,1 1  827,Crippa_2019,2-6 months,NA,6-12 yo,6,13.7 NA,NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no high high
1318 Gillies (2023) Gillies 2023,10.1002/14651858.CD007986.pub2,100   0,100,100 High Polyunsaturated fatty acids NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks) Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 3.45224396, 502.7000000 mg/d Gustafsson 2010,NA RCT (parallel, crossover, open-label) G, 36, 36,  72 NA reverse, 0.2400000000 -0.170000000, 6.500000e-01, 18.6000000  18.4000000 NA,NA,NA,NA NA NA,100 100 100,100 100 100 100,some,low some low low Placebo   0,NA  9.500000,NA,DSM-IV,0 1 1.0,1.0,1.0,1.0,1 1,0 1,1,1,1 1.0,1,1 1,1, 828,Gustafsson_2010,2-6 months NA,6-12 yo,6 13.7,NA NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low,low
1318,Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2,100   0 100,100 High Polyunsaturated fatty acids,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks) Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 3.45224396, 420.0000000 mg/d Manor,2012,NA,RCT (parallel, crossover, open-label) G  20  20   40 NA reverse -0.1900000000,-0.550000000  1.700000e-01  10.0600000,  9.4400000,NA,NA,NA NA,NA,NA,  0   0 100,100,  0   0 100,low low high low high Placebo   0, 29.200000  9.200000 NA DSM-IV 0,1,1.0,1.0 1.0 1.0 1,1 0 1 1 1 1,1.0 1,1,1,1, 829,Manor_2012,2-6 months,NA,6-12 yo 6,13.7 NA,NA, 28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no high high
1318,Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2 100,  0 100,100,High Polyunsaturated fatty acids NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks),Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 2.76179517, 792.0000000 mg/d Matsudaira,2015,NA RCT (parallel, crossover, open-label) G, 19, 19,  38 NA reverse  0.2400000000,-0.430000000, 9.100000e-01   4.7100000,  6.7900000 NA NA,NA NA,NA NA,100 100,100 100 100,100,100 low some some,some low Placebo,  0,  0.000000 13.700000,NA DSM-IV,0,1,1.0 1.0,1.0 1.0 1,1,0 1,1 1 1 1.0 1,1,1 1, 830,Matsudaira_2015,2-6 months,NA,13-19 yo 6 13.7 NA,NA  28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low low
1318 Gillies (2023),Gillies 2023,10.1002/14651858.CD007986.pub2,100   0 100 100 High Polyunsaturated fatty acids NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks) Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.,NA, 600.0000000 mg/d NCT01807299 2013,NA,RCT (parallel, crossover, open-label) G, 11, 13,  24 NA reverse -0.4400000000,-1.260000000, 3.700000e-01  12.7500000  12.1000000,NA NA,NA,NA NA,NA,100 100 100 100,100,100,100,some,some,some,some low Placebo   0   0.000000 10.510000,NA DSM (clinical diag) 0 1 1.0 1.0,1.0,1.0 1,1,0 1 1,1,1 1.0 1 1 1,1, 831 NCT01807299_2013,NA,NA,6-12 yo 6,13.7 NA,NA, 28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no low low
1318 Gillies (2023) Gillies 2023,10.1002/14651858.CD007986.pub2,100   0 100 100 High Polyunsaturated fatty acids,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At follow-up (closest to 26 weeks),Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 6.00000000, 954.2400000 mg/d Perera,2012,NA RCT (parallel, crossover, open-label) G  48  46,  94,NA,reverse -0.2500000000 -0.660000000  1.500000e-01   3.6500000  29.3000000 NA NA,NA NA NA,NA,100,100,100 100,100,100 100 some low,some low,low Placebo   0, 26.600000  9.300000,NA,DSM (clinical diag) 0 1,1.0 1.0 1.0,1.0 1 1,0,1,1,1,1,1.0 1 1 1,1  832,Perera_2012 2-6 months,NA 6-12 yo,6,13.7,NA NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low,low
1318 Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2 100   0 100,100 High,Polyunsaturated fatty acids NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks),Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 6.00000000 1090.0000000,mg/d,Rodriguez,2019 NA,RCT (parallel, crossover, open-label),G  33, 33   66 NA,reverse, 0.0800000000 -0.410000000  5.600000e-01   3.9000000,  3.8000000 NA,NA NA NA NA NA,100,100 100,100   0 100 100 some low,high low low Placebo   0 NA 11.700000,NA,DSM-5,0 1 1.0,1.0,1.0,1.0,1,1,0,1,1 1,1 1.0,1 1 1 1  833 Rodriguez_2019,2-6 months NA,6-12 yo 6,13.7,NA,NA, 28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low low
1318 Gillies (2023),Gillies 2023,10.1002/14651858.CD007986.pub2,100   0,100 100 High Polyunsaturated fatty acids NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks),Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 4.00000000  656.0000000,mg/d Stevens,2003 NA RCT (parallel, crossover, open-label),G, 18, 18,  36,NA,reverse -0.3500000000,-1.040000000  3.400000e-01   3.7500000   4.0000000,NA NA,NA NA,NA NA,100 100,100 100   0,100 100,some,low,high low,low Placebo,  0, 14.600000  9.800000 NA DSM (clinical diag),0 1 1.0 1.0 1.0,1.0,1,1,0,1 1 1,1,1.0,1 1 1 1, 834,Stevens_2003,2-6 months NA,6-12 yo,6 13.7,NA,NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low low
1318 Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2 100,  0 100,100 High Polyunsaturated fatty acids,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks),Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 3.00000000, 145.0000000 mg/d,Vaisman,2008 NA,RCT (parallel, crossover, open-label) G, 29, 26   55 NA reverse -0.4000000000,-0.930000000, 1.400000e-01,  3.2200000,  3.7300000,NA,NA,NA,NA,NA NA 100,100,100 100,  0 100 100,some,low high,low low Placebo,  0  25.000000  9.300000 NA DSM (clinical diag) 0,1,1.0,1.0,1.0,1.0,1 1,0 1,1,1 1,1.0,1 1 1,1, 835,Vaisman_2008,2-6 months NA 6-12 yo 6 13.7,NA NA, 28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,low,low
1318 Gillies (2023),Gillies 2023 10.1002/14651858.CD007986.pub2,100   0 100 100,High,Polyunsaturated fatty acids,NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks),Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 3.68239356, 720.0000000,mg/d,Widenhorn-Muller 2014,NA,RCT (parallel, crossover, open-label) G  45, 45,  90 NA,reverse, 0.0200000000 -0.390000000, 4.300000e-01,  0.5400000   0.5500000 NA,NA,NA NA,NA NA,100 100 100 100,100,100 100,some,low,some,low low Placebo   0, 22.100000, 8.900000,NA DSM-IV,0,1,1.0,1.0,1.0 1.0 1,1 0,1 1 1,1,1.0 1,1,1 1  836 Widenhorn-Muller_2014 2-6 months NA,6-12 yo,6,13.7 NA,NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low,low
1318 Gillies (2023),Gillies,2023 10.1002/14651858.CD007986.pub2   0,  0,100,100 High,Polyunsaturated fatty acids NA,100,Dexamfetamine Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 1.00000000  390.0000000 mg/d,Arnold 1989,NA RCT (parallel, crossover, open-label),G, 18  18,  36 NA reverse,-0.4000000000 -1.060000000  2.600000e-01   0.5800000   0.3900000,NA,NA NA,NA,NA,NA,  0,  0,100 100,100,  0,100 some,some,some,low,high,Active (any credible active intervention),100,  0.000000,NA NA,DSM-III,0,1,1.0,1.0,1.0 1.0,1,1,0 1 1,1 1,1.0,1 1 1 1  837,Arnold_1989,< 2 months,NA NA,8.7,11,NA,NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high,high
1318 Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2,100,  0,100 100,High,Polyunsaturated fatty acids NA,100 Metilphenidate,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks) Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  1.84119678, 600.0000000,mg/d Behdani,2013,NA,RCT (parallel, crossover, open-label) G, 36, 33,  69 NA,reverse, 0.7200000000  0.230000000, 1.210000e+00,  2.7500000   9.5500000,NA NA NA,NA NA NA,100 100 100,100,100 100 100 some,some,some some low,Active (any credible active intervention) 100  20.300000  8.700000,NA DSM-IV TR,0 1 1.0 1.0,1.0 1.0 1 1 0,1,1 1 1,1.0,1 1 1 1, 838 Behdani_2013,< 2 months,NA,6-12 yo,8.7 11,NA NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
1318,Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2,100,  0,100,100,High Polyunsaturated fatty acids NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  1.84119678  600.0000000 mg/d Dubnov-Raz,2014 NA RCT (parallel, crossover, open-label) G,  8   9,  17 NA,reverse, 1.4300000000, 0.330000000  2.530000e+00,  7.3000000   2.5000000,NA,NA NA,NA NA,NA 100 100,100 100,  0 100 100,low some high some low Placebo   0  41.180000 11.000000,NA,DSM (clinical diag) 0,1 1.0 1.0 1.0 1.0,1,1 0 1,1 1 1 1.0 1 1,1 1  839 Dubnov-Raz_2014,< 2 months,NA 6-12 yo 8.7 11 NA NA  28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
1318,Gillies (2023),Gillies 2023,10.1002/14651858.CD007986.pub2 100,  0,100 100 High Polyunsaturated fatty acids,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks),Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 1.61104718, 600.0000000,mg/d Raz,2009,NA,RCT (parallel, crossover, open-label),G  32, 31   63 NA reverse,-0.0200000000 -0.510000000, 4.800000e-01,  1.4800000   1.1200000 NA NA NA,NA NA,NA   0   0 100 100   0   0 100,some some,high,low,high Placebo,  0, 39.700000,10.500000,NA DSM (clinical diag) 0 1,1.0,1.0 1.0 1.0,1,1 0 1,1 1,1 1.0,1,1,1 1, 840,Raz_2009,< 2 months,NA 6-12 yo 8.7,11,NA,NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high,high
1318,Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2,100   0 100 100 High,Polyunsaturated fatty acids,NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At follow-up (closest to 26 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 2.76179517,NA mg/d,Chang,2019,NA,RCT (parallel, crossover, open-label) G, 44  39   83,NA,reverse  0.4500000000, 0.010000000, 8.900000e-01  13.3200000   9.5000000,NA,NA,NA,NA,NA NA 100,100 100,100 100,100 100 some some,some,low some,Placebo   0, 14.130000, 9.490000,NA DSM-5,0 1 1.0,1.0 1.0,1.0 1 1 0 1 1,1,1 1.0,1,1 1 1, 841 Chang_2019,2-6 months,NA 6-12 yo,8.9 13.7 NA,NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,low,low
1318,Gillies (2023),Gillies,2023 10.1002/14651858.CD007986.pub2,100   0 100 100 High,Polyunsaturated fatty acids NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At follow-up (closest to 26 weeks),Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  3.45224396  502.7000000 mg/d,Gustafsson,2010 NA,RCT (parallel, crossover, open-label) G  46  46,  92,NA reverse  0.1300000000 -0.280000000, 5.400000e-01, 18.8000000  17.9000000,NA,NA NA NA,NA NA 100,100 100,100 100,100,100,some low some low low Placebo   0 NA  9.500000,NA,DSM-IV 0 1 1.0,1.0 1.0,1.0 1 1,0,1 1,1 1,1.0 1,1 1,1, 842 Gustafsson_2010 2-6 months NA 6-12 yo,8.9 13.7,NA,NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low,low
1318,Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2,100   0 100 100 High,Polyunsaturated fatty acids NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At follow-up (closest to 26 weeks),Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 3.45224396, 420.0000000 mg/d Manor,2012,NA RCT (parallel, crossover, open-label) G, 94, 42  136 NA,reverse  0.0700000000,-0.290000000  4.400000e-01   8.5700000,  8.8700000,NA NA NA,NA,NA,NA   0,  0 100 100   0   0 100 low,low high low,high Placebo   0, 29.200000  9.200000 NA DSM-IV,0 1,1.0,1.0,1.0 1.0,1 1 0 1,1 1 1 1.0 1 1,1 1  843,Manor_2012,2-6 months NA 6-12 yo,8.9,13.7,NA NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,high high
1318,Gillies (2023) Gillies 2023 10.1002/14651858.CD007986.pub2,100,  0 100 100 High Polyunsaturated fatty acids,NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At follow-up (closest to 26 weeks),Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998., 2.76179517, 792.0000000,mg/d Matsudaira,2015,NA RCT (parallel, crossover, open-label) G, 33  36   69 NA,reverse,-0.1800000000 -0.650000000, 2.900000e-01, 10.6000000  11.5000000 NA,NA NA NA NA,NA 100 100 100,100 100 100 100,low some,some,some low Placebo   0,  0.000000 13.700000,NA DSM-IV 0 1 1.0 1.0 1.0 1.0,1,1,0 1,1 1,1 1.0,1 1,1,1  844,Matsudaira_2015 2-6 months NA 13-19 yo 8.9,13.7 NA,NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7 NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low,low
1318,Gillies (2023),Gillies 2023 10.1002/14651858.CD007986.pub2 100,  0 100,100,High Polyunsaturated fatty acids,NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At follow-up (closest to 26 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  4.00000000, 656.0000000 mg/d,Stevens 2003,NA,RCT (parallel, crossover, open-label) G  18, 15   33 NA reverse,-0.1200000000,-0.810000000, 5.600000e-01,  2.7500000   5.0000000,NA,NA,NA,NA,NA,NA,100 100,100 100,  0 100 100,some low,high,low low,Placebo,  0  14.600000  9.800000,NA,DSM (clinical diag) 0 1,1.0,1.0 1.0 1.0,1,1,0 1,1 1,1 1.0,1 1,1,1  845,Stevens_2003,2-6 months,NA 6-12 yo 8.9,13.7 NA NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low,low
1318 Gillies (2023),Gillies,2023 10.1002/14651858.CD007986.pub2,100,  0 100,100 High Polyunsaturated fatty acids NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At follow-up (closest to 26 weeks) Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.  3.68239356  720.0000000,mg/d,Widenhorn-Muller,2014 NA,RCT (parallel, crossover, open-label),G, 40  45   85,NA reverse,-0.1200000000 -0.550000000  3.100000e-01,  0.6200000,  0.5400000 NA,NA,NA,NA,NA,NA 100,100,100 100,100,100 100 some low,some low low,Placebo,  0  22.100000, 8.900000,NA DSM-IV,0 1 1.0,1.0 1.0 1.0 1,1 0,1 1 1,1,1.0 1 1,1 1, 846,Widenhorn-Muller_2014 2-6 months NA 6-12 yo 8.9 13.7,NA,NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks),1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no low low
1318 Gillies (2023),Gillies,2023,10.1002/14651858.CD007986.pub2   0   0 100,100 High,Polyunsaturated fatty acids,NA 100,Dexamfetamine Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA NA  1.00000000, 390.0000000,mg/d,Arnold 1989,NA RCT (parallel, crossover, open-label),RR, 18, 18   36 NA,NA  1.0000000000  0.020900000  4.784689e+01,NA NA,NA,NA,NA,NA,NA NA,  0,  0,100 100 100   0 100,some,some some,low,high Active (any credible active intervention) 100   0.000000 NA,NA,DSM-III,0,1,1.0 1.0,1.0 1.0 1,1,0,1 1,1 1,1.0,1,1 1,1, 847 Arnold_1989,< 2 months NA NA 7.95 11 NA,NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high high
1318 Gillies (2023) Gillies 2023 10.1002/14651858.CD007986.pub2,100,  0,100 100,High,Polyunsaturated fatty acids,NA 100 Metilphenidate,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA NA  1.84119678, 600.0000000,mg/d Behdani,2013,NA RCT (parallel, crossover, open-label) RR, 40  35   75 NA,NA, 1.7500000000  0.340950096, 8.982253e+00,NA,NA,NA,NA,NA,NA NA,NA,100 100,100 100,100 100 100,some some,some,some,low,Active (any credible active intervention) 100  20.300000  8.700000 NA DSM-IV TR 0,1,1.0,1.0 1.0,1.0 1,1,0 1,1 1,1 1.0 1,1,1,1  848 Behdani_2013 < 2 months NA,6-12 yo,7.95 11,NA,NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
1318,Gillies (2023) Gillies 2023 10.1002/14651858.CD007986.pub2 100,  0 100 100,High Polyunsaturated fatty acids NA,  0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,NA, 1.84119678  600.0000000,mg/d,Dubnov-Raz,2014,NA,RCT (parallel, crossover, open-label) RR, 20  20   40,NA NA  1.0909090909, 0.639525307  1.860884e+00,NA,NA NA NA,NA NA,NA NA 100,100,100,100   0 100 100 low,some,high,some,low,Placebo   0, 41.180000 11.000000 NA DSM (clinical diag),0,1 1.0,1.0,1.0 1.0,1,1,0,1,1 1 1 1.0,1 1,1,1  849 Dubnov-Raz_2014,< 2 months NA,6-12 yo 7.95 11 NA NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
1318 Gillies (2023),Gillies,2023,10.1002/14651858.CD007986.pub2 100,  0 100 100 High,Polyunsaturated fatty acids,NA   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA NA, 2.00000000, 614.2857143,mg/d,Hirayama,2004 NA,RCT (parallel, crossover, open-label),RR, 20  20   40,NA,NA, 1.0000000000  0.020796283  4.808552e+01 NA,NA NA NA,NA NA NA NA 100,100,100,100 100,100,100,low low low low low,Placebo,  0, 20.000000, 9.000000 NA DSM-IV 0 1,1.0 1.0 1.0,1.0 1,1 0 1 1,1,1 1.0 1,1,1,1, 850,Hirayama_2004,2-6 months NA,6-12 yo 7.95,11 NA,NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
1318 Gillies (2023),Gillies 2023,10.1002/14651858.CD007986.pub2,100,  0 100 100 High,Polyunsaturated fatty acids,NA   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,NA, 3.45224396  420.0000000 mg/d,Manor,2012,NA,RCT (parallel, crossover, open-label) RR,137, 63, 200,NA,NA  1.0634124088  0.641855392  1.761839e+00 NA,NA,NA,NA,NA,NA,NA NA   0,  0 100 100   0,  0 100,low low,high low,high,Placebo,  0, 29.200000  9.200000,NA,DSM-IV,0 1,1.0 1.0 1.0 1.0 1 1,0 1,1,1 1,1.0,1,1 1 1  851,Manor_2012,2-6 months NA,6-12 yo 7.95 11 NA NA  28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7 NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high high
1318 Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2 100   0,100,100 High,Polyunsaturated fatty acids,NA,100 MPH Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,NA, 1.84119678  600.0000000,mg/d,Mohammadzadeh 2019 NA,RCT (parallel, crossover, open-label) RR  33  33,  66,NA NA  0.5000000000, 0.098224424, 2.545192e+00,NA,NA NA NA,NA NA NA NA,  0,  0 100,100 100   0 100 low,low,some low high,Active (any credible active intervention),100, 25.760000  7.950000 NA,DSM-IV TR,0 1 1.0 1.0,1.0 1.0 1,1,0 1,1,1,1 1.0,1,1 1,1  852,Mohammadzadeh_2019,< 2 months NA,6-12 yo 7.95,11,NA,NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high,high
1318,Gillies (2023),Gillies 2023,10.1002/14651858.CD007986.pub2 100   0,100,100,High,Polyunsaturated fatty acids NA,  0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA NA  3.00000000  145.0000000 mg/d,Vaisman,2008 NA RCT (parallel, crossover, open-label) RR  57, 26   83 NA,NA, 1.6421052632, 0.684164340, 3.941319e+00 NA,NA NA,NA NA NA,NA NA,100 100 100 100   0 100 100 some low,high low low,Placebo   0  25.000000  9.300000,NA DSM (clinical diag) 0 1,1.0 1.0 1.0,1.0,1,1,0 1,1,1 1 1.0,1,1 1 1  853 Vaisman_2008 2-6 months,NA 6-12 yo,7.95,11,NA NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA NA Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
1318 Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2 100   0,100,100,High,Polyunsaturated fatty acids NA,  0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,NA, 4.00000000, 345.0000000,mg/d,Voigt,2001 NA RCT (parallel, crossover, open-label),RR, 32, 31,  63 NA,NA, 0.9687500000, 0.310775922  3.019785e+00,NA,NA NA NA,NA,NA,NA,NA   0,  0,100,100   0,  0,100,some,low,high,low,high,Placebo   0  22.200000  9.300000 NA DSM (clinical diag) 0 1 1.0 1.0,1.0,1.0,1 1,0 1 1 1,1 1.0,1 1 1 1, 854,Voigt_2001,2-6 months NA,6-12 yo,7.95,11,NA NA, 28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA,NA Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high high
1318 Gillies (2023) Gillies 2023 10.1002/14651858.CD007986.pub2,100,  0,100 100,High,Polyunsaturated fatty acids,NA   0,NA Conduct Disorder symptoms Mixed,At follow-up (closest to 26 weeks),Questionnaire Measured by scales such as the Child Behavior Checklist  2.76179517,NA,mg/d Chang,2019 NA RCT (parallel, crossover, open-label),G, 48  44,  92,NA,reverse, 0.1400000000,-0.260000000, 5.500000e-01,  2.0400000,  1.9200000,NA,NA,NA,NA NA NA 100 100 100 100 100,100,100,some some some low some Placebo   0, 14.130000  9.490000,NA,DSM-5 0,1 1.0 1.0 1.0,1.0,1,1,0,1,1 1,1,1.0 1 1,1 1  855 Chang_2019,2-6 months NA,6-12 yo,8.82,10.985 NA NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low low
1318 Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2 100,  0 100,100 High,Polyunsaturated fatty acids,NA   0,NA,Conduct Disorder symptoms Mixed At follow-up (closest to 26 weeks) Questionnaire Measured by scales such as the Child Behavior Checklist, 6.00000000  500.0000000,mg/d,Crippa 2019,NA RCT (parallel, crossover, open-label),G, 25  25,  50 NA,reverse -0.0900000000,-0.650000000, 4.600000e-01   1.7000000,  2.1800000 NA,NA NA,NA NA,NA,  0   0 100 100,100   0 100 low low,low,low high Placebo   0,  8.000000 10.985000 NA,DSM-IV TR,0 1,1.0 1.0,1.0,1.0 1 1,0 1,1 1 1,1.0 1 1,1,1, 856,Crippa_2019,2-6 months,NA,6-12 yo 8.82 10.985,NA,NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA NA,Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,high high
1318,Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2 100,  0,100 100 High Polyunsaturated fatty acids NA   0 NA Conduct Disorder symptoms,Mixed At follow-up (closest to 26 weeks) Questionnaire,Measured by scales such as the Child Behavior Checklist  3.22209436   55.5000000 mg/d Kean,2017 NA RCT (parallel, crossover, open-label) G  29, 36,  65 NA reverse  0.2200000000 -0.270000000  7.100000e-01  14.4300000  17.1600000,NA,NA NA NA,NA NA   0   0,100,100,  0   0,100,low,low high low high Placebo   0, 14.600000  8.820000 NA DSM-IV,0 1,1.0,1.0 1.0 1.0,1,1,0,1,1 1 1 1.0 1 1 1,1  857 Kean_2017,2-6 months,NA,6-12 yo 8.82,10.985,NA NA, 28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,high high
1318,Gillies (2023),Gillies,2023,10.1002/14651858.CD007986.pub2,100   0 100 100 High Polyunsaturated fatty acids NA   0 NA Conduct Disorder symptoms,Mixed At follow-up (closest to 26 weeks),Questionnaire Measured by scales such as the Child Behavior Checklist  4.00000000  656.0000000,mg/d,Stevens 2003,NA RCT (parallel, crossover, open-label),G  18, 15   33 outcomes reverse, 0.3100000000 -0.380000000, 1.000000e+00,  4.0000000,  4.2500000 NA,NA NA,NA NA,NA,100 100 100,100,  0 100 100 some low,high,low,low Placebo,  0  14.600000  9.800000 NA,DSM (clinical diag),0,1 1.0,1.0,1.0,1.0 1 1 0 1,1,1 1,1.0,1 1,1 1  858 Stevens_2003 2-6 months,NA,6-12 yo 8.82 10.985 NA NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA NA,Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks),1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low,low
1318 Gillies (2023),Gillies 2023,10.1002/14651858.CD007986.pub2,100   0 100,100 High,Polyunsaturated fatty acids,NA   0 NA,Conduct Disorder symptoms Mixed At follow-up (closest to 26 weeks) Questionnaire,Measured by scales such as the Child Behavior Checklist, 3.68239356, 720.0000000,mg/d,Widenhorn-Muller 2014 NA,RCT (parallel, crossover, open-label) G, 45  47,  92,outcomes reverse  0.2300000000 -0.180000000  6.400000e-01,  7.1100000   7.6100000 NA,NA,NA,NA,NA NA,100 100 100 100 100 100,100,some,low some,low low Placebo,  0  22.100000, 8.900000 NA,DSM-IV 0,1 1.0 1.0,1.0,1.0,1,1 0,1,1 1,1,1.0,1,1,1,1, 859 Widenhorn-Muller_2014,2-6 months,NA 6-12 yo 8.82,10.985,NA,NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA NA Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,low low
1318 Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2 100,  0 100 100,High,Polyunsaturated fatty acids,NA,  0 NA,Conduct Disorder symptoms Mixed,At follow-up (closest to 26 weeks),Questionnaire,Measured by scales such as the Child Behavior Checklist, 4.00000000  656.0000000,mg/d,Stevens 2003 NA RCT (parallel, crossover, open-label) G, 18, 15,  33,outcomes,reverse, 0.0500000000 -0.640000000  7.300000e-01   5.0000000,  2.5000000 NA,NA NA,NA,NA,NA 100 100 100,100   0,100 100 some,low high low low Placebo   0, 14.600000, 9.800000,NA,DSM (clinical diag),0 1,1.0 1.0 1.0 1.0,1 1 0 1,1,1,1,1.0 1,1 1 1  860 Stevens_2003 2-6 months NA,6-12 yo,8.82 10.985 NA NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA,NA Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no low low
1318,Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2 100   0 100,100 High,Polyunsaturated fatty acids NA   0,NA,Conduct Disorder symptoms,Mixed At follow-up (closest to 26 weeks),Questionnaire,Measured by scales such as the Child Behavior Checklist, 3.68239356  720.0000000,mg/d Widenhorn-Muller 2014 NA,RCT (parallel, crossover, open-label) G  40  45,  85 outcomes,reverse,-0.0500000000,-0.480000000  3.700000e-01,  5.1200000,  5.1000000 NA,NA,NA,NA NA,NA 100,100,100 100 100 100,100,some,low,some low low,Placebo,  0, 22.100000  8.900000 NA,DSM-IV,0 1,1.0,1.0,1.0,1.0,1,1 0,1,1 1,1,1.0,1,1 1 1  861,Widenhorn-Muller_2014 2-6 months,NA 6-12 yo,8.82,10.985 NA NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) 1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no low low
1318,Gillies (2023) Gillies 2023 10.1002/14651858.CD007986.pub2,100,  0,100 100 High Polyunsaturated fatty acids NA,  0 NA,Oppositional Defiant Disorder symptoms,Mixed,At follow-up (closest to 26 weeks) Questionnaire,Measured by scales such as the Child Behavior Checklist  2.76179517 NA,mg/d Chang,2019,NA RCT (parallel, crossover, open-label) G, 48  44   92 NA reverse, 0.1500000000 -0.260000000  5.600000e-01,  6.0300000   5.4400000 NA NA,NA,NA,NA,NA,100,100,100 100,100,100 100 some some some,low,some,Placebo   0  14.130000, 9.490000,NA,DSM-5,0,1 1.0 1.0,1.0,1.0,1,1,0,1,1 1,1,1.0 1,1,1 1, 862,Chang_2019,2-6 months NA 6-12 yo 8.82 9.8,NA NA  28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) 1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low low
1318 Gillies (2023),Gillies,2023,10.1002/14651858.CD007986.pub2 100   0,100 100,High Polyunsaturated fatty acids,NA,  0,NA,Oppositional Defiant Disorder symptoms,Mixed At follow-up (closest to 26 weeks),Questionnaire Measured by scales such as the Child Behavior Checklist  3.45224396, 502.7000000 mg/d Gustafsson 2010,NA RCT (parallel, crossover, open-label) G, 46, 46   92,outcomes,reverse  0.2400000000,-0.170000000, 6.500000e-01, 18.6000000, 18.4000000 NA NA,NA NA,NA NA,100,100,100,100 100 100 100 some low some low,low Placebo,  0,NA  9.500000 NA,DSM-IV,0 1 1.0,1.0 1.0,1.0 1,1 0,1,1 1 1,1.0,1,1 1,1  863,Gustafsson_2010 2-6 months,NA,6-12 yo 8.82,9.8 NA,NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA,NA Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) 1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low low
1318,Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2,100,  0,100,100,High Polyunsaturated fatty acids,NA,  0 NA,Oppositional Defiant Disorder symptoms Mixed,At follow-up (closest to 26 weeks),Questionnaire Measured by scales such as the Child Behavior Checklist, 3.22209436,  55.5000000,mg/d,Kean,2017 NA,RCT (parallel, crossover, open-label),G, 29  36   65 NA reverse, 0.0900000000 -0.400000000, 5.800000e-01  18.6700000  15.5100000,NA,NA NA NA NA NA   0,  0 100 100,  0   0,100 low,low high low,high Placebo   0, 14.600000, 8.820000,NA DSM-IV 0,1,1.0 1.0 1.0 1.0 1 1,0,1 1 1,1,1.0 1,1 1 1, 864,Kean_2017,2-6 months NA 6-12 yo,8.82 9.8 NA NA, 28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA,NA Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks),1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,high,high
1318,Gillies (2023),Gillies 2023 10.1002/14651858.CD007986.pub2 100,  0,100,100,High Polyunsaturated fatty acids NA,  0 NA,Oppositional Defiant Disorder symptoms,Mixed,At follow-up (closest to 26 weeks),Questionnaire,Measured by scales such as the Child Behavior Checklist  3.45224396, 420.0000000 mg/d Manor 2012,NA,RCT (parallel, crossover, open-label) G  99  42  141,outcomes,reverse, 0.0300000000,-0.330000000, 3.900000e-01, 10.2500000  12.2600000,NA NA,NA NA NA,NA,  0,  0,100,100,  0,  0,100,low low high low high Placebo   0  29.200000  9.200000,NA,DSM-IV,0 1,1.0 1.0,1.0,1.0,1 1 0 1,1 1,1,1.0,1 1 1 1  865,Manor_2012,2-6 months,NA,6-12 yo 8.82 9.8 NA NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks),1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no high,high
1318,Gillies (2023) Gillies,2023,10.1002/14651858.CD007986.pub2,100   0 100 100,High Polyunsaturated fatty acids NA   0,NA Oppositional Defiant Disorder symptoms,Mixed,At follow-up (closest to 26 weeks) Questionnaire Measured by scales such as the Child Behavior Checklist, 4.00000000, 656.0000000,mg/d Stevens,2003 NA RCT (parallel, crossover, open-label),G  18  15,  33,NA,reverse -0.0200000000 -0.700000000, 6.700000e-01,  5.2500000,  6.0000000 NA NA,NA NA NA,NA 100 100 100,100,  0,100,100 some,low high low low Placebo   0, 14.600000  9.800000,NA DSM (clinical diag) 0 1,1.0 1.0,1.0,1.0 1 1 0 1,1 1 1,1.0,1,1 1,1, 866,Stevens_2003 2-6 months NA,6-12 yo,8.82 9.8 NA NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA,NA,Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no,low,low
1318,Gillies (2023) Gillies,2023 10.1002/14651858.CD007986.pub2 100,  0 100,100 High,Polyunsaturated fatty acids NA,  0 NA,Oppositional Defiant Disorder symptoms Mixed,At follow-up (closest to 26 weeks) Questionnaire,Measured by scales such as the Child Behavior Checklist  3.45224396  502.7000000,mg/d Gustafsson 2010,NA,RCT (parallel, crossover, open-label),G  46, 46   92 outcomes reverse, 0.2400000000 -0.170000000  6.500000e-01  18.6000000, 18.4000000 NA,NA,NA,NA,NA NA 100,100,100 100,100,100,100,some,low,some low,low Placebo   0,NA  9.500000,NA DSM-IV,0,1,1.0,1.0,1.0 1.0,1,1 0 1,1,1,1 1.0 1,1,1 1, 867 Gustafsson_2010 2-6 months,NA 6-12 yo,8.82 9.8,NA NA  28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA NA,Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks),1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,100.00000 no,low low
1318,Gillies (2023),Gillies 2023 10.1002/14651858.CD007986.pub2 100   0,100 100,High Polyunsaturated fatty acids,NA   0,NA Oppositional Defiant Disorder symptoms Mixed,At follow-up (closest to 26 weeks),Questionnaire,Measured by scales such as the Child Behavior Checklist  3.45224396  420.0000000 mg/d,Manor 2012,NA,RCT (parallel, crossover, open-label),G  92, 40, 132,outcomes,reverse -0.0200000000 -0.390000000  3.500000e-01  11.9800000, 12.3200000,NA,NA,NA,NA NA,NA,  0   0 100 100   0,  0 100,low low high,low,high Placebo,  0, 29.200000, 9.200000,NA DSM-IV,0 1 1.0 1.0 1.0,1.0,1 1 0 1 1,1,1 1.0 1 1,1 1, 868,Manor_2012 2-6 months NA,6-12 yo,8.82,9.8 NA NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA NA,Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks),1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,high,high
1318,Gillies (2023) Gillies 2023,10.1002/14651858.CD007986.pub2,100,  0 100 100 High Polyunsaturated fatty acids,NA   0,NA,Social-communication skills,Mixed At follow-up (closest to 26 weeks),Unclear (not able to identify the tools used to measure the outcome) NA, 4.00000000, 345.0000000 mg/d,Voigt,2001 NA,RCT (parallel, crossover, open-label) G, 27, 26,  53,NA reverse, 0.0500000000,-0.490000000  5.900000e-01,  8.3100000   7.6500000,NA NA NA NA,NA NA,  0,  0 100,100,  0   0 100,some low high,low high Placebo   0  22.200000, 9.300000,NA,DSM (clinical diag),0 1 1.0,1.0,1.0,1.0,1,1,0 1,1 1 1 1.0 1 1 1 1, 869,Voigt_2001,2-6 months NA,6-12 yo 8.9 9.3 NA NA  28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA NA Gillies (2023)_Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks),1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no high high
1318 Gillies (2023),Gillies 2023 10.1002/14651858.CD007986.pub2,100   0 100 100 High Polyunsaturated fatty acids,NA,  0 NA Social-communication skills,Mixed At follow-up (closest to 26 weeks),Unclear (not able to identify the tools used to measure the outcome) NA, 3.68239356  720.0000000 mg/d Widenhorn-Muller 2014 NA,RCT (parallel, crossover, open-label) G, 45  47   92 outcomes,reverse, 0.4000000000 -0.010000000  8.100000e-01, 10.1300000   7.6100000,NA NA NA,NA NA,NA,100 100,100 100 100 100,100 some,low,some low low,Placebo   0, 22.100000  8.900000 NA DSM-IV 0,1,1.0,1.0,1.0,1.0,1,1,0,1,1,1 1,1.0,1,1 1 1, 870,Widenhorn-Muller_2014 2-6 months,NA,6-12 yo 8.9 9.3,NA NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7 NA NA,Gillies (2023)_Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks),1,Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low low
1318,Gillies (2023),Gillies,2023 10.1002/14651858.CD007986.pub2,100   0 100 100 High Polyunsaturated fatty acids NA   0,NA Social-communication skills Mixed,At follow-up (closest to 26 weeks),Unclear (not able to identify the tools used to measure the outcome),NA  3.68239356, 720.0000000,mg/d,Widenhorn-Muller,2014 NA RCT (parallel, crossover, open-label) G, 40, 45   85,outcomes,reverse -0.1600000000,-0.580000000, 2.700000e-01   5.3100000,  6.4400000,NA NA NA NA NA,NA,100 100,100 100,100 100,100,some low some,low,low Placebo,  0, 22.100000, 8.900000 NA DSM-IV,0,1,1.0,1.0 1.0,1.0,1,1 0 1,1 1 1 1.0,1,1 1,1  871,Widenhorn-Muller_2014 2-6 months,NA,6-12 yo 8.9,9.3,NA NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA,NA Gillies (2023)_Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks) 1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,low low
1318 Gillies (2023),Gillies,2023,10.1002/14651858.CD007986.pub2 100   0,100,100 High Polyunsaturated fatty acids NA,100,Metilphenidate,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome) NA 12.00000000, 792.0000000 mg/d Barragan,2017,NA RCT (parallel, crossover, open-label) RR, 30  30   60,NA,NA, 0.0769230769  0.004525704  1.307456e+00 NA,NA,NA,NA NA NA NA,NA   0   0   0   0 100 100   0 high,high some high low,Active (any credible active intervention),100,NA, 8.270000,NA DSM-IV TR 0 1 1.0 1.0,1.0,1.0 1 1 0 1,1,1 1 1.0,1,1,1 1, 872 Barragan_2017,7-12 months,NA 6-12 yo 7.93387096774194 8.27,NA NA, 28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7,NA NA,Gillies (2023)_Polyunsaturated fatty acids_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Gillies (2023) - Polyunsaturated fatty acids_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
1318,Gillies (2023),Gillies,2023 10.1002/14651858.CD007986.pub2,100   0,100,100 High,Polyunsaturated fatty acids NA,100 MPH,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks) Unclear (not able to identify the tools used to measure the outcome),NA  1.84119678, 600.0000000,mg/d,Mohammadzadeh 2019 NA,RCT (parallel, crossover, open-label) RR  33  29,  62,NA,NA  0.8787878788  0.132043510  5.848588e+00,NA,NA NA,NA,NA NA NA NA   0   0,100 100 100   0 100,low,low,some,low high,Active (any credible active intervention) 100  25.760000  7.933871 NA DSM-IV TR,0,1 1.0,1.0,1.0 1.0,1 1,0,1,1,1 1,1.0,1,1,1,1, 873 Mohammadzadeh_2019 < 2 months NA 6-12 yo 7.93387096774194,8.27,NA,NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA NA Gillies (2023)_Polyunsaturated fatty acids_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Gillies (2023) - Polyunsaturated fatty acids_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high high
1459 Handel (2021) Handel 2021,10.3390/nu13041226,100,  0 100,100 Moderate,Polyunsaturated fatty acids,Supplementation of PUFAs:  omega 3 and 6 fatty acids,  0 NA Quality of life (patients),Mixed,At follow-up (closest to 26 weeks) NA,NA, 6.00000000 1000.0000000 mg/d,Crippa 2019 NA RCT (parallel, crossover, open-label),SMD  25  25   50 NA reverse, 0.0700000000,-0.490000000, 6.200000e-01   0.8600000   1.1300000,NA NA,NA NA NA,NA   0   0 100,100,100,100,  0,some,some low,high low Placebo,  0,  9.000000,10.985000,NA,DSM,0,1 0.5 1.0 1.0 1.0,1,1,2 1,1,1,1 1.0 1 0,0 1  874 Crippa_2019 2-6 months,NA 6-12 yo,9.2 10.985,NA,NA  28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA,NA Handel (2021)_Polyunsaturated fatty acids_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks),1,Homogeneous,Handel (2021) - Polyunsaturated fatty acids_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,100.00000,no low,high
1459 Handel (2021),Handel,2021 10.3390/nu13041226,100,  0,100,100 Moderate Polyunsaturated fatty acids,Supplementation of PUFAs:  omega 3 and 6 fatty acids,  0,NA,Quality of life (patients) Mixed At follow-up (closest to 26 weeks),NA,NA, 3.45224396, 420.0000000,mg/d Manor,2011,NA RCT (parallel, crossover, open-label),SMD, 94  44  138,NA,reverse,-0.0100000000 -0.370000000, 3.500000e-01   9.5500000  10.2600000,NA,NA,NA NA NA NA,  0,  0,100 100,  0,  0,100 low low high low high,Placebo   0  29.275362  9.200000 NA,DSM,0 1 0.5 1.0 1.0 1.0 1 1,2,1 1 1,1 1.0,1 0 0 1, 875 Manor_2011,2-6 months NA,6-12 yo 9.2 10.985 NA NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA,NA Handel (2021)_Polyunsaturated fatty acids_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous,Handel (2021) - Polyunsaturated fatty acids_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,high high
3367,Sonuga-Barke (2014),Sonuga-Barke,2014 10.1176/appi.ajp.2012.12070991 100   0,100,100,Moderate,Diet (restricted/elimination),oligoantigenic diet,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),Questionnaire CTRS  0.23014960,NA,NA,Schmidt,1997,NA RCT (parallel, crossover, open-label),G, 49  49,  98 outcomes,NA, 0.0529284165,-0.340997831, 4.467679e-01,NA NA NA NA NA NA,NA,NA   0,  0,100   0 100   0,100,some high some,low,high Not a therapeutic intervention,  0   4.000000, 9.500000 NA,DSM-III-R,0 1 0.5 1.0,1.0,1.0,1 1,2 1,1,1,0 1.0,0,1,1 1  876 Schmidt_1997 < 2 months,NA,6-12 yo,4.5,9.5 NA,NA,  8, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Sonuga-Barke (2014) | Catala-Lopez (2017),4.5 9.5 NA,NA,Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Mixed,Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious,high high
3367 Sonuga-Barke (2014) Sonuga-Barke,2014,10.1176/appi.ajp.2012.12070991 100,  0,100 100 Moderate,Diet (restricted/elimination),known antigenic food,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks),Questionnaire CPRS, 0.80552359 NA,NA Kaplan,1989 NA,RCT (parallel, crossover, open-label) G, 25, 25   50 outcomes NA  0.5113232104,-0.060390456  1.090499e+00 NA,NA,NA,NA,NA NA,NA,NA,  0   0,  0   0,100,  0 100,high high some low,high Placebo   0,  0.000000, 4.500000,NA DSM-III,0 1,0.5 1.0,1.0 1.0 1 1,2,1 1 1,0,1.0,0,1 1,1, 877 Kaplan_1989,< 2 months NA < 6 yo 4.5,9.5,NA,NA   8, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2,Sonuga-Barke (2014) | Catala-Lopez (2017),4.5,9.5 NA NA,Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Mixed,Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious,high,high
3367,Sonuga-Barke (2014) Sonuga-Barke,2014,10.1176/appi.ajp.2012.12070991 100,  0 100 100,Moderate,Diet (restricted/elimination) specific provoking food   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks),Questionnaire CPRS, 0.23014960,NA NA Carter 1993,NA,RCT (parallel, crossover, open-label),G, 19  19,  38,outcomes,NA  0.6170932755 -0.046941432, 1.281302e+00 NA NA NA NA,NA NA NA NA   0,  0 100,  0,100,  0,100,low,high,some low,high Placebo   0  26.000000, 7.500000 NA DSM-III,0,1 0.5,1.0,1.0,1.0,1,1,2,1,1,1,0,1.0 0 1,1 1  878,Carter_1993,< 2 months,NA 6-12 yo,4.5,9.5,NA NA,  8  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Sonuga-Barke (2014) | Catala-Lopez (2017),4.5,9.5,NA,NA,Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Mixed Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious,high high
3367,Sonuga-Barke (2014),Sonuga-Barke 2014 10.1176/appi.ajp.2012.12070991 100   0,100,100 Moderate,Diet (restricted/elimination),known antigenic food   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) Questionnaire,CPRS, 0.23014960 NA,NA Boris,1994,NA RCT (parallel, crossover, open-label),G  16  16   32,outcomes NA, 1.9661605206, 1.093275488, 2.831497e+00 NA,NA NA NA,NA,NA,NA NA   0   0,100,  0,100,  0,100 low high some,low high Placebo   0, 31.000000, 7.500000,NA,DSM-III-R 0 1,0.5 1.0,1.0 1.0,1 1,2 1 1,1,0,1.0 0,1 1 1  879,Boris_1994 < 2 months,NA 6-12 yo,4.5 9.5 NA,NA,  8, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Sonuga-Barke (2014) | Catala-Lopez (2017),4.5,9.5 NA,NA,Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Mixed Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious high,high
3367,Sonuga-Barke (2014),Sonuga-Barke 2014 10.1176/appi.ajp.2012.12070991,100   0 100,100 Moderate Diet (restricted/elimination),oligoantigenic diet   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),Questionnaire CTRS  0.23014960,NA NA Schmidt,1997,NA RCT (parallel, crossover, open-label) G  49  49   98 outcomes,NA  0.0542438058,-0.350370705  4.514005e-01,NA,NA,NA NA,NA,NA,NA,NA   0   0 100   0 100   0,100 some,high,some,low high Not a therapeutic intervention   0   4.000000, 9.500000 NA,DSM-III-R 0 1 0.5 1.0,1.0 1.0,1,1,2 1,1 1,0,1.0,0,1,1 1  880 Schmidt_1997 < 2 months,NA 6-12 yo 4.5 9.5,NA,NA   8  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Sonuga-Barke (2014) | Catala-Lopez (2017),4.5,9.5 NA NA,Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Mixed Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious high high
3367,Sonuga-Barke (2014) Sonuga-Barke,2014 10.1176/appi.ajp.2012.12070991,100   0,100 100 Moderate,Diet (restricted/elimination),known antigenic food,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) Questionnaire CTRS  0.80552359,NA NA Kaplan 1989,NA,RCT (parallel, crossover, open-label) G  25, 25,  50 outcomes,NA  0.2633533859,-0.652644458  1.164086e+00,NA NA NA NA NA NA NA,NA,  0,  0   0   0,100   0,100 high,high,some low high Placebo   0   0.000000, 4.500000,NA,DSM-III,0 1,0.5 1.0 1.0,1.0,1 1,2 1,1 1 0 1.0 0,1,1 1, 881,Kaplan_1989 < 2 months,NA,< 6 yo 4.5,9.5,NA NA,  8  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Sonuga-Barke (2014) | Catala-Lopez (2017),4.5,9.5,NA,NA Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Mixed Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious high,high
3367,Sonuga-Barke (2014) Sonuga-Barke 2014,10.1176/appi.ajp.2012.12070991 100,  0,100 100,Moderate,Diet (restricted/elimination) specific provoking food,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),Observational tool,Test session observation  0.23014960,NA,NA Carter 1993 NA,RCT (parallel, crossover, open-label),G, 19, 19,  38,outcomes,NA, 0.7339227710  0.062255109, 1.405590e+00,NA,NA,NA NA,NA NA,NA,NA   0,  0,100   0 100,  0,100,low high some low high Placebo,  0, 26.000000, 7.500000 NA,DSM-III 0,1,0.5 1.0 1.0 1.0 1 1,2 1 1 1,0 1.0 0,1 1,1, 882 Carter_1993 < 2 months,NA 6-12 yo 4.5 9.5,NA NA,  8  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5 9.5 NA,NA Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Mixed Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious,high high
3367,Sonuga-Barke (2014),Sonuga-Barke 2014 10.1176/appi.ajp.2012.12070991 100   0 100,100 Moderate Diet (restricted/elimination),known antigenic food,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),Questionnaire CPRS  0.23014960,NA NA Boris 1994,NA,RCT (parallel, crossover, open-label) G  16, 16   32 outcomes NA  1.9756456382, 1.105355920, 2.838303e+00,NA NA,NA,NA NA NA,NA NA   0,  0 100   0 100   0,100 low high some low high,Placebo   0, 31.000000  7.500000 NA,DSM-III-R 0,1,0.5,1.0 1.0,1.0 1,1 2,1,1,1,0,1.0,0 1 1,1  883 Boris_1994,< 2 months NA 6-12 yo,4.5,9.5 NA,NA   8  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Sonuga-Barke (2014) | Catala-Lopez (2017),4.5,9.5 NA NA Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Mixed,Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 serious high,high
4036 Zhang (2023) Zhang 2023,10.1177/10870547231154897 100,  0 100 100,Critically low,Mindfulness yoga   0 NA Executive functioning (mixed) Mixed,At study endpoint (closest to 12 weeks),Mixed (different types of tool are used),NA, 1.38089758 NA,NA Rezaei,2018 NA RCT (parallel, crossover, open-label) SMD,  7   7   14,NA,reverse,-1.1000000000,-2.250000000, 6.000000e-02 NA NA NA,NA NA,NA,NA,NA,  0,  0,  0   0,100,  0   0 high,high,low high,high WLC (wait-list control)   0 NA, 9.000000 NA DSM-5 2,1 1.0,0.0,1.0 1.0 0 1,2 1,1,1,1,0.5,0 0 1 1, 884,Rezaei_2018,< 2 months,NA,6-12 yo 9 11.1864077669903,NA,NA  13, 8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08 39.35 NA NA,Zhang (2023)_Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Zhang (2023) - Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high high
4036 Zhang (2023),Zhang,2023,10.1177/10870547231154897 100,  0,100 100,Critically low Mindfulness mindfulness based intervention,  0 NA,Executive functioning (mixed) Mixed At study endpoint (closest to 12 weeks),Mixed (different types of tool are used),NA NA,NA NA Robe 2022,NA,RCT (parallel, crossover, open-label) SMD  35  35,  70,NA,reverse,-0.6100000000 -1.090000000 -1.300000e-01,NA,NA,NA,NA,NA,NA NA,NA   0   0,  0   0,100   0,100 high,high low low high,Not a therapeutic intervention,  0,NA,11.030000 NA,DSM-5 2,1,1.0,0.0 1.0 1.0,0,1 2 1,1 1,1,0.5 0 0 1,1  885 Robe_2022,NA NA 6-12 yo 9,11.1864077669903,NA NA, 13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35 NA,NA,Zhang (2023)_Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Zhang (2023) - Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high,high
4036 Zhang (2023) Zhang,2023 10.1177/10870547231154897 100,  0,100 100,Critically low Mindfulness mindfulness based intervention   0 NA Executive functioning (mixed),Mixed,At study endpoint (closest to 12 weeks) Mixed (different types of tool are used) NA  1.84119678 NA,NA Siebelink 2022,NA,RCT (parallel, crossover, open-label),SMD  55  48, 103 NA,reverse -0.0400000000,-0.430000000, 3.400000e-01,NA,NA,NA NA NA,NA NA,NA 100,100 100,  0,100,100,100,low,high low low,low TAU   0,NA,11.186408 NA,DSM-5 2,1 1.0 0.0 1.0 1.0 0,1,2 1,1 1,1,0.5 0 0 1,1, 886,Siebelink_2022,< 2 months NA 6-12 yo 9,11.1864077669903,NA,NA  13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35,NA NA,Zhang (2023)_Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Zhang (2023) - Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
4036,Zhang (2023),Zhang,2023,10.1177/10870547231154897 100,  0,  0,100,Critically low Mindfulness mindful parent training   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),Questionnaire CTRS, 1.84119678,NA NA,Amiri,2022,NA RCT (parallel, crossover, open-label) SMD, 12  12,  24,outcomes,reverse,-0.6600000000 -1.480000000, 1.700000e-01 NA,NA NA,NA,NA,NA,NA NA,  0   0   0   0,  0,  0   0,high,high,high,high high,NA   0 NA  9.750000,NA,DSM-5 2,1 1.0,0.0,1.0,1.0 0,1,2 1 1,1,1 0.5 0 0 1 1  887,Amiri_2022 < 2 months,NA 6-12 yo,6.08 11.1864077669903 NA,NA  13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08 39.35,NA NA Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo, 90.66148,no,high high
4036,Zhang (2023),Zhang,2023 10.1177/10870547231154897 100,  0 100 100,Critically low,Mindfulness,family based mindfullness intervention,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),Questionnaire SWAN, 1.38089758,NA NA,Lo,2020,NA,RCT (parallel, crossover, open-label),SMD, 50, 50, 100 outcomes,reverse  0.0600000000,-0.330000000, 4.500000e-01 NA,NA NA NA,NA,NA NA,NA,  0   0,100,  0 100   0,  0 low high,low high,high WLC (wait-list control)   0 NA, 6.080000,NA DSM-5,2 1,1.0 0.0,1.0,1.0 0,1,2 1 1 1,1,0.5 0 0 1,1, 888,Lo_2020,< 2 months NA 6-12 yo 6.08,11.1864077669903,NA NA  13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35,NA,NA Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo  90.66148,no,high,high
4036,Zhang (2023),Zhang,2023 10.1177/10870547231154897,100,  0,100 100,Critically low Mindfulness mindfulness based intervention,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) Questionnaire,CPRS  1.84119678,NA,NA,Siebelink 2022,NA RCT (parallel, crossover, open-label) SMD, 55  48, 103,outcomes reverse -0.0900000000 -0.470000000, 3.000000e-01,NA NA,NA,NA NA,NA NA,NA,100 100,100   0 100 100 100 low high,low,low low,TAU   0 NA 11.186408 NA,DSM-5,2,1,1.0 0.0,1.0,1.0,0 1 2,1,1 1,1,0.5,0 0,1 1  889,Siebelink_2022,< 2 months NA,6-12 yo,6.08 11.1864077669903 NA,NA, 13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35 NA,NA,Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo  90.66148 no low,low
4036,Zhang (2023) Zhang,2023 10.1177/10870547231154897,100,  0 100 100,Critically low,Mindfulness mindfulness based intervention,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire,Conners-3  1.84119678,NA NA,Valero 2022,NA RCT (parallel, crossover, open-label) SMD  15, 15   30,outcomes,reverse,-0.2000000000,-0.910000000, 5.200000e-01,NA,NA,NA,NA NA NA,NA NA   0   0   0   0 100,  0   0 high,high low,high,high WLC (wait-list control)   0 NA,10.965000 NA,DSM-5 2 1,1.0,0.0,1.0 1.0,0 1,2 1 1,1,1,0.5 0,0,1 1  890 Valero_2022,< 2 months,NA,6-12 yo 6.08,11.1864077669903,NA,NA, 13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35,NA NA Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo, 90.66148,no high,high
4036,Zhang (2023),Zhang 2023,10.1177/10870547231154897,100   0   0 100,Critically low,Mindfulness mindful parent training,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire CTRS, 1.84119678 NA,NA Amiri 2022 NA RCT (parallel, crossover, open-label) SMD, 12, 12   24,outcomes,reverse -0.7400000000 -1.570000000, 9.000000e-02 NA,NA,NA NA,NA,NA NA NA,  0   0   0   0   0   0   0,high high,high high,high,NA,  0 NA  9.750000 NA DSM-5 2 1,1.0,0.0,1.0,1.0 0 1,2,1,1,1,1,0.5 0 0 1 1, 891 Amiri_2022 < 2 months NA,6-12 yo 6.08 11.1864077669903,NA NA  13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35,NA,NA Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo  90.66148,no high high
4036 Zhang (2023) Zhang 2023 10.1177/10870547231154897,100   0 100 100,Critically low Mindfulness,family based mindfullness intervention,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),Questionnaire,SWAN  1.38089758 NA NA,Lo,2020,NA,RCT (parallel, crossover, open-label),SMD  50  50  100,outcomes,reverse -0.0500000000,-0.450000000  3.400000e-01,NA,NA,NA,NA,NA,NA NA NA,  0,  0 100   0 100,  0,  0 low high low high,high,WLC (wait-list control)   0,NA  6.080000 NA DSM-5 2,1 1.0,0.0 1.0,1.0,0,1,2 1 1 1 1,0.5 0 0,1 1  892,Lo_2020,< 2 months,NA,6-12 yo 6.08,11.1864077669903,NA NA  13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35 NA,NA Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo  90.66148,no high,high
4036,Zhang (2023),Zhang,2023 10.1177/10870547231154897,100,  0 100 100,Critically low,Mindfulness mindfulness based intervention   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),Questionnaire,CPRS  1.84119678 NA NA Siebelink,2022 NA RCT (parallel, crossover, open-label) SMD, 55, 48, 103,outcomes,reverse,-0.1600000000,-0.550000000, 2.200000e-01,NA NA,NA,NA NA NA,NA NA,100,100 100   0,100,100 100,low high low,low,low TAU,  0 NA,11.186408 NA DSM-5,2,1,1.0,0.0,1.0 1.0,0,1 2,1 1 1 1 0.5,0 0 1 1  893 Siebelink_2022 < 2 months NA,6-12 yo 6.08,11.1864077669903,NA NA  13, 8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35,NA NA Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo  90.66148,no,low low
4036 Zhang (2023) Zhang 2023 10.1177/10870547231154897 100,  0 100 100,Critically low Mindfulness mindfulness based intervention   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),Questionnaire,Conners-3, 1.84119678,NA NA,Valero,2022 NA RCT (parallel, crossover, open-label) SMD, 15  15,  30 outcomes reverse -0.7100000000 -1.450000000  3.000000e-02 NA,NA NA NA NA NA,NA,NA,  0,  0   0   0,100,  0,  0,high,high low,high,high WLC (wait-list control),  0 NA,10.965000 NA DSM-5,2,1,1.0 0.0 1.0,1.0,0,1,2,1 1 1,1 0.5,0,0 1 1  894,Valero_2022 < 2 months,NA 6-12 yo 6.08 11.1864077669903,NA NA, 13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35 NA NA Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo  90.66148 no high,high
9002,Groenman - Preschool (2022),Groenman - Preschool 2022,10.1016/j.jaac.2021.02.024,100   0 100,100 Critically low Parent-mediated behavioral interventions Triple P Online   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire Conners Early Childhood Behaviour scale (mother-rated) Inattention/ hyperactivity scales (T-score),NA,NA NA Franke,2016 NA,RCT (parallel, crossover, open-label) G  27, 26,  53,NA reverse -0.6378940566 -1.195411778,-8.037634e-02,NA,NA,NA NA NA,NA NA NA,  0   0,100,  0 100,100   0 some,high,low high,some,WLC (wait-list control)   0  71.700000  3.970000,NA,DSM,3,1,0.5,0.0,1.0,1.0,0,0 1 1,1 1,1,0.5,0 1,1 1  895 Franke_2016,NA,NA,< 6 yo 3.51 5.36 NA,NA  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000 no low,high
9002 Groenman (2022),Groenman,2022,10.1016/j.jaac.2021.02.024 100 100 100 100,Critically low,Parent-mediated behavioral interventions,Behavioral parent training with consequence-based techniques only,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,SWAN total  2.00000000 NA,NA,Hornstra,2021,NA,RCT (parallel, crossover, open-label),G, 32  30,  62,outcomes reverse, 0.4415557687,-0.066627758, 9.497393e-01,NA NA,NA NA,NA,NA NA,NA,100,100,100 100,100,100 100 low,low,low some low WLC (wait-list control)   0  31.520000, 8.350000  95.59000 DSM,3 1 0.5,0.0 1.0 1.0,0 0 1 1,1 1,1,0.5 0 1,1,1, 896,Hornstra_2021 2-6 months,Average (80-119) 6-12 yo,7.28 13.99,95.59,108.21, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
9002 Groenman (2022),Groenman 2022,10.1016/j.jaac.2021.02.024,100,100,100,100 Critically low Parent-mediated behavioral interventions Behavioral parent training with consequence-based techniques only   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,SWAN total, 2.00000000,NA NA,Hornstra,2021 NA RCT (parallel, crossover, open-label) G, 30, 30   60 outcomes,reverse  0.4889622303 -0.028927533, 1.006852e+00,NA NA,NA,NA NA,NA NA NA 100,100 100,100 100,100,100,low,low,low some,low WLC (wait-list control)   0, 31.520000  8.350000  95.59000,DSM,3,1,0.5,0.0 1.0,1.0 0 0 1,1 1,1 1 0.5 0,1 1,1, 897,Hornstra_2021 2-6 months Average (80-119) 6-12 yo 7.28 13.99,95.59,108.21  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
9002,Groenman (2022) Groenman 2022 10.1016/j.jaac.2021.02.024 100,  0,100 100,Critically low Parent-mediated behavioral interventions New Forest Parenting Programme Self Help   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire Dupaul ADHD rating scale  7.00000000,NA NA Daley 2013,NA,RCT (parallel, crossover, open-label) G  24  19   43 NA,reverse,-0.1713102406 -0.781187646, 4.385672e-01,NA,NA,NA,NA NA,NA NA NA,  0,  0 100,  0 100 100   0,low,high some,high some WLC (wait-list control)   0, 18.600000  7.280000,NA,DSM 3,1,0.5 0.0,1.0 1.0 0,0,1 1,1,1 1,0.5 0,1 1 1  898,Daley_2013,7-12 months NA 6-12 yo 7.28 13.99 95.59,108.21  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
9002,Groenman - Preschool (2022),Groenman - Preschool,2022 10.1016/j.jaac.2021.02.024,100   0 100,100,Critically low,Parent-mediated behavioral interventions,Parenting Your Hyperactive Preschooler (parent training and emotion socialization)   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,DBRS mother total symptoms,14.00000000 NA NA,Herbert 2013,NA,RCT (parallel, crossover, open-label) G  17  14,  31,NA,reverse,-0.5874048955,-1.322267483  1.474577e-01 NA NA,NA NA NA,NA,NA NA   0   0,100   0,100 100   0 some high,low,high some,WLC (wait-list control),  0  25.800000, 4.580000 NA,DSM 3,1 0.5,0.0 1.0,1.0 0 0,1 1,1 1,1,0.5,0,1 1,1, 899,Herbert_2013 > 12 months NA,< 6 yo 3.51 5.36,NA,NA  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15,108.21,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000,no low,high
9002,Groenman - Preschool (2022),Groenman - Preschool 2022 10.1016/j.jaac.2021.02.024,100   0,100 100,Critically low,Parent-mediated behavioral interventions,New forest parenting plan,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire Werry Weis peters total score  8.00000000,NA,NA Thompson,2009,NA,RCT (parallel, crossover, open-label) G  21, 20   41 NA reverse,-1.3920060263,-2.085358577,-6.986535e-01 NA,NA NA NA NA,NA,NA NA,100,100,100,  0   0 100,100,some,high high,low some,TAU   0 100.000000, 4.180000 NA,DSM,3 1,0.5,0.0 1.0,1.0,0,0,1 1,1 1 1 0.5,0,1 1 1  900,Thompson_2009,7-12 months NA,< 6 yo,3.51 5.36 NA,NA, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21 Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000,no,low,low
9002 Groenman (2022),Groenman,2022,10.1016/j.jaac.2021.02.024,100,100 100,100,Critically low,Parent-mediated behavioral interventions Behavioral parent training Groningen,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),Questionnaire CPRS ADHD index t scores,22.00000000,NA NA,Vdhoofdakker 2007,NA,RCT (parallel, crossover, open-label),G  47  47   94,NA,reverse  0.0385037474 -0.367882293  4.448898e-01 NA NA,NA NA NA NA NA NA,  0,  0 100,  0 100,100   0,some high low high,some TAU   0  19.100000  7.430000, 97.45000 DSM,3,1 0.5,0.0 1.0 1.0,0 0 1,1,1,1 1,0.5 0 1 1 1, 901,Vdhoofdakker_2007 > 12 months Average (80-119) 6-12 yo 7.28,13.99,95.59 108.21, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
9002 Groenman - Preschool (2022),Groenman - Preschool 2022 10.1016/j.jaac.2021.02.024 100   0 100,100,Critically low Parent-mediated behavioral interventions Incredible years   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,Conners parent ADHD Dsm total,20.00000000,NA NA Websterstratton,2011 NA,RCT (parallel, crossover, open-label),G, 49  50,  99 NA reverse,-0.6723302242 -1.079400817,-2.652596e-01,NA,NA,NA NA NA,NA NA,NA   0   0 100,  0 100 100,  0,some high low,high some,WLC (wait-list control),  0, 24.200000, 5.360000,NA DSM 3,1,0.5,0.0 1.0 1.0,0 0,1,1,1 1,1 0.5,0,1,1,1  902,Websterstratton_2011 > 12 months NA,< 6 yo,3.51,5.36,NA NA  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000,no low high
9002 Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024,100   0,100,100,Critically low,Parent-mediated behavioral interventions,Learning skills training for adolescents with ADHD (LeJa)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,Fremdbeurteilungsbogen fur hyperkinetische storungen (ADHD symptom checklist) NA,NA NA Schramm 2016 NA,RCT (parallel, crossover, open-label) G, 40  73  113,outcomes reverse,-0.2158837638 -0.604100426  1.723329e-01,NA NA NA,NA NA NA NA NA,  0,  0,100,  0 100,100,  0 low high low high some,WLC (wait-list control),  0  14.200000,13.990000,NA,DSM,3 1,0.5 0.0 1.0 1.0,0,0,1 1,1 1,1,0.5,0 1 1 1, 903,Schramm_2016 NA NA 13-19 yo 7.28,13.99 95.59 108.21  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
9002,Groenman (2022),Groenman 2022 10.1016/j.jaac.2021.02.024,100,  0 100,100 Critically low Parent-mediated behavioral interventions,Learning skills training for adolescents with ADHD (LeJa),  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,Fremdbeurteilungsbogen fur hyperkinetische storungen (ADHD symptom checklist) NA,NA NA,Schramm,2016,NA,RCT (parallel, crossover, open-label) G, 40, 73, 113 outcomes,reverse,-0.3938465026,-0.784483747 -3.209258e-03,NA,NA NA,NA,NA,NA NA NA,  0   0 100   0 100 100   0 low high,low high some WLC (wait-list control),  0  14.200000,13.990000 NA DSM 3 1,0.5,0.0 1.0 1.0 0 0 1 1 1 1 1 0.5,0 1 1,1  904,Schramm_2016 NA NA 13-19 yo,7.28,13.99 95.59 108.21, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
9002,Groenman (2022) Groenman 2022,10.1016/j.jaac.2021.02.024,100,100 100,100,Critically low,Parent-mediated behavioral interventions,Child life and attentions kills program   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),Questionnaire average score Child symptom Inverntory 12.00000000 NA,NA,Pfiffner 2007,NA,RCT (parallel, crossover, open-label) G  36  33   69,NA,reverse -0.7616490510 -1.254569511 -2.687286e-01,NA NA,NA,NA,NA,NA,NA NA,  0,  0 100,  0,100 100,  0 some,high,low,high some,TAU,  0, 33.300000, 8.670000 108.06000 DSM,3 1,0.5 0.0,1.0 1.0,0,0,1 1 1,1 1,0.5,0,1 1,1  905,Pfiffner_2007 7-12 months Average (80-119),6-12 yo,7.28 13.99 95.59,108.21  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
9002 Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024,100,100,100,100,Critically low Parent-mediated behavioral interventions,Parent Focused treatment+Child life and attentions kills program (IPT),  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) Questionnaire average score Child symptom Inventory,NA NA,NA Pfiffner 2014 NA,RCT (parallel, crossover, open-label) G  74, 51  125,outcomes reverse,-0.3461667704 -0.706821588, 1.448805e-02,NA NA NA,NA,NA,NA NA,NA   0,  0 100   0 100 100   0 some,high,low,high,some,TAU,  0, 41.700000, 8.640000,103.76000 DSM,3 1 0.5 0.0,1.0 1.0,0,0,1 1 1 1,1,0.5 0 1,1 1  906,Pfiffner_2014,NA,Average (80-119) 6-12 yo 7.28,13.99,95.59 108.21, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
9002,Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024,100,100 100,100 Critically low,Parent-mediated behavioral interventions,Parent Focused treatment+Child life and attentions kills program (IPT)   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,average score Child symptom Inventory,NA NA NA,Pfiffner,2014,NA,RCT (parallel, crossover, open-label) G  74, 51, 125,outcomes,reverse -0.7545966507 -1.124891273,-3.843020e-01 NA NA,NA,NA NA NA NA NA   0   0 100,  0 100 100,  0,some high low high some TAU   0  41.700000, 8.640000 103.76000,DSM,3,1,0.5,0.0,1.0,1.0 0 0 1 1,1,1,1,0.5,0,1 1 1  907 Pfiffner_2014 NA Average (80-119) 6-12 yo 7.28,13.99,95.59 108.21, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
9002,Groenman - Preschool (2022),Groenman - Preschool,2022,10.1016/j.jaac.2021.02.024,100   0,100 100,Critically low,Parent-mediated behavioral interventions,Incredible years+a-New forest parenting program   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,SNAP ADHD sum score,12.00000000 NA NA,SonugaBarkeCoppi 2018,NA,RCT (parallel, crossover, open-label) G,131  42  173 outcomes,reverse,-0.1066478409,-0.455315785  2.420201e-01,NA,NA NA,NA NA,NA,NA,NA,100,100 100,  0 100,100 100,low,high,low low,low,TAU   0  26.800000  3.510000,NA,DSM 3 1 0.5,0.0 1.0,1.0 0 0,1,1,1 1,1 0.5 0 1,1 1  908 SonugaBarkeCoppi_2018 7-12 months NA,< 6 yo 3.51,5.36 NA NA, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15 108.21 Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000 no,low,low
9002 Groenman - Preschool (2022),Groenman - Preschool 2022 10.1016/j.jaac.2021.02.024,100,  0,100,100 Critically low Parent-mediated behavioral interventions Incredible years+a-New forest parenting program   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),Questionnaire SNAP ADHD sum score 12.00000000,NA,NA SonugaBarkeCoppi,2018,NA RCT (parallel, crossover, open-label),G,133, 42, 175 outcomes,reverse -0.1869915795,-0.535387227  1.614041e-01,NA NA,NA NA,NA NA NA,NA 100 100 100,  0,100,100,100,low high,low,low low TAU   0  26.800000, 3.510000,NA,DSM,3 1,0.5,0.0,1.0 1.0,0,0,1 1 1 1,1,0.5 0 1 1,1, 909 SonugaBarkeCoppi_2018 7-12 months NA < 6 yo,3.51 5.36 NA,NA, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15,108.21,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000 no low,low
9002,Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024,100 100 100 100 Critically low,Parent-mediated behavioral interventions parent training, child docused treatment and a school-based intervention   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),Questionnaire SNAP total ADHD parent,NA NA NA,MTA 1999 NA RCT (parallel, crossover, open-label) G,143,144, 287 NA reverse,-0.1711623932,-0.403350697  6.102591e-02,NA,NA,NA NA,NA NA,NA NA,  0,  0,100   0,100,100,  0,low high low,high,some TAU   0, 19.900000  7.760000 101.97000 DSM 3,1 0.5,0.0 1.0 1.0,0,0 1,1 1,1 1 0.5,0 1 1,1, 910,MTA_1999 NA,Average (80-119),6-12 yo 7.28 13.99 95.59 108.21, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
9002 Groenman (2022),Groenman,2022,10.1016/j.jaac.2021.02.024,100   0,100 100 Critically low Parent-mediated behavioral interventions collaborative life skills,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,Child symptom Inventory ADHD severity 12.00000000,NA,NA,Pfiffner,2016,NA,RCT (parallel, crossover, open-label) G, 72  63, 135,NA reverse -0.9682391688 -1.327001384 -6.094770e-01 NA NA NA,NA NA,NA,NA NA,  0   0,100   0 100,100,  0 some high low high,low,TAU   0, 28.900000  8.390000,NA,DSM,3,1,0.5 0.0,1.0 1.0,0 0,1 1,1,1,1 0.5 0 1 1,1, 911,Pfiffner_2016 7-12 months NA,6-12 yo,7.28,13.99,95.59 108.21  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
9002 Groenman (2022) Groenman 2022 10.1016/j.jaac.2021.02.024 100,  0,100,100,Critically low Parent-mediated behavioral interventions,online BPT+Face to face BPT   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire Conners early beahvior inattention hyperactivity t scores 10.00000000,NA,NA,Dupaul 2018 NA,RCT (parallel, crossover, open-label),G  15, 15,  30 outcomes,reverse -0.6173421811 -1.363155874, 1.284715e-01 NA,NA,NA,NA NA,NA,NA NA,  0   0 100,  0,100,100   0,some,high,low,high,some,WLC (wait-list control),  0, 24.400000  8.580000,NA,DSM 3,1,0.5,0.0,1.0 1.0,0,0 1,1 1 1 1 0.5,0,1 1,1  912,Dupaul_2018 7-12 months,NA,6-12 yo,7.28,13.99 95.59 108.21  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low high
9002 Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024 100   0,100,100 Critically low Parent-mediated behavioral interventions online BPT+Face to face BPT,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire Conners early beahvior inattention hyperactivity t scores,10.00000000,NA,NA,Dupaul 2018 NA RCT (parallel, crossover, open-label),G  15  15,  30,outcomes reverse -0.6051650524,-1.350280480  1.399504e-01 NA,NA,NA NA,NA NA,NA NA   0,  0 100   0,100,100   0 some,high low,high some WLC (wait-list control)   0, 24.400000  8.580000 NA DSM,3 1 0.5,0.0,1.0,1.0,0 0,1 1 1 1,1 0.5,0 1 1 1  913 Dupaul_2018 7-12 months NA,6-12 yo 7.28,13.99 95.59 108.21, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
9002,Groenman (2022) Groenman 2022 10.1016/j.jaac.2021.02.024 100   0 100,100 Critically low Parent-mediated behavioral interventions,psychoeducation,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,CPRS ADHD index scores, 6.00000000 NA NA Ferrin 2016 NA,RCT (parallel, crossover, open-label),G  35, 34   69,NA reverse  0.3957439141 -0.084218664, 8.757065e-01 NA NA,NA,NA,NA,NA NA,NA,  0,  0,100,  0,100 100,  0 low high low,high,low TAU,  0, 13.000000 10.710000,NA,DSM,3 1 0.5 0.0 1.0,1.0 0,0 1,1,1,1,1,0.5 0 1 1 1, 914 Ferrin_2016,2-6 months,NA 6-12 yo 7.28 13.99,95.59 108.21  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
9002 Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024,100,100 100 100,Critically low Parent-mediated behavioral interventions,NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire SNAP mother SUM,13.00000000 NA,NA Shimabukuro 2020 NA RCT (parallel, crossover, open-label),G  28, 24,  52,NA reverse,-0.2814034121,-0.834486828  2.716800e-01,NA,NA,NA NA,NA,NA NA,NA 100,100 100 100 100 100 100 some,low low some some,WLC (wait-list control),  0, 17.650000  8.350000,100.69000 DSM 3 1,0.5,0.0 1.0,1.0,0,0,1 1,1 1 1 0.5 0,1 1 1  915,Shimabukuro_2020 > 12 months,Average (80-119),6-12 yo 7.28,13.99 95.59 108.21  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
9002 Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024 100   0,100,100,Critically low,Parent-mediated behavioral interventions,Telephone-assisted self-help (TASH) intervention,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,German questionnaire FBB-ADHS 26.00000000,NA,NA,Dose,2017,NA RCT (parallel, crossover, open-label) G  51  90, 141 NA,reverse -0.5086079752 -0.858434182 -1.587818e-01,NA NA,NA NA,NA,NA NA NA   0   0,100,100,100,100   0,some some,low,high,some,TAU   0, 20.570000  9.790000 NA DSM 3,1,0.5,0.0,1.0 1.0 0 0 1 1 1 1,1 0.5,0,1,1,1, 916 Dose_2017 > 12 months NA,6-12 yo,7.28 13.99,95.59 108.21, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
9002 Groenman (2022),Groenman 2022 10.1016/j.jaac.2021.02.024,100,  0,100,100 Critically low,Parent-mediated behavioral interventions,COACHES   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),Questionnaire DBD rating symptoms NA NA,NA,Fabiano,2012 NA,RCT (parallel, crossover, open-label) G  28, 27   55,NA reverse,-0.4721724333,-1.013063943  6.871908e-02 NA NA,NA,NA,NA NA NA NA,  0   0,100,  0 100,100   0 some,high,low,high,some WLC (wait-list control)   0  13.000000, 8.510000,NA,DSM 3,1 0.5,0.0 1.0,1.0 0,0,1,1 1,1,1 0.5 0 1 1 1, 917 Fabiano_2012 NA NA 6-12 yo,7.28 13.99,95.59,108.21, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
9002,Groenman (2022),Groenman 2022 10.1016/j.jaac.2021.02.024 100 100 100,100,Critically low Parent-mediated behavioral interventions Standard Behavioral Parent Training (BPT)+Combination of Standard BPT & Child training+Attention and social skills child training,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,Conners total 10.00000000 NA,NA Lauth,2005,NA RCT (parallel, crossover, open-label) G  15  15   30,outcomes,reverse,-0.9043031843,-1.670315228 -1.382911e-01,NA NA,NA NA NA NA NA NA 100 100,100,100 100 100 100 some some,low,low some,WLC (wait-list control),  0  11.670000  9.370000 108.21000 DSM,3,1 0.5,0.0,1.0 1.0 0,0,1,1 1,1,1,0.5 0,1 1,1  918,Lauth_2005 7-12 months Average (80-119),6-12 yo,7.28,13.99 95.59,108.21  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
9002,Groenman (2022),Groenman 2022,10.1016/j.jaac.2021.02.024,100 100,100 100,Critically low,Parent-mediated behavioral interventions Standard Behavioral Parent Training (BPT)+Combination of Standard BPT & Child training+Attention and social skills child training,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,Conners total,10.00000000,NA,NA Lauth 2005,NA RCT (parallel, crossover, open-label),G, 15  15   30 outcomes,reverse -1.1088053434 -1.893384699 -3.242260e-01,NA NA NA,NA NA NA NA NA,100 100,100,100,100 100,100,some,some low,low,some,WLC (wait-list control)   0, 11.670000  9.370000 108.21000 DSM 3 1,0.5,0.0,1.0,1.0 0,0,1,1 1 1 1,0.5 0,1,1 1  919,Lauth_2005,7-12 months Average (80-119),6-12 yo,7.28,13.99,95.59 108.21  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
9002 Groenman (2022),Groenman 2022 10.1016/j.jaac.2021.02.024 100,100,100 100 Critically low,Parent-mediated behavioral interventions,Standard Behavioral Parent Training (BPT)+Combination of Standard BPT & Child training+Attention and social skills child training   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,Conners total 10.00000000,NA NA Lauth 2005,NA RCT (parallel, crossover, open-label) G  15  15   30,outcomes reverse,-1.1459221216 -1.934222396,-3.576218e-01 NA,NA,NA NA NA,NA NA,NA 100,100 100 100 100,100,100,some some low,low,some WLC (wait-list control)   0  11.670000  9.370000 108.21000 DSM,3 1 0.5 0.0,1.0 1.0 0 0,1,1 1,1,1,0.5,0,1,1,1  920,Lauth_2005,7-12 months Average (80-119) 6-12 yo 7.28,13.99 95.59 108.21  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
9002,Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024 100   0 100,100,Critically low Parent-mediated behavioral interventions Cognitive-behavioral Training (BPT),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire CBCL Attention Scale,11.00000000,NA NA,Lauthprecondis 2013,NA RCT (parallel, crossover, open-label) G,190, 95, 285,NA reverse -0.0850366254,-0.331819404  1.617462e-01 NA NA,NA,NA NA,NA,NA NA,  0,  0,  0,  0,  0   0   0 high,high,high,high high WLC (wait-list control),  0, 14.740000  8.580000,NA,DSM,3 1,0.5,0.0,1.0 1.0,0 0,1,1,1 1,1,0.5 0,1,1,1, 921,Lauthprecondis_2013 7-12 months,NA,6-12 yo 7.28 13.99 95.59,108.21  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high,high
9002 Groenman (2022),Groenman 2022,10.1016/j.jaac.2021.02.024,100   0 100,100 Critically low,Parent-mediated behavioral interventions,Tuning into Kids+Mindful Parenting   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,SNAP ADHD symptoms, 8.00000000 NA NA Shum 2025 NA RCT (parallel, crossover, open-label),G, 18, 17   35 outcomes reverse,-0.7938007608 -1.493258395 -9.434313e-02 NA,NA NA,NA,NA NA,NA,NA,  0   0   0,  0,  0   0   0 high high,high,high high WLC (wait-list control),  0  25.000000, 8.290000,NA DSM 3 1 0.5,0.0,1.0,1.0,0 0 1 1 1 1,1,0.5,0,1 1,1, 922,Shum_2025,7-12 months,NA,6-12 yo 7.28,13.99 95.59,108.21  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
9002,Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024,100   0 100 100,Critically low Parent-mediated behavioral interventions,Tuning into Kids+Mindful Parenting,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,SNAP ADHD symptoms  8.00000000 NA NA Shum,2025,NA RCT (parallel, crossover, open-label),G  17, 17,  34 outcomes,reverse,-0.8742891557,-1.589796072,-1.587822e-01 NA,NA,NA NA,NA,NA,NA NA   0   0   0,  0,  0   0,  0 high,high high high,high WLC (wait-list control),  0  25.000000, 8.290000,NA,DSM,3 1,0.5 0.0,1.0 1.0 0 0,1 1,1 1 1 0.5 0 1 1 1  923 Shum_2025,7-12 months NA,6-12 yo 7.28 13.99,95.59,108.21, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,high high
9002 Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024,100,100,100,100,Critically low Parent-mediated behavioral interventions Behavioral parent training with consequence-based techniques only,  0 NA,Conduct Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks),Questionnaire SDQ conduct problems  2.00000000 NA,NA Hornstra,2021 NA RCT (parallel, crossover, open-label) G, 32, 30   62,outcomes reverse -0.3855293514 -0.892239582  1.211809e-01,NA NA NA NA,NA,NA,NA NA,100,100,100 100 100,100,100,low low low,some low WLC (wait-list control),  0, 31.520000  8.350000, 95.59000,DSM 3 1,0.5,0.0 1.0,1.0 0,0,1 1,1 1 1 0.5,0 1,1 1  924,Hornstra_2021,2-6 months Average (80-119) 6-12 yo 7.76,13.99 95.59,108.06, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
9002,Groenman (2022) Groenman 2022,10.1016/j.jaac.2021.02.024,100 100,100,100,Critically low,Parent-mediated behavioral interventions Behavioral parent training with consequence-based techniques only,  0,NA Conduct Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,SDQ conduct problems  2.00000000 NA NA Hornstra 2021 NA RCT (parallel, crossover, open-label),G  30  30,  60 outcomes reverse, 0.1003588313,-0.410094841, 6.108125e-01,NA NA,NA,NA,NA,NA,NA NA 100,100 100 100,100 100 100,low,low,low some low,WLC (wait-list control)   0  31.520000, 8.350000  95.59000 DSM 3,1,0.5 0.0 1.0,1.0,0,0,1,1 1 1,1,0.5 0,1,1,1  925,Hornstra_2021 2-6 months,Average (80-119),6-12 yo 7.76,13.99,95.59 108.06, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
9002 Groenman - Preschool (2022),Groenman - Preschool,2022 10.1016/j.jaac.2021.02.024 100   0,100 100 Critically low Parent-mediated behavioral interventions New forest parenting plan,  0,NA,Conduct Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,PACS conduct problems in last 6 months  8.00000000,NA,NA,Thompson,2009 NA RCT (parallel, crossover, open-label) G, 21, 20,  41 NA reverse,-0.4211132822,-1.047936837, 2.057103e-01,NA NA NA NA NA NA,NA NA 100 100 100   0   0,100,100 some high,high,low some,TAU,  0 100.000000, 4.180000,NA,DSM,3,1,0.5,0.0 1.0 1.0 0 0 1,1 1,1,1,0.5 0 1,1 1  926 Thompson_2009 7-12 months NA < 6 yo 3.51,5.36,NA,NA, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15,108.21,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000 no low low
9002,Groenman - Preschool (2022) Groenman - Preschool 2022 10.1016/j.jaac.2021.02.024,100,  0,100,100 Critically low,Parent-mediated behavioral interventions Incredible years,  0 NA Conduct Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire Child symptom inventory CD symptoms 20.00000000,NA,NA,Websterstratton,2011,NA RCT (parallel, crossover, open-label),G  49, 50,  99,NA,reverse,-0.4427435009,-0.843509435 -4.197757e-02 NA NA NA,NA,NA NA,NA NA,  0   0 100,  0,100,100   0,some high,low,high some WLC (wait-list control),  0, 24.200000, 5.360000 NA DSM,3,1,0.5 0.0,1.0,1.0 0 0 1,1 1 1 1 0.5 0 1 1,1, 927,Websterstratton_2011 > 12 months NA,< 6 yo 3.51 5.36,NA NA  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15 108.21,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000,no low high
9002 Groenman (2022),Groenman 2022,10.1016/j.jaac.2021.02.024 100   0 100,100,Critically low Parent-mediated behavioral interventions Learning skills training for adolescents with ADHD (LeJa),  0,NA Conduct Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,SDQ conduct problems NA NA NA Schramm,2016 NA,RCT (parallel, crossover, open-label) G, 40  73  113,NA,reverse -0.1570135045 -0.544738620  2.307116e-01,NA,NA NA,NA,NA,NA NA NA,  0,  0 100   0 100 100,  0 low,high low,high some WLC (wait-list control)   0  14.200000 13.990000 NA,DSM,3,1 0.5,0.0 1.0 1.0,0,0 1,1 1 1,1 0.5 0,1 1,1  928,Schramm_2016 NA NA 13-19 yo 7.76 13.99,95.59,108.06, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
9002 Groenman (2022) Groenman 2022,10.1016/j.jaac.2021.02.024,100,100 100,100,Critically low Parent-mediated behavioral interventions Child life and attentions kills program   0 NA Conduct Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire CSI average CD 12.00000000 NA NA Pfiffner,2007,NA,RCT (parallel, crossover, open-label),G  36, 33   69,NA,reverse,-0.1964409963 -0.673239626, 2.803576e-01 NA,NA,NA,NA NA NA,NA,NA   0   0 100   0,100,100   0 some,high low,high some TAU,  0, 33.300000, 8.670000 108.06000 DSM,3,1,0.5,0.0 1.0,1.0 0 0,1,1 1 1 1,0.5,0 1,1 1, 929,Pfiffner_2007 7-12 months,Average (80-119),6-12 yo 7.76,13.99,95.59 108.06, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
9002 Groenman (2022),Groenman,2022,10.1016/j.jaac.2021.02.024,100 100,100 100,Critically low,Parent-mediated behavioral interventions Parent Focused treatment+Child life and attentions kills program (IPT)   0,NA Conduct Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks) Questionnaire CSI average CD NA,NA NA,Pfiffner 2014 NA,RCT (parallel, crossover, open-label),G, 74  51  125,outcomes reverse,-0.0767943948 -0.434965083  2.813763e-01 NA NA,NA,NA NA,NA,NA NA   0,  0 100,  0 100,100,  0,some high low,high some TAU   0  41.700000, 8.640000 103.76000,DSM,3 1,0.5,0.0 1.0,1.0 0 0 1 1 1,1,1,0.5,0 1,1 1  930 Pfiffner_2014 NA Average (80-119) 6-12 yo 7.76,13.99,95.59 108.06  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
9002 Groenman (2022) Groenman 2022 10.1016/j.jaac.2021.02.024 100,100 100,100 Critically low Parent-mediated behavioral interventions Parent Focused treatment+Child life and attentions kills program (IPT)   0,NA,Conduct Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks) Questionnaire CSI average CD NA,NA,NA Pfiffner,2014,NA,RCT (parallel, crossover, open-label),G  74, 51  125 outcomes reverse,-0.2764918239,-0.636202759  8.321911e-02 NA NA,NA NA NA,NA,NA,NA   0,  0 100,  0 100,100,  0 some high,low high,some TAU   0, 41.700000, 8.640000,103.76000,DSM 3,1,0.5 0.0 1.0,1.0,0,0 1,1,1,1,1 0.5 0,1,1 1  931,Pfiffner_2014,NA,Average (80-119) 6-12 yo 7.76,13.99 95.59 108.06, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
9002,Groenman - Preschool (2022) Groenman - Preschool,2022,10.1016/j.jaac.2021.02.024,100   0 100 100,Critically low,Parent-mediated behavioral interventions Incredible years+a-New forest parenting program   0,NA Conduct Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks),Questionnaire ECBI CD symptoms 12.00000000 NA,NA,SonugaBarkeCoppi,2018 NA,RCT (parallel, crossover, open-label),G,131, 42, 173 outcomes reverse  0.1671022032 -0.181832895  5.160373e-01 NA,NA,NA NA,NA,NA NA,NA 100 100 100,  0 100 100,100 low high low,low low TAU   0, 26.800000  3.510000,NA DSM 3 1,0.5,0.0 1.0,1.0,0 0 1,1 1 1,1 0.5 0,1 1,1  932 SonugaBarkeCoppi_2018 7-12 months NA,< 6 yo 3.51,5.36 NA NA, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15 108.21 Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000 no low low
9002 Groenman - Preschool (2022),Groenman - Preschool,2022 10.1016/j.jaac.2021.02.024,100   0,100 100,Critically low,Parent-mediated behavioral interventions Incredible years+a-New forest parenting program,  0,NA,Conduct Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire,ECBI CD symptoms 12.00000000,NA,NA,SonugaBarkeCoppi 2018 NA,RCT (parallel, crossover, open-label),G 133, 42  175,outcomes,reverse,-0.1248219118,-0.472907753, 2.232639e-01 NA NA NA,NA,NA,NA,NA,NA 100,100 100,  0 100 100,100 low high,low,low,low TAU,  0  26.800000  3.510000 NA,DSM,3 1,0.5 0.0 1.0,1.0,0 0 1 1 1,1 1 0.5,0,1,1 1, 933 SonugaBarkeCoppi_2018 7-12 months,NA < 6 yo,3.51 5.36 NA,NA, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21 Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000 no,low low
9002,Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024,100 100,100,100 Critically low Parent-mediated behavioral interventions,parent training, child docused treatment and a school-based intervention,  0,NA Conduct Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,Aggression-Conduct Problems Scale - DSM-IV NA NA NA,MTA,1999,NA RCT (parallel, crossover, open-label),G,143 144  287,NA reverse -0.0465873133,-0.278381007  1.852064e-01,NA NA NA,NA NA,NA,NA NA   0,  0 100,  0,100,100,  0 low,high,low high some TAU,  0  19.900000, 7.760000 101.97000,DSM,3 1 0.5,0.0 1.0,1.0 0 0 1,1,1 1,1 0.5,0,1 1,1  934,MTA_1999,NA Average (80-119) 6-12 yo,7.76 13.99 95.59 108.06, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,high
9002 Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024 100,  0 100 100,Critically low,Parent-mediated behavioral interventions,collaborative life skills   0 NA Conduct Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,CSI average CD 12.00000000,NA,NA Pfiffner 2016,NA,RCT (parallel, crossover, open-label) G  72, 63, 135,NA,reverse -0.4959255478 -0.840439353,-1.514117e-01 NA,NA NA NA,NA NA NA NA,  0   0,100,  0 100 100,  0 some high,low,high,low TAU,  0  28.900000  8.390000,NA DSM 3,1,0.5,0.0,1.0,1.0 0 0 1,1 1 1,1,0.5 0 1 1,1, 935,Pfiffner_2016,7-12 months,NA,6-12 yo 7.76,13.99,95.59,108.06  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low high
9002,Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024,100   0,100,100,Critically low,Parent-mediated behavioral interventions psychoeducation   0 NA Conduct Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire SDQ conduct problems, 6.00000000,NA,NA,Ferrin 2016 NA RCT (parallel, crossover, open-label),G  35  34,  69,NA reverse, 0.0000000000,-0.475229065  4.752291e-01,NA,NA,NA NA,NA NA NA NA,  0   0 100,  0 100 100   0,low high low,high low TAU,  0  13.000000 10.710000 NA,DSM,3 1 0.5,0.0 1.0 1.0,0 0,1 1,1,1 1,0.5 0,1,1,1, 936 Ferrin_2016,2-6 months,NA,6-12 yo 7.76,13.99,95.59 108.06  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
9002,Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024,100,100 100 100,Critically low,Parent-mediated behavioral interventions,NA,  0,NA Conduct Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,CBCL DSM conduct problems subscale 13.00000000,NA NA,Shimabukuro,2020 NA RCT (parallel, crossover, open-label),G  28, 24   52,NA reverse -0.1638734483,-0.715118565, 3.873717e-01,NA NA,NA NA,NA NA,NA,NA,100,100,100 100,100,100 100,some,low,low some,some,WLC (wait-list control)   0, 17.650000, 8.350000,100.69000 DSM,3 1,0.5,0.0,1.0,1.0 0 0,1 1 1 1 1 0.5 0,1,1 1, 937,Shimabukuro_2020,> 12 months Average (80-119),6-12 yo 7.76,13.99,95.59,108.06  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
9002 Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024,100   0,100,100,Critically low Parent-mediated behavioral interventions,Telephone-assisted self-help (TASH) intervention   0 NA Conduct Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks) Questionnaire German questionnaire FBB-SSV Conduct Problems,26.00000000,NA,NA Dose,2017 NA,RCT (parallel, crossover, open-label),G  51, 90  141,NA,reverse,-0.1446149404,-0.489697977, 2.004681e-01,NA,NA NA,NA,NA NA NA NA,  0   0,100 100 100,100   0,some some,low,high,some TAU   0, 20.570000  9.790000,NA,DSM 3,1,0.5,0.0,1.0,1.0,0 0 1 1 1 1 1,0.5,0,1 1 1, 938,Dose_2017,> 12 months,NA,6-12 yo,7.76,13.99,95.59 108.06, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
9002 Groenman (2022),Groenman 2022 10.1016/j.jaac.2021.02.024 100,  0,100 100,Critically low Parent-mediated behavioral interventions,COACHES   0 NA Conduct Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,DBD rating conduct symptoms NA,NA NA Fabiano 2012,NA,RCT (parallel, crossover, open-label) G  28, 27   55,NA reverse, 0.1011849543 -0.432466866, 6.348368e-01,NA NA NA NA,NA NA NA,NA,  0,  0,100,  0,100,100   0 some,high low high,some WLC (wait-list control)   0  13.000000, 8.510000 NA,DSM 3,1 0.5 0.0,1.0,1.0,0 0 1,1,1 1 1 0.5 0 1 1 1, 939,Fabiano_2012 NA NA,6-12 yo,7.76 13.99 95.59,108.06, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
9002,Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024 100   0 100,100 Critically low,Parent-mediated behavioral interventions Cognitive-behavioral Training (BPT)   0,NA Conduct Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire CBCL Rule-breaking behavior,11.00000000 NA,NA Lauthprecondis 2013 NA,RCT (parallel, crossover, open-label),G 190  95  285 NA reverse -0.1973774979 -0.444596831  4.984184e-02,NA,NA NA,NA NA NA NA,NA,  0   0   0,  0   0   0,  0,high high,high,high high,WLC (wait-list control)   0  14.740000, 8.580000,NA,DSM 3,1 0.5 0.0,1.0,1.0 0 0 1 1 1,1,1 0.5,0 1,1,1  940 Lauthprecondis_2013,7-12 months,NA,6-12 yo 7.76 13.99 95.59,108.06, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
9002 Groenman (2022),Groenman 2022,10.1016/j.jaac.2021.02.024 100,  0 100,100,Critically low Parent-mediated behavioral interventions,Tuning into Kids+Mindful Parenting,  0,NA,Conduct Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks),Questionnaire SDQ CD symptoms  8.00000000,NA,NA,Shum 2025 NA,RCT (parallel, crossover, open-label) G  18, 17   35 outcomes reverse -0.4566739863,-1.138078945, 2.247310e-01,NA NA,NA NA NA NA NA NA,  0,  0,  0,  0   0   0,  0,high,high high,high high,WLC (wait-list control),  0  25.000000, 8.290000,NA DSM,3,1 0.5 0.0,1.0,1.0,0,0 1,1,1,1 1 0.5,0,1,1,1  941 Shum_2025 7-12 months,NA 6-12 yo,7.76,13.99 95.59,108.06  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high high
9002 Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024,100,  0 100 100,Critically low Parent-mediated behavioral interventions Tuning into Kids+Mindful Parenting   0,NA Conduct Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire SDQ CD symptoms, 8.00000000 NA NA,Shum 2025,NA,RCT (parallel, crossover, open-label) G, 17, 17,  34,outcomes,reverse -0.3291908465,-1.016157112, 3.577754e-01 NA,NA,NA NA,NA NA,NA NA,  0,  0,  0   0,  0,  0   0,high,high high,high high,WLC (wait-list control)   0, 25.000000  8.290000 NA DSM 3,1 0.5,0.0 1.0,1.0,0 0,1,1,1 1 1,0.5,0,1,1 1  942 Shum_2025 7-12 months,NA 6-12 yo 7.76,13.99 95.59,108.06, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high high
9002 Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024 100 100 100 100 Critically low Parent-mediated behavioral interventions,Behavioral parent training with consequence-based techniques only,  0 NA Oppositional Defiant Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire Dutch version of Disruptive Behavior Disorder Rating Scale  2.00000000,NA,NA,Hornstra 2021 NA,RCT (parallel, crossover, open-label),G  32, 30   62 outcomes reverse,-0.1669015859 -0.669751537, 3.359484e-01,NA NA NA NA NA,NA NA,NA 100 100 100,100,100,100,100 low,low,low some low,WLC (wait-list control),  0, 31.520000, 8.350000, 95.59000 DSM,3,1,0.5,0.0 1.0,1.0 0 0 1 1 1 1 1 0.5 0 1 1 1  943,Hornstra_2021,2-6 months,Average (80-119),6-12 yo 7.43 10.71,95.59 108.06, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
9002 Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024 100,100,100,100 Critically low Parent-mediated behavioral interventions,Behavioral parent training with consequence-based techniques only,  0,NA Oppositional Defiant Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,Dutch version of Disruptive Behavior Disorder Rating Scale  2.00000000 NA,NA,Hornstra 2021 NA,RCT (parallel, crossover, open-label) G  30, 30   60 outcomes,reverse  0.0086657646,-0.501460840  5.187924e-01,NA,NA,NA NA,NA,NA NA NA 100 100 100,100,100,100 100 low low low,some low WLC (wait-list control),  0  31.520000  8.350000  95.59000 DSM,3 1,0.5,0.0 1.0,1.0 0 0 1 1 1,1 1 0.5 0 1,1 1, 944 Hornstra_2021,2-6 months Average (80-119) 6-12 yo,7.43,10.71,95.59 108.06, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
9002,Groenman - Preschool (2022) Groenman - Preschool 2022,10.1016/j.jaac.2021.02.024,100   0,100 100 Critically low,Parent-mediated behavioral interventions,Parenting Your Hyperactive Preschooler (parent training and emotion socialization)   0 NA Oppositional Defiant Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,DBRS ODD average score mother,14.00000000 NA,NA Herbert,2013 NA RCT (parallel, crossover, open-label),G  17  14   31,NA reverse -0.0310645730,-0.749958831  6.878297e-01,NA NA NA,NA NA,NA NA NA,  0,  0 100   0,100 100   0 some,high low,high some WLC (wait-list control),  0  25.800000, 4.580000 NA,DSM 3 1,0.5,0.0 1.0 1.0,0 0 1 1,1 1,1 0.5 0,1,1 1  945,Herbert_2013 > 12 months,NA,< 6 yo,3.51 5.36 NA,NA  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000,no,low,high
9002 Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024 100 100,100,100 Critically low,Parent-mediated behavioral interventions Behavioral parent training Groningen   0,NA,Oppositional Defiant Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,CPRS oppositional 22.00000000 NA NA,Vdhoofdakker,2007 NA,RCT (parallel, crossover, open-label) G, 47  47   94 NA reverse -0.1460338352,-0.552931806  2.608641e-01 NA,NA,NA NA NA NA NA,NA,  0,  0,100   0 100,100,  0,some,high low high,some,TAU   0  19.100000  7.430000, 97.45000 DSM 3 1,0.5 0.0,1.0 1.0 0 0 1 1 1 1,1,0.5,0,1,1 1, 946,Vdhoofdakker_2007,> 12 months Average (80-119) 6-12 yo,7.43 10.71,95.59 108.06, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
9002 Groenman - Preschool (2022),Groenman - Preschool 2022 10.1016/j.jaac.2021.02.024 100,  0,100 100 Critically low Parent-mediated behavioral interventions Incredible years   0 NA Oppositional Defiant Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,Conners parent oppositional 20.00000000 NA,NA Websterstratton 2011,NA RCT (parallel, crossover, open-label),G  49, 50   99 NA reverse -0.4268176823,-0.827239741,-2.639562e-02,NA NA NA,NA,NA NA,NA,NA,  0,  0 100,  0 100,100   0 some,high low high some WLC (wait-list control),  0, 24.200000, 5.360000,NA DSM 3 1,0.5 0.0 1.0 1.0,0,0,1 1 1,1 1 0.5,0,1 1 1  947,Websterstratton_2011 > 12 months,NA,< 6 yo,3.51 5.36,NA NA, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15,108.21 Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000 no low,high
9002 Groenman (2022) Groenman 2022 10.1016/j.jaac.2021.02.024 100 100 100 100,Critically low Parent-mediated behavioral interventions Child life and attentions kills program,  0 NA,Oppositional Defiant Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,CSI ODD average score,12.00000000,NA NA,Pfiffner,2007 NA,RCT (parallel, crossover, open-label),G  36, 33,  69 NA reverse -0.1460573683 -0.622333281, 3.302185e-01,NA,NA NA,NA,NA,NA NA NA   0   0 100,  0,100,100   0 some high low high some TAU   0, 33.300000  8.670000,108.06000,DSM 3,1,0.5,0.0,1.0 1.0,0,0 1,1,1 1 1 0.5 0 1,1 1  948 Pfiffner_2007 7-12 months,Average (80-119),6-12 yo 7.43,10.71,95.59 108.06  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
9002,Groenman (2022) Groenman 2022 10.1016/j.jaac.2021.02.024,100,100,100,100,Critically low,Parent-mediated behavioral interventions,Parent Focused treatment+Child life and attentions kills program (IPT),  0 NA,Oppositional Defiant Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire CSI ODD average score,NA,NA NA,Pfiffner,2014,NA RCT (parallel, crossover, open-label),G  74, 51, 125,outcomes,reverse -0.1266997883 -0.485092597, 2.316930e-01,NA NA NA NA,NA,NA,NA,NA,  0   0 100,  0 100 100   0,some,high,low high,some,TAU   0  41.700000, 8.640000,103.76000 DSM 3,1 0.5,0.0,1.0 1.0,0 0,1 1,1 1,1 0.5,0,1 1,1  949 Pfiffner_2014,NA,Average (80-119) 6-12 yo,7.43,10.71,95.59,108.06, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
9002 Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024 100 100,100,100 Critically low Parent-mediated behavioral interventions Parent Focused treatment+Child life and attentions kills program (IPT)   0 NA,Oppositional Defiant Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire CSI ODD average score,NA,NA,NA,Pfiffner 2014 NA,RCT (parallel, crossover, open-label) G, 74, 51, 125 outcomes,reverse -0.0369691649 -0.395040714  3.211024e-01,NA,NA,NA,NA NA,NA NA NA,  0,  0 100   0 100,100,  0,some,high low high some TAU   0  41.700000, 8.640000,103.76000,DSM 3 1,0.5,0.0,1.0 1.0,0,0,1 1 1 1,1,0.5 0,1 1,1, 950 Pfiffner_2014 NA Average (80-119),6-12 yo 7.43,10.71,95.59 108.06, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15 108.21,Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,high
9002,Groenman - Preschool (2022),Groenman - Preschool,2022 10.1016/j.jaac.2021.02.024 100,  0 100 100,Critically low,Parent-mediated behavioral interventions Incredible years+a-New forest parenting program   0 NA,Oppositional Defiant Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,SNAP ODD average score 12.00000000 NA,NA SonugaBarkeCoppi 2018 NA RCT (parallel, crossover, open-label) G,131  42  173,outcomes reverse,-0.0929521691 -0.441575964  2.556716e-01 NA NA,NA NA,NA NA,NA NA,100,100,100,  0,100,100,100,low,high,low low low,TAU,  0  26.800000  3.510000 NA,DSM,3,1,0.5 0.0,1.0 1.0,0 0,1,1 1 1,1,0.5,0,1 1 1, 951 SonugaBarkeCoppi_2018 7-12 months NA < 6 yo 3.51 5.36 NA NA  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15 108.21 Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000,no,low low
9002,Groenman - Preschool (2022) Groenman - Preschool 2022,10.1016/j.jaac.2021.02.024,100,  0 100 100,Critically low Parent-mediated behavioral interventions Incredible years+a-New forest parenting program   0 NA Oppositional Defiant Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks),Questionnaire SNAP ODD average score 12.00000000,NA,NA,SonugaBarkeCoppi,2018,NA,RCT (parallel, crossover, open-label),G 133  42, 175 outcomes reverse,-0.2317176379,-0.580412311, 1.169770e-01 NA NA,NA,NA NA NA NA NA 100,100 100,  0 100,100 100,low,high low low low,TAU,  0, 26.800000  3.510000,NA DSM 3 1,0.5 0.0,1.0 1.0 0,0,1,1 1 1,1,0.5 0 1 1 1  952,SonugaBarkeCoppi_2018 7-12 months,NA,< 6 yo 3.51 5.36 NA,NA  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15 108.21,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,100.00000 no low low
9002,Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024 100,100 100,100 Critically low,Parent-mediated behavioral interventions parent training, child docused treatment and a school-based intervention,  0,NA Oppositional Defiant Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,SNAP ODD,NA,NA NA MTA,1999 NA,RCT (parallel, crossover, open-label) G 143,144  287 NA,reverse,-0.0613724024 -0.293189335, 1.704445e-01,NA NA,NA NA NA NA,NA,NA   0,  0,100   0,100,100,  0,low,high low,high some,TAU   0  19.900000  7.760000 101.97000,DSM 3 1,0.5 0.0 1.0 1.0,0,0,1,1 1 1,1 0.5,0,1 1,1  953 MTA_1999,NA Average (80-119),6-12 yo 7.43 10.71 95.59 108.06  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
9002,Groenman (2022) Groenman 2022 10.1016/j.jaac.2021.02.024,100,  0 100,100 Critically low,Parent-mediated behavioral interventions collaborative life skills,  0,NA,Oppositional Defiant Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks) Questionnaire CSI ODD average score 12.00000000 NA,NA Pfiffner,2016 NA RCT (parallel, crossover, open-label) G, 72  63  135 NA,reverse -0.7490821357 -1.100161591 -3.980027e-01,NA NA,NA NA NA NA NA,NA   0,  0,100   0 100,100   0,some high low high low TAU,  0  28.900000  8.390000 NA DSM 3 1 0.5,0.0 1.0 1.0,0,0,1,1,1,1 1 0.5,0 1,1,1  954 Pfiffner_2016 7-12 months NA,6-12 yo,7.43,10.71 95.59,108.06  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
9002,Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024 100   0,100,100,Critically low,Parent-mediated behavioral interventions,online BPT+Face to face BPT,  0,NA,Oppositional Defiant Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire CERS defiant temp t score,10.00000000 NA,NA Dupaul,2018,NA RCT (parallel, crossover, open-label) G, 15, 15,  30 outcomes reverse -0.3724467948,-1.106808222  3.619146e-01 NA,NA,NA,NA NA NA NA NA   0   0 100   0 100 100,  0 some,high,low high,some WLC (wait-list control),  0, 24.400000  8.580000,NA,DSM 3 1,0.5 0.0,1.0 1.0 0 0,1,1 1 1 1,0.5,0 1,1 1  955 Dupaul_2018,7-12 months,NA 6-12 yo 7.43,10.71 95.59,108.06, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
9002,Groenman (2022),Groenman 2022,10.1016/j.jaac.2021.02.024 100   0 100 100,Critically low,Parent-mediated behavioral interventions online BPT+Face to face BPT,  0 NA,Oppositional Defiant Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire,CERS defiant temp t score 10.00000000,NA NA Dupaul,2018,NA RCT (parallel, crossover, open-label),G, 15  15,  30 outcomes,reverse,-0.5095131795 -1.249608231  2.305819e-01,NA,NA,NA NA NA,NA NA NA,  0,  0,100,  0 100,100,  0 some high low high,some WLC (wait-list control)   0, 24.400000, 8.580000 NA DSM,3 1,0.5 0.0 1.0 1.0,0 0,1,1 1,1 1 0.5,0 1,1 1  956,Dupaul_2018 7-12 months,NA,6-12 yo,7.43 10.71,95.59 108.06  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
9002,Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024 100,  0 100,100 Critically low Parent-mediated behavioral interventions psychoeducation   0 NA,Oppositional Defiant Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire CPRS oppositional  6.00000000,NA,NA Ferrin 2016 NA,RCT (parallel, crossover, open-label),G  35  34,  69 NA reverse  0.0759972208 -0.399407243  5.514017e-01,NA,NA NA NA,NA NA NA NA,  0   0 100   0 100,100,  0,low,high low,high low TAU   0  13.000000 10.710000 NA,DSM,3 1 0.5 0.0,1.0 1.0,0 0 1 1,1 1,1 0.5 0 1 1,1  957,Ferrin_2016,2-6 months NA 6-12 yo,7.43,10.71,95.59,108.06  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
9002 Groenman (2022) Groenman 2022,10.1016/j.jaac.2021.02.024,100,100,100 100,Critically low,Parent-mediated behavioral interventions,NA   0,NA,Oppositional Defiant Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,SNAP ODD sum Mother,13.00000000 NA,NA Shimabukuro,2020,NA,RCT (parallel, crossover, open-label) G  28  24   52,NA,reverse,-0.3592135094,-0.914042205, 1.956152e-01 NA,NA,NA,NA NA NA,NA,NA,100 100,100,100,100 100,100 some low,low,some,some,WLC (wait-list control),  0  17.650000  8.350000,100.69000,DSM,3 1,0.5,0.0 1.0,1.0 0 0,1,1 1 1 1 0.5,0,1 1,1  958 Shimabukuro_2020 > 12 months Average (80-119),6-12 yo,7.43 10.71 95.59,108.06, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
9002,Groenman (2022),Groenman,2022,10.1016/j.jaac.2021.02.024,100,  0,100,100,Critically low Parent-mediated behavioral interventions,Telephone-assisted self-help (TASH) intervention,  0,NA Oppositional Defiant Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire German questionnaire FBB-SSV Oppositional,26.00000000,NA NA Dose 2017 NA,RCT (parallel, crossover, open-label) G, 51, 90  141,NA reverse -0.4464192672 -0.795066730 -9.777180e-02,NA NA NA NA,NA NA,NA NA,  0   0,100,100,100 100,  0 some,some low,high,some,TAU,  0  20.570000  9.790000,NA DSM,3 1,0.5 0.0,1.0,1.0,0 0,1 1 1 1 1 0.5 0 1,1 1, 959 Dose_2017 > 12 months NA,6-12 yo,7.43 10.71 95.59,108.06  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
9002,Groenman (2022) Groenman,2022 10.1016/j.jaac.2021.02.024,100   0 100,100,Critically low,Parent-mediated behavioral interventions COACHES,  0 NA Oppositional Defiant Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,DBD rating oppositional symptoms NA NA,NA,Fabiano,2012 NA,RCT (parallel, crossover, open-label) G, 28  27,  55 NA,reverse -0.4134090170 -0.952538297  1.257203e-01 NA,NA,NA NA,NA NA,NA NA   0   0 100   0 100 100   0 some high low,high,some,WLC (wait-list control),  0  13.000000, 8.510000,NA,DSM 3 1 0.5 0.0 1.0 1.0,0 0,1 1,1 1,1 0.5,0 1 1,1, 960 Fabiano_2012,NA,NA,6-12 yo 7.43 10.71,95.59,108.06  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low high
9002,Groenman (2022),Groenman,2022 10.1016/j.jaac.2021.02.024,100,  0 100,100,Critically low Parent-mediated behavioral interventions,Cognitive-behavioral Training (BPT),  0 NA,Oppositional Defiant Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,CBCL Aggression Scale,11.00000000 NA,NA Lauthprecondis 2013,NA RCT (parallel, crossover, open-label),G 190  95, 285 NA reverse,-0.1923454883 -0.439537860, 5.484688e-02,NA NA,NA,NA NA NA NA NA,  0,  0   0   0   0,  0,  0,high,high high high,high WLC (wait-list control)   0  14.740000, 8.580000,NA,DSM 3 1,0.5 0.0,1.0,1.0,0 0,1,1 1 1 1 0.5,0,1 1,1, 961,Lauthprecondis_2013,7-12 months NA,6-12 yo,7.43,10.71,95.59,108.06, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
9002,Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024 100,  0 100 100 Critically low Parent-mediated behavioral interventions,Tuning into Kids+Mindful Parenting,  0 NA Oppositional Defiant Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks) Questionnaire,SNAP ODD symptoms  8.00000000 NA,NA,Shum 2025,NA RCT (parallel, crossover, open-label) G, 18, 17   35 outcomes,reverse -0.4444159794 -1.125341503  2.365095e-01,NA,NA NA,NA NA NA NA,NA,  0,  0,  0   0,  0,  0   0,high high high high high WLC (wait-list control)   0, 25.000000  8.290000,NA,DSM 3 1,0.5 0.0 1.0,1.0,0 0,1,1,1 1 1,0.5 0,1,1,1, 962,Shum_2025 7-12 months,NA 6-12 yo 7.43,10.71 95.59 108.06, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21 Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no high,high
9002 Groenman (2022) Groenman,2022,10.1016/j.jaac.2021.02.024,100,  0,100 100,Critically low Parent-mediated behavioral interventions,Tuning into Kids+Mindful Parenting,  0,NA,Oppositional Defiant Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks),Questionnaire SNAP ODD symptoms  8.00000000 NA,NA Shum,2025 NA RCT (parallel, crossover, open-label) G, 17, 17   34,outcomes,reverse,-0.5331651194 -1.227899093  1.615689e-01 NA NA NA NA,NA NA NA,NA   0,  0   0   0   0   0,  0,high high,high high,high WLC (wait-list control),  0, 25.000000  8.290000 NA,DSM,3 1,0.5 0.0 1.0 1.0 0,0 1,1,1,1 1 0.5 0 1,1 1, 963 Shum_2025 7-12 months NA 6-12 yo 7.43 10.71 95.59,108.06, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21,Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
 973,Doffer (2023) Doffer,2023 10.1002/jcv2.12196,100 100 100 100 Critically low,Parent-mediated behavioral interventions NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated Closest to 52 weeks Questionnaire CPRS-H/I,NA    2.0000000 h/wk Ferrin,2016 NA RCT (parallel, crossover, open-label) G, 35  34,  69,outcomes NA  0.1577953403 -0.322245004, 6.378357e-01   4.3600000   4.4600000,12.09, 4.800,12.71, 4.470 NA,NA,  0   0 100   0,100,100,  0,low high low,high,low,TAU,  0, 13.010145 10.712174  94.58725 DSM-IV 3,0 1.0,0.5,1.0 0.0 0 1 2 1 1,1,1 1.0 0 0 1,1, 964 Ferrin_2016,NA,Average (80-119),6-12 yo 8.6368 13.97 94.15,104.416  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 1,Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000 no,low high
 973,Doffer (2023),Doffer 2023 10.1002/jcv2.12196,100 100 100,100,Critically low,Parent-mediated behavioral interventions,NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated Closest to 52 weeks,Questionnaire,CPRS-I,NA,   2.0000000 h/wk Ferrin,2016 NA,RCT (parallel, crossover, open-label),G, 35, 34,  69 outcomes NA, 0.8027421646, 0.192052586, 1.413432e+00   4.6300000   3.8500000 13.94  2.910 13.56  4.180 NA NA,  0,  0 100,  0,100,100,  0 low,high low,high,low,TAU,  0  13.010145,10.712174, 94.58725,DSM-IV,3 0 1.0,0.5,1.0 0.0 0 1 2,1 1 1 1,1.0 0 0 1,1  965 Ferrin_2016 NA Average (80-119),6-12 yo 8.6368 13.97,94.15 104.416  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15,108.21 Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1,Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000 no low high
 973 Doffer (2023),Doffer 2023 10.1002/jcv2.12196,100 100 100 100,Critically low Parent-mediated behavioral interventions NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,Closest to 52 weeks,Questionnaire CTRS-Total,NA    2.0000000,h/wk,Ferrin 2016,NA,RCT (parallel, crossover, open-label) G  35  34   69 outcomes NA  0.4573551539 -0.111379629, 1.026090e+00, 10.1300000  10.2000000,21.40  7.430,18.38, 9.640,NA,NA,  0   0 100   0,100 100,  0,low,high low high,low,TAU,  0  13.010145 10.712174, 94.58725 DSM-IV,3,0 1.0 0.5,1.0,0.0 0,1,2,1,1 1,1 1.0 0 0 1 1  966 Ferrin_2016,NA Average (80-119) 6-12 yo 8.6368 13.97 94.15,104.416, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 1 Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,100.00000 no,low,high
 973 Doffer (2023),Doffer,2023 10.1002/jcv2.12196,100 100 100,100,Critically low Parent-mediated behavioral interventions,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated Closest to 52 weeks Questionnaire P-CSI,NA,   0.9550000,h/wk,Pfiffner,2014,NA,RCT (parallel, crossover, open-label),G, 70, 45  115 outcomes,NA, 0.5381217357  0.047630486, 1.028613e+00   0.3480000   0.4360000  1.32, 0.351  1.42  0.363,NA,NA,  0   0 100,  0 100,100,  0 some high low high,some TAU   0, 45.820000, 8.636800,104.41600,DSM-IV 3 0,1.0,0.5,1.0,0.0 0,1,2 1 1 1,1,1.0 0,0,1,1, 967 Pfiffner_2014 NA Average (80-119) 6-12 yo 8.6368,13.97 94.15,104.416  33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21 Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1,Homogeneous Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000 no,low,high
 973 Doffer (2023),Doffer 2023,10.1002/jcv2.12196 100 100,100,100,Critically low Parent-mediated behavioral interventions,NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated Closest to 52 weeks Questionnaire T-CSI,NA    0.9550000 h/wk,Pfiffner 2014 NA,RCT (parallel, crossover, open-label),G, 67  41  108,outcomes NA  0.3433404824 -0.197044549, 8.837255e-01,  0.5370000,  0.5060000, 1.33, 0.378, 1.36  0.377,NA,NA,  0,  0 100,  0,100 100,  0 some high,low,high,some,TAU,  0, 45.820000  8.636800,104.41600 DSM-IV,3 0 1.0 0.5 1.0,0.0,0,1 2,1 1 1,1 1.0 0 0 1 1, 968 Pfiffner_2014,NA Average (80-119) 6-12 yo,8.6368 13.97 94.15 104.416, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15 108.21 Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1,Homogeneous Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000 no,low,high
 973,Doffer (2023),Doffer 2023,10.1002/jcv2.12196,100,100 100,100,Critically low Parent-mediated behavioral interventions,NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated Closest to 52 weeks Questionnaire P-CSI,NA    0.9550000,h/wk,Pfiffner 2014,NA,RCT (parallel, crossover, open-label) G, 73, 45  118,outcomes,NA, 0.3413758758 -0.132470383, 8.152221e-01   0.4200000   0.4360000  1.49, 0.414, 1.42  0.363,NA NA   0   0 100   0 100 100   0 some high,low high some TAU,  0, 45.820000  8.636800,104.41600,DSM-IV 3,0,1.0,0.5,1.0 0.0,0,1 2 1 1,1,1 1.0 0 0 1,1  969,Pfiffner_2014,NA,Average (80-119),6-12 yo,8.6368,13.97 94.15,104.416, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15 108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 1 Homogeneous Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000,no,low high
 973,Doffer (2023) Doffer 2023 10.1002/jcv2.12196,100,100,100 100,Critically low Parent-mediated behavioral interventions,NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,Closest to 52 weeks,Questionnaire T-CSI,NA    0.9550000,h/wk,Pfiffner 2014 NA,RCT (parallel, crossover, open-label) G, 71  41  112,outcomes NA, 0.1535822041,-0.357936601, 6.651010e-01,  0.6120000,  0.5060000  1.30  0.435, 1.36  0.377,NA,NA   0   0 100,  0,100,100,  0,some,high,low,high,some,TAU   0, 45.820000  8.636800,104.41600 DSM-IV 3 0 1.0,0.5 1.0 0.0 0 1 2 1,1,1 1 1.0,0,0 1 1, 970,Pfiffner_2014,NA,Average (80-119),6-12 yo 8.6368 13.97 94.15 104.416, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1 Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000,no low,high
 973 Doffer - Preschool (2023) Doffer - Preschool 2023,10.1002/jcv2.12196,100 100,100 100 Critically low Parent-mediated behavioral interventions NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks) Questionnaire,Attention on-task parent supervised,NA,   1.0000000 h/wk,Pisterman 1992 NA RCT (parallel, crossover, open-label),G, 23, 22   45 outcomes NA,-0.5987930085,-2.529496282, 1.331910e+00, 65.0000000 126.1000000,40.10 30.900,47.20 29.400,NA,NA 100,100 100   0,  0 100 100 some high high low some,WLC (wait-list control)   0  15.800000  4.146000,103.44333,DSM-III,3,0 1.0,0.5 1.0 0.0,0,1 2 1,1,1 1 1.0 0 0,1,1, 971 Pisterman_1992,NA,Average (80-119),< 6 yo 3.5,4.46 103.4433333 103.4433333, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15 108.21,Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo,100.00000 no low low
 973 Doffer - Preschool (2023) Doffer - Preschool 2023 10.1002/jcv2.12196,100 100,100 100,Critically low Parent-mediated behavioral interventions NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks) Questionnaire,Attention on-task independent,NA,   1.0000000,h/wk Pisterman,1992,NA RCT (parallel, crossover, open-label) G  23  22,  45,outcomes,NA,-0.6833348711 -1.784832907, 4.181632e-01  32.0000000, 56.7000000 30.20,22.400 26.10 24.000,NA NA 100 100 100,  0   0 100 100 some high,high low,some,WLC (wait-list control)   0, 15.800000, 4.146000,103.44333,DSM-III,3 0 1.0,0.5 1.0,0.0,0 1,2 1 1,1,1 1.0,0,0 1 1  972,Pisterman_1992,NA Average (80-119),< 6 yo 3.5 4.46,103.4433333 103.4433333, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21,Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous,Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo 100.00000 no low low
 973 Doffer - Preschool (2023) Doffer - Preschool 2023,10.1002/jcv2.12196,100,100,100,100,Critically low Parent-mediated behavioral interventions,NA,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks),Questionnaire,Attention free play,NA,   1.0000000,h/wk,Pisterman,1992 NA,RCT (parallel, crossover, open-label) G  23, 22,  45 outcomes NA,-0.5036784710,-1.148610777, 1.412538e-01  30.0000000, 38.9000000,72.00 51.100,59.90,30.800,NA,NA 100,100,100   0,  0 100,100,some high high,low some,WLC (wait-list control),  0, 15.800000  4.146000 103.44333 DSM-III 3,0 1.0,0.5 1.0,0.0 0,1,2,1,1,1 1,1.0,0 0 1 1  973 Pisterman_1992 NA,Average (80-119) < 6 yo 3.5 4.46 103.4433333,103.4433333  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15,108.21,Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo 100.00000,no,low low
 973 Doffer (2023) Doffer,2023,10.1002/jcv2.12196,100,100,100 100 Critically low Parent-mediated behavioral interventions NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,Closest to 52 weeks Questionnaire DBD-Total,NA,   0.8333333,h/wk Sibley,2016 NA RCT (parallel, crossover, open-label),G, 55, 51  106 outcomes NA, 0.5549293816  0.135308199, 9.745506e-01   0.6000000,  0.5100000  1.85, 0.600, 1.87  0.620,NA,NA   0,  0,100,  0,100,100,  0 some,high,low high some TAU,  0  35.130469,12.745313,100.76367,DSM-IV 3 0,1.0 0.5,1.0,0.0,0,1,2,1,1 1,1,1.0 0,0 1,1  974 Sibley_2016,NA Average (80-119) 6-12 yo,8.6368 13.97 94.15 104.416, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15 108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 1 Homogeneous Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000 no low,high
 973,Doffer (2023),Doffer 2023 10.1002/jcv2.12196 100 100 100,100 Critically low Parent-mediated behavioral interventions,NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated Closest to 52 weeks Questionnaire DBD-Total NA,   0.8333333,h/wk Sibley 2016 NA,RCT (parallel, crossover, open-label),G, 55, 51, 106 outcomes NA, 0.1253795149 -0.297280155, 5.480392e-01   0.7200000   0.7200000  1.52  0.730, 1.54  0.620 NA,NA   0,  0,100   0 100,100,  0 some,high,low,high some TAU   0, 35.130469,12.745313 100.76367 DSM-IV 3,0,1.0 0.5,1.0 0.0,0 1,2 1 1 1,1 1.0,0,0,1,1, 975 Sibley_2016 NA Average (80-119) 6-12 yo,8.6368 13.97 94.15 104.416  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15 108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 1 Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000 no low high
 973 Doffer (2023),Doffer 2023,10.1002/jcv2.12196 100 100 100 100,Critically low,Parent-mediated behavioral interventions,NA   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated Closest to 52 weeks,Questionnaire C3RS-H/I,NA,   1.0000000,h/wk Sibley 2021 NA RCT (parallel, crossover, open-label),G,138,140  278,outcomes,NA, 0.0935879873 -0.142079773  3.292557e-01, 16.7100000, 15.3300000 65.37 17.190,63.02 16.710,NA NA,  0   0,  0   0,100 100,100,high high,low low low,TAU   0, 29.700000,13.970000, 94.15000 DSM-V 3 0 1.0,0.5,1.0 0.0,0,1,2 1,1,1 1 1.0,0,0 1 1  976,Sibley_2021 NA Average (80-119) 13-19 yo 8.6368 13.97,94.15,104.416  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 1,Homogeneous Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,100.00000 no low,high
 973,Doffer (2023),Doffer,2023 10.1002/jcv2.12196,100 100 100 100 Critically low,Parent-mediated behavioral interventions,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated Closest to 52 weeks Questionnaire,DSM-checklist-H/I-p,NA,   1.0000000,h/wk Sibley,2021,NA RCT (parallel, crossover, open-label) G 138,140  278,outcomes NA, 0.0969748625 -0.140498045, 3.344478e-01,  0.6900000,  0.7800000, 1.02  0.790  1.06  0.780 NA NA   0   0   0,  0,100 100 100 high high low low low TAU,  0, 29.700000,13.970000  94.15000 DSM-V,3 0,1.0 0.5,1.0,0.0 0,1,2 1,1 1 1 1.0 0 0 1,1  977,Sibley_2021,NA,Average (80-119),13-19 yo 8.6368 13.97,94.15,104.416, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15 108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1,Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,100.00000,no,low high
 973,Doffer (2023),Doffer,2023,10.1002/jcv2.12196,100 100 100 100 Critically low,Parent-mediated behavioral interventions NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated Closest to 52 weeks,Questionnaire,DSM-checklist-H/I-t NA,   1.0000000,h/wk,Sibley,2021 NA RCT (parallel, crossover, open-label) G,138,140  278 outcomes,NA, 0.0003843142 -0.235723607, 2.364922e-01   0.7000000,  0.7200000  0.99, 0.870  0.90  0.810 NA NA,  0,  0   0,  0 100 100 100,high,high,low low low TAU,  0  29.700000 13.970000  94.15000 DSM-V 3 0,1.0,0.5 1.0 0.0 0 1,2,1 1 1,1 1.0,0,0,1 1  978,Sibley_2021,NA Average (80-119),13-19 yo 8.6368,13.97 94.15,104.416  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15,108.21 Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 1 Homogeneous Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,100.00000,no low,high
 973 Doffer (2023),Doffer 2023,10.1002/jcv2.12196,100,100 100,100,Critically low Parent-mediated behavioral interventions,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated Closest to 52 weeks Questionnaire C3RS-I NA,   1.0000000,h/wk,Sibley,2021 NA RCT (parallel, crossover, open-label) G 138 140, 278 outcomes,NA  0.0420413916,-0.232863042, 3.169458e-01, 14.6700000  13.8400000 75.51 13.320,73.74 12.660,NA NA,  0   0   0   0 100 100,100,high high,low low low TAU   0, 29.700000 13.970000  94.15000 DSM-V,3,0,1.0 0.5 1.0,0.0,0,1,2 1 1,1 1,1.0 0 0,1,1, 979 Sibley_2021,NA,Average (80-119),13-19 yo 8.6368,13.97,94.15,104.416  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15 108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 1,Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,100.00000 no,low high
 973 Doffer (2023),Doffer,2023 10.1002/jcv2.12196,100,100,100,100,Critically low Parent-mediated behavioral interventions NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,Closest to 52 weeks,Questionnaire,DSM-checklist-I-p NA,   1.0000000 h/wk,Sibley,2021,NA,RCT (parallel, crossover, open-label),G,138,140  278 outcomes NA  0.1822005127 -0.093174112  4.575751e-01,  0.6500000   0.7400000  1.92  0.690  2.00, 0.660 NA,NA,  0,  0   0,  0 100 100 100,high,high low,low low,TAU,  0, 29.700000,13.970000, 94.15000,DSM-V,3 0 1.0,0.5,1.0 0.0 0 1,2 1,1 1 1 1.0 0,0 1,1, 980,Sibley_2021 NA,Average (80-119),13-19 yo,8.6368,13.97 94.15 104.416  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15,108.21,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1,Homogeneous Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000 no low high
 973 Doffer (2023),Doffer 2023 10.1002/jcv2.12196,100 100,100,100,Critically low Parent-mediated behavioral interventions NA   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated Closest to 52 weeks,Questionnaire DSM-checklist-I-t,NA,   1.0000000,h/wk Sibley 2021,NA,RCT (parallel, crossover, open-label),G 138,140, 278,outcomes NA, 0.0683508079 -0.214705343, 3.514070e-01   0.8300000   0.8000000  1.84, 0.660, 1.63  0.650 NA NA   0   0   0   0 100,100 100 high,high low low low,TAU   0, 29.700000 13.970000  94.15000 DSM-V 3,0,1.0 0.5,1.0,0.0,0 1,2 1 1 1,1 1.0,0,0,1,1, 981,Sibley_2021 NA,Average (80-119),13-19 yo 8.6368,13.97,94.15,104.416  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21 Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,1,Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo 100.00000 no,low,high
 973,Doffer - Preschool (2023),Doffer - Preschool,2023,10.1002/jcv2.12196 100   0 100,100,Critically low Parent-mediated behavioral interventions NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks),Questionnaire,PACS-ADHD,NA    1.0000000 h/wk Sonuga-Barke 2004,NA,RCT (parallel, crossover, open-label),G  59, 30,  89 outcomes,NA  0.6410065765,-0.085909944  1.367923e+00,  0.7830000   0.2980000, 2.26  0.333  2.07  0.202 NA,NA 100 100,100,  0 100 100 100 some high,low,low,some,WLC (wait-list control),  0 NA  3.500000,NA,DSM-IV 3,0 1.0,0.5 1.0 0.0,0,1,2 1,1,1,1 1.0 0 0 1,1  982,Sonuga-Barke_2004,NA NA,< 6 yo 3.5,4.46 103.4433333,103.4433333, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21,Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo 100.00000 no,low low
 973,Doffer - Preschool (2023) Doffer - Preschool 2023,10.1002/jcv2.12196 100   0 100 100,Critically low Parent-mediated behavioral interventions,NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks) Questionnaire,WWP NA,   1.0000000 h/wk,Sonuga-Barke,2004,NA RCT (parallel, crossover, open-label) G  59, 30,  89 outcomes NA,-0.0825475740 -0.826880975, 6.617858e-01  11.2470000,  8.1560000 28.18, 5.623,30.97  4.832 NA NA,100,100,100,  0 100 100,100,some,high,low,low,some,WLC (wait-list control)   0,NA  3.500000 NA,DSM-IV,3,0 1.0 0.5 1.0 0.0 0,1 2,1 1,1,1,1.0,0,0,1 1  983,Sonuga-Barke_2004 NA NA < 6 yo 3.5 4.46 103.4433333,103.4433333  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15,108.21,Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo,100.00000 no low,low
 973,Doffer - Preschool (2023) Doffer - Preschool,2023,10.1002/jcv2.12196,100,  0,100 100 Critically low Parent-mediated behavioral interventions,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks) Questionnaire,BCL-Hyperactivity,NA    1.0000000 h/wk,Sonuga-Barke,2004 NA RCT (parallel, crossover, open-label) G, 59  30,  89 outcomes NA  0.7279114069, 0.207791210  1.248032e+00   1.6450000,  0.8790000, 3.83, 1.822, 3.57  0.742 NA NA 100,100,100   0,100,100,100,some,high low low some,WLC (wait-list control)   0 NA  3.500000 NA,DSM-IV,3 0,1.0 0.5,1.0 0.0 0,1,2,1,1 1,1,1.0 0 0 1,1, 984,Sonuga-Barke_2004 NA,NA < 6 yo,3.5,4.46 103.4433333 103.4433333, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15 108.21 Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo,100.00000,no low low
 973 Doffer - Preschool (2023),Doffer - Preschool 2023,10.1002/jcv2.12196,100,  0,100 100,Critically low,Parent-mediated behavioral interventions NA   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks) Questionnaire PACS-ADHD NA    1.2500000 h/wk,Thompson,2009 NA RCT (parallel, crossover, open-label) G, 17, 13,  30,outcomes,NA, 0.8542048151, 0.001501114  1.706909e+00   3.9900000,  6.9300000,16.81  6.100 17.77  6.020,NA,NA 100 100 100,  0,  0 100,100 some high,high low,some TAU,  0  24.400000, 4.460000 NA DSM-IV 3,0,1.0,0.5,1.0,0.0 0,1,2 1,1 1 1 1.0,0 0 1 1, 985 Thompson_2009,NA,NA,< 6 yo,3.5 4.46,103.4433333 103.4433333, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21 Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous,Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo 100.00000,no,low low
 973 Doffer - Preschool (2023),Doffer - Preschool,2023 10.1002/jcv2.12196 100,  0 100 100,Critically low Parent-mediated behavioral interventions NA   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At follow-up (closest to 26 weeks),Questionnaire WWP NA    1.2500000 h/wk,Thompson 2009 NA,RCT (parallel, crossover, open-label) G  17  13   30 outcomes NA  1.2338432246  0.252271392  2.215415e+00, 12.9300000,  9.4400000,32.35, 9.960,29.54, 8.110,NA NA,100,100 100   0   0,100,100,some,high,high low,some TAU   0, 24.400000  4.460000,NA DSM-IV 3,0,1.0 0.5 1.0,0.0 0 1 2 1 1,1 1,1.0,0,0 1 1  986 Thompson_2009 NA NA,< 6 yo,3.5 4.46 103.4433333 103.4433333, 33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15,108.21 Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo,100.00000,no,low,low
 973 Doffer - Preschool (2023),Doffer - Preschool 2023,10.1002/jcv2.12196,100   0 100 100 Critically low,Parent-mediated behavioral interventions,NA,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks),Questionnaire Observation FarmYard NA    1.2500000 h/wk,Thompson 2009,NA,RCT (parallel, crossover, open-label),G  17  13,  30 outcomes,NA,-1.0633595591 -2.368632648  2.419135e-01,  1.1100000   0.8800000  4.09  0.800, 4.34  0.450,NA,NA 100,100,100,  0   0,100 100,some high high,low,some TAU   0, 24.400000, 4.460000 NA,DSM-IV 3 0 1.0 0.5,1.0,0.0,0,1 2,1 1 1 1 1.0 0,0 1,1, 987 Thompson_2009,NA,NA,< 6 yo 3.5,4.46,103.4433333,103.4433333, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15 108.21,Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo 100.00000,no low low
 973 Doffer (2023),Doffer 2023,10.1002/jcv2.12196,100,  0,100,100,Critically low,Parent-mediated behavioral interventions,NA,  0,NA,Oppositional Defiant Disorder symptoms,Parent-rated,At follow-up (closest to 26 weeks),Questionnaire DBD-ODD,NA    2.5000000 h/wk,Chacko,2009 NA,RCT (parallel, crossover, open-label),G, 40  40   80,outcomes,NA  0.2348050260 -0.205169997, 6.747800e-01   0.6500000   0.7200000, 1.75, 0.720, 1.54, 0.750 NA NA,100,100 100   0 100,100,100 some,high,low low,some WLC (wait-list control)   0  29.333000  7.850000 NA DSM-IV 3,0,1.0 0.5,1.0 0.0,0 1 2 1,1,1,1,1.0 0,0,1 1, 988 Chacko_2009,NA,NA 6-12 yo,7.85,10.71217391 94.58724638,94.58724638, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21,Doffer (2023)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000 no,low,low
 973 Doffer (2023) Doffer 2023,10.1002/jcv2.12196,100,  0 100 100,Critically low,Parent-mediated behavioral interventions,NA   0,NA Oppositional Defiant Disorder symptoms Parent-rated At follow-up (closest to 26 weeks) Questionnaire DBD-ODD,NA    2.5000000,h/wk,Chacko,2009 NA,RCT (parallel, crossover, open-label),G  40  40,  80,outcomes,NA, 0.4189681530 -0.022282655  8.602190e-01   0.6200000,  0.7200000, 1.51  0.690  1.54, 0.750 NA,NA 100,100 100,  0 100 100 100 some,high low low some,WLC (wait-list control),  0  29.333000  7.850000 NA,DSM-IV,3 0 1.0 0.5 1.0,0.0 0,1,2,1 1,1,1 1.0 0 0,1,1, 989 Chacko_2009 NA NA,6-12 yo,7.85 10.71217391,94.58724638,94.58724638, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15,108.21,Doffer (2023)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks) 1 Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no low,low
 973,Doffer (2023),Doffer 2023,10.1002/jcv2.12196 100,100 100,100,Critically low Parent-mediated behavioral interventions NA   0 NA Oppositional Defiant Disorder symptoms,Parent-rated,At follow-up (closest to 26 weeks),Questionnaire,CPRS-Opposition,NA    2.0000000,h/wk Ferrin 2016 NA,RCT (parallel, crossover, open-label),G  35  34,  69,outcomes NA  0.2667691422 -0.252396099  7.859344e-01   4.1500000,  4.6200000 12.57  4.390 12.79  3.830 NA NA   0   0,100   0 100,100,  0 low,high,low high,low,TAU,  0  13.010145 10.712174, 94.58725,DSM-IV 3 0 1.0 0.5,1.0 0.0 0,1,2,1 1,1 1 1.0 0 0 1 1, 990,Ferrin_2016,NA,Average (80-119) 6-12 yo 7.85,10.71217391 94.58724638,94.58724638, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21 Doffer (2023)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks),1 Homogeneous,Doffer (2023) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo 100.00000,no,low high
2027,Lenzi (2018),Lenzi,2018,10.1016/j.neubiorev.2017.08.010,100   0 100,100 Critically low,Atomoxetine,NA,  0,NA Emotional dysregulation,Mixed At study endpoint (closest to 12 weeks) NA,BRIEF-A (self-reported and informant), 2.30149597   80.0000000,mg/d,Goto 2017 NA NA,SMD 193 195, 388,NA reverse,-0.3300000000,-0.530000000,-1.300000e-01 NA,NA NA NA NA NA,NA NA,100 100 100,100,100,100 100,some,some low,some,some,Placebo   0  52.344588,32.247165 NA NA 2 1 1.0 1.0 1.0 0.0 0 1,3 1 1,1,1 1.0 0 0 0,1  991 Goto_2017,2-6 months,NA >= 20 yo 24,41.1758252427185 NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA,Lenzi (2018)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Lenzi (2018) - Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
2027 Lenzi (2018),Lenzi 2018,10.1016/j.neubiorev.2017.08.010,100,  0 100 100,Critically low Atomoxetine,NA   0,NA Emotional dysregulation Mixed,At study endpoint (closest to 12 weeks) NA,BADDS NA  100.0000000 mg/d Brown,2011 NA,NA SMD 250 251  501 NA,reverse,-0.3300000000,-0.530000000,-1.300000e-01,NA NA NA,NA NA,NA,NA NA 100 100 100,100 100,100,100,low low some some some,Placebo,  0  50.000000,37.549701 NA NA,2,1 1.0 1.0,1.0 0.0 0 1 3 1,1 1 1,1.0 0,0 0,1, 992,Brown_2011,NA NA >= 20 yo,24 41.1758252427185 NA NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA NA,Lenzi (2018)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Lenzi (2018) - Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
2027 Lenzi (2018) Lenzi 2018 10.1016/j.neubiorev.2017.08.010,100,  0 100,100,Critically low,Atomoxetine NA,  0,NA Emotional dysregulation Mixed,At study endpoint (closest to 12 weeks),NA WRAADDS, 2.30149597   90.0000000,mg/d Robison 2008,NA,NA,SMD,257 258  515,NA,reverse -0.3100000000 -0.700000000, 8.000000e-02,NA NA,NA,NA NA NA NA,NA,100,100 100,100 100,100 100 low,low,low,low,some,Placebo,  0  34.000000,41.175825,NA NA 2,1,1.0,1.0 1.0 0.0 0 1,3,1,1,1 1,1.0,0,0 0,1  993,Robison_2008,2-6 months,NA,>= 20 yo,24 41.1758252427185 NA NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA Lenzi (2018)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Lenzi (2018) - Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
2027 Lenzi (2018) Lenzi,2018,10.1016/j.neubiorev.2017.08.010 100   0 100,100 Critically low Atomoxetine,NA,  0 NA,Emotional dysregulation,Mixed,At study endpoint (closest to 12 weeks) NA BRIEF-A,NA, 100.0000000,mg/d,Adler,2014b,NA,NA,SMD 266,258  524 NA,reverse -0.2000000000,-0.400000000  0.000000e+00 NA,NA,NA,NA NA,NA NA,NA 100 100,100 100,100 100,100 some low,low,low,some,Placebo,  0  41.575191 33.059924 NA,NA 2,1,1.0 1.0,1.0,0.0,0,1 3 1 1 1,1,1.0,0,0,0 1  994 Adler_2014b NA,NA,>= 20 yo,24 41.1758252427185,NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA Lenzi (2018)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Lenzi (2018) - Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
2027,Lenzi (2018) Lenzi 2018,10.1016/j.neubiorev.2017.08.010,100,  0 100,100,Critically low Atomoxetine NA,  0 NA Emotional dysregulation Mixed At study endpoint (closest to 12 weeks) NA,BRIEF-A  2.76179517   50.0000000 mg/dbid Adler,2014a NA,NA SMD 220 225  445 NA,reverse,-0.1000000000 -0.300000000  1.000000e-01,NA,NA,NA,NA NA NA NA,NA,100 100,100 100,100 100,100,low,low,low,some,some,Placebo,  0, 41.800000 24.000000,NA,NA,2 1 1.0 1.0 1.0,0.0,0,1 3 1 1 1 1 1.0,0 0,0 1  995 Adler_2014a,2-6 months NA >= 20 yo,24,41.1758252427185,NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA NA Lenzi (2018)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Lenzi (2018) - Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
2027 Lenzi (2018) Lenzi,2018,10.1016/j.neubiorev.2017.08.010 100   0 100,100,Critically low Amphetamine NA   0 NA,Emotional dysregulation Mixed,At study endpoint (closest to 12 weeks),NA BADDS, 0.92059839,  70.0000000,mg/d,Waxmonsky,2014 NA,NA,SMD, 14  14   28 NA,reverse,-0.8100000000,-1.670000000, 5.000000e-02 NA,NA,NA,NA,NA NA NA NA 100,100 100 100 100 100 100 some,some some some some,Placebo   0  51.500000 40.700000 NA NA 2 1 1.0,1.0,1.0,0.0 0 1 3,1 1 1 1,1.0 0,0 0 1  996 Waxmonsky_2014,< 2 months,NA,>= 20 yo,20.085 40.7 NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA Lenzi (2018)_Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Lenzi (2018) - Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
2027,Lenzi (2018) Lenzi 2018 10.1016/j.neubiorev.2017.08.010,100   0,100,100,Critically low,Amphetamine NA,  0,NA Emotional dysregulation,Mixed,At study endpoint (closest to 12 weeks) NA BRIEF-A  2.30149597   70.0000000,mg/d,Adler,2013 NA NA,SMD, 79, 80  159,NA reverse -0.4600000000,-0.770000000 -1.500000e-01 NA,NA NA,NA NA NA,NA NA,100 100,100 100,100,100,100 low,low,low some,some,Placebo   0  47.789937 34.552201 NA NA 2 1,1.0,1.0 1.0,0.0,0,1,3,1,1,1,1,1.0 0,0 0 1  997,Adler_2013,2-6 months,NA,>= 20 yo,20.085,40.7 NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA,Lenzi (2018)_Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Lenzi (2018) - Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
2027,Lenzi (2018),Lenzi,2018,10.1016/j.neubiorev.2017.08.010 100,  0 100,100 Critically low Amphetamine,NA,  0 NA Emotional dysregulation,Mixed,At study endpoint (closest to 12 weeks) NA,CAARS, BRIEF-A, 3.68239356   70.0000000 mg/d DuPaul 2012 NA,NA SMD  50, 50, 100,NA,reverse -0.2400000000 -0.360000000 -1.200000e-01 NA,NA,NA,NA,NA NA,NA,NA 100,100 100 100,100,100 100,some,some,some,low some,Placebo   0, 41.750000 20.085000 NA,NA 2 1,1.0 1.0,1.0 0.0 0 1,3,1 1,1 1 1.0,0,0,0,1  998 DuPaul_2012,2-6 months,NA >= 20 yo 20.085,40.7 NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA Lenzi (2018)_Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Lenzi (2018) - Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
2902,Radonjic (2023) Radonjic,2023 10.1007/s40263-023-01005-8,100   0 100 100 Critically low Alpha-2 agonists (guanfacine / clonidine),Guanfacine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks),NA ADHD-RS Total,NA NA,NA Iwanami,2020 NA RCT (parallel, crossover, open-label) G,101,100, 201 NA reverse -0.6628000000,-0.970900000,-3.548000e-01   5.9300000   6.8300000 NA NA,NA,NA,NA,NA,  0   0,  0,100   0   0   0 high low high high,high Placebo,  0  35.500000,33.800000,NA,DSM-V 2,1 1.0 0.0,1.0,0.5 0,1 3 1 1,1 1,1.0,0 0,0 1  999,Iwanami_2020 NA NA,>= 20 yo,33.8,41.2 NA NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA,NA Radonjic (2023)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Radonjic (2023) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high high
2902 Radonjic (2023),Radonjic 2023,10.1007/s40263-023-01005-8,100   0,100 100 Critically low Alpha-2 agonists (guanfacine / clonidine) Guanfacine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks),NA ADHD Behavior Checklist for Adults, 0.46029919,   1.1000000,mg Taylor,2021,NA RCT (parallel, crossover, open-label) G  17, 17,  34 NA reverse,-0.6494000000 -1.340000000  4.120000e-02   8.2000000  10.6000000,NA,NA,NA NA,NA,NA 100,100 100,100 100,100,100 some,low some,some some Placebo   0  59.000000,41.200000 NA DSM/ICD 2 1,1.0,0.0 1.0 0.5 0 1 3 1 1,1,1 1.0,0,0 0 1,1000 Taylor_2021 < 2 months NA,>= 20 yo 33.8 41.2 NA,NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA,NA Radonjic (2023)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Radonjic (2023) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
3448 Sugaya (2023) Sugaya 2023 10.1002/jcv2.12146,100   0 100 100,Low,Methylphenidate,MPH-IR   0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,NA  0.92059839,  14.2000000,mg/d Greenhill 2006 NA,RCT (parallel, crossover, open-label) RR  61  53  114,NA reverse, 0.3258196721  0.166410122  6.379327e-01 NA NA NA NA,NA NA,NA,NA 100 100 100,100,  0 100 100 low,low,high low,some,Placebo   0  25.000000  4.760000,NA,NA 1,1,1.0 0.0,1.0,1.0,1,1 0,1 1,1,1 1.0 1 1,1,1 1001,Greenhill_2006 < 2 months,NA,< 6 yo,4.76,5.02,NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Sugaya (2023)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Sugaya (2023) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000 no low low
3448 Sugaya (2023),Sugaya,2023 10.1002/jcv2.12146 100   0,100 100,Low,Methylphenidate MPH-IR,  0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA, 1.84119678,  26.9900000 mg/d Sugaya,2022,NA,RCT (parallel, crossover, open-label) RR, 51  51  102 NA reverse, 0.5000000000, 0.095794107  2.609764e+00,NA NA NA,NA NA,NA NA NA 100 100 100,100,100,100 100 low low,low low,low Placebo,  0  17.000000, 5.020000 NA NA,1,1 1.0 0.0,1.0,1.0,1 1,0,1 1,1,1 1.0 1,1,1,1,1002,Sugaya_2022,< 2 months,NA < 6 yo,4.76 5.02 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Sugaya (2023)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Sugaya (2023) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_< 6 yo 100.00000 no,low,low
 474,Bryant (2021),Bryant,2021 10.1007/s00787-022-02004-8,100,  0,100 100 Critically low,Methylphenidate,NA   0,NA,Generalized anxiety,Mixed,At study endpoint (closest to 12 weeks) NA RBPC -Anxiety/ Withdrawal scale  0.92059839    0.4000000 mg/kg Aman,1993 NA RCT (parallel, crossover, open-label),SMD  28  28,  56,NA reverse,-0.3200000000,-0.850000000  2.000000e-01   0.4000000   0.6100000 NA NA,NA NA NA,NA 100 100 100 100   0,100 100,some low,high,low,some,Placebo   0, 28.600000  8.800000,NA,DSM 4 1,0.0,0.0 1.0,1.0,0,0,6 1 1 0 0,1.0 0 0 0,0,1003 Aman_1993,< 2 months,NA,6-12 yo,8.8 13.6,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Bryant (2021)_Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Bryant (2021) - Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 474,Bryant (2021),Bryant,2021 10.1007/s00787-022-02004-8,100   0,100,100 Critically low Methylphenidate,NA,  0 NA,Generalized anxiety Mixed,At study endpoint (closest to 12 weeks),NA,CPRS - Anxiety subscale, 1.84119678,   0.3250000 mg/kg Brown,1988,NA RCT (parallel, crossover, open-label),SMD  11  11,  22 NA reverse -1.1600000000 -2.080000000 -2.400000e-01,  0.8300000,  0.5100000,NA,NA,NA NA NA NA 100,100,100   0,  0 100 100 some,high,high,low,some Placebo,  0,  0.000000,13.600000,NA DSM 4 1,0.0 0.0 1.0,1.0 0 0,6 1 1 0,0 1.0,0 0,0,0 1004 Brown_1988 < 2 months,NA 13-19 yo 8.8 13.6,NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Bryant (2021)_Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Bryant (2021) - Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 474,Bryant (2021) Bryant 2021,10.1007/s00787-022-02004-8 100,  0 100 100 Critically low,Atomoxetine,NA   0,NA Generalized anxiety,Mixed At study endpoint (closest to 12 weeks) NA SCARED, 1.84119678    1.2000000,mg/kg,DellAgnello,2009,NA RCT (parallel, crossover, open-label) SMD,103  32, 135 NA reverse,-0.0500000000 -0.450000000, 3.400000e-01   7.6000000,  6.5000000,NA NA NA NA,NA NA,100 100,100,100 100,100,100,some,low,low,low,some Placebo,  0   7.300000, 9.800000 NA DSM,4,1 0.0,0.0,1.0 1.0,0 0 6,1,1 0 0,1.0 0 0 0 0 1005,DellAgnello_2009 < 2 months,NA,6-12 yo,9.8,12 NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA,Bryant (2021)_Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Bryant (2021) - Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 474,Bryant (2021) Bryant,2021,10.1007/s00787-022-02004-8,100,  0,100,100 Critically low Atomoxetine,NA   0,NA Generalized anxiety,Mixed,At study endpoint (closest to 12 weeks) NA MASC  2.30149597,   1.2000000,mg/kg Geller,2007 NA,RCT (parallel, crossover, open-label),SMD, 75  76, 151 NA,reverse -0.4700000000 -0.800000000,-1.500000e-01  15.2000000  12.8000000 NA,NA,NA NA NA,NA,100,100,100,100 100 100,100 some low,low,low some Placebo   0  35.200000 12.000000 NA DSM,4,1 0.0 0.0 1.0,1.0,0 0 6 1 1 0 0 1.0,0 0,0,0,1006,Geller_2007 2-6 months,NA 6-12 yo 9.8,12 NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA,Bryant (2021)_Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Bryant (2021) - Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 474,Bryant (2021),Bryant,2021,10.1007/s00787-022-02004-8 100,  0 100,100 Critically low,Atomoxetine,NA,  0,NA Generalized anxiety Mixed,At study endpoint (closest to 12 weeks) NA,STAI and STAI-C, 1.38089758,   1.3500000 mg/kg Griffiths 2018 NA,RCT (parallel, crossover, open-label) SMD,103,109  212,NA reverse  0.0000000000,-0.270000000, 2.600000e-01   5.7600000,  6.3000000,NA NA NA,NA NA NA 100 100,100 100,100,100,100 low,low,low low,some Placebo   0  21.500000,11.280000,NA DSM,4 1 0.0,0.0,1.0,1.0 0,0,6,1,1 0,0,1.0,0,0,0,0 1007,Griffiths_2018 < 2 months NA 6-12 yo 9.8 12 NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA,Bryant (2021)_Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Bryant (2021) - Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 474 Bryant (2021) Bryant 2021 10.1007/s00787-022-02004-8 100   0 100,100 Critically low,Methylphenidate,NA,  0 NA,Generalized anxiety Mixed,At study endpoint (closest to 12 weeks),NA CBRS, 1.84119678,  36.0000000,mg/d,Lin 2014,NA RCT (parallel, crossover, open-label),SMD, 24  60,  84,NA,reverse, 0.0400000000 -0.440000000  5.100000e-01   8.3100000,  8.0000000,NA NA NA,NA NA,NA,100,100 100 100,100,100,100,low low low low low Placebo   0  29.900000,10.920000 NA,DSM 4,1 0.0,0.0 1.0 1.0,0,0,6 1 1 0 0,1.0 0 0 0 0,1008 Lin_2014,< 2 months NA 6-12 yo 8.8 13.6,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Bryant (2021)_Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Bryant (2021) - Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 474 Bryant (2021) Bryant,2021 10.1007/s00787-022-02004-8,100   0,100,100 Critically low,Atomoxetine NA,  0 NA,Depressive disorder symptoms Mixed,At study endpoint (closest to 12 weeks),NA CDRS-R, 2.07134638,   1.5000000,mg/kg,Bangs,2007,NA,RCT (parallel, crossover, open-label) SMD  59  61, 120,NA reverse -0.1700000000 -0.530000000  1.900000e-01, 13.2600000, 10.4300000 NA,NA NA,NA,NA NA,100,100,100,100,100 100 100 some,low low low,some Placebo,  0, 26.800000,14.400000,NA,DSM 4 1 0.0 0.0 1.0,1.0,0,0,6,1,1,0 0 1.0 0 0 0 0,1009 Bangs_2007,2-6 months NA 13-19 yo,9.8,14.4,NA NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA,Bryant (2021)_Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Bryant (2021) - Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 474 Bryant (2021) Bryant,2021,10.1007/s00787-022-02004-8,100,  0,100,100,Critically low,Atomoxetine,NA   0,NA Depressive disorder symptoms Mixed At study endpoint (closest to 12 weeks),NA,CDRS-R  1.84119678    1.2000000,mg/kg,DellAgnello 2009 NA,RCT (parallel, crossover, open-label) SMD,105  32, 137 NA,reverse,-0.0900000000 -0.480000000, 3.100000e-01,  4.4000000,114.0000000,NA,NA,NA NA NA,NA 100 100,100 100 100 100 100,some,low,low low some,Placebo,  0   7.300000, 9.800000,NA,DSM 4 1,0.0 0.0,1.0 1.0 0 0,6 1,1 0 0,1.0,0 0 0,0 1010 DellAgnello_2009,< 2 months NA 6-12 yo 9.8 14.4,NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA,Bryant (2021)_Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Bryant (2021) - Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 474 Bryant (2021) Bryant,2021,10.1007/s00787-022-02004-8 100,  0,100 100,Critically low,Atomoxetine NA   0,NA Depressive disorder symptoms Mixed,At study endpoint (closest to 12 weeks) NA DASS  1.38089758,   1.3500000,mg/kg Griffiths 2018,NA RCT (parallel, crossover, open-label) SMD,111,114, 225,NA,reverse  0.0300000000 -0.230000000, 2.900000e-01,  4.2300000,  4.1300000 NA,NA NA,NA,NA NA 100 100 100,100 100,100 100,low,low low low some,Placebo   0  21.500000 11.280000 NA DSM,4,1,0.0,0.0 1.0 1.0 0,0 6 1,1,0,0 1.0,0,0,0,0 1011,Griffiths_2018,< 2 months NA,6-12 yo 9.8,14.4,NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA,Bryant (2021)_Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Bryant (2021) - Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 474,Bryant (2021),Bryant,2021 10.1007/s00787-022-02004-8 100,  0 100,100,Critically low Atomoxetine NA   0,NA Depressive disorder symptoms,Mixed At study endpoint (closest to 12 weeks) NA CDRS-R, 1.84119678,   1.1500000 mg/kg Michelson,2001,NA RCT (parallel, crossover, open-label),SMD 209  83  292 NA reverse,-0.3600000000 -0.620000000,-1.000000e-01,  7.3100000,  6.4000000 NA,NA,NA NA,NA,NA,100 100,100 100 100,100 100,some,low low some,some Placebo,  0  28.400000,11.000000 NA DSM 4 1 0.0 0.0,1.0,1.0 0 0 6 1,1 0,0 1.0,0 0 0 0,1012 Michelson_2001 < 2 months,NA 6-12 yo 9.8,14.4,NA NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA,Bryant (2021)_Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Bryant (2021) - Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 662,Chiu (2022),Chiu,2022 10.1192/j.eurpsy.2023.11,100 100,  0 100 High Methylphenidate,MPH IR,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),Questionnaire SWAN total, inattention, hyperactivity/impulsivity  0.92059839,NA NA,Abikoff,2007 NA RCT (parallel, crossover, open-label) G, 46  38   84,NA,NA, 0.2100000000 -0.210000000, 6.400000e-01   0.6900000   0.7000000 NA,NA,NA,NA,NA NA 100,100,100 100,  0 100,100,low,low high,low low NA,  0  25.400000  4.420000, 97.41000 NA,0 1,1.0 1.0,1.0 0.5 1 1 1,1,1,1,1,1.0 0,1 1,1,1013 Abikoff_2007,< 2 months Average (80-119),< 6 yo,4.42,5.25 97.41,97.93 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo  72.14171,serious,low,low
 662 Chiu (2022) Chiu,2022,10.1192/j.eurpsy.2023.11,100 100,100 100,High Methylphenidate MPH IR,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,CLAM/SKAMP composite, SKAMP Attention and SKAMP Deportment  0.23014960   12.3750000 mg/d Greenhill 2006 NA,RCT (parallel, crossover, open-label) G 165,165  330,NA,NA, 0.4300000000  0.210000000, 6.500000e-01,  0.6000000   0.6000000,NA NA,NA NA,NA NA 100 100 100 100,100 100,100 low low,low,low,low Placebo   0  26.000000  4.740000, 97.93000,DSM-IV 0,1,1.0 1.0,1.0 0.5,1 1 1,1,1,1 1 1.0,0 1,1,1 1014 Greenhill_2006 < 2 months,Average (80-119) < 6 yo,4.42,5.25 97.41 97.93,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo  72.14171,serious,low low
 662 Chiu (2022),Chiu,2022 10.1192/j.eurpsy.2023.11,100,  0,  0,100,High,Methylphenidate,MPH-MLR   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,ADHD-RS-IV total score, 0.46029919,  27.5000000,mg/d,Childress,2020 NA RCT (parallel, crossover, open-label) G  39, 50,  89 NA NA, 0.6100000000, 0.180000000, 1.040000e+00  23.0000000, 13.5800000,NA,NA,NA,NA NA,NA 100 100 100,100,100 100 100 some low low,low,low NA   0,NA  4.900000,NA,NA 0,1,1.0,1.0,1.0,0.5,1,1,1 1 1 1 1,1.0,0 1,1,1,1015 Childress_2020 < 2 months,NA < 6 yo 4.42 5.25,97.41 97.93,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo, 72.14171 serious,low low
 662,Chiu (2022),Chiu 2022 10.1192/j.eurpsy.2023.11,100,  0,100 100 High,Methylphenidate,MPH IR   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) Questionnaire CPRS Learning, conduct and hyperactivity index, 0.23014960    0.4000000 mg/kg Musten,1997 NA RCT (parallel, crossover, open-label) G  31  31   62 NA NA  0.7300000000  0.210000000, 1.240000e+00, 15.5700000, 15.2500000 NA,NA,NA,NA,NA,NA,100 100 100 100   0 100 100 some low,high,low,low,Placebo,  0,NA, 4.890000,NA DSM-III-R 0,1 1.0,1.0 1.0,0.5 1,1 1,1,1,1 1,1.0,0,1 1 1 1016,Musten_1997,< 2 months,NA < 6 yo 4.42,5.25,97.41,97.93 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo  72.14171,serious low low
 662,Chiu (2022),Chiu,2022,10.1192/j.eurpsy.2023.11,100   0,100,100 High,Methylphenidate MPH IR or MAS   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),Questionnaire,NA  0.92059839 NA NA Short 2004,NA,RCT (parallel, crossover, open-label),G  28, 28   56,NA,NA  1.3800000000  0.790000000, 1.960000e+00, 12.9500000  14.2300000 NA NA,NA,NA NA NA,100,100,100,100 100 100 100,some low,low low,low Placebo,  0, 15.000000  5.250000,NA,DSM-IV 0 1,1.0 1.0 1.0,0.5 1,1 1 1,1,1,1 1.0,0 1 1 1 1017 Short_2004 < 2 months NA < 6 yo,4.42,5.25,97.41 97.93 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo  72.14171,serious low low
 662 Chiu (2022) Chiu,2022,10.1192/j.eurpsy.2023.11,100 100,100 100,High Methylphenidate MPH IR   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks),Questionnaire,CLAM/SKAMP composite, SKAMP Attention and SKAMP Deportment  0.23014960   12.3750000,mg/d Greenhill 2006,NA,RCT (parallel, crossover, open-label),G,165,165, 330,NA NA, 0.1600000000,-0.060000000, 3.700000e-01,  0.7200000   0.6700000,NA,NA,NA,NA NA,NA 100 100,100 100 100,100,100,low,low,low,low,low,Placebo,  0  26.000000  4.740000  97.93000,DSM-IV,0,1,1.0,1.0,1.0,0.5 1 1,1,1 1,1 1 1.0,0,1 1 1,1018,Greenhill_2006 < 2 months Average (80-119),< 6 yo 4.42 6.13 60,102,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_< 6 yo, 87.83270 no,low,low
 662,Chiu (2022),Chiu,2022,10.1192/j.eurpsy.2023.11 100 100,  0 100 High,Methylphenidate MPH IR,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks) Questionnaire,SWAN total, inattention, hyperactivity/impulsivity  0.92059839 NA,NA,Abikoff,2007,NA,RCT (parallel, crossover, open-label),G  32, 32,  64,NA,NA  0.3200000000,-0.180000000  8.100000e-01   0.7200000   0.7800000 NA NA NA,NA NA NA 100 100,100 100,  0 100 100,low low high,low,low NA   0  25.400000  4.420000  97.41000,NA,0,1,1.0,1.0 1.0,0.5,1,1 1 1 1,1 1,1.0 0 1,1 1 1019,Abikoff_2007 < 2 months,Average (80-119),< 6 yo,4.42,6.13 60 102,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_< 6 yo  87.83270,no low low
 662 Chiu (2022),Chiu 2022 10.1192/j.eurpsy.2023.11,100,  0 100,100 High Methylphenidate MPH IR or MAS,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks),Questionnaire,NA  0.92059839,NA,NA Short 2004 NA RCT (parallel, crossover, open-label) G, 19  19,  38,NA NA  0.8400000000, 0.170000000, 1.510000e+00,  6.7000000   7.5000000,NA,NA,NA NA NA,NA 100 100,100 100 100 100,100,some,low,low low,low Placebo   0  15.000000, 5.250000,NA,DSM-IV 0 1 1.0 1.0,1.0 0.5,1,1 1 1,1,1 1,1.0,0,1,1,1,1020,Short_2004 < 2 months,NA < 6 yo 4.42 6.13,60,102 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_< 6 yo  87.83270 no low low
 662,Chiu (2022) Chiu 2022,10.1192/j.eurpsy.2023.11 100 100,100 100,High,Methylphenidate,MPH IR,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),Questionnaire NA, 0.69044879,   0.4500000,mg/kg Handen 1999,NA,RCT (parallel, crossover, open-label) G  11, 11   22 NA NA, 1.1700000000  0.250000000  2.080000e+00   4.1200000   3.9600000 NA NA,NA,NA,NA NA 100 100 100,100,100,100,100,some low low low low Placebo   0  18.100000  4.910000  60.00000 DSM-III-R 0,1,1.0 1.0,1.0,0.5 1,1 1,1,1,1,1,1.0,0,1,1 1 1021,Handen_1999,< 2 months,Low (< 70) < 6 yo 4.42 6.13 60 102,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_< 6 yo, 87.83270,no,low,low
 662 Chiu (2022),Chiu 2022,10.1192/j.eurpsy.2023.11 100 100,100 100,High Methylphenidate MPH IR   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks) Observational tool,point system - Percentage following activity rules, 1.38089758,   0.4500000 mg/kg,Chaco,2004,NA,RCT (parallel, crossover, open-label),G, 36  36   72 NA NA  1.1700000000  0.670000000  1.670000e+00  12.5500000  18.0300000 NA,NA NA,NA NA NA 100,100,100,100,100,100,100,some low some low,low Placebo,  0  11.000000  6.130000 102.00000,DSM-llI-R or DSM-IV,0 1,1.0,1.0,1.0,0.5,1 1,1 1 1,1,1,1.0,0,1 1,1 1022 Chaco_2004,< 2 months,Average (80-119) 6-12 yo,4.42 6.13,60 102,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_< 6 yo  87.83270,no,low,low
8993 Maji (2024.0),Maji 2024,10.1016/j.jpsychires.2024.06.048 100,  0 100 100,Critically low,Centafanadine,NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks),Questionnaire AISRS (modified ADHD-RS)  1.38089758, 200.0000000 mg/d,Adler,2022.0 200mg,RCT (parallel, crossover, open-label),SMD,147 144  291,outcomes reverse -0.2254862000,-0.484004000  3.303171e-02, 11.8800000, 11.7600000,NA,NA NA NA,NA NA 100 100 100,100 100 100,100 low low,low low low,Placebo,  0  49.053608,35.808247,NA DSM-V,5 0,0.0,0.0 1.0,0.0 0 1,2,1 1 1,1,0.5,0 1,0 1 1023,Adler_2022.0,< 2 months NA,>= 20 yo,35.1494661921708,38,NA,NA,  2  1,Combined ADHD symptoms (inattentive + hyperactive/impulsive)  1,Maji (2024.0),35.1494661921708 38 NA,NA,Maji (2024.0)_Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Maji (2024.0) - Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
8993,Maji (2024.0),Maji 2024,10.1016/j.jpsychires.2024.06.048,100,  0,100 100,Critically low Centafanadine NA,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) Questionnaire,AISRS (modified ADHD-RS), 1.38089758  400.0000000 mg/d,Adler 2022.0 400mg RCT (parallel, crossover, open-label),SMD,140,141  281,outcomes reverse,-0.3434915000 -0.622938300,-6.404464e-02  11.7100000  11.1600000,NA,NA,NA,NA,NA NA 100 100,100,100 100,100,100,low low,low low low,Placebo,  0  48.401068,35.149466 NA,DSM-V,5 0,0.0 0.0 1.0 0.0,0 1,2,1,1 1 1,0.5,0,1 0,1 1024 Adler_2022.0 < 2 months NA,>= 20 yo,35.1494661921708 38,NA,NA,  2  1,Combined ADHD symptoms (inattentive + hyperactive/impulsive), 1,Maji (2024.0),35.1494661921708,38 NA NA,Maji (2024.0)_Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Maji (2024.0) - Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
8993,Maji (2024.0),Maji 2024 10.1016/j.jpsychires.2024.06.048 100,  0,100,100,Critically low Centafanadine NA,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks),Questionnaire,ADHD-RS-IV  0.69044879 NA,NA Wigal,2020.0,NA RCT (parallel, crossover, open-label) SMD  79, 74, 153 NA,reverse -0.6595719000 -1.073295000 -2.458487e-01, 11.3400000, 10.5600000,NA,NA NA,NA,NA,NA,100 100,100,100 100 100,100,some low low,low,low Placebo   0  44.000000 38.000000,NA,DSM-IV 5,0,0.0,0.0 1.0 0.0 0 1,2 1 1 1 1,0.5 0 1 0 1 1025 Wigal_2020.0,< 2 months,NA,>= 20 yo,35.1494661921708,38 NA,NA   2  1 Combined ADHD symptoms (inattentive + hyperactive/impulsive)  1 Maji (2024.0),35.1494661921708,38 NA,NA,Maji (2024.0)_Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Maji (2024.0) - Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
9001,Liang (2024),Liang,2024 10.1192/bjo.2023.645 100,  0,100,100 Moderate,Probiotics Probiotics,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks) NA,ADHD rating scale  2.76179517,NA,NA,Kumperscak,2020,NA,RCT (parallel, crossover, open-label) SMD, 18  14,  32 NA,NA,-0.0200000000 -0.720000000  6.800000e-01   8.7000000, 11.2000000,NA NA,NA,NA,NA NA 100,100 100 100,100,100 100,some low low,low low,Placebo   0, 28.130000,11.880000 NA NA 0,1 1.0,1.0 1.0 1.0,1,1,3 1,1,0,1,0.5,0,0,1 1,1026 Kumperscak_2020,2-6 months NA 6-12 yo 8.8 12,NA NA,  5, 2,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation, 1,Liang (2024),8.8,12 NA,NA,Liang (2024)_Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Liang (2024) - Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
9001,Liang (2024) Liang,2024 10.1192/bjo.2023.645 100   0,100 100,Moderate,Probiotics Probiotics,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks) NA SNAP  2.07134638,NA NA,Skott,2020,NA RCT (parallel, crossover, open-label) SMD  42, 26,  68 NA,NA  0.2000000000 -0.290000000  6.900000e-01,  0.3200000   0.3600000 NA NA,NA NA NA NA,100 100,100,100,  0,100 100 some,low,high,low,low Placebo,  0, 26.500000 12.000000,NA NA,0,1,1.0,1.0,1.0 1.0,1 1 3 1,1 0 1 0.5 0,0 1,1 1027 Skott_2020 2-6 months NA,6-12 yo 8.8,12,NA,NA   5, 2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation  1,Liang (2024),8.8,12 NA NA,Liang (2024)_Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Liang (2024) - Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
9001,Liang (2024) Liang 2024,10.1192/bjo.2023.645 100   0 100 100 Moderate Probiotics,Probiotics   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks) NA DBD, 0.92059839,NA,NA,Bazinet,2017 NA RCT (parallel, crossover, open-label) SMD  25  23,  48 NA NA, 0.0300000000,-0.540000000, 6.000000e-01,  8.9000000, 10.7000000 NA NA,NA NA,NA,NA 100,100,100 100 100 100 100,low low,low,low low,Placebo,  0, 27.100000  9.750000 NA,NA 0,1,1.0,1.0,1.0,1.0 1 1 3,1,1 0,1 0.5,0 0,1 1,1028,Bazinet_2017,< 2 months NA,6-12 yo,8.8,12 NA NA,  5, 2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation  1,Liang (2024),8.8 12,NA,NA,Liang (2024)_Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Liang (2024) - Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
9001,Liang (2024) Liang 2024,10.1192/bjo.2023.645,100,  0 100,100 Moderate Probiotics,Probiotics 100 aug Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks),NA CPRS-r: total, 1.84119678,NA,NA Ghanaatgar,2022,NA,RCT (parallel, crossover, open-label) SMD, 21  17   38 NA NA  1.3800000000  0.660000000  2.100000e+00  13.7100000  15.7500000,NA NA NA,NA NA,NA,100 100,100 100   0 100,100 low,low high,low,low,Active (any credible active intervention),100  31.600000, 8.800000,NA NA,0 1,1.0 1.0 1.0,1.0 1,1,3 1 1,0 1 0.5,0,0 1 1 1029 Ghanaatgar_2022,< 2 months,NA,6-12 yo 8.8,12,NA,NA,  5  2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation  1 Liang (2024),8.8,12,NA NA,Liang (2024)_Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Liang (2024) - Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
9001 Liang (2024),Liang,2024 10.1192/bjo.2023.645 100,  0,100 100,Moderate Probiotics,Probiotics,100 aug,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks) NA,ADHD rating scale, 1.84119678 NA NA,Sepehrmanesh 2021,NA,RCT (parallel, crossover, open-label) SMD, 17, 17,  34,NA,NA, 0.3100000000,-0.370000000  9.900000e-01  10.9500000   7.6000000,NA,NA,NA NA,NA,NA 100 100 100 100,100 100 100 low low,low low,low Active (any credible active intervention) 100, 20.600000  9.100000 NA,NA 0 1,1.0 1.0 1.0,1.0 1,1,3,1 1 0,1 0.5,0,0 1,1,1030 Sepehrmanesh_2021,< 2 months,NA 6-12 yo,8.8 12,NA NA,  5, 2,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation, 1 Liang (2024) 8.8,12,NA,NA Liang (2024)_Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Liang (2024) - Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
9001 Liang (2024) Liang,2024 10.1192/bjo.2023.645 100   0,100 100,Moderate Probiotics,Probiotics   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA NA, 2.76179517,NA,NA Kumperscak,2020,NA RCT (parallel, crossover, open-label),RR  21, 14,  35 NA,reverse, 0.6818181818, 0.014298633, 3.251192e+01,NA,NA,NA NA NA,NA,NA,NA 100,100 100,100,100,100 100,some low,low low,low Placebo,  0  28.130000 11.880000,NA NA,0,1,1.0,1.0,1.0 1.0 1 1 3 1 1,0,1,0.5,0 0 1,1 1031,Kumperscak_2020,2-6 months NA,6-12 yo,8.8,12,NA,NA,  5  2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation, 1 Liang (2024),8.8,12,NA NA Liang (2024)_Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Liang (2024) - Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
9001 Liang (2024),Liang 2024 10.1192/bjo.2023.645 100,  0,100 100 Moderate Probiotics,Probiotics   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA NA  2.07134638 NA NA,Skott,2020 NA,RCT (parallel, crossover, open-label) RR, 65, 34   99 NA,reverse, 1.7186813187, 0.822165218  3.592788e+00,NA NA NA,NA NA,NA,NA NA 100 100 100,100   0 100 100,some,low,high,low,low Placebo,  0  26.500000 12.000000,NA,NA,0 1 1.0,1.0 1.0,1.0 1 1,3 1,1 0,1,0.5,0,0,1,1,1032,Skott_2020 2-6 months NA,6-12 yo,8.8 12 NA NA,  5, 2,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation, 1 Liang (2024),8.8 12,NA,NA,Liang (2024)_Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Liang (2024) - Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
9001 Liang (2024),Liang 2024 10.1192/bjo.2023.645,100   0 100 100,Moderate,Probiotics,Probiotics 100,aug Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA NA  1.84119678 NA NA Ghanaatgar,2022,NA RCT (parallel, crossover, open-label),RR  25  25   50 NA reverse  0.5000000000, 0.172444453, 1.449742e+00 NA NA,NA,NA,NA,NA,NA,NA 100 100 100,100,  0,100,100,low low,high low,low,Active (any credible active intervention),100  31.600000  8.800000 NA NA,0 1,1.0 1.0 1.0 1.0 1 1 3 1 1,0 1 0.5 0,0 1 1,1033,Ghanaatgar_2022 < 2 months,NA,6-12 yo,8.8,12 NA,NA,  5, 2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation  1 Liang (2024),8.8,12 NA NA Liang (2024)_Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Liang (2024) - Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
9001 Liang (2024) Liang,2024 10.1192/bjo.2023.645,100,  0 100 100,Moderate,Probiotics Probiotics,100,aug,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,NA, 1.84119678,NA NA,Sepehrmanesh 2021 NA,RCT (parallel, crossover, open-label),RR  20, 20   40 NA,reverse  1.0000000000  0.228685567  4.372816e+00 NA NA,NA,NA,NA,NA NA NA,100 100,100,100,100 100 100 low,low low,low low,Active (any credible active intervention),100  20.600000, 9.100000,NA,NA,0,1 1.0,1.0,1.0 1.0,1,1,3,1,1,0 1,0.5 0 0 1 1,1034,Sepehrmanesh_2021,< 2 months,NA,6-12 yo,8.8 12,NA NA,  5  2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation  1 Liang (2024) 8.8 12,NA NA Liang (2024)_Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Liang (2024) - Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0 100,100 High Amphetamine,Amphetamine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA ADHD-SRS total  0.92059839   30.0000000,mg/d,Weisler,2006,NA,RCT,G 128  60  188 outcomes,reverse,-0.6520000000,-0.966000000,-3.370000e-01  12.0000000  12.2400000,NA NA,NA,NA NA NA,100,100 100 100,  0,100,100 low low,high low,low Placebo,  0  36.425532,39.027660 NA NA 0,1,1.0,1.0,1.0,1.0 1 1,1 1,1,1,1,1.0,0,1 1 1,1035 Weisler_2006 < 2 months,NA >= 20 yo,22.2059016393443 39.0276595744681,NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA NA,Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100 100 High Amphetamine,Amphetamine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) NA,CAARS-S:S, 0.92059839,  30.0000000 mg/d Weisler 2006 NA,RCT,G,119  58, 177,outcomes,reverse,-0.4800000000,-0.798000000 -1.610000e-01,  7.0000000   7.3680000,NA NA NA NA NA,NA,100 100,100 100,  0 100 100,low,low high low,low,Placebo   0  36.370056,39.031073,NA,NA,0 1 1.0,1.0 1.0 1.0,1 1,1 1,1,1,1 1.0 0,1 1,1 1036 Weisler_2006 < 2 months,NA >= 20 yo,39.0310734463277 41.2 NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100,100 High,Amphetamine,Amphetamine   0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability  0.92059839   30.0000000,mg/d,Weisler 2006,NA RCT,RR,130, 64  194 outcomes reverse  0.7610000000  0.488000000, 1.187000e+00 NA,NA,NA NA,NA NA NA NA,100 100,100,100,100,100 100,low,low,low low low Placebo   0, 36.355670,39.031959,NA NA,0,1 1.0,1.0,1.0,1.0 1,1 1 1 1 1 1 1.0,0,1,1,1 1037 Weisler_2006 < 2 months,NA >= 20 yo 22.2057971014493,39.0319587628866 NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100,High Amphetamine Amphetamine,  0 NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability, 0.92059839,  30.0000000 mg/d,Weisler 2006 NA RCT RR,130  64  194 outcomes reverse, 7.3850000000  0.997000000, 5.467400e+01 NA,NA NA,NA,NA NA,NA NA 100 100 100,100 100 100,100,low,low,low low,low Placebo,  0  36.355670,39.031959,NA NA 0 1 1.0 1.0,1.0 1.0,1,1,1 1 1,1,1 1.0,0 1 1,1 1038 Weisler_2006 < 2 months NA,>= 20 yo,22.2057971014493 39.0319587628866 NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA,Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100 100 High Methylphenidate Methylphenidate   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA Other, 0.46029919,  43.0701754,mg/d,Wender 2011,NA,RCT G  57  57  114,outcomes reverse,-0.9020000000,-1.289000000 -5.150000e-01   2.4985912   2.5355874 NA,NA,NA,NA,NA,NA,100 100,100,100,100,100 100,low some,some,low low Placebo,  0  28.000000 36.900000 NA,NA,0,1,1.0,1.0 1.0,1.0,1 1 1,1,1 1 1 1.0,0,1,1 1 1039 Wender_2011,< 2 months NA,>= 20 yo,30.6,40 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100,High,Methylphenidate,Methylphenidate,  0,NA,Emotional dysregulation,Mixed,At study endpoint (closest to 12 weeks),NA WRAADDS  0.46029919   43.0701754,mg/d Wender,2011,NA,RCT,G, 57, 57, 114 outcomes,reverse -0.9140000000 -1.301000000,-5.260000e-01   2.5000000,  2.5000000,NA NA NA NA NA NA,100 100,100,100,100 100,100,low,some some,low low,Placebo   0, 28.000000 36.900000 NA NA 0,1 1.0,1.0,1.0,1.0 1,1,1,1,1,1 1 1.0,0 1,1 1,1040,Wender_2011 < 2 months NA,>= 20 yo 34.0471698113208,36.9 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100,100,High Methylphenidate,Methylphenidate,  0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability  0.46029919   43.0701754,mg/d,Wender 2011,NA,RCT RR  59, 57  116 outcomes,reverse, 0.9670000000  0.020000000  4.791200e+01 NA,NA NA NA NA NA,NA NA 100 100 100 100 100 100 100,low some low low low,Placebo,  0  28.000000,36.900000 NA,NA,0,1 1.0,1.0,1.0,1.0,1 1 1,1,1 1 1 1.0 0,1,1 1 1041 Wender_2011,< 2 months NA,>= 20 yo,28.7959183673469,40,NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100 High,Methylphenidate Methylphenidate,  0 NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability, 0.46029919   43.0701754 mg/d Wender,2011,NA RCT,RR, 59  57, 116 outcomes reverse  0.9670000000  0.020000000, 4.791200e+01,NA NA,NA,NA NA NA,NA NA,100,100 100 100 100 100 100 low,some low low low Placebo,  0  28.000000,36.900000 NA NA,0,1,1.0,1.0,1.0,1.0 1,1 1,1,1 1 1 1.0 0 1 1 1 1042 Wender_2011,< 2 months,NA,>= 20 yo,28.7959183673469 40 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0 100,100 High,Bupropion Bupropion,  0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 1.38089758, 362.0000000,mg/d,Wilens 2001,NA RCT RR  21  19   40,outcomes,reverse, 4.5450000000  0.232000000, 8.907700e+01,NA,NA,NA,NA NA,NA,NA,NA,100,100,100,100 100 100 100,some some,low,low low,Placebo,  0, 44.900000,38.235000 NA,NA,0 1 1.0,1.0 1.0,1.0 1 1,1 1,1 1 1,1.0,0,1 1,1 1043,Wilens_2001 < 2 months,NA,>= 20 yo,34.4220338983051,38.235 NA NA, 10, 7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5 40.25 NA NA Ostinelli (2025)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High Bupropion Bupropion,  0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 1.38089758, 362.0000000 mg/d Wilens,2001 NA RCT RR, 21, 19   40 outcomes reverse, 0.9090000000  0.019000000  4.370900e+01 NA,NA NA,NA NA NA NA NA 100,100 100,100,100,100 100 some some low low low,Placebo,  0, 44.900000 38.235000 NA,NA 0 1 1.0 1.0 1.0 1.0 1 1 1,1,1,1 1,1.0 0,1 1,1 1044,Wilens_2001,< 2 months NA >= 20 yo 34.4220338983051,38.235,NA NA, 10  7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5 40.25 NA NA Ostinelli (2025)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100 High,Atomoxetine,Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA CAARS-INV:SV  5.52359033   90.3000000,mg/d Young 2011 NA RCT,G,264 232  496 outcomes reverse -0.3780000000 -0.596000000,-1.590000e-01 NA NA,NA NA,NA NA 11.1000000,11.1000000 100,100 100,100   0,100 100,low,low,high,low,low,Placebo   0, 52.408065 41.293548,NA NA,0,1 1.0 1.0,1.0,1.0,1,1 1,1,1,1 1 1.0,0 1 1 1 1045 Young_2011 2-6 months,NA >= 20 yo,24.7 42.1 NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100,100,High Atomoxetine,Atomoxetine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At follow-up (closest to 26 weeks) NA,CAARS-O:L, 5.52359033   90.3000000,mg/d,Young 2011 NA,RCT,G 264,232, 496,outcomes,reverse -0.4560000000 -0.672000000 -2.410000e-01 NA NA,NA,NA NA NA,11.0000000 11.0000000 100 100,100,100   0,100,100 low low high low low Placebo   0, 52.408065 41.293548 NA,NA,0,1 1.0 1.0 1.0 1.0 1,1 1 1,1,1,1 1.0,0,1 1,1,1046 Young_2011,2-6 months,NA,>= 20 yo 36.6921768707483,41.2935483870968 NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100 100 High,Atomoxetine,Atomoxetine,  0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability  5.52359033   90.3000000 mg/d,Young 2011 NA RCT,RR 268 234  502,outcomes reverse  1.3010000000  1.084000000, 1.562000e+00,NA,NA,NA NA,NA NA NA,NA 100 100 100 100 100,100 100,low low low low low Placebo,  0  52.396016 41.293227 NA,NA 0,1,1.0,1.0,1.0,1.0,1 1 1 1 1 1 1,1.0 0 1 1,1,1047 Young_2011,2-6 months,NA >= 20 yo 24.7 42.10703125 NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100,High,Atomoxetine,Atomoxetine   0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability, 5.52359033   90.3000000 mg/d Young,2011 NA RCT,RR 268,234, 502 outcomes,reverse  2.2620000000, 1.429000000  3.582000e+00,NA NA,NA,NA,NA,NA NA,NA 100 100,100 100 100 100 100,low low,low low,low,Placebo,  0, 52.396016 41.293227,NA NA,0,1 1.0 1.0,1.0,1.0,1 1 1 1,1 1,1 1.0 0,1,1 1,1048,Young_2011,2-6 months,NA >= 20 yo 24.7 42.10703125,NA NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100 100 High,Atomoxetine,Atomoxetine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA ADHD-SRS total, 2.76179517   89.9000000,mg/d Wilens,2008 NA RCT,G  72  75, 147 outcomes,reverse -0.4600000000,-0.854000000 -6.500000e-02 NA,NA NA NA,NA NA 11.4000000,11.4000000,100 100,100 100   0,100 100,low low,high low some Placebo   0, 14.993878 34.555102,NA NA 0,1,1.0,1.0 1.0 1.0,1 1,1 1 1 1 1 1.0,0,1 1 1 1049 Wilens_2008,2-6 months NA,>= 20 yo 24.7,42.1,NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100 100,High Atomoxetine Atomoxetine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) NA ASRS  2.76179517   89.9000000 mg/d,Wilens,2008 NA,RCT G, 72  75  147,outcomes,reverse -0.3600000000 -0.737000000  1.600000e-02 NA,NA,NA NA,NA,NA 12.9000000,12.9000000 100 100 100,100,  0,100,100,low,low,high low,some Placebo,  0, 14.993878 34.555102,NA,NA 0 1,1.0,1.0,1.0 1.0,1 1 1,1 1,1 1,1.0,0 1,1,1 1050 Wilens_2008 2-6 months NA >= 20 yo,24.7 42.1,NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100 100,High Atomoxetine Atomoxetine   0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability  2.76179517,  89.9000000 mg/d,Wilens,2008 NA,RCT,RR  72, 75, 147,outcomes,reverse  1.5430000000, 1.071000000  2.225000e+00,NA NA,NA,NA,NA NA NA,NA,100 100,100 100 100,100 100 low,low,low low,low,Placebo   0  14.993878 34.555102,NA,NA,0,1 1.0 1.0 1.0 1.0,1 1 1 1 1,1 1 1.0 0 1 1,1,1051,Wilens_2008 2-6 months,NA,>= 20 yo,24.7 42.10703125 NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100,100,High Atomoxetine,Atomoxetine   0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 2.76179517,  89.9000000 mg/d,Wilens 2008,NA,RCT RR  72  75, 147,outcomes,reverse, 3.6460000000, 0.783000000, 1.697000e+01 NA NA NA NA NA NA,NA,NA,100 100 100,100,100,100,100,low low low,low,low Placebo   0  14.993878 34.555102,NA,NA,0,1,1.0,1.0,1.0 1.0,1 1,1,1,1,1 1 1.0,0 1 1 1,1052 Wilens_2008,2-6 months,NA,>= 20 yo,24.7,42.10703125,NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0,100,100,High Methylphenidate Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA ADHD-RS total  2.53164557 NA,NA,Winhusen 2010 NA,RCT,G,107 108  215 outcomes,reverse,-0.5970000000 -0.871000000 -3.230000e-01  11.7600000, 12.3900000 NA,NA NA,NA,NA NA 100,100 100 100,100 100 100,low low low low,low Placebo   0  43.569302 37.798605,NA NA,0 1,1.0,1.0,1.0,1.0,1 1,1 1 1,1 1 1.0 0 1,1 1 1053,Winhusen_2010,2-6 months,NA,>= 20 yo 30.6 40 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100 High Methylphenidate Methylphenidate,  0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability, 2.53164557,NA,NA Winhusen,2010,NA,RCT RR,127 128  255 outcomes,reverse, 1.0080000000, 0.570000000  1.781000e+00 NA NA NA,NA NA,NA,NA,NA 100 100,100 100 100,100,100 low,low low,low low,Placebo   0  43.566275,37.798824,NA NA,0 1 1.0 1.0,1.0,1.0 1,1 1 1 1 1,1 1.0,0 1,1,1 1054,Winhusen_2010,2-6 months,NA,>= 20 yo 28.7959183673469,40,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100,100,High Methylphenidate Methylphenidate,  0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA Tolerability  2.53164557 NA NA Winhusen 2010,NA RCT RR 127 128  255,outcomes,reverse  1.0080000000  0.020000000, 5.040400e+01 NA,NA NA NA NA,NA NA NA 100 100,100 100,100,100 100,low low,low,low,low,Placebo   0  43.566275,37.798824 NA NA 0,1,1.0 1.0 1.0 1.0,1 1,1 1,1 1 1,1.0 0,1,1,1 1055 Winhusen_2010,2-6 months,NA,>= 20 yo,28.7959183673469,40 NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100 High Atomoxetine Atomoxetine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,CAARS-INV:SV, 3.22209436,  82.9000000,mg/d Adler,2009,NA RCT G 209 204, 413,outcomes,reverse,-0.4330000000,-0.628000000 -2.370000e-01  11.2500000, 10.5600000 NA NA,NA,NA,NA,NA,100,100 100,100,  0,100 100,low,low high low,low,Placebo   0, 46.384649,37.988668 NA,NA,0 1 1.0,1.0,1.0 1.0,1,1,1 1 1 1,1,1.0,0,1,1,1,1056,Adler_2009,2-6 months NA >= 20 yo,24.7,42.1,NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100 High Atomoxetine Atomoxetine   0 NA Quality of life (patients),Mixed,At study endpoint (closest to 12 weeks) NA AAQoL, 3.22209436,  82.9000000 mg/d Adler 2009 NA RCT G 127,137  264,outcomes reverse  0.1550000000,-0.087000000, 3.970000e-01, 18.3000000, 16.5000000,NA NA NA NA NA,NA 100 100,100,100   0,100 100 low low high low,low Placebo,  0, 46.427386,37.994167,NA,NA,0 1 1.0 1.0,1.0 1.0,1,1 1 1,1,1,1 1.0,0 1,1,1,1057,Adler_2009,2-6 months NA,>= 20 yo 24.7,37.9941666666667 NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100 100,High,Atomoxetine,Atomoxetine,  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,Acceptability, 3.22209436,  82.9000000 mg/d Adler,2009 NA,RCT,RR 224,218  442 outcomes,reverse, 1.1650000000, 0.927000000, 1.465000e+00,NA,NA NA NA NA NA NA NA,100,100,100 100,100,100,100,low,low low,low low Placebo   0, 46.383394 37.988507 NA,NA,0 1 1.0 1.0,1.0 1.0 1 1 1,1,1 1 1 1.0 0 1 1,1,1058 Adler_2009 2-6 months,NA >= 20 yo 24.7,42.10703125,NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0,100 100,High,Atomoxetine Atomoxetine,  0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA Tolerability  3.22209436,  82.9000000,mg/d,Adler,2009,NA,RCT,RR,224,218  442 outcomes reverse, 1.2440000000, 0.691000000  2.239000e+00 NA,NA NA,NA,NA NA NA NA,100,100 100 100 100 100 100 low,low,low low low,Placebo   0  46.383394,37.988507,NA,NA 0 1 1.0 1.0,1.0,1.0 1 1,1,1,1,1,1,1.0 0 1 1,1,1059 Adler_2009 2-6 months NA,>= 20 yo 24.7,42.10703125 NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100,100 High,Atomoxetine Atomoxetine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At follow-up (closest to 26 weeks),NA,CAARS-INV:SV  5.98388953   85.2000000 mg/d Adler 2008,NA,RCT G,185,109, 294 outcomes,reverse,-0.0740000000,-0.360000000  2.110000e-01,NA NA,NA,NA,NA,NA 12.3100000 12.3100000 100 100,100 100 100,100,100 low,low low,low,low,Placebo   0, 41.230612 36.692177,NA,NA,0 1 1.0,1.0,1.0 1.0,1 1 1 1 1,1 1 1.0 0,1 1 1 1060 Adler_2008 2-6 months NA,>= 20 yo,36.6921768707483,41.2935483870968 NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100,100,High,Atomoxetine Atomoxetine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks),NA,CAARS-S:S, 5.98388953,  85.2000000,mg/d,Adler 2008 NA,RCT G,251 134, 385 outcomes,reverse,-0.2980000000 -0.509000000,-8.700000e-02,  9.8226473   9.4921863,NA NA NA,NA,NA NA,100,100,100,100,100 100 100,low,low,low,low,low Placebo,  0  41.394026,36.717143,NA,NA 0 1,1.0,1.0,1.0 1.0,1 1 1 1,1 1,1,1.0,0,1 1,1,1061,Adler_2008,2-6 months NA,>= 20 yo 24.7 42.1,NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0 100,100,High,Atomoxetine,Atomoxetine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At follow-up (closest to 26 weeks),NA CAARS-S:S  5.98388953   85.2000000 mg/d,Adler,2008,NA,RCT,G,251,134, 385,outcomes,reverse,-0.2710000000 -0.482000000 -6.000000e-02  10.2000000, 10.3200000,NA NA NA NA NA,NA 100,100,100,100,100,100 100 low,low low low low Placebo   0  41.394026 36.717143,NA,NA 0 1,1.0 1.0,1.0,1.0,1 1 1,1 1 1 1,1.0 0 1 1,1 1062,Adler_2008,2-6 months NA >= 20 yo,36.7171428571429,37.5691375770021 NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),1,Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100,High,Atomoxetine Atomoxetine,  0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability, 5.98388953,  85.2000000,mg/d,Adler 2008,NA RCT,RR 271 139  410,outcomes reverse  1.2060000000  1.000000000  1.456000e+00,NA,NA NA NA,NA,NA NA,NA,100,100,100 100 100,100,100,low low low low,low Placebo   0  41.459024,36.727073 NA NA,0,1 1.0 1.0 1.0,1.0 1 1,1,1 1 1,1,1.0,0 1,1 1 1063 Adler_2008 2-6 months,NA,>= 20 yo 24.7 42.10703125 NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0 100,100 High Atomoxetine Atomoxetine   0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 5.98388953,  85.2000000,mg/d,Adler,2008 NA RCT RR 271 139  410,outcomes reverse, 6.4970000000  2.042000000, 2.067300e+01,NA,NA NA NA NA,NA NA NA 100 100 100 100,100,100,100 low low,low,low,low Placebo   0  41.459024,36.727073 NA,NA,0 1,1.0 1.0 1.0 1.0,1,1 1 1,1 1,1,1.0 0,1 1,1,1064 Adler_2008 2-6 months,NA >= 20 yo,24.7 42.10703125,NA NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100,High Amphetamine,Amphetamine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,ADHD-RS total  0.92059839,  50.0000000,mg/d,Adler,2008 NA,RCT G,352, 62, 414 outcomes,reverse -0.1620000000,-0.466000000  1.410000e-01 NA NA NA,NA NA,NA,11.2598313,11.2598313 100 100,100,100,100 100 100,low,low low low low Placebo   0  45.449275,35.114976,NA NA 0,1 1.0,1.0,1.0,1.0,1,1,1 1,1 1,1,1.0 0 1,1,1 1065,Adler_2008 < 2 months NA,>= 20 yo 22.2059016393443,39.0276595744681,NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0 100 100 High Amphetamine Amphetamine   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability  0.92059839   50.0000000,mg/d Adler 2008 NA RCT RR 358  62  420 outcomes,reverse, 1.0560000000  0.573000000, 1.948000e+00 NA NA NA NA NA,NA NA NA 100 100,100,100,100 100 100,low low low low low Placebo   0, 45.442857 35.114762 NA NA,0,1,1.0,1.0 1.0,1.0 1,1 1 1 1,1 1 1.0,0 1,1 1 1066,Adler_2008 < 2 months,NA,>= 20 yo,22.2057971014493 39.0319587628866 NA,NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0,100 100 High,Amphetamine,Amphetamine,  0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,Tolerability  0.92059839   50.0000000 mg/d Adler 2008,NA,RCT,RR,358, 62  420,outcomes,reverse  3.6370000000, 0.498000000  2.655000e+01 NA NA,NA,NA NA,NA,NA NA 100,100,100 100,100 100 100,low,low low low,low Placebo,  0, 45.442857,35.114762 NA NA,0,1,1.0 1.0 1.0,1.0 1 1 1 1 1,1,1,1.0,0,1,1 1,1067,Adler_2008,< 2 months,NA >= 20 yo,22.2057971014493,39.0319587628866 NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA,Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100,High,Amphetamine,Amphetamine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,ADHD-SRS total  2.30149597,  56.9000000,mg/d,Adler 2013,NA,RCT,G, 79  75  154 outcomes,reverse,-0.9130000000 -1.355000000,-4.710000e-01 NA,NA,NA,NA NA,NA,11.9511506 11.9511506,100,100 100,100 100 100 100,low low,some,low,low,Placebo,  0  47.841558,34.540909,NA,NA 0 1,1.0 1.0,1.0 1.0,1 1,1 1,1,1 1 1.0 0,1 1,1 1068 Adler_2013 2-6 months NA >= 20 yo,22.2059016393443,39.0276595744681,NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100 High,Amphetamine,Amphetamine,  0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,Acceptability  2.30149597   56.9000000,mg/d Adler 2013,NA RCT RR, 80  81  161,outcomes,reverse  0.6510000000  0.393000000  1.079000e+00,NA NA,NA NA,NA,NA NA,NA 100,100 100,100 100 100 100 low,low,low low low Placebo   0  47.790062 34.552174 NA,NA 0,1 1.0,1.0,1.0 1.0 1 1 1 1 1 1,1,1.0 0 1,1,1,1069,Adler_2013,2-6 months NA >= 20 yo 22.2057971014493,39.0319587628866,NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA,Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0,100 100,High,Amphetamine,Amphetamine   0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability, 2.30149597,  56.9000000,mg/d Adler 2013 NA RCT RR, 80, 81, 161 outcomes,reverse  3.0380000000, 0.632000000, 1.460300e+01,NA,NA,NA,NA,NA NA,NA,NA,100 100 100,100,100,100,100,low low low low low Placebo   0, 47.790062 34.552174 NA,NA 0 1,1.0 1.0 1.0 1.0,1 1 1,1 1,1,1,1.0 0 1 1 1,1070,Adler_2013 2-6 months NA,>= 20 yo,22.2057971014493,39.0319587628866,NA NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Atomoxetine,Atomoxetine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA Other  5.98388953   84.5000000,mg/d Adler,2009 NA RCT,G,191 197  388,outcomes,reverse,-0.4260000000,-0.690000000 -1.620000e-01,NA,NA,NA,NA,NA,NA 10.6671083 10.6671083,100 100,100,100,100 100 100,low low,some low low,Placebo,  0  49.288067 37.567835 NA,NA 0 1 1.0 1.0,1.0 1.0 1,1 1 1,1,1,1,1.0,0,1,1 1 1071 Adler_2009 2-6 months NA,>= 20 yo 24.7 42.1,NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100 High Atomoxetine Atomoxetine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At follow-up (closest to 26 weeks) NA Other, 5.98388953   84.5000000 mg/d Adler 2009 NA RCT,G,101,115, 216,outcomes,reverse,-0.4620000000 -0.834000000,-9.100000e-02,NA NA NA,NA NA,NA,10.2948531,10.2948531 100 100 100,100 100 100,100 low,low some,low,low Placebo   0  49.234028 37.560926 NA NA,0,1,1.0,1.0,1.0,1.0 1,1 1,1,1 1,1 1.0 0 1 1,1,1072,Adler_2009 2-6 months NA >= 20 yo,36.6921768707483,41.2935483870968 NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks),1,Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0,100 100,High,Atomoxetine Atomoxetine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks),NA,ASRS  5.98388953,  84.5000000 mg/d Adler,2009 NA RCT G,242,245, 487 outcomes reverse -0.4320000000 -0.612000000 -2.520000e-01, 13.3100000  14.1300000 NA,NA,NA,NA NA NA,100,100,100 100 100,100 100 low low some low low,Placebo   0  49.298255 37.569138 NA,NA,0 1,1.0 1.0 1.0,1.0 1,1 1,1,1 1 1 1.0 0,1,1 1,1073,Adler_2009,2-6 months,NA,>= 20 yo 24.7 42.1,NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100,100 High,Atomoxetine Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At follow-up (closest to 26 weeks) NA,ASRS  5.98388953,  84.5000000,mg/d Adler 2009,NA,RCT G 242,245  487 outcomes reverse -0.4150000000 -0.595000000,-2.360000e-01, 14.4200000  15.0400000,NA NA,NA NA,NA,NA,100,100 100,100 100 100 100,low low some low,low,Placebo   0, 49.298255 37.569138 NA,NA 0,1 1.0,1.0 1.0,1.0 1 1,1 1 1 1,1,1.0 0 1 1,1,1074 Adler_2009 2-6 months NA >= 20 yo 36.7171428571429 37.5691375770021 NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 1,Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100 100 High Atomoxetine,Atomoxetine   0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability, 5.98388953   84.5000000,mg/d Adler 2009,NA RCT RR,250,251, 501 outcomes reverse  1.1270000000, 0.973000000  1.305000e+00,NA NA NA NA NA,NA NA NA,100,100,100,100 100 100 100 low,low,low low,low Placebo,  0, 49.302814,37.569721,NA,NA,0 1 1.0,1.0 1.0 1.0 1,1,1 1,1 1 1 1.0 0,1 1 1,1075 Adler_2009,2-6 months,NA >= 20 yo 24.7,42.10703125,NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100 High Atomoxetine Atomoxetine,  0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA Tolerability  5.98388953   84.5000000,mg/d Adler,2009,NA,RCT,RR,250,251, 501 outcomes reverse, 3.0840000000  1.732000000  5.492000e+00,NA NA,NA,NA,NA,NA NA,NA 100 100,100 100,100,100 100 low low low low low Placebo   0, 49.302814 37.569721 NA NA 0 1,1.0 1.0,1.0,1.0 1,1,1,1,1 1 1,1.0,0 1,1 1 1076 Adler_2009 2-6 months NA >= 20 yo,24.7 42.10703125 NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100 High Methylphenidate Methylphenidate   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA Other  1.61104718   67.7000000,mg/d Adler,2009 NA RCT,G 110,116  226,outcomes reverse,-0.3290000000 -0.627000000,-3.100000e-02,NA,NA NA,NA,NA NA,11.4165494 11.4165494 100,100 100 100 100,100,100 low,low some,low low Placebo,  0, 43.777876 39.027434 NA,NA,0,1 1.0,1.0 1.0,1.0 1 1,1,1 1 1 1,1.0,0,1,1 1 1077,Adler_2009,< 2 months NA,>= 20 yo 30.6,40 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100 100,High Methylphenidate,Methylphenidate   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA Acceptability, 1.61104718,  67.7000000,mg/d,Adler,2009,NA RCT,RR 113,116, 229,outcomes,reverse, 1.6580000000  1.095000000  2.511000e+00 NA,NA,NA,NA,NA,NA,NA NA,100,100,100,100,100,100,100,low,low,low low low,Placebo,  0  43.763755,39.038865,NA,NA 0 1,1.0,1.0 1.0,1.0 1 1 1 1,1,1 1,1.0 0,1 1,1 1078,Adler_2009 < 2 months NA >= 20 yo 28.7959183673469 40,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100 100 High,Methylphenidate Methylphenidate,  0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability, 1.61104718   67.7000000,mg/d Adler,2009 NA RCT,RR,113,116, 229 outcomes reverse  2.7370000000  1.111000000  6.745000e+00,NA,NA,NA,NA,NA NA NA NA,100 100,100 100 100 100,100,low low low low low,Placebo   0  43.763755 39.038865 NA NA 0 1 1.0 1.0 1.0,1.0,1,1 1,1,1 1 1,1.0 0 1 1 1,1079 Adler_2009,< 2 months NA >= 20 yo 28.7959183673469,40,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100,High Modafinil Modafinil   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks) NA,ASRS, 2.07134638, 298.0000000,mg/d,Arnold,2014,NA RCT,G 141, 72, 213,outcomes reverse  0.0340000000 -0.297000000  3.650000e-01,NA,NA NA,NA,NA NA 15.0300000 15.0300000,100,100 100,100,100,100 100 low low,low,low low,Placebo,  0  39.718310 39.129577,NA NA 0,1,1.0 1.0 1.0 1.0,1 1,1 1 1,1 1,1.0,0,1,1,1,1080 Arnold_2014,2-6 months NA >= 20 yo 39.1295774647887 40.8,NA NA,  8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8,NA,NA Ostinelli (2025)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100,High Modafinil Modafinil   0 NA,Quality of life (patients),Mixed At study endpoint (closest to 12 weeks) NA,Q-LES-Q  2.07134638  298.0000000,mg/d Arnold 2014,NA RCT G, 80  51, 131,NA,reverse, 0.1220000000,-0.254000000  4.980000e-01 NA,NA NA,NA,NA NA, 8.6400000  8.6400000 100,100 100,100,100,100 100 low,low low,low,low Placebo   0  40.282443,39.088550,NA,NA 0,1 1.0 1.0,1.0 1.0 1 1 1,1,1,1,1 1.0,0,1,1 1 1081,Arnold_2014 2-6 months,NA,>= 20 yo,39.0885496183206 39.0885496183206,NA,NA,  8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8,NA NA,Ostinelli (2025)_Modafinil_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Modafinil_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100,100,High,Atomoxetine,Atomoxetine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,CAARS-INV:SV  0.92059839 NA NA Bain 2013 NA RCT G, 53,105  158,outcomes,reverse,-2.0960000000,-2.768000000 -1.424000e+00 NA NA,NA NA,NA,NA  7.7876826  7.7876826,100,100,100 100 100 100,100,low,low some low,low Placebo,  0, 47.000000,36.200000,NA,NA 0 1 1.0 1.0,1.0,1.0,1 1,1,1,1 1,1 1.0,0,1,1 1 1082,Bain_2013,< 2 months,NA,>= 20 yo 24.7 42.1,NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2   0   0 100,100,High,Methylphenidate,Methylphenidate   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA Other, 1.38089758 NA,NA,Biederman 2006 NA RCT,G, 67  74, 141,outcomes reverse -0.6570000000,-0.998000000,-3.170000e-01   7.3668175   7.7420927,NA NA NA NA NA NA,100,100,100,100,100,100,100,low,low low low some Placebo,  0, 48.248227,NA NA NA,0 1,1.0,1.0,1.0,1.0 1 1 1 1 1,1,1 1.0,0 1 1 1 1083,Biederman_2006,< 2 months NA NA,30.6,40 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100 High,Amphetamine Amphetamine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA ADHD-SRS total  1.38089758 NA NA Biederman,2012 NA RCT,G, 31  30   61 outcomes reverse -1.1590000000,-1.706000000,-6.110000e-01  10.2000000,  9.9000000,NA NA,NA,NA NA,NA 100 100 100,100 100,100,100 some some low some,some,Placebo   0, 43.472131,22.205902,NA,NA,0 1,1.0,1.0 1.0 1.0 1,1 1 1,1,1,1 1.0 0,1,1 1 1084,Biederman_2012 < 2 months NA,>= 20 yo 22.2059016393443 39.0276595744681,NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA,Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Amphetamine Amphetamine,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability, 1.38089758,NA,NA Biederman,2012,NA,RCT RR, 35, 34   69 outcomes reverse, 0.9710000000  0.264000000  3.575000e+00,NA NA NA NA,NA NA,NA NA 100,100 100 100,100 100,100 some some low,some,low,Placebo   0, 43.478841 22.205797 NA NA 0,1 1.0 1.0 1.0,1.0 1,1,1 1 1,1 1 1.0 0 1 1 1 1085,Biederman_2012 < 2 months NA >= 20 yo,22.2057971014493 39.0319587628866,NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100 High Amphetamine,Amphetamine,  0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,Tolerability  1.38089758,NA,NA Biederman 2012,NA RCT RR, 35  34,  69 outcomes reverse, 0.9710000000, 0.063000000  1.491500e+01,NA NA NA NA,NA,NA,NA NA 100,100,100,100,100,100 100 some,some,low,some,low Placebo   0  43.478841,22.205797,NA NA,0,1 1.0 1.0 1.0 1.0,1,1 1,1 1 1,1 1.0,0,1,1 1 1086,Biederman_2012,< 2 months NA,>= 20 yo 22.2057971014493,39.0319587628866,NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA,Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100,High Methylphenidate,Methylphenidate   0 NA,Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks) NA,CPT omission, 0.46029919,  72.0000000 mg/d,Bron 2014,NA RCT,G  10  12,  22,outcomes reverse, 0.0930000000,-0.767000000, 9.540000e-01 NA NA NA NA,NA NA, 2.5600000, 2.5600000,100 100 100 100,100,100,100,low low low low,low,Placebo,  0, 22.700000 30.500000 NA,NA 0,1 1.0,1.0,1.0 1.0,1,1,1 1 1,1 1,1.0 0 1 1,1,1087 Bron_2014,< 2 months,NA >= 20 yo 30.5,38.4408163265306,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100,100 High Methylphenidate Methylphenidate   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability  0.46029919,  72.0000000 mg/d,Bron 2014 NA,RCT RR  14, 13,  27 outcomes reverse, 3.7140000000, 0.475000000, 2.906000e+01,NA NA,NA,NA NA,NA,NA,NA 100,100,100 100,100,100 100 low low low low low,Placebo   0, 22.700000 30.500000,NA NA 0,1 1.0,1.0 1.0 1.0,1 1,1,1,1,1,1,1.0 0,1 1,1,1088 Bron_2014 < 2 months,NA,>= 20 yo 28.7959183673469,40 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100,100,High Methylphenidate Methylphenidate   0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability  0.46029919,  72.0000000 mg/d,Bron 2014,NA RCT RR  14, 13,  27,outcomes reverse, 6.5330000000  0.370000000, 1.154910e+02,NA,NA,NA,NA NA,NA,NA,NA,100 100,100 100,100 100 100,low,low low,low,low,Placebo,  0  22.700000 30.500000,NA NA 0 1 1.0,1.0 1.0 1.0 1,1 1 1 1,1 1,1.0 0,1 1 1 1089 Bron_2014 < 2 months,NA >= 20 yo 28.7959183673469 40,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100,100 High Methylphenidate,Methylphenidate   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,Other  2.99194476 NA NA Casas 2013 NA RCT,G,182  97, 279 outcomes,reverse,-0.3140000000,-0.562000000,-6.600000e-02,  6.0000000,  6.1000000,NA NA NA,NA NA,NA 100,100 100,100,  0 100,100,low low high low,low,Placebo,  0, 47.704659 35.695699 NA NA,0 1,1.0 1.0 1.0 1.0 1,1,1 1,1 1 1,1.0,0 1 1,1,1090 Casas_2013,2-6 months,NA,>= 20 yo,30.6 40,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100,100 High Methylphenidate,Methylphenidate,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA CAARS-S:S  2.99194476,NA,NA,Casas 2013 NA RCT G,182  97  279 outcomes reverse -0.3170000000,-0.565000000 -6.900000e-02  15.4000000, 14.5000000,NA NA,NA,NA,NA,NA 100,100 100,100,  0,100,100,low low,high low low,Placebo,  0, 47.704659 35.695699,NA NA 0,1 1.0,1.0 1.0 1.0,1 1 1,1,1,1 1 1.0 0,1,1,1,1091,Casas_2013 2-6 months,NA,>= 20 yo,33.7462897526502 42,NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100,100,High Methylphenidate,Methylphenidate,  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability, 2.99194476 NA,NA,Casas,2013,NA RCT,RR 182, 97, 279,outcomes reverse, 1.3230000000, 0.929000000  1.885000e+00 NA,NA NA,NA,NA,NA,NA NA,100 100 100 100,100 100,100 low low,low low,low Placebo,  0  47.704659,35.695699 NA NA 0,1,1.0,1.0,1.0 1.0 1 1,1 1,1,1,1 1.0 0 1,1 1 1092 Casas_2013 2-6 months NA >= 20 yo 28.7959183673469 40 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100,High,Methylphenidate Methylphenidate,  0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,Tolerability  2.99194476,NA,NA,Casas,2013,NA RCT,RR 182  97, 279,outcomes,reverse, 9.0600000000  2.224000000  3.691300e+01,NA NA,NA NA NA NA,NA,NA,100,100 100 100 100 100 100 low,low low low,low Placebo,  0  47.704659,35.695699 NA NA 0,1 1.0 1.0 1.0 1.0,1 1,1 1,1,1 1 1.0 0 1,1 1,1093 Casas_2013 2-6 months,NA,>= 20 yo,28.7959183673469 40,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100,High,Atomoxetine Atomoxetine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA CAARS-INV:SV  2.76179517,  87.0000000,mg/kg/d,Durell 2013,NA,RCT,G,119 134  253 outcomes,reverse,-0.5480000000,-0.885000000,-2.110000e-01 NA,NA,NA NA NA NA, 9.8394614, 9.8394614,100 100,100,100   0,100 100,low low,high,low low,Placebo,  0, 42.753360,24.700000,NA NA,0 1 1.0 1.0 1.0 1.0 1,1,1 1 1,1,1,1.0 0 1 1,1,1094,Durell_2013 2-6 months NA,>= 20 yo 24.7,42.1,NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100 100,High Atomoxetine Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks),NA,CAARS-S:S, 2.76179517   87.0000000 mg/d Durell,2013 NA,RCT,G,189,197, 386,outcomes,reverse,-0.3850000000,-0.628000000 -1.430000e-01,NA,NA,NA,NA NA,NA,10.2460383,10.2460383 100,100,100 100,  0,100,100 low low,high low,low Placebo   0, 42.718653 24.700000 NA,NA 0,1 1.0 1.0 1.0,1.0,1 1 1,1 1 1 1 1.0,0,1,1,1,1095 Durell_2013,2-6 months,NA,>= 20 yo 24.7,42.1,NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100,High,Atomoxetine Atomoxetine,  0 NA,Quality of life (patients),Mixed,At study endpoint (closest to 12 weeks),NA AAQoL, 2.76179517   87.0000000 mg/d,Durell,2013 NA RCT G 189,198  387,outcomes reverse, 0.2680000000  0.067000000  4.680000e-01, 17.2000000, 15.6000000 NA NA,NA NA,NA,NA,100,100,100 100,  0 100,100,low low high low low,Placebo,  0, 42.720930,24.700000 NA NA 0 1,1.0,1.0,1.0,1.0 1 1,1 1,1,1,1 1.0,0 1 1,1,1096,Durell_2013,2-6 months,NA >= 20 yo,24.7,37.9941666666667 NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA,Ostinelli (2025)_Atomoxetine_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Atomoxetine_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0,100 100 High,Atomoxetine Atomoxetine,  0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability, 2.76179517,  87.0000000 mg/d Durell 2013,NA RCT,RR 220,225  445,outcomes,reverse  1.1300000000  0.920000000, 1.389000e+00,NA,NA,NA,NA,NA,NA NA,NA 100 100 100 100,100,100,100,low low low,low,low,Placebo,  0  42.710112 24.700000 NA NA,0 1 1.0,1.0,1.0,1.0,1 1,1,1,1,1 1,1.0 0 1,1,1,1097,Durell_2013 2-6 months,NA,>= 20 yo,24.7 42.10703125 NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0 100,100,High,Atomoxetine Atomoxetine   0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA Tolerability, 2.76179517,  87.0000000 mg/d,Durell 2013 NA RCT,RR,220 225  445,outcomes,reverse, 3.5800000000, 1.473000000, 8.700000e+00,NA NA,NA,NA,NA,NA,NA NA 100 100 100,100,100,100 100 low,low,low low,low,Placebo   0  42.710112 24.700000,NA,NA 0,1,1.0 1.0,1.0,1.0,1 1,1,1,1 1 1,1.0 0,1,1 1 1098 Durell_2013,2-6 months,NA >= 20 yo,24.7 42.10703125,NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100 High Methylphenidate Methylphenidate,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,CAARS-O:S  1.15074799 NA,NA Ginsberg 2012,NA RCT G, 15  15   30,outcomes,reverse -2.1050000000 -3.021000000 -1.189000e+00  10.1800000,  5.5000000 NA NA,NA NA,NA NA 100 100 100,100,100 100,100,low,low low low,low,Placebo,  0   0.000000 34.400000,NA,NA 0 1 1.0,1.0,1.0 1.0 1,1 1 1 1,1 1 1.0,0,1 1 1,1099 Ginsberg_2012,< 2 months,NA >= 20 yo,30.6 40 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100,High Methylphenidate Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks) NA,ASRS  1.15074799,NA,NA Ginsberg,2012,NA,RCT,G  15  15   30,outcomes,reverse -1.6380000000,-2.485000000 -7.910000e-01, 12.1200000,  8.9000000 NA,NA NA NA NA NA,100 100 100 100 100,100,100 low low,low low,low,Placebo,  0,  0.000000 34.400000 NA,NA 0,1 1.0,1.0 1.0,1.0,1 1 1 1,1 1 1,1.0 0,1 1,1 1100 Ginsberg_2012 < 2 months NA >= 20 yo 33.7462897526502,42,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Methylphenidate Methylphenidate,  0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability  1.15074799,NA,NA,Ginsberg 2012 NA RCT,RR  15  15   30,outcomes,reverse  1.0000000000, 0.021000000, 4.738000e+01 NA,NA,NA NA NA NA NA NA 100 100 100 100,100 100 100 low low,low low,low Placebo   0   0.000000,34.400000 NA,NA,0,1 1.0 1.0 1.0,1.0 1 1,1,1,1 1 1 1.0,0,1 1 1,1101,Ginsberg_2012,< 2 months NA,>= 20 yo,28.7959183673469 40,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100 High,Methylphenidate Methylphenidate,  0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA Tolerability, 1.15074799 NA NA,Ginsberg,2012,NA RCT RR  15, 15   30 outcomes reverse, 1.0000000000, 0.021000000  4.738000e+01,NA NA,NA,NA NA,NA,NA,NA 100 100 100,100,100,100,100,low low low low low Placebo,  0,  0.000000,34.400000,NA,NA,0 1,1.0 1.0 1.0,1.0,1,1 1 1 1 1,1,1.0 0 1,1,1,1102 Ginsberg_2012,< 2 months,NA >= 20 yo,28.7959183673469 40,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0 100,100,High,Atomoxetine Atomoxetine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA ADHD-RS total, 2.30149597,NA NA,Goto 2013 NA RCT,G 191 195  386 outcomes,reverse,-0.4560000000 -0.715000000,-1.980000e-01 NA NA NA,NA,NA NA  9.6000000, 9.6000000,100,100,100,100,100,100,100,low,low,low low low,Placebo   0  52.339119 32.244301,NA NA,0 1,1.0 1.0,1.0,1.0,1 1 1,1,1,1 1 1.0,0,1,1,1 1103,Goto_2013 2-6 months,NA >= 20 yo,24.7,42.1 NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100 100 High,Atomoxetine Atomoxetine,  0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability, 2.30149597,NA,NA,Goto,2013 NA,RCT RR,195,196  391,outcomes,reverse  1.6080000000  1.017000000  2.544000e+00 NA NA NA NA,NA NA NA NA,100,100,100 100 100,100 100,low,low,low,low,low,Placebo,  0, 52.347315,32.248593,NA,NA,0,1 1.0 1.0,1.0 1.0 1,1,1 1,1,1 1,1.0 0 1,1 1 1104 Goto_2013 2-6 months NA >= 20 yo,24.7 42.10703125,NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100 100,High Atomoxetine Atomoxetine,  0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability, 2.30149597 NA NA Goto,2013 NA,RCT RR,195 196, 391 outcomes reverse, 3.3500000000, 0.936000000, 1.198900e+01,NA NA,NA NA,NA NA,NA,NA,100 100 100 100,100 100 100 low,low low low low,Placebo,  0, 52.347315 32.248593 NA NA 0,1 1.0 1.0 1.0,1.0 1 1,1,1,1,1,1,1.0 0 1 1,1 1105 Goto_2013,2-6 months NA >= 20 yo,24.7,42.10703125 NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0 100 100 High,Methylphenidate Methylphenidate,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA Other  0.92059839 NA,NA Herring,2012,NA RCT,G  39, 48,  87 outcomes,reverse,-0.3620000000,-0.790000000  6.700000e-02  20.6084934  21.4774300,NA NA,NA NA NA NA 100 100 100 100 100 100 100,low low low low,low Placebo,  0, 35.737931,38.434483,NA NA 0,1 1.0 1.0,1.0,1.0 1,1,1 1 1,1,1 1.0 0 1 1 1 1106 Herring_2012 < 2 months NA >= 20 yo 30.6 40 NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Methylphenidate,Methylphenidate   0 NA,Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks) NA CPT commission, 0.92059839 NA NA,Herring,2012 NA RCT G  23, 26,  49 outcomes,reverse,-0.2640000000 -0.823000000, 2.960000e-01 NA NA,NA,NA NA,NA, 8.9100000  8.9100000 100,100,100,100 100,100,100,low,low low,low low,Placebo   0  35.763265,38.440816 NA,NA,0 1,1.0 1.0 1.0,1.0,1,1,1,1 1,1,1,1.0 0 1 1,1 1107,Herring_2012 < 2 months,NA >= 20 yo,30.5,38.4408163265306,NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100 100 High,Methylphenidate Methylphenidate   0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability, 0.92059839,NA NA Herring,2012,NA,RCT RR, 39, 48   87 outcomes reverse, 1.8460000000, 0.324000000  1.050300e+01 NA,NA,NA NA NA,NA NA,NA,  0,  0,  0,  0,  0   0   0 high,high high high,high Placebo,  0, 35.737931,38.434483 NA,NA,0 1 1.0,1.0 1.0 1.0,1 1 1 1 1,1,1 1.0,0,1 1,1,1108 Herring_2012,< 2 months,NA >= 20 yo,28.7959183673469 40 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high high
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100,100 High,Methylphenidate,Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA ADHD-SRS total, 2.07134638 NA NA Huss,2014 NA,RCT,G 471 161, 632,outcomes,reverse -0.5320000000 -0.754000000 -3.110000e-01,NA NA NA,NA,NA,NA 11.0500000 11.0500000,100 100,100 100 100 100 100 low,low,some,low low,Placebo,  0, 45.541456,35.384019,NA NA 0 1,1.0,1.0 1.0 1.0 1 1,1 1 1,1,1,1.0 0 1 1 1,1109,Huss_2014,2-6 months,NA >= 20 yo 30.6,40 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100,100,High Methylphenidate Methylphenidate   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks) NA,ASRS  2.07134638 NA,NA,Huss,2014,NA,RCT,G,455,147, 602,outcomes,reverse,-0.4860000000,-0.694000000 -2.790000e-01 NA NA,NA,NA,NA,NA 12.2000000 12.2000000 100,100 100,100 100 100 100,low,low some,low low,Placebo   0, 45.560465 35.363953 NA NA,0 1 1.0,1.0 1.0,1.0 1,1,1 1,1,1,1 1.0 0,1 1 1 1110,Huss_2014 2-6 months NA >= 20 yo 33.7462897526502,42,NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100 100 High,Methylphenidate,Methylphenidate   0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability  2.07134638 NA,NA Huss 2014 NA RCT,RR 544 181, 725,outcomes reverse  1.3430000000, 0.920000000, 1.960000e+00,NA NA NA NA NA,NA,NA NA 100 100,100,100 100,100 100,low,low,low low low,Placebo   0  45.550621 35.374345,NA,NA,0 1,1.0,1.0 1.0,1.0,1,1,1 1,1 1,1,1.0,0,1 1 1 1111 Huss_2014,2-6 months,NA,>= 20 yo 28.7959183673469,40 NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100 100 High Methylphenidate,Methylphenidate,  0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability  2.07134638 NA NA,Huss 2014,NA,RCT,RR,544,181, 725 outcomes reverse, 6.3220000000, 2.004000000, 1.994000e+01 NA,NA,NA,NA,NA,NA,NA NA,100 100,100 100 100 100,100,low low low low,low,Placebo,  0, 45.550621,35.374345,NA,NA,0 1,1.0,1.0,1.0,1.0,1 1 1 1,1 1,1,1.0 0,1,1,1,1112,Huss_2014 2-6 months,NA,>= 20 yo,28.7959183673469 40,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100,High,Bupropion,Bupropion,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks),NA Other, 1.61104718,NA NA,Kuperman 2001 NA,RCT,G  11  11,  22,outcomes reverse -0.7530000000 -2.005000000  5.000000e-01,NA NA NA,NA,NA,NA,10.6000000 10.6000000 100,100 100,100,100 100,100,low low,low low low,Placebo,  0, 31.500000 32.700000 NA,NA 0,1 1.0 1.0,1.0,1.0,1,1,1 1 1 1 1,1.0 0,1 1,1,1113 Kuperman_2001,< 2 months,NA,>= 20 yo,32.7,33.545,NA NA  10  7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5 40.25 NA,NA Ostinelli (2025)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100 100 High Bupropion,Bupropion   0,NA,Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks),NA CPT d', 1.61104718 NA NA,Kuperman 2001,NA RCT G,  8  10   18 NA reverse  0.2080000000 -0.722000000  1.137000e+00 NA NA NA,NA NA,NA  1.1000000  1.1000000,100,100,100,100,100,100,100,low low,low,low,low,Placebo,  0, 31.000000,32.644444 NA NA,0,1,1.0 1.0 1.0 1.0 1,1 1,1 1,1,1,1.0,0 1 1 1 1114,Kuperman_2001,< 2 months NA >= 20 yo 32.6444444444444,32.6444444444444,NA NA  10  7 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5,40.25,NA,NA Ostinelli (2025)_Bupropion_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Bupropion_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0,100,100,High Atomoxetine,Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks),NA,CAARS-S:L  2.76179517 NA,NA,McRae-Clark,2010,NA,RCT G, 19, 19,  38,outcomes reverse,-0.3350000000,-1.254000000  5.830000e-01 NA NA NA NA,NA NA, 7.7300000  7.7300000 100 100 100,100,100,100,100,some,low,low,low,low Placebo,  0, 23.685000,29.900000,NA,NA 0 1 1.0 1.0 1.0,1.0,1 1,1 1 1 1 1 1.0 0,1,1,1,1115,McRae-Clark_2010,2-6 months,NA,>= 20 yo,24.7,42.1,NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100 High Atomoxetine Atomoxetine   0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability  2.76179517,NA,NA McRae-Clark 2010,NA,RCT,RR  39  39   78,outcomes,reverse, 1.0000000000  0.649000000  1.541000e+00 NA NA,NA,NA,NA,NA,NA,NA,100 100,100,100,100,100 100 some low low,low,low Placebo,  0, 23.685000,29.900000,NA NA,0,1,1.0,1.0,1.0 1.0,1,1,1 1 1 1 1 1.0,0 1 1,1 1116 McRae-Clark_2010,2-6 months,NA,>= 20 yo,24.7,42.10703125 NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100 High,Atomoxetine,Atomoxetine,  0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability, 2.76179517 NA,NA McRae-Clark 2010,NA RCT,RR  39, 39   78,outcomes reverse  1.0000000000  0.020000000, 4.917300e+01,NA,NA NA NA NA,NA,NA NA,100 100 100,100 100,100,100 some low low,low low,Placebo   0  23.685000,29.900000 NA NA,0,1 1.0 1.0,1.0,1.0 1,1 1,1,1 1 1 1.0,0 1 1 1,1117,McRae-Clark_2010,2-6 months NA,>= 20 yo 24.7 42.10703125 NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0 100,100,High Methylphenidate Methylphenidate,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA CAARS-O:S  1.15074799    0.5700000,mg/kg/d,Medori 2008 NA,RCT G 299  95  394,outcomes,reverse,-0.3740000000 -0.645000000 -1.040000e-01,NA,NA,NA NA NA,NA  9.9300000, 9.9300000,100,100,100,100,100,100 100,low low low low low Placebo,  0, 45.633503 34.044670 NA NA,0 1,1.0,1.0,1.0 1.0,1 1 1 1,1 1 1 1.0 0,1,1 1 1118,Medori_2008,< 2 months,NA >= 20 yo 30.6 40 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100 100 High Methylphenidate,Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) NA,CAARS-S:S  1.15074799,   0.5700000,mg/d Medori 2008 NA RCT,G,280, 91, 371 outcomes reverse,-0.3500000000,-0.607000000,-9.300000e-02,NA,NA NA NA NA,NA,11.2600000 11.2600000 100,100,100,100,100,100,100,low,low,low,low,low Placebo   0  45.594340,34.047170,NA,NA,0,1 1.0 1.0 1.0 1.0 1 1,1 1 1,1,1 1.0,0,1 1,1 1119,Medori_2008 < 2 months,NA,>= 20 yo,33.7462897526502,42,NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100,High,Methylphenidate,Methylphenidate,  0 NA,Emotional dysregulation,Mixed At study endpoint (closest to 12 weeks) NA,CAARS impulsivity/emotional lability, 1.15074799    0.5700000 mg/d Medori,2008 NA,RCT,G 280, 91, 371,outcomes,reverse -0.2810000000,-0.533000000 -2.900000e-02,NA NA NA NA,NA NA, 2.8228813  2.8228813 100 100,100,100,100 100 100,low,low low,low,low,Placebo,  0  45.594340 34.047170,NA NA 0,1 1.0 1.0,1.0,1.0,1 1,1 1,1,1,1,1.0,0,1,1 1,1120 Medori_2008 < 2 months,NA,>= 20 yo 34.0471698113208,36.9 NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100,100,High Methylphenidate,Methylphenidate,  0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability  1.15074799    0.5700000,mg/d,Medori,2008,NA RCT RR 305  96, 401 outcomes,reverse, 4.0920000000, 0.542000000, 3.087500e+01 NA NA NA,NA NA,NA,NA,NA,  0,  0,  0   0,  0   0,  0,high,high,high high,high Placebo   0, 45.649626,34.043641 NA,NA 0 1 1.0 1.0,1.0,1.0 1,1,1 1 1 1,1 1.0,0 1,1,1 1121,Medori_2008,< 2 months NA,>= 20 yo 28.7959183673469,40 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no high,high
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100,100,High,Atomoxetine,Atomoxetine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA CAARS-INV:SV, 2.30149597,NA NA Michelson,2003 NA,RCT G 133,134  267 outcomes,reverse -0.2940000000 -0.570000000,-1.800000e-02,NA,NA,NA,NA,NA,NA  9.3000000, 9.3000000 100 100,100,100 100 100 100,low low,low,low,low Placebo,  0, 36.453558 40.250187,NA NA,0 1 1.0 1.0,1.0,1.0,1 1 1,1,1 1 1,1.0 0 1 1 1 1122 Michelson_2003 2-6 months NA,>= 20 yo 24.7 42.1 NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100,High Atomoxetine,Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks) NA CAARS-S:L, 2.30149597 NA,NA,Michelson 2003,NA,RCT G,133 134  267,outcomes,reverse,-0.3210000000 -0.600000000 -4.300000e-02 NA,NA,NA,NA,NA,NA 14.0000000 14.0000000,100,100,100 100,100,100,100,low low low,low,low Placebo   0, 36.453558 40.250187 NA,NA,0,1 1.0,1.0,1.0 1.0 1,1 1 1 1 1,1 1.0,0,1 1 1 1123,Michelson_2003,2-6 months NA,>= 20 yo,24.7 42.1 NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100 100,High Atomoxetine Atomoxetine,  0 NA Emotional dysregulation,Mixed At study endpoint (closest to 12 weeks),NA,WRAADDS  2.30149597 NA NA Michelson 2003,NA RCT G,133,134  267,outcomes reverse -0.1980000000,-0.466000000, 7.100000e-02 NA NA NA NA NA NA  4.8000000, 4.8000000 100 100 100,100,100 100,100,low low,low low low Placebo,  0, 36.453558,40.250187,NA NA 0,1 1.0,1.0 1.0 1.0 1 1 1 1,1 1,1 1.0,0 1 1 1,1124,Michelson_2003,2-6 months,NA >= 20 yo 40.2501872659176 42.1,NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100,100,High,Atomoxetine,Atomoxetine,  0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability  2.30149597 NA NA Michelson 2003,NA RCT RR,141 139  280 outcomes reverse, 1.2010000000  0.802000000  1.801000e+00 NA,NA NA,NA NA,NA NA NA 100 100,100,100,100 100 100,low,low,low low low,Placebo,  0, 36.443214,40.249643 NA NA 0 1 1.0,1.0 1.0 1.0 1,1 1,1 1,1 1 1.0 0,1 1,1,1125 Michelson_2003 2-6 months,NA >= 20 yo,24.7 42.10703125,NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100,100,High,Atomoxetine Atomoxetine   0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability, 2.30149597,NA NA Michelson 2003 NA,RCT,RR 141,139, 280 outcomes reverse  1.8070000000  0.687000000, 4.752000e+00,NA,NA,NA,NA NA NA,NA,NA,100,100 100,100,100,100 100,low low,low,low low,Placebo   0  36.443214 40.249643,NA,NA,0,1,1.0,1.0 1.0 1.0 1,1 1 1 1,1 1 1.0 0,1,1,1 1126,Michelson_2003 2-6 months,NA,>= 20 yo 24.7,42.10703125 NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,  0   0,100,100,High,Amphetamine,Amphetamine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) NA,Other  1.38089758,NA NA,Paterson,1999 NA,RCT G, 24, 21   45 outcomes,reverse,-0.4570000000,-1.057000000  1.430000e-01,  6.2000000,  7.8000000,NA,NA,NA NA,NA,NA 100,100,100,100 100 100,100,some low low low low,Placebo   0 NA NA NA,NA 0,1 1.0 1.0,1.0 1.0 1,1 1 1,1,1 1,1.0,0 1,1 1 1127,Paterson_1999,< 2 months,NA NA 39.0310734463277 41.2 NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100 100 High,Bupropion,Bupropion   0,NA Emotional dysregulation Mixed,At study endpoint (closest to 12 weeks) NA WRAADDS, 1.38089758, 298.0000000,mg/d,Reimherr 2005 NA,RCT,G, 29, 18   47 NA reverse -0.3270000000,-0.925000000  2.710000e-01,  5.6000000   5.1000000,NA NA NA,NA NA,NA,  0,  0,  0   0   0,  0   0,high high high high high Placebo   0  27.221277 34.414894,NA NA 0,1,1.0,1.0,1.0 1.0,1,1 1 1 1 1,1,1.0,0 1 1 1 1128 Reimherr_2005,< 2 months NA >= 20 yo 34.4148936170213,34.4148936170213,NA,NA, 10, 7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5 40.25 NA NA,Ostinelli (2025)_Bupropion_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Bupropion_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,high,high
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100,100 High Bupropion Bupropion   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability  1.38089758  298.0000000 mg/d Reimherr 2005 NA RCT RR  35, 24   59,outcomes,reverse  0.6860000000, 0.251000000, 1.874000e+00 NA,NA,NA,NA NA,NA,NA,NA,100 100 100 100,100 100 100,low low low,low,low,Placebo   0  27.135593 34.422034 NA NA 0,1 1.0 1.0 1.0 1.0,1 1 1,1,1,1,1 1.0 0,1,1 1 1129 Reimherr_2005 < 2 months,NA >= 20 yo 34.4220338983051,38.235,NA,NA  10  7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5,40.25 NA NA Ostinelli (2025)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100 High,Bupropion,Bupropion   0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability  1.38089758  298.0000000,mg/d Reimherr,2005,NA RCT RR  35  24   59 outcomes,reverse  0.6940000000  0.014000000, 3.385000e+01 NA,NA,NA,NA NA NA,NA,NA 100,100 100,100,100 100,100,low,low,low low low Placebo   0  27.135593,34.422034,NA,NA 0,1 1.0 1.0,1.0 1.0,1,1 1,1,1,1,1 1.0 0,1 1,1,1130,Reimherr_2005 < 2 months,NA >= 20 yo 34.4220338983051 38.235,NA,NA, 10  7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5,40.25,NA NA Ostinelli (2025)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0 100,100 High,Methylphenidate Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,Other, 0.92059839   60.5000000 mg/d Reimherr 2007,NA,RCT,G  41  41   82 outcomes reverse,-0.8530000000,-1.308000000 -3.980000e-01   2.5270023   2.2253312 NA,NA,NA NA,NA NA 100,100,100 100,100 100,100,low low,low low low Placebo   0  34.000000 30.600000 NA,NA 0,1 1.0,1.0 1.0 1.0,1,1 1,1 1 1 1 1.0,0,1 1 1 1131,Reimherr_2007,< 2 months NA,>= 20 yo,30.6 40,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100,High,Methylphenidate Methylphenidate,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At follow-up (closest to 26 weeks),NA,Other  5.52359033,  41.2000000,mg/d,Rosler,2009 NA RCT,G 241,118  359,outcomes reverse -0.3510000000,-0.573000000 -1.290000e-01,  0.5952914,  0.6623094,NA,NA NA,NA,NA,NA 100,100,100 100   0,100,100,low low high low low,Placebo   0, 50.000000 34.739833 NA NA,0 1 1.0,1.0 1.0,1.0 1,1,1 1,1 1 1,1.0 0 1 1 1,1132 Rosler_2009 2-6 months NA,>= 20 yo,34.7398328690808 35.3047619047619 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100 High Methylphenidate Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA,CAARS-S:L, 5.52359033,  41.2000000,mg/d Rosler 2009 NA,RCT G 239,118  357,outcomes reverse -0.2750000000 -0.497000000 -5.300000e-02  36.3000000  38.5000000 NA,NA NA NA NA NA 100,100,100,100,  0,100 100 low,low high low low,Placebo,  0, 50.000000,34.737255 NA,NA 0,1,1.0 1.0 1.0 1.0,1,1 1,1,1 1 1 1.0 0,1 1,1 1133,Rosler_2009,2-6 months,NA >= 20 yo 33.7462897526502,42,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100 100,High,Methylphenidate,Methylphenidate   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At follow-up (closest to 26 weeks) NA CAARS-S:L  5.52359033,  41.2000000,mg/d,Rosler 2009,NA RCT,G,239 118  357 outcomes reverse -0.2850000000,-0.507000000,-6.300000e-02, 36.8000000  39.8000000,NA,NA NA,NA,NA,NA 100 100,100,100,  0 100 100 low,low,high,low,low Placebo   0  50.000000 34.737255 NA,NA 0,1 1.0,1.0,1.0,1.0 1 1 1 1 1,1 1 1.0,0,1,1,1,1134 Rosler_2009 2-6 months,NA,>= 20 yo 34.7372549019608 35.3120567375887 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100,High Methylphenidate Methylphenidate,  0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 5.52359033   41.2000000,mg/d,Rosler,2009 NA RCT,RR,241,118, 359 outcomes reverse, 0.5460000000, 0.403000000, 7.390000e-01,NA,NA NA,NA,NA NA,NA,NA 100 100 100 100 100 100 100 low low,low low low Placebo   0, 50.000000,34.739833,NA,NA 0,1 1.0,1.0 1.0 1.0 1 1 1 1,1 1 1,1.0 0 1 1,1 1135,Rosler_2009,2-6 months,NA,>= 20 yo 28.7959183673469 40 NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100,High,Methylphenidate Methylphenidate,  0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,Tolerability  5.52359033,  41.2000000,mg/d,Rosler,2009 NA RCT RR,241 118, 359 outcomes,reverse  1.5180000000, 0.771000000, 2.990000e+00 NA,NA NA NA NA NA NA,NA,100,100 100,100,100 100,100 low low low low low Placebo,  0  50.000000,34.739833 NA NA 0,1,1.0,1.0 1.0 1.0 1 1,1,1,1 1,1,1.0 0,1 1 1,1136 Rosler_2009,2-6 months NA,>= 20 yo,28.7959183673469 40 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100 High,Methylphenidate Methylphenidate   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,ADHD-SRS total, 0.69044879,NA NA Spencer,1995,NA,RCT G, 24  25,  49 outcomes,reverse,-1.0180000000 -1.620000000 -4.150000e-01   7.2000000,  7.3000000 NA NA,NA NA NA NA,100 100,100 100 100 100 100,some low,some low,low Placebo,  0  57.000000,40.000000 NA NA,0 1 1.0,1.0,1.0,1.0 1 1 1,1,1,1 1,1.0 0 1 1 1 1137,Spencer_1995,< 2 months NA,>= 20 yo,30.6 40,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100,High,Methylphenidate,Methylphenidate,  0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability  0.69044879 NA NA Spencer,1995,NA,RCT RR  25  25,  50,outcomes reverse, 3.0000000000  0.128000000, 7.029600e+01 NA,NA,NA,NA,NA NA,NA,NA,100,100,100 100 100 100,100 some low low,low,low,Placebo   0  57.000000,40.000000,NA NA 0,1,1.0 1.0,1.0 1.0 1 1 1,1,1,1,1,1.0,0,1,1 1,1138 Spencer_1995,< 2 months NA >= 20 yo,28.7959183673469 40 NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100,High,Methylphenidate Methylphenidate   0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA Tolerability, 0.69044879,NA NA,Spencer,1995 NA,RCT RR, 25, 25,  50 outcomes reverse, 1.0000000000  0.021000000, 4.852400e+01 NA NA,NA NA,NA NA,NA,NA,100 100 100 100 100,100 100,some,low low,low low Placebo,  0, 57.000000 40.000000,NA,NA 0 1,1.0,1.0,1.0,1.0,1,1,1 1 1 1,1,1.0,0 1,1,1,1139 Spencer_1995,< 2 months,NA,>= 20 yo 28.7959183673469 40,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100,100,High,Amphetamine Amphetamine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA ADHD-SRS total  0.69044879 NA NA,Spencer 2001,NA,RCT G  15, 11   26,outcomes,reverse,-1.0330000000,-1.880000000,-1.860000e-01   7.5000000   7.5000000 NA NA NA,NA,NA NA 100 100,100,100 100 100 100 low,low,some,low low,Placebo,  0  44.000000 38.800000,NA NA 0,1,1.0 1.0,1.0,1.0,1 1 1 1,1 1,1,1.0,0,1 1 1,1140 Spencer_2001,< 2 months,NA >= 20 yo,22.2059016393443 39.0276595744681 NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA,Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100,High Amphetamine Amphetamine   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 0.69044879 NA NA Spencer,2001,NA,RCT,RR, 30  30   60 outcomes,reverse  0.3330000000, 0.014000000  7.870000e+00 NA NA,NA,NA,NA NA NA,NA,100,100,100,100 100 100,100 low low,low,low low Placebo   0  44.000000 38.800000,NA,NA,0 1,1.0,1.0,1.0 1.0 1,1,1 1,1 1 1,1.0,0 1,1,1,1141,Spencer_2001,< 2 months,NA,>= 20 yo 22.2057971014493 39.0319587628866 NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100 100 High,Amphetamine,Amphetamine   0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,Tolerability, 0.69044879 NA,NA,Spencer,2001 NA,RCT,RR, 30  30,  60,outcomes reverse, 1.0000000000, 0.020000000, 4.882200e+01,NA,NA NA NA,NA,NA NA,NA,100,100 100,100 100 100 100 low,low,low low,low Placebo,  0  44.000000,38.800000 NA NA 0,1,1.0 1.0,1.0 1.0,1,1 1,1,1,1,1,1.0 0,1,1 1,1142 Spencer_2001,< 2 months,NA >= 20 yo 22.2057971014493 39.0319587628866 NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0,100 100 High Methylphenidate Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA Other, 1.38089758 NA,NA,Spencer 2005,NA RCT G, 78  32, 110,outcomes reverse,-0.7400000000,-1.165000000,-3.160000e-01  10.2000000,  9.7000000 NA,NA NA NA,NA,NA,100,100 100,100,  0 100,100 some low,high,low,low Placebo,  0, 41.796364,36.967273 NA,NA 0 1,1.0,1.0,1.0 1.0 1 1 1,1,1 1 1,1.0,0 1 1 1 1143,Spencer_2005,< 2 months NA >= 20 yo,30.6,40 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0 100 100,High Methylphenidate,Methylphenidate,  0 NA,Quality of life (patients) Mixed,At study endpoint (closest to 12 weeks),NA Q-LES-Q, 1.15074799 NA NA Spencer,2007,NA,RCT,G,160  48, 208 outcomes,reverse, 0.0510000000 -0.273000000  3.740000e-01,  7.6300000,  8.6200000,NA NA,NA NA NA,NA,100 100 100 100,100,100 100,low,some,low some low,Placebo   0, 49.060000,38.100000,NA,NA,0 1,1.0,1.0 1.0 1.0,1,1,1 1,1 1,1,1.0,0 1 1,1,1144 Spencer_2007 < 2 months NA,>= 20 yo 33.7475177304965 38.1 NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100 High Methylphenidate Methylphenidate   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability, 1.15074799 NA NA,Spencer 2007,NA RCT RR,168  53, 221,outcomes,reverse  0.8520000000, 0.442000000, 1.642000e+00,NA NA NA NA NA NA NA NA,100,100 100,100 100,100,100 low,some low,some,low,Placebo,  0, 49.060000,38.100000 NA,NA,0 1,1.0 1.0 1.0 1.0,1 1,1,1 1 1,1 1.0,0 1,1,1 1145 Spencer_2007 < 2 months NA,>= 20 yo 28.7959183673469 40,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100,High Methylphenidate Methylphenidate,  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability, 1.15074799,NA,NA Spencer,2007,NA,RCT RR,168, 53  221,outcomes,reverse  1.4200000000  0.503000000  4.010000e+00,NA,NA,NA NA NA NA NA,NA,100 100,100 100 100,100 100 low some low some low Placebo   0, 49.060000,38.100000 NA NA 0,1,1.0 1.0,1.0,1.0,1,1 1,1 1,1 1,1.0,0 1 1 1 1146,Spencer_2007,< 2 months,NA,>= 20 yo 28.7959183673469 40 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,  0   0 100 100 High,Atomoxetine Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA Other  1.84119678   89.7000000,mg/d Sutherland 2012,NA RCT,G  97  47, 144 outcomes reverse,-0.3130000000,-0.665000000, 3.800000e-02  11.4000000, 14.2000000 NA,NA NA NA,NA NA 100 100 100,100 100 100 100,low,some,some low,low Placebo   0 NA,NA NA NA,0,1 1.0 1.0 1.0,1.0 1,1,1,1,1 1 1,1.0 0 1,1,1 1147,Sutherland_2012,< 2 months,NA NA 24.7,42.1,NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,  0,  0,100,100 High,Atomoxetine,Atomoxetine   0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 1.84119678,  89.7000000,mg/d Sutherland 2012,NA RCT RR, 97, 47, 144 outcomes reverse, 0.6540000000, 0.412000000  1.038000e+00,NA NA,NA,NA NA,NA NA,NA 100 100 100 100,100 100,100,low,some,low some,low,Placebo   0,NA,NA,NA,NA,0 1,1.0,1.0 1.0 1.0,1,1 1,1 1,1 1 1.0,0 1 1,1 1148 Sutherland_2012 < 2 months NA,NA,24.7,42.10703125 NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,  0   0,100,100,High,Atomoxetine,Atomoxetine,  0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability, 1.84119678   89.7000000 mg/d Sutherland,2012,NA RCT RR  97  47  144,outcomes reverse  0.7610000000, 0.315000000, 1.838000e+00,NA NA NA,NA NA NA NA,NA,100,100 100,100 100 100,100,low some,low,some low,Placebo,  0 NA,NA,NA,NA,0,1,1.0 1.0 1.0 1.0,1,1 1 1 1,1,1 1.0 0,1 1 1 1149,Sutherland_2012,< 2 months NA,NA 24.7 42.10703125 NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100 100 High,Methylphenidate,Methylphenidate,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,CAARS-O:S, 1.84119678,  51.5000000,mg/d,Takahashi 2014 NA,RCT,G 143,140, 283,outcomes,reverse -0.5190000000 -0.817000000,-2.200000e-01,NA NA,NA NA NA,NA  9.3500000  9.3500000 100,100,100,100,100,100 100,low low,low,low low,Placebo,  0, 51.042049,33.746290 NA NA 0 1,1.0 1.0 1.0 1.0 1 1 1,1,1,1,1,1.0 0,1 1 1,1150,Takahashi_2014,< 2 months,NA,>= 20 yo 30.6 40 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100,High Methylphenidate,Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks) NA,CAARS-S:S  1.84119678,  51.5000000,mg/d,Takahashi 2014 NA,RCT,G,143,140, 283 outcomes,reverse,-0.4280000000,-0.704000000 -1.530000e-01,NA,NA,NA NA,NA NA 10.0600000,10.0600000 100,100 100,100,100 100,100 low,low,low,low low Placebo,  0, 51.042049 33.746290,NA NA,0 1,1.0 1.0 1.0,1.0,1,1 1 1 1,1,1 1.0,0,1,1,1,1151 Takahashi_2014 < 2 months NA >= 20 yo 33.7462897526502 42,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100 100,High,Methylphenidate Methylphenidate   0,NA,Quality of life (patients),Mixed,At study endpoint (closest to 12 weeks),NA Q-LES-Q  1.84119678,  51.5000000 mg/d Takahashi,2014,NA RCT G 142 140, 282,outcomes,reverse, 0.1080000000,-0.126000000  3.420000e-01 NA,NA,NA NA,NA,NA 12.6900000,12.6900000,100,100 100 100 100,100,100 low,low,low low low Placebo   0  51.044681,33.747518,NA,NA,0 1 1.0 1.0,1.0 1.0 1 1 1,1 1,1,1 1.0,0,1,1,1 1152,Takahashi_2014 < 2 months NA,>= 20 yo 33.7475177304965 38.1,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100,High Methylphenidate,Methylphenidate,  0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability, 1.84119678,  51.5000000 mg/d Takahashi 2014 NA RCT,RR,143,141  284,outcomes reverse  1.4790000000, 0.541000000  4.046000e+00 NA NA NA NA NA NA NA NA,100,100 100,100,100,100,100,low,low low low low Placebo,  0, 51.044718,33.747535 NA,NA,0 1 1.0 1.0,1.0,1.0 1,1,1 1,1 1,1 1.0,0 1 1,1,1153 Takahashi_2014,< 2 months NA,>= 20 yo 28.7959183673469 40 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100,High,Methylphenidate,Methylphenidate   0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA Tolerability  1.84119678   51.5000000,mg/d Takahashi 2014 NA RCT,RR 143 141, 284 outcomes reverse, 5.9160000000, 0.721000000  4.851400e+01,NA,NA,NA,NA,NA,NA NA NA 100 100,100,100 100,100,100 low low,low low,low,Placebo   0  51.044718,33.747535 NA NA 0 1 1.0,1.0 1.0,1.0,1 1,1,1,1,1 1,1.0 0,1 1,1,1154 Takahashi_2014,< 2 months NA,>= 20 yo,28.7959183673469,40,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100,High Modafinil,Modafinil   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) NA Other  0.46029919, 206.8000000,mg/d,Taylor 2000,NA RCT G  22  22,  44 outcomes,reverse,-0.9710000000 -1.604000000,-3.380000e-01, 11.2000000, 10.0000000 NA NA,NA,NA NA,NA,100,100 100,100 100 100,100 some low,low low,low,Placebo   0, 41.000000 40.800000 NA,NA,0,1,1.0 1.0,1.0,1.0,1,1,1,1 1,1,1 1.0 0,1 1 1 1155,Taylor_2000 < 2 months NA,>= 20 yo 39.1295774647887,40.8 NA NA,  8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8,NA,NA,Ostinelli (2025)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100,High,Amphetamine Amphetamine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks),NA,Other  0.46029919,  21.8000000 mg/d,Taylor,2000 NA RCT G, 22  22,  44 outcomes,reverse -0.8100000000 -1.432000000,-1.880000e-01  11.3000000, 10.0000000,NA,NA NA,NA NA NA,100 100 100,100 100 100,100 some,low,low,low low,Placebo   0  41.000000 40.800000 NA NA,0 1,1.0,1.0,1.0 1.0 1,1 1 1,1 1 1,1.0,0 1,1,1,1156 Taylor_2000,< 2 months,NA >= 20 yo 39.0310734463277,41.2 NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100,100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) NA,Other  0.46029919    1.1000000 mg/d Taylor 2001,NA RCT,G, 17  17   34,NA,reverse -0.8350000000,-1.547000000 -1.220000e-01   8.2000000, 10.6000000 NA NA NA,NA NA,NA,100 100,100 100 100 100,100 some low some low low Placebo   0  59.000000,41.200000 NA NA,0 1,1.0,1.0,1.0 1.0 1,1,1,1,1 1,1,1.0,0 1,1 1 1157,Taylor_2001 < 2 months NA >= 20 yo,41.2 41.2,NA,NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA NA Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100 100 High,Amphetamine,Amphetamine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks),NA,Other  0.46029919   10.2000000 mg/d,Taylor,2001 NA RCT,G  17, 17   34,outcomes,reverse -0.5350000000,-1.229000000  1.600000e-01, 12.0000000  10.6000000,NA,NA,NA NA,NA,NA 100,100,100 100 100 100 100 some low some,low,low,Placebo,  0, 59.000000,41.200000,NA NA,0,1 1.0,1.0,1.0 1.0,1 1,1 1 1 1,1 1.0,0,1,1 1 1158,Taylor_2001,< 2 months,NA >= 20 yo 39.0310734463277 41.2 NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100,100,High Methylphenidate Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA BADDS-adults, 0.69044879,NA,NA,Tenenbaum,2002,NA,RCT G  24, 24,  48,outcomes reverse -0.0080000000 -0.580000000, 5.630000e-01,  2.6000000,  2.2000000,NA,NA,NA NA NA NA 100 100,100,  0,100,100,100 some high,some low low,Placebo,  0, 54.200000 42.000000,NA NA 0,1 1.0 1.0,1.0 1.0,1 1 1,1 1,1 1 1.0 0,1,1 1 1159 Tenenbaum_2002 < 2 months NA,>= 20 yo 33.7462897526502 42 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100 High Methylphenidate Methylphenidate   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,Other  1.38089758   54.9800000,mg/kg/d,Goodman 2016 NA,RCT G,169,172  341,outcomes,reverse -0.3420000000,-0.556000000 -1.280000e-01, 12.7600000  13.4700000 NA,NA,NA,NA NA NA,100,100 100 100,100 100,100,low low some,low,low Placebo,  0, 47.231085,35.740762,NA,NA,0 1 1.0,1.0 1.0 1.0 1,1 1,1 1 1 1,1.0 0 1,1 1,1160 Goodman_2016 < 2 months NA >= 20 yo,30.6,40,NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100,100,High,Methylphenidate Methylphenidate   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks),NA ASRS, 1.38089758   54.9800000 mg/d Goodman 2016,NA,RCT G 166,167  333 outcomes reverse,-0.3020000000 -0.518000000,-8.600000e-02  16.0400000, 16.3300000 NA NA,NA,NA,NA NA,100,100,100 100,100 100 100,low,low some,low low Placebo,  0  47.243544 35.746847 NA,NA 0 1 1.0,1.0,1.0,1.0 1,1,1 1 1 1,1,1.0,0 1,1 1,1161 Goodman_2016,< 2 months NA,>= 20 yo,33.7462897526502,42 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100,High,Methylphenidate,Methylphenidate   0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability, 1.38089758   54.9800000 mg/d,Goodman,2016 NA,RCT RR,178 179  357 outcomes,reverse, 0.9080000000  0.613000000, 1.344000e+00,NA NA NA NA NA NA,NA,NA 100,100 100 100,100,100,100,low,low low low low Placebo   0, 47.243978 35.747059 NA,NA,0 1,1.0 1.0 1.0,1.0 1,1 1,1 1,1 1,1.0 0 1 1,1,1162 Goodman_2016 < 2 months NA >= 20 yo,28.7959183673469,40,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0 100,100 High,Methylphenidate,Methylphenidate   0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability  1.38089758   54.9800000,mg/d,Goodman,2016,NA RCT,RR 178,179  357 outcomes reverse, 1.6090000000, 0.537000000, 4.824000e+00,NA,NA NA NA NA,NA,NA,NA,100,100,100,100,100 100 100 low low low,low,low,Placebo   0, 47.243978 35.747059 NA NA,0 1 1.0 1.0 1.0,1.0,1 1 1,1,1,1 1,1.0,0 1 1 1,1163,Goodman_2016 < 2 months,NA,>= 20 yo 28.7959183673469,40 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100,High,Methylphenidate,Methylphenidate   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA CAARS-S:L  1.38089758,  44.0000000 mg/d,Biehl 2016,NA,RCT,G  14, 13   27,outcomes reverse -0.7500000000,-1.547000000, 4.800000e-02  12.6000000, 13.8000000 NA,NA NA NA,NA NA,100 100,100,100,100 100 100 low,some low low some Placebo   0  37.814815 36.122222,NA,NA,0 1,1.0 1.0 1.0,1.0 1 1 1 1 1 1,1,1.0 0 1 1,1 1164 Biehl_2016,< 2 months NA >= 20 yo 33.7462897526502,42,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0,100,100 High,Methylphenidate Methylphenidate   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability, 1.38089758   44.0000000 mg/d,Biehl 2016,NA,RCT RR, 19, 16   35 outcomes reverse  0.2830000000  0.012000000  6.511000e+00 NA,NA NA,NA,NA,NA,NA,NA 100 100,100 100,100 100,100,low,low,low low,low Placebo   0  37.571429,36.151429,NA,NA 0 1 1.0 1.0 1.0,1.0,1 1,1,1 1 1 1 1.0,0,1 1 1 1165 Biehl_2016,< 2 months NA,>= 20 yo,28.7959183673469,40 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100,100,High Methylphenidate,Methylphenidate,  0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 1.38089758   44.0000000 mg/d Biehl 2016,NA RCT,RR, 19  16,  35 outcomes,reverse  0.8500000000, 0.018000000  4.059800e+01 NA,NA,NA,NA NA NA NA NA 100 100 100 100 100 100,100 low,low low low low Placebo   0, 37.571429,36.151429,NA NA,0 1,1.0 1.0,1.0,1.0,1,1 1,1 1 1 1 1.0 0,1,1 1,1166,Biehl_2016 < 2 months,NA,>= 20 yo 28.7959183673469,40,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100,100,High Bupropion Bupropion,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) NA,CAARS-S:L, 1.38089758, 150.0000000,mg/d Hamedi,2014,NA RCT,G  21  21,  42 outcomes reverse -0.8100000000,-1.448000000 -1.730000e-01, 15.3400000  10.0900000 NA,NA,NA NA NA,NA 100 100,100 100,100,100 100,low low,low low,low,Placebo   0, 28.950000 33.545000,NA,NA 0,1 1.0 1.0 1.0 1.0 1 1,1,1,1,1 1,1.0,0,1,1 1,1167 Hamedi_2014 < 2 months NA,>= 20 yo,32.7 33.545 NA NA  10, 7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5,40.25,NA NA,Ostinelli (2025)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100 100,High,Methylphenidate Methylphenidate   0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability, 3.68239356,NA,NA,Schrantee 2016,NA,RCT,RR, 25  24   49,outcomes reverse  0.6400000000, 0.117000000  3.501000e+00 NA,NA NA NA NA,NA NA NA 100,100,100,100,100,100 100,low low,low,low low,Placebo   0   0.000000 28.795918,NA NA,0,1 1.0,1.0 1.0,1.0,1,1,1,1 1 1,1 1.0,0 1,1,1 1168 Schrantee_2016,2-6 months,NA,>= 20 yo 28.7959183673469,40 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100 100,High,Methylphenidate,Methylphenidate   0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,Tolerability  3.68239356,NA,NA,Schrantee,2016,NA,RCT,RR, 25  24,  49 outcomes reverse  0.9600000000  0.064000000  1.449500e+01 NA NA NA NA,NA NA NA,NA 100 100 100,100 100 100 100 low,low low low,low,Placebo,  0   0.000000,28.795918 NA NA 0 1,1.0 1.0,1.0,1.0,1 1,1 1,1 1 1,1.0 0 1 1,1 1169 Schrantee_2016,2-6 months,NA,>= 20 yo 28.7959183673469 40 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100,100 High,Atomoxetine Atomoxetine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA,ASRS, 1.84119678,NA,NA Lin 2016,NA,RCT,G, 12  12,  24,outcomes reverse -0.6630000000,-1.504000000, 1.780000e-01,  6.4320613, 11.3366019,NA,NA NA NA,NA NA 100 100 100,100,100 100 100,some some,low,some some,Placebo,  0  54.165000,30.125000 NA NA 0 1 1.0 1.0,1.0,1.0 1 1 1,1,1 1,1,1.0,0 1 1 1,1170,Lin_2016 < 2 months,NA >= 20 yo 24.7,42.1,NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100,100,High Atomoxetine,Atomoxetine   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability, 1.84119678,NA NA,Lin,2016 NA RCT RR  12  12,  24,outcomes,reverse  1.0000000000, 0.021000000, 4.670300e+01,NA,NA,NA,NA,NA,NA NA NA 100,100 100 100,100 100,100,some some,low some low Placebo   0  54.165000,30.125000 NA NA 0 1,1.0,1.0 1.0,1.0,1,1 1 1,1,1 1,1.0,0,1,1 1 1171,Lin_2016,< 2 months NA,>= 20 yo,24.7 42.10703125 NA NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100,100,High,Atomoxetine Atomoxetine,  0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability  1.84119678 NA,NA Lin 2016,NA RCT RR  12  12   24,outcomes reverse  1.0000000000  0.021000000  4.670300e+01 NA,NA NA,NA NA NA,NA NA 100 100,100 100,100 100,100 some some,low,some,low,Placebo,  0, 54.165000,30.125000 NA NA 0 1 1.0,1.0,1.0 1.0,1,1 1,1 1,1,1 1.0 0,1 1,1,1172,Lin_2016 < 2 months NA,>= 20 yo,24.7,42.10703125,NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100,100,High,Atomoxetine Atomoxetine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA ADHD-RS total, 0.69044879,  76.0000000,mg/d Spencer 1998 NA RCT G  21, 21,  42 outcomes reverse,-0.8490000000 -1.489000000,-2.090000e-01  10.1000000,  8.8000000 NA,NA NA NA,NA NA 100,100,100,100,100 100,100 some,some,low some,some Placebo,  0  52.380000 34.000000,NA,NA,0,1,1.0 1.0 1.0 1.0 1,1,1 1,1,1,1 1.0,0,1,1,1,1173,Spencer_1998,< 2 months NA >= 20 yo 24.7,42.1 NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100 100 High Atomoxetine,Atomoxetine   0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability, 0.69044879,  76.0000000 mg/d Spencer 1998,NA,RCT,RR, 22  22,  44,outcomes reverse, 3.0000000000, 0.129000000, 6.986800e+01,NA,NA,NA NA,NA,NA,NA,NA,100 100,100,100 100,100,100 some some,low some,low Placebo   0  52.380000,34.000000 NA,NA,0,1 1.0,1.0 1.0 1.0,1 1 1,1 1 1,1 1.0 0 1,1 1,1174 Spencer_1998,< 2 months,NA >= 20 yo,24.7,42.10703125 NA NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100 100,High,Atomoxetine Atomoxetine   0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,Tolerability  0.69044879,  76.0000000,mg/d Spencer 1998,NA,RCT RR, 22, 22,  44,outcomes reverse, 3.0000000000, 0.129000000  6.986800e+01 NA NA NA NA NA NA,NA NA,100 100,100,100 100 100 100,some,some low some low,Placebo   0  52.380000,34.000000,NA NA,0 1 1.0,1.0 1.0,1.0 1,1,1 1 1 1 1 1.0,0 1 1 1 1175,Spencer_1998 < 2 months NA,>= 20 yo,24.7,42.10703125,NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,  0   0,100 100,High,Amphetamine,Amphetamine,  0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability  0.69044879 NA NA Kay,2009 NA RCT RR   9, 10   19 outcomes,reverse  0.3700000000  0.046000000  2.954000e+00,NA NA,NA NA,NA,NA,NA NA,100,100,100,100 100,100,100,low,low,low,low low Placebo   0, 53.000000 NA NA,NA 0 1,1.0 1.0 1.0,1.0,1,1 1 1,1 1 1,1.0 0,1 1 1 1176,Kay_2009,< 2 months NA NA,22.2057971014493,39.0319587628866 NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA,Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,  0,  0 100 100 High,Amphetamine Amphetamine   0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability  0.69044879,NA,NA,Kay,2009,NA RCT,RR,  9  10,  19,outcomes,reverse, 1.1110000000  0.081000000  1.528400e+01,NA,NA NA,NA,NA NA NA,NA 100,100,100,100 100,100 100 low,low low,low low,Placebo   0  53.000000 NA,NA NA,0 1 1.0 1.0,1.0 1.0 1,1 1,1 1,1,1,1.0,0,1 1 1,1177 Kay_2009,< 2 months,NA NA,22.2057971014493 39.0319587628866 NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA,Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,  0,  0,100,100 High Atomoxetine,Atomoxetine   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability  0.69044879,NA,NA Kay,2009,NA,RCT RR,  8   8   16 outcomes,reverse, 1.0000000000, 0.022000000  4.512700e+01 NA,NA NA NA,NA,NA NA,NA 100 100,100 100,100 100 100,low,low low,low low Placebo   0,NA NA NA,NA,0 1,1.0,1.0 1.0,1.0 1,1,1 1 1 1,1,1.0 0 1 1,1,1178,Kay_2009 < 2 months NA,NA 24.7 42.10703125,NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2   0,  0,100 100 High,Atomoxetine,Atomoxetine,  0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability  0.69044879 NA NA Kay,2009 NA,RCT RR,  8,  8,  16 outcomes reverse, 1.0000000000, 0.022000000  4.512700e+01 NA NA,NA NA NA NA NA NA 100 100 100 100,100 100 100 low,low low,low,low Placebo   0,NA NA NA,NA,0 1 1.0 1.0,1.0,1.0,1,1 1,1,1 1 1 1.0,0,1,1 1,1179,Kay_2009,< 2 months NA,NA,24.7 42.10703125,NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High Amphetamine,Amphetamine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA,ADHD-RS total  1.38089758,NA,NA,Frick,2017 NA,RCT G,204 103, 307 outcomes reverse -0.8530000000 -1.100000000,-6.060000e-01, 12.3103000, 10.9400000,NA,NA NA NA NA,NA 100,100 100 100,100,100 100,low,low,some,low,low,Placebo,  0, 42.339414,36.928990,NA,NA 0 1,1.0 1.0,1.0 1.0,1,1 1,1 1,1,1,1.0 0 1 1 1,1180,Frick_2017 < 2 months,NA >= 20 yo 22.2059016393443 39.0276595744681,NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100,100,High,Amphetamine,Amphetamine,  0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability  1.38089758,NA NA,Frick 2017 NA RCT RR 205 104  309 outcomes,reverse, 0.5650000000, 0.405000000, 7.870000e-01,NA,NA NA,NA NA,NA,NA NA,100,100,100,100 100 100,100,low,low low,low,low Placebo   0  42.342395 36.926861,NA,NA,0,1 1.0 1.0 1.0,1.0 1,1 1,1,1,1,1,1.0 0 1 1,1 1181,Frick_2017,< 2 months,NA,>= 20 yo,22.2057971014493,39.0319587628866 NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA,Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0 100 100 High,Amphetamine,Amphetamine,  0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability  1.38089758 NA NA Frick 2017,NA,RCT RR,205 104  309,outcomes,reverse, 3.2130000000  0.973000000, 1.061000e+01 NA,NA,NA NA NA,NA,NA NA 100 100,100,100 100 100 100 low low low low low Placebo   0  42.342395 36.926861 NA,NA 0,1,1.0 1.0 1.0 1.0 1 1 1 1 1,1 1 1.0,0 1,1 1 1182 Frick_2017 < 2 months,NA >= 20 yo,22.2057971014493,39.0319587628866,NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA,Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100 100 High,Atomoxetine Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA,CAARS-INV:SV  2.30149597 NA NA,Michelson 2003,NA RCT,G,124,124  248 outcomes,reverse -0.2410000000 -0.532000000, 4.900000e-02,NA NA NA,NA,NA NA, 9.3000000, 9.3000000,100 100 100,100,100,100 100 low,low low low,low Placebo,  0, 33.600000,42.100000,NA,NA,0,1,1.0 1.0 1.0 1.0 1 1 1 1 1 1 1,1.0 0,1,1 1,1183 Michelson_2003 2-6 months,NA,>= 20 yo,24.7 42.1 NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High Atomoxetine,Atomoxetine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks),NA,CAARS-S:L, 2.30149597,NA NA Michelson,2003,NA RCT G 124 124, 248 outcomes,reverse -0.2610000000 -0.552000000, 3.000000e-02 NA,NA,NA NA,NA NA,16.1000000 16.1000000,100,100 100 100 100,100 100 low low low low low,Placebo   0  33.600000,42.100000,NA,NA,0,1 1.0,1.0 1.0,1.0 1,1 1,1 1 1,1 1.0 0,1,1 1,1184,Michelson_2003,2-6 months,NA,>= 20 yo,24.7 42.1 NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100,High,Atomoxetine Atomoxetine   0,NA Emotional dysregulation Mixed,At study endpoint (closest to 12 weeks),NA,WRAADDS  2.30149597 NA,NA Michelson,2003 NA,RCT G,124 124, 248,outcomes,reverse,-0.2700000000 -0.543000000  3.000000e-03,NA,NA NA,NA,NA NA  5.7000000, 5.7000000,100 100 100,100,100,100 100 low,low low,low low Placebo,  0, 33.600000,42.100000,NA,NA,0,1,1.0 1.0 1.0,1.0 1,1,1,1 1,1,1,1.0 0,1 1 1,1185 Michelson_2003,2-6 months NA,>= 20 yo 40.2501872659176,42.1 NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA NA Ostinelli (2025)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100 High Atomoxetine,Atomoxetine   0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA Acceptability  2.30149597,NA,NA,Michelson,2003 NA RCT RR 129 127  256 outcomes reverse, 1.4460000000, 0.992000000, 2.107000e+00 NA NA,NA NA NA,NA,NA NA 100,100,100 100,100,100 100,low low,low low low Placebo   0  33.616406 42.107031,NA,NA,0,1 1.0 1.0,1.0,1.0 1,1 1,1,1 1 1,1.0 0 1,1 1,1186,Michelson_2003,2-6 months,NA >= 20 yo,24.7,42.10703125 NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100,High,Atomoxetine Atomoxetine   0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 2.30149597 NA NA,Michelson 2003,NA RCT,RR,129 127  256,outcomes,reverse, 3.9380000000  1.138000000, 1.362500e+01,NA,NA NA,NA,NA,NA,NA NA,100,100,100 100,100,100 100,low low low,low low Placebo,  0, 33.616406,42.107031,NA NA 0 1,1.0 1.0,1.0,1.0 1,1 1 1,1,1,1 1.0,0 1 1 1,1187 Michelson_2003 2-6 months NA,>= 20 yo,24.7,42.10703125 NA NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100,100 High,Amphetamine Amphetamine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,Other  0.92059839,  25.0000000,mg/d,Weisler,2017,NA,RCT G 177  86  263 outcomes reverse -0.7010000000 -1.042000000,-3.600000e-01 NA NA,NA,NA NA NA 11.4700000,11.4700000,100 100 100 100,100 100 100,low,low low,low low,Placebo,  0, 99.450663,33.288593,NA,NA,0 1,1.0 1.0 1.0 1.0,1 1 1,1,1 1 1,1.0,0,1 1 1 1188,Weisler_2017,< 2 months,NA,>= 20 yo 22.2059016393443,39.0276595744681,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Amphetamine,Amphetamine   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability, 0.92059839,  25.0000000 mg/d,Weisler 2017 NA,RCT RR,184, 91  275,outcomes reverse  1.2590000000, 0.657000000  2.413000e+00 NA NA,NA NA,NA,NA,NA,NA,100,100,100,100,100,100,100,low,low low low,low Placebo,  0, 99.451113,33.295636 NA,NA,0,1 1.0,1.0,1.0,1.0,1 1,1,1,1,1,1 1.0,0,1,1 1 1189 Weisler_2017 < 2 months,NA >= 20 yo,22.2057971014493,39.0319587628866 NA NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA NA,Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100,High,Amphetamine Amphetamine,  0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA Tolerability  0.92059839,  25.0000000,mg/d,Weisler 2017 NA,RCT RR 184  91  275 outcomes reverse 12.4320000000, 0.744000000  2.076650e+02,NA,NA NA NA NA,NA NA,NA,100 100,100 100,100 100 100 low,low low,low low,Placebo,  0  99.451113 33.295636 NA NA,0 1,1.0 1.0,1.0,1.0 1 1 1 1 1,1,1,1.0 0 1 1,1,1190 Weisler_2017 < 2 months,NA >= 20 yo,22.2057971014493 39.0319587628866,NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA,Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0,100 100 High Methylphenidate Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,ADHD-RS total  0.92059839,NA,NA Weiss,2020 NA RCT,G 297  78, 375,outcomes,reverse -0.3710000000 -0.622000000 -1.200000e-01, 11.8000000  12.0000000,NA,NA NA,NA NA,NA 100,100,100,100 100,100 100 low low low,low,low,Placebo,  0, 52.724000 36.053600,NA NA 0 1,1.0,1.0,1.0,1.0,1 1 1,1,1 1 1,1.0 0 1,1,1,1191,Weiss_2020 < 2 months,NA >= 20 yo 30.6,40,NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100 High Methylphenidate Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks),NA CAARS-S  0.92059839,NA NA,Weiss 2020 NA,RCT,G,297, 78  375 outcomes reverse,-0.2150000000,-0.465000000  3.500000e-02  12.4000000, 13.1000000 NA,NA NA,NA,NA NA 100 100 100 100 100 100,100,low,low low low low Placebo   0, 52.724000 36.053600,NA,NA,0,1,1.0 1.0,1.0 1.0,1 1,1 1 1,1,1 1.0,0 1,1,1 1192 Weiss_2020 < 2 months,NA,>= 20 yo,33.7462897526502 42 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100,High,Methylphenidate Methylphenidate,  0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability, 0.92059839 NA,NA,Weiss 2020 NA,RCT RR 297, 78, 375 outcomes,reverse, 0.9630000000, 0.481000000, 1.927000e+00 NA,NA,NA,NA NA,NA,NA NA,100,100 100,100,100 100 100 low,low,low low,low,Placebo,  0, 52.724000,36.053600,NA NA 0 1 1.0 1.0 1.0 1.0 1,1,1,1 1 1 1 1.0 0,1 1,1 1193 Weiss_2020 < 2 months NA,>= 20 yo,28.7959183673469 40 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100,100,High Methylphenidate Methylphenidate,  0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 0.92059839 NA NA,Weiss 2020 NA RCT RR 297  78  375,outcomes,reverse, 1.0510000000  0.228000000  4.848000e+00 NA,NA,NA,NA,NA NA,NA NA,100,100,100 100,100 100 100 low low,low,low,low Placebo,  0, 52.724000 36.053600,NA,NA,0 1 1.0 1.0 1.0,1.0 1 1,1 1,1 1,1 1.0 0,1 1,1,1194,Weiss_2020,< 2 months NA,>= 20 yo,28.7959183673469,40 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100,100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,ADHD-RS total, 2.76179517    5.0700000,mg/d Iwanami,2020,NA,RCT,G 100,100, 200,NA,reverse,-0.3680000000,-0.694000000 -4.100000e-02 NA,NA,NA,NA NA,NA 10.7000000 10.7000000 100 100 100 100   0,100,100 low,low high low low,Placebo,  0  35.500000 32.450000 NA,NA,0,1 1.0 1.0 1.0 1.0 1,1,1 1,1,1 1,1.0 0,1 1,1,1195,Iwanami_2020 2-6 months,NA >= 20 yo,32.45 32.45,NA,NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA NA,Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100,100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA Emotional dysregulation Mixed At study endpoint (closest to 12 weeks) NA BRIEF-ASR Emotional control, 2.76179517,   5.0700000 mg/d,Iwanami,2020,NA,RCT,G,100 100  200 NA,reverse, 0.1170000000 -0.161000000, 3.940000e-01 NA NA NA,NA NA,NA,13.3000000,13.3000000 100 100 100 100   0,100,100 low low high low,low,Placebo   0  35.500000 32.450000,NA,NA 0 1 1.0,1.0 1.0 1.0 1 1,1 1,1,1 1,1.0 0,1,1 1 1196 Iwanami_2020 2-6 months NA >= 20 yo 32.45,32.45,NA,NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA,NA Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA,Quality of life (patients) Mixed,At study endpoint (closest to 12 weeks),NA,AAQoL, 2.76179517    5.0700000 mg/d,Iwanami 2020,NA RCT,G,100 100  200,NA reverse,-0.1520000000 -0.431000000  1.270000e-01 NA,NA,NA,NA,NA NA,24.3000000,24.3000000,100,100 100,100,  0,100,100,low,low,high low,low Placebo   0, 35.500000,32.450000 NA NA 0,1 1.0 1.0 1.0 1.0,1 1,1,1,1 1 1,1.0 0 1 1,1 1197,Iwanami_2020 2-6 months NA,>= 20 yo,32.45 32.45 NA,NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA,NA,Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0 100,100 High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability  2.76179517,   5.0700000,mg/d Iwanami 2020,NA RCT RR 101,100  201 NA,reverse, 3.1120000000  1.392000000  6.955000e+00,NA,NA NA NA NA,NA,NA NA 100 100,100,100 100 100 100 low,low low,low low,Placebo,  0  35.492537 32.443284,NA NA 0,1,1.0,1.0,1.0,1.0,1 1,1,1 1,1,1,1.0,0 1,1 1,1198,Iwanami_2020 2-6 months NA,>= 20 yo 32.4432835820896,32.4432835820896 NA NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2,NA NA,Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100 100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability  2.76179517,   5.0700000,mg/d,Iwanami,2020,NA,RCT,RR 101 100, 201,NA reverse, 6.6010000000, 2.025000000  2.151500e+01 NA,NA,NA NA NA NA,NA NA 100 100,100,100,100,100 100,low,low low,low low,Placebo   0, 35.492537,32.443284 NA NA 0 1,1.0 1.0,1.0,1.0,1,1 1,1 1,1,1 1.0,0 1,1 1,1199,Iwanami_2020 2-6 months,NA,>= 20 yo 32.4432835820896 32.4432835820896 NA,NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA,NA Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Amphetamine,Amphetamine   0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA Tolerability, 0.92059839   59.1000000,mg/d Adler 2021 NA,RCT RR, 17, 21,  38,outcomes,reverse, 0.4070000000  0.018000000, 9.407000e+00 NA,NA,NA,NA NA,NA NA,NA,  0   0,  0   0,  0   0   0,high high,high,high,high,Placebo,  0  65.800000 34.000000,NA,NA 0,1 1.0,1.0,1.0 1.0 1,1 1,1 1,1 1,1.0,0 1,1 1 1200,Adler_2021,< 2 months NA,>= 20 yo 22.2057971014493 39.0319587628866 NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA,Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high high
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100,High Amphetamine Amphetamine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA ADHD-SRS total, 1.15074799,  30.0000000,mg/d Faraone 2021,NA,RCT,G 214,106  320,outcomes,reverse,-0.1320000000,-0.406000000, 1.420000e-01 NA NA NA,NA,NA,NA 13.2813629,13.2813629,  0   0   0   0,  0   0   0 high,high high high high Placebo,  0  45.622500,34.467500,NA,NA 0,1,1.0 1.0 1.0,1.0,1 1 1 1 1 1 1 1.0 0 1 1 1 1201,Faraone_2021,< 2 months,NA,>= 20 yo,22.2059016393443,39.0276595744681,NA,NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no high high
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100 High,Amphetamine Amphetamine,  0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability  1.15074799,  30.0000000 mg/d Faraone 2021,NA RCT RR,214,106, 320 outcomes,reverse, 1.4150000000  0.806000000, 2.483000e+00 NA NA NA,NA NA NA NA,NA 100,100,100,100 100,100,100,low,low low,low,low,Placebo   0  45.622500 34.467500 NA,NA 0,1,1.0 1.0 1.0,1.0 1,1,1,1,1,1 1 1.0 0,1 1,1 1202 Faraone_2021,< 2 months,NA >= 20 yo 22.2057971014493,39.0319587628866,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA,Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100 100 High,Amphetamine Amphetamine   0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability, 1.15074799   30.0000000 mg/d,Faraone,2021,NA,RCT RR,214 106  320,outcomes reverse  1.1560000000, 0.305000000, 4.380000e+00,NA NA NA,NA,NA,NA NA,NA,100 100 100 100 100,100 100,low low low low low Placebo   0, 45.622500 34.467500,NA NA,0,1,1.0,1.0 1.0,1.0,1,1 1,1,1,1 1 1.0 0,1 1 1,1203 Faraone_2021,< 2 months NA,>= 20 yo,22.2057971014493,39.0319587628866,NA,NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100,High TMS ([repetitive] transcranial magnetic stimulation),TMS ([repetitive] transcranial magnetic stimulation),  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks),NA CAARS-S:L  0.69044879 NA,NA,Alyagon 2020 NA RCT,G  15, 14   29,outcomes,reverse,-0.8570000000,-1.692000000,-2.200000e-02 NA NA NA,NA,NA,NA  7.1091490  7.1091490,100,100 100 100,100 100 100,low low some,low,low Sham   0  82.789655,27.112414 NA,NA 0,1,1.0,1.0 1.0 1.0 1,1 1 1 1,1 1 1.0 0 1,1,1 1204 Alyagon_2020,< 2 months NA >= 20 yo,27.1124137931034 35.24,NA NA   4, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1 Ostinelli (2025) 27.0733333333333 35.24,NA NA Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100 High TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation),  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability, 0.69044879,NA NA,Alyagon,2020 NA RCT RR, 20, 16   36,outcomes reverse, 1.8000000000, 0.677000000, 4.783000e+00 NA NA,NA,NA,NA,NA,NA NA 100 100 100,100 100,100 100,low low low low,low Sham,  0  83.100000,27.073333 NA NA 0,1 1.0,1.0,1.0 1.0,1 1,1 1 1,1,1 1.0,0,1 1,1 1205 Alyagon_2020,< 2 months NA >= 20 yo 27.0733333333333,35.22,NA NA   4, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1 Ostinelli (2025),27.0733333333333,35.24 NA NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation),  0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability  0.69044879 NA,NA Alyagon,2020 NA RCT,RR  20, 16,  36,outcomes,reverse, 0.8100000000  0.017000000, 3.871100e+01 NA NA,NA,NA NA NA NA,NA 100 100 100,100 100,100 100 low,low low,low,low,Sham   0  83.100000 27.073333,NA NA,0 1,1.0,1.0 1.0,1.0 1 1 1,1 1,1 1,1.0,0 1,1 1 1206,Alyagon_2020,< 2 months NA,>= 20 yo 27.0733333333333,35.22 NA NA   4  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests), 1 Ostinelli (2025) 27.0733333333333,35.24 NA NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100,100 High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA,CAARS-S:L  1.84119678,NA,NA Anastopoulos 2021,NA RCT,G,111,109  220,outcomes reverse -0.1930000000,-0.458000000, 7.200000e-02,  9.1600000  10.4300000 NA,NA NA NA NA,NA 100,100,100 100,100,100 100 some some,some some low,WLC,  0  65.443182 19.650455,NA,NA 0,1 1.0,1.0,1.0,1.0 1,1,1 1 1,1,1 1.0 0 1,1,1 1207 Anastopoulos_2021 < 2 months,NA 13-19 yo 19.6504545454545 43.1027777777778,NA,NA  19, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15,NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0,100,100 High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At follow-up (closest to 26 weeks),NA,CAARS-S:L, 1.84119678,NA NA Anastopoulos,2021,NA RCT G, 95 102, 197 outcomes,reverse,-0.3380000000,-0.620000000,-5.600000e-02   9.4800000   9.4800000 NA,NA NA NA NA,NA,100 100 100 100,100,100,100 some some some some low,WLC   0  65.476650 19.648223 NA,NA 0 1 1.0 1.0 1.0 1.0 1,1,1,1 1 1 1 1.0,0 1,1,1 1208 Anastopoulos_2021 < 2 months NA 13-19 yo,19.6482233502538 43.0524590163934 NA NA  19, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15,NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100 100 High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 1.84119678,NA NA,Anastopoulos 2021,NA RCT RR,149,131, 280,outcomes reverse, 1.6370000000  1.114000000, 2.407000e+00 NA NA,NA NA,NA,NA NA,NA,100,100 100 100,100 100 100,some some low some low WLC,  0, 65.401786 19.653214,NA,NA,0,1 1.0,1.0,1.0,1.0 1 1 1,1,1 1 1 1.0 0,1 1,1 1209,Anastopoulos_2021,< 2 months,NA,13-19 yo 19.6532142857143,43.15,NA NA, 19, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100 100,High,TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks),NA,CAARS-S:L, 1.84119678,NA NA Bleich-Cohen,2021,NA RCT,G, 24, 16,  40 outcomes reverse, 0.1090000000,-0.532000000, 7.500000e-01, 13.0200000, 12.4700000 NA NA,NA NA NA NA,100,100 100 100 100,100 100 some some low low,some,Sham,  0  37.520000 35.240000 NA NA 0 1,1.0 1.0,1.0 1.0 1 1,1,1 1,1,1,1.0,0 1 1,1,1210 Bleich-Cohen_2021,< 2 months NA >= 20 yo 27.1124137931034 35.24 NA,NA   4, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1,Ostinelli (2025) 27.0733333333333,35.24 NA NA Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0,100,100 High TMS ([repetitive] transcranial magnetic stimulation),TMS ([repetitive] transcranial magnetic stimulation),  0,NA,Quality of life (patients),Mixed At study endpoint (closest to 12 weeks) NA,AAQoL  1.84119678 NA NA Bleich-Cohen,2021 NA RCT G, 24  16   40,outcomes reverse,-0.2190000000 -0.861000000, 4.230000e-01, 15.1100000, 18.5700000 NA NA NA,NA,NA NA,100 100,100 100,100 100,100,some,some low,low,some Sham   0, 37.520000 35.240000 NA NA,0 1,1.0 1.0 1.0,1.0 1 1,1 1,1 1 1 1.0 0,1,1 1,1211 Bleich-Cohen_2021,< 2 months,NA,>= 20 yo,34.9315789473684 35.24,NA,NA   4  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1 Ostinelli (2025),27.0733333333333 35.24 NA,NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0,100 100 High,TMS ([repetitive] transcranial magnetic stimulation),TMS ([repetitive] transcranial magnetic stimulation),  0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability  1.84119678 NA,NA,Bleich-Cohen 2021 NA RCT,RR  26, 19   45 outcomes,reverse  0.4870000000, 0.090000000  2.636000e+00,NA NA,NA NA,NA,NA,NA,NA,100,100,100,100 100 100 100 some,some low,some low,Sham   0  37.982222,35.220000,NA NA 0 1,1.0,1.0,1.0,1.0,1,1 1,1 1 1 1,1.0 0 1 1 1 1212,Bleich-Cohen_2021,< 2 months,NA,>= 20 yo,27.0733333333333,35.22,NA,NA,  4  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests), 1,Ostinelli (2025),27.0733333333333,35.24 NA,NA Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100,100,High TMS ([repetitive] transcranial magnetic stimulation),TMS ([repetitive] transcranial magnetic stimulation)   0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA Tolerability  1.84119678 NA,NA Bleich-Cohen,2021,NA,RCT RR  26  19,  45,outcomes reverse  0.7310000000  0.113000000, 4.735000e+00 NA,NA NA NA NA NA,NA,NA,100,100,100,100 100,100 100,some,some low some,low,Sham   0  37.982222,35.220000,NA,NA,0 1,1.0 1.0 1.0,1.0 1 1,1 1 1,1,1 1.0,0,1 1,1,1213,Bleich-Cohen_2021 < 2 months,NA,>= 20 yo 27.0733333333333,35.22 NA NA   4  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1,Ostinelli (2025),27.0733333333333,35.24,NA NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100,100,High,TMS ([repetitive] transcranial magnetic stimulation),TMS ([repetitive] transcranial magnetic stimulation)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks) NA CAARS-S:L  1.84119678 NA NA,Bleich-Cohen 2021,NA RCT G, 22  16   38,outcomes reverse  0.5760000000 -0.090000000  1.242000e+00  12.7400000, 12.4700000,NA,NA NA,NA NA NA 100,100,100,100 100,100,100,some some,low,low,some Sham   0  39.521053 34.931579 NA NA,0,1 1.0 1.0 1.0 1.0,1 1 1 1,1,1 1,1.0 0 1,1,1,1214,Bleich-Cohen_2021,< 2 months NA,>= 20 yo 27.1124137931034,35.24 NA NA,  4  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1,Ostinelli (2025) 27.0733333333333,35.24,NA,NA Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0 100,100 High,TMS ([repetitive] transcranial magnetic stimulation),TMS ([repetitive] transcranial magnetic stimulation),  0 NA,Quality of life (patients),Mixed,At study endpoint (closest to 12 weeks),NA,AAQoL  1.84119678 NA,NA,Bleich-Cohen 2021,NA RCT G  22, 16   38 outcomes reverse,-0.5310000000 -1.195000000  1.330000e-01  16.3000000  18.5700000 NA NA NA,NA NA NA 100 100,100,100 100,100 100,some some,low,low,some,Sham,  0  39.521053 34.931579 NA,NA,0 1,1.0 1.0,1.0 1.0,1,1 1 1 1 1 1,1.0,0 1 1 1,1215 Bleich-Cohen_2021 < 2 months,NA >= 20 yo,34.9315789473684,35.24 NA,NA   4  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1,Ostinelli (2025),27.0733333333333 35.24,NA,NA Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100 100,High,TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation),  0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,Acceptability, 1.84119678,NA,NA Bleich-Cohen,2021,NA,RCT,RR  28, 19   47,outcomes reverse, 0.9050000000, 0.228000000, 3.593000e+00,NA NA,NA,NA NA,NA NA,NA,100 100,100 100,100,100,100 some some,low,some,low Sham,  0  39.217021,34.938298,NA,NA 0,1,1.0,1.0 1.0,1.0 1,1 1 1,1 1,1,1.0,0 1 1 1 1216 Bleich-Cohen_2021,< 2 months,NA,>= 20 yo 27.0733333333333 35.22 NA NA   4, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1 Ostinelli (2025),27.0733333333333,35.24 NA,NA Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100 100,High,TMS ([repetitive] transcranial magnetic stimulation),TMS ([repetitive] transcranial magnetic stimulation)   0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability, 1.84119678 NA,NA Bleich-Cohen,2021,NA RCT RR  28, 19,  47 outcomes,reverse  1.3570000000, 0.276000000  6.684000e+00,NA NA,NA,NA NA,NA,NA,NA,100,100,100 100,100 100 100,some,some low,some,low Sham,  0, 39.217021,34.938298,NA NA,0,1,1.0,1.0 1.0 1.0 1,1 1,1,1,1,1,1.0 0 1,1,1,1217 Bleich-Cohen_2021,< 2 months,NA,>= 20 yo 27.0733333333333,35.22,NA NA   4  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests), 1,Ostinelli (2025) 27.0733333333333 35.24,NA,NA Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100,High,tDCS (transcranial direct current stimulation) tDCS (transcranial direct current stimulation)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks),NA,ASRS  0.92059839,NA NA Cachoeira,2016 NA RCT,G   8   8,  16,NA reverse,-0.6350000000 -1.677000000, 4.070000e-01, 11.9076782, 12.0490996 NA,NA NA,NA NA NA,100 100 100 100 100,100 100,low low low low,low,Sham   0, 52.800000 32.375000 NA,NA 0 1 1.0 1.0,1.0 1.0,1,1 1,1 1,1 1,1.0,0 1 1 1 1218 Cachoeira_2016 < 2 months NA >= 20 yo 32.375,32.375,NA NA  19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA,NA,Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100,High,tDCS (transcranial direct current stimulation),tDCS (transcranial direct current stimulation)   0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability, 0.92059839,NA NA Cachoeira 2016,NA RCT RR   9   8,  17,outcomes,reverse  2.7000000000  0.125000000  5.823900e+01,NA,NA,NA NA,NA,NA NA NA,100,100 100,100,100,100 100,low low,low low low,Sham,  0, 52.964706,32.294118,NA NA 0 1 1.0 1.0,1.0,1.0,1,1,1 1 1,1 1,1.0 0,1 1,1,1219 Cachoeira_2016 < 2 months,NA >= 20 yo,22.085 38.3 NA NA, 19  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857,NA,NA,Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100 High tDCS (transcranial direct current stimulation),tDCS (transcranial direct current stimulation),  0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability  0.92059839 NA,NA,Cachoeira 2016 NA RCT,RR,  9   8   17,outcomes,reverse, 2.7000000000  0.125000000, 5.823900e+01 NA,NA NA NA,NA,NA NA NA 100 100 100 100 100,100,100 low low,low,low,low,Sham,  0, 52.964706,32.294118,NA NA,0,1 1.0 1.0,1.0 1.0,1 1,1,1 1 1 1 1.0,0,1 1,1,1220 Cachoeira_2016 < 2 months,NA,>= 20 yo 32.2941176470588 38.3 NA,NA, 19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA NA Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Cognitive training,Cognitive training   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) NA CAARS hyperactivity, 1.15074799 NA,NA,Dentz,2017,NA RCT,G, 23  21   44 outcomes,reverse, 0.0000000000 -0.598000000  5.980000e-01,  3.1400000,  4.0800000 NA,NA NA NA,NA,NA,100,100,100,100,100 100,100 low some some,low,low,Cognitive placebo   0, 61.390909 41.589545,NA NA,0,1 1.0 1.0 1.0,1.0 1 1 1,1 1 1 1,1.0 0 1,1 1,1221,Dentz_2017,< 2 months,NA >= 20 yo,25.7931034482759 41.5895454545455,NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA Ostinelli (2025)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2   0   0,100,100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT) 100 tau,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,Kiddie SADS, 1.84119678,NA,NA Emilsson,2011 NA RCT G  17  17   34 outcomes,reverse,-1.0080000000 -1.734000000,-2.820000e-01,  7.2300000,  4.0800000 NA,NA NA NA NA NA 100,100,100 100,100 100,100,low some,some some,some TAU,  0 NA NA,NA,NA,0,1,1.0,1.0,1.0,1.0 1 1 1,1 1 1 1 1.0 0 1 1,1,1222,Emilsson_2011 < 2 months NA,NA,39.1739024390244 43.1064102564103 NA,NA, 19, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,  0,  0 100,100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),100 tau,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) NA,Other, 1.84119678 NA NA Emilsson,2011,NA RCT G, 18  17   35,outcomes reverse -0.7440000000 -1.440000000 -4.700000e-02   7.6200000   8.8000000,NA,NA,NA NA,NA NA,100,100 100 100,100,100 100,low some,some some,some TAU,  0 NA NA,NA,NA 0 1,1.0 1.0,1.0 1.0 1,1,1,1,1,1,1,1.0,0,1,1,1 1223 Emilsson_2011,< 2 months NA NA 19.6504545454545 43.1027777777778 NA NA  19  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,  0   0 100 100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),100 tau Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 1.84119678,NA,NA,Emilsson 2011 NA RCT RR  27, 27,  54,outcomes reverse, 1.1670000000  0.451000000  3.020000e+00 NA NA NA,NA NA NA NA NA 100 100,100 100,100,100 100 low,some,low,some low TAU,  0,NA NA,NA,NA 0 1 1.0 1.0 1.0 1.0 1 1 1,1 1,1,1,1.0 0,1 1,1,1224 Emilsson_2011,< 2 months NA NA,19.6532142857143,43.15,NA,NA, 19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100,High Mindfulness,Mindfulness   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks) NA,CAARS-S:L, 1.38089758,NA,NA,Gu 2017,NA,RCT G, 28, 26,  54 outcomes,reverse,-1.2450000000,-1.835000000,-6.550000e-01,  8.3500000   9.1700000,NA NA NA NA,NA NA 100,100,100,100,100,100,100 some some low,some,some WLC   0, 44.488889,20.291852 NA,NA 0 1,1.0,1.0,1.0,1.0 1,1 1 1,1 1 1 1.0,0,1 1,1,1225,Gu_2017,< 2 months,NA,>= 20 yo 20.2918518518519,39.3401869158878,NA NA  13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35,NA,NA Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100,100,High,Mindfulness,Mindfulness   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At follow-up (closest to 26 weeks),NA CAARS-S:S, 1.38089758,NA NA,Gu,2017 NA,RCT,G, 28, 26   54 outcomes,reverse -1.1440000000,-1.726000000,-5.620000e-01,  9.8100000,  8.4400000 NA NA NA NA NA,NA 100,100 100 100,100,100 100 some,some low,some some WLC   0  44.488889 20.291852,NA,NA,0,1,1.0 1.0,1.0 1.0,1,1 1 1 1,1,1,1.0,0,1 1,1,1226,Gu_2017,< 2 months,NA,>= 20 yo 20.2918518518519 39.337037037037,NA NA  13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08 39.35,NA NA Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100,100,High,Mindfulness Mindfulness,  0,NA Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks) NA ANT alerting error score  1.38089758 NA NA,Gu,2017 NA,RCT G, 28, 26,  54 outcomes,reverse -1.2610000000 -1.852000000 -6.700000e-01,  0.0050000,  0.0100000,NA NA NA,NA NA,NA 100 100 100 100 100 100,100,some some low some some,WLC,  0  44.488889,20.291852 NA,NA,0,1,1.0,1.0 1.0,1.0 1,1,1,1 1,1,1,1.0,0 1 1,1,1227 Gu_2017 < 2 months NA,>= 20 yo,20.2918518518519,38.6015,NA NA, 13, 8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35 NA NA Ostinelli (2025)_Mindfulness_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Mindfulness_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100,100 High Mindfulness Mindfulness,  0,NA,Executive functioning (tests) Mixed,At follow-up (closest to 26 weeks) NA ANT alerting error score, 1.38089758 NA NA,Gu 2017,NA RCT G  28  26,  54,outcomes reverse -1.2310000000 -1.820000000,-6.420000e-01   0.0050000,  0.0090000 NA NA,NA,NA,NA NA,100 100 100,100,100 100,100,some,some,low,some,some WLC   0, 44.488889 20.291852,NA,NA 0 1 1.0 1.0 1.0 1.0,1,1,1 1 1,1 1 1.0,0,1 1,1 1228 Gu_2017,< 2 months NA >= 20 yo 20.2918518518519,39.337037037037,NA NA  13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35,NA,NA Ostinelli (2025)_Mindfulness_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous,Ostinelli (2025) - Mindfulness_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Mindfulness,Mindfulness,  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability  1.38089758,NA,NA Gu 2017 NA,RCT RR  30, 26   56,outcomes reverse  4.3550000000, 0.219000000, 8.679000e+01 NA,NA NA,NA,NA NA,NA NA 100,100 100,100 100,100 100 some some low some low WLC,  0, 44.432143,20.288929,NA,NA 0 1 1.0 1.0 1.0,1.0,1 1,1,1 1,1,1,1.0 0 1 1 1,1229 Gu_2017 < 2 months,NA >= 20 yo,20.2889285714286 39.35 NA NA  13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35,NA,NA,Ostinelli (2025)_Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100,100 High,Mindfulness,Mindfulness   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA CAARS-O:L  2.76179517,NA,NA,Hepark,2015,NA,RCT,G, 41, 42   83,outcomes,reverse,-0.8470000000 -1.299000000,-3.950000e-01,  7.7000000,  7.5000000,NA NA,NA,NA,NA,NA,100,100 100,100,100 100,100 low some some,low some WLC,  0  53.903614 35.842169 NA,NA 0 1 1.0 1.0,1.0 1.0 1,1,1,1,1,1 1,1.0,0,1,1 1,1230 Hepark_2015,2-6 months NA,>= 20 yo 35.8421686746988,39.3401869158878,NA,NA  13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35,NA,NA,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100 High,Mindfulness,Mindfulness   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks),NA,CAARS-S:L  2.76179517 NA,NA,Hepark 2015,NA RCT,G, 41  42   83,outcomes reverse -0.8090000000 -1.260000000,-3.590000e-01   7.3000000   6.9000000,NA,NA,NA NA NA,NA 100 100,100 100 100,100 100 low,some,some low some WLC   0  53.903614,35.842169 NA NA 0,1 1.0 1.0,1.0,1.0,1,1,1 1,1 1,1 1.0 0 1 1,1,1231 Hepark_2015 2-6 months,NA,>= 20 yo 20.2918518518519,39.3401869158878,NA,NA  13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35 NA,NA Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100 High,Mindfulness Mindfulness,  0,NA,Emotional dysregulation,Mixed,At study endpoint (closest to 12 weeks),NA BRIEF-ASR Emotional control  2.76179517 NA,NA Hepark 2015,NA RCT,G, 41  42   83 outcomes reverse,-0.3510000000,-0.787000000, 8.500000e-02,  4.7000000,  4.9000000 NA NA NA NA,NA,NA,100 100,100 100 100,100,100 low some some low some,WLC,  0  53.903614,35.842169 NA,NA,0 1,1.0,1.0,1.0 1.0 1,1,1 1,1 1,1 1.0,0 1,1,1,1232,Hepark_2015,2-6 months NA >= 20 yo,35.8421686746988,38.6015 NA,NA, 13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35,NA NA Ostinelli (2025)_Mindfulness_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Mindfulness_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100 High,Mindfulness Mindfulness   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability, 2.76179517 NA,NA Hepark 2015 NA,RCT RR  55, 48  103,outcomes,reverse 16.6250000000  0.993000000  2.783170e+02,NA,NA,NA,NA NA,NA,NA NA,100,100,100,100,100 100,100,low some low,some,low WLC,  0  54.543689,35.894175,NA,NA,0,1,1.0,1.0,1.0,1.0 1 1 1 1 1 1 1,1.0 0,1 1,1 1233,Hepark_2015 2-6 months NA >= 20 yo 20.2889285714286,39.35 NA NA, 13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35,NA NA Ostinelli (2025)_Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100,100 High Mindfulness Mindfulness 100,tau Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA CAARS-INV:SV, 1.84119678 NA,NA Janssen 2018,NA,RCT,G, 52, 55, 107 outcomes,reverse -0.4330000000 -0.818000000 -4.700000e-02, 10.2000000,  8.6000000,NA,NA NA NA NA NA 100,100,100 100,100 100,100,some some,low,low,low TAU,  0, 53.000000,39.340187,NA,NA,0,1 1.0,1.0,1.0,1.0 1 1,1 1,1 1 1 1.0 0 1,1 1,1234 Janssen_2018,< 2 months NA,>= 20 yo 35.8421686746988 39.3401869158878 NA NA  13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08 39.35,NA NA,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100 100 High,Mindfulness,Mindfulness,100 tau Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At follow-up (closest to 26 weeks),NA CAARS-INV:SV, 1.84119678 NA,NA Janssen 2018,NA,RCT G, 52  56  108,NA reverse -0.4280000000 -0.811000000 -4.500000e-02   9.7000000   7.4000000 NA NA NA,NA NA NA 100 100 100 100,100 100,100,some,some low,low low,TAU,  0, 53.000000,39.337037 NA NA 0,1,1.0,1.0,1.0 1.0,1,1,1,1 1 1,1 1.0,0 1,1,1,1235 Janssen_2018,< 2 months NA,>= 20 yo,39.337037037037 39.337037037037 NA,NA  13, 8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08 39.35,NA NA,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks),1 Homogeneous Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100,100,High,Mindfulness Mindfulness,100,tau,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks),NA,CAARS-S:S, 1.84119678 NA NA,Janssen 2018,NA RCT,G, 52, 55, 107 outcomes,reverse,-0.3940000000,-0.779000000 -1.000000e-02,  6.8000000,  6.3000000,NA NA NA NA NA NA 100,100 100,100,100,100 100 some some low,low,low,TAU   0, 53.000000 39.340187,NA,NA,0,1 1.0,1.0 1.0 1.0 1,1,1 1 1,1,1,1.0,0,1 1,1,1236 Janssen_2018 < 2 months,NA >= 20 yo 20.2918518518519 39.3401869158878,NA,NA  13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35 NA,NA,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100,High Mindfulness Mindfulness 100 tau,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At follow-up (closest to 26 weeks) NA,CAARS-S:S, 1.84119678,NA,NA,Janssen,2018 NA RCT G  52  56, 108,outcomes,reverse,-0.6730000000 -1.063000000 -2.840000e-01,  8.0000000   6.1000000,NA NA,NA NA NA,NA,100 100,100,100 100,100,100 some some,low,low,low TAU   0, 53.000000 39.337037,NA NA,0,1 1.0,1.0,1.0,1.0 1 1,1,1,1 1,1 1.0,0 1,1 1 1237,Janssen_2018 < 2 months,NA,>= 20 yo,20.2918518518519,39.337037037037 NA,NA  13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08 39.35,NA,NA,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 1 Homogeneous,Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000,no low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100,100,High Mindfulness Mindfulness 100,tau Executive functioning (tests) Mixed At follow-up (closest to 26 weeks),NA,BRIEF-A Executive function  1.84119678,NA,NA,Janssen 2018 NA RCT,G, 52, 56, 108 outcomes,reverse -0.4860000000 -0.870000000,-1.010000e-01, 25.7000000, 17.6000000,NA,NA,NA NA,NA NA,100,100 100,100 100,100 100,some some,low,low,low,TAU   0  53.000000 39.337037 NA NA,0,1 1.0,1.0,1.0 1.0 1 1,1 1 1,1 1,1.0 0 1,1,1,1238,Janssen_2018 < 2 months,NA >= 20 yo 20.2918518518519,39.337037037037,NA,NA  13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35,NA,NA Ostinelli (2025)_Mindfulness_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks),1 Homogeneous Ostinelli (2025) - Mindfulness_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100,100,High,Mindfulness,Mindfulness 100 tau,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability  1.84119678,NA NA Janssen 2018,NA,RCT RR  60  60  120 outcomes,reverse,19.0000000000, 1.131000000, 3.192650e+02 NA NA,NA,NA,NA,NA NA NA,100,100 100 100 100 100,100,some some low,some low,TAU,  0, 53.000000,39.350000 NA NA 0,1,1.0 1.0 1.0 1.0,1,1,1,1 1,1 1 1.0 0,1,1,1,1239 Janssen_2018 < 2 months NA,>= 20 yo 20.2889285714286 39.35 NA,NA  13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35,NA NA Ostinelli (2025)_Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100 100,High Methylphenidate Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA,CAARS-O:S  2.76179517 NA,NA,Konstenius 2010 NA,RCT G, 12  12   24,outcomes reverse,-0.0350000000,-0.841000000  7.710000e-01,NA,NA,NA,NA,NA NA 13.8000000 13.8000000 100,100 100 100 100,100 100,low some low some,some Active [Placebo + skill training] 100  21.000000,37.150000 NA,NA 0,1,1.0 1.0 1.0 1.0 1,1 1,1 1 1 1 1.0 0 1,1,1 1240 Konstenius_2010 2-6 months NA >= 20 yo 30.6,40,NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100 100 High Methylphenidate,Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks) NA,CAARS-S:L, 2.76179517,NA,NA Konstenius,2010 NA,RCT,G, 12  12   24,outcomes,reverse,-0.9460000000 -1.933000000  4.000000e-02 NA,NA,NA,NA NA,NA,19.8000000,19.8000000,100 100 100,100 100 100 100 low some,low some some Active [Placebo + skill training] 100, 21.000000,37.150000,NA,NA 0 1,1.0 1.0,1.0 1.0 1,1,1 1 1 1,1,1.0,0 1,1,1 1241 Konstenius_2010 2-6 months,NA,>= 20 yo,33.7462897526502,42 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100,High,Methylphenidate,Methylphenidate   0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability  2.76179517 NA NA,Konstenius 2010 NA,RCT RR  12  12,  24 outcomes reverse  2.5000000000  0.597000000  1.046100e+01,NA,NA,NA NA,NA,NA NA,NA 100 100,100,100,100 100,100,low,some,low,some,low,Active [Placebo + skill training] 100  21.000000 37.150000,NA,NA,0 1,1.0,1.0 1.0 1.0,1 1,1,1,1 1 1,1.0 0,1,1 1,1242 Konstenius_2010 2-6 months NA,>= 20 yo,28.7959183673469,40 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100,100 High,Methylphenidate Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks),NA Other  0.69044879 NA NA,Kooij 2004 NA RCT G  25  20,  45 outcomes reverse,-0.2890000000 -0.887000000, 3.090000e-01,  0.6500000   0.5600000 NA NA,NA NA NA,NA,100 100 100,100 100 100,100,low low,low low low Placebo   0  46.700000 39.100000 NA NA 0 1 1.0 1.0,1.0,1.0,1 1,1,1 1,1 1,1.0 0 1,1 1 1243,Kooij_2004,< 2 months,NA >= 20 yo 33.7462897526502,42 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100 100,High Methylphenidate,Methylphenidate,  0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability, 0.69044879 NA,NA,Kooij,2004,NA RCT,RR, 25, 20   45 outcomes reverse, 0.8080000000  0.017000000, 3.901500e+01,NA,NA NA NA NA,NA,NA,NA 100,100,100,100,100 100,100 low,low,low,low,low,Placebo   0  46.700000,39.100000,NA NA 0,1 1.0,1.0,1.0 1.0 1 1,1,1 1 1,1,1.0,0 1,1,1,1244,Kooij_2004 < 2 months NA,>= 20 yo,28.7959183673469,40 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100,High Methylphenidate,Methylphenidate,  0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability  0.69044879 NA NA,Kooij 2004 NA RCT RR, 25, 20   45,outcomes,reverse, 0.8080000000  0.017000000, 3.901500e+01,NA,NA,NA,NA,NA,NA NA NA,100 100,100,100 100,100,100,low,low low low low,Placebo   0  46.700000 39.100000,NA NA,0,1 1.0 1.0 1.0,1.0,1 1 1 1,1 1,1,1.0,0 1 1 1 1245 Kooij_2004 < 2 months NA >= 20 yo 28.7959183673469 40 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0,100,100 High Mindfulness,Mindfulness,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA,Current ADHD Symptom Scale, 1.84119678,NA NA,Mitchell,2017 NA,RCT G  11,  9,  20 outcomes reverse -2.4090000000,-3.617000000 -1.201000e+00,  4.2600000   3.8400000 NA NA,NA,NA NA,NA,100 100,100 100,100,100 100 some some some,some,some,WLC,  0  59.990000 38.601500 NA,NA,0 1 1.0 1.0 1.0 1.0,1 1 1,1,1 1 1,1.0,0 1 1 1 1246 Mitchell_2017,< 2 months,NA,>= 20 yo,35.8421686746988 39.3401869158878 NA,NA  13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35,NA,NA Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0 100 100,High Mindfulness,Mindfulness   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks),NA,CASS-L  1.84119678,NA NA,Mitchell 2017,NA,RCT,G  11   9   20 outcomes,reverse -1.7140000000,-2.783000000,-6.460000e-01,  4.8800000   5.0100000,NA NA,NA,NA,NA,NA 100 100,100,100 100 100 100 some,some,some,some some,WLC   0  59.990000 38.601500 NA NA,0 1 1.0 1.0,1.0 1.0 1 1,1 1,1,1,1 1.0 0,1,1,1 1247 Mitchell_2017 < 2 months NA >= 20 yo 20.2918518518519,39.3401869158878,NA NA  13  8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35 NA,NA,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100,100,High Mindfulness Mindfulness   0,NA,Emotional dysregulation,Mixed,At study endpoint (closest to 12 weeks) NA,BRIEF-ASR Emotional control, 1.84119678,NA NA,Mitchell 2017 NA RCT,G  11   9   20,outcomes,reverse, 0.3060000000,-0.604000000  1.216000e+00,  2.7900000,  5.0300000,NA,NA NA,NA NA NA 100 100 100,100 100,100 100,some,some,some,some some WLC   0, 59.990000,38.601500 NA NA 0,1 1.0,1.0,1.0,1.0,1,1,1 1 1,1 1,1.0 0 1 1 1 1248 Mitchell_2017,< 2 months NA,>= 20 yo 35.8421686746988 38.6015,NA,NA, 13  8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35,NA NA Ostinelli (2025)_Mindfulness_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Mindfulness_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100 100 High Mindfulness Mindfulness,  0,NA Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks) NA CPT omission, 1.84119678,NA,NA,Mitchell,2017,NA RCT G  11   9   20 outcomes reverse -0.1700000000 -1.076000000  7.360000e-01   1.2900000   2.2800000,NA NA NA NA NA,NA 100 100 100,100,100 100,100,some,some some,some,some WLC   0, 59.990000,38.601500,NA,NA 0,1 1.0 1.0,1.0 1.0 1 1,1 1 1 1,1,1.0 0,1,1 1,1249,Mitchell_2017 < 2 months,NA,>= 20 yo,20.2918518518519 38.6015,NA,NA, 13, 8,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation, 4 Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35 NA NA Ostinelli (2025)_Mindfulness_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Mindfulness_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0,100,100,High Mindfulness Mindfulness,  0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability, 1.84119678 NA NA,Mitchell,2017,NA RCT RR, 11  11   22,outcomes reverse, 0.2000000000, 0.011000000, 3.742000e+00 NA,NA NA,NA NA NA,NA NA 100 100 100,100 100,100 100 some some low some,low,WLC   0  60.600000 38.385000 NA,NA,0 1,1.0,1.0 1.0 1.0,1 1,1,1 1,1 1,1.0,0 1,1,1 1250,Mitchell_2017,< 2 months NA >= 20 yo 20.2889285714286,39.35,NA,NA  13, 8 Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation  4,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35,NA NA,Ostinelli (2025)_Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2   0,  0 100 100,High,Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT),100 tau Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks),NA,ASRS, 2.76179517,NA NA Moritz,2020,NA RCT,G, 13  14,  27 outcomes reverse -0.0020000000,-0.772000000  7.670000e-01,  8.2280000,  7.9340000,NA NA NA,NA NA NA,100,100,100,100 100 100 100,low,some,some some,low TAU   0,NA NA,NA NA 0,1,1.0,1.0 1.0 1.0,1 1,1 1,1,1 1,1.0,0 1,1 1 1251 Moritz_2020,2-6 months NA,NA 35.260736196319,36.9895833333333 NA NA   3  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events)  1 Ostinelli (2025),35.2532407407407,37.004132231405,NA,NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2   0,  0 100,100,High,Dialectical Behavioral Therapy (DBT) Dialectical Behavioral Therapy (DBT) 100 tau Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability  2.76179517,NA NA,Moritz 2020,NA RCT,RR  16  15   31 outcomes reverse, 2.8120000000, 0.327000000  2.416300e+01,NA NA,NA NA,NA,NA NA NA 100,100 100 100,100 100 100,low some low some low,TAU   0,NA NA,NA NA 0,1,1.0 1.0,1.0 1.0 1,1,1 1,1,1 1,1.0,0,1,1 1,1252,Moritz_2020 2-6 months,NA NA,35.2532407407407 37.004132231405,NA NA,  3, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1 Ostinelli (2025) 35.2532407407407 37.004132231405,NA NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100,High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT) 100 tau,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA CAARS-Ob-IN  1.84119678 NA NA Nakashima,2021 NA RCT G, 23, 18   41 outcomes,reverse,-0.1070000000,-0.731000000, 5.180000e-01, 13.6800000, 14.7800000,NA NA,NA,NA,NA NA 100,100 100,100 100,100 100,low some some,some some,TAU   0, 87.500000 39.173902,NA NA,0 1,1.0 1.0 1.0 1.0,1,1 1 1,1 1 1,1.0,0 1,1 1 1253 Nakashima_2021 < 2 months NA >= 20 yo,39.1739024390244,43.1064102564103,NA,NA, 19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15 NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100,High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT) 100,tau,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At follow-up (closest to 26 weeks),NA,CAARS-Ob-IN, 1.84119678,NA NA,Nakashima 2021,NA RCT,G, 23  19   42,outcomes,reverse -0.3180000000 -0.937000000  3.010000e-01, 13.8800000, 16.2600000 NA NA NA,NA,NA NA 100 100 100,100,100 100 100,low some some some some TAU,  0  87.500000 39.158810 NA,NA 0 1,1.0,1.0,1.0,1.0,1,1 1 1,1,1 1 1.0 0 1,1 1,1254 Nakashima_2021 < 2 months,NA >= 20 yo 39.1588095238095 43.0611940298507 NA NA, 19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks),1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0 100,100,High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),100 tau,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks),NA CAARS-S, 1.84119678 NA,NA Nakashima 2021,NA RCT,G, 23, 18,  41 outcomes reverse,-0.3770000000 -1.007000000, 2.530000e-01   9.7700000, 11.1600000,NA,NA,NA NA,NA,NA,100,100 100 100,100,100,100 low some,some,some,some,TAU,  0  87.500000 39.173902 NA NA,0 1,1.0 1.0 1.0 1.0 1,1 1 1,1,1 1,1.0 0 1 1,1,1255,Nakashima_2021,< 2 months NA >= 20 yo 19.6504545454545 43.1027777777778,NA,NA, 19, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100 High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT) 100 tau,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At follow-up (closest to 26 weeks) NA,CAARS-S, 1.84119678,NA NA Nakashima,2021,NA RCT,G  23, 19   42 outcomes,reverse,-0.6230000000 -1.253000000, 7.000000e-03, 12.3500000, 10.9500000,NA NA NA NA,NA NA,100 100 100 100 100 100 100,low,some some,some,some,TAU   0, 87.500000,39.158810,NA,NA 0,1,1.0 1.0 1.0 1.0,1,1,1,1,1 1,1,1.0 0,1,1,1 1256 Nakashima_2021,< 2 months,NA,>= 20 yo 19.6482233502538 43.0524590163934 NA,NA, 19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100 100 High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),100,tau,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability, 1.84119678,NA,NA Nakashima 2021 NA,RCT,RR  24  24,  48,outcomes reverse  0.1670000000  0.022000000, 1.282000e+00,NA NA,NA NA NA NA NA NA 100 100,100,100 100,100 100 low some low,some,low,TAU,  0, 87.500000 39.105000,NA,NA,0 1,1.0 1.0,1.0 1.0,1 1 1,1 1 1 1,1.0,0,1,1 1 1257,Nakashima_2021,< 2 months NA,>= 20 yo 19.6532142857143,43.15 NA NA  19, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100,High,Cognitive training,Cognitive training   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) NA ASRS  2.30149597 NA NA NCT02489279,2019,NA,RCT G  28, 30,  58 outcomes,reverse, 0.2710000000 -0.311000000  8.530000e-01,NA NA,NA,NA NA,NA, 4.6700000  4.6700000 100 100,100 100,100,100,100,low,some low low some Cognitive placebo   0  58.089655,25.793103,NA NA,0,1,1.0 1.0,1.0 1.0 1,1,1 1 1 1 1,1.0,0 1 1,1 1258,NCT02489279_2019 2-6 months NA,>= 20 yo 25.7931034482759,41.5895454545455 NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA NA,Ostinelli (2025)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100,100,High Cognitive training Cognitive training,  0,NA Executive functioning (tests) Mixed,At study endpoint (closest to 12 weeks),NA,CPT reaction time variability, 2.30149597,NA,NA NCT02489279,2019,NA,RCT,G, 29  30,  59,NA,reverse -0.5920000000,-1.115000000 -6.800000e-02 NA,NA NA NA,NA NA,14.8000000 14.8000000 100 100 100 100,100,100 100 low some,low,low,some,Cognitive placebo,  0  58.323729,25.771186,NA NA 0,1,1.0,1.0 1.0,1.0,1 1 1,1 1,1,1,1.0,0 1 1,1,1259,NCT02489279_2019 2-6 months NA,>= 20 yo 25.771186440678,25.771186440678 NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA Ostinelli (2025)_Cognitive training_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive training_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100,High Cognitive training,Cognitive training,  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 2.30149597,NA,NA,NCT02489279 2019,NA,RCT,RR  44, 41   85,outcomes,reverse  1.1180000000  0.542000000  2.305000e+00 NA,NA NA,NA NA NA,NA,NA,  0   0,  0,  0,  0   0   0,high,high,high,high high Cognitive placebo,  0, 59.021176 25.705882,NA,NA 0 1 1.0,1.0,1.0,1.0 1 1 1,1 1 1,1,1.0 0,1,1 1 1260,NCT02489279_2019 2-6 months,NA,>= 20 yo,25.7058823529412 37.3053333333333,NA,NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA Ostinelli (2025)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no high,high
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0 100 100,High,TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation),  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks) NA,CAARS-S:L  0.92059839,NA,NA,Paz,2017,NA RCT,G,  9, 13,  22 outcomes reverse  0.1090000000 -0.762000000, 9.800000e-01  13.0200000, 10.9969314,NA,NA,NA,NA NA,NA,100 100 100 100 100 100 100,some,some,some,low,low,Sham,  0, 36.413636 31.361364,NA,NA 0 1 1.0,1.0,1.0,1.0,1 1,1,1 1 1,1 1.0,0 1,1,1 1261,Paz_2017 < 2 months,NA >= 20 yo 27.1124137931034,35.24 NA NA,  4, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests), 1 Ostinelli (2025),27.0733333333333,35.24 NA,NA Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100 High TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation)   0,NA,Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks),NA TOVA  0.92059839 NA NA Paz,2017 NA,RCT,G,  9  13   22 NA,reverse,-0.5010000000 -1.385000000  3.840000e-01,  6.1500000   4.5790501,NA,NA NA,NA,NA,NA 100,100,100,100 100,100,100,some some some low low Sham   0  36.413636,31.361364 NA,NA 0,1,1.0,1.0 1.0 1.0,1,1 1,1 1 1,1,1.0,0,1,1,1,1262,Paz_2017,< 2 months NA >= 20 yo,31.3613636363636 31.3613636363636 NA,NA   4, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1 Ostinelli (2025),27.0733333333333,35.24,NA,NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0 100 100,High,TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation),  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability, 0.92059839 NA,NA Paz 2017 NA,RCT,RR  12, 14   26,outcomes reverse  3.5000000000  0.417000000  2.938700e+01 NA,NA NA NA NA,NA,NA NA 100,100 100,100 100 100 100 some,some,low low low,Sham,  0  36.146154 31.426923 NA NA,0,1 1.0,1.0 1.0,1.0 1,1,1 1,1,1,1,1.0,0,1 1 1,1263,Paz_2017 < 2 months NA,>= 20 yo,27.0733333333333,35.22,NA NA,  4  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1 Ostinelli (2025),27.0733333333333 35.24,NA NA Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT)   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks),NA,Current Symptoms Scale- self report  2.30149597,NA NA,Pettersson,2014,NA,RCT,G  27, 18,  45,outcomes reverse,-0.2240000000 -0.829000000, 3.800000e-01, 11.6600000,  8.1700000 NA NA NA NA NA,NA 100 100 100 100,100 100,100,low,some low,some some WLC,  0  64.390000 37.080000,NA,NA,0 1 1.0,1.0 1.0 1.0,1,1,1,1 1,1,1 1.0,0,1 1,1,1264,Pettersson_2014,2-6 months NA >= 20 yo,19.6504545454545 43.1027777777778,NA NA, 19, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100 100 High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability  2.30149597,NA NA,Pettersson,2014,NA,RCT RR  27, 18,  45 outcomes,reverse  0.6670000000  0.151000000  2.943000e+00 NA,NA NA,NA NA,NA,NA,NA 100 100 100,100,100,100,100 low some low some low,WLC   0, 64.390000 37.080000,NA,NA 0,1,1.0 1.0 1.0,1.0,1,1 1,1 1 1 1,1.0,0,1,1,1 1265,Pettersson_2014 2-6 months NA >= 20 yo,19.6532142857143 43.15 NA,NA, 19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15,NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2   0   0,100 100 High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA Kiddie SADS  3.45224396 NA,NA Safren,2004 NA,RCT,G, 16, 15,  31,outcomes,reverse -0.6000000000,-1.332000000  1.330000e-01   7.1200000  10.8400000,NA,NA,NA NA NA NA 100 100 100 100,100,100,100 some some low,low low,TAU   0 NA,NA NA NA 0 1 1.0 1.0 1.0 1.0 1,1,1 1,1 1,1 1.0 0 1 1,1 1266,Safren_2004 2-6 months,NA,NA 39.1739024390244,43.1064102564103 NA,NA  19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15 NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2   0   0 100 100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks),NA Current Symptoms Scale- self report  3.45224396,NA,NA Safren,2004 NA RCT,G, 16, 15   31,outcomes,reverse -0.9570000000 -1.714000000,-1.990000e-01,  8.6500000   9.9200000,NA NA,NA NA NA NA,100,100,100,100 100 100 100 some,some low,low,low,TAU,  0,NA NA,NA NA 0,1 1.0 1.0,1.0 1.0,1,1,1,1,1,1 1,1.0 0,1 1 1 1267,Safren_2004,2-6 months,NA NA,19.6504545454545 43.1027777777778 NA NA  19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2   0,  0,100,100,High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability, 3.45224396 NA NA,Safren 2004,NA,RCT RR  16  15,  31,outcomes reverse, 0.9410000000, 0.020000000  4.467400e+01 NA,NA NA NA NA,NA NA,NA 100 100,100,100,100,100 100 some some low,some low TAU   0,NA NA,NA,NA,0 1,1.0 1.0 1.0,1.0 1,1 1,1 1 1,1 1.0,0,1,1 1 1268,Safren_2004,2-6 months,NA,NA,19.6532142857143,43.15 NA,NA  19, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2   0,  0 100 100 High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability  3.45224396,NA NA Safren 2004 NA RCT RR, 16, 15,  31,outcomes reverse  0.9410000000, 0.020000000  4.467400e+01,NA,NA,NA NA NA NA NA,NA 100 100,100 100 100,100,100,some,some low some,low TAU,  0 NA NA NA,NA 0,1,1.0 1.0,1.0 1.0,1 1 1,1,1 1 1,1.0 0,1,1 1 1269 Safren_2004 2-6 months NA NA 36.9420895522388,43.15,NA NA  19, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15 NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100,High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,ADHD-RS total, 3.45224396 NA,NA,Safren,2010 NA,RCT,G, 41  37   78 outcomes reverse,-0.5160000000,-0.971000000,-6.100000e-02   8.4600000   9.7100000,NA,NA,NA NA,NA NA 100 100 100,100 100 100,100 low low,low,low,low Relaxation therapy   0  44.200000,43.106410 NA NA 0 1 1.0 1.0,1.0 1.0,1,1 1 1,1,1,1 1.0,0 1 1,1,1270 Safren_2010,2-6 months,NA,>= 20 yo 39.1739024390244 43.1064102564103 NA NA  19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100 High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At follow-up (closest to 26 weeks),NA,ADHD-RS total, 3.45224396 NA,NA,Safren,2010,NA RCT G  37  30   67 outcomes,reverse,-0.3050000000 -0.793000000  1.820000e-01,  7.7000000,  9.8100000,NA,NA,NA NA,NA NA,100 100,100 100 100,100 100 low,low low,low,low,Relaxation therapy,  0, 44.200000 43.061194 NA NA 0,1 1.0,1.0,1.0,1.0,1,1 1,1 1,1 1,1.0 0,1 1 1,1271,Safren_2010,2-6 months,NA,>= 20 yo 39.1588095238095,43.0611940298507,NA,NA, 19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15 NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) 1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100,High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At follow-up (closest to 52 weeks) NA ADHD-RS total, 3.45224396 NA NA,Safren 2010 NA,RCT,G, 38, 32,  70 NA reverse -0.3390000000 -0.816000000  1.380000e-01,  8.4900000  10.7200000,NA,NA NA NA,NA NA,100 100,100,100 100 100,100,low low,low low low Relaxation therapy   0, 44.200000 43.077143 NA NA 0,1 1.0 1.0,1.0 1.0 1,1,1,1 1 1 1,1.0,0 1 1 1,1272 Safren_2010,2-6 months NA,>= 20 yo,43.0771428571429 43.0771428571429 NA,NA  19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks) 1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0,100 100 High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks),NA Current Symptoms Scale- self report  3.45224396,NA NA Safren,2010 NA,RCT G, 38  34,  72 outcomes reverse -0.7750000000 -1.258000000 -2.920000e-01   7.1600000  11.2100000,NA,NA,NA NA NA,NA,100 100,100 100,100,100 100,low,low,low,low,low Relaxation therapy,  0  44.200000,43.102778,NA NA 0 1 1.0 1.0,1.0 1.0,1 1 1 1 1,1,1,1.0,0,1,1 1,1273 Safren_2010,2-6 months NA,>= 20 yo 19.6504545454545 43.1027777777778 NA NA, 19, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100,High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At follow-up (closest to 26 weeks),NA Current Symptoms Scale- self report  3.45224396,NA,NA Safren 2010 NA,RCT G, 34  27,  61 outcomes,reverse -0.3890000000 -0.903000000  1.250000e-01,  6.0500000  11.7500000 NA,NA,NA NA NA,NA,100,100,100 100,100,100,100 low,low,low low low Relaxation therapy   0  44.200000,43.052459 NA NA 0,1,1.0,1.0,1.0 1.0,1 1,1 1,1,1,1 1.0 0 1 1,1 1274 Safren_2010 2-6 months NA,>= 20 yo,19.6482233502538 43.0524590163934 NA NA  19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100,100 High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT)   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At follow-up (closest to 52 weeks),NA Current Symptoms Scale- self report, 3.45224396 NA,NA,Safren 2010,NA,RCT,G, 36, 29,  65,outcomes,reverse -0.2720000000,-0.767000000  2.230000e-01,  9.1400000,  9.1800000,NA NA NA NA,NA NA,100 100 100 100,100,100,100,low low low low,low Relaxation therapy   0, 44.200000 43.058462,NA,NA,0,1,1.0 1.0,1.0,1.0,1,1,1,1,1 1,1 1.0,0,1 1,1,1275 Safren_2010 2-6 months NA >= 20 yo,35.8545454545455 43.0584615384615,NA,NA  19, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks),1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100,100,High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT)   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability, 3.45224396 NA NA,Safren 2010 NA,RCT RR  43  43   86 outcomes,reverse  0.4000000000, 0.082000000  1.951000e+00,NA NA NA NA,NA,NA NA NA 100 100,100 100 100 100,100,low,low low some low,Relaxation therapy   0, 44.200000,43.150000 NA NA,0,1 1.0 1.0 1.0,1.0 1,1 1 1,1 1 1 1.0 0 1 1 1,1276 Safren_2010,2-6 months,NA >= 20 yo 19.6532142857143 43.15 NA,NA  19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15,NA NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100 100 High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0,NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability  3.45224396,NA,NA,Safren 2010 NA RCT RR, 43, 43,  86 outcomes,reverse  1.0000000000, 0.020000000, 4.928400e+01 NA,NA,NA NA,NA,NA,NA,NA,100,100,100 100,100 100 100,low,low,low some,low,Relaxation therapy   0, 44.200000,43.150000 NA NA,0,1,1.0,1.0,1.0,1.0,1 1 1,1 1,1,1 1.0 0 1 1,1 1277 Safren_2010 2-6 months,NA >= 20 yo,36.9420895522388 43.15,NA,NA  19, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100,High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA ADHD-SRS total  2.76179517 NA,NA Solanto 2010 NA RCT,G, 41, 40   81 outcomes reverse -0.5450000000 -0.991000000,-9.800000e-02,  4.2700000,  4.7100000,NA NA,NA,NA NA,NA,100,100 100 100,100,100,100 some some,some,low,some,Psychological placebo,  0, 66.061728,41.696790 NA,NA 0 1,1.0 1.0 1.0 1.0,1 1,1 1 1 1 1,1.0 0 1 1 1,1278,Solanto_2010 2-6 months NA,>= 20 yo 39.1739024390244,43.1064102564103,NA NA  19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT)   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability  2.76179517 NA,NA,Solanto 2010,NA,RCT RR, 45  43   88 outcomes reverse  0.4180000000, 0.191000000  9.150000e-01 NA NA NA NA NA,NA NA NA,100 100 100 100,100 100 100 some some low some,low,Psychological placebo,  0, 66.113636 41.689886 NA,NA 0,1 1.0,1.0 1.0 1.0,1 1,1,1,1,1,1,1.0,0,1 1 1 1279,Solanto_2010 2-6 months,NA,>= 20 yo,19.6532142857143,43.15 NA,NA  19, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100 100 High,Cognitive training Cognitive training,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks),NA ASRS  2.76179517,NA NA Stern,2014 NA,RCT G, 26, 13   39,outcomes,reverse -0.0190000000 -0.693000000  6.550000e-01  10.0000000,  8.9200000 NA,NA,NA NA,NA NA,100,100,100 100 100 100 100 low some some,low low,Cognitive placebo,  0  56.666667 37.463333,NA NA 0,1,1.0 1.0 1.0,1.0,1,1,1 1,1,1,1 1.0,0 1,1 1,1280 Stern_2014,2-6 months NA,>= 20 yo,25.7931034482759 41.5895454545455 NA NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA,Ostinelli (2025)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0,100,100,High,Cognitive training,Cognitive training,  0 NA Quality of life (patients) Mixed At study endpoint (closest to 12 weeks),NA AAQoL, 2.76179517 NA,NA Stern,2014,NA RCT,G, 26, 13,  39,outcomes reverse, 0.3060000000 -0.372000000, 9.840000e-01, 16.7900000  14.6400000 NA,NA NA NA,NA,NA 100 100 100,100 100,100,100,low,some,some low,low Cognitive placebo   0, 56.666667 37.463333 NA NA 0,1 1.0,1.0 1.0 1.0 1 1,1,1 1 1,1 1.0 0,1,1,1,1281 Stern_2014 2-6 months NA,>= 20 yo 33.0526315789474 37.4633333333333 NA NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA Ostinelli (2025)_Cognitive training_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Cognitive training_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100,High Cognitive training,Cognitive training   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability, 2.76179517 NA NA Stern 2014,NA,RCT RR, 34, 26,  60 outcomes reverse  0.4710000000  0.230000000, 9.640000e-01,NA NA,NA NA,NA NA,NA NA,100,100,100,100 100 100,100,low some low,low,low,Cognitive placebo   0  56.866667,37.305333,NA NA 0,1 1.0 1.0,1.0,1.0,1 1,1 1,1 1 1 1.0 0,1,1,1 1282 Stern_2014 2-6 months,NA,>= 20 yo 25.7058823529412,37.3053333333333,NA NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA,Ostinelli (2025)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100,High Cognitive training,Cognitive training,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA DSM-IIIR symptom checklist, 1.84119678,NA NA,Stevenson,2002,NA,RCT,G, 22, 21   43,NA,reverse -1.6820000000 -2.389000000 -9.750000e-01, 26.7000000, 18.0000000,NA NA NA,NA NA NA 100 100 100 100,100 100,100 some some,low some some WLC   0  36.441860 35.862791,NA NA,0,1,1.0 1.0,1.0 1.0 1 1 1 1,1 1,1 1.0 0 1,1,1 1283 Stevenson_2002,< 2 months NA >= 20 yo,35.8627906976744,35.8627906976744,NA NA  28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA Ostinelli (2025)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100,High Cognitive training Cognitive training,  0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability, 1.84119678 NA NA Stevenson 2002,NA RCT RR  23  21,  44 outcomes,reverse, 2.7500000000, 0.118000000, 6.403900e+01,NA,NA NA,NA NA NA NA,NA 100 100,100,100,100,100,100,some,some,low some,low WLC   0  36.386364,35.875000,NA,NA 0,1,1.0,1.0,1.0 1.0,1 1 1,1,1,1 1 1.0 0 1,1,1 1284 Stevenson_2002 < 2 months NA,>= 20 yo 25.7058823529412 37.3053333333333,NA,NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA,NA,Ostinelli (2025)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100,High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT)   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks),NA,BADDS-adults, 2.76179517,NA NA,Virta,2010 NA,RCT G, 10  10,  20,outcomes reverse  0.0870000000,-0.813000000  9.870000e-01  18.6000000  14.2000000,NA NA NA,NA NA NA 100,100,100,100,100 100,100 some some,some some some No treatment   0  65.000000 36.100000 NA NA 0,1 1.0,1.0 1.0 1.0 1,1 1,1,1,1 1,1.0,0 1 1 1 1285,Virta_2010,2-6 months,NA,>= 20 yo 19.6504545454545 43.1027777777778,NA,NA  19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100,100 High Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0,NA Quality of life (patients) Mixed,At study endpoint (closest to 12 weeks) NA Q-LES-Q  2.76179517,NA,NA,Virta 2010,NA,RCT,G, 10, 10   20,outcomes reverse, 0.0900000000,-0.810000000, 9.900000e-01, 14.5000000  21.0000000,NA,NA,NA,NA,NA,NA 100,100 100 100 100,100,100 some,some,some some some,No treatment   0, 65.000000 36.100000 NA,NA,0 1 1.0 1.0,1.0 1.0 1 1,1,1,1 1 1,1.0 0,1 1 1,1286,Virta_2010,2-6 months,NA >= 20 yo,36.1 36.9642105263158 NA,NA  19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15 NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100,100 High Cognitive training,Cognitive training,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) NA,BADDS-adults, 2.76179517,NA,NA Virta,2010,NA RCT,G   9  10,  19,outcomes,reverse,-0.5250000000,-1.469000000, 4.180000e-01, 17.8000000, 14.2000000 NA NA,NA,NA,NA,NA,100 100 100 100 100 100 100,some some,some some some,No treatment,  0, 42.473684,33.052632 NA NA 0 1,1.0,1.0 1.0,1.0,1,1 1,1 1,1 1 1.0,0 1 1,1 1287 Virta_2010,2-6 months NA >= 20 yo 25.7931034482759,41.5895454545455,NA NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA NA Ostinelli (2025)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100 100,High Cognitive training Cognitive training,  0 NA,Quality of life (patients) Mixed,At study endpoint (closest to 12 weeks) NA,Q-LES-Q, 2.76179517,NA NA Virta 2010,NA RCT G,  9  10,  19,outcomes reverse  0.3150000000,-0.617000000  1.247000e+00, 14.4000000, 21.0000000 NA NA,NA,NA NA,NA 100,100,100 100,100,100 100 some some,some,some,some,No treatment,  0  42.473684 33.052632 NA,NA 0,1,1.0 1.0,1.0 1.0 1 1,1,1,1,1 1,1.0,0 1,1,1 1288,Virta_2010,2-6 months,NA >= 20 yo 33.0526315789474 37.4633333333333 NA NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA,Ostinelli (2025)_Cognitive training_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Cognitive training_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100 100,High,Hypnotherapy Hypnotherapy,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks),NA BADDS-adults, 2.76179517,NA,NA,Virta,2010,NA,RCT,G   8, 10,  18 NA reverse,-0.4450000000 -1.416000000  5.250000e-01  17.7000000  14.2000000,NA NA,NA NA NA,NA,100 100,100 100,100 100,100 some,some some,some some,No treatment   0, 60.000000,34.000000,NA NA,0 1,1.0,1.0 1.0 1.0 1,1 1,1,1,1,1 1.0,0 1,1,1 1289,Virta_2010,2-6 months NA,>= 20 yo,34,34,NA NA,  1  2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients), 1,Ostinelli (2025) 34 34 NA NA,Ostinelli (2025)_Hypnotherapy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Hypnotherapy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0 100,100 High,Hypnotherapy Hypnotherapy,  0,NA Quality of life (patients),Mixed,At study endpoint (closest to 12 weeks) NA,Q-LES-Q  2.76179517 NA,NA Virta,2010,NA RCT G   8  10,  18,NA,reverse  0.3090000000 -0.655000000, 1.272000e+00  13.8000000  21.0000000,NA NA NA,NA NA,NA,100 100,100,100,100,100 100 some some some,some,some,No treatment   0, 60.000000 34.000000,NA NA,0,1 1.0,1.0 1.0 1.0,1,1 1 1,1 1 1,1.0,0,1,1,1 1290,Virta_2010,2-6 months NA >= 20 yo 34,34 NA,NA   1, 2 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients)  1 Ostinelli (2025) 34 34,NA NA,Ostinelli (2025)_Hypnotherapy_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Hypnotherapy_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100,High,Methylphenidate Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA ADHD-RS total, 1.38089758 NA NA,Weisler,2012 NA,RCT,G, 58, 65  123,outcomes,reverse -0.4160000000 -0.848000000  1.600000e-02 NA NA,NA,NA,NA NA,11.7400000,11.7400000,100 100 100,100,100,100 100,low low,low low low Placebo,  0, 37.657724 33.305691 NA,NA,0,1,1.0,1.0 1.0 1.0 1 1,1 1,1 1,1 1.0 0 1 1 1,1291 Weisler_2012 < 2 months NA,>= 20 yo 30.6,40,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100,High Methylphenidate,Methylphenidate,  0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,Acceptability, 1.38089758 NA NA Weisler,2012,NA,RCT,RR  68  74, 142,outcomes,reverse  1.2860000000  0.618000000  2.675000e+00 NA NA NA NA,NA NA,NA NA 100,100 100,100,100,100,100 low low low low low Placebo   0, 37.604225,33.304225,NA NA 0,1 1.0 1.0,1.0,1.0,1,1,1 1 1,1,1,1.0,0 1,1 1,1292,Weisler_2012,< 2 months,NA,>= 20 yo 28.7959183673469 40 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0,100 100,High,Methylphenidate,Methylphenidate   0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability  1.38089758 NA,NA,Weisler,2012 NA,RCT RR, 68  74  142 outcomes,reverse, 3.2650000000  0.682000000  1.563100e+01 NA NA,NA,NA,NA NA,NA,NA 100 100,100 100 100 100,100,low,low low,low,low Placebo   0, 37.604225 33.304225 NA,NA 0 1,1.0 1.0 1.0,1.0,1,1 1 1 1,1,1,1.0 0,1,1 1,1293,Weisler_2012 < 2 months,NA >= 20 yo,28.7959183673469 40,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0 100,100 High Atomoxetine Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,ADHD-RS total, 1.38089758,NA NA Weisler,2012,NA,RCT,G  57  65, 122 outcomes reverse,-0.2990000000,-0.723000000, 1.250000e-01 NA,NA NA NA,NA NA 11.7400000 11.7400000,100,100 100 100,100 100,100 low low,low,low low,Placebo,  0  43.669672,33.960656,NA NA 0 1,1.0 1.0 1.0 1.0 1 1 1,1,1 1 1,1.0 0,1,1,1 1294,Weisler_2012,< 2 months NA,>= 20 yo 24.7 42.1 NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100 100 High,Atomoxetine Atomoxetine   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability, 1.38089758 NA NA,Weisler 2012 NA RCT RR  74  74, 148,outcomes reverse, 1.8180000000  0.938000000, 3.523000e+00 NA NA NA NA,NA,NA,NA,NA,100 100 100,100,100 100 100 low,low low,low low Placebo,  0  43.850000,34.000000 NA NA,0,1,1.0,1.0 1.0 1.0 1,1 1,1,1 1,1,1.0,0 1,1,1 1295,Weisler_2012 < 2 months NA >= 20 yo,24.7,42.10703125,NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100,100 High,Atomoxetine Atomoxetine   0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability  1.38089758,NA NA Weisler 2012 NA,RCT RR, 74, 74, 148,outcomes,reverse, 4.0000000000, 0.879000000  1.820900e+01,NA NA NA,NA,NA,NA,NA,NA 100 100,100 100,100 100,100,low,low,low,low,low,Placebo   0, 43.850000 34.000000 NA NA 0,1,1.0 1.0 1.0 1.0,1 1 1,1,1 1 1 1.0,0,1,1 1,1296 Weisler_2012 < 2 months,NA,>= 20 yo 24.7 42.10703125 NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100 100,High tDCS (transcranial direct current stimulation) tDCS (transcranial direct current stimulation),  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA ADHD-RS total, 0.92059839 NA,NA Leffa,2022,NA,RCT,G  32  32   64 NA reverse -0.9450000000 -1.466000000,-4.240000e-01,  5.7900000,  3.9700000,NA NA,NA,NA NA NA 100,100 100,100 100,100 100,low low,some some low,Sham   0  46.900000,38.300000,NA NA,0 1,1.0,1.0 1.0 1.0 1,1 1,1,1 1 1,1.0,0 1 1 1 1297,Leffa_2022 < 2 months,NA >= 20 yo 38.3 38.3 NA,NA, 19  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857,NA NA,Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0,100,100 High tDCS (transcranial direct current stimulation),tDCS (transcranial direct current stimulation)   0 NA,Emotional dysregulation,Mixed At study endpoint (closest to 12 weeks) NA BRIEF-ASR Emotional control, 0.92059839 NA,NA Leffa 2022 NA,RCT,G, 21, 28,  49 NA reverse -0.2060000000 -0.779000000, 3.670000e-01,  9.7400000,  8.8700000 NA,NA NA,NA,NA,NA,100,100,100,100 100,100 100 low low some,some low Sham   0, 45.114286,38.314286,NA NA 0,1,1.0 1.0 1.0 1.0 1,1 1,1,1,1,1,1.0 0 1 1 1 1298,Leffa_2022,< 2 months,NA >= 20 yo 38.3142857142857,38.3142857142857 NA,NA  19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857,NA NA,Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100   0 100,100,High,tDCS (transcranial direct current stimulation) tDCS (transcranial direct current stimulation)   0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability  0.92059839 NA,NA,Leffa 2022 NA,RCT,RR  32  32   64 outcomes reverse, 3.5000000000  0.786000000, 1.557800e+01 NA NA NA,NA NA NA,NA,NA,100,100 100,100 100,100,100,low,low,low some,low,Sham   0, 46.900000,38.300000 NA,NA,0,1,1.0,1.0,1.0 1.0 1,1,1,1,1,1,1 1.0 0,1,1 1,1299,Leffa_2022 < 2 months,NA >= 20 yo,22.085 38.3,NA,NA  19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation  3,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86 38.3142857142857,NA NA Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0,100,100,High,tDCS (transcranial direct current stimulation) tDCS (transcranial direct current stimulation),  0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability  0.92059839,NA NA,Leffa 2022 NA,RCT RR, 32  32   64 outcomes,reverse, 3.0000000000  0.329000000  2.733300e+01 NA,NA,NA,NA,NA,NA NA,NA 100,100,100,100,100,100,100,low low low some,low Sham   0  46.900000,38.300000 NA,NA 0 1 1.0 1.0,1.0,1.0 1 1 1,1,1,1 1,1.0,0,1 1,1,1300,Leffa_2022 < 2 months NA >= 20 yo 32.2941176470588,38.3,NA NA, 19, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857,NA NA Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100 High Methylphenidate,Methylphenidate,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability  3.22209436,NA NA,Levin,2007,NA,RCT RR, 53, 53  106,outcomes,reverse  0.9670000000, 0.688000000, 1.358000e+00,NA NA NA NA,NA NA NA NA,100,100,100,100,100,100,100 some,some low,some low,Active [Placebo + cbt],100, 17.000000,37.000000 NA,NA,0,1,1.0,1.0 1.0,1.0 1,1,1,1,1 1,1 1.0,0 1 1,1 1301 Levin_2007,2-6 months NA >= 20 yo 28.7959183673469 40 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100,100,High Methylphenidate,Methylphenidate,  0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,Tolerability, 3.22209436,NA NA Levin 2007,NA,RCT,RR, 53  53, 106,outcomes,reverse, 0.7500000000  0.176000000, 3.190000e+00 NA NA,NA,NA NA,NA NA NA,100 100 100 100,100,100,100 some,some low some low Active [Placebo + cbt] 100, 17.000000 37.000000 NA,NA,0,1 1.0,1.0,1.0 1.0,1 1,1 1,1,1 1,1.0,0,1 1,1 1302 Levin_2007,2-6 months,NA,>= 20 yo,28.7959183673469 40,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100 High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks),NA ASRS, 2.76179517 NA NA,Nasri,2022 NA,RCT G, 36  31,  67 outcomes,reverse -0.4160000000 -0.905000000, 7.300000e-02  12.4000000   9.5500000,NA,NA,NA NA,NA NA,100,100 100 100,100 100,100,low low low,some low,WLC   0  62.059701 36.942090,NA,NA,0 1,1.0,1.0 1.0 1.0,1 1,1,1 1,1,1 1.0,0 1,1,1,1303 Nasri_2022,2-6 months,NA >= 20 yo 19.6504545454545 43.1027777777778 NA NA, 19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15,NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100 100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At follow-up (closest to 26 weeks) NA ASRS, 2.76179517 NA NA Nasri 2022,NA RCT,G, 36  31,  67 outcomes reverse,-0.6590000000 -1.156000000 -1.620000e-01  13.1000000,  9.0200000,NA NA,NA NA NA,NA 100,100,100 100,100,100,100 low low low some,low WLC   0  62.059701 36.942090,NA NA,0 1,1.0,1.0,1.0,1.0,1,1,1 1,1 1,1,1.0,0 1,1,1 1304,Nasri_2022,2-6 months NA >= 20 yo 19.6482233502538,43.0524590163934 NA,NA  19, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15 NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100,100 High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0,NA Emotional dysregulation Mixed,At study endpoint (closest to 12 weeks) NA DERS, 2.76179517 NA,NA Nasri 2022 NA,RCT,G, 28, 29   57,NA,reverse, 0.1820000000 -0.343000000  7.070000e-01, 29.0000000  26.2000000,NA,NA NA,NA NA,NA 100 100 100 100,100,100,100,low,low low,some,low WLC   0  61.368421 36.964211,NA NA 0,1 1.0 1.0 1.0 1.0,1,1 1 1,1 1,1 1.0,0 1,1,1,1305,Nasri_2022,2-6 months NA,>= 20 yo 36.9642105263158,36.9642105263158 NA,NA, 19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100 100,High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0,NA,Emotional dysregulation,Mixed At follow-up (closest to 26 weeks),NA,DERS, 2.76179517,NA NA Nasri,2022,NA RCT,G  26  28,  54 NA reverse -0.0370000000,-0.576000000  5.010000e-01  27.3000000, 30.5000000 NA,NA NA,NA NA NA,100 100,100 100 100 100,100 low,low low,some,low WLC   0, 61.222222 36.968889 NA,NA 0,1 1.0,1.0 1.0 1.0 1,1 1,1 1,1 1,1.0 0,1,1,1,1306 Nasri_2022,2-6 months NA >= 20 yo,36.9688888888889 36.9688888888889,NA NA, 19  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks),1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0,100 100,High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0 NA,Quality of life (patients),Mixed,At study endpoint (closest to 12 weeks) NA AAQoL, 2.76179517,NA NA Nasri 2022 NA,RCT,G, 28  29   57 outcomes,reverse,-0.3920000000,-0.921000000  1.370000e-01  11.2000000,  9.3800000 NA NA NA,NA NA,NA,100 100,100 100 100 100 100 low,low,low some low WLC   0  61.368421 36.964211 NA,NA,0,1 1.0,1.0,1.0,1.0 1 1 1,1,1,1,1 1.0,0,1,1,1 1307,Nasri_2022,2-6 months,NA >= 20 yo,36.1 36.9642105263158 NA,NA  19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100 100,High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),  0,NA,Quality of life (patients),Mixed At follow-up (closest to 26 weeks) NA,AAQoL, 2.76179517,NA NA,Nasri,2022,NA,RCT,G  26  28   54,NA,reverse,-0.4190000000,-0.964000000, 1.260000e-01, 10.9000000, 11.2000000,NA,NA NA NA,NA,NA 100 100,100 100,100,100,100,low low,low,some low,WLC,  0, 61.222222,36.968889 NA,NA 0 1 1.0,1.0 1.0,1.0 1,1,1 1,1 1,1,1.0 0 1,1 1,1308 Nasri_2022 2-6 months,NA >= 20 yo 36.9688888888889,36.9688888888889,NA,NA, 19, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15 NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks) 1,Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000,no low,low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100 100 High,Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT)   0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 2.76179517,NA,NA Nasri 2022 NA,RCT RR, 36, 31   67 outcomes reverse  0.8650000000  0.018000000, 4.235500e+01 NA,NA,NA NA NA NA,NA NA 100,100,100 100,100,100,100,low,low,low,some low,WLC,  0  62.059701,36.942090 NA NA 0 1 1.0,1.0 1.0 1.0 1 1,1 1 1 1,1,1.0,0,1 1,1,1309 Nasri_2022,2-6 months,NA,>= 20 yo,19.6532142857143 43.15,NA,NA  19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation, 4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),  0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability  2.76179517 NA NA Nasri 2022 NA RCT,RR  36, 31   67,outcomes reverse, 0.8650000000  0.018000000  4.235500e+01,NA,NA NA NA,NA NA NA NA 100,100 100,100,100 100,100,low,low low,some,low,WLC   0, 62.059701,36.942090,NA NA,0,1 1.0 1.0,1.0,1.0 1 1,1,1 1,1 1 1.0,0 1,1,1,1310,Nasri_2022 2-6 months NA,>= 20 yo,36.9420895522388,43.15,NA,NA, 19  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15,NA,NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100,100,High Amphetamine Amphetamine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,AISRS, 1.15074799   20.0000000,mg/d Cutler 2022,NA,RCT,G  62  62  124,outcomes,reverse -0.4970000000 -0.961000000 -3.200000e-02,NA NA NA,NA,NA,NA 10.0500000,10.0500000 100 100 100 100,100,100 100 low low some,low some Placebo   0, 59.950000 32.450000,NA NA 0 1 1.0,1.0,1.0 1.0,1 1 1 1 1 1 1,1.0 0,1,1,1 1311,Cutler_2022 < 2 months,NA,>= 20 yo 22.2059016393443 39.0276595744681 NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA,Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100 High Amphetamine Amphetamine   0,NA Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks) NA,DSST, 1.15074799,  20.0000000 mg/d Cutler,2022 NA,RCT G  62  62  124 NA,reverse,-0.2700000000,-0.671000000  1.310000e-01 NA NA NA,NA NA NA, 7.2100000, 7.2100000,100,100,100,100 100 100,100 low,low some low some,Placebo,  0  59.950000 32.450000 NA,NA 0 1,1.0 1.0,1.0 1.0 1,1 1 1,1,1 1 1.0,0,1,1,1,1312 Cutler_2022 < 2 months,NA,>= 20 yo,32.45,32.45,NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA NA,Ostinelli (2025)_Amphetamine_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Amphetamine_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100 100,High,Amphetamine,Amphetamine,  0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability, 1.15074799   20.0000000,mg/d,Cutler,2022,NA,RCT RR  65  65, 130,outcomes reverse  1.0530000000  0.622000000, 1.780000e+00,NA,NA NA NA NA NA NA NA 100 100 100 100,100 100 100,low,low low low low Placebo,  0  59.950000 32.450000,NA,NA,0,1 1.0 1.0 1.0,1.0 1 1 1 1 1 1 1 1.0,0 1 1 1,1313,Cutler_2022 < 2 months,NA >= 20 yo,22.2057971014493,39.0319587628866,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA,Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100 100,High,Amphetamine Amphetamine,  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability  1.15074799   20.0000000,mg/kg/d,Cutler,2022,NA RCT,RR  65  65, 130,outcomes,reverse  7.0000000000  0.369000000  1.328720e+02 NA NA NA,NA NA,NA,NA,NA 100 100,100,100,100,100,100,low,low,low,low,low,Placebo,  0  59.950000,32.450000,NA NA,0 1 1.0 1.0 1.0 1.0 1,1,1 1,1,1,1,1.0 0 1 1 1 1314,Cutler_2022 < 2 months,NA >= 20 yo 22.2057971014493 39.0319587628866,NA NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0 100,100,High tDCS (transcranial direct current stimulation),tDCS (transcranial direct current stimulation),  0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,Acceptability  0.23014960,NA,NA,Barham,2022 NA,RCT RR, 11, 11,  22,outcomes reverse, 1.0000000000  0.022000000, 4.640400e+01,NA,NA NA,NA,NA NA,NA,NA 100 100,100 100 100 100,100 some low,low low low,Sham   0, 31.850000,22.085000 NA NA 0,1 1.0 1.0 1.0,1.0,1 1 1,1,1,1 1 1.0,0,1,1,1,1315 Barham_2022 < 2 months,NA,>= 20 yo,22.085,38.3 NA,NA, 19, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation, 3 Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857,NA,NA,Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100,100 High Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT)   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks),NA,ASRS, 3.22209436 NA,NA,Halmoy 2022 NA RCT G  49  47,  96,outcomes reverse,-0.7270000000,-1.142000000 -3.110000e-01   9.0000000,  9.3000000,NA,NA NA,NA NA NA,100 100 100 100,100 100 100 low,some,low some low WLC,  0, 56.090625,36.989583 NA,NA 0 1 1.0,1.0 1.0,1.0 1 1 1 1,1 1 1,1.0,0 1 1 1,1316 Halmoy_2022,2-6 months,NA >= 20 yo,35.260736196319,36.9895833333333 NA,NA   3  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1,Ostinelli (2025) 35.2532407407407,37.004132231405 NA,NA Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0,100,100 High Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT),  0 NA Quality of life (patients) Mixed At study endpoint (closest to 12 weeks),NA AAQoL  3.22209436 NA,NA Halmoy 2022 NA RCT,G  49, 47   96 NA reverse, 0.3080000000,-0.096000000  7.130000e-01  16.8000000  17.3000000,NA NA NA,NA NA,NA 100,100,100,100,100 100 100,low some,low some,low,WLC   0, 56.090625 36.989583,NA NA 0,1 1.0 1.0,1.0 1.0,1 1 1 1 1 1 1 1.0 0 1,1,1,1317,Halmoy_2022 2-6 months NA >= 20 yo 36.9895833333333,36.9895833333333,NA NA,  3, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events)  1,Ostinelli (2025),35.2532407407407,37.004132231405 NA,NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100 High,Dialectical Behavioral Therapy (DBT) Dialectical Behavioral Therapy (DBT),  0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability  3.22209436,NA NA Halmoy 2022 NA,RCT RR  60, 61, 121,outcomes reverse  1.8300000000, 0.651000000, 5.144000e+00,NA NA NA NA,NA,NA,NA NA,100,100,100,100,100 100,100 low some,low some low WLC   0, 56.173554 37.004132 NA,NA,0 1 1.0,1.0,1.0,1.0,1,1 1,1 1,1,1 1.0,0,1,1 1 1318 Halmoy_2022,2-6 months NA,>= 20 yo,35.2532407407407,37.004132231405 NA,NA   3, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events)  1,Ostinelli (2025),35.2532407407407 37.004132231405,NA,NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Physical training,Physical training   0,NA,Executive functioning (tests) Mixed At follow-up (closest to 26 weeks) NA,CPT, 5.52359033,NA NA,Kouhbanani 2023,NA RCT G, 25  27,  52,NA,reverse,-1.9270000000 -2.594000000,-1.259000e+00   0.4700000   0.4900000 NA,NA,NA,NA NA NA   0   0   0,  0,  0,  0   0,high high,high,high,high,WLC,  0 100.000000 35.323077 NA NA 0 1,1.0 1.0,1.0,1.0 1,1,1 1 1,1,1 1.0 0 1,1 1 1319 Kouhbanani_2023,2-6 months NA,>= 20 yo,35.3230769230769 35.3230769230769,NA NA, 22, 4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA,NA Ostinelli (2025)_Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks),1 Homogeneous Ostinelli (2025) - Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000,no high,high
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100   0,100 100,High,Physical training Physical training,  0 NA,Executive functioning (tests) Mixed At follow-up (closest to 52 weeks),NA CPT, 5.52359033,NA NA,Kouhbanani 2023 NA RCT G  25  27,  52,NA reverse -1.4530000000,-2.073000000,-8.340000e-01   0.3300000   0.5000000,NA NA NA NA,NA,NA   0   0   0,  0   0,  0,  0 high high high high,high WLC   0 100.000000 35.323077,NA NA 0,1 1.0,1.0 1.0,1.0,1 1,1 1,1 1 1 1.0,0 1 1,1 1320 Kouhbanani_2023 2-6 months,NA >= 20 yo 35.3230769230769 35.3230769230769 NA,NA, 22, 4 Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA NA,Ostinelli (2025)_Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 52 weeks) 1,Homogeneous Ostinelli (2025) - Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 52 weeks)_>= 18 yo,100.00000,no,high,high
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100,High Physical training Physical training   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability  5.52359033,NA NA,Kouhbanani 2023,NA RCT,RR, 30  30   60,NA,reverse  1.6670000000  0.437000000  6.358000e+00 NA,NA,NA,NA,NA,NA NA,NA,100 100,100,100,100,100 100 some,some,low some low,WLC,  0,100.000000 35.320000,NA,NA,0,1 1.0,1.0,1.0,1.0,1,1 1 1,1,1,1,1.0 0,1 1,1,1321 Kouhbanani_2023,2-6 months NA >= 20 yo,35.32 35.32,NA,NA  22  4,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive)  3 Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769 NA NA Ostinelli (2025)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0,100 100 High Methylphenidate Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,CAARS-O:L,11.96777906,NA,NA,Philipsen 2015,NA,RCT G, 95  80  175 outcomes,reverse -0.1480000000 -0.446000000  1.510000e-01   9.1000000,  9.8000000,NA,NA,NA NA,NA,NA 100,100 100 100,100,100 100,low low some,low low,Placebo   0  52.408571,35.280000,NA,NA 0 1 1.0 1.0 1.0,1.0 1,1,1,1,1,1 1 1.0,0,1,1 1,1322 Philipsen_2015,7-12 months NA >= 20 yo,30.6,40 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100,100 High,Methylphenidate Methylphenidate,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At follow-up (closest to 26 weeks) NA,CAARS-O:L 11.96777906 NA NA Philipsen,2015,NA RCT,G, 85  62  147 outcomes,reverse,-0.3110000000,-0.642000000, 1.900000e-02,  9.1000000   9.5000000 NA,NA NA NA NA NA,100 100,100,100,100,100,100,low low some,low,low Placebo   0  52.291837 35.304762 NA NA 0 1 1.0,1.0,1.0,1.0 1 1 1,1,1,1,1 1.0 0 1,1,1,1323,Philipsen_2015 7-12 months NA >= 20 yo,34.7398328690808 35.3047619047619,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks),1,Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100 100 High Methylphenidate,Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At follow-up (closest to 52 weeks) NA CAARS-O:L 11.96777906 NA,NA Philipsen,2015,NA RCT,G  70, 45  115 NA,reverse,-0.2360000000 -0.614000000, 1.410000e-01,  8.6000000,  8.1000000 NA,NA NA NA NA,NA,100,100 100 100 100 100 100,low,low,some,low,low,Placebo,  0, 52.191304 35.326087,NA NA,0 1 1.0 1.0,1.0 1.0 1 1 1 1,1,1 1,1.0 0 1 1 1,1324,Philipsen_2015 7-12 months NA >= 20 yo,35.3260869565217,35.3260869565217 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks)_>= 18 yo 100.00000 no,low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100,High,Methylphenidate Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks),NA,CAARS-S:L 11.96777906 NA NA Philipsen 2015,NA,RCT,G, 91  79, 170 outcomes reverse -0.1640000000 -0.467000000, 1.380000e-01   9.6000000   9.8000000,NA,NA,NA NA,NA,NA,100 100,100 100 100,100,100 low low some low low,Placebo   0  52.433529 35.274706 NA NA 0 1,1.0 1.0 1.0 1.0,1 1 1,1,1 1,1 1.0 0,1 1 1,1325,Philipsen_2015,7-12 months,NA >= 20 yo,33.7462897526502 42,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100,High,Methylphenidate,Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At follow-up (closest to 26 weeks),NA CAARS-S:L,11.96777906,NA,NA,Philipsen,2015,NA,RCT,G, 83  58, 141,outcomes reverse,-0.1880000000,-0.526000000, 1.490000e-01,  9.7000000, 10.5000000,NA,NA NA NA,NA NA,100,100 100 100 100,100 100,low,low some,low,low Placebo   0, 52.257447,35.312057 NA,NA 0 1,1.0 1.0 1.0,1.0,1 1,1,1 1,1 1 1.0 0,1 1,1,1326 Philipsen_2015,7-12 months NA >= 20 yo,34.7372549019608,35.3120567375887 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100,100 High,Methylphenidate Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At follow-up (closest to 52 weeks) NA,CAARS-S:L,11.96777906 NA,NA,Philipsen,2015,NA RCT G, 65, 43  108,NA reverse -0.3290000000,-0.719000000, 6.000000e-02   9.5000000, 10.6000000,NA,NA,NA NA,NA,NA,100 100 100 100 100 100,100 low,low some low low,Placebo,  0, 52.213889,35.321296,NA,NA 0,1,1.0,1.0 1.0,1.0,1 1 1 1,1 1,1,1.0,0,1,1 1 1327 Philipsen_2015 7-12 months,NA,>= 20 yo,35.3212962962963,35.3212962962963 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo 100.00000,no,low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0,100,100 High,Methylphenidate,Methylphenidate,  0,NA,Emotional dysregulation,Mixed,At study endpoint (closest to 12 weeks),NA CAARS impulsivity/emotional lability 11.96777906 NA NA,Philipsen 2015 NA,RCT,G, 91, 79  170,outcomes reverse -0.1470000000,-0.450000000, 1.560000e-01,  7.5000000   7.4000000,NA NA,NA,NA,NA,NA 100,100 100 100,100,100 100,low low,some low low,Placebo,  0, 52.433529 35.274706 NA NA,0 1 1.0,1.0 1.0 1.0,1,1,1 1 1,1,1,1.0,0,1 1 1,1328,Philipsen_2015,7-12 months,NA >= 20 yo 34.0471698113208,36.9,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0,100,100,High Methylphenidate Methylphenidate,  0 NA Emotional dysregulation Mixed,At follow-up (closest to 26 weeks) NA CAARS impulsivity/emotional lability 11.96777906 NA,NA,Philipsen,2015,NA,RCT,G  83, 58, 141,NA,reverse -0.1800000000 -0.517000000  1.570000e-01,  7.6000000,  7.9000000,NA NA,NA,NA NA,NA,100 100,100 100,100,100 100,low low some,low,low Placebo,  0  52.257447,35.312057 NA,NA 0,1,1.0,1.0 1.0,1.0 1 1 1,1,1,1,1 1.0,0,1 1 1 1329 Philipsen_2015,7-12 months NA,>= 20 yo,35.3120567375887 35.3120567375887 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks) 1 Homogeneous Ostinelli (2025) - Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000,no,low,low
 999 Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100   0 100 100,High,Methylphenidate Methylphenidate   0,NA,Emotional dysregulation,Mixed At follow-up (closest to 52 weeks),NA,CAARS impulsivity/emotional lability,11.96777906,NA,NA Philipsen,2015 NA,RCT,G  65, 43, 108,NA,reverse -0.5080000000,-0.901000000,-1.150000e-01,  6.9000000,  7.7000000,NA,NA,NA NA NA NA 100,100,100 100,100,100,100 low,low,some,low low Placebo,  0, 52.213889 35.321296 NA NA 0 1 1.0 1.0,1.0 1.0,1,1 1 1 1,1,1 1.0 0 1,1,1 1330,Philipsen_2015 7-12 months NA >= 20 yo 35.3212962962963 35.3212962962963,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks),1,Homogeneous,Ostinelli (2025) - Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks)_>= 18 yo,100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100,100 High,Methylphenidate Methylphenidate,  0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability 11.96777906 NA NA Philipsen,2015 NA RCT RR,110,107, 217 outcomes,reverse  0.3600000000  0.183000000, 7.080000e-01,NA,NA,NA NA,NA NA,NA,NA,100 100 100 100,100,100 100 low,low low low,low Placebo   0, 52.527189 35.254839 NA NA 0,1 1.0 1.0,1.0,1.0,1 1,1,1 1 1 1 1.0,0 1,1 1,1331,Philipsen_2015,7-12 months NA >= 20 yo,28.7959183673469 40 NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100,100 High,Methylphenidate,Methylphenidate,  0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA Tolerability,11.96777906 NA,NA,Philipsen 2015,NA,RCT,RR 110,107  217,outcomes reverse, 0.4860000000  0.091000000, 2.600000e+00,NA NA NA NA NA,NA,NA NA 100 100 100,100,100,100,100 low low,low low low Placebo   0  52.527189 35.254839 NA NA,0,1 1.0,1.0 1.0 1.0,1,1 1,1,1,1,1,1.0,0,1,1 1 1332,Philipsen_2015,7-12 months NA >= 20 yo,28.7959183673469,40 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0 100,100,High,Dialectical Behavioral Therapy (DBT) Dialectical Behavioral Therapy (DBT),100,placebo Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA CAARS-O:L 11.96777906 NA NA,Philipsen,2015 NA RCT,G  86  80  166,NA reverse, 0.0970000000 -0.209000000  4.020000e-01,  8.7000000   9.8000000,NA,NA NA NA,NA,NA,100 100 100 100,100,100,100,low low some low low,Placebo   0, 49.900000,35.262651,NA,NA 0 1 1.0,1.0,1.0,1.0,1,1,1 1,1,1,1 1.0,0,1 1 1,1333,Philipsen_2015 7-12 months NA >= 20 yo 35.2626506024096 35.2626506024096,NA NA   3, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events)  1 Ostinelli (2025) 35.2532407407407 37.004132231405,NA NA Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100 100 High Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT) 100,placebo,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At follow-up (closest to 26 weeks),NA,CAARS-O:L 11.96777906 NA,NA,Philipsen,2015,NA RCT G, 75  62, 137,NA reverse,-0.1120000000,-0.449000000, 2.260000e-01,  8.4000000   9.5000000,NA,NA,NA NA,NA,NA,100,100,100,100,100 100 100 low,low,some low,low,Placebo,  0, 49.656204 35.283212 NA NA 0 1,1.0 1.0,1.0 1.0 1 1,1 1,1 1 1 1.0,0 1,1 1,1334 Philipsen_2015 7-12 months NA,>= 20 yo 35.2832116788321 35.2832116788321,NA,NA   3  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1,Ostinelli (2025),35.2532407407407,37.004132231405 NA NA Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) 1 Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no,low low
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0 100,100 High,Dialectical Behavioral Therapy (DBT) Dialectical Behavioral Therapy (DBT),100 placebo Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At follow-up (closest to 52 weeks),NA CAARS-O:L 11.96777906 NA,NA Philipsen 2015,NA,RCT G  59  45  104,NA reverse -0.2760000000,-0.668000000, 1.160000e-01,  8.4000000,  8.1000000 NA NA NA,NA,NA,NA 100 100,100 100 100,100,100 low low,some,low low,Placebo   0, 49.491346 35.297115 NA NA,0 1 1.0 1.0,1.0 1.0,1,1,1 1 1,1,1,1.0,0,1 1 1 1335,Philipsen_2015,7-12 months,NA >= 20 yo 35.2971153846154 35.2971153846154,NA NA,  3, 5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1 Ostinelli (2025) 35.2532407407407 37.004132231405 NA NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks),1,Homogeneous,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100   0 100,100 High Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT),100 placebo,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks),NA,CAARS-S:L,11.96777906,NA NA Philipsen,2015,NA,RCT,G, 84  79, 163,outcomes reverse, 0.0950000000 -0.213000000, 4.030000e-01,  9.1000000,  9.8000000,NA,NA,NA NA,NA,NA,100,100,100,100 100,100,100,low,low some,low low,Placebo,  0  49.922699 35.260736,NA,NA 0 1 1.0,1.0 1.0,1.0 1 1,1,1 1,1,1 1.0 0,1,1,1 1336,Philipsen_2015,7-12 months,NA >= 20 yo,35.260736196319,36.9895833333333 NA,NA   3  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1,Ostinelli (2025) 35.2532407407407 37.004132231405,NA NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 999 Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0,100 100,High Dialectical Behavioral Therapy (DBT) Dialectical Behavioral Therapy (DBT) 100,placebo,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At follow-up (closest to 26 weeks),NA CAARS-S:L,11.96777906,NA NA Philipsen 2015 NA,RCT G  69  58, 127 NA,reverse  0.0100000000,-0.340000000, 3.610000e-01,  9.1000000, 10.5000000 NA,NA,NA,NA NA,NA 100 100,100,100,100,100 100,low low,some,low,low Placebo,  0, 49.690551,35.280315,NA NA 0,1 1.0 1.0 1.0,1.0 1,1 1 1 1,1 1,1.0 0 1 1,1,1337 Philipsen_2015,7-12 months NA >= 20 yo 35.2803149606299,35.2803149606299 NA,NA,  3  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1,Ostinelli (2025),35.2532407407407,37.004132231405 NA,NA Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),1,Homogeneous,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2,100,  0,100,100,High,Dialectical Behavioral Therapy (DBT) Dialectical Behavioral Therapy (DBT),100 placebo,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At follow-up (closest to 52 weeks) NA CAARS-S:L 11.96777906 NA NA,Philipsen 2015,NA RCT,G, 56  43   99,NA,reverse,-0.3580000000 -0.761000000  4.400000e-02   8.4000000, 10.6000000,NA,NA,NA NA,NA,NA 100 100,100,100,100,100,100 low,low some,low low,Placebo   0, 49.505051 35.295960,NA NA,0,1 1.0,1.0 1.0 1.0,1 1 1,1 1,1,1 1.0 0 1 1,1,1338,Philipsen_2015,7-12 months NA,>= 20 yo 35.2959595959596 35.2959595959596 NA NA,  3  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events), 1 Ostinelli (2025) 35.2532407407407,37.004132231405 NA NA Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks) 1,Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo,100.00000 no,low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100 100,High,Dialectical Behavioral Therapy (DBT) Dialectical Behavioral Therapy (DBT) 100 placebo Emotional dysregulation,Mixed At study endpoint (closest to 12 weeks),NA,CAARS impulsivity/emotional lability,11.96777906,NA NA Philipsen 2015 NA RCT,G, 84  79  163 NA reverse  0.1910000000,-0.118000000  5.000000e-01,  7.2000000,  7.4000000 NA NA NA,NA,NA NA,100 100,100 100 100,100 100,low low some,low low Placebo,  0  49.922699,35.260736 NA NA,0 1,1.0 1.0,1.0 1.0,1,1 1,1 1 1,1,1.0 0,1,1 1,1339,Philipsen_2015,7-12 months,NA,>= 20 yo,35.260736196319 35.260736196319,NA,NA,  3, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events)  1 Ostinelli (2025),35.2532407407407,37.004132231405,NA NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100,High Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT),100,placebo Emotional dysregulation,Mixed,At follow-up (closest to 26 weeks) NA,CAARS impulsivity/emotional lability,11.96777906,NA NA,Philipsen 2015,NA,RCT,G  69, 58  127,NA reverse, 0.1230000000,-0.228000000, 4.740000e-01,  6.7000000   7.9000000,NA NA NA,NA,NA,NA 100 100 100 100,100,100,100 low,low some,low,low,Placebo,  0  49.690551 35.280315,NA,NA 0,1,1.0 1.0,1.0,1.0 1,1 1,1,1 1 1 1.0 0 1 1 1 1340,Philipsen_2015 7-12 months,NA,>= 20 yo 35.2803149606299,35.2803149606299,NA NA   3, 5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events)  1 Ostinelli (2025),35.2532407407407,37.004132231405 NA,NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks),1,Homogeneous Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo,100.00000 no low low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100,High,Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT) 100,placebo Emotional dysregulation,Mixed,At follow-up (closest to 52 weeks) NA,CAARS impulsivity/emotional lability 11.96777906 NA,NA Philipsen 2015 NA,RCT G  56, 43   99,NA,reverse -0.2250000000 -0.626000000, 1.750000e-01   6.5000000   7.7000000 NA NA NA NA,NA,NA,100 100 100 100 100 100,100 low low,some low,low,Placebo,  0, 49.505051 35.295960 NA,NA,0 1 1.0,1.0,1.0 1.0 1,1,1 1,1 1,1,1.0,0,1,1 1 1341,Philipsen_2015,7-12 months,NA >= 20 yo 35.2959595959596,35.2959595959596 NA NA,  3  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events)  1 Ostinelli (2025),35.2532407407407,37.004132231405 NA,NA Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks) 1,Homogeneous,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks)_>= 18 yo,100.00000 no low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100 High,Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT),100 placebo,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability,11.96777906 NA,NA,Philipsen 2015 NA,RCT,RR,109 107, 216 outcomes reverse  0.9090000000  0.566000000, 1.460000e+00,NA,NA,NA NA,NA,NA NA NA,100 100 100 100 100,100 100 low low low low,low Placebo   0  50.011574 35.253241,NA NA,0 1 1.0 1.0 1.0 1.0,1 1 1,1 1 1 1,1.0 0,1,1 1,1342,Philipsen_2015,7-12 months NA,>= 20 yo,35.2532407407407 37.004132231405 NA,NA,  3  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events)  1 Ostinelli (2025) 35.2532407407407,37.004132231405,NA NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100,  0 100 100 High Dialectical Behavioral Therapy (DBT),Dialectical Behavioral Therapy (DBT),100,placebo,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA Tolerability,11.96777906,NA NA Philipsen 2015,NA RCT,RR,109,107  216,NA,reverse  0.7360000000, 0.169000000  3.212000e+00,NA NA,NA NA NA,NA NA,NA 100 100,100,100 100,100 100 low low low,low,low Placebo   0, 50.011574 35.253241,NA NA,0,1,1.0,1.0,1.0,1.0 1,1 1,1 1,1 1 1.0 0,1,1,1 1343 Philipsen_2015,7-12 months,NA >= 20 yo 35.2532407407407,35.2532407407407,NA,NA   3  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events)  1,Ostinelli (2025),35.2532407407407,37.004132231405,NA NA,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 999 Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100 100,High Goal Management Training (GMT),Goal Management Training (GMT) 100 tau Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 1.84119678,NA NA,Hanssen,2023,NA RCT RR  41  40   81,NA,reverse 18.5480000000  1.115000000, 3.084050e+02,NA,NA,NA,NA NA,NA,NA,NA 100 100,100 100,100,100 100,low,some,low,some,low,TAU   0, 58.034568,31.298765,NA NA 0 1,1.0,1.0 1.0,1.0,1,1 1 1,1,1 1,1.0,0,1 1,1 1344 Hanssen_2023,< 2 months,NA >= 20 yo 31.2987654320988 31.2987654320988,NA NA,  1, 1 Acceptability: all-cause discontinuation  1,Ostinelli (2025),31.2987654320988 31.2987654320988 NA,NA,Ostinelli (2025)_Goal Management Training (GMT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - Goal Management Training (GMT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 999 Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0,100 100 High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT)   0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability, 0.46029919,NA NA,Huang 2015 NA RCT RR  86, 22  108,outcomes,reverse, 1.0230000000, 0.477000000, 2.193000e+00,NA,NA NA,NA,NA,NA NA NA 100,100 100,100,100,100 100,low low,low some,low WLC,  0  37.935185 26.623333,NA,NA,0,1,1.0,1.0,1.0,1.0,1 1 1 1,1 1,1 1.0 0,1 1,1,1345 Huang_2015,< 2 months,NA,>= 20 yo,19.6532142857143,43.15,NA,NA  19  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 999,Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100,100,High Viloxazine Viloxazine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,AISRS, 1.38089758 NA NA,Nasser,2022,NA,RCT,G 175,179  354,NA reverse,-0.3140000000,-0.582000000,-4.700000e-02 NA NA,NA,NA,NA NA,12.0411793,12.0411793,100 100,100 100   0 100,100 low low,high,low low,Placebo,  0  45.213559,34.757345,NA NA,0 1 1.0,1.0,1.0,1.0,1,1 1,1,1 1 1,1.0 0 1 1 1,1346 Nasser_2022 < 2 months,NA,>= 20 yo 34.7573446327684,34.7573446327684,NA NA   6, 6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2 Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA,NA Ostinelli (2025)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low low
 999,Ostinelli (2025) Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100 100,High Viloxazine,Viloxazine   0 NA Emotional dysregulation Mixed,At study endpoint (closest to 12 weeks) NA BRIEF-ASR Emotional control  1.38089758 NA NA,Nasser 2022,NA RCT G 175 179, 354,NA reverse  0.0980000000 -0.118000000, 3.140000e-01 NA,NA NA,NA NA NA, 9.2315708  9.2315708 100 100 100 100,  0,100,100 low,low,high low,low,Placebo,  0, 45.213559 34.757345 NA,NA 0 1,1.0,1.0 1.0 1.0,1 1,1 1,1,1 1,1.0,0,1,1,1 1347 Nasser_2022 < 2 months,NA >= 20 yo 34.7573446327684,34.7573446327684,NA,NA   6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA NA,Ostinelli (2025)_Viloxazine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Viloxazine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100,100,High,Viloxazine,Viloxazine   0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability, 1.38089758 NA NA,Nasser 2022 NA RCT,RR,190 184, 374,NA reverse, 1.3870000000, 0.999000000  1.924000e+00,NA,NA,NA,NA NA NA,NA NA 100,100 100 100,100,100,100,low,low low,low,low Placebo   0, 45.180749 34.739572 NA NA 0 1 1.0,1.0 1.0 1.0 1,1 1 1,1,1,1 1.0,0,1,1 1 1348 Nasser_2022,< 2 months,NA >= 20 yo 34.7395721925134 34.7395721925134,NA,NA,  6  6,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation  2 Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA NA,Ostinelli (2025)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100,High Viloxazine,Viloxazine,  0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 1.38089758,NA NA Nasser,2022 NA,RCT,RR,190 184, 374,NA reverse, 1.8290000000, 0.837000000  3.999000e+00,NA,NA NA,NA NA,NA,NA NA,100,100 100 100 100,100 100,low low low,low,low Placebo   0, 45.180749,34.739572,NA,NA,0,1 1.0 1.0 1.0 1.0,1 1 1 1,1,1,1,1.0,0 1 1,1,1349,Nasser_2022,< 2 months NA,>= 20 yo 34.7395721925134,34.7395721925134 NA,NA,  6  6 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation, 2,Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA NA Ostinelli (2025)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Ostinelli (2025) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no,low,low
 999,Ostinelli (2025),Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100,100 High Atomoxetine,Atomoxetine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA CAARS-O, 1.38089758 NA NA,NCT03324581,2018,NA RCT G, 50, 59, 109 outcomes,reverse -0.7500000000 -1.249000000,-2.520000e-01 NA NA,NA NA,NA NA 13.5200000,13.5200000,100,100 100 100   0,100 100,low low high,low low,Placebo   0, 54.089908,34.829358,NA,NA 0 1 1.0,1.0,1.0 1.0 1,1 1,1 1 1,1 1.0,0,1 1,1,1350,NCT03324581_2018 < 2 months NA,>= 20 yo,24.7 42.1,NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low,low
 999,Ostinelli (2025),Ostinelli 2025,10.1016/S2215-0366(24)00360-2 100   0 100,100 High Atomoxetine Atomoxetine,  0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA Acceptability  1.38089758 NA,NA NCT03324581,2018 NA,RCT RR, 80, 82  162 outcomes reverse, 1.4760000000, 0.983000000  2.217000e+00,NA NA,NA NA NA,NA,NA NA 100 100,100 100 100 100,100,low,low low low,low Placebo,  0, 54.311111,34.846914 NA,NA 0 1,1.0 1.0,1.0 1.0 1 1,1 1 1,1,1,1.0 0 1,1,1,1351,NCT03324581_2018 < 2 months NA,>= 20 yo 24.7 42.10703125,NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100   0,100 100,High,Atomoxetine,Atomoxetine,  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 1.38089758 NA NA,NCT03324581 2018 NA RCT,RR, 80  82  162,outcomes,reverse, 1.6110000000  0.657000000  3.947000e+00 NA,NA NA NA NA,NA NA NA 100 100,100 100 100 100 100 low,low low low low Placebo,  0, 54.311111 34.846914 NA NA 0,1 1.0 1.0 1.0,1.0,1,1 1,1 1 1 1 1.0,0,1,1,1 1352 NCT03324581_2018 < 2 months NA >= 20 yo 24.7,42.10703125,NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100 100 High,TMS ([repetitive] transcranial magnetic stimulation) TMS ([repetitive] transcranial magnetic stimulation)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks) NA CAARS-S:L, 0.92059839,NA NA,NCT03663179 2020,NA RCT G, 14, 13,  27 outcomes reverse, 0.1880000000,-0.617000000, 9.920000e-01,NA,NA NA NA NA,NA, 7.6000000  7.6000000   0,  0,  0   0,  0,  0   0,high high high high,high,Sham,  0, 33.340741,34.392593 NA NA 0,1,1.0 1.0,1.0 1.0 1 1,1 1,1,1,1 1.0 0 1,1,1 1353 NCT03663179_2020,< 2 months,NA,>= 20 yo 27.1124137931034 35.24,NA,NA,  4  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests)  1 Ostinelli (2025) 27.0733333333333,35.24,NA,NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,high high
 999 Ostinelli (2025),Ostinelli,2025,10.1016/S2215-0366(24)00360-2 100   0 100,100,High TMS ([repetitive] transcranial magnetic stimulation),TMS ([repetitive] transcranial magnetic stimulation)   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability, 0.92059839,NA NA NCT03663179,2020,NA,RCT RR  18  14   32,outcomes reverse  3.1110000000  0.390000000, 2.482900e+01,NA NA NA,NA NA NA NA,NA,  0,  0,  0   0   0,  0,  0,high high high,high,high Sham   0  33.556250 34.256250 NA,NA,0 1 1.0,1.0,1.0 1.0 1 1 1,1 1 1,1 1.0 0,1,1,1 1354,NCT03663179_2020,< 2 months,NA,>= 20 yo 27.0733333333333,35.22 NA NA   4  5 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests), 1,Ostinelli (2025) 27.0733333333333,35.24,NA,NA Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high,high
 999 Ostinelli (2025) Ostinelli,2025,10.1016/S2215-0366(24)00360-2,100,  0,100 100,High,TMS ([repetitive] transcranial magnetic stimulation),TMS ([repetitive] transcranial magnetic stimulation),  0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,Tolerability, 0.92059839 NA NA NCT03663179,2020,NA RCT,RR  18  14   32,outcomes,reverse  0.7890000000  0.017000000  3.751100e+01,NA NA,NA NA NA NA,NA NA,  0,  0,  0,  0   0,  0   0,high,high high high,high,Sham   0  33.556250,34.256250,NA NA,0,1,1.0 1.0 1.0,1.0,1 1 1,1,1,1,1,1.0 0 1 1,1,1355 NCT03663179_2020,< 2 months NA,>= 20 yo 27.0733333333333,35.22,NA,NA,  4  5,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests), 1,Ostinelli (2025) 27.0733333333333,35.24 NA NA,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no high high
 999,Ostinelli (2025),Ostinelli,2025 10.1016/S2215-0366(24)00360-2,100,  0 100,100 High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),100,tau,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At follow-up (closest to 26 weeks),NA,Adult Barkley CSS NA NA,NA Dittner 2018,NA,RCT G, 27, 19   46 outcomes reverse,-1.1620000000 -1.804000000 -5.210000e-01  10.6000000,  7.8000000 NA,NA,NA NA,NA NA   0   0   0   0,  0   0,  0,high,high,high,high,high,TAU   0, 28.671739 35.865217 NA,NA,0,1 1.0,1.0 1.0 1.0,1,1,1 1,1 1,1 1.0,0,1,1 1,1356 Dittner_2018 NA,NA >= 20 yo 19.6482233502538,43.0524590163934 NA,NA, 19, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 1 Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000,no,high high
 999 Ostinelli (2025) Ostinelli 2025 10.1016/S2215-0366(24)00360-2 100   0,100 100 High Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),100 tau Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At follow-up (closest to 52 weeks) NA Adult Barkley CSS,NA NA NA Dittner 2018 NA RCT G  27  17   44,outcomes reverse,-0.9790000000 -1.627000000 -3.300000e-01,  8.8000000,  7.5000000 NA,NA,NA,NA NA NA   0,  0,  0,  0,  0,  0,  0 high high,high high,high,TAU   0  28.156818,35.854545,NA,NA 0 1,1.0 1.0,1.0 1.0 1,1 1,1,1,1 1 1.0,0,1 1 1,1357 Dittner_2018,NA NA >= 20 yo 35.8545454545455 43.0584615384615 NA NA  19, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4 Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA NA,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks) 1 Homogeneous Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo,100.00000 no high,high
 999,Ostinelli (2025) Ostinelli,2025 10.1016/S2215-0366(24)00360-2 100,  0 100 100,High,Cognitive Behavioral Therapy (CBT) Cognitive Behavioral Therapy (CBT),100,tau,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability,NA NA NA Dittner 2018,NA,RCT RR, 30  30   60 outcomes reverse  1.0000000000  0.151000000, 6.643000e+00,NA,NA NA,NA,NA NA,NA NA 100 100 100,  0 100 100 100 low high,low,low,low TAU,  0  30.350000,35.900000,NA,NA,0,1,1.0 1.0 1.0 1.0 1,1,1,1 1,1,1,1.0,0 1 1 1 1358,Dittner_2018 NA,NA,>= 20 yo 19.6532142857143 43.15,NA NA, 19  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Emotional dysregulation  4,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3 43.15 NA,NA Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100,100 High Methylphenidate,Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),NA,21:SNAP-IV-short-Total  1.05868815   48.3000000,mg/d,Abikoff,2009,NA RCT G, 19  19,  38 outcomes reverse,-0.6790000000 -1.342000000 -1.600000e-02,  0.5500000,  0.6300000,NA NA NA,NA NA NA 100,100 100 100 100,100 100 some,some,low,some some Placebo   0  21.100000,10.050000 NA NA,0 1 1.0,1.0 1.0,1.0,1 1 0,1,1,1,1,1.0 1,1 1 1,1359 Abikoff_2009 < 2 months,NA,6-12 yo,8.60731707317073,10.9714285714286 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100 High Methylphenidate Methylphenidate,  0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability, 1.05868815,  48.3000000,mg/d,Abikoff,2009 NA RCT,RR  19  19,  38 outcomes reverse, 1.0000000000, 0.021000000  4.797200e+01 NA,NA,NA,NA NA NA NA,NA,100,100 100 100 100 100 100,some,some low some,some,Placebo,  0, 21.100000 10.050000 NA NA,0 1 1.0 1.0,1.0,1.0,1 1,0 1 1 1 1,1.0,1 1,1 1,1360,Abikoff_2009 < 2 months NA 6-12 yo,7.9578947368421,14.7,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100,High,Methylphenidate,Methylphenidate   0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 1.05868815   48.3000000,mg/d Abikoff,2009,NA RCT,RR  19, 19   38 outcomes,reverse  1.0000000000  0.021000000  4.797200e+01 NA NA,NA NA NA,NA NA,NA 100,100 100,100,100,100 100 some some,low some,some Placebo,  0, 21.100000 10.050000 NA,NA 0,1 1.0 1.0 1.0 1.0,1 1 0 1 1,1 1 1.0 1,1,1 1 1361 Abikoff_2009 < 2 months NA 6-12 yo,7.9578947368421 14.7 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757 Cortese - Adults (2018) Cortese - Adults 2018,10.1016/S2215-0366(18)30269-4 100,  0 100 100 High Atomoxetine,Atomoxetine,  0 NA,CGI Clinician-rated At follow-up (closest to 26 weeks) NA,CGI-I  5.52359033   85.2000000,mg/d Adler 2008a,NA RCT,G 271 139  410 NA,reverse,-0.0940000000 -0.298000000  1.110000e-01,  1.1000000   1.0000000 NA,NA NA,NA,NA,NA,100 100,100 100 100,100 100 low some,some some low,Placebo   0  41.459024,36.727073,NA NA 0 1,1.0,1.0,1.0 1.0,1,1,0,1 1 1 1,1.0,1,1,1 1,1362 Adler_2008a,2-6 months NA >= 20 yo 36.7270731707317 36.7270731707317 NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA,NA,Cortese - Adults (2018)_Atomoxetine_CGI_Clinician-rated_At follow-up (closest to 26 weeks) 1 Homogeneous,Cortese - Adults (2018) - Atomoxetine_CGI_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo 100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100,High,Atomoxetine,Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),NA 24:Other, 1.38089758,  44.2000000 mg/kg/d,Arnold 2006,NA,RCT,G  16, 16,  32,outcomes reverse,-0.5060000000,-1.222000000  2.090000e-01,  6.2000000   6.5000000 NA,NA,NA NA,NA NA,100 100,100,100,100,100 100,some low,low low,some,Placebo   0, 25.000000, 9.260000,NA NA 0 1,1.0,1.0 1.0 1.0 1 1,0,1,1,1,1 1.0,1,1 1 1 1363 Arnold_2006,< 2 months,NA,6-12 yo 9.26,11.2017964071856,NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100 100,High,Atomoxetine,Atomoxetine,  0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability, 1.38089758,  44.2000000 mg/kg/d,Arnold,2006 NA RCT,RR, 16, 16   32 outcomes reverse  0.5000000000  0.050000000, 4.978000e+00,NA,NA NA,NA NA NA,NA,NA,100 100 100 100,100 100 100 some,low,low low,some Placebo,  0, 25.000000  9.260000,NA,NA 0,1,1.0,1.0,1.0 1.0,1 1 0 1,1,1 1 1.0 1 1 1 1,1364 Arnold_2006 < 2 months NA,6-12 yo 8.65154639175258 12.2493548387097,NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757 Cortese - Adults (2018),Cortese - Adults,2018,10.1016/S2215-0366(18)30269-4,100   0 100,100 High Modafinil,Modafinil,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,17:Other, 2.07134638  255.0000000,mg/d,Arnold,2014,NA RCT G, 71  72  143 outcomes,reverse  0.2550000000,-0.075000000, 5.860000e-01, 10.5326872  12.7279221 NA,NA,NA,NA,NA NA,100 100,100 100,100,100,100,some,low,low,low some,Placebo,  0  38.559441,39.841259 NA,NA,0 1 1.0,1.0,1.0 1.0 1,1 0 1 1,1 1,1.0 1 1 1,1 1365,Arnold_2014,2-6 months,NA,>= 20 yo,38.1070422535211 39.8412587412587 NA NA   8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA NA Cortese - Adults (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Adults (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low,low
 757 Cortese - Adults (2018) Cortese - Adults 2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Modafinil,Modafinil   0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability  2.07134638  255.0000000,mg/d Arnold,2014 NA RCT RR, 73  74, 147 outcomes,reverse  1.3220000000  0.855000000  2.046000e+00,NA NA NA,NA,NA,NA NA,NA,100 100,100,100 100 100,100,some,low,low,low some Placebo,  0, 38.557823 39.841497 NA,NA,0,1,1.0 1.0,1.0 1.0,1 1,0 1 1 1 1 1.0,1,1,1 1 1366 Arnold_2014,2-6 months NA,>= 20 yo 38.1034013605442 39.8414965986395,NA,NA,  8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA,NA,Cortese - Adults (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Adults (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 757,Cortese - Adults (2018),Cortese - Adults,2018,10.1016/S2215-0366(18)30269-4,100   0,100,100 High Modafinil Modafinil   0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability, 2.07134638, 255.0000000 mg/d,Arnold,2014,NA RCT RR, 73, 74  147 outcomes,reverse, 3.2100000000, 1.360000000, 7.578000e+00,NA NA NA NA,NA,NA,NA,NA 100 100,100,100,100,100,100 some low,low low,some,Placebo   0, 38.557823 39.841497,NA,NA 0 1,1.0,1.0 1.0 1.0 1 1,0,1,1,1,1,1.0 1 1 1,1,1367,Arnold_2014,2-6 months NA,>= 20 yo,38.1034013605442,39.8414965986395 NA,NA,  8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA NA,Cortese - Adults (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Adults (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low low
 757,Cortese - Adults (2018) Cortese - Adults 2018,10.1016/S2215-0366(18)30269-4 100   0,100 100,High Modafinil Modafinil   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA 17:Other  2.07134638, 340.0000000,mg/d Arnold 2014,NA,RCT G, 70  72  142 outcomes,reverse, 0.0000000000 -0.330000000  3.300000e-01  12.5499004  12.7279221,NA,NA NA NA,NA,NA 100,100 100 100 100 100 100 some,low low low some Placebo,  0  44.535211,38.107042,NA NA 0,1 1.0,1.0 1.0,1.0 1,1,0,1,1,1 1 1.0,1,1,1,1 1368 Arnold_2014,2-6 months NA,>= 20 yo 38.1070422535211,39.8412587412587 NA NA   8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8,NA NA,Cortese - Adults (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Adults (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 757 Cortese - Adults (2018) Cortese - Adults 2018 10.1016/S2215-0366(18)30269-4,100   0 100 100 High Modafinil Modafinil   0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,Acceptability  2.07134638  340.0000000 mg/d,Arnold 2014,NA RCT RR, 73, 74  147 outcomes reverse  1.5870000000  1.052000000, 2.394000e+00 NA NA,NA,NA NA NA,NA NA 100 100 100 100 100,100,100,some,low,low,low,some,Placebo   0, 44.517007,38.103401 NA NA,0,1,1.0 1.0 1.0,1.0 1 1 0,1 1,1 1 1.0 1 1,1,1 1369,Arnold_2014,2-6 months NA >= 20 yo 38.1034013605442 39.8414965986395,NA,NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8,NA,NA Cortese - Adults (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Adults (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no,low,low
 757 Cortese - Adults (2018) Cortese - Adults,2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100,High,Modafinil,Modafinil   0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability, 2.07134638  340.0000000 mg/d Arnold 2014,NA RCT RR  73, 74, 147,outcomes,reverse, 3.2100000000  1.360000000  7.578000e+00,NA,NA,NA,NA,NA,NA NA NA 100,100,100 100,100,100 100,some,low,low,low some Placebo   0  44.517007,38.103401,NA,NA,0 1,1.0 1.0 1.0,1.0 1,1,0,1,1 1 1,1.0 1 1,1,1,1370,Arnold_2014 2-6 months,NA,>= 20 yo,38.1034013605442 39.8414965986395 NA NA,  8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8,NA,NA,Cortese - Adults (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Adults (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 757 Cortese - Adults (2018),Cortese - Adults 2018,10.1016/S2215-0366(18)30269-4 100   0 100 100,High Modafinil Modafinil   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,17:Other  2.07134638, 425.0000000 mg/d Arnold 2014,NA,RCT G  72, 72, 144,outcomes,reverse  0.1560000000 -0.172000000, 4.850000e-01  12.7279221, 12.7279221,NA,NA NA NA,NA NA,100 100,100 100,100,100 100 some,low low low,some Placebo,  0, 46.000000 39.100000,NA NA,0,1 1.0,1.0,1.0 1.0 1,1,0,1,1,1,1,1.0,1 1,1 1 1371,Arnold_2014,2-6 months NA,>= 20 yo,38.1070422535211,39.8412587412587 NA NA   8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8,NA,NA Cortese - Adults (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Adults (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low,low
 757 Cortese - Adults (2018) Cortese - Adults,2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100,High Modafinil,Modafinil,  0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability  2.07134638  425.0000000 mg/d Arnold 2014,NA RCT,RR  74  74  148,outcomes reverse  1.5220000000, 1.004000000  2.306000e+00,NA NA NA NA NA NA,NA,NA 100,100 100,100 100 100,100 some low,low,low,some Placebo,  0, 46.000000 39.100000,NA NA,0 1,1.0 1.0 1.0 1.0 1,1 0 1 1 1,1 1.0 1,1,1,1,1372 Arnold_2014 2-6 months NA,>= 20 yo 38.1034013605442,39.8414965986395,NA NA   8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA,NA,Cortese - Adults (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Adults (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no,low low
 757 Cortese - Adults (2018) Cortese - Adults 2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100 High Modafinil Modafinil,  0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability  2.07134638  425.0000000 mg/d,Arnold,2014 NA,RCT,RR, 74, 74, 148,outcomes reverse  3.6670000000, 1.578000000  8.521000e+00,NA NA,NA NA NA NA,NA NA 100 100 100 100,100,100 100,some,low,low,low,some Placebo   0  46.000000,39.100000,NA,NA,0,1,1.0,1.0,1.0,1.0,1,1 0,1 1 1 1 1.0 1 1,1 1 1373 Arnold_2014 2-6 months,NA >= 20 yo,38.1034013605442,39.8414965986395 NA,NA   8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8,NA NA,Cortese - Adults (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Adults (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000 no low low
 757,Cortese - Adults (2018),Cortese - Adults,2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100,High Modafinil,Modafinil   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA,17:Other, 2.07134638  510.0000000,mg/d,Arnold,2014 NA RCT,G  41, 72  113 outcomes reverse, 0.2510000000,-0.136000000, 6.370000e-01  10.2449988, 12.7279221,NA,NA NA NA,NA NA 100 100,100,100,100,100,100 some low,low low,some,Placebo,  0, 42.283186,38.962832 NA NA 0,1,1.0 1.0,1.0 1.0 1 1 0 1 1 1 1 1.0 1 1 1,1 1374,Arnold_2014 2-6 months,NA >= 20 yo,38.1070422535211,39.8412587412587,NA NA,  8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA NA Cortese - Adults (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Adults (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no low low
 757,Cortese - Adults (2018) Cortese - Adults 2018 10.1016/S2215-0366(18)30269-4,100,  0,100,100,High Modafinil Modafinil,  0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability, 2.07134638, 510.0000000,mg/d,Arnold,2014,NA RCT,RR  44, 74  118 outcomes,reverse  1.5360000000  0.970000000  2.430000e+00,NA NA,NA NA,NA NA NA,NA,100 100,100 100,100,100,100,some low,low low,some,Placebo,  0  42.152542,38.972881 NA,NA,0,1 1.0,1.0 1.0 1.0,1,1 0,1,1,1,1 1.0 1,1 1 1 1375,Arnold_2014 2-6 months,NA,>= 20 yo,38.1034013605442 39.8414965986395 NA NA,  8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA,NA Cortese - Adults (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Adults (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low,low
 757 Cortese - Adults (2018),Cortese - Adults 2018 10.1016/S2215-0366(18)30269-4,100,  0,100,100 High Modafinil Modafinil,  0,NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,Tolerability  2.07134638, 510.0000000,mg/d,Arnold 2014,NA,RCT,RR, 44, 74  118,outcomes,reverse, 2.5230000000, 0.963000000  6.610000e+00 NA NA NA,NA,NA,NA NA NA 100 100,100,100,100 100 100,some low low low,some,Placebo   0  42.152542 38.972881 NA NA,0,1,1.0,1.0 1.0 1.0 1 1 0 1,1,1 1,1.0,1,1,1,1,1376 Arnold_2014,2-6 months NA,>= 20 yo,38.1034013605442 39.8414965986395,NA NA   8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8,NA,NA Cortese - Adults (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Adults (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100,High,Atomoxetine Atomoxetine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA 16:SNAP-IV-Short-Hyper-Impuls  1.84119678,   1.2000000,mg/kg/d Bangs,2008,NA RCT G,153  68  221,outcomes,reverse -0.3200000000,-0.632000000 -8.000000e-03,NA,NA NA NA NA NA, 8.4000000, 8.4000000 100 100 100,100 100 100 100,low,low,some,low,low,Placebo   0,  6.638462, 9.561538 NA NA 0,1 1.0,1.0,1.0,1.0,1,1,0 1,1 1,1,1.0,1,1 1 1,1377,Bangs_2008,< 2 months NA 6-12 yo 8.65157894736842 12.2493333333333 NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0 100,100 High Atomoxetine,Atomoxetine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA,24:Other  1.84119678,   1.2000000 mg/kg/d,Bangs,2008 NA,RCT G,150  67  217 outcomes,reverse,-0.4040000000 -0.706000000,-1.010000e-01,NA NA,NA NA NA,NA, 3.9000000, 3.9000000,100,100 100 100 100,100,100,low,low,some,low,low,Placebo,  0,  6.632719  9.561751 NA NA,0 1,1.0 1.0,1.0,1.0 1 1 0,1,1 1,1 1.0,1,1 1,1,1378,Bangs_2008,< 2 months,NA 6-12 yo 9.26 11.2017964071856 NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100,High,Atomoxetine Atomoxetine   0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability  1.84119678    1.2000000,mg/kg/d Bangs 2008 NA RCT,RR,156  70, 226,outcomes,reverse  2.1540000000, 0.857000000, 5.412000e+00 NA NA NA NA,NA NA,NA NA,100,100,100 100 100,100 100,low,low,some,low low,Placebo,  0,  6.627434  9.561947,NA NA 0 1 1.0,1.0,1.0,1.0 1,1,0,1 1 1,1 1.0,1 1 1,1,1379 Bangs_2008 < 2 months,NA 6-12 yo 8.65154639175258,12.2493548387097 NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100,High,Atomoxetine,Atomoxetine,  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability  1.84119678    1.2000000 mg/kg/d,Bangs 2008,NA RCT RR,156, 70  226 outcomes,reverse, 5.8790000000, 0.336000000  1.029390e+02 NA,NA,NA,NA,NA,NA NA NA 100 100,100,100 100,100 100 low,low some,low,low,Placebo,  0   6.627434, 9.561947 NA,NA,0 1 1.0,1.0 1.0 1.0 1,1 0,1 1,1 1 1.0,1,1,1 1 1380,Bangs_2008 < 2 months,NA,6-12 yo 8.65154639175258 12.2493548387097,NA NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100 High,Amphetamine,Amphetamine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total, 0.92059839   30.0000000,mg/d Biederman 2007b NA RCT,G, 69  72, 141,outcomes reverse,-1.1960000000 -1.556000000 -8.360000e-01, 13.0200000, 12.6400000,NA NA NA NA,NA,NA 100 100,100 100,100 100 100,low,low some,low low,Placebo,  0, 28.553191, 9.204255,NA NA 0 1,1.0,1.0,1.0,1.0 1 1 0,1,1,1,1 1.0 1,1 1 1,1381,Biederman_2007b,< 2 months,NA 6-12 yo,9.04758620689655 14.6347014925373 NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0 100,100 High,Amphetamine Amphetamine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) NA 13:CPRS-R:S  0.92059839,  30.0000000,mg/d Biederman 2007b,NA RCT G  69  72, 141,outcomes reverse,-0.5820000000 -0.942000000 -2.220000e-01 NA,NA NA,NA,NA,NA  9.3338095  9.3338095 100 100,100,100 100 100,100,low,low some low low,Placebo   0, 28.553191, 9.204255,NA,NA,0,1,1.0,1.0 1.0 1.0 1,1,0 1 1,1,1,1.0,1 1,1,1,1382 Biederman_2007b,< 2 months,NA,6-12 yo,9.05,9.20425531914894 NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100 100,High Amphetamine,Amphetamine   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability, 0.92059839   30.0000000 mg/d Biederman,2007b NA,RCT,RR, 71, 72  143 outcomes reverse, 0.8450000000, 0.463000000  1.542000e+00 NA NA NA NA NA NA,NA,NA 100,100 100,100,100 100 100 low,low some,low low,Placebo,  0, 28.517483  9.201399,NA,NA,0,1,1.0,1.0 1.0,1.0,1,1,0 1,1,1 1,1.0,1 1,1,1 1383,Biederman_2007b < 2 months NA,6-12 yo,8.22105263157895,14.6335365853659 NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100 High Amphetamine Amphetamine   0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability  0.92059839,  30.0000000,mg/d,Biederman 2007b,NA RCT,RR, 71, 72  143,outcomes,reverse  6.0850000000  0.751000000, 4.926500e+01,NA NA,NA,NA NA,NA,NA NA,100,100 100 100 100,100,100,low low some low low,Placebo,  0  28.517483, 9.201399,NA NA,0,1 1.0,1.0 1.0,1.0 1 1,0 1,1 1 1 1.0 1 1,1 1,1384 Biederman_2007b,< 2 months,NA,6-12 yo 8.22105263157895,14.6335365853659 NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100,100,High Amphetamine Amphetamine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA 1:ADHD-RS Total, 0.92059839,  50.0000000 mg/d,Biederman,2007b,NA,RCT G, 71, 72  143,outcomes,reverse,-1.2450000000 -1.605000000 -8.850000e-01  14.4900000, 12.6400000,NA NA,NA,NA,NA,NA 100 100 100,100 100,100 100 low,low,some,low low,Placebo   0  34.475524  9.151748,NA,NA 0 1,1.0 1.0 1.0,1.0 1 1,0,1 1 1 1 1.0 1 1 1,1,1385 Biederman_2007b,< 2 months,NA,6-12 yo,9.04758620689655,14.6347014925373,NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100,100 High Amphetamine,Amphetamine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA,13:CPRS-R:S, 0.92059839,  50.0000000,mg/d,Biederman 2007b,NA RCT G, 68  72, 140 outcomes,reverse -1.2890000000,-1.711000000 -8.660000e-01,NA NA,NA NA,NA NA, 9.3338095, 9.3338095,100,100 100,100 100,100 100,low low some,low,low,Placebo   0  34.400000  9.157143 NA NA,0,1 1.0 1.0,1.0 1.0 1,1,0 1 1,1 1,1.0,1,1,1 1 1386 Biederman_2007b,< 2 months NA 6-12 yo,9.05 9.20425531914894 NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100,High,Amphetamine Amphetamine,  0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability, 0.92059839   50.0000000,mg/d,Biederman 2007b NA RCT RR  74, 72, 146,outcomes reverse, 0.7570000000  0.408000000  1.405000e+00,NA NA NA NA,NA NA,NA,NA 100 100,100,100 100,100 100,low low,some,low,low,Placebo,  0, 34.547945  9.146575 NA NA,0,1 1.0 1.0 1.0,1.0 1 1 0,1 1 1,1,1.0,1,1 1 1 1387 Biederman_2007b < 2 months,NA,6-12 yo,8.22105263157895,14.6335365853659,NA,NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100,100 High Amphetamine Amphetamine,  0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability  0.92059839,  50.0000000,mg/d Biederman,2007b,NA,RCT RR  74  72  146 outcomes,reverse, 3.8920000000, 0.446000000, 3.398900e+01,NA,NA NA NA NA NA,NA,NA 100,100,100 100,100 100,100 low low some low low,Placebo   0, 34.547945  9.146575,NA,NA 0,1 1.0,1.0 1.0,1.0 1,1,0,1 1 1 1,1.0 1,1 1 1 1388,Biederman_2007b < 2 months NA,6-12 yo,8.22105263157895,14.6335365853659,NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Amphetamine,Amphetamine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA 1:ADHD-RS Total, 0.92059839,  70.0000000,mg/d,Biederman 2007b,NA RCT,G, 73  72, 145,outcomes reverse -1.3760000000 -1.740000000,-1.013000e+00, 14.4100000  12.6400000 NA,NA,NA,NA NA NA,100 100,100,100 100 100,100 low,low some low,low Placebo   0, 29.993103  9.047586 NA,NA,0,1 1.0,1.0,1.0,1.0,1,1 0,1 1 1,1,1.0 1,1,1 1,1389 Biederman_2007b,< 2 months NA 6-12 yo,9.04758620689655 14.6347014925373 NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100 High Amphetamine Amphetamine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),NA,13:CPRS-R:S, 0.92059839   70.0000000,mg/d,Biederman,2007b NA RCT,G  72  72  144,outcomes,reverse -1.3530000000 -1.774000000 -9.320000e-01,NA NA,NA,NA NA NA, 9.3338095  9.3338095,100 100,100 100,100 100 100 low low some low low Placebo,  0, 30.000000, 9.050000,NA NA 0,1 1.0 1.0 1.0 1.0,1 1 0 1 1 1 1 1.0,1,1,1,1,1390 Biederman_2007b,< 2 months,NA 6-12 yo 9.05,9.20425531914894,NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100,100 High,Amphetamine,Amphetamine,  0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability  0.92059839,  70.0000000,mg/d Biederman 2007b,NA RCT RR, 73  72  145,outcomes,reverse, 0.7120000000  0.378000000  1.344000e+00,NA NA,NA,NA NA NA NA,NA 100 100,100,100,100 100,100,low low some,low low,Placebo,  0  29.993103  9.047586 NA,NA 0 1 1.0 1.0 1.0,1.0,1,1 0 1 1 1,1 1.0,1,1 1,1 1391 Biederman_2007b,< 2 months,NA 6-12 yo,8.22105263157895 14.6335365853659 NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Amphetamine,Amphetamine   0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability, 0.92059839,  70.0000000 mg/d Biederman,2007b,NA RCT,RR, 73  72, 145 outcomes,reverse, 9.8630000000, 1.296000000, 7.507400e+01 NA,NA NA NA NA NA,NA NA,100,100,100,100 100 100 100 low,low some low,low Placebo   0, 29.993103  9.047586,NA,NA 0,1,1.0,1.0 1.0 1.0 1,1 0,1,1,1,1 1.0 1,1,1,1 1392,Biederman_2007b < 2 months NA 6-12 yo,8.22105263157895,14.6335365853659,NA NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100,100,High,Amphetamine,Amphetamine   0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability  0.69044879,NA NA,Biederman,2002 NA,RCT RR 129 210, 339,outcomes,reverse  0.4400000000  0.227000000, 8.540000e-01,NA NA NA NA,NA,NA NA NA 100 100,100 100,100 100,100,some some low some some Placebo   0, 25.121239  8.561947 NA NA 0,1,1.0,1.0,1.0 1.0,1,1,0,1 1 1 1,1.0 1,1 1 1 1393,Biederman_2002,< 2 months,NA,6-12 yo 8.22105263157895 14.6335365853659 NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100,100,High,Amphetamine Amphetamine   0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,Tolerability  0.69044879 NA NA Biederman,2002 NA,RCT RR 129,210  339,outcomes reverse, 0.1250000000, 0.007000000  2.198000e+00 NA,NA NA,NA,NA,NA,NA NA 100,100,100,100,100 100 100,some,some,low some,some,Placebo   0, 25.121239  8.561947,NA NA,0,1 1.0,1.0 1.0,1.0 1 1,0,1 1 1,1 1.0,1 1,1 1,1394 Biederman_2002,< 2 months,NA,6-12 yo,8.22105263157895 14.6335365853659 NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100,100 High Amphetamine,Amphetamine,  0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability  0.69044879,NA NA Biederman 2002 NA,RCT,RR,121 210  331 outcomes reverse, 0.7510000000, 0.436000000  1.291000e+00,NA NA NA NA,NA,NA,NA NA,100,100,100 100 100 100 100 some,some low some,some Placebo   0  24.358308  8.526888,NA NA 0,1,1.0 1.0,1.0,1.0,1,1,0 1,1 1 1,1.0 1 1,1 1,1395 Biederman_2002,< 2 months NA,6-12 yo,8.22105263157895 14.6335365853659,NA,NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA,NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0,100 100,High Amphetamine,Amphetamine   0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability, 0.69044879,NA,NA,Biederman,2002 NA RCT RR 121,210  331,outcomes reverse  1.1570000000  0.333000000, 4.019000e+00 NA NA NA NA NA,NA,NA NA,100 100 100 100,100,100 100,some,some,low,some,some Placebo   0  24.358308  8.526888,NA,NA,0,1,1.0 1.0,1.0,1.0 1,1 0,1 1,1 1,1.0,1,1 1 1,1396,Biederman_2002,< 2 months,NA,6-12 yo 8.22105263157895 14.6335365853659,NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100 100 High,Amphetamine,Amphetamine,  0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability, 0.69044879,NA NA,Biederman,2002 NA RCT,RR 124,210, 334,outcomes,reverse, 0.5490000000  0.298000000  1.013000e+00,NA,NA NA,NA,NA NA,NA,NA 100 100 100 100,100 100 100 some some low some,some,Placebo,  0  24.464072  8.674251,NA,NA,0,1,1.0 1.0 1.0,1.0,1 1 0 1 1,1,1 1.0 1 1 1 1,1397,Biederman_2002,< 2 months,NA 6-12 yo 8.22105263157895,14.6335365853659 NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA,Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100 High,Amphetamine Amphetamine,  0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 0.69044879 NA,NA,Biederman,2002,NA RCT,RR 124,210  334 outcomes,reverse, 1.4110000000  0.440000000  4.528000e+00 NA,NA NA,NA,NA NA NA,NA,100,100,100 100 100 100 100,some,some,low,some some Placebo   0  24.464072, 8.674251,NA,NA,0 1 1.0 1.0 1.0 1.0,1,1,0 1,1,1 1 1.0,1,1 1 1 1398,Biederman_2002,< 2 months,NA 6-12 yo,8.22105263157895 14.6335365853659 NA NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0,100 100 High,Modafinil Modafinil   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total, 2.07134638, 368.5000000 mg/d Biederman 2005,NA RCT G 163, 81, 244,outcomes,reverse -0.4490000000,-0.719000000,-1.790000e-01, 14.5000000  12.1000000,NA,NA NA NA NA NA,100 100,100,100,  0,100,100,low,some high some some,Placebo   0, 29.340164 10.300410 NA NA 0,1 1.0 1.0,1.0 1.0 1 1,0,1,1,1,1,1.0 1,1,1,1 1399 Biederman_2005 2-6 months NA 6-12 yo 8.85049504950495 10.3004098360656,NA,NA   8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100 100,High,Modafinil,Modafinil,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),NA,13:CPRS-R:S  2.07134638  368.5000000,mg/d Biederman,2005,NA,RCT,G 163, 81  244,outcomes,reverse -0.4390000000 -0.732000000,-1.460000e-01,NA NA,NA NA NA,NA, 9.9000000, 9.9000000 100,100 100 100,  0,100 100 low some high,some some Placebo   0, 29.340164 10.300410 NA,NA 0,1,1.0,1.0,1.0,1.0,1,1,0 1 1,1,1 1.0 1 1,1 1 1400 Biederman_2005 2-6 months NA 6-12 yo,8.85049504950495 10.3004098360656,NA,NA   8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100 100 High,Modafinil,Modafinil,  0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability  2.07134638, 368.5000000,mg/d,Biederman,2005 NA,RCT,RR,164  84, 248,outcomes,reverse, 0.6730000000, 0.523000000  8.660000e-01 NA NA,NA,NA NA NA,NA,NA,100 100 100,100   0 100,100,low some,high,some some,Placebo   0  29.306452,10.298387 NA NA 0,1 1.0,1.0 1.0,1.0,1 1,0 1 1 1 1 1.0 1 1,1,1 1401,Biederman_2005,2-6 months NA 6-12 yo 7.875 10.2983870967742,NA NA,  8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8,NA,NA Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0,100,100,High Modafinil,Modafinil   0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 2.07134638, 368.5000000,mg/d Biederman,2005,NA,RCT,RR,164  84, 248,outcomes reverse  0.8540000000, 0.209000000  3.486000e+00,NA,NA NA,NA NA,NA,NA NA,100,100 100,100   0 100,100,low,some,high some,some,Placebo,  0, 29.306452,10.298387 NA NA,0 1 1.0,1.0,1.0 1.0,1 1,0,1 1,1,1 1.0 1,1,1,1 1402 Biederman_2005,2-6 months,NA,6-12 yo,7.875,10.2983870967742,NA NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8,NA NA Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0 100 100,High,Modafinil,Modafinil,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total, 0.92059839  300.0000000 mg/d,Biederman 2006b,NA RCT,G, 50  51, 101 outcomes,reverse -0.5740000000,-1.004000000 -1.430000e-01 NA,NA NA,NA,NA,NA,12.1404283 12.1404283 100,100 100 100,100 100,100 some some low some some,Placebo   0, 29.455446, 8.850495,NA,NA,0,1,1.0 1.0,1.0,1.0 1 1,0,1 1,1,1 1.0 1 1 1,1 1403,Biederman_2006b,< 2 months NA,6-12 yo 8.85049504950495 10.3004098360656,NA,NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0,100,100 High,Modafinil Modafinil,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA,24:Other, 0.92059839, 300.0000000,mg/d Biederman 2006b NA RCT G, 50, 51, 101,outcomes reverse,-0.2710000000 -0.683000000  1.410000e-01,NA,NA NA,NA,NA,NA,12.1404283,12.1404283,100,100,100,100 100,100,100,some some low,some,some Placebo,  0, 29.455446  8.850495,NA NA,0 1,1.0 1.0 1.0 1.0,1 1 0 1,1 1 1 1.0,1 1 1,1 1404 Biederman_2006b,< 2 months NA,6-12 yo 8.85049504950495,10.3004098360656 NA,NA   8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8 NA,NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100,High Modafinil,Modafinil   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks),NA,5:ADHD-RS Total  0.92059839  300.0000000,mg/d,Biederman,2006b NA RCT G  50, 51, 101 outcomes,reverse,-0.4410000000 -0.851000000 -3.200000e-02 NA NA,NA,NA NA NA,13.5687140,13.5687140,100,100,100 100 100 100,100,some some,low some,some,Placebo   0, 29.455446, 8.850495,NA,NA 0,1,1.0 1.0,1.0,1.0 1,1,0 1,1,1,1 1.0 1 1,1,1 1405,Biederman_2006b,< 2 months NA 6-12 yo 8.85049504950495 9.96229508196721 NA NA,  8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA,NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100,High,Modafinil Modafinil,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 0.92059839  300.0000000,mg/d,Biederman,2006b,NA,RCT,RR, 50, 51, 101,outcomes,reverse  2.0400000000  0.540000000, 7.712000e+00 NA NA NA,NA NA NA NA,NA 100,100 100 100 100,100,100 some,some,low some some Placebo   0, 29.455446  8.850495 NA,NA,0,1,1.0 1.0,1.0,1.0 1,1,0,1,1 1 1 1.0,1 1,1 1,1406 Biederman_2006b < 2 months NA 6-12 yo,7.875 10.2983870967742,NA,NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA NA,Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100,100,High,Modafinil Modafinil,  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 0.92059839  300.0000000 mg/d Biederman,2006b,NA,RCT RR  50  51  101,outcomes,reverse  5.0980000000  0.251000000, 1.036010e+02 NA NA NA NA,NA NA,NA NA,100,100,100,100,100,100 100,some some,low some,some Placebo,  0  29.455446, 8.850495,NA NA,0,1,1.0 1.0,1.0 1.0 1 1 0,1 1 1 1 1.0,1 1 1 1 1407,Biederman_2006b,< 2 months,NA,6-12 yo,7.875,10.2983870967742,NA NA,  8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8 NA,NA,Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Modafinil,Modafinil,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total  0.92059839, 300.0000000 mg/d,Biederman 2006b,NA RCT G, 49, 51  100 outcomes reverse,-0.3780000000,-0.797000000, 4.100000e-02,NA NA,NA NA,NA,NA 12.1404283 12.1404283,100,100 100,100,100 100,100,some,some low,some,some Placebo   0, 22.550000, 8.851000 NA NA 0,1 1.0,1.0,1.0,1.0,1,1 0,1,1 1,1,1.0,1,1,1 1,1408,Biederman_2006b,< 2 months NA 6-12 yo,8.85049504950495,10.3004098360656 NA NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA,NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100,100,High,Modafinil Modafinil,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA,24:Other  0.92059839, 300.0000000,mg/d Biederman,2006b,NA RCT G  49  51, 100,outcomes,reverse -0.0310000000,-0.434000000, 3.720000e-01 NA,NA NA NA NA NA 12.1404283,12.1404283 100 100 100 100,100 100 100,some some,low,some some,Placebo   0  22.550000  8.851000 NA,NA 0 1 1.0,1.0 1.0 1.0 1 1 0,1 1,1 1 1.0,1 1 1,1,1409 Biederman_2006b,< 2 months NA,6-12 yo 8.85049504950495 10.3004098360656 NA,NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100 High Modafinil Modafinil   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks) NA 5:ADHD-RS Total  0.92059839, 300.0000000,mg/d,Biederman,2006b,NA,RCT,G, 49, 51, 100,outcomes,reverse -0.4720000000,-0.886000000,-5.800000e-02 NA NA,NA,NA,NA NA 13.5687140,13.5687140,100 100,100 100,100 100 100,some,some low some,some Placebo,  0  22.550000, 8.851000,NA NA 0,1 1.0,1.0 1.0,1.0 1,1 0,1,1 1,1 1.0 1,1,1,1,1410 Biederman_2006b < 2 months,NA 6-12 yo 8.85049504950495 9.96229508196721,NA NA,  8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8,NA,NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100,100 High Modafinil Modafinil   0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability, 0.92059839, 300.0000000 mg/d,Biederman 2006b NA RCT RR  49, 51, 100,outcomes reverse, 1.3880000000  0.327000000, 5.885000e+00,NA,NA NA,NA,NA,NA NA,NA 100,100,100,100,100 100 100 some,some low,some some Placebo   0, 22.550000, 8.851000 NA NA 0 1 1.0 1.0 1.0,1.0 1,1 0,1,1 1,1 1.0 1 1 1 1,1411 Biederman_2006b < 2 months NA 6-12 yo 7.875,10.2983870967742 NA NA   8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8 NA NA Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100 100 High Modafinil,Modafinil,  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,Tolerability  0.92059839, 300.0000000 mg/d Biederman,2006b,NA RCT,RR  49, 51  100 outcomes reverse  5.2000000000, 0.256000000  1.056470e+02 NA NA,NA NA NA NA,NA,NA,100 100,100,100 100,100 100 some some low some some Placebo   0  22.550000  8.851000,NA,NA 0 1,1.0 1.0 1.0 1.0 1 1 0,1,1,1 1,1.0 1 1 1,1,1412,Biederman_2006b < 2 months NA,6-12 yo 7.875,10.2983870967742 NA NA   8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA NA Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100 100 High Modafinil,Modafinil   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA 1:ADHD-RS Total, 0.92059839  300.0000000 mg/d Biederman 2006b,NA RCT G, 47, 51,  98,outcomes reverse -0.3840000000 -0.808000000  4.000000e-02,NA,NA NA,NA,NA,NA,12.1404283 12.1404283,100 100,100,100 100 100,100,some,some,low,some some,Placebo   0  23.081633, 9.043878,NA,NA,0,1 1.0 1.0 1.0 1.0 1,1 0 1,1 1,1 1.0,1 1 1,1,1413,Biederman_2006b,< 2 months NA 6-12 yo 8.85049504950495,10.3004098360656 NA NA,  8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8,NA NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100 High,Modafinil Modafinil   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),NA 24:Other, 0.92059839, 300.0000000 mg/d,Biederman 2006b,NA RCT G, 47  51,  98,outcomes,reverse -0.3560000000,-0.781000000, 6.800000e-02,NA,NA NA,NA,NA,NA 12.1404283,12.1404283,100,100 100 100 100,100 100,some some,low some,some Placebo,  0  23.081633, 9.043878,NA,NA 0,1,1.0,1.0 1.0,1.0,1,1 0 1,1,1 1,1.0 1 1 1,1,1414,Biederman_2006b,< 2 months,NA 6-12 yo,8.85049504950495,10.3004098360656,NA NA,  8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8 NA NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0 100 100,High Modafinil Modafinil   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks) NA,5:ADHD-RS Total, 0.92059839  300.0000000,mg/d,Biederman 2006b,NA RCT G, 47, 51,  98,outcomes,reverse,-0.3080000000,-0.717000000, 1.010000e-01,NA NA NA NA,NA,NA,13.5687140,13.5687140,100 100 100,100,100 100,100,some some,low,some some,Placebo   0, 23.081633, 9.043878,NA NA 0 1,1.0 1.0,1.0,1.0,1 1,0 1 1 1 1 1.0,1,1,1,1,1415 Biederman_2006b,< 2 months NA,6-12 yo 8.85049504950495,9.96229508196721,NA NA,  8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA,NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0 100 100,High Modafinil,Modafinil,  0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability, 0.92059839  300.0000000 mg/d Biederman,2006b,NA RCT,RR  48, 51,  99 outcomes,reverse  2.8330000000  0.798000000, 1.005900e+01 NA NA,NA NA NA NA,NA,NA,100,100,100 100 100 100 100,some some,low some some Placebo,  0  23.060606, 9.045455 NA NA,0 1,1.0 1.0,1.0 1.0 1 1,0,1,1 1 1,1.0 1,1 1 1 1416,Biederman_2006b < 2 months NA,6-12 yo,7.875 10.2983870967742 NA NA,  8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8,NA NA,Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100,High,Modafinil Modafinil,  0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability  0.92059839, 300.0000000,mg/d,Biederman 2006b NA,RCT,RR, 48, 51,  99,outcomes reverse  9.5510000000, 0.528000000  1.728140e+02 NA,NA,NA,NA NA NA NA,NA 100 100 100 100,100,100,100 some,some,low some some Placebo   0  23.060606  9.045455 NA NA,0 1 1.0,1.0 1.0 1.0 1,1 0 1,1 1,1,1.0,1 1,1,1,1417,Biederman_2006b,< 2 months,NA,6-12 yo,7.875,10.2983870967742,NA NA   8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8 NA,NA,Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100,High Modafinil,Modafinil,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total  0.92059839  400.0000000 mg/d Biederman,2006b NA RCT,G  50  51  101,outcomes,reverse,-0.5040000000,-0.929000000,-7.900000e-02 NA,NA,NA NA NA,NA,12.1404283 12.1404283 100 100 100,100 100,100 100,some,some,low,some,some Placebo   0, 25.495050  9.692079 NA NA,0,1 1.0 1.0,1.0,1.0,1,1 0,1 1,1,1 1.0,1 1 1 1 1418 Biederman_2006b < 2 months,NA 6-12 yo,8.85049504950495,10.3004098360656,NA NA,  8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8,NA,NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100 100,High Modafinil Modafinil   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),NA 24:Other, 0.92059839  400.0000000,mg/d Biederman,2006b,NA,RCT G, 50, 51, 101,outcomes,reverse,-0.3390000000 -0.755000000, 7.700000e-02 NA,NA NA NA NA,NA 12.1404283 12.1404283,100 100,100 100,100 100 100,some,some low some some Placebo,  0  25.495050  9.692079,NA,NA,0 1 1.0 1.0,1.0 1.0,1,1 0 1,1 1,1 1.0 1 1,1,1,1419 Biederman_2006b,< 2 months NA 6-12 yo 8.85049504950495 10.3004098360656 NA NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100,100,High Modafinil,Modafinil   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks) NA 5:ADHD-RS Total  0.92059839, 400.0000000,mg/d,Biederman,2006b,NA,RCT,G, 50  51, 101,outcomes,reverse,-0.3150000000 -0.717000000  8.800000e-02,NA,NA,NA NA NA,NA,13.5687140 13.5687140,100,100 100,100 100 100 100 some some low some,some,Placebo,  0, 25.495050  9.692079 NA,NA 0,1 1.0 1.0,1.0 1.0 1 1 0,1,1,1,1,1.0 1,1,1 1,1420,Biederman_2006b < 2 months NA,6-12 yo 8.85049504950495 9.96229508196721 NA,NA   8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0 100,100,High,Modafinil,Modafinil   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability  0.92059839  400.0000000 mg/d Biederman 2006b,NA,RCT,RR  50  51  101 outcomes,reverse, 1.3600000000, 0.321000000  5.770000e+00,NA,NA,NA,NA NA,NA NA,NA 100 100,100 100,100 100 100 some,some low,some some Placebo,  0  25.495050, 9.692079 NA NA 0 1 1.0,1.0,1.0 1.0,1 1,0 1,1 1 1,1.0,1,1 1 1,1421,Biederman_2006b < 2 months NA,6-12 yo,7.875 10.2983870967742,NA,NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8,NA NA,Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0 100 100 High Modafinil Modafinil,  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability, 0.92059839, 400.0000000,mg/d,Biederman,2006b,NA RCT,RR, 50  51  101 outcomes reverse  3.0590000000  0.128000000, 7.335000e+01 NA NA NA,NA NA,NA NA,NA,100,100 100,100,100,100 100 some some,low,some some Placebo   0, 25.495050  9.692079,NA,NA,0,1,1.0 1.0 1.0 1.0,1,1 0 1,1 1 1,1.0,1,1 1,1 1422,Biederman_2006b < 2 months,NA,6-12 yo,7.875 10.2983870967742 NA,NA,  8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA,NA Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100,High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total, 1.84119678,NA NA,Biederman,2008,NA RCT,G  84, 78, 162 outcomes,reverse,-0.5850000000 -0.963000000,-2.080000e-01 NA,NA,NA,NA,NA NA 12.5411004,12.5411004,100,100 100 100 100,100 100,low low,some,low low Placebo   0, 24.251852,10.600000,NA,NA,0 1 1.0,1.0 1.0 1.0 1,1,0,1 1 1 1,1.0 1,1 1 1,1423,Biederman_2008,< 2 months,NA 6-12 yo,8.99719626168224 14.5496794871795 NA,NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability, 1.84119678,NA,NA Biederman,2008 NA RCT RR  87  86  173,outcomes reverse, 0.8690000000, 0.582000000  1.296000e+00,NA,NA NA NA NA NA,NA NA,100 100,100,100,100 100,100,low low some,low,low Placebo   0, 24.292486 10.600000,NA,NA 0,1 1.0,1.0 1.0,1.0 1,1,0 1,1,1 1 1.0,1,1 1 1 1424,Biederman_2008,< 2 months,NA,6-12 yo 8.23931034482759,12.6640449438202,NA,NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100,High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability, 1.84119678 NA,NA Biederman 2008 NA RCT RR, 87  86, 173,outcomes reverse, 8.8970000000  1.152000000  6.872000e+01 NA NA NA,NA NA NA,NA NA,100 100,100,100,100,100,100 low low some low,low,Placebo,  0  24.292486 10.600000,NA,NA,0,1 1.0,1.0,1.0,1.0,1 1 0 1,1 1,1,1.0,1,1 1,1 1425,Biederman_2008,< 2 months,NA 6-12 yo 9 12.6640449438202 NA,NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100,High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total, 1.84119678,NA,NA Biederman,2008,NA RCT,G, 82  78  160,outcomes reverse,-0.5990000000,-0.980000000,-2.180000e-01,NA,NA NA,NA NA NA,12.5411004 12.5411004 100,100,100,100,100,100 100,low,low,some,low low,Placebo,  0  22.627500 10.702500 NA NA,0 1 1.0,1.0,1.0,1.0,1 1,0,1,1,1,1,1.0 1,1 1 1 1426,Biederman_2008 < 2 months,NA 6-12 yo,8.99719626168224 14.5496794871795 NA,NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2,NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability  1.84119678,NA NA Biederman 2008,NA RCT RR  86  86  172,outcomes,reverse  0.9390000000, 0.637000000  1.385000e+00,NA,NA NA NA,NA NA NA NA,100,100,100,100,100 100,100 low,low some,low low,Placebo   0  22.700000 10.700000 NA,NA,0 1 1.0,1.0 1.0,1.0 1 1 0 1 1 1,1 1.0,1 1 1,1,1427 Biederman_2008 < 2 months NA 6-12 yo 8.23931034482759,12.6640449438202,NA,NA, 20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0,100,100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 1.84119678,NA NA,Biederman 2008 NA,RCT RR  86, 86, 172 outcomes reverse,13.0000000000, 1.739000000  9.720500e+01,NA NA NA,NA NA NA NA,NA 100 100 100,100,100,100 100,low low some,low,low,Placebo   0, 22.700000 10.700000 NA,NA,0 1,1.0,1.0,1.0 1.0,1 1 0 1 1 1,1,1.0,1 1 1,1 1428 Biederman_2008,< 2 months NA 6-12 yo,9 12.6640449438202 NA NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100 High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA 1:ADHD-RS Total  1.84119678 NA NA Biederman,2008,NA RCT G, 81, 78, 159,outcomes reverse,-0.7940000000 -1.193000000 -3.950000e-01 NA,NA NA,NA,NA,NA 12.5411004,12.5411004 100,100 100,100 100 100 100,low,low some low,low,Placebo,  0, 29.726415,10.345283 NA NA 0,1,1.0 1.0,1.0 1.0 1,1,0,1 1,1,1 1.0 1 1 1,1 1429 Biederman_2008 < 2 months NA 6-12 yo 8.99719626168224 14.5496794871795 NA NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2,NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100 High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA Acceptability, 1.84119678 NA,NA Biederman,2008,NA RCT RR, 86, 86, 172 outcomes reverse, 1.1210000000  0.781000000  1.610000e+00 NA,NA NA,NA NA,NA,NA,NA,100 100 100,100 100 100,100,low low,some low,low,Placebo,  0, 29.650000 10.350000,NA NA 0 1 1.0,1.0 1.0,1.0,1 1,0 1 1 1 1,1.0 1,1 1 1,1430,Biederman_2008 < 2 months,NA,6-12 yo 8.23931034482759,12.6640449438202,NA,NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100,100,High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 1.84119678,NA,NA,Biederman,2008 NA RCT,RR  86, 86  172,outcomes reverse 20.0000000000, 2.745000000  1.457270e+02 NA NA NA,NA,NA,NA,NA NA 100 100 100,100 100 100,100,low low some,low,low,Placebo,  0  29.650000,10.350000 NA,NA 0,1 1.0,1.0 1.0 1.0 1,1,0 1 1,1,1,1.0 1,1,1,1,1431 Biederman_2008 < 2 months NA,6-12 yo,9,12.6640449438202,NA NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4   0   0,100 100 High Methylphenidate Methylphenidate,  0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability  0.92059839 NA NA,Buitelaar 1996,NA,RCT RR, 21, 21,  42,outcomes reverse, 5.0000000000, 0.254000000, 9.827200e+01 NA,NA NA,NA NA NA NA,NA,100,100 100 100,100,100,100 some,some low some,some Placebo,  0,NA,NA NA,NA,0 1,1.0,1.0,1.0,1.0,1 1,0 1,1,1 1 1.0 1 1 1,1 1432 Buitelaar_1996,< 2 months,NA,NA,7.9578947368421,14.7 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,  0,  0,100,100,High Methylphenidate Methylphenidate,  0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA Tolerability  0.92059839,NA NA Buitelaar,1996 NA,RCT,RR  21, 21   42,outcomes,reverse, 5.0000000000, 0.254000000  9.827200e+01 NA,NA,NA,NA NA NA NA,NA,100 100,100,100,100 100,100 some,some,low some some Placebo   0 NA NA NA,NA,0 1,1.0 1.0 1.0,1.0 1 1 0,1,1,1 1,1.0 1 1 1,1 1433,Buitelaar_1996 < 2 months,NA,NA 7.9578947368421,14.7,NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100 High,Bupropion Bupropion,  0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability  0.92059839,NA,NA Casat 1989,NA RCT,RR  20  10   30 NA reverse, 0.5000000000  0.035000000, 7.190000e+00 NA,NA,NA NA,NA,NA,NA,NA 100,100,100,100 100,100 100,some,some,low some,some Placebo   0,NA,11.500000 NA,NA 0,1,1.0,1.0 1.0 1.0 1,1,0,1,1 1,1,1.0 1,1,1 1,1434,Casat_1989 < 2 months,NA 6-12 yo 11.5,11.5 NA,NA  10  7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5 40.25 NA,NA,Cortese - Children (2018)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0,100,100,High Bupropion,Bupropion,  0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability  0.92059839 NA,NA Casat,1989 NA RCT,RR, 20, 10,  30,NA,reverse, 1.5710000000, 0.070000000, 3.545800e+01 NA,NA,NA,NA NA,NA NA NA,100 100 100,100,100 100,100 some,some,low,some,some Placebo,  0,NA,11.500000,NA NA 0 1 1.0,1.0,1.0 1.0,1,1,0,1 1 1 1 1.0,1,1 1,1 1435,Casat_1989 < 2 months,NA 6-12 yo,11.5,11.5 NA NA, 10, 7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5 40.25 NA,NA Cortese - Children (2018)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100,100,High Methylphenidate Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA 24:Other  1.15074799 NA NA Childress,2009,NA,RCT G, 60  63, 123,outcomes,reverse -0.8040000000 -1.173000000 -4.350000e-01  14.1800000  13.0300000,NA,NA NA,NA NA NA 100,100,100,100,100 100,100,low,some low,some some Placebo,  0, 35.068293  8.607317,NA NA,0,1,1.0,1.0 1.0 1.0,1 1,0,1,1 1,1,1.0,1 1,1,1,1436 Childress_2009 < 2 months,NA 6-12 yo,8.60731707317073,10.9714285714286,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100,100 High,Methylphenidate,Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks),NA 24:Other  1.15074799,NA,NA,Childress 2009 NA,RCT G  61  63, 124,outcomes,reverse,-0.8900000000,-1.261000000,-5.190000e-01, 13.1200000, 13.0100000,NA NA NA NA NA,NA 100 100 100 100,100,100,100,low,some low some some Placebo,  0, 35.079032, 8.604839,NA,NA 0 1,1.0,1.0 1.0 1.0 1 1 0 1 1 1 1,1.0 1 1,1 1,1437,Childress_2009,< 2 months,NA 6-12 yo,8.60483870967742 9.97113402061856 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100 High,Methylphenidate,Methylphenidate   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability  1.15074799 NA,NA Childress,2009 NA RCT RR  66  65  131 outcomes reverse, 1.2310000000, 0.519000000, 2.922000e+00 NA,NA NA NA NA NA NA NA,100,100 100 100,100 100 100,low,some,low,some some,Placebo   0, 35.109924, 8.597710,NA NA 0 1,1.0,1.0 1.0 1.0,1 1,0 1,1 1,1 1.0 1 1,1 1,1438,Childress_2009 < 2 months,NA,6-12 yo 7.9578947368421,14.7 NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0,100,100,High Methylphenidate Methylphenidate   0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,Tolerability  1.15074799,NA NA,Childress 2009,NA,RCT,RR, 66, 65, 131,outcomes reverse, 2.9550000000, 0.123000000, 7.124200e+01 NA NA,NA NA,NA NA,NA NA,100 100,100 100 100 100,100,low,some,low,some some Placebo   0  35.109924  8.597710,NA,NA 0 1,1.0 1.0,1.0 1.0 1,1 0 1,1 1 1,1.0 1 1,1,1 1439,Childress_2009,< 2 months NA,6-12 yo,7.9578947368421 14.7 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0 100,100 High Methylphenidate,Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA 24:Other  1.15074799,NA,NA Childress 2009,NA RCT G, 58, 63, 121 outcomes reverse -1.0680000000,-1.451000000 -6.850000e-01  13.9700000, 13.0300000 NA NA,NA NA NA NA 100,100,100 100 100 100,100,low some low some some Placebo   0, 36.148760  8.804132,NA,NA 0,1 1.0 1.0,1.0,1.0 1,1 0,1 1 1 1,1.0 1 1 1 1,1440,Childress_2009 < 2 months,NA,6-12 yo,8.60731707317073 10.9714285714286,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100 100,High Methylphenidate,Methylphenidate,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA 24:Other, 1.15074799,NA,NA Childress 2009 NA,RCT G, 59, 63  122 outcomes,reverse,-0.8990000000,-1.273000000,-5.250000e-01  13.3100000  13.0100000,NA NA,NA,NA NA NA,100 100,100,100 100 100 100 low some low,some some Placebo,  0, 36.169672, 8.803279 NA NA 0 1,1.0,1.0 1.0,1.0,1 1,0,1,1,1,1,1.0 1 1 1 1,1441,Childress_2009 < 2 months,NA 6-12 yo,8.60483870967742,9.97113402061856 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0 100 100 High Methylphenidate Methylphenidate   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability  1.15074799 NA,NA Childress,2009 NA RCT RR  62, 65, 127 outcomes,reverse  1.0480000000  0.419000000  2.621000e+00 NA,NA NA,NA,NA NA NA,NA,100,100,100,100,100 100 100 low,some low some,some Placebo   0, 36.192126, 8.802362,NA,NA 0 1,1.0,1.0 1.0 1.0,1 1,0,1 1,1,1 1.0 1,1 1,1 1442,Childress_2009,< 2 months,NA,6-12 yo,7.9578947368421,14.7,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0 100 100 High Methylphenidate Methylphenidate   0 NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability  1.15074799,NA NA,Childress,2009 NA,RCT,RR  62, 65, 127 outcomes,reverse, 3.1430000000, 0.130000000  7.572200e+01,NA,NA,NA NA,NA NA NA,NA 100 100,100,100 100 100,100 low,some,low some some Placebo   0, 36.192126  8.802362 NA,NA 0,1,1.0,1.0,1.0 1.0 1,1,0,1 1 1 1 1.0,1 1,1,1 1443 Childress_2009,< 2 months,NA,6-12 yo,7.9578947368421,14.7,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100,High,Amphetamine Amphetamine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total  1.61104718,  53.8000000,mg/d Coghill 2013 NA RCT,G, 98,104, 202,outcomes,reverse -1.6090000000,-2.018000000 -1.199000e+00 NA NA,NA NA NA,NA 11.5237841 11.5237841 100 100,100,100,  0 100 100,low,low,high,low,low,Placebo   0  19.386139,10.951485 NA,NA,0 1,1.0,1.0,1.0,1.0 1 1 0,1 1,1 1,1.0 1,1 1 1 1444,Coghill_2013,< 2 months NA,6-12 yo 9.04758620689655,14.6347014925373 NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100,100,High,Amphetamine,Amphetamine,  0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 1.61104718,  53.8000000 mg/d Coghill 2013 NA RCT,RR 113,111, 224,outcomes reverse  0.4770000000  0.345000000, 6.580000e-01 NA,NA,NA,NA NA NA NA,NA,100 100,100,100,  0 100,100 low,low,high,low low,Placebo   0  19.469196,10.949554 NA,NA,0,1,1.0 1.0,1.0 1.0 1 1 0 1 1 1 1 1.0,1 1,1 1,1445,Coghill_2013 < 2 months,NA 6-12 yo 8.22105263157895,14.6335365853659 NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA,NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100,100,High Amphetamine,Amphetamine,  0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability  1.61104718,  53.8000000 mg/d,Coghill 2013,NA,RCT,RR,113 111, 224 outcomes reverse, 1.2280000000  0.339000000, 4.454000e+00,NA NA NA,NA,NA NA,NA,NA,100,100,100,100,  0 100 100,low,low,high low low,Placebo   0, 19.469196,10.949554,NA,NA 0 1,1.0 1.0 1.0 1.0,1 1,0,1,1,1,1 1.0 1,1 1,1 1446,Coghill_2013,< 2 months NA 6-12 yo,8.22105263157895,14.6335365853659,NA NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA,Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100 High,Methylphenidate,Methylphenidate,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total, 1.61104718   45.4000000 mg/d,Coghill,2013 NA RCT G 103 104  207 outcomes,reverse,-1.1130000000 -1.470000000,-7.570000e-01 NA,NA NA,NA NA,NA 11.5237841 11.5237841 100,100,100 100   0,100,100 low,low high low low,Placebo   0  18.096135,10.950242,NA,NA,0 1 1.0 1.0,1.0,1.0,1 1,0 1,1 1 1,1.0 1 1,1,1,1447 Coghill_2013,< 2 months,NA 6-12 yo 9.745,14.7,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100,High,Methylphenidate Methylphenidate   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability  1.61104718   45.4000000,mg/d Coghill,2013,NA,RCT,RR,112,111, 223,outcomes reverse  0.5540000000  0.411000000  7.460000e-01,NA,NA NA,NA NA NA NA,NA,100,100 100 100,  0 100,100 low low,high,low,low Placebo,  0, 18.103587,10.949776 NA NA 0 1,1.0 1.0,1.0,1.0,1,1,0,1,1,1,1 1.0,1,1 1 1 1448,Coghill_2013 < 2 months,NA 6-12 yo 7.9578947368421,14.7 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0 100 100 High Methylphenidate Methylphenidate,  0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability, 1.61104718,  45.4000000 mg/d,Coghill 2013,NA,RCT,RR 112 111, 223,outcomes,reverse, 0.4960000000, 0.093000000  2.651000e+00 NA NA NA NA NA NA NA,NA 100,100 100,100   0,100,100,low low high low low,Placebo   0  18.103587 10.949776,NA,NA 0,1 1.0 1.0 1.0 1.0 1,1,0 1 1 1 1,1.0 1 1,1,1 1449 Coghill_2013 < 2 months NA 6-12 yo,7.9578947368421,14.7 NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total, 2.07134638,NA,NA Connor 2010,NA RCT,G 130, 75  205 outcomes,reverse,-0.7480000000 -1.123000000,-3.720000e-01,NA,NA NA NA,NA,NA,12.6500000,12.6500000 100 100 100 100,100 100 100,low,low,low,low,low,Placebo,  0  31.280488  9.363415 NA NA,0 1,1.0 1.0 1.0 1.0 1 1,0 1 1 1 1,1.0,1,1,1 1,1450,Connor_2010,2-6 months,NA,6-12 yo,8.99719626168224,14.5496794871795 NA NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability  2.07134638 NA NA Connor,2010,NA,RCT RR 138, 79, 217,outcomes reverse, 0.5360000000, 0.350000000, 8.180000e-01 NA,NA,NA NA NA NA NA NA 100 100,100 100 100 100 100 low low low,low,low Placebo   0  31.303687  9.363594 NA NA 0,1 1.0,1.0,1.0 1.0,1,1,0 1,1,1,1,1.0,1,1 1,1 1451,Connor_2010,2-6 months NA 6-12 yo 8.23931034482759,12.6640449438202 NA,NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability, 2.07134638 NA NA Connor 2010 NA,RCT,RR 138  79, 217,outcomes reverse, 8.0140000000  1.074000000, 5.980400e+01,NA,NA NA NA NA,NA,NA NA,100,100,100 100,100 100 100,low low,low,low,low,Placebo,  0  31.303687, 9.363594 NA,NA,0,1 1.0 1.0 1.0,1.0 1,1 0 1,1,1 1,1.0 1 1,1 1,1452,Connor_2010 2-6 months,NA 6-12 yo,9,12.6640449438202,NA,NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0 100,100 High,Methylphenidate Methylphenidate,  0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability  0.69044879    0.3000000 mg/kg/d,Cook,1993 NA,RCT,RR  15, 15   30,outcomes,reverse  1.0000000000  0.021000000  4.738000e+01 NA,NA NA,NA NA,NA NA,NA 100,100,100 100 100 100 100 low some some,some,some Placebo,  0,  0.000000, 8.700000 NA NA,0 1,1.0,1.0,1.0,1.0,1,1 0,1,1,1 1,1.0,1 1,1,1 1453 Cook_1993,< 2 months,NA 6-12 yo 7.9578947368421,14.7,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100 100 High Methylphenidate Methylphenidate   0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability  0.69044879    0.3000000 mg/kg/d,Cook 1993,NA RCT,RR  15, 15,  30 outcomes reverse  1.0000000000, 0.021000000  4.738000e+01,NA,NA,NA NA NA NA NA NA,100 100 100 100,100 100 100,low some,some,some,some Placebo   0,  0.000000, 8.700000,NA NA 0 1 1.0 1.0 1.0 1.0,1,1,0 1,1,1 1 1.0 1,1,1 1 1454,Cook_1993 < 2 months NA,6-12 yo,7.9578947368421 14.7 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0,100 100,High,Atomoxetine Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA,13:CPRS-R:S, 1.84119678,   1.1000000,mg/kg/d Dell'Agnello 2009 NA RCT,G 103, 32, 135,outcomes,reverse,-0.7160000000 -1.121000000,-3.100000e-01 NA,NA,NA,NA NA NA, 3.9000000, 3.9000000,100 100,100 100 100 100 100 some,some low some some,Placebo   0,  7.340000, 9.771111,NA,NA 0 1,1.0 1.0 1.0 1.0 1,1 0,1,1,1,1,1.0,1,1,1 1,1455 Dell'Agnello_2009,< 2 months,NA 6-12 yo 9.26,11.2017964071856,NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0,100,100 High,Atomoxetine,Atomoxetine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks) NA 13:CTRS-R:S  1.84119678    1.1000000,mg/kg/d Dell'Agnello,2009 NA RCT,G  58  18   76 outcomes reverse,-0.2260000000 -0.758000000, 3.060000e-01 NA NA,NA,NA,NA NA  3.3000000, 3.3000000 100 100 100,100 100,100,100 some some,low,some some Placebo,  0   7.339474  9.771053,NA,NA 0 1 1.0,1.0,1.0 1.0,1 1 0,1 1,1,1,1.0 1,1 1 1 1456 Dell'Agnello_2009 < 2 months NA 6-12 yo 9.77105263157895 12.2504651162791 NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100,High Atomoxetine Atomoxetine   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability  1.84119678,   1.1000000,mg/kg/d,Dell'Agnello 2009 NA,RCT,RR 107, 32  139,outcomes reverse, 3.3610000000  0.191000000  5.920200e+01,NA,NA,NA NA,NA,NA NA NA,100 100,100,100 100 100,100 some,some,low some,some,Placebo   0,  7.321583  9.769065 NA,NA,0 1 1.0 1.0,1.0,1.0,1,1 0 1,1,1 1 1.0 1,1 1 1,1457,Dell'Agnello_2009 < 2 months NA,6-12 yo,8.65154639175258,12.2493548387097,NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100,100 High Atomoxetine,Atomoxetine,  0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability  1.84119678    1.1000000,mg/kg/d,Dell'Agnello 2009,NA,RCT,RR 107, 32  139 outcomes reverse  2.1390000000, 0.113000000  4.035500e+01,NA,NA NA NA,NA,NA,NA,NA 100 100 100 100 100 100,100 some some,low,some some Placebo   0,  7.321583, 9.769065 NA NA 0 1,1.0,1.0 1.0,1.0,1 1 0 1 1 1,1 1.0 1,1 1 1 1458,Dell'Agnello_2009 < 2 months NA,6-12 yo,8.65154639175258 12.2493548387097,NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100 High Atomoxetine,Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA 16:SNAP-IV-Short-Hyper-Impuls, 2.07134638,   1.2000000,mg/kg/d,Dittman,2011 NA,RCT,G, 61  59, 120,outcomes,reverse -0.7350000000 -1.106000000,-3.630000e-01  10.9343495, 11.5217186,NA NA NA NA,NA NA,100,100,100,100 100,100 100 low low some low low,Placebo   0, 15.804167 10.947500,NA,NA 0 1 1.0 1.0,1.0,1.0 1 1 0,1,1 1 1 1.0,1 1,1 1,1459,Dittman_2011,2-6 months NA,6-12 yo,8.65157894736842 12.2493333333333 NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100,100 High,Atomoxetine Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) NA 24:Other  2.07134638    1.2000000 mg/kg/d Dittman 2011 NA RCT,G  61, 59  120 outcomes,reverse,-0.5130000000 -0.878000000,-1.480000e-01,  0.7810250,  0.7681146,NA,NA NA,NA NA NA,100,100 100,100,100 100,100 low low,some,low,low Placebo,  0  15.804167,10.947500,NA NA,0 1 1.0,1.0 1.0 1.0 1 1 0,1 1,1 1 1.0 1,1,1 1,1460,Dittman_2011 2-6 months,NA,6-12 yo 9.26,11.2017964071856 NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100,High,Atomoxetine,Atomoxetine,  0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability, 2.07134638,   1.2000000 mg/kg/d Dittman,2011 NA RCT RR  61, 59, 120,outcomes,reverse, 0.5720000000, 0.318000000  1.026000e+00 NA NA NA NA NA NA,NA,NA 100 100,100 100 100 100 100 low low some,low low Placebo,  0, 15.804167,10.947500,NA,NA 0,1 1.0 1.0,1.0,1.0,1 1,0 1 1,1,1,1.0 1,1,1 1 1461 Dittman_2011 2-6 months,NA 6-12 yo,8.65154639175258 12.2493548387097,NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100,High,Atomoxetine,Atomoxetine,  0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA,Tolerability  2.07134638    1.2000000 mg/kg/d Dittman,2011 NA RCT RR  61, 59  120 outcomes reverse  1.9340000000, 0.180000000, 2.076900e+01,NA NA NA,NA,NA NA,NA,NA 100,100 100,100,100,100 100,low,low some,low low,Placebo,  0, 15.804167,10.947500 NA NA,0,1,1.0 1.0,1.0,1.0 1 1,0 1 1 1 1,1.0 1,1 1,1 1462,Dittman_2011 2-6 months NA,6-12 yo 8.65154639175258 12.2493548387097 NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0,100,100 High,Atomoxetine Atomoxetine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,16:SNAP-IV-Short-Hyper-Impuls, 2.07134638    1.2000000,mg/kg/d Dittman,2011,NA,RCT G  60, 59, 119,outcomes,reverse -0.5750000000,-0.944000000 -2.070000e-01  11.6189500  11.5217186 NA NA NA,NA,NA,NA 100 100 100,100 100 100,100,low low,some low,low,Placebo,  0  16.784874,11.100000 NA,NA,0 1,1.0,1.0 1.0 1.0 1 1,0,1 1 1,1 1.0,1 1,1 1 1463 Dittman_2011 2-6 months,NA,6-12 yo,8.65157894736842 12.2493333333333 NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100 High,Atomoxetine,Atomoxetine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),NA,24:Other, 2.07134638,   1.2000000,mg/kg/d Dittman 2011 NA,RCT G, 50  59  109,outcomes reverse -0.4020000000,-0.784000000 -2.000000e-02   0.7071068   0.7681146 NA NA NA NA,NA,NA 100 100,100,100 100 100 100,low low,some low,low,Placebo   0, 16.948624 11.100000,NA,NA 0,1,1.0 1.0 1.0,1.0,1 1 0,1,1 1 1 1.0,1,1,1,1 1464 Dittman_2011,2-6 months,NA,6-12 yo,9.26,11.2017964071856,NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100 High Atomoxetine Atomoxetine   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability  2.07134638,   1.2000000 mg/kg/d Dittman 2011,NA,RCT RR  60  59, 119,outcomes,reverse, 0.7150000000  0.419000000  1.220000e+00 NA,NA,NA,NA NA NA NA,NA 100 100 100 100,100,100,100,low low some,low low Placebo   0  16.784874 11.100000,NA,NA 0,1 1.0,1.0,1.0,1.0,1,1 0,1 1,1,1 1.0,1,1 1 1 1465 Dittman_2011 2-6 months,NA 6-12 yo,8.65154639175258 12.2493548387097,NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100,100,High,Atomoxetine Atomoxetine   0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 2.07134638    1.2000000,mg/kg/d,Dittman 2011 NA,RCT RR, 60  59, 119,outcomes,reverse, 5.9000000000  0.732000000  4.752400e+01 NA,NA NA,NA,NA,NA,NA NA,100 100,100,100,100,100,100 low low some low,low Placebo,  0, 16.784874,11.100000 NA NA 0 1,1.0,1.0,1.0 1.0 1,1 0 1,1 1,1,1.0,1 1,1,1 1466 Dittman_2011 2-6 months NA,6-12 yo,8.65154639175258 12.2493548387097 NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0 100 100,High Methylphenidate Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA 24:Other  0.92059839 NA,NA,Dopfner,2003 NA RCT G, 43  42,  85,outcomes reverse,-0.9430000000,-1.395000000 -4.920000e-01   0.7000000   0.6200000,NA,NA,NA NA NA,NA 100 100,100 100,100,100,100,low low low,low low,Placebo   0, 11.776471  9.800000 NA,NA 0 1 1.0,1.0,1.0,1.0 1 1 0,1 1,1,1 1.0 1 1 1,1,1467,Dopfner_2003 < 2 months NA 6-12 yo,8.60731707317073,10.9714285714286 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0,100,100 High Methylphenidate Methylphenidate   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks),NA 24:Other, 0.92059839,NA,NA,Dopfner 2003,NA,RCT G, 43, 42   85 outcomes reverse,-1.1940000000,-1.659000000 -7.290000e-01   0.6200000   0.6900000,NA NA,NA NA,NA,NA,100 100,100,100 100 100 100 low low low low low Placebo,  0  11.776471  9.800000,NA NA 0,1 1.0,1.0,1.0 1.0 1 1 0,1,1 1 1 1.0 1 1,1 1 1468 Dopfner_2003 < 2 months,NA,6-12 yo 8.60483870967742 9.97113402061856 NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0,100,100 High,Methylphenidate Methylphenidate   0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability, 0.92059839 NA,NA,Dopfner 2003 NA RCT RR  43, 42   85,outcomes reverse  0.9770000000, 0.209000000  4.569000e+00 NA NA NA NA NA NA NA NA 100,100 100 100,100,100,100,low,low,low,low low Placebo   0  11.776471  9.800000 NA NA,0 1 1.0 1.0 1.0,1.0 1 1,0 1,1 1,1 1.0,1 1 1,1,1469,Dopfner_2003,< 2 months,NA,6-12 yo 7.9578947368421 14.7,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100,High Methylphenidate Methylphenidate   0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability  0.92059839 NA NA Dopfner 2003,NA RCT,RR, 43  42,  85,outcomes reverse  4.8860000000, 0.242000000, 9.884800e+01 NA NA,NA NA,NA NA NA,NA,100 100,100,100,100,100,100 low,low low low,low,Placebo   0, 11.776471  9.800000,NA NA 0,1 1.0,1.0 1.0 1.0 1 1,0,1,1 1,1,1.0 1 1 1 1 1470,Dopfner_2003 < 2 months NA 6-12 yo 7.9578947368421 14.7 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100,100,High Methylphenidate Methylphenidate   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability  1.61104718,NA,NA Findling,2008 NA,RCT RR, 94, 88  182 outcomes,reverse, 0.4770000000  0.336000000, 6.760000e-01 NA NA,NA NA,NA,NA,NA,NA,100,100 100,100 100,100 100 some some,some,some some,Placebo   0  30.180220  8.654945,NA NA,0 1 1.0,1.0,1.0,1.0,1 1 0,1,1,1,1,1.0,1,1,1 1,1471 Findling_2008 < 2 months NA 6-12 yo,7.9578947368421,14.7 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0,100,100,High Methylphenidate,Methylphenidate,  0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability  1.61104718 NA NA,Findling,2008 NA RCT RR  94, 88  182 outcomes reverse  1.8720000000, 0.173000000, 2.028700e+01 NA,NA,NA NA,NA,NA,NA NA,100,100 100 100,100,100,100,some some,some,some,some Placebo   0  30.180220  8.654945 NA,NA,0,1,1.0 1.0,1.0 1.0,1,1 0,1 1,1,1,1.0,1 1,1 1 1472 Findling_2008,< 2 months NA,6-12 yo 7.9578947368421 14.7 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0,100,100 High Amphetamine,Amphetamine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA 4:ADHD-SRS Total  0.92059839   30.0000000 mg/d,Findling 2011,NA,RCT G  78, 77  155,outcomes,reverse -0.4180000000 -0.737000000,-9.900000e-02  13.0300000  12.6800000 NA NA NA NA,NA NA,100,100,100 100 100 100,100,low low,some,low low,Placebo,  0, 27.976774,14.550323,NA,NA,0,1 1.0 1.0 1.0 1.0 1,1 0,1 1,1,1 1.0,1,1,1,1,1473 Findling_2011 < 2 months,NA 13-19 yo 9.04758620689655 14.6347014925373 NA,NA  43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100,High,Amphetamine,Amphetamine,  0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability, 0.92059839,  30.0000000 mg/d Findling 2011,NA,RCT RR, 78, 79, 157 outcomes reverse, 1.5190000000  0.727000000, 3.173000e+00 NA,NA NA,NA,NA,NA,NA,NA,100,100,100,100 100,100,100 low,low,some,low low,Placebo   0, 28.022930,14.549682,NA NA,0 1,1.0 1.0 1.0 1.0,1 1,0 1,1 1,1,1.0,1,1,1,1,1474,Findling_2011,< 2 months NA,13-19 yo,8.22105263157895,14.6335365853659,NA,NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100 100,High Amphetamine,Amphetamine   0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability, 0.92059839,  30.0000000,mg/d,Findling,2011 NA,RCT RR, 78  79, 157 outcomes,reverse  3.0380000000, 0.323000000  2.858300e+01,NA,NA,NA,NA NA,NA,NA NA,100 100,100 100 100,100,100,low low,some low,low Placebo,  0  28.022930 14.549682 NA,NA,0,1,1.0,1.0,1.0,1.0,1,1,0 1 1 1,1 1.0,1 1 1 1,1475 Findling_2011 < 2 months NA 13-19 yo,8.22105263157895 14.6335365853659 NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100,100,High,Amphetamine Amphetamine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA 4:ADHD-SRS Total, 0.92059839   50.0000000,mg/d,Findling,2011,NA,RCT G  76  77  153,outcomes,reverse,-0.7560000000,-1.086000000 -4.270000e-01, 10.3400000, 12.6800000,NA,NA,NA,NA,NA,NA 100,100 100,100,100,100,100,low,low some low low,Placebo,  0, 25.986928 14.599346,NA,NA 0 1,1.0 1.0,1.0,1.0,1,1,0,1 1,1 1 1.0,1 1,1 1 1476,Findling_2011 < 2 months NA,13-19 yo 9.04758620689655,14.6347014925373 NA NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA,NA Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0 100 100 High,Amphetamine,Amphetamine,  0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability, 0.92059839   50.0000000 mg/d,Findling,2011,NA,RCT,RR, 79, 79  158,outcomes reverse  1.3000000000, 0.606000000, 2.789000e+00,NA NA,NA,NA NA NA NA,NA 100 100 100,100,100,100,100,low,low some,low low Placebo   0, 25.950000,14.600000,NA NA,0,1 1.0,1.0 1.0,1.0 1 1,0,1 1,1,1 1.0,1 1,1 1 1477 Findling_2011 < 2 months,NA,13-19 yo,8.22105263157895 14.6335365853659 NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100,High Amphetamine,Amphetamine,  0 NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,Tolerability, 0.92059839,  50.0000000 mg/d Findling,2011 NA RCT,RR, 79  79  158 outcomes,reverse  3.0000000000  0.319000000  2.822500e+01,NA,NA NA,NA NA NA NA NA 100,100 100,100,100 100,100 low,low,some,low,low,Placebo   0, 25.950000,14.600000,NA,NA,0,1 1.0,1.0,1.0 1.0 1 1,0,1 1,1 1,1.0,1 1 1,1 1478 Findling_2011 < 2 months,NA,13-19 yo 8.22105263157895 14.6335365853659,NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA NA Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100 High,Amphetamine,Amphetamine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total, 0.92059839   70.0000000,mg/d Findling 2011,NA,RCT G, 78, 77  155 outcomes,reverse,-0.7670000000,-1.095000000 -4.400000e-01,  9.4000000  12.6800000,NA,NA,NA NA NA NA,100 100 100,100,100,100 100 low low,some,low low Placebo   0, 37.638710,14.449677 NA,NA 0,1,1.0,1.0,1.0,1.0 1 1 0,1,1 1,1,1.0,1 1 1 1,1479 Findling_2011,< 2 months,NA 13-19 yo,9.04758620689655,14.6347014925373,NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0,100 100 High Amphetamine,Amphetamine   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability, 0.92059839   70.0000000,mg/d,Findling,2011,NA RCT,RR, 78, 79  157 outcomes,reverse, 1.1140000000  0.502000000  2.472000e+00,NA NA,NA NA,NA NA NA NA 100 100 100,100,100,100 100,low,low some,low,low Placebo   0, 37.561783,14.450318 NA NA,0,1,1.0 1.0,1.0 1.0 1 1,0 1,1,1,1 1.0,1,1 1,1 1480,Findling_2011,< 2 months NA,13-19 yo,8.22105263157895 14.6335365853659,NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA,Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100,High Amphetamine,Amphetamine   0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability, 0.92059839   70.0000000 mg/d,Findling 2011,NA,RCT,RR, 78  79, 157,outcomes reverse  4.0510000000  0.463000000, 3.544200e+01,NA NA,NA,NA NA,NA,NA,NA,100,100,100,100,100 100 100 low,low,some low,low,Placebo,  0, 37.561783,14.450318,NA,NA 0,1 1.0 1.0 1.0,1.0 1,1 0 1 1 1,1,1.0 1,1 1 1,1481,Findling_2011 < 2 months NA 13-19 yo,8.22105263157895,14.6335365853659,NA,NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA,Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100,High Atomoxetine Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA 1:ADHD-RS Total, 0.92059839,NA NA,Gau 2007,NA RCT G  72, 34  106,outcomes reverse -0.9370000000 -1.366000000 -5.080000e-01, 10.1000000  11.9000000 NA,NA NA NA,NA,NA,100 100,100,100,100,100 100 low low,some,low,low,Placebo   0  11.303774, 9.228302,NA NA 0 1 1.0 1.0,1.0,1.0 1 1 0,1,1 1,1,1.0 1 1 1,1 1482 Gau_2007 < 2 months NA 6-12 yo 8.65157894736842 12.2493333333333 NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0 100,100 High Atomoxetine Atomoxetine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total  1.38089758 NA NA,Geller 2007,NA RCT,G  55, 58  113 outcomes reverse,-0.8030000000 -1.215000000,-3.900000e-01,NA,NA,NA NA NA NA  8.4535081  8.4535081,100,100 100,100,100 100 100,low low low low low,Placebo,  0, 35.179646,11.994690,NA NA,0,1 1.0,1.0 1.0 1.0 1 1,0,1,1 1,1 1.0 1,1 1,1,1483,Geller_2007 < 2 months,NA 6-12 yo 8.65157894736842,12.2493333333333 NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100 High Methylphenidate,Methylphenidate   0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability, 0.69044879,  40.7000000 mg/d,Greenhill 2002,NA,RCT,RR 158 163  321,outcomes,reverse, 0.6260000000, 0.357000000, 1.098000e+00,NA,NA,NA,NA,NA,NA NA NA,100 100,100,100 100 100,100 some some low some,some,Placebo,  0  18.015576, 9.000000,NA,NA,0,1 1.0,1.0 1.0 1.0 1,1,0 1 1 1 1 1.0,1 1,1 1 1484 Greenhill_2002 < 2 months NA,6-12 yo,7.9578947368421 14.7 NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0 100,100,High,Methylphenidate Methylphenidate   0,NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability  0.69044879,  40.7000000 mg/d Greenhill 2002,NA RCT,RR 158 163, 321 outcomes,reverse, 5.1570000000, 0.250000000, 1.065820e+02 NA,NA NA NA NA,NA,NA,NA 100,100 100 100,100,100 100 some some,low some,some Placebo   0, 18.015576, 9.000000 NA,NA 0,1 1.0,1.0,1.0,1.0 1,1 0,1,1 1,1 1.0 1 1 1 1,1485,Greenhill_2002 < 2 months NA,6-12 yo 7.9578947368421 14.7 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100 High,Modafinil,Modafinil,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total, 2.07134638  361.4000000,mg/d,Greenhill 2006a NA RCT G 128  66  194 outcomes reverse -0.5660000000 -0.869000000 -2.630000e-01, 14.0000000  13.2000000 NA,NA NA NA,NA NA 100 100 100 100   0,100 100 some,some high,some,some,Placebo,  0, 27.000000, 9.900000 NA,NA 0,1,1.0,1.0,1.0,1.0,1,1 0 1,1 1,1,1.0,1 1,1 1 1486 Greenhill_2006a,2-6 months NA,6-12 yo,8.85049504950495 10.3004098360656 NA NA   8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8 NA NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100 100 High,Modafinil,Modafinil   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),NA 13:CPRS-R:S  2.07134638, 361.4000000,mg/d Greenhill 2006a NA RCT G,128, 66  194,outcomes reverse,-0.4580000000,-0.759000000,-1.560000e-01, 11.9000000, 10.8000000,NA NA,NA,NA,NA,NA 100,100,100,100   0 100 100 some,some high some,some,Placebo   0, 27.000000, 9.900000,NA NA 0,1 1.0,1.0 1.0,1.0,1,1,0,1 1,1 1,1.0 1,1,1 1 1487 Greenhill_2006a 2-6 months NA 6-12 yo,8.85049504950495,10.3004098360656,NA NA   8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Modafinil Modafinil   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA 1:ACTeRS-2, 2.07134638  361.4000000,mg/d,Greenhill 2006a NA,RCT G 128, 66  194 outcomes,reverse,-0.5170000000,-0.819000000 -2.140000e-01  13.6000000  12.7000000 NA,NA NA NA NA NA,100 100,100,100,  0 100 100 some,some,high some some,Placebo   0  27.000000, 9.900000 NA NA,0 1 1.0,1.0,1.0 1.0 1 1 0,1 1 1 1,1.0,1 1,1,1,1488 Greenhill_2006a 2-6 months NA,6-12 yo 8.85049504950495 9.96229508196721,NA NA   8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0,100 100,High,Modafinil,Modafinil   0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability, 2.07134638  361.4000000,mg/d,Greenhill,2006a NA RCT,RR,133, 67  200 outcomes reverse, 0.6390000000, 0.419000000  9.750000e-01,NA,NA NA NA,NA NA,NA NA 100,100 100,100   0 100,100 some some,high,some some Placebo   0  27.000000, 9.900000,NA NA 0,1 1.0,1.0,1.0,1.0 1 1 0 1 1 1,1 1.0 1,1 1 1 1489 Greenhill_2006a,2-6 months NA,6-12 yo,7.875,10.2983870967742,NA,NA,  8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA,NA,Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100,High Modafinil,Modafinil   0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 2.07134638, 361.4000000 mg/d,Greenhill 2006a,NA,RCT,RR,133  67  200,outcomes,reverse, 0.7560000000  0.221000000, 2.587000e+00,NA,NA,NA NA NA,NA,NA NA,100 100,100 100,  0,100 100 some some high some some,Placebo,  0, 27.000000  9.900000 NA NA 0 1 1.0,1.0 1.0 1.0,1,1,0 1 1 1 1,1.0,1,1 1,1 1490 Greenhill_2006a 2-6 months NA,6-12 yo 7.875,10.2983870967742 NA NA,  8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8 NA NA Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100,100 High Methylphenidate,Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA 24:Other  1.61104718   24.0000000 mg/d,Greenhill 2006b,NA RCT G  52, 45   97 outcomes,reverse -0.8610000000 -1.280000000,-4.410000e-01, 13.6500000  11.7200000,NA,NA,NA,NA,NA,NA,100 100,100 100,100 100,100,some some,low some some Placebo   0  36.164948  9.971134 NA,NA 0 1,1.0,1.0 1.0,1.0,1,1,0,1 1 1 1 1.0 1,1 1,1,1491 Greenhill_2006b < 2 months NA,6-12 yo 8.60731707317073,10.9714285714286,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100,High,Methylphenidate Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks) NA,24:Other  1.61104718,  24.0000000,mg/d,Greenhill,2006b NA RCT G, 52  45,  97 outcomes,reverse -0.8220000000,-1.240000000 -4.050000e-01, 12.4200000, 15.6200000,NA,NA,NA NA,NA NA,100 100,100,100 100 100,100,some some low,some,some,Placebo   0  36.164948  9.971134 NA,NA 0,1,1.0 1.0 1.0,1.0 1 1,0 1,1 1,1,1.0,1,1 1,1,1492,Greenhill_2006b,< 2 months NA 6-12 yo 8.60483870967742 9.97113402061856,NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0 100,100,High,Methylphenidate Methylphenidate   0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability, 1.61104718,  24.0000000,mg/d,Greenhill,2006b NA,RCT,RR, 53, 50, 103,outcomes,reverse  0.3630000000  0.139000000  9.440000e-01,NA,NA,NA,NA,NA NA NA NA 100 100,100 100 100,100,100 some some,low,some some,Placebo,  0  35.917476  9.988350 NA,NA,0 1 1.0 1.0,1.0,1.0,1,1,0 1,1,1 1,1.0,1 1,1,1 1493,Greenhill_2006b,< 2 months,NA 6-12 yo 7.9578947368421 14.7,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Methylphenidate Methylphenidate,  0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA Tolerability  1.61104718,  24.0000000,mg/d Greenhill 2006b NA,RCT,RR  53, 50, 103,outcomes reverse, 0.3150000000  0.013000000  7.552000e+00 NA NA,NA,NA,NA NA,NA,NA 100,100,100,100 100,100,100 some some,low some,some Placebo,  0, 35.917476, 9.988350 NA NA,0 1,1.0 1.0 1.0,1.0 1,1 0,1,1 1 1 1.0,1 1 1,1 1494 Greenhill_2006b,< 2 months NA 6-12 yo 7.9578947368421,14.7 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,  0,  0,100,100 High Methylphenidate,Methylphenidate,  0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability  0.46029919 NA NA,Grizenko,2012,NA RCT,RR,237 258  495 outcomes reverse  0.3630000000  0.015000000, 8.861000e+00,NA,NA NA,NA,NA NA NA,NA 100 100,100,100 100,100,100 low,low,low low low Placebo,  0 NA NA,NA,NA,0,1 1.0 1.0 1.0 1.0 1,1,0,1 1,1 1 1.0 1,1,1 1,1495,Grizenko_2012 < 2 months,NA NA 7.9578947368421,14.7,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,  0   0 100 100,High Methylphenidate Methylphenidate   0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability, 0.46029919,NA,NA Grizenko 2012 NA,RCT,RR 237 258, 495 outcomes,reverse  1.0880000000  0.022000000  5.462700e+01 NA,NA NA NA,NA,NA NA NA 100 100,100,100,100,100 100,low low low,low,low Placebo   0 NA,NA NA NA 0 1 1.0 1.0 1.0 1.0 1,1 0 1 1,1,1 1.0,1,1,1,1 1496,Grizenko_2012 < 2 months NA,NA,7.9578947368421 14.7 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100,100,High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA 4:ADHD-SRS Total  1.84119678,NA NA Jain,2011,NA,RCT G, 78, 76, 154 outcomes,reverse -0.4180000000 -0.807000000 -2.800000e-02 NA NA NA,NA NA NA, 9.4100000, 9.4100000,100,100,100 100 100,100 100 some low low,low,low,Placebo,  0, 30.536364  9.400000,NA NA,0 1 1.0,1.0 1.0,1.0 1,1,0,1 1,1 1,1.0,1 1,1,1,1497 Jain_2011,< 2 months NA,6-12 yo,8.99719626168224 14.5496794871795,NA NA, 20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0,100 100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability  1.84119678,NA,NA,Jain 2011 NA,RCT,RR  80  78  158,outcomes reverse  0.8430000000  0.591000000, 1.204000e+00,NA NA,NA NA,NA NA,NA NA,100,100,100 100,100,100,100,some,low low low,low Placebo   0  30.536709  9.400000 NA NA,0,1,1.0 1.0,1.0 1.0 1,1 0 1 1,1,1,1.0 1,1,1,1,1498,Jain_2011 < 2 months,NA 6-12 yo 8.23931034482759,12.6640449438202,NA,NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100 100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 1.84119678 NA NA,Jain,2011 NA,RCT RR, 80, 78, 158,outcomes,reverse,14.6250000000, 1.979000000, 1.080730e+02 NA NA NA,NA NA,NA NA,NA,100,100,100,100,100 100,100,some low low low low,Placebo,  0  30.536709  9.400000 NA NA 0,1 1.0,1.0 1.0 1.0 1,1 0 1,1 1 1,1.0,1,1 1 1 1499,Jain_2011,< 2 months,NA,6-12 yo 9 12.6640449438202,NA,NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0,100,100,High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total, 1.84119678,NA NA,Jain 2011 NA RCT,G, 74  76  150 outcomes reverse,-0.4020000000 -0.797000000 -8.000000e-03 NA,NA NA NA,NA NA  9.4100000  9.4100000 100 100 100,100 100 100,100 some,low low low low,Placebo,  0, 26.666667  9.498667,NA NA 0 1 1.0,1.0,1.0 1.0 1,1,0,1,1 1,1 1.0 1 1 1 1 1500,Jain_2011 < 2 months NA 6-12 yo,8.99719626168224,14.5496794871795,NA,NA  20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100 High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability  1.84119678,NA NA Jain,2011,NA RCT,RR, 78  78, 156,outcomes,reverse  0.6490000000, 0.432000000  9.740000e-01 NA,NA,NA,NA NA NA NA NA 100,100,100,100 100,100,100 some low,low,low,low Placebo   0  26.600000, 9.500000,NA NA,0 1 1.0,1.0 1.0,1.0,1,1 0 1,1 1,1,1.0,1,1 1 1 1501,Jain_2011 < 2 months,NA 6-12 yo 8.23931034482759 12.6640449438202,NA,NA, 20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability  1.84119678,NA NA,Jain,2011,NA,RCT RR  78  78  156 outcomes,reverse, 5.0000000000  0.598000000  4.182100e+01 NA,NA NA NA,NA,NA NA,NA,100 100,100 100 100,100,100,some low,low,low low,Placebo,  0  26.600000  9.500000 NA NA,0 1 1.0,1.0,1.0,1.0 1,1 0,1,1 1 1,1.0 1,1 1,1,1502 Jain_2011,< 2 months,NA,6-12 yo,9 12.6640449438202 NA,NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0,100,100,High,Modafinil,Modafinil,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA 1:ADHD-RS Total  1.38089758 NA,NA,Kahbazi 2009 NA,RCT G, 23  23,  46 outcomes reverse -1.1430000000,-2.142000000,-1.440000e-01 NA,NA,NA NA,NA,NA  6.1500000  6.1500000,100,100 100 100,100,100 100 low low,low low,some,Placebo,  0, 23.915000, 9.065000,NA NA 0,1,1.0 1.0,1.0,1.0 1,1,0,1 1 1 1 1.0 1,1,1,1 1503,Kahbazi_2009 < 2 months NA,6-12 yo,8.85049504950495,10.3004098360656 NA NA,  8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA,NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100,High Modafinil Modafinil   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks),NA 5:ADHD-RS Total  1.38089758 NA,NA Kahbazi 2009,NA RCT G  23, 23,  46,outcomes,reverse -1.2820000000,-2.374000000,-1.910000e-01 NA NA,NA NA NA NA  5.0400000, 5.0400000,100 100 100,100 100,100 100,low,low low low some,Placebo,  0  23.915000  9.065000 NA NA,0,1,1.0,1.0,1.0 1.0 1 1 0 1 1 1 1 1.0,1 1,1 1 1504 Kahbazi_2009,< 2 months NA,6-12 yo 8.85049504950495 9.96229508196721,NA,NA   8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8,NA NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100 100,High,Modafinil,Modafinil,  0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability  1.38089758,NA,NA,Kahbazi,2009 NA RCT,RR, 23, 23,  46,outcomes reverse, 0.5000000000, 0.049000000, 5.138000e+00,NA NA,NA NA NA NA NA,NA,100 100,100 100,100 100,100 low low,low,low some,Placebo,  0, 23.915000  9.065000,NA,NA 0,1,1.0,1.0,1.0,1.0,1 1,0,1,1,1,1 1.0 1 1 1 1 1505,Kahbazi_2009 < 2 months NA,6-12 yo,7.875 10.2983870967742 NA NA   8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8 NA NA,Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100,High Modafinil,Modafinil,  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability  1.38089758 NA,NA Kahbazi 2009,NA,RCT,RR  23  23,  46 outcomes,reverse  1.0000000000  0.021000000  4.837000e+01,NA,NA NA NA NA,NA,NA,NA 100 100,100 100 100 100 100,low,low,low low some Placebo,  0, 23.915000, 9.065000 NA NA,0,1 1.0,1.0,1.0,1.0 1,1 0 1 1,1 1,1.0 1 1,1,1,1506,Kahbazi_2009,< 2 months,NA,6-12 yo,7.875,10.2983870967742 NA NA,  8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA NA Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100 100,High,Atomoxetine Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA 4:ADHD-SRS Total  0.92059839,NA,NA,Kelsey 2004 NA RCT,G 126, 60  186,outcomes,reverse,-0.3510000000,-0.662000000,-4.100000e-02  19.0824527  16.2665301 NA NA,NA,NA NA,NA,100 100 100,100,100 100,100 low,low some,low,low,Placebo,  0, 29.429032, 9.467742 NA NA 0,1 1.0 1.0 1.0 1.0,1 1,0 1 1,1,1 1.0 1 1,1,1,1507 Kelsey_2004,< 2 months,NA 6-12 yo 8.65157894736842 12.2493333333333,NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA 4:ADHD-SRS Total, 1.38089758 NA,NA Kollins 2011 NA,RCT,G 121, 57  178,outcomes reverse -0.7740000000 -1.187000000 -3.610000e-01 NA,NA NA NA,NA,NA 13.1200000 13.1200000 100,100,100 100,100,100 100 low low low low low Placebo   0  30.345506 12.664045,NA NA,0 1 1.0 1.0,1.0,1.0,1,1,0,1 1,1,1 1.0 1,1 1 1,1508,Kollins_2011,< 2 months NA,6-12 yo,8.99719626168224,14.5496794871795 NA NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0 100 100,High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability, 1.38089758 NA,NA,Kollins 2011 NA RCT RR,121, 57  178 outcomes reverse, 1.0990000000  0.295000000  4.096000e+00,NA NA NA NA,NA,NA NA NA,100,100,100,100,100,100,100 low,low,low low low Placebo,  0  30.345506 12.664045,NA,NA 0,1 1.0,1.0,1.0,1.0,1,1 0 1,1,1,1,1.0,1 1 1 1,1509 Kollins_2011,< 2 months NA,6-12 yo,8.23931034482759,12.6640449438202 NA NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2,NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100 High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability  1.38089758,NA NA Kollins 2011 NA,RCT RR 121, 57  178 outcomes reverse  1.8840000000, 0.215000000, 1.648000e+01 NA NA NA NA NA NA NA NA 100,100,100,100 100,100,100,low low,low,low,low,Placebo   0  30.345506,12.664045 NA,NA 0,1,1.0,1.0 1.0 1.0 1 1,0 1,1 1 1,1.0 1,1 1 1 1510 Kollins_2011,< 2 months NA,6-12 yo 9 12.6640449438202 NA,NA  20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0 100 100 High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability  3.68239356,   0.2500000 mg/d Kurlan 2002 NA RCT,RR, 34, 32   66,outcomes reverse  0.5380000000  0.174000000  1.664000e+00 NA NA NA NA,NA NA NA,NA 100,100 100 100 100 100 100,low low low low,low Placebo,  0, 12.090909  9.700000,NA NA 0,1,1.0 1.0,1.0 1.0 1 1,0,1 1,1 1 1.0 1 1,1 1,1511,Kurlan_2002 2-6 months,NA,6-12 yo 8.23931034482759 12.6640449438202 NA NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100 100 High Methylphenidate Methylphenidate,  0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA Acceptability, 3.68239356,  25.7000000,mg/d Kurlan,2002 NA RCT RR, 37, 32,  69 outcomes,reverse, 0.4940000000  0.159000000  1.536000e+00,NA,NA,NA NA,NA NA NA,NA,100 100,100 100,100,100 100 low low,low low,low,Placebo,  0   8.463768 10.236232 NA NA 0,1,1.0 1.0,1.0 1.0 1 1,0 1 1 1,1,1.0,1,1 1 1 1512 Kurlan_2002 2-6 months NA,6-12 yo 7.9578947368421,14.7 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0 100 100 High Methylphenidate Methylphenidate   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA 1:ADHD-RS Total  1.84119678,NA NA,Lin 2014,NA RCT,G, 26, 63   89 outcomes reverse,-0.6330000000,-1.260000000 -6.000000e-03,NA,NA NA NA NA,NA,12.0646260,12.0646260 100,100 100,100,100 100 100 low some low,some low,Placebo   0, 30.025843 10.961798,NA,NA,0 1 1.0,1.0,1.0,1.0,1,1,0 1,1 1,1 1.0,1,1 1,1 1513,Lin_2014 < 2 months,NA,6-12 yo 9.745,14.7,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0,100,100 High Methylphenidate Methylphenidate   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA 24:Other, 1.84119678 NA,NA,Lin 2014 NA RCT,G, 24  60,  84 outcomes reverse -0.3880000000 -0.973000000  1.970000e-01,NA,NA,NA,NA NA,NA 12.8869985,12.8869985 100,100,100 100,100,100 100 low some low some,low Placebo,  0  30.071429 10.971429 NA,NA 0,1,1.0 1.0 1.0 1.0 1,1 0,1 1 1 1,1.0,1,1 1,1 1514,Lin_2014,< 2 months,NA,6-12 yo,8.60731707317073,10.9714285714286,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100 High Methylphenidate Methylphenidate   0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability  1.84119678 NA,NA Lin 2014 NA,RCT,RR, 36, 78  114,outcomes,reverse, 1.0110000000, 0.452000000, 2.263000e+00,NA,NA,NA,NA,NA,NA NA NA 100 100 100,100,100,100,100 low some,low some low,Placebo,  0  29.857895 10.926316,NA,NA,0 1 1.0,1.0 1.0,1.0 1,1 0,1,1 1,1 1.0 1 1 1,1 1515,Lin_2014,< 2 months,NA 6-12 yo 7.9578947368421 14.7,NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100,High,Methylphenidate Methylphenidate,  0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA Tolerability, 1.84119678,NA NA Lin,2014,NA,RCT RR, 36, 78  114,outcomes,reverse, 2.1670000000  0.459000000  1.021600e+01 NA,NA NA,NA,NA NA NA,NA,100 100 100,100 100 100,100,low some low,some,low Placebo   0  29.857895 10.926316,NA,NA,0 1,1.0,1.0 1.0 1.0,1 1,0 1 1 1 1,1.0 1,1 1,1,1516,Lin_2014 < 2 months,NA 6-12 yo,7.9578947368421,14.7 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100,High,Atomoxetine Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total, 0.92059839 NA NA Martenyi 2010,NA,RCT G  72, 33  105,outcomes,reverse -0.4480000000,-1.070000000  1.750000e-01 NA,NA,NA,NA NA,NA  6.7916012, 6.7916012 100,100,100,100 100,100,100 low,low low low low,Placebo   0, 14.291429  9.805714 NA,NA 0 1 1.0,1.0 1.0,1.0 1 1 0,1 1,1,1 1.0,1 1 1,1,1517 Martenyi_2010,< 2 months,NA 6-12 yo 8.65157894736842,12.2493333333333 NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100,High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total, 0.92059839    2.2000000,mg/d,McCracken,2016 NA RCT,G, 68  69  137,outcomes,reverse,-1.0200000000 -1.377000000 -6.630000e-01,  6.5969690,  8.3066239,NA NA NA,NA,NA,NA,100 100,100,100,100,100 100,some,some,low some,some Placebo   0  33.548175,10.100000 NA NA,0 1 1.0,1.0 1.0 1.0,1,1 0 1,1,1,1 1.0,1 1,1,1 1518,McCracken_2016,< 2 months NA,6-12 yo 8.99719626168224,14.5496794871795,NA NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0 100 100,High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA Acceptability  0.92059839,   2.2000000 mg/d McCracken 2016,NA,RCT,RR  71  70  141 outcomes reverse  2.9580000000, 0.315000000  2.775400e+01,NA NA,NA NA,NA NA,NA,NA 100 100 100 100,100,100,100,some some,low some,some Placebo   0  33.551773,10.100000 NA NA 0 1,1.0 1.0,1.0 1.0 1 1,0 1 1 1 1,1.0,1,1,1 1 1519 McCracken_2016 < 2 months NA,6-12 yo 8.23931034482759 12.6640449438202,NA,NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100,100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,Tolerability, 0.92059839    2.2000000,mg/d McCracken 2016 NA RCT RR, 71, 70, 141,outcomes reverse, 0.9860000000, 0.020000000, 4.901900e+01,NA,NA,NA,NA NA NA,NA,NA,100 100,100,100 100,100 100,some some,low some some Placebo   0  33.551773,10.100000 NA,NA 0 1,1.0,1.0 1.0 1.0 1 1 0,1 1,1 1,1.0 1 1 1 1 1520 McCracken_2016,< 2 months NA,6-12 yo 9 12.6640449438202 NA,NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100 100,High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total, 0.92059839,   2.4000000 mg/d,McCracken,2016,NA RCT G, 70, 69, 139,outcomes reverse,-1.0160000000 -1.371000000 -6.610000e-01   6.6932802   8.3066239 NA NA,NA NA NA,NA 100 100 100,100,100,100,100 some,some,low some some Placebo   0  30.177698, 9.999281,NA,NA,0,1,1.0 1.0 1.0,1.0 1,1,0 1 1,1 1,1.0 1 1,1,1,1521,McCracken_2016 < 2 months,NA,6-12 yo 8.99719626168224,14.5496794871795,NA NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100 High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability, 0.92059839    2.4000000 mg/d,McCracken,2016,NA,RCT,RR  71  70, 141,outcomes reverse  0.9860000000, 0.063000000  1.545400e+01,NA,NA,NA NA,NA NA,NA,NA 100 100 100,100 100 100 100,some some low,some some,Placebo   0  30.178014  9.999291 NA NA,0,1 1.0,1.0 1.0,1.0 1 1,0,1,1 1,1,1.0 1,1,1 1 1522,McCracken_2016 < 2 months NA,6-12 yo 8.23931034482759 12.6640449438202 NA NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100 100,High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,Tolerability, 0.92059839    2.4000000 mg/d,McCracken 2016 NA RCT,RR, 71, 70, 141,outcomes reverse  0.9860000000, 0.020000000  4.901900e+01 NA,NA NA,NA,NA NA NA NA,100,100 100 100,100,100,100 some,some low some,some,Placebo,  0  30.178014, 9.999291 NA,NA 0,1 1.0,1.0,1.0 1.0,1 1,0 1 1 1,1,1.0 1 1,1,1,1523 McCracken_2016,< 2 months,NA,6-12 yo,9 12.6640449438202 NA NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100,100 High,Atomoxetine,Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total, 1.84119678 NA,NA,Michelson 2001 NA RCT G, 43, 83  126 outcomes,reverse,-0.1390000000 -0.540000000, 2.630000e-01,NA,NA NA NA NA NA,10.9000000 10.9000000,100,100 100,100 100,100 100 low,low low low,low Placebo   0, 28.911032 11.036508 NA,NA,0,1 1.0,1.0 1.0,1.0,1,1 0,1,1 1,1 1.0,1,1,1,1,1524 Michelson_2001,< 2 months NA,6-12 yo 8.65157894736842 12.2493333333333 NA NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100,High,Atomoxetine,Atomoxetine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),NA,13:CPRS-R:S, 1.84119678 NA NA Michelson 2001,NA,RCT G, 43  83  126,outcomes reverse -0.6200000000,-1.024000000 -2.150000e-01 NA NA,NA,NA,NA,NA, 8.5000000, 8.5000000 100 100 100 100 100 100 100,low,low,low,low,low,Placebo   0, 28.911032,11.036508 NA NA,0,1,1.0,1.0,1.0,1.0,1,1,0,1 1 1,1 1.0,1,1 1,1,1525 Michelson_2001 < 2 months NA 6-12 yo,9.26,11.2017964071856,NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0 100,100 High Atomoxetine,Atomoxetine   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA Acceptability  1.84119678,NA NA Michelson 2001,NA,RCT RR  44, 84, 128,outcomes reverse  1.5910000000, 0.747000000, 3.388000e+00 NA,NA,NA,NA NA NA,NA NA 100,100,100,100,100 100,100,low,low,low,low,low Placebo,  0  28.913438,11.037500 NA,NA,0,1,1.0 1.0 1.0,1.0,1,1,0,1,1 1,1 1.0 1,1,1,1,1526,Michelson_2001 < 2 months NA,6-12 yo 8.65154639175258,12.2493548387097,NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Atomoxetine,Atomoxetine   0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA Tolerability, 1.84119678 NA NA Michelson 2001,NA,RCT,RR  44, 84  128 outcomes,reverse, 5.6670000000  0.236000000  1.362850e+02,NA NA NA,NA NA,NA,NA NA,100,100 100,100,100 100,100 low,low low,low,low Placebo   0  28.913438 11.037500 NA,NA,0 1,1.0 1.0,1.0 1.0,1 1 0,1 1,1 1,1.0,1 1 1 1 1527 Michelson_2001,< 2 months NA 6-12 yo,8.65154639175258,12.2493548387097,NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100,100 High Atomoxetine Atomoxetine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),NA 4:ADHD-SRS Total  1.84119678,NA,NA Michelson,2001 NA RCT G  84  83  167,outcomes reverse -0.4350000000,-0.781000000,-8.900000e-02 NA NA,NA NA NA NA 10.9000000,10.9000000 100 100 100,100,100 100,100 low,low,low,low low,Placebo   0  28.580000 11.201796 NA,NA,0 1,1.0 1.0 1.0,1.0,1 1 0,1 1,1,1 1.0 1,1 1,1,1528,Michelson_2001,< 2 months NA 6-12 yo 8.65157894736842 12.2493333333333,NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100 100,High Atomoxetine,Atomoxetine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) NA,13:CPRS-R:S, 1.84119678 NA,NA,Michelson,2001,NA RCT G  84  83, 167,outcomes reverse -0.7340000000,-1.068000000 -4.000000e-01,NA NA,NA NA,NA NA  8.5000000  8.5000000 100 100,100,100,100 100,100,low,low low low,low,Placebo   0  28.580000 11.201796,NA NA 0 1 1.0,1.0 1.0,1.0 1 1 0,1,1,1,1 1.0 1,1,1,1,1529,Michelson_2001 < 2 months,NA,6-12 yo 9.26,11.2017964071856 NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100 100 High,Atomoxetine,Atomoxetine,  0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability  1.84119678,NA,NA,Michelson 2001,NA,RCT,RR, 84, 84, 168,outcomes,reverse  1.2500000000, 0.623000000, 2.508000e+00 NA,NA,NA NA NA NA NA,NA,100,100 100,100,100,100 100 low,low low,low,low,Placebo,  0, 28.580000 11.200000,NA,NA 0,1,1.0 1.0,1.0 1.0 1 1,0 1,1 1 1 1.0,1,1 1,1,1530,Michelson_2001 < 2 months,NA 6-12 yo 8.65154639175258,12.2493548387097,NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100,High,Atomoxetine,Atomoxetine   0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 1.84119678,NA NA Michelson,2001 NA,RCT,RR  84  84, 168 outcomes,reverse, 5.0000000000  0.244000000  1.026040e+02,NA NA,NA NA,NA,NA,NA NA,100,100,100,100 100,100 100,low low low,low,low Placebo   0  28.580000 11.200000,NA NA,0 1 1.0,1.0 1.0 1.0 1,1,0 1 1,1,1,1.0,1,1,1,1,1531 Michelson_2001 < 2 months NA 6-12 yo,8.65154639175258,12.2493548387097,NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0,100,100,High Atomoxetine Atomoxetine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total  0.92059839,NA NA Michelson,2002 NA,RCT,G  84  83, 167,outcomes reverse -0.6260000000,-0.938000000 -3.140000e-01, 11.1814847  11.2058333,NA NA NA NA,NA,NA 100,100,100,100,100,100 100,low,low,low,low,low Placebo   0  29.400000,10.298802,NA,NA,0 1 1.0 1.0 1.0,1.0,1,1,0,1,1,1 1,1.0 1 1 1 1,1532 Michelson_2002 < 2 months,NA,6-12 yo 8.65157894736842 12.2493333333333 NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100,100 High Atomoxetine Atomoxetine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,6:ADHD-SRS-Hyp-Imp, 2.76179517 NA NA,Montoya,2009,NA RCT G, 99, 50  149 outcomes,reverse -0.6730000000 -1.023000000 -3.230000e-01  12.7000000, 12.3000000,NA NA,NA NA NA,NA,100,100 100,100 100,100 100 low low low low,low Placebo,  0, 20.530201,10.300000 NA NA 0,1,1.0,1.0,1.0 1.0,1 1,0,1,1 1 1,1.0,1,1,1 1,1533,Montoya_2009,2-6 months,NA 6-12 yo,8.65157894736842,12.2493333333333 NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Atomoxetine Atomoxetine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) NA,NA, 2.76179517 NA NA Montoya 2009 NA RCT G, 99, 50  149 outcomes,reverse,-0.7560000000 -1.108000000 -4.040000e-01   8.5000000   7.0000000 NA,NA NA NA NA NA 100,100 100 100 100 100,100,low low low low low,Placebo,  0, 20.530201,10.300000,NA,NA 0,1 1.0 1.0,1.0 1.0 1,1 0,1,1 1 1,1.0 1,1 1,1,1534,Montoya_2009 2-6 months NA 6-12 yo 9.26 11.2017964071856,NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100 100 High,Atomoxetine Atomoxetine,  0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability, 2.76179517 NA NA Montoya 2009,NA RCT,RR,100  51  151 outcomes,reverse  1.0200000000, 0.266000000, 3.912000e+00,NA,NA NA NA NA NA,NA NA 100 100,100 100,100 100,100,low low low low low,Placebo   0, 20.527152,10.300000 NA NA,0 1 1.0 1.0 1.0 1.0 1 1 0,1,1 1,1,1.0 1 1 1,1 1535 Montoya_2009,2-6 months NA,6-12 yo 8.65154639175258 12.2493548387097 NA NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0 100 100,High,Atomoxetine,Atomoxetine,  0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability  2.76179517,NA NA Montoya,2009,NA,RCT,RR,100, 51, 151,outcomes reverse, 0.5150000000  0.010000000, 2.557800e+01,NA,NA,NA NA,NA,NA,NA NA 100,100 100,100,100 100,100,low low low,low,low Placebo   0, 20.527152,10.300000 NA,NA,0 1 1.0,1.0,1.0,1.0,1 1 0 1,1 1 1 1.0 1,1,1,1,1536 Montoya_2009,2-6 months NA,6-12 yo 8.65154639175258 12.2493548387097,NA NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100 100 High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability  0.92059839 NA,NA NCT01069523,NA,NA RCT RR  16  13,  29 outcomes,reverse  1.4220000000  0.530000000  3.814000e+00 NA,NA NA NA,NA NA,NA,NA 100,100 100 100 100 100,100 low some low low,low Placebo,  0  44.896552, 8.239310 NA NA 0 1 1.0,1.0,1.0,1.0,1 1,0 1,1,1 1,1.0,1,1,1 1,1537 NCT01069523_NA,< 2 months NA,6-12 yo,8.23931034482759,12.6640449438202,NA NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0 100 100 High Amphetamine Amphetamine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA 4:ADHD-SRS Total  1.38089758,NA,NA NCT01552902 NA NA RCT G,175, 93, 268 outcomes reverse -0.8860000000,-1.330000000,-4.420000e-01,NA,NA NA NA NA,NA, 9.9329603  9.9329603,100 100,100 100 100,100 100 some,some low,some,low,Placebo   0  35.570896,14.634701 NA,NA,0 1,1.0 1.0 1.0,1.0 1 1 0,1,1,1,1 1.0,1,1,1 1 1538,NCT01552902_NA,< 2 months,NA,13-19 yo 9.04758620689655,14.6347014925373,NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100,High Amphetamine Amphetamine   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA Acceptability, 1.38089758,NA NA NCT01552902,NA NA,RCT,RR,218,110, 328,outcomes,reverse  1.4360000000, 0.797000000  2.588000e+00 NA,NA NA NA NA,NA NA,NA 100,100,100 100,100,100 100,some some,low,some low,Placebo   0  35.652439,14.633537 NA,NA 0 1,1.0,1.0,1.0,1.0,1,1,0,1 1,1,1,1.0,1 1 1 1,1539,NCT01552902_NA,< 2 months NA,13-19 yo,8.22105263157895 14.6335365853659,NA,NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100,100 High,Amphetamine,Amphetamine,  0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability  1.38089758,NA,NA NCT01552902,NA,NA,RCT,RR,218,110, 328 outcomes reverse  7.5690000000  1.013000000  5.655700e+01 NA NA NA,NA,NA NA NA NA,100,100 100,100,100,100 100,some some,low,some low Placebo,  0, 35.652439,14.633537,NA,NA 0,1 1.0 1.0,1.0,1.0 1,1,0 1 1 1 1 1.0 1 1,1,1 1540 NCT01552902_NA,< 2 months NA,13-19 yo,8.22105263157895 14.6335365853659 NA,NA  43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100,100,High Methylphenidate,Methylphenidate,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA 4:ADHD-SRS Total  1.38089758,NA,NA,NCT01552902 NA NA RCT,G 181  93  274 outcomes,reverse,-0.5430000000,-0.963000000 -1.240000e-01 NA,NA,NA NA NA NA, 9.9329603  9.9329603,100 100,100 100 100 100,100,some some,low some low,Placebo   0, 31.660584,14.700000 NA,NA 0 1,1.0,1.0 1.0 1.0,1,1 0 1 1 1 1,1.0,1,1,1 1 1541 NCT01552902_NA,< 2 months NA 13-19 yo 9.745,14.7 NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100,100,High Methylphenidate Methylphenidate   0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability  1.38089758,NA,NA,NCT01552902 NA NA RCT,RR 219 110, 329 outcomes reverse  1.2750000000, 0.700000000, 2.322000e+00,NA NA,NA,NA,NA NA NA,NA,100 100,100 100,100,100,100,some,some low,some,low,Placebo,  0, 31.665653,14.700000,NA,NA 0,1 1.0 1.0,1.0,1.0,1,1 0,1,1,1 1 1.0 1,1 1,1 1542,NCT01552902_NA < 2 months,NA 13-19 yo,7.9578947368421,14.7 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100,High Methylphenidate,Methylphenidate   0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability, 1.38089758 NA,NA NCT01552902 NA NA,RCT RR,219,110  329 outcomes,reverse  7.0320000000  0.937000000  5.278600e+01,NA NA NA NA NA,NA NA,NA,100 100,100,100,100,100 100 some,some,low,some low Placebo   0  31.665653 14.700000,NA NA,0,1,1.0,1.0 1.0,1.0 1 1 0 1 1,1 1,1.0,1,1,1 1 1543,NCT01552902_NA < 2 months NA,13-19 yo 7.9578947368421 14.7,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0,100 100,High Atomoxetine,Atomoxetine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA 1:ADHD-RS Total  1.38089758,   1.4500000 mg/kg/d Newcorn 2008 NA,RCT G,222, 74  296 outcomes reverse -0.5020000000,-0.802000000 -2.020000e-01 NA NA,NA NA,NA,NA 11.5000000,11.5000000,100 100 100 100,100 100,100 low,low low,low low,Placebo,  0  23.000000 10.250000 NA,NA,0,1 1.0 1.0,1.0,1.0,1 1,0,1 1 1 1,1.0,1,1,1,1,1544,Newcorn_2008,< 2 months NA,6-12 yo 8.65157894736842 12.2493333333333,NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0 100,100 High Atomoxetine,Atomoxetine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) NA 13:CPRS-R:S  1.38089758    1.4500000 mg/kg/d,Newcorn 2008 NA,RCT G,208, 66  274,outcomes reverse -0.5740000000,-0.865000000 -2.830000e-01,NA,NA NA,NA NA NA, 8.4000000, 8.4000000,100,100 100,100 100 100,100,low low,low,low low Placebo   0, 22.963504,10.251825 NA,NA 0 1,1.0 1.0,1.0,1.0 1,1,0 1 1,1,1 1.0 1 1,1 1,1545 Newcorn_2008,< 2 months,NA,6-12 yo,9.26,11.2017964071856 NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100,100,High Atomoxetine,Atomoxetine   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability, 1.38089758,   1.4500000 mg/kg/d,Newcorn,2008 NA,RCT RR,222  74  296 outcomes reverse, 0.7060000000, 0.422000000, 1.179000e+00 NA,NA,NA NA,NA,NA NA,NA,100 100 100,100 100,100 100,low low,low low,low Placebo   0  23.000000,10.250000 NA NA 0,1 1.0,1.0,1.0 1.0 1,1,0 1 1,1 1 1.0,1 1,1 1 1546 Newcorn_2008,< 2 months NA,6-12 yo,8.65154639175258 12.2493548387097 NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100,High,Atomoxetine,Atomoxetine,  0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability  1.38089758,   1.4500000,mg/kg/d Newcorn 2008 NA RCT RR 222, 74, 296,outcomes reverse  0.8330000000, 0.165000000  4.205000e+00 NA NA NA,NA,NA NA,NA NA 100,100 100 100 100 100,100 low low,low low,low Placebo,  0, 23.000000,10.250000 NA,NA 0 1 1.0 1.0,1.0,1.0,1,1,0 1 1,1 1,1.0 1,1,1 1,1547 Newcorn_2008,< 2 months NA,6-12 yo 8.65154639175258,12.2493548387097,NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0,100 100 High,Methylphenidate,Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA 1:ADHD-RS Total  1.38089758   39.9000000,mg/kg/d,Newcorn,2008,NA,RCT G 220, 74  294,outcomes reverse,-0.6570000000 -0.963000000 -3.510000e-01,NA,NA NA,NA NA,NA 11.5000000 11.5000000,100 100,100 100,100,100 100 low,low low low,low Placebo   0  28.244898 10.174830,NA NA 0,1,1.0,1.0,1.0,1.0 1 1 0,1,1 1 1 1.0 1 1 1 1 1548,Newcorn_2008,< 2 months,NA,6-12 yo 9.745 14.7,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100,100 High,Methylphenidate,Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks) NA,13:CPRS-R:S  1.38089758   39.9000000 mg/kg/d,Newcorn 2008,NA RCT,G 195  66, 261 outcomes reverse -0.8460000000 -1.149000000 -5.430000e-01 NA,NA,NA,NA,NA NA, 8.4000000  8.4000000 100,100,100,100,100 100,100 low low low low low,Placebo   0  28.241379 10.174713,NA,NA 0 1 1.0,1.0 1.0,1.0 1 1 0,1 1,1,1 1.0,1 1,1 1,1549,Newcorn_2008,< 2 months,NA 6-12 yo,8.60731707317073 10.9714285714286 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100,High Methylphenidate Methylphenidate,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability  1.38089758   39.9000000,mg/kg/d Newcorn,2008 NA RCT,RR 220  74, 294,outcomes,reverse, 0.7910000000, 0.479000000  1.308000e+00,NA,NA NA,NA NA NA NA,NA 100,100,100,100 100 100,100 low,low,low,low low Placebo   0, 28.244898,10.174830 NA NA 0,1 1.0 1.0 1.0,1.0 1,1,0 1,1,1 1 1.0 1 1 1,1,1550 Newcorn_2008 < 2 months NA,6-12 yo,7.9578947368421,14.7,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100,High Methylphenidate,Methylphenidate,  0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability, 1.38089758   39.9000000,mg/kg/d,Newcorn 2008,NA RCT,RR,220  74, 294 outcomes reverse  0.8410000000, 0.167000000, 4.243000e+00,NA,NA,NA NA NA NA NA,NA,100 100,100 100,100,100 100 low low,low low,low Placebo   0  28.244898 10.174830,NA,NA,0,1,1.0 1.0 1.0,1.0,1 1 0 1,1,1 1,1.0 1 1,1 1 1551 Newcorn_2008 < 2 months NA 6-12 yo 7.9578947368421,14.7,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100,100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total, 1.84119678    2.9000000 mg/d Newcorn 2013 NA RCT,G 104 110  214,outcomes,reverse,-0.6730000000,-1.030000000,-3.160000e-01 NA,NA NA,NA NA,NA,12.9300000 12.9300000,  0   0 100   0   0 100,  0,some,high,high,high low,Placebo   0, 28.279439  8.997196,NA NA,0 1,1.0 1.0,1.0,1.0,1 1 0 1 1,1,1 1.0,1 1 1 1,1552,Newcorn_2013,< 2 months,NA,6-12 yo,8.99719626168224,14.5496794871795,NA NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0 100 100,High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability  1.84119678,   2.9000000 mg/d,Newcorn,2013,NA,RCT RR 113 113  226 outcomes reverse, 0.9190000000, 0.625000000  1.351000e+00 NA NA NA NA NA,NA,NA NA,  0   0,100,  0   0,100,  0,some high high high low,Placebo   0, 28.400000  9.000000 NA NA 0,1,1.0 1.0 1.0 1.0,1,1 0,1 1,1 1,1.0 1,1,1,1,1553 Newcorn_2013,< 2 months NA,6-12 yo 8.23931034482759 12.6640449438202,NA NA, 20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability, 1.84119678,   2.9000000 mg/d,Newcorn 2013 NA,RCT RR 113,113, 226 outcomes reverse, 8.0000000000, 1.017000000  6.292100e+01,NA NA NA NA,NA NA NA NA,  0,  0 100,  0,  0,100   0 some,high high high low Placebo   0  28.400000  9.000000 NA NA 0,1,1.0 1.0,1.0 1.0 1 1,0,1,1 1,1,1.0 1,1 1 1 1554 Newcorn_2013 < 2 months NA,6-12 yo 9 12.6640449438202,NA,NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total, 1.84119678    3.0000000 mg/d Newcorn,2013 NA RCT G,111,110, 221 outcomes reverse -0.6860000000 -1.037000000,-3.350000e-01 NA,NA NA,NA,NA,NA,12.9300000 12.9300000,  0,  0 100   0   0 100   0 some,high high,high,low Placebo   0  27.866968, 9.100905,NA,NA 0 1,1.0 1.0 1.0,1.0 1,1,0 1 1,1 1,1.0 1,1,1,1,1555,Newcorn_2013 < 2 months,NA,6-12 yo,8.99719626168224 14.5496794871795 NA,NA  20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,high
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100,High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability  1.84119678    3.0000000 mg/d,Newcorn 2013,NA,RCT,RR,114 113  227 outcomes,reverse, 0.6970000000  0.454000000  1.069000e+00 NA NA,NA NA,NA,NA,NA NA,  0,  0,100,  0,  0 100   0,some,high high,high low,Placebo   0, 27.866520  9.100881,NA,NA 0 1,1.0,1.0 1.0,1.0,1,1 0,1,1 1 1,1.0 1 1 1,1 1556,Newcorn_2013 < 2 months,NA,6-12 yo,8.23931034482759,12.6640449438202 NA,NA, 20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2,NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,high
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,Tolerability, 1.84119678,   3.0000000,mg/d,Newcorn,2013,NA RCT,RR,114 113  227 outcomes reverse, 7.9300000000, 1.008000000  6.237400e+01 NA,NA,NA,NA,NA,NA NA,NA   0   0,100,  0,  0 100   0 some,high,high,high,low Placebo,  0, 27.866520, 9.100881 NA,NA,0,1 1.0 1.0 1.0 1.0,1,1 0 1 1 1,1,1.0 1 1 1 1 1557 Newcorn_2013 < 2 months,NA,6-12 yo 9,12.6640449438202,NA,NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2,NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100,100,High,Methylphenidate Methylphenidate   0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,Acceptability  3.68239356   30.2000000,mgTDS,Palumbo 2008,NA,RCT RR  29, 30,  59,outcomes reverse  0.5690000000  0.335000000  9.670000e-01 NA NA,NA NA NA,NA NA,NA 100,100 100,100   0,100,100 low,some high some low,Placebo   0  20.301695, 9.196610,NA NA 0 1,1.0 1.0 1.0,1.0,1,1 0 1 1,1 1,1.0,1,1 1 1 1558 Palumbo_2008 2-6 months,NA 6-12 yo 7.9578947368421 14.7 NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100 100,High Methylphenidate,Methylphenidate   0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA,Tolerability  3.68239356,  30.2000000,mgTDS,Palumbo,2008 NA,RCT,RR  29  30   59,outcomes reverse, 3.1000000000  0.131000000, 7.314200e+01 NA NA NA NA NA NA,NA,NA 100 100 100,100   0,100 100 low,some high,some low,Placebo,  0, 20.301695, 9.196610,NA,NA,0,1 1.0,1.0,1.0 1.0 1,1 0,1,1,1 1,1.0,1 1,1,1 1559,Palumbo_2008 2-6 months,NA 6-12 yo 7.9578947368421,14.7 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100,High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability, 3.68239356    0.2400000 mgTDS,Palumbo 2008,NA RCT,RR, 31  30   61 outcomes reverse, 0.2420000000, 0.104000000  5.610000e-01,NA NA,NA NA NA,NA,NA,NA 100,100,100,100   0 100,100 low,some high some,low,Placebo,  0, 18.014754  9.203279,NA NA 0 1,1.0,1.0 1.0 1.0,1 1,0 1 1 1,1,1.0,1 1 1 1 1560 Palumbo_2008,2-6 months,NA 6-12 yo,8.23931034482759 12.6640449438202 NA NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100 100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA,Tolerability, 3.68239356    0.2400000,mgTDS,Palumbo,2008 NA RCT,RR  31  30,  61 outcomes reverse, 2.9060000000, 0.123000000  6.865700e+01 NA NA,NA,NA,NA NA,NA,NA 100,100,100 100,  0,100,100,low,some,high,some low,Placebo   0  18.014754  9.203279,NA,NA 0 1,1.0,1.0 1.0 1.0 1 1 0 1 1,1 1,1.0 1,1 1 1 1561 Palumbo_2008 2-6 months,NA 6-12 yo 9,12.6640449438202 NA NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0,100 100,High Methylphenidate,Methylphenidate   0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability  0.69044879,  25.2000000,mg/d,Plizka 2000 NA RCT RR, 20, 18   38 outcomes reverse, 0.4500000000, 0.044000000  4.554000e+00 NA,NA NA,NA NA NA NA,NA 100 100,100 100,100,100,100 low,low,low low low Placebo,  0  15.500000  7.957895,NA,NA 0,1,1.0 1.0 1.0 1.0,1 1 0,1 1,1,1,1.0 1 1,1,1 1562 Plizka_2000 < 2 months NA,6-12 yo 7.9578947368421 14.7 NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100 High,Methylphenidate,Methylphenidate,  0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability, 0.69044879,  25.2000000 mg/d Plizka,2000 NA,RCT,RR, 20  18   38 outcomes,reverse, 2.7140000000, 0.117000000, 6.270200e+01,NA NA,NA,NA NA,NA,NA,NA 100,100,100,100,100 100 100 low low low low low,Placebo   0  15.500000  7.957895,NA,NA,0 1 1.0,1.0 1.0 1.0,1 1,0,1 1,1,1,1.0 1,1,1 1,1563,Plizka_2000,< 2 months,NA,6-12 yo,7.9578947368421,14.7 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Amphetamine,Amphetamine   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability  0.69044879,  12.5000000 mg/d Plizka,2000 NA RCT,RR  20  18   38 outcomes,reverse  0.9000000000  0.141000000, 5.745000e+00 NA NA NA NA,NA,NA NA,NA,100,100 100,100,100,100,100 low,low low,low,low Placebo,  0, 15.500000  8.221053 NA NA 0 1,1.0,1.0 1.0 1.0,1,1,0 1,1 1,1 1.0 1 1 1,1 1564 Plizka_2000,< 2 months NA,6-12 yo,8.22105263157895,14.6335365853659 NA NA  43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA,Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100 100,High Amphetamine Amphetamine,  0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 0.69044879,  12.5000000,mg/d Plizka 2000 NA,RCT,RR, 20  18,  38,outcomes,reverse, 4.5240000000  0.232000000, 8.837800e+01 NA,NA,NA NA,NA,NA NA NA,100,100 100,100,100 100 100 low low low low,low Placebo,  0, 15.500000  8.221053 NA,NA 0 1,1.0,1.0,1.0 1.0 1,1,0 1,1,1 1 1.0 1 1 1,1,1565 Plizka_2000,< 2 months,NA,6-12 yo,8.22105263157895,14.6335365853659 NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0 100 100 High Modafinil,Modafinil,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 1.38089758  264.0000000,mg/d,Rugino,2003 NA RCT RR, 13, 11,  24,outcomes reverse  4.2860000000  0.227000000  8.081200e+01,NA NA,NA,NA,NA,NA NA,NA,100 100 100,100,100,100 100 low,some,low,some,some,Placebo,  0, 36.400000, 7.875000,NA,NA 0,1,1.0 1.0,1.0,1.0 1,1 0 1,1 1 1,1.0,1 1 1 1 1566 Rugino_2003,< 2 months NA 6-12 yo,7.875 10.2983870967742 NA,NA   8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA NA Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100 High,Modafinil Modafinil   0,NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability, 1.38089758, 264.0000000,mg/d Rugino,2003,NA,RCT,RR  13, 11,  24 outcomes reverse  2.5710000000  0.115000000  5.744400e+01,NA NA NA NA,NA,NA NA,NA 100,100 100,100 100,100 100 low some low,some,some Placebo   0, 36.400000  7.875000 NA NA,0 1,1.0,1.0 1.0 1.0,1 1,0 1,1 1 1 1.0 1 1,1,1,1567,Rugino_2003,< 2 months,NA 6-12 yo,7.875 10.2983870967742 NA NA,  8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8 NA,NA Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100 High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total  2.07134638,NA NA,Sallee,2009,NA RCT,G  57  63  120,outcomes reverse -0.4120000000,-0.775000000 -4.800000e-02, 12.7800000, 15.0200000,NA,NA,NA,NA NA,NA,100 100,100,100 100,100 100 some,low,low,low,low,Placebo,  0, 32.793255,10.087500 NA,NA 0,1 1.0,1.0,1.0,1.0,1 1 0 1 1 1,1,1.0 1 1 1 1,1568,Sallee_2009 2-6 months NA 6-12 yo 8.99719626168224,14.5496794871795 NA NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0,100 100,High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,Acceptability  2.07134638 NA,NA Sallee 2009 NA,RCT,RR, 62, 66, 128,outcomes,reverse  0.7240000000  0.435000000, 1.205000e+00,NA NA NA,NA,NA,NA NA NA 100,100,100 100,100 100 100,some,low,low,low low,Placebo   0  32.812500,10.073438 NA,NA,0,1,1.0 1.0 1.0 1.0 1 1 0 1 1,1,1 1.0,1 1 1,1,1569 Sallee_2009,2-6 months NA,6-12 yo,8.23931034482759,12.6640449438202,NA NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability  2.07134638,NA NA,Sallee,2009 NA,RCT,RR  62  66, 128 outcomes,reverse  0.4260000000, 0.086000000, 2.115000e+00 NA,NA NA NA NA NA NA,NA,100,100 100 100 100 100 100,some low low,low,low Placebo,  0  32.812500,10.073438,NA NA,0 1 1.0 1.0,1.0,1.0,1 1 0,1 1 1,1 1.0,1,1,1,1 1570,Sallee_2009,2-6 months NA 6-12 yo 9 12.6640449438202 NA NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100,100 High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA 1:ADHD-RS Total  2.07134638 NA,NA Sallee,2009,NA,RCT G, 63, 63, 126,outcomes reverse,-0.3550000000 -0.708000000,-2.000000e-03, 14.0800000  15.0200000,NA NA,NA,NA,NA,NA 100,100,100,100,100,100 100 some low,low,low low Placebo,  0, 30.524476,10.700000 NA,NA,0,1 1.0 1.0 1.0 1.0,1,1,0 1 1,1 1,1.0 1 1,1,1,1571 Sallee_2009 2-6 months NA 6-12 yo,8.99719626168224 14.5496794871795,NA NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100 High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability, 2.07134638,NA,NA Sallee,2009 NA RCT RR, 65  66, 131 outcomes,reverse, 0.7310000000, 0.444000000, 1.205000e+00 NA,NA NA NA NA NA,NA,NA,100 100 100 100 100 100,100 some,low low,low,low,Placebo,  0, 30.534351,10.700763,NA,NA,0 1 1.0,1.0 1.0,1.0,1,1 0,1 1 1 1 1.0 1,1,1 1 1572,Sallee_2009 2-6 months NA,6-12 yo,8.23931034482759,12.6640449438202 NA,NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2,NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100,100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 2.07134638,NA,NA Sallee 2009,NA RCT RR, 65  66  131,outcomes reverse  0.4060000000  0.082000000, 2.019000e+00 NA NA NA,NA NA,NA,NA,NA,100 100,100,100,100,100 100 some low,low,low,low,Placebo   0  30.534351,10.700763,NA NA,0 1,1.0,1.0 1.0,1.0,1 1,0 1 1,1,1,1.0,1 1,1,1,1573 Sallee_2009 2-6 months NA,6-12 yo 9 12.6640449438202,NA,NA  20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100,High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total, 2.07134638,NA,NA Sallee,2009 NA,RCT,G  60, 63, 123,outcomes,reverse,-0.5320000000,-0.893000000 -1.710000e-01, 12.4600000, 15.0200000,NA,NA,NA NA NA,NA 100,100,100,100,100 100 100 some low low low,low Placebo,  0  29.055091,10.946341,NA NA,0 1,1.0,1.0,1.0,1.0,1,1,0 1 1,1 1,1.0 1,1 1 1,1574,Sallee_2009,2-6 months NA,6-12 yo 8.99719626168224 14.5496794871795 NA NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2 NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100 High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability  2.07134638,NA NA Sallee 2009,NA,RCT,RR  65  66  131,outcomes,reverse, 1.0970000000  0.719000000, 1.673000e+00,NA NA NA,NA NA,NA,NA,NA,100 100 100 100 100 100,100 some low,low low low Placebo,  0, 29.007634,10.948855 NA,NA 0 1,1.0 1.0 1.0,1.0,1 1 0 1 1 1,1 1.0,1 1,1,1 1575 Sallee_2009 2-6 months,NA 6-12 yo,8.23931034482759 12.6640449438202 NA NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA Tolerability, 2.07134638,NA,NA Sallee 2009 NA RCT,RR, 65, 66  131 outcomes reverse, 1.2180000000, 0.391000000, 3.796000e+00 NA NA,NA,NA NA,NA NA NA 100,100 100,100,100,100 100 some,low low,low low,Placebo,  0, 29.007634,10.948855 NA,NA 0 1 1.0 1.0 1.0 1.0 1,1,0,1,1,1 1 1.0 1,1 1 1 1576,Sallee_2009,2-6 months NA 6-12 yo,9 12.6640449438202,NA,NA  20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100 100 High Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total, 2.07134638,NA NA Sallee 2009 NA,RCT,G  63  63, 126,outcomes reverse -0.5590000000,-0.916000000,-2.010000e-01, 11.0100000, 15.0200000,NA NA NA NA,NA,NA,100 100,100 100,100 100 100 some,low low low low,Placebo   0  25.139860,10.650000 NA,NA,0,1 1.0 1.0,1.0 1.0,1 1,0 1,1,1 1 1.0,1,1 1 1 1577,Sallee_2009,2-6 months NA,6-12 yo,8.99719626168224 14.5496794871795 NA,NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2,NA NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0 100,100,High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine)   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability  2.07134638,NA,NA,Sallee,2009 NA RCT,RR, 66, 66, 132,outcomes,reverse  1.0400000000  0.676000000  1.599000e+00,NA,NA,NA,NA,NA NA,NA NA 100 100,100 100 100,100,100 some low,low low low Placebo,  0  25.139860,10.650000,NA NA,0,1,1.0 1.0 1.0 1.0 1 1 0 1,1 1,1,1.0,1 1 1,1,1578,Sallee_2009 2-6 months,NA 6-12 yo 8.23931034482759,12.6640449438202,NA,NA, 20  7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA,NA Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100,High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability  2.07134638 NA,NA Sallee 2009,NA,RCT,RR, 66, 66  132,outcomes,reverse  1.8000000000  0.637000000, 5.086000e+00 NA,NA,NA,NA,NA,NA NA,NA 100 100,100 100,100,100 100 some,low,low low,low,Placebo   0, 25.139860,10.650000,NA,NA,0 1 1.0,1.0 1.0,1.0,1 1,0,1 1 1,1,1.0 1 1,1 1 1579 Sallee_2009 2-6 months,NA 6-12 yo,9 12.6640449438202,NA NA, 20, 7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100,High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine),  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA 24:Other, 1.84119678    1.0000000,mg/d Schahill 2001 NA,RCT G  17  17,  34,NA,reverse,-0.2260000000 -0.911000000  4.580000e-01,  6.7000000   5.3000000 NA NA,NA NA NA,NA,100,100,100 100 100 100,100 some some,some some some,Placebo   0 NA,10.600000 NA NA,0 1,1.0 1.0 1.0,1.0 1 1,0 1,1 1 1 1.0,1 1 1 1,1580 Schahill_2001,< 2 months NA,6-12 yo,10.6 10.6,NA NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100,100 High Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks),NA,5:ADHD-RS Total, 1.84119678,   1.0000000 mg/d Schahill 2001 NA RCT G, 17, 17   34,NA reverse,-0.6350000000,-1.335000000  6.500000e-02  13.6000000, 11.2000000,NA NA,NA NA NA NA,100,100,100 100,100,100,100,some some,some some,some,Placebo,  0,NA,10.600000,NA,NA 0 1,1.0 1.0 1.0,1.0,1,1 0,1 1,1,1,1.0 1 1 1 1 1581 Schahill_2001,< 2 months,NA,6-12 yo 10.6 10.6,NA NA, 20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA,NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0,100 100 High Methylphenidate,Methylphenidate   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability, 3.68239356 NA NA Schrantee 2016,NA RCT RR  25  25,  50,outcomes,reverse, 5.0000000000, 0.252000000, 9.916100e+01,NA NA,NA NA,NA,NA NA,NA,100 100,100,100,100,100,100 low,low,low,low,low Placebo,  0,  0.000000,11.350000 NA,NA 0,1 1.0 1.0 1.0,1.0 1,1,0 1,1,1 1,1.0 1,1 1 1 1582,Schrantee_2016 2-6 months NA 6-12 yo,7.9578947368421,14.7 NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100 100 High,Methylphenidate,Methylphenidate   0,NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,Tolerability  3.68239356,NA NA Schrantee,2016,NA RCT,RR, 25  25   50,outcomes reverse, 3.0000000000, 0.128000000, 7.029600e+01,NA NA NA NA,NA,NA,NA NA,100 100,100,100 100 100 100,low low,low low,low,Placebo,  0   0.000000 11.350000,NA NA 0,1 1.0 1.0 1.0 1.0 1,1,0,1,1,1 1,1.0 1,1,1,1,1583,Schrantee_2016 2-6 months,NA,6-12 yo 7.9578947368421,14.7 NA NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4   0   0,100,100 High,Alpha-2 agonists (guanfacine / clonidine) Alpha-2 agonists (guanfacine / clonidine),  0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability, 1.38089758,NA NA,Singer,1995,NA RCT,RR  37  37   74 outcomes,reverse, 0.1430000000, 0.008000000, 2.672000e+00,NA,NA NA NA,NA NA,NA,NA 100 100 100 100 100,100,100 some low low low some,Placebo,  0 NA,NA,NA NA 0 1,1.0 1.0,1.0,1.0,1,1,0 1,1 1,1,1.0,1,1,1 1 1584 Singer_1995 < 2 months NA,NA,8.23931034482759 12.6640449438202 NA NA, 20  7 Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 5,Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100 High Atomoxetine Atomoxetine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total  2.07134638,NA,NA Spencer,2002 NA RCT,G  63  60  123,outcomes,reverse,-0.5820000000,-0.944000000,-2.190000e-01  14.3000000  14.4000000,NA NA,NA NA,NA NA,100 100 100,100 100 100,100,low low some low,low Placebo,  0, 19.860976  9.878293 NA NA,0,1,1.0,1.0 1.0,1.0 1 1 0 1,1,1 1,1.0 1 1,1 1,1585,Spencer_2002 2-6 months NA 6-12 yo,8.65157894736842 12.2493333333333,NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100,100 High Atomoxetine Atomoxetine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks),NA,13:CPRS-R:S, 2.07134638,NA,NA Spencer,2002,NA,RCT,G, 61, 60  121 outcomes,reverse,-0.6710000000,-1.062000000 -2.790000e-01,NA,NA NA NA,NA NA, 9.6000000  9.6000000 100,100 100,100 100 100 100 low low,some,low,low,Placebo,  0, 19.853719  9.879421 NA NA,0 1 1.0 1.0 1.0,1.0,1 1,0,1,1 1,1,1.0,1 1 1,1,1586 Spencer_2002,2-6 months,NA 6-12 yo,9.26,11.2017964071856 NA NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0,100 100,High Atomoxetine,Atomoxetine,  0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 2.07134638,NA,NA Spencer 2002,NA RCT,RR  64  62  126 outcomes reverse  0.6270000000, 0.320000000  1.229000e+00 NA NA NA NA,NA NA NA,NA,100 100 100,100 100 100,100,low low some,low,low,Placebo   0  19.857143, 9.878889 NA,NA,0 1 1.0,1.0,1.0 1.0 1 1,0,1,1 1,1 1.0 1,1,1,1 1587 Spencer_2002,2-6 months NA 6-12 yo 8.65154639175258,12.2493548387097 NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100 High,Atomoxetine,Atomoxetine   0 NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,Tolerability  2.07134638,NA,NA Spencer,2002 NA,RCT,RR  64, 62, 126 outcomes,reverse, 1.9380000000, 0.180000000  2.082800e+01 NA NA,NA NA NA,NA NA,NA 100 100,100,100,100,100,100 low,low some low low,Placebo   0  19.857143  9.878889 NA NA,0 1 1.0,1.0,1.0 1.0,1,1,0 1 1,1,1,1.0 1 1,1 1,1588 Spencer_2002,2-6 months NA,6-12 yo,8.65154639175258,12.2493548387097 NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0 100,100,High Methylphenidate Methylphenidate   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total, 2.07134638 NA NA Spencer,2002,NA,RCT G, 17  60,  77,outcomes,reverse,-1.1810000000,-1.755000000 -6.070000e-01, 13.7000000, 14.4000000 NA NA,NA NA,NA,NA 100,100 100 100 100 100 100 low low,some,low,low Placebo   0  17.567532, 9.901429 NA,NA,0 1 1.0 1.0 1.0,1.0,1,1,0,1,1,1,1 1.0 1,1 1 1 1589,Spencer_2002,2-6 months NA,6-12 yo 9.745,14.7 NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0 100 100,High,Methylphenidate,Methylphenidate,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) NA,13:CPRS-R:S  2.07134638,NA,NA,Spencer 2002,NA,RCT G  17, 60,  77 outcomes,reverse,-0.8990000000,-1.549000000,-2.490000e-01,NA,NA,NA NA NA,NA  9.6000000, 9.6000000 100 100,100,100,100,100,100 low,low some low,low,Placebo,  0  17.567532  9.901429,NA,NA,0 1,1.0,1.0 1.0,1.0,1 1 0,1,1 1,1 1.0,1 1,1,1 1590,Spencer_2002 2-6 months NA,6-12 yo 8.60731707317073,10.9714285714286,NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0 100 100,High Methylphenidate Methylphenidate,  0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA Acceptability, 2.07134638,NA,NA Spencer,2002,NA RCT,RR, 18  62,  80 outcomes reverse, 0.2030000000  0.029000000  1.420000e+00,NA,NA NA,NA NA,NA,NA NA,100,100 100 100 100 100,100,low low,some low low Placebo   0  17.532500, 9.900500,NA,NA 0,1 1.0 1.0 1.0 1.0 1 1 0,1 1,1,1 1.0,1 1 1,1,1591 Spencer_2002,2-6 months,NA 6-12 yo,7.9578947368421,14.7,NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100,High Methylphenidate Methylphenidate,  0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability  2.07134638 NA,NA,Spencer 2002 NA RCT,RR, 18, 62,  80,outcomes reverse, 1.1050000000  0.047000000  2.603200e+01 NA NA,NA,NA,NA NA NA,NA 100 100 100 100 100 100,100,low low some low low Placebo   0, 17.532500  9.900500,NA NA 0 1,1.0,1.0 1.0,1.0,1,1 0,1,1,1,1 1.0,1,1 1,1,1592 Spencer_2002 2-6 months,NA 6-12 yo,7.9578947368421,14.7,NA,NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100,High Atomoxetine Atomoxetine   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA 4:ADHD-SRS Total  2.07134638 NA NA Spencer 2002 NA RCT G, 64  60  124 outcomes,reverse,-0.4180000000 -0.775000000 -6.100000e-02  14.6000000, 14.4000000,NA,NA NA,NA NA,NA 100,100,100,100,100 100 100 low low some low,low,Placebo   0, 23.683871  9.759032,NA,NA 0 1 1.0 1.0,1.0 1.0,1 1,0,1 1 1,1,1.0 1 1 1 1,1593,Spencer_2002 2-6 months,NA,6-12 yo 8.65157894736842 12.2493333333333 NA,NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100 High Atomoxetine Atomoxetine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),NA,13:CPRS-R:S, 2.07134638,NA NA,Spencer,2002,NA RCT,G, 64, 60  124,outcomes,reverse, 2.4480000000, 1.979000000, 2.916000e+00,  9.8000000,  9.6000000 NA NA,NA,NA,NA,NA 100 100,100 100 100,100 100,low low some low,low,Placebo,  0  23.683871  9.759032 NA,NA 0,1,1.0,1.0 1.0 1.0,1,1,0 1,1 1,1,1.0,1,1 1 1 1594 Spencer_2002 2-6 months NA,6-12 yo 9.26 11.2017964071856 NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100,High,Atomoxetine Atomoxetine,  0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability  2.07134638 NA NA Spencer,2002,NA,RCT,RR, 65  62  127 outcomes,reverse  0.8980000000  0.499000000  1.615000e+00,NA,NA,NA NA,NA,NA,NA,NA,100 100,100 100 100 100,100 low,low,some low,low Placebo   0  23.648031  9.760630,NA,NA,0,1,1.0 1.0,1.0,1.0,1,1,0 1 1,1 1,1.0,1 1,1 1,1595 Spencer_2002,2-6 months NA,6-12 yo 8.65154639175258 12.2493548387097 NA,NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100 100 High,Atomoxetine Atomoxetine,  0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA Tolerability, 2.07134638 NA,NA,Spencer 2002 NA,RCT,RR  65, 62  127 outcomes,reverse, 3.8150000000, 0.438000000, 3.320000e+01,NA,NA,NA,NA NA NA NA NA 100 100,100,100 100,100,100 low low,some low,low Placebo,  0  23.648031  9.760630 NA NA,0 1 1.0 1.0 1.0 1.0,1,1 0 1 1 1 1,1.0 1 1,1 1,1596,Spencer_2002,2-6 months,NA,6-12 yo 8.65154639175258,12.2493548387097 NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757,Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100 High Methylphenidate Methylphenidate,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total, 2.07134638,NA,NA Spencer,2002 NA RCT G  20  60,  80 outcomes reverse,-0.7260000000 -1.248000000,-2.040000e-01  13.5000000  14.4000000 NA,NA NA,NA NA NA,100,100 100 100 100 100,100,low low some low,low Placebo   0  15.800000  9.745000,NA,NA 0,1 1.0 1.0 1.0 1.0 1,1,0,1 1 1,1 1.0,1 1 1,1,1597,Spencer_2002 2-6 months,NA,6-12 yo,9.745 14.7,NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100 High Methylphenidate,Methylphenidate   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA Acceptability, 2.07134638,NA,NA,Spencer 2002 NA,RCT,RR, 20  62,  82,outcomes,reverse  1.6410000000  0.873000000  3.086000e+00 NA,NA,NA NA NA,NA NA NA 100 100 100 100,100,100 100,low,low,some,low low Placebo   0  15.887805, 9.750000,NA,NA,0,1,1.0,1.0,1.0,1.0,1,1 0,1 1,1 1 1.0 1 1,1,1 1598 Spencer_2002 2-6 months,NA 6-12 yo 7.9578947368421,14.7 NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0 100,100,High,Methylphenidate Methylphenidate   0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability  2.07134638 NA NA Spencer 2002,NA,RCT RR  20, 62   82,outcomes reverse  6.2000000000  0.593000000  6.481200e+01 NA,NA,NA,NA NA NA NA,NA 100 100,100,100,100 100,100,low low,some low,low Placebo,  0, 15.887805, 9.750000,NA NA 0 1 1.0,1.0 1.0,1.0,1 1,0,1,1,1 1,1.0,1 1 1 1 1599 Spencer_2002 2-6 months NA,6-12 yo 7.9578947368421,14.7,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100 100 High Amphetamine,Amphetamine,  0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total  0.92059839 NA,NA Spencer 2006b NA,RCT,G, 54  52  106 outcomes reverse,-0.4490000000,-0.836000000 -6.100000e-02, 11.8000000  13.4000000,NA,NA,NA,NA NA,NA 100,100,100 100,100 100,100,some,low,low low low,Placebo,  0  35.858491 14.449057 NA,NA,0,1 1.0,1.0,1.0,1.0 1,1 0 1 1 1,1 1.0,1,1,1,1,1600 Spencer_2006b < 2 months NA,13-19 yo,9.04758620689655,14.6347014925373,NA,NA, 43 14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100,High,Amphetamine Amphetamine   0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA Acceptability  0.92059839,NA,NA Spencer 2006b NA,RCT,RR, 56, 54  110 outcomes reverse  1.6880000000  0.524000000, 5.438000e+00,NA,NA,NA,NA NA,NA NA,NA 100,100 100 100 100,100,100,some,low low low,low Placebo   0, 35.856364 14.449091,NA,NA,0 1 1.0,1.0 1.0,1.0 1 1 0 1,1 1 1 1.0,1 1 1 1 1601,Spencer_2006b,< 2 months,NA 13-19 yo,8.22105263157895,14.6335365853659,NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA,NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100 High Amphetamine,Amphetamine,  0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 0.92059839 NA,NA Spencer,2006b NA RCT RR  56, 54, 110,outcomes,reverse  2.8950000000, 0.120000000, 6.954600e+01,NA,NA,NA NA NA NA NA,NA,100 100 100,100,100,100,100 some low low low,low,Placebo   0, 35.856364,14.449091,NA,NA,0,1 1.0,1.0,1.0 1.0 1,1 0,1 1,1 1,1.0,1 1,1 1,1602,Spencer_2006b < 2 months,NA 13-19 yo,8.22105263157895,14.6335365853659 NA NA  43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9 Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA,Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0 100 100,High Amphetamine Amphetamine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total, 0.92059839,NA,NA,Spencer 2006b,NA,RCT G, 53  52  105 outcomes reverse -1.0310000000 -1.441000000,-6.220000e-01, 10.3000000  13.4000000,NA,NA NA,NA,NA NA 100,100 100 100 100,100,100 some low low,low,low Placebo,  0  31.438095,14.348571,NA,NA,0 1 1.0,1.0 1.0 1.0 1 1,0 1 1 1,1 1.0 1,1 1,1,1603,Spencer_2006b,< 2 months NA 13-19 yo,9.04758620689655 14.6347014925373 NA,NA, 43,14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests), 9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA NA,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100,High,Amphetamine Amphetamine,  0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability  0.92059839,NA,NA,Spencer 2006b,NA RCT,RR, 56  54  110 outcomes reverse, 1.2050000000  0.342000000  4.252000e+00,NA,NA,NA,NA NA,NA,NA,NA,100 100 100,100,100 100 100 some,low,low low,low Placebo,  0  31.427273,14.347273,NA,NA,0,1 1.0,1.0,1.0 1.0 1 1 0 1 1 1 1 1.0,1,1 1 1 1604,Spencer_2006b < 2 months,NA 13-19 yo,8.22105263157895 14.6335365853659,NA NA, 43 14 Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA,NA Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0,100,100 High Amphetamine,Amphetamine   0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 0.92059839,NA,NA Spencer 2006b NA RCT RR, 56  54  110,outcomes,reverse, 2.8950000000, 0.120000000  6.954600e+01 NA NA,NA,NA,NA NA NA,NA 100 100 100 100 100 100,100 some,low low low,low Placebo   0, 31.427273 14.347273,NA,NA 0 1 1.0 1.0 1.0 1.0,1,1 0 1 1 1 1,1.0,1,1 1,1 1605,Spencer_2006b < 2 months,NA 13-19 yo 8.22105263157895,14.6335365853659,NA NA, 43,14,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests)  9,Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100 100,High Atomoxetine,Atomoxetine,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,1:ADHD-RS Total, 2.30149597,NA,mg/kg/d,Svanborg,2009,NA RCT,G  49, 50   99,outcomes,reverse,-1.1960000000,-1.740000000 -6.530000e-01 NA,NA,NA NA,NA,NA 10.6066017,10.6066017,100,100,100 100,100 100,100,some some,low some low Placebo   0, 59.989899,11.448485,NA,NA,0 1,1.0 1.0,1.0 1.0 1 1 0 1 1,1,1,1.0 1,1,1 1,1606,Svanborg_2009 2-6 months,NA 6-12 yo,8.65157894736842 12.2493333333333,NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100,High,Atomoxetine,Atomoxetine   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability, 2.30149597 NA mg/kg/d Svanborg,2009 NA,RCT RR  49, 50   99 outcomes,reverse, 1.0200000000, 0.021000000  5.041400e+01,NA NA NA,NA,NA,NA,NA NA 100,100,100 100,100,100,100,some,some low,some,low,Placebo,  0, 59.989899,11.448485 NA NA 0 1,1.0,1.0 1.0,1.0,1 1,0 1 1,1 1,1.0 1 1 1 1,1607,Svanborg_2009,2-6 months,NA 6-12 yo 8.65154639175258 12.2493548387097,NA,NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Atomoxetine Atomoxetine,  0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability, 2.30149597,NA mg/kg/d Svanborg 2009 NA,RCT RR, 49, 50,  99 outcomes,reverse  1.0200000000, 0.021000000, 5.041400e+01 NA,NA,NA,NA NA NA NA,NA,100 100 100,100 100 100,100,some,some low some low Placebo,  0  59.989899 11.448485,NA NA,0 1 1.0,1.0,1.0 1.0 1 1 0 1 1 1 1 1.0 1,1,1 1 1608 Svanborg_2009 2-6 months NA 6-12 yo,8.65154639175258 12.2493548387097 NA NA  44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0 100,100,High,Modafinil Modafinil,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA 6:ADHD-SRS-Hyp-Imp  1.61104718 NA,NA Swanson,2006 NA,RCT,G,120, 63  183 outcomes,reverse -0.4150000000,-0.724000000 -1.070000e-01  13.8000000  14.8000000 NA NA NA NA,NA NA,100 100 100 100   0,100,100,some,some,high some,some Placebo,  0  24.967213  9.962295 NA NA 0 1 1.0 1.0,1.0,1.0,1,1,0 1,1,1 1 1.0 1 1,1,1 1609,Swanson_2006 < 2 months NA 6-12 yo 8.85049504950495 10.3004098360656 NA NA,  8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100 100 High Modafinil Modafinil   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) NA NA  1.61104718,NA,NA Swanson,2006,NA,RCT G 120  63, 183,outcomes reverse,-0.6620000000,-0.975000000 -3.490000e-01   7.4000000  12.2000000 NA,NA NA,NA NA,NA 100,100,100 100   0,100,100,some some,high some some,Placebo,  0  24.967213  9.962295,NA,NA,0,1,1.0,1.0 1.0 1.0,1 1,0 1 1 1,1,1.0 1 1,1 1,1610,Swanson_2006 < 2 months,NA 6-12 yo,8.85049504950495 10.3004098360656 NA NA,  8, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3 Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA,NA Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100 100,High,Modafinil,Modafinil   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA,5:ADHD-RS Total  1.61104718 NA NA,Swanson,2006 NA RCT G,120  63  183 outcomes,reverse -0.5910000000 -0.903000000 -2.800000e-01  13.1000000  12.7000000 NA NA,NA,NA,NA NA,100 100 100,100   0 100,100 some some,high,some some Placebo   0, 24.967213  9.962295 NA,NA,0,1 1.0 1.0,1.0,1.0 1 1 0 1 1,1 1 1.0,1,1 1 1,1611 Swanson_2006,< 2 months,NA,6-12 yo 8.85049504950495,9.96229508196721,NA NA,  8  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8 NA,NA,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0,100 100,High Modafinil,Modafinil,  0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability, 1.61104718 NA,NA Swanson 2006,NA RCT RR,126  64, 190,outcomes,reverse  0.9740000000  0.658000000, 1.440000e+00,NA,NA,NA NA,NA,NA,NA,NA,100 100,100,100,  0,100 100,some some high some some Placebo,  0, 24.989474  9.965263 NA NA 0 1,1.0 1.0 1.0,1.0,1,1 0 1,1 1,1 1.0,1 1,1,1,1612,Swanson_2006 < 2 months NA 6-12 yo 7.875 10.2983870967742,NA NA   8, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA,NA Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0,100,100,High Modafinil Modafinil,  0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA,Tolerability, 1.61104718,NA NA Swanson 2006 NA RCT,RR 126  64, 190 outcomes,reverse 12.7950000000, 0.770000000  2.127100e+02,NA,NA NA NA,NA NA,NA NA,100,100,100 100,  0,100,100 some some high,some,some Placebo,  0, 24.989474  9.965263 NA,NA 0 1,1.0 1.0 1.0,1.0,1 1 0,1,1,1 1,1.0,1,1 1 1 1613,Swanson_2006,< 2 months,NA 6-12 yo 7.875,10.2983870967742,NA NA   8  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  3,Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875,40.8 NA NA Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0 100 100 High Atomoxetine Atomoxetine   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,1:ADHD-RS Total  1.84119678    0.5000000 mg/kg/d,Takahashi,2009,NA RCT G, 62, 61  123 outcomes reverse -0.1310000000,-0.486000000, 2.240000e-01  11.4000000, 11.4000000 NA NA,NA NA,NA NA 100 100 100 100,100 100,100,low low,low,low low,Placebo   0  16.100000,10.502927,NA NA,0,1 1.0 1.0,1.0,1.0 1 1,0 1 1 1,1,1.0,1,1 1 1 1614 Takahashi_2009 < 2 months,NA,6-12 yo,8.65157894736842 12.2493333333333 NA,NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Atomoxetine Atomoxetine,  0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,Acceptability, 1.84119678    0.5000000,mg/kg/d,Takahashi,2009 NA RCT RR, 62, 62, 124 outcomes reverse  2.0000000000  0.186000000  2.149100e+01 NA,NA,NA,NA NA NA NA NA,100 100 100 100 100,100,100,low,low,low,low,low Placebo   0, 16.100000,10.505000 NA,NA,0 1 1.0 1.0 1.0,1.0,1 1,0 1 1,1,1,1.0 1 1 1 1 1615,Takahashi_2009,< 2 months NA 6-12 yo,8.65154639175258,12.2493548387097,NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0 100 100 High,Atomoxetine Atomoxetine   0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability, 1.84119678    0.5000000 mg/kg/d,Takahashi 2009 NA RCT RR  62, 62  124 outcomes reverse  1.0000000000  0.020000000, 4.961700e+01,NA NA,NA NA NA,NA,NA NA,100 100,100,100 100 100,100,low low low low,low Placebo,  0  16.100000 10.505000,NA,NA 0,1,1.0 1.0,1.0 1.0 1,1,0 1 1,1 1,1.0 1,1 1,1 1616 Takahashi_2009 < 2 months NA 6-12 yo,8.65154639175258 12.2493548387097,NA NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100,100 High Atomoxetine Atomoxetine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA 1:ADHD-RS Total  1.84119678    1.2000000,mg/kg/d,Takahashi,2009 NA RCT G  58  61, 119 outcomes reverse -0.1550000000 -0.517000000  2.060000e-01, 10.3000000  11.4000000,NA,NA NA,NA,NA,NA,100,100 100 100 100,100,100,low,low,low low,low Placebo,  0  14.735294 10.682017 NA NA,0,1,1.0 1.0,1.0,1.0,1,1 0 1 1,1 1,1.0,1 1 1 1 1617 Takahashi_2009,< 2 months,NA 6-12 yo 8.65157894736842,12.2493333333333 NA NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100 100,High Atomoxetine Atomoxetine   0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA Acceptability, 1.84119678    1.2000000,mg/kg/d,Takahashi 2009 NA RCT,RR, 60, 62, 122,outcomes,reverse, 3.1000000000  0.332000000, 2.897900e+01 NA NA NA NA,NA NA,NA,NA 100,100,100 100,100 100 100,low,low low,low,low Placebo,  0  14.722951 10.681311,NA NA 0 1,1.0 1.0 1.0,1.0,1,1,0,1 1 1 1 1.0,1,1 1,1 1618 Takahashi_2009,< 2 months,NA 6-12 yo 8.65154639175258,12.2493548387097,NA NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100,High,Atomoxetine,Atomoxetine   0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA Tolerability, 1.84119678,   1.2000000 mg/kg/d Takahashi,2009,NA RCT RR  60  62, 122,outcomes,reverse, 3.0980000000  0.129000000  7.459400e+01,NA,NA,NA,NA NA,NA NA NA,100 100,100,100 100 100 100,low low,low,low low Placebo,  0  14.722951,10.681311 NA,NA 0,1,1.0 1.0 1.0,1.0,1,1 0 1 1,1 1,1.0 1 1,1,1,1619,Takahashi_2009,< 2 months NA,6-12 yo,8.65154639175258 12.2493548387097 NA NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100 100,High Methylphenidate,Methylphenidate   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA Acceptability  0.69044879,NA,NA Taylor,1987,NA,RCT RR, 39  39,  78 outcomes,reverse  0.3330000000  0.014000000  7.939000e+00 NA,NA NA,NA NA NA NA,NA,100 100 100 100,100 100,100,low,low low some,low Placebo   0,  0.000000  8.500000,NA NA 0 1,1.0,1.0,1.0,1.0 1,1,0,1,1 1 1,1.0,1,1 1 1 1620 Taylor_1987 < 2 months,NA,6-12 yo,7.9578947368421,14.7 NA NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0 100 100 High Methylphenidate,Methylphenidate,  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA Tolerability  0.69044879,NA,NA,Taylor 1987 NA,RCT,RR, 39  39,  78 outcomes,reverse  0.3330000000  0.014000000, 7.939000e+00,NA,NA NA,NA,NA,NA,NA,NA 100,100 100,100,100 100,100 low low low,some,low Placebo,  0   0.000000, 8.500000,NA NA 0,1,1.0,1.0,1.0,1.0 1 1,0,1 1,1 1 1.0,1 1 1,1,1621 Taylor_1987,< 2 months,NA,6-12 yo 7.9578947368421,14.7 NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0,100 100 High,Methylphenidate,Methylphenidate   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks) NA,13:CTRS-R:S, 1.61104718 NA,mg/d van der Meere 1999,NA RCT G, 24, 24,  48 outcomes,reverse,-0.3800000000 -0.956000000, 1.970000e-01,  4.4090815   5.3888774,NA NA,NA NA,NA,NA 100 100 100,100,100 100,100,some,some,some some,some,Placebo,  0 NA, 8.800000,NA NA 0 1,1.0 1.0 1.0,1.0 1 1,0 1 1 1,1 1.0,1 1 1,1,1622,van der Meere_1999,< 2 months NA 6-12 yo,8.60483870967742,9.97113402061856 NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100,High Atomoxetine Atomoxetine,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total  1.84119678 NA,NA,Wehmeier 2012 NA,RCT,G, 63, 62, 125 outcomes reverse -0.6440000000,-1.044000000,-2.450000e-01,NA NA,NA,NA,NA,NA 10.8900000 10.8900000 100,100,100,100 100,100,100 low,low some low,low Placebo,  0  22.424000, 9.000800,NA NA,0,1 1.0,1.0 1.0,1.0 1,1,0 1 1 1,1,1.0 1 1,1,1 1623,Wehmeier_2012,< 2 months,NA,6-12 yo,8.65157894736842,12.2493333333333 NA,NA, 44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100,100 High Atomoxetine Atomoxetine   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA Acceptability, 1.84119678 NA NA,Wehmeier 2012,NA,RCT,RR, 64, 64, 128 outcomes,reverse  0.8180000000  0.364000000, 1.839000e+00 NA,NA NA,NA,NA,NA NA NA 100,100 100 100,100 100,100,low low,some,low,low Placebo   0, 22.400000  9.000000,NA NA,0 1,1.0 1.0 1.0,1.0,1 1 0,1,1,1 1 1.0 1 1,1 1 1624,Wehmeier_2012,< 2 months,NA,6-12 yo 8.65154639175258,12.2493548387097,NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0 100 100 High Atomoxetine,Atomoxetine,  0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,Tolerability  1.84119678,NA,NA Wehmeier 2012,NA RCT,RR, 64, 64  128,outcomes,reverse, 0.6670000000, 0.115000000, 3.857000e+00 NA,NA,NA NA NA NA NA NA 100 100,100,100,100,100 100 low low,some low,low,Placebo   0  22.400000  9.000000,NA,NA,0 1 1.0 1.0,1.0 1.0 1,1 0 1 1,1,1,1.0,1,1,1,1 1625,Wehmeier_2012,< 2 months NA,6-12 yo 8.65154639175258 12.2493548387097,NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA NA Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100   0,100 100,High,Atomoxetine,Atomoxetine   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA 4:ADHD-SRS Total  0.69044879,NA NA Weiss,2005,NA,RCT,G,100, 51  151 outcomes,reverse -0.2980000000,-0.638000000  4.200000e-02, 25.5000000, 18.4248853,NA NA,NA,NA,NA NA,100,100,100,100,100 100,100,low low,low low low Placebo,  0  19.590066, 9.933245,NA NA,0,1,1.0 1.0,1.0 1.0 1,1,0,1,1 1 1,1.0 1,1 1 1,1626 Weiss_2005,< 2 months,NA,6-12 yo 8.65157894736842 12.2493333333333 NA,NA  44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100,  0,100 100 High,Atomoxetine Atomoxetine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks) NA 1:ADHD-RS Total  3.68239356 NA,NA Wietecha,2013,NA RCT,G, 62, 58, 120,outcomes reverse,-0.4040000000 -0.910000000, 1.020000e-01 NA,NA NA NA,NA NA,10.7500000,10.7500000,100 100 100 100 100,100 100,low some low,some low,Placebo,  0  36.296667 12.249333 NA,NA 0,1 1.0,1.0,1.0 1.0 1,1 0 1,1,1 1,1.0,1,1,1,1 1627,Wietecha_2013,2-6 months NA,6-12 yo,8.65157894736842,12.2493333333333 NA NA, 44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100   0 100,100,High Atomoxetine,Atomoxetine,  0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks),NA 5:ADHD-RS Total, 3.68239356 NA,NA Wietecha 2013,NA,RCT G  21, 22   43 outcomes reverse -0.7470000000,-1.424000000,-7.100000e-02,NA,NA NA NA,NA NA,10.8300000 10.8300000,100,100 100,100,100,100 100 low,some,low,some low Placebo   0, 36.132558 12.250465,NA NA 0 1 1.0 1.0,1.0,1.0,1,1,0,1 1 1,1,1.0,1 1,1,1,1628 Wietecha_2013,2-6 months,NA 6-12 yo,9.77105263157895,12.2504651162791 NA NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100 100,High Atomoxetine Atomoxetine   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA Acceptability  3.68239356,NA,NA,Wietecha 2013,NA RCT RR, 64, 60, 124 outcomes reverse  2.1090000000, 0.992000000  4.487000e+00,NA,NA NA,NA NA,NA,NA,NA 100,100,100 100,100,100 100,low,some,low,some,low Placebo   0  36.293548 12.249355 NA NA,0 1,1.0,1.0 1.0,1.0,1,1,0 1,1,1 1 1.0 1,1,1 1 1629,Wietecha_2013 2-6 months,NA 6-12 yo 8.65154639175258 12.2493548387097 NA NA, 44  9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA,NA Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100 High,Atomoxetine Atomoxetine,  0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability  3.68239356,NA,NA,Wietecha 2013,NA,RCT RR, 64  60, 124,outcomes reverse  5.6250000000  0.697000000, 4.536400e+01,NA NA,NA NA NA NA NA NA 100,100,100,100 100,100 100,low some low,some low Placebo   0  36.293548,12.249355 NA NA 0 1,1.0 1.0 1.0,1.0 1,1,0,1,1 1 1 1.0 1,1 1,1,1630,Wietecha_2013 2-6 months,NA,6-12 yo,8.65154639175258 12.2493548387097,NA NA  44, 9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100,100 High Methylphenidate Methylphenidate   0,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks) NA,18:SNAP-IV-Long Total, 0.92059839   36.5000000,mg/d,Wigal 2004,NA,RCT,G, 43  41,  84,outcomes reverse,-0.5700000000 -1.050000000,-9.000000e-02,NA,NA,NA NA NA,NA  0.5122499  0.5122499 100 100,100 100,100 100,100,some some,some some some,Placebo   0, 11.632143, 9.804762,NA,NA 0,1 1.0,1.0 1.0 1.0,1 1 0,1,1,1,1 1.0 1,1 1 1 1631,Wigal_2004,< 2 months,NA 6-12 yo 8.60731707317073 10.9714285714286,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0 100,100,High,Methylphenidate,Methylphenidate   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks) NA,21:SNAP-IV-short Total  0.92059839,  36.5000000,mg/d Wigal,2004,NA RCT,G  42  41   83 outcomes,reverse,-0.9540000000 -1.411000000,-4.970000e-01   0.6600000,  0.7700000 NA NA NA NA,NA NA 100,100,100,100,100 100 100 some,some some,some,some,Placebo   0  11.690361, 9.802410,NA,NA,0,1 1.0,1.0 1.0,1.0,1 1,0 1 1,1 1,1.0 1,1,1 1 1632,Wigal_2004,< 2 months,NA,6-12 yo,8.60483870967742,9.97113402061856,NA,NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0,100,100 High,Methylphenidate,Methylphenidate,  0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA Acceptability, 0.92059839   36.5000000 mg/d,Wigal 2004 NA RCT RR, 44, 42,  86,outcomes,reverse, 0.3180000000, 0.068000000  1.489000e+00,NA NA NA,NA,NA NA NA NA,100 100 100,100 100,100,100,some,some some some some Placebo   0, 11.634884, 9.804651 NA,NA,0,1 1.0 1.0 1.0 1.0,1,1,0 1,1,1 1,1.0,1 1,1 1 1633,Wigal_2004 < 2 months,NA 6-12 yo 7.9578947368421 14.7,NA,NA 141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757,Cortese - Children (2018) Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Methylphenidate Methylphenidate,  0 NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA Tolerability  0.92059839   36.5000000 mg/d,Wigal 2004 NA RCT,RR  44  42   86 outcomes reverse  0.1910000000  0.009000000, 3.867000e+00,NA NA NA NA,NA NA,NA NA 100 100 100 100 100 100,100 some,some some some some,Placebo,  0  11.634884  9.804651 NA NA 0,1,1.0,1.0 1.0 1.0 1 1 0 1 1 1 1,1.0 1 1,1,1 1634 Wigal_2004,< 2 months,NA,6-12 yo 7.9578947368421,14.7 NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4,100   0,100,100 High Methylphenidate Methylphenidate,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks) NA,18:SNAP-IV-Long Total, 0.92059839,  64.2800000,mg/d,Wigal,2004,NA,RCT G, 46, 41,  87,outcomes reverse,-0.2860000000 -0.736000000, 1.640000e-01 NA,NA,NA,NA NA NA, 0.5122499, 0.5122499 100,100,100,100,100 100,100,some,some some,some,some Placebo,  0, 14.743678  9.705747,NA NA,0 1 1.0,1.0,1.0 1.0,1 1 0,1,1,1,1,1.0,1,1,1 1,1635 Wigal_2004,< 2 months,NA,6-12 yo 8.60731707317073 10.9714285714286 NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4,100   0,100 100 High Methylphenidate Methylphenidate,  0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks) NA 21:SNAP-IV-short Total, 0.92059839   64.2800000,mg/d Wigal 2004,NA,RCT,G  41, 41,  82,outcomes reverse,-0.4170000000,-0.857000000  2.400000e-02   0.8900000   0.7700000,NA NA NA NA,NA,NA 100 100 100,100 100,100,100,some some some,some,some,Placebo,  0, 14.850000  9.700000 NA NA 0,1 1.0 1.0,1.0,1.0,1 1 0,1,1 1,1 1.0,1 1 1,1,1636 Wigal_2004,< 2 months,NA 6-12 yo 8.60483870967742,9.97113402061856 NA,NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Methylphenidate,Methylphenidate   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,Acceptability  0.92059839,  64.2800000,mg/d Wigal 2004 NA RCT RR, 46  42,  88 outcomes,reverse  0.9130000000, 0.319000000, 2.613000e+00,NA NA NA,NA NA NA NA,NA 100 100 100 100,100,100 100,some,some some,some,some Placebo   0, 14.765909, 9.704545 NA,NA 0,1,1.0,1.0 1.0,1.0,1 1 0,1 1 1 1 1.0,1,1 1 1 1637 Wigal_2004,< 2 months NA 6-12 yo,7.9578947368421 14.7 NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0 100 100,High,Methylphenidate Methylphenidate,  0,NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,Tolerability, 0.92059839   64.2800000 mg/d Wigal 2004 NA RCT RR  46  42,  88 outcomes,reverse  0.9130000000  0.135000000, 6.196000e+00 NA,NA,NA,NA NA,NA NA NA,100 100 100,100,100 100 100,some some some,some some,Placebo,  0  14.765909, 9.704545,NA NA,0,1,1.0,1.0 1.0 1.0,1 1,0,1 1,1,1 1.0 1,1,1,1,1638 Wigal_2004 < 2 months NA 6-12 yo 7.9578947368421 14.7 NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low,low
 757 Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100,100,High,Methylphenidate,Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA 4:ADHD-SRS Total  0.23014960,NA NA,Wigal 2015 NA,RCT,G, 48, 46   94,outcomes,reverse,-0.5410000000,-1.006000000 -7.700000e-02 NA,NA NA NA,NA NA 10.3000000 10.3000000,100,100 100,100,100 100 100,some,some low,some low Placebo   0, 37.527660 10.695745 NA NA 0,1 1.0 1.0,1.0 1.0,1 1 0 1,1 1 1 1.0,1,1,1,1,1639,Wigal_2015,< 2 months,NA 6-12 yo,9.745,14.7 NA NA 141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4,100,  0 100 100 High,Methylphenidate,Methylphenidate,  0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,Acceptability  0.23014960 NA,NA,Wigal,2015,NA RCT,RR  49, 47   96,outcomes reverse  0.9590000000, 0.062000000, 1.489600e+01 NA NA NA NA NA NA NA NA 100,100 100,100 100 100,100 some some low some,low Placebo,  0  37.527083,10.695833,NA NA,0,1 1.0 1.0,1.0 1.0,1,1,0 1,1,1 1 1.0 1,1 1 1 1640,Wigal_2015,< 2 months NA 6-12 yo 7.9578947368421 14.7 NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0,100,100 High,Methylphenidate Methylphenidate,  0,NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA,Tolerability, 0.23014960 NA NA Wigal,2015 NA RCT RR  49, 47   96,outcomes,reverse, 0.9600000000  0.019000000  4.742000e+01 NA NA,NA,NA,NA NA,NA,NA,100 100,100 100 100,100,100,some,some low,some low,Placebo   0, 37.527083,10.695833 NA,NA,0,1 1.0,1.0,1.0 1.0 1,1,0 1 1,1 1 1.0,1,1 1,1 1641,Wigal_2015,< 2 months NA 6-12 yo 7.9578947368421,14.7,NA,NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100 100 High Methylphenidate Methylphenidate,  0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),NA 4:ADHD-SRS Total  0.23014960 NA,NA,Wigal,2015,NA,RCT G  40, 46,  86 outcomes,reverse -0.4210000000 -0.899000000  5.800000e-02,NA,NA NA,NA,NA,NA 10.3000000 10.3000000 100 100,100,100,100,100 100,some some,low,some low Placebo,  0, 34.153488 10.574419,NA,NA,0,1 1.0 1.0,1.0 1.0 1 1 0,1 1 1,1 1.0,1 1 1,1,1642,Wigal_2015 < 2 months NA 6-12 yo 9.745 14.7,NA NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 757 Cortese - Children (2018) Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100,  0,100,100 High,Methylphenidate,Methylphenidate,  0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,Acceptability  0.23014960 NA NA Wigal 2015,NA RCT RR  44  47,  91,outcomes,reverse, 4.2730000000  0.497000000  3.676900e+01,NA,NA NA,NA,NA NA NA,NA 100 100,100 100,100 100 100 some some,low some,low Placebo   0  34.072527 10.561538 NA,NA 0,1 1.0 1.0 1.0 1.0 1,1,0 1 1,1 1,1.0 1,1,1 1 1643 Wigal_2015,< 2 months,NA 6-12 yo 7.9578947368421,14.7,NA NA,141 14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 757 Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0,100 100,High,Methylphenidate Methylphenidate   0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability  0.23014960,NA NA Wigal 2015 NA RCT RR, 44, 47,  91 outcomes reverse  3.2000000000, 0.134000000  7.654000e+01,NA NA,NA NA,NA,NA,NA NA,100,100 100,100 100,100,100,some some,low some,low,Placebo,  0, 34.072527 10.561538,NA NA 0 1,1.0 1.0 1.0,1.0,1 1,0 1,1,1,1 1.0 1,1,1,1,1644 Wigal_2015 < 2 months,NA,6-12 yo,7.9578947368421,14.7 NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100,High,Methylphenidate,Methylphenidate   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA 4:ADHD-SRS Total  0.23014960,NA,NA Wigal,2015,NA,RCT G, 44  46,  90,outcomes reverse,-0.7460000000,-1.244000000 -2.480000e-01 NA,NA,NA,NA NA,NA,10.3000000 10.3000000 100 100 100,100,100,100,100 some,some low,some,low Placebo,  0  33.706667,10.997778,NA NA 0,1 1.0,1.0,1.0,1.0 1,1 0 1 1,1,1 1.0 1 1,1 1 1645,Wigal_2015,< 2 months,NA,6-12 yo,9.745 14.7,NA,NA,141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100 100,High Methylphenidate Methylphenidate   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA Acceptability, 0.23014960 NA,NA,Wigal,2015 NA,RCT RR  45, 47,  92 outcomes,reverse  1.0440000000, 0.067000000  1.620000e+01,NA,NA NA NA,NA,NA,NA,NA 100 100,100 100 100,100,100,some,some low,some low,Placebo,  0, 33.705435,10.997826,NA NA 0 1,1.0 1.0 1.0,1.0,1,1,0 1 1,1 1 1.0 1 1 1 1,1646,Wigal_2015 < 2 months,NA 6-12 yo,7.9578947368421 14.7,NA,NA,141 14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low low
 757,Cortese - Children (2018),Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100   0 100 100,High,Methylphenidate Methylphenidate   0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA Tolerability  0.23014960,NA NA Wigal,2015 NA RCT,RR, 45  47   92,outcomes reverse, 1.0430000000, 0.021000000  5.149900e+01 NA,NA NA,NA,NA,NA,NA,NA,100,100,100 100 100,100,100,some some,low,some low Placebo   0  33.705435 10.997826,NA,NA,0,1 1.0 1.0 1.0 1.0,1,1,0,1,1 1 1,1.0,1 1 1 1,1647,Wigal_2015,< 2 months,NA,6-12 yo 7.9578947368421 14.7,NA NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 757 Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100   0 100,100,High,Methylphenidate,Methylphenidate   0 NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total  0.23014960 NA,NA Wigal 2015 NA RCT,G  43, 46   89 outcomes reverse,-0.7720000000,-1.276000000,-2.670000e-01 NA NA,NA,NA NA,NA,10.3000000 10.3000000 100 100,100 100,100,100,100,some some,low some low Placebo,  0  31.610112,11.044944,NA,NA 0,1 1.0,1.0,1.0,1.0,1 1 0 1,1 1,1 1.0 1 1,1 1,1648 Wigal_2015 < 2 months NA 6-12 yo,9.745 14.7 NA,NA 141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9 Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children 2018 10.1016/S2215-0366(18)30269-4 100   0,100,100,High,Methylphenidate Methylphenidate   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,Acceptability  0.23014960,NA NA Wigal,2015 NA,RCT,RR, 45  47,  92,outcomes,reverse  2.0890000000, 0.196000000  2.224300e+01,NA NA NA NA,NA NA,NA NA,100 100 100,100 100,100 100,some,some low,some,low,Placebo,  0, 31.553261,11.046739,NA NA 0,1 1.0 1.0,1.0 1.0 1 1,0 1,1,1,1,1.0 1 1 1 1,1649,Wigal_2015,< 2 months NA,6-12 yo,7.9578947368421,14.7,NA NA,141,14 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) 11 Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 757,Cortese - Children (2018),Cortese - Children 2018,10.1016/S2215-0366(18)30269-4,100,  0,100 100,High Methylphenidate,Methylphenidate,  0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,Tolerability, 0.23014960 NA NA Wigal,2015,NA,RCT,RR, 45, 47   92,outcomes,reverse, 5.2170000000, 0.257000000  1.057750e+02 NA,NA,NA,NA NA NA,NA,NA 100,100 100 100 100 100 100,some,some,low,some,low Placebo,  0, 31.553261 11.046739,NA,NA 0 1 1.0,1.0 1.0 1.0,1 1 0,1 1,1,1,1.0,1,1 1,1 1650 Wigal_2015 < 2 months NA,6-12 yo,7.9578947368421,14.7,NA NA 141,14,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),11,Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60 109.9,Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757,Cortese - Adults (2018),Cortese - Adults,2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100,High Bupropion Bupropion   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),NA 1:ADHD-RS Total, 1.38089758  724.0000000,mg/d Wilens 2001,NA,RCT G  21  19   40 outcomes reverse -0.3960000000 -1.031000000, 2.390000e-01  11.0000000, 11.8000000,NA NA,NA NA,NA,NA,100 100,100,100 100,100,100,some some,low some,some,Placebo,  0, 44.900000,38.235000 NA NA 0 1 1.0,1.0,1.0 1.0,1 1,0 1,1 1 1,1.0 1,1,1 1,1651 Wilens_2001,< 2 months NA,>= 20 yo,38.235,40.25 NA,NA, 10  7 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5 40.25 NA,NA,Cortese - Adults (2018)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Adults (2018) - Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,100.00000,no low low
 757,Cortese - Children (2018) Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100   0 100,100,High,Alpha-2 agonists (guanfacine / clonidine),Alpha-2 agonists (guanfacine / clonidine)   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total, 0.92059839 NA NA,Wilens 2015,NA,RCT,G,157,155  312 outcomes reverse -0.3910000000,-0.687000000,-9.400000e-02 NA,NA,NA NA NA,NA,12.4498996 12.4498996 100 100 100 100 100,100 100,some some,some,some low,Placebo   0  35.254423,14.549679 NA,NA 0,1 1.0 1.0,1.0,1.0 1,1,0,1,1 1,1 1.0 1 1,1 1,1652,Wilens_2015 < 2 months,NA,13-19 yo 8.99719626168224 14.5496794871795,NA NA  20, 7,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  5 Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA NA,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1,Homogeneous Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 757,Cortese - Adults (2018) Cortese - Adults,2018 10.1016/S2215-0366(18)30269-4 100   0 100,100,High Bupropion Bupropion   0,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks),NA,4:ADHD-SRS Total, 1.84119678  398.0000000 mg/d,Wilens,2005a NA RCT G, 81, 81, 162 outcomes,reverse,-0.3830000000 -0.740000000,-2.500000e-02,NA NA NA,NA,NA NA,11.1000000 11.1000000 100 100 100,100,100,100 100 some,some some,some,low,Placebo   0  40.500000,40.250000 NA,NA,0 1 1.0 1.0 1.0 1.0,1,1,0,1,1,1 1 1.0 1 1,1 1,1653 Wilens_2005a,< 2 months NA,>= 20 yo 38.235 40.25,NA NA  10, 7 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5,40.25,NA,NA,Cortese - Adults (2018)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 1 Homogeneous Cortese - Adults (2018) - Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo 100.00000,no low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0 100 100,High Atomoxetine,Atomoxetine   0 NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) NA,4:ADHD-SRS Total, 1.84119678 NA NA Wilens 2011,NA RCT,G, 49, 46,  95,outcomes,reverse -0.6870000000 -1.184000000,-1.900000e-01 NA,NA,NA NA,NA,NA 12.2081940,12.2081940 100,100 100 100,100 100 100 some,low,low low some,Placebo   0, 34.873684  8.651579 NA NA,0 1,1.0,1.0 1.0,1.0 1 1 0 1,1 1,1 1.0,1,1 1,1,1654,Wilens_2011,< 2 months,NA 6-12 yo 8.65157894736842,12.2493333333333 NA NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125 NA NA Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),1 Homogeneous,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,low,low
 757,Cortese - Children (2018) Cortese - Children,2018,10.1016/S2215-0366(18)30269-4 100,  0,100,100,High Atomoxetine,Atomoxetine,  0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,Acceptability, 1.84119678 NA,NA,Wilens 2011,NA,RCT RR, 50, 47,  97,outcomes,reverse, 1.3160000000, 0.449000000, 3.861000e+00 NA NA NA NA NA,NA,NA,NA,100,100,100 100 100,100 100 some,low low low some,Placebo,  0  34.876289  8.651546,NA NA,0 1,1.0 1.0 1.0,1.0 1 1 0,1 1,1,1,1.0 1,1 1 1 1655 Wilens_2011 < 2 months NA 6-12 yo 8.65154639175258 12.2493548387097,NA,NA, 44, 9,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI  7 Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA,NA,Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 757,Cortese - Children (2018),Cortese - Children,2018 10.1016/S2215-0366(18)30269-4 100,  0 100,100 High Atomoxetine Atomoxetine   0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA,Tolerability  1.84119678 NA,NA,Wilens 2011,NA,RCT RR  50, 47,  97 outcomes,reverse  1.8800000000, 0.176000000  2.005500e+01 NA,NA,NA,NA NA,NA,NA,NA 100 100 100,100 100 100,100 some low low,low,some Placebo   0  34.876289  8.651546 NA,NA,0 1 1.0 1.0 1.0 1.0,1,1,0 1,1 1 1,1.0 1 1,1,1,1656 Wilens_2011 < 2 months,NA,6-12 yo 8.65154639175258 12.2493548387097 NA,NA  44  9 Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI, 7,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA,NA Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 575 Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355,100,  0,100,100,Low,Carnitine,NA 100,stimulant Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,NA NA NA NA,Abbasi,2011,NA,RCT RR, 20, 20   40 outcomes,reverse  1.0000000000, 0.067096465  1.490391e+01 NA,NA NA,NA,NA NA,NA NA,100,100 100,100 100 100 100 some,low,low low some,Active (any credible active intervention),100  30.000000  8.600000 NA NA 1 1 1.0 0.0,1.0,1.0,1 1 0 1,1,1 1 0.5 1,1,1 1 1657,Abbasi_2011,NA,NA 6-12 yo 8.4,9.5,NA NA,  4, 1 Acceptability: all-cause discontinuation  1,Catala-Lopez (2017) 8.4,9.5 NA NA Catala-Lopez (2017)_Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Catala-Lopez (2017) - Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 575 Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355 100,  0,100 100,Low,Parent-mediated behavioral interventions NA,  0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA NA NA,NA,NA Abikoff 2015 NA RCT,RR 130, 34  164,outcomes,reverse, 3.1384615385, 0.422729292  2.330082e+01 NA NA NA,NA NA,NA,NA,NA,100 100 100,100 100 100 100 some,some,low some,some Waiting list,  0  56.200000, 4.000000,NA,NA,1,1 1.0,0.0 1.0,1.0 1 1,0 1,1,1 1,0.5 1 1 1,1,1658,Abikoff_2015,NA NA < 6 yo 3.6 12.5 NA,NA  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99,94.15,108.21,Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Mixed,Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious,low,low
 575 Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355 100,  0 100,100 Low Zinc NA,100 stimulant Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA,NA NA NA,Akhondzadeh,2004 NA RCT,RR  22  22,  44 outcomes reverse, 1.0000000000, 0.154316076  6.480206e+00,NA NA,NA NA,NA NA NA,NA 100,100 100,100 100,100 100,some,some some some,some Active (any credible active intervention) 100  40.900000  7.900000,NA,NA,1 1 1.0 0.0,1.0 1.0,1 1,0 1,1 1,1 0.5 1 1 1,1,1659 Akhondzadeh_2004 NA,NA,6-12 yo 7.9,9.6 NA NA   6, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2 Talebi (2021) | Catala-Lopez (2017) 7.14,9.92 NA NA Catala-Lopez (2017)_Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Catala-Lopez (2017) - Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 575,Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355 100   0,100,100 Low Risperidone,NA,100,stimulant+bt Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,NA NA,NA NA Aman,2014 NA RCT,RR  84  84, 168 outcomes reverse, 1.5333333333  0.862043122, 2.727371e+00,NA,NA,NA,NA,NA NA,NA,NA 100 100 100,100 100,100 100 low some,low low some,Active (any credible active intervention) 100  23.200000, 8.900000 NA NA,1 1 1.0,0.0,1.0 1.0 1 1,0,1,1 1,1,0.5,1 1 1,1 1660 Aman_2014,NA,NA,6-12 yo 8.1 8.9 NA NA   2, 1 Acceptability: all-cause discontinuation  1 Catala-Lopez (2017),8.1 8.9,NA,NA Catala-Lopez (2017)_Risperidone_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Risperidone_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 575,Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355 100   0,100 100,Low Risperidone NA 100,stimulant,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA,NA,NA,NA Armenteros,2007 NA,RCT,RR, 12, 13   25 outcomes,reverse  1.0833333333  0.075895602, 1.546349e+01,NA,NA,NA,NA,NA,NA NA NA,  0   0,100 100,100   0,100,low low some,low high,Active (any credible active intervention) 100, 12.000000, 8.100000 NA,NA,1,1 1.0,0.0 1.0 1.0 1,1,0 1,1 1 1,0.5 1 1,1 1,1661 Armenteros_2007 NA,NA,6-12 yo,8.1,8.9,NA NA   2, 1 Acceptability: all-cause discontinuation  1 Catala-Lopez (2017) 8.1 8.9,NA NA,Catala-Lopez (2017)_Risperidone_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Risperidone_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
 575,Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355 100   0 100 100 Low Carnitine,NA   0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA NA,NA NA NA,Arnold,2007,NA RCT RR  58, 60, 118,outcomes reverse, 0.7881773399  0.458815786  1.353972e+00 NA,NA NA NA NA,NA,NA,NA,100 100,100,100 100,100,100,some,some some,some some Placebo   0  26.000000  8.400000 NA NA 1 1 1.0 0.0,1.0 1.0 1,1,0,1 1,1 1 0.5,1 1,1,1,1662,Arnold_2007 NA,NA,6-12 yo 8.4 9.5,NA NA   4, 1,Acceptability: all-cause discontinuation  1,Catala-Lopez (2017),8.4,9.5 NA,NA Catala-Lopez (2017)_Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 575,Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355,100,  0 100 100 Low Zinc NA,  0,NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA NA NA,NA,NA,Arnold 2011 NA RCT RR  28  24   52,outcomes reverse  0.8571428571  0.130451199, 5.631944e+00,NA NA,NA,NA,NA NA NA,NA,100,100,100,100 100,100 100,some some some,some some Placebo,  0  17.300000  9.600000,NA,NA,1 1 1.0,0.0 1.0 1.0,1,1 0 1 1,1,1,0.5 1,1,1 1 1663 Arnold_2011 NA,NA,6-12 yo,7.9 9.6 NA NA   6  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2 Talebi (2021) | Catala-Lopez (2017) 7.14 9.92,NA,NA,Catala-Lopez (2017)_Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 575 Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0 100,100 Low,Zinc,NA   0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,NA,NA NA,NA,Arnold,2011 NA,RCT,RR, 28, 24   52 outcomes,reverse, 0.8571428571  0.056596501  1.298126e+01 NA NA,NA,NA,NA,NA,NA NA,100,100 100,100 100 100 100,some some some,some some Placebo,  0  17.300000, 9.600000,NA NA 1,1 1.0 0.0,1.0 1.0,1,1 0 1 1,1,1 0.5,1,1 1,1,1664,Arnold_2011 NA,NA,6-12 yo 9.6,9.6,NA NA   6  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2 Talebi (2021) | Catala-Lopez (2017),7.14 9.92 NA,NA Catala-Lopez (2017)_Zinc_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Catala-Lopez (2017) - Zinc_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 575,Catala-Lopez (2017) Catala-Lopez 2017,10.1371/journal.pone.0180355 100,  0 100,100,Low Neurofeedback NA   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA NA,NA NA,NA,Arnold 2013,NA RCT,RR, 26  13   39 outcomes reverse  0.3333333333  0.063334434  1.754355e+00 NA NA NA,NA,NA NA,NA,NA 100 100,100 100,100 100,100,some some low some some,Placebo,  0  20.500000  8.900000,NA,NA,1,1 1.0 0.0 1.0 1.0 1 1,0,1 1 1 1 0.5 1 1 1 1 1665,Arnold_2013 NA NA 6-12 yo 8.6,12.4,NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA,Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low low
 575,Catala-Lopez (2017) Catala-Lopez 2017,10.1371/journal.pone.0180355,100,  0,100,100 Low,Neurofeedback,NA,  0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA NA NA,NA,NA,Bakhshayesh,2011,NA,RCT,RR  18, 17,  35,outcomes reverse, 0.4722222222, 0.047008528, 4.743689e+00 NA NA NA,NA NA,NA,NA,NA,  0,  0 100 100 100,100   0 some low,some,high,some Control   0, 25.700000, 9.300000 NA NA 1 1,1.0,0.0 1.0,1.0 1,1,0 1 1 1,1 0.5,1,1,1 1 1666,Bakhshayesh_2011,NA NA,6-12 yo,8.6 12.4,NA NA, 36, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low high
 575 Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355 100   0,100,100 Low,Polyunsaturated fatty acids NA 100,stimulant+bt Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA NA NA NA,NA Barragán 2014,NA RCT,RR, 30, 30   60 outcomes,reverse  0.1666666667  0.021335412  1.301956e+00,NA,NA NA,NA,NA NA,NA NA   0,  0,100   0,  0,  0   0 some,high high,high,high,Active (any credible active intervention),100, 33.300000  8.300000,NA,NA,1,1 1.0 0.0 1.0 1.0 1 1,0 1,1 1,1,0.5 1 1 1,1,1667 Barragán_2014,NA NA 6-12 yo 8.3 13.7 NA NA, 28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA NA Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Catala-Lopez (2017) - Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high,high
 575,Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100,  0 100,100,Low,Desipramine,NA   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,NA NA,NA NA Biederman 1989 NA,RCT,RR, 37, 36   73,outcomes reverse, 1.1675675676  0.390779688  3.488446e+00,NA NA NA,NA,NA,NA NA NA 100 100 100 100 100 100,100 some,low some,low,some,Placebo,  0,  6.500000 11.500000,NA NA,1 1 1.0,0.0 1.0,1.0 1 1,0,1 1,1 1 0.5 1,1,1 1,1668 Biederman_1989 NA,NA 6-12 yo,11,11.5 NA NA,  4  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Otasowie (2014) | Catala-Lopez (2017) 11,11.5,NA,NA,Catala-Lopez (2017)_Desipramine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Catala-Lopez (2017) - Desipramine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 575,Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355 100,  0 100 100,Low Desipramine NA   0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,NA,NA NA,NA Biederman,1989 NA,RCT,RR, 37, 36,  73,outcomes,reverse, 2.9210526316, 0.122886973  6.943412e+01 NA,NA NA NA,NA,NA,NA,NA 100 100,100 100 100 100 100 some low some,low,some,Placebo   0,  6.500000,11.500000 NA,NA 1,1 1.0 0.0,1.0,1.0,1,1 0,1,1,1 1 0.5,1 1 1,1 1669,Biederman_1989 NA NA 6-12 yo 11,11.5 NA NA,  4  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2 Otasowie (2014) | Catala-Lopez (2017),11,11.5 NA,NA Catala-Lopez (2017)_Desipramine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Desipramine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 575 Catala-Lopez (2017),Catala-Lopez,2017,10.1371/journal.pone.0180355 100   0 100 100,Low,Cognitive training NA   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,NA NA NA NA Bigorra,2015,NA RCT RR  36  30   66 outcomes,reverse, 7.5405405405  0.422227534, 1.346661e+02 NA NA,NA,NA,NA NA,NA NA,100,100 100 100,100,100,100,some,low,low,low some,Placebo   0  54.500000, 8.900000,NA NA,1 1 1.0 0.0 1.0 1.0 1 1 0,1 1,1 1,0.5,1 1,1,1 1670 Bigorra_2015,NA NA 6-12 yo 6.6 10.4,NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA NA,Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 575,Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0 100,100,Low,Zinc NA   0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,NA,NA,NA NA Bilici,2004 NA,RCT RR 202 198  400,outcomes,reverse  1.0488118812  0.867787205, 1.267599e+00,NA NA,NA NA NA NA,NA,NA,100,100,100 100 100,100,100 some some some some,some,Placebo,  0, 18.000000  9.600000,NA NA,1 1,1.0 0.0,1.0,1.0,1,1 0,1,1,1 1 0.5,1,1,1 1 1671,Bilici_2004,NA,NA 6-12 yo 7.9,9.6,NA,NA   6, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2,Talebi (2021) | Catala-Lopez (2017),7.14,9.92,NA,NA Catala-Lopez (2017)_Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Catala-Lopez (2017) - Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 575 Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355 100,  0,100,100 Low Zinc NA,  0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,NA NA,NA NA,Bilici 2004,NA,RCT RR 202,202  404 outcomes,reverse, 1.4705882353, 0.819716708, 2.638265e+00,NA,NA,NA,NA,NA,NA NA NA 100,100,100,100 100,100,100 some,some some some,some,Placebo,  0, 18.000000, 9.600000 NA NA 1,1 1.0 0.0 1.0 1.0,1,1,0,1 1 1,1 0.5 1 1 1,1,1672,Bilici_2004,NA NA,6-12 yo,9.6,9.6,NA NA   6, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Talebi (2021) | Catala-Lopez (2017) 7.14 9.92,NA,NA,Catala-Lopez (2017)_Zinc_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Catala-Lopez (2017) - Zinc_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 575 Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355,100   0 100 100 Low Parent-mediated behavioral interventions,NA   0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,NA,NA NA NA Bor,2002,NA RCT,RR  55, 32,  87 outcomes reverse  2.2109090909  0.913837430, 5.349003e+00,NA,NA,NA NA,NA,NA NA,NA,100,100 100 100 100 100 100 some some,some,low some,Waiting list,  0, 32.000000  3.600000 NA NA 1 1,1.0 0.0,1.0 1.0,1 1 0,1 1 1 1,0.5,1,1 1 1 1673 Bor_2002 NA NA,< 6 yo,3.6 12.5 NA NA  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15,108.21,Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Mixed Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious low low
 575 Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355,100   0,100 100 Low Polyunsaturated fatty acids NA,  0,NA,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA NA,NA NA NA,Bos,2015 NA RCT RR  20  20,  40 outcomes reverse, 0.3333333333  0.014385324  7.723921e+00,NA,NA NA NA,NA,NA,NA NA,100,100 100 100,100,100,100 some,some some,some some Placebo,  0   0.000000 10.300000 NA NA 1 1,1.0 0.0,1.0 1.0 1 1,0 1 1,1,1,0.5 1,1 1 1 1674,Bos_2015 NA,NA,6-12 yo 8.3 13.7,NA,NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7 NA,NA,Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 575,Catala-Lopez (2017),Catala-Lopez 2017 10.1371/journal.pone.0180355 100   0 100,100,Low Bupropion NA   0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,NA,NA,NA,NA Casat 1987 NA,RCT,RR, 20, 10   30 outcomes reverse  0.5000000000, 0.034770484, 7.190006e+00,NA,NA,NA NA NA NA NA,NA,  0   0,100,100,  0,  0,100,some some,high some high,Placebo,  0  20.000000  8.700000,NA NA 1,1,1.0,0.0,1.0 1.0,1,1,0,1 1 1 1 0.5 1 1 1,1 1675,Casat_1987,NA,NA,6-12 yo,8.5 8.7,NA NA  10, 7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation  6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5 40.25,NA NA,Catala-Lopez (2017)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Catala-Lopez (2017) - Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,high,high
 575 Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355,100,  0,100,100 Low,Bupropion NA   0 NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,NA,NA,NA NA,Casat,1987 NA RCT,RR  20  10   30 outcomes,reverse, 1.5714285714  0.069642424, 3.545810e+01 NA,NA,NA NA NA NA NA,NA,  0,  0 100 100,  0   0,100 some some high some high,Placebo   0, 20.000000, 8.700000 NA NA 1,1,1.0,0.0,1.0,1.0 1,1 0,1 1,1 1,0.5 1 1 1 1 1676,Casat_1987 NA,NA 6-12 yo 8.5,8.7 NA,NA  10  7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5 40.25,NA,NA,Catala-Lopez (2017)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high,high
 575 Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355 100   0 100 100,Low,Cognitive training NA,  0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA,NA NA NA,NA Chacko 2014 NA RCT,RR  44, 41   85 outcomes reverse  1.0871212121, 0.398331639  2.966956e+00,NA,NA NA NA NA,NA NA NA 100,100,100,100,100 100 100 some low some,low some,Placebo   0  22.400000, 8.400000,NA,NA,1 1,1.0,0.0,1.0 1.0,1 1,0,1,1,1 1 0.5 1 1,1,1 1677,Chacko_2014 NA NA 6-12 yo,6.6,10.4,NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low low
 575 Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355,100   0 100,100 Low Bupropion,NA   0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA,NA NA,NA Conners,1996 NA,RCT RR  72, 37  109,outcomes reverse  2.0555555556, 0.459615944, 9.193129e+00 NA NA NA NA,NA NA,NA NA,  0,  0,100,100   0   0 100 some some,high,some,high,Placebo,  0  10.000000, 8.500000,NA NA,1,1,1.0,0.0,1.0,1.0,1 1 0,1 1,1 1 0.5 1 1,1,1 1678 Conners_1996,NA NA,6-12 yo 8.5 8.7 NA NA  10  7 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5,40.25 NA,NA Catala-Lopez (2017)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Catala-Lopez (2017) - Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
 575 Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355,100,  0,100 100,Low,Bupropion NA   0 NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) NA,NA,NA,NA NA,Conners 1996 NA RCT RR, 72, 37  109 outcomes,reverse, 4.6849315068  0.258989993, 8.474684e+01,NA NA,NA,NA NA NA NA NA,  0,  0,100,100,  0   0,100 some,some high some high,Placebo,  0, 10.000000, 8.500000 NA,NA 1 1,1.0,0.0,1.0,1.0 1,1 0 1,1 1 1 0.5 1,1,1 1,1679,Conners_1996 NA NA 6-12 yo,8.5,8.7 NA,NA, 10, 7,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation, 6 Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5,40.25 NA NA Catala-Lopez (2017)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Catala-Lopez (2017) - Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
 575,Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355 100   0 100 100 Low Neurofeedback NA,100 stimulant Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA NA,NA NA NA,Duric,2012,NA RCT RR, 44, 44,  88,outcomes,reverse, 0.7333333333  0.380435291, 1.413585e+00,NA NA NA NA,NA,NA NA,NA,  0,  0 100,  0,100 100,  0,some,high some high,some,Active (any credible active intervention) 100, 20.900000 11.200000 NA,NA 1 1,1.0 0.0 1.0 1.0,1 1,0,1 1,1,1 0.5 1,1,1,1 1680,Duric_2012,NA NA 6-12 yo 8.6,12.4 NA,NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA,NA,Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,high
 575,Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355,100   0 100 100 Low Diet (restricted/elimination) NA   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA NA,NA NA NA Egger,1992,NA RCT,RR, 20  20,  40 outcomes,reverse  2.0000000000  0.196731882, 2.033224e+01,NA,NA,NA,NA,NA NA,NA NA   0   0,100,100,  0,  0 100,some,some,high,some,high Placebo,  0  10.000000  9.300000 NA NA,1 1,1.0 0.0 1.0 1.0,1,1,0,1,1 1 1,0.5,1,1 1 1 1681 Egger_1992 NA,NA,6-12 yo,6.2 9.3 NA NA,  8  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Sonuga-Barke (2014) | Catala-Lopez (2017),4.5,9.5,NA NA,Catala-Lopez (2017)_Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no high high
 575,Catala-Lopez (2017),Catala-Lopez,2017,10.1371/journal.pone.0180355 100,  0,100 100,Low Multimodal behavioral interventions NA,  0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA,NA,NA NA,Fabiano 2010,NA RCT RR  33  30,  63 outcomes,reverse  0.1302521008, 0.007004357  2.422151e+00 NA,NA,NA,NA,NA,NA,NA,NA,  0   0 100,  0 100 100,  0 some,high,low,high some Control   0, 14.000000  8.200000,NA,NA,1 1,1.0,0.0,1.0,1.0 1,1,0 1 1 1,1 0.5,1 1,1,1,1682 Fabiano_2010 NA NA 6-12 yo 8.2,9.9,NA,NA,  5, 1,Acceptability: all-cause discontinuation  1,Catala-Lopez (2017) 8.2,9.9 NA NA,Catala-Lopez (2017)_Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low high
 575,Catala-Lopez (2017),Catala-Lopez 2017 10.1371/journal.pone.0180355 100,  0,100 100 Low,Parent-mediated behavioral interventions,NA   0 NA,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA NA NA NA,NA,Fabiano,2012 NA,RCT RR  28  27,  55,outcomes reverse  1.2053571429, 0.361662002  4.017248e+00 NA NA,NA NA NA NA NA,NA   0,  0,100,100 100 100   0 some some low,high some Waiting list   0  12.700000, 8.500000 NA NA 1 1 1.0,0.0,1.0,1.0,1 1 0 1,1,1,1,0.5 1 1 1,1 1683 Fabiano_2012,NA,NA,6-12 yo,3.6 12.5,NA NA  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15,108.21,Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Mixed Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious,low high
 575 Catala-Lopez (2017) Catala-Lopez 2017,10.1371/journal.pone.0180355,100   0,100,100,Low,Parent-mediated behavioral interventions NA   0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,NA,NA,NA NA,Ferrin 2014 NA,RCT,RR, 44  37,  81,outcomes,reverse  1.6818181818  0.158748568, 1.781756e+01,NA NA,NA,NA NA NA NA,NA 100 100 100,100,100,100,100,low low low low,some,Control (parent counseling with support),  0  19.800000,10.600000 NA,NA,1,1 1.0,0.0 1.0,1.0 1,1,0 1,1 1 1 0.5 1 1 1,1,1684 Ferrin_2014 NA NA 6-12 yo 3.6 12.5 NA NA  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21,Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Mixed,Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,serious low,low
 575,Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0,100 100,Low Parent-mediated behavioral interventions,NA   0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA NA,NA NA,NA,Ferrin 2016 NA,RCT RR  35  34   69 outcomes reverse, 0.7285714286, 0.175999888, 3.016004e+00,NA,NA,NA NA NA NA,NA NA,  0   0 100,100 100 100,  0 low some,low high,some,Control (usual care)   0  18.900000,10.700000 NA,NA 1,1 1.0 0.0,1.0,1.0,1 1,0,1,1,1 1,0.5,1,1,1 1,1685 Ferrin_2016 NA,NA 6-12 yo 3.6 12.5,NA NA, 33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15,108.21,Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Mixed Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious,low high
 575,Catala-Lopez (2017),Catala-Lopez 2017 10.1371/journal.pone.0180355,100   0,100,100 Low Parent-mediated behavioral interventions,NA 100,stimulant,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA NA,NA,NA,NA Firestone,1986 NA RCT,RR, 22  30   52,outcomes,reverse  1.1363636364  0.602967863  2.141611e+00,NA,NA,NA NA,NA,NA NA NA   0,  0,100 100,  0   0,100,some,low high low,high Active (any credible active intervention),100,NA, 7.000000 NA,NA,1,1 1.0,0.0 1.0 1.0 1 1 0 1 1,1,1,0.5 1,1,1,1 1686,Firestone_1986 NA,NA,6-12 yo 3.6 12.5,NA NA, 33  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15,108.21,Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Mixed Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,serious high,high
 575,Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0 100 100 Low,Diet (restricted/elimination) NA,100,stimulant,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,NA,NA NA,NA,Ghanizadeh,2015,NA RCT,RR  53  53  106,outcomes,reverse, 0.9090909091, 0.422152689  1.957695e+00 NA NA NA NA,NA NA NA NA 100,100 100,100,100,100 100,some some some some some Active (any credible active intervention),100,NA  8.400000 NA NA 1,1,1.0 0.0,1.0 1.0 1,1 0 1,1 1,1 0.5,1 1 1 1,1687,Ghanizadeh_2015 NA,NA,6-12 yo,6.2 9.3 NA,NA   8, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5,9.5,NA NA Catala-Lopez (2017)_Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Catala-Lopez (2017) - Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 575 Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355 100   0,100 100 Low Cognitive training NA,  0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,NA,NA,NA NA,Green 2012,NA RCT RR, 15  15,  30 outcomes,reverse  3.0000000000, 0.350490848  2.567827e+01,NA,NA NA NA NA,NA,NA,NA,  0,  0 100 100,  0,  0,100,some some,high,some,high,Placebo   0  34.600000, 9.700000,NA NA,1,1 1.0,0.0 1.0 1.0 1 1 0 1 1 1 1 0.5 1,1 1 1 1688,Green_2012 NA NA 6-12 yo,6.6 10.4,NA,NA  28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA,Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high high
 575 Catala-Lopez (2017),Catala-Lopez,2017,10.1371/journal.pone.0180355 100   0,100 100,Low,Parent-mediated behavioral interventions NA   0,NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA NA,NA NA NA Hiscock,2015,NA,RCT RR,122,122, 244,outcomes,reverse  0.6666666667, 0.373015709  1.191490e+00 NA,NA NA NA,NA NA,NA NA,100,100,100,  0 100,100,100 low,high,low low some,Control (usual care)   0, 14.800000,10.100000,NA NA 1,1,1.0 0.0,1.0,1.0 1 1,0 1 1,1,1,0.5 1,1 1,1 1689,Hiscock_2015 NA NA 6-12 yo 3.6 12.5 NA,NA  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15,108.21 Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Mixed Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 serious low,low
 575 Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355 100   0 100 100 Low,Cognitive training,NA,  0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,NA,NA NA NA Hovik,2013 NA,RCT,RR, 38  37,  75,outcomes,reverse  1.6228070175  0.417390898, 6.309439e+00 NA,NA NA,NA,NA NA NA NA,  0   0 100   0,100 100,  0 some high low high,some Control   0  26.900000 10.400000,NA,NA,1 1,1.0 0.0,1.0 1.0,1,1,0,1 1 1,1,0.5 1 1 1 1 1690 Hovik_2013,NA,NA,6-12 yo,6.6,10.4,NA,NA  28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA NA,Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
 575,Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355 100   0 100 100,Low Homeopathy NA   0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA NA NA NA NA Jacobs 2005 NA RCT,RR  22, 21,  43 outcomes reverse  0.4772727273, 0.097467378  2.337082e+00 NA,NA NA,NA NA,NA,NA NA,100 100,100 100,100,100 100,low low,some,low some,Placebo,  0, 23.300000, 9.300000 NA NA,1,1,1.0,0.0,1.0 1.0,1 1 0,1 1 1 1 0.5,1 1 1,1,1691,Jacobs_2005,NA,NA 6-12 yo 9.3,9.3,NA NA   3  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  2 Heirs (2007) | Catala-Lopez (2017),8.5,9.3,NA NA,Catala-Lopez (2017)_Homeopathy_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Catala-Lopez (2017) - Homeopathy_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 575,Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355 100   0,100,100,Low Polyunsaturated fatty acids NA,  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA NA NA,NA,NA,Johnson 2009 NA,RCT RR, 37  38,  75 outcomes reverse  2.0540540541, 0.194451659  2.169762e+01,NA NA NA,NA,NA NA NA NA,100 100,100 100 100,100 100 some,low,some,some,some Placebo   0, 14.700000,12.000000 NA NA,1 1 1.0,0.0 1.0 1.0,1 1 0,1,1 1 1,0.5,1,1 1 1,1692,Johnson_2009,NA,NA 6-12 yo 8.3,13.7 NA,NA, 28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA,NA,Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Catala-Lopez (2017) - Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 575,Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355,100,  0,100 100,Low,Cognitive training NA   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA NA,NA NA NA,Klingberg,2005,NA,RCT RR, 27  26,  53 outcomes reverse  3.3703703704, 0.770061336  1.475129e+01,NA NA,NA NA,NA,NA NA,NA,100,100 100,100,100 100 100,low,low some,low some,Control,  0  18.000000, 9.800000 NA,NA,1 1 1.0 0.0,1.0,1.0 1 1,0,1,1,1 1 0.5,1,1 1,1,1693 Klingberg_2005,NA,NA,6-12 yo 6.6,10.4,NA,NA, 28  6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA,Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low low
 575,Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100,  0 100 100 Low Neurofeedback NA,100 stimulant Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA NA NA NA NA,Li,2013,NA RCT RR  32, 32   64 outcomes reverse  0.3333333333  0.036585472  3.037028e+00,NA NA NA NA NA,NA,NA NA,100,100,100 100,100,100,100,low low low low,some,Active (any credible active intervention),100, 15.600000 10.600000 NA,NA 1,1 1.0 0.0 1.0 1.0,1 1 0 1 1 1 1 0.5,1 1,1,1,1694,Li_2013 NA NA,6-12 yo,8.6 12.4,NA NA, 36, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 575 Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100   0,100 100,Low,Multimodal behavioral interventions NA   0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,NA,NA,NA,NA,MTA Cooperative,1999 NA RCT RR,144,146, 290 outcomes,reverse  0.5069444444  0.129249949, 1.988339e+00,NA,NA,NA NA NA,NA,NA,NA   0   0 100,  0,100,100,  0,low high,low,high low,Standard care   0, 20.000000  8.500000,NA NA 1,1 1.0 0.0,1.0 1.0,1 1,0,1 1,1,1 0.5,1 1,1,1,1695,MTA Cooperative_1999,NA,NA 6-12 yo,8.2 9.9 NA,NA   5, 1,Acceptability: all-cause discontinuation  1,Catala-Lopez (2017),8.2 9.9,NA,NA,Catala-Lopez (2017)_Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Catala-Lopez (2017) - Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
 575 Catala-Lopez (2017) Catala-Lopez 2017,10.1371/journal.pone.0180355,100   0,100 100 Low,Polyunsaturated fatty acids,NA,  0 NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,NA NA NA NA Manor 2012 NA RCT,RR 137, 63, 200 outcomes reverse  0.9197080292, 0.084962836  9.955681e+00 NA,NA NA,NA,NA NA NA NA   0   0 100 100 100,  0 100,some some low,some,high Placebo   0, 33.500000  9.200000,NA NA 1 1 1.0 0.0,1.0,1.0,1,1,0,1,1,1 1 0.5 1,1,1 1,1696,Manor_2012 NA NA 6-12 yo 8.3,13.7,NA,NA, 28  8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3 Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7,NA NA,Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Catala-Lopez (2017) - Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high,high
 575 Catala-Lopez (2017) Catala-Lopez 2017,10.1371/journal.pone.0180355,100,  0,100,100 Low Polyunsaturated fatty acids NA,  0,NA,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks) NA,NA NA NA NA,Matsudaira,2015 NA,RCT RR, 38  38,  76,outcomes,reverse, 7.0000000000, 0.373869893, 1.310616e+02,NA,NA NA,NA NA NA,NA NA,  0   0 100,100   0   0 100,some,some,high,some,high,Placebo   0   0.000000,13.700000,NA,NA 1,1,1.0 0.0 1.0 1.0 1 1 0 1,1 1,1 0.5 1,1,1 1,1697 Matsudaira_2015 NA,NA,13-19 yo,8.3 13.7 NA NA  28  8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events), 3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA NA Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no high high
 575,Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355,100   0,100 100,Low Homeopathy NA   0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA NA NA NA NA Oberai,2013 NA RCT RR  30, 31   61 outcomes reverse, 0.7515151515, 0.351495584  1.606777e+00 NA NA NA,NA,NA NA NA,NA,  0,  0 100   0 100,  0,100 low high,some some,high,Placebo   0  20.400000  9.300000,NA NA,1,1 1.0 0.0 1.0,1.0,1,1 0,1,1,1 1 0.5,1,1 1 1 1698 Oberai_2013 NA NA 6-12 yo,9.3,9.3,NA NA   3  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 2,Heirs (2007) | Catala-Lopez (2017),8.5 9.3,NA,NA,Catala-Lopez (2017)_Homeopathy_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Homeopathy_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high,high
 575 Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355 100,  0 100,100,Low,Methylphenidate + Alpha-2 agonists (guanfacine / clonidine) NA   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,NA,NA,NA,NA Palumbo 2008,NA RCT,RR, 32  30   62,outcomes reverse  0.3750000000, 0.195517429  7.192453e-01,NA NA,NA NA NA,NA,NA,NA,100 100,100 100,100,100 100,low low,some,low some,Placebo,  0  19.600000, 9.500000 NA NA 1 1 1.0,0.0,1.0 1.0,1,1 0 1,1,1 1 0.5 1,1,1 1,1699,Palumbo_2008,NA NA 6-12 yo 9.5,10.2 NA NA,  2  2 Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  1 Catala-Lopez (2017),9.5 10.2,NA,NA Catala-Lopez (2017)_Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Catala-Lopez (2017) - Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 575,Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355,100,  0 100 100 Low Methylphenidate + Alpha-2 agonists (guanfacine / clonidine),NA   0,NA Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),NA,NA NA NA,NA Palumbo 2008,NA,RCT RR  32, 30,  62,outcomes,reverse  2.8181818182, 0.119224233  6.661522e+01,NA NA NA,NA NA NA NA,NA 100,100 100,100 100,100 100,low low some,low,some,Placebo   0  19.600000, 9.500000,NA,NA 1,1,1.0,0.0,1.0 1.0,1 1,0 1 1,1 1,0.5 1 1 1 1,1700 Palumbo_2008 NA,NA 6-12 yo,9.5 10.2,NA NA   2  2,Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 1 Catala-Lopez (2017) 9.5 10.2 NA,NA Catala-Lopez (2017)_Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Catala-Lopez (2017) - Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 575 Catala-Lopez (2017),Catala-Lopez 2017 10.1371/journal.pone.0180355,100,  0,100,100 Low,Diet (restricted/elimination) NA   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,NA,NA,NA,NA Pelsser,2009 NA RCT RR, 15, 12,  27,outcomes reverse  1.6000000000  0.164101731  1.560008e+01 NA NA NA,NA NA,NA,NA,NA   0   0 100,  0 100,100,  0 some high low high,some,Waiting list,  0, 18.500000  6.200000,NA NA,1,1,1.0 0.0 1.0,1.0,1,1,0,1 1,1 1 0.5 1,1 1,1,1701,Pelsser_2009 NA NA,6-12 yo 6.2,9.3,NA NA   8, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2 Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5,9.5,NA,NA,Catala-Lopez (2017)_Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low high
 575,Catala-Lopez (2017) Catala-Lopez 2017,10.1371/journal.pone.0180355,100   0,100 100 Low Diet (restricted/elimination),NA   0 NA Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),NA NA NA NA,NA,Pelsser 2009 NA RCT RR, 15, 12,  27,outcomes reverse  2.4375000000, 0.108084503  5.497001e+01,NA,NA,NA,NA,NA,NA,NA,NA,  0,  0,100   0,100,100,  0 some high,low,high some,Waiting list   0  18.500000, 6.200000 NA,NA 1 1,1.0,0.0 1.0 1.0 1 1 0 1 1 1 1 0.5,1 1,1 1 1702,Pelsser_2009 NA NA,6-12 yo,6.2,6.9,NA NA   8  3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2 Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5,9.5,NA,NA Catala-Lopez (2017)_Diet (restricted/elimination)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Catala-Lopez (2017) - Diet (restricted/elimination)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,high
 575 Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355 100   0 100,100 Low Diet (restricted/elimination),NA   0,NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA NA NA NA NA Pelsser 2011 NA,RCT RR  50, 50, 100 outcomes,reverse, 1.1250000000, 0.472283459, 2.679800e+00,NA,NA,NA,NA NA NA,NA NA,100 100 100 100 100 100,100,low,some low some some,Control   0, 14.000000  6.900000 NA,NA 1 1 1.0,0.0,1.0,1.0,1 1 0 1,1 1,1 0.5 1 1,1,1,1703,Pelsser_2011,NA,NA 6-12 yo,6.2,9.3 NA NA,  8, 3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2,Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5,9.5 NA,NA Catala-Lopez (2017)_Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Catala-Lopez (2017) - Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 575,Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355,100   0 100 100 Low,Diet (restricted/elimination),NA   0,NA,Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) NA,NA,NA,NA,NA Pelsser,2011 NA RCT RR, 50, 50  100,outcomes reverse, 3.0000000000  0.125133458  7.192321e+01 NA NA NA NA,NA,NA NA,NA 100,100,100,100 100 100 100,low,some low,some some,Control   0  14.000000  6.900000,NA,NA,1 1,1.0,0.0 1.0,1.0 1 1,0 1 1,1,1,0.5,1,1 1 1,1704 Pelsser_2011,NA NA 6-12 yo,6.2 6.9,NA NA,  8, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2,Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5 9.5,NA,NA Catala-Lopez (2017)_Diet (restricted/elimination)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Diet (restricted/elimination)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,low
 575 Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355,100,  0 100 100 Low,Neurofeedback NA,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,NA NA,NA,NA,Perreau-Linck 2010 NA,RCT RR,  5   4,   9 outcomes,reverse  0.8000000000  0.069719235, 9.179676e+00,NA NA,NA,NA NA,NA NA NA,100,100,100   0 100,100,100,some,high,low some,some,Placebo   0, 11.100000,10.300000,NA,NA 1,1,1.0,0.0 1.0 1.0,1,1,0 1 1 1 1,0.5,1 1,1,1 1705 Perreau-Linck_2010 NA NA,6-12 yo,8.6,12.4,NA,NA  36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,low
 575,Catala-Lopez (2017),Catala-Lopez,2017,10.1371/journal.pone.0180355,100,  0,100 100,Low,Multimodal behavioral interventions NA   0 NA Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,NA,NA NA NA,Pfiffner,2014 NA RCT,RR  74  51, 125,outcomes reverse  0.2297297297  0.024582101, 2.146918e+00,NA NA NA,NA,NA NA NA,NA,  0,  0,100,  0 100 100,  0 some,high low,high,low,Control (usual care)   0, 41.600000, 8.600000 NA,NA 1 1,1.0 0.0 1.0 1.0,1,1,0,1 1 1 1 0.5,1,1 1 1,1706,Pfiffner_2014 NA NA 6-12 yo 8.2,9.9,NA NA   5, 1 Acceptability: all-cause discontinuation, 1 Catala-Lopez (2017) 8.2 9.9 NA NA Catala-Lopez (2017)_Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Catala-Lopez (2017) - Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
 575,Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355 100   0 100 100 Low,Parent-mediated behavioral interventions NA   0 NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) NA,NA NA,NA NA Pfiffner 2014 NA,RCT RR, 74, 51, 125 outcomes,reverse  0.0990476190, 0.005225745  1.877327e+00 NA,NA,NA NA NA NA,NA NA   0,  0 100   0,100 100,  0,some high,low,high low Control (usual care),  0  41.600000  8.600000 NA NA 1 1 1.0 0.0 1.0 1.0 1,1,0 1 1,1 1,0.5 1,1 1 1 1707,Pfiffner_2014 NA,NA,6-12 yo 3.6,12.5,NA,NA  33, 4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15,108.21 Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Mixed Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,serious low high
 575 Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355,100   0,100 100,Low,Parent-mediated behavioral interventions,NA   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,NA,NA NA NA,Pisterman 1992,NA RCT RR, 28, 29   57 outcomes reverse  0.7397959184, 0.265852758  2.058651e+00 NA NA NA NA NA,NA NA,NA,  0   0   0 100,  0,  0 100,high some,high some high Waiting list,  0, 15.800000  4.100000,NA,NA,1 1 1.0,0.0 1.0,1.0,1 1,0,1 1,1 1 0.5,1,1,1,1 1708,Pisterman_1992 NA,NA,< 6 yo,3.6,12.5,NA,NA  33  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation  5,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15,108.21,Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Mixed,Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious high high
 575,Catala-Lopez (2017) Catala-Lopez 2017,10.1371/journal.pone.0180355,100   0,100,100,Low,Polyunsaturated fatty acids,NA,  0,NA,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA,NA NA NA,NA,Raz,2009,NA,RCT,RR  39, 39   78 outcomes,reverse, 3.0000000000  0.125952829  7.145532e+01 NA NA,NA NA NA NA,NA,NA,  0,  0,100 100,  0   0 100 some some,high low,high,Placebo   0  39.700000 10.500000 NA NA 1 1,1.0 0.0 1.0 1.0 1 1 0,1,1 1 1 0.5,1,1,1 1,1709 Raz_2009 NA NA,6-12 yo 8.3,13.7,NA,NA  28, 8,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA,NA,Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous Catala-Lopez (2017) - Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
 575 Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355 100   0,100,100 Low Desipramine,NA   0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA NA NA,NA NA Spencer 2002c,2002 NA,RCT,RR  21  20,  41 outcomes,reverse, 0.1909090909, 0.009726873  3.746968e+00,NA,NA NA NA,NA NA NA,NA 100,100,100,100 100 100 100 low some some some,some Placebo   0  17.100000,11.000000,NA NA,1,1,1.0 0.0 1.0 1.0,1,1 0 1 1 1,1 0.5,1 1,1,1,1710 Spencer 2002c_2002,NA,NA 6-12 yo,11,11.5,NA,NA   4  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  2,Otasowie (2014) | Catala-Lopez (2017),11 11.5 NA NA,Catala-Lopez (2017)_Desipramine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Desipramine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no,low,low
 575,Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100,  0 100 100 Low Desipramine NA,  0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),NA NA,NA NA NA,Spencer 2002c 2002,NA,RCT RR, 21, 20   41,outcomes,reverse, 0.1909090909  0.009726873, 3.746968e+00,NA NA,NA,NA NA,NA,NA,NA,100,100 100,100 100,100 100 low,some,some some,some,Placebo,  0  17.100000,11.000000 NA NA,1 1,1.0 0.0,1.0 1.0 1 1 0 1,1 1 1 0.5,1,1 1,1 1711 Spencer 2002c_2002 NA NA 6-12 yo 11 11.5,NA NA,  4  3 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2,Otasowie (2014) | Catala-Lopez (2017) 11 11.5,NA NA Catala-Lopez (2017)_Desipramine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Desipramine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low low
 575,Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355,100   0 100 100 Low,Parent-mediated behavioral interventions,NA,  0,NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA NA NA,NA,NA Steeger 2016 NA,RCT,RR, 26  26,  52 outcomes,reverse, 3.0000000000  0.127807565, 7.041837e+01 NA,NA NA NA NA NA NA,NA,100,100 100,100 100 100,100,some some some,some some,Placebo,  0, 31.000000,12.500000,NA,NA 1,1 1.0,0.0,1.0,1.0,1 1 0,1 1,1,1,0.5,1,1 1 1,1712,Steeger_2016 NA,NA 6-12 yo 3.6 12.5 NA NA  33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99,94.15,108.21 Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Mixed Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 serious low,low
 575 Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355 100   0,100 100,Low,Neurofeedback NA,  0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA NA NA,NA NA Steiner,2011,NA RCT,RR  13  13   26,outcomes reverse  1.5000000000  0.298151645  7.546495e+00 NA,NA NA NA NA,NA NA NA 100,100,100,100 100,100 100,some,some,low,some,some Control,  0  47.800000 12.400000,NA,NA 1,1 1.0 0.0 1.0,1.0 1,1 0 1,1,1 1,0.5 1,1,1,1,1713 Steiner_2011,NA NA 6-12 yo 8.6 12.4,NA NA, 36  4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation  3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA,NA,Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,low,low
 575 Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355 100,  0,100,100,Low Neurofeedback NA   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA,NA,NA,NA,NA Steiner,2011 NA RCT RR  13, 15,  28 outcomes reverse, 8.0000000000  0.451299980, 1.418125e+02 NA,NA NA NA,NA NA NA,NA 100 100,100 100,100 100,100 some,some low some,some,Waiting list,  0  47.800000,12.400000,NA NA 1,1 1.0,0.0 1.0,1.0,1,1,0 1,1 1 1 0.5 1 1,1,1 1714 Steiner_2011 NA,NA 6-12 yo,8.6 12.4,NA,NA  36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3 Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 575 Catala-Lopez (2017),Catala-Lopez 2017 10.1371/journal.pone.0180355 100,  0 100 100,Low,Cognitive training,NA,  0,NA,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks),NA,NA,NA NA NA,Steiner 2014 NA RCT RR, 34, 36   70,outcomes,reverse, 2.1176470588, 0.414337234, 1.082314e+01 NA,NA,NA,NA,NA,NA NA NA,  0   0,100 100 100,100,  0,some,some low,high,some,Control,  0  32.700000, 8.600000,NA,NA 1 1 1.0,0.0 1.0,1.0 1,1,0,1,1,1,1,0.5,1,1 1 1 1715,Steiner_2014 NA NA,6-12 yo 6.6 10.4 NA NA, 28, 6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low high
 575 Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100,  0 100 100 Low Neurofeedback NA,  0 NA Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA,NA,NA,NA,NA,Steiner 2014 NA RCT,RR  34  36   70 outcomes,reverse, 0.2114285714, 0.010516026, 4.250849e+00 NA,NA,NA NA,NA,NA NA NA,  0,  0 100 100,100 100,  0,some,some low,high some Control   0  32.700000, 8.600000,NA NA 1 1 1.0 0.0 1.0 1.0 1,1 0 1 1,1 1,0.5,1,1,1 1,1716,Steiner_2014,NA,NA,6-12 yo,8.6 12.4 NA NA, 36  4,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation, 3,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low high
 575 Catala-Lopez (2017),Catala-Lopez 2017 10.1371/journal.pone.0180355 100,  0,100 100,Low,Methylphenidate + Alpha-2 agonists (guanfacine / clonidine) NA,  0,NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA NA,NA,NA,NA TSSG 2002,NA RCT RR  33, 32,  65,outcomes,reverse  0.5541125541  0.179330722, 1.712148e+00,NA,NA NA NA,NA NA,NA NA,100 100 100,100,100 100,100,low low,low,low,low,Placebo,  0, 14.700000 10.200000,NA,NA 1,1 1.0,0.0,1.0 1.0,1 1,0 1,1 1,1 0.5 1,1 1,1,1717,TSSG_2002,NA,NA,6-12 yo 9.5 10.2,NA,NA   2  2 Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events)  1,Catala-Lopez (2017) 9.5,10.2 NA NA,Catala-Lopez (2017)_Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 no low,low
 575,Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355 100   0,100,100,Low,Methylphenidate + Alpha-2 agonists (guanfacine / clonidine) NA   0,NA Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks),NA NA,NA,NA NA,TSSG 2002 NA,RCT,RR  33  32,  65 outcomes reverse, 2.9117647059  0.122970612  6.894634e+01 NA NA,NA NA NA NA,NA NA 100 100 100,100,100 100,100 low,low,low low,low Placebo   0, 14.700000 10.200000 NA NA,1 1,1.0,0.0 1.0 1.0,1,1,0,1,1 1,1,0.5 1,1,1,1,1718,TSSG_2002,NA,NA,6-12 yo 9.5 10.2,NA NA   2, 2 Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 1 Catala-Lopez (2017) 9.5 10.2,NA NA Catala-Lopez (2017)_Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low low
 575,Catala-Lopez (2017),Catala-Lopez,2017,10.1371/journal.pone.0180355,100   0,100,100,Low,Cognitive training NA   0 NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA,NA,NA,NA NA Tamm 2013 NA RCT,RR, 54, 51, 105 outcomes reverse  1.7000000000  0.610539306  4.733520e+00,NA,NA,NA,NA NA NA NA,NA,  0   0 100   0,100,100,  0 some high some,high,some Waiting list,  0, 32.400000, 9.300000,NA NA,1 1,1.0 0.0 1.0 1.0,1 1,0,1 1,1 1 0.5,1 1 1,1 1719 Tamm_2013,NA,NA 6-12 yo,6.6,10.4 NA,NA, 28, 6 Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients), 4 Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA,Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no,low,high
 575,Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355 100   0,100 100,Low,Parent-mediated behavioral interventions NA,  0,NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA NA,NA NA,Thompson,2009,NA RCT,RR, 21, 20,  41,outcomes,reverse  0.3809523810, 0.185051658, 7.842389e-01,NA,NA,NA,NA NA NA,NA,NA 100,100 100 100,100,100,100,some,some low,low some Control   0  27.000000  4.200000 NA NA,1 1,1.0,0.0,1.0 1.0,1,1,0 1,1 1,1 0.5 1 1 1,1,1720 Thompson_2009 NA NA < 6 yo 3.6,12.5 NA NA, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15,108.21 Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Mixed,Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,serious low low
 575,Catala-Lopez (2017),Catala-Lopez 2017,10.1371/journal.pone.0180355,100,  0,100,100,Low Carnitine,NA   0 NA,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) NA NA NA,NA NA Torrioli 2008 NA RCT RR, 30  33   63,outcomes reverse, 0.8250000000, 0.200827259  3.389107e+00 NA,NA,NA NA NA NA,NA NA   0   0,100,100,  0   0 100,some some high,some high Placebo   0   0.000000  9.200000 NA,NA,1,1,1.0,0.0 1.0 1.0,1,1,0 1 1 1 1,0.5 1,1 1 1 1721 Torrioli_2008,NA NA 6-12 yo 8.4,9.5 NA NA   4  1,Acceptability: all-cause discontinuation  1 Catala-Lopez (2017) 8.4 9.5 NA,NA,Catala-Lopez (2017)_Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous Catala-Lopez (2017) - Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no,high high
 575,Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355 100   0,100 100 Low,Polyunsaturated fatty acids,NA,  0 NA Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) NA,NA,NA NA NA,Vaisman,2008 NA,RCT,RR  29  26   55 outcomes reverse, 4.5000000000, 0.225950350, 8.962146e+01 NA,NA NA NA NA,NA,NA,NA,100 100,100 100 100,100 100 some,some low,some some,Placebo   0  45.800000, 9.300000 NA NA,1 1 1.0 0.0 1.0 1.0,1 1,0 1,1,1,1 0.5 1 1 1 1,1722 Vaisman_2008 NA NA 6-12 yo,8.3,13.7,NA NA, 28, 8 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events)  3,Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA NA,Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),1,Homogeneous,Catala-Lopez (2017) - Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000,no low,low
 575,Catala-Lopez (2017) Catala-Lopez,2017 10.1371/journal.pone.0180355 100   0,100,100,Low Multimodal behavioral interventions NA 100,non-stimulant,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) NA NA NA,NA,NA,Waxmonsky,2010,NA,RCT,RR, 29  27   56,outcomes,reverse, 2.3275862069  0.492153878  1.100806e+01 NA,NA,NA NA,NA,NA NA,NA   0   0 100,  0,100   0   0,some high some,high high,Active (any credible active intervention),100  19.600000, 8.600000,NA,NA,1 1 1.0,0.0,1.0 1.0 1,1 0,1 1 1 1,0.5 1 1 1 1,1723,Waxmonsky_2010,NA NA 6-12 yo 8.2,9.9,NA NA   5  1 Acceptability: all-cause discontinuation  1 Catala-Lopez (2017),8.2 9.9,NA,NA,Catala-Lopez (2017)_Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Catala-Lopez (2017) - Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no,high high
 575,Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355 100,  0,100,100 Low,Zinc,NA,100 stimulant,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks),NA,NA NA NA,NA,Zamora,2011,NA,RCT RR  20, 20,  40,outcomes,reverse  0.3333333333  0.037807004  2.938903e+00 NA NA NA NA,NA NA,NA NA,  0,  0,  0,100,  0   0,100 high,some high some high Active (any credible active intervention),100  27.500000, 9.600000 NA NA 1 1,1.0 0.0 1.0,1.0 1,1,0 1,1,1,1,0.5,1 1,1 1 1724 Zamora_2011 NA NA 6-12 yo,7.9 9.6,NA NA,  6, 3,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events), 2 Talebi (2021) | Catala-Lopez (2017),7.14,9.92,NA NA Catala-Lopez (2017)_Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Homogeneous,Catala-Lopez (2017) - Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no high high
 575 Catala-Lopez (2017) Catala-Lopez 2017 10.1371/journal.pone.0180355,100   0 100,100 Low,Cognitive training NA   0,NA Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),NA NA NA,NA NA van Dongen-Boomsma,2014 NA RCT RR  27, 24,  51,outcomes,reverse, 0.2962962963  0.032983234, 2.661701e+00,NA NA,NA,NA,NA,NA NA,NA 100,100 100 100,100 100 100 some low,some,low,some,Placebo,  0, 27.700000, 6.600000,NA,NA 1 1 1.0,0.0 1.0 1.0,1,1 0,1,1,1 1,0.5 1,1 1,1,1725,van Dongen-Boomsma_2014 NA,NA,6-12 yo 6.6 10.4 NA NA, 28  6,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients)  4,Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous,Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low low
 575,Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355,100,  0 100,100 Low Carnitine NA   0 NA,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA,NA NA NA,van Oudheusden,2002,NA,RCT,RR, 13, 13,  26 outcomes,reverse, 1.0000000000  0.069734044, 1.434020e+01 NA NA,NA,NA,NA,NA,NA,NA,100 100,100 100,100,100,100 some,some,some,some some,Placebo   0,  0.000000  9.500000,NA,NA 1 1,1.0,0.0 1.0 1.0 1,1,0 1,1,1,1,0.5,1 1,1 1,1726,van Oudheusden_2002,NA,NA,6-12 yo,8.4,9.5,NA NA,  4, 1,Acceptability: all-cause discontinuation  1 Catala-Lopez (2017),8.4,9.5,NA NA Catala-Lopez (2017)_Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1 Homogeneous Catala-Lopez (2017) - Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo 100.00000 no low low
 575 Catala-Lopez (2017) Catala-Lopez,2017,10.1371/journal.pone.0180355,100,  0,100,100,Low,Parent-mediated behavioral interventions NA   0 NA Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks) NA NA,NA,NA,NA van den Hoofdakker,2007 NA,RCT,RR  48, 48,  96 outcomes reverse  7.0000000000  0.895091374, 5.474301e+01,NA NA,NA,NA,NA NA NA,NA,  0   0,100,100 100,100   0 some,some,some high some,Control   0, 19.100000  7.400000,NA NA 1 1,1.0 0.0,1.0,1.0,1 1,0 1,1 1,1 0.5,1 1,1,1,1727,van den Hoofdakker_2007 NA,NA,6-12 yo,3.6,12.5 NA,NA, 33, 4 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation, 5 Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15,108.21 Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),1 Mixed,Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000 serious,low,high
 575,Catala-Lopez (2017),Catala-Lopez,2017 10.1371/journal.pone.0180355 100   0,100 100,Low,Multimodal behavioral interventions,NA,100 stimulant Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),NA,NA NA,NA,NA,van der Oord,2007,NA RCT,RR, 27, 23   50,outcomes,reverse, 1.2777777778  0.233297223  6.998438e+00 NA NA,NA NA NA,NA,NA,NA   0   0 100,  0,100 100,  0,some,high some high,some,Active (any credible active intervention),100, 12.000000  9.900000 NA,NA,1 1,1.0 0.0 1.0,1.0 1 1,0,1,1 1,1,0.5 1 1,1,1,1728 van der Oord_2007 NA,NA 6-12 yo 8.2 9.9 NA NA   5, 1 Acceptability: all-cause discontinuation, 1,Catala-Lopez (2017) 8.2,9.9,NA NA Catala-Lopez (2017)_Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 1,Homogeneous,Catala-Lopez (2017) - Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,100.00000,no low,high
